FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Chemali, Z Chahine, LM Fricchione, G AF Chemali, Zeina Chahine, Lama M. Fricchione, Gregory TI The Use of Selective Serotonin Reuptake Inhibitors in Elderly Patients SO HARVARD REVIEW OF PSYCHIATRY LA English DT Review DE geriatrics; selective serotonin reuptake inhibitors ID LATE-LIFE DEPRESSION; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; PRIMARY-CARE PATIENTS; DRUG-INTERACTIONS; MAJOR DEPRESSION; FRONTOTEMPORAL DEMENTIA; DOUBLE-BLIND; ANTIDEPRESSANT THERAPY; PARKINSONS-DISEASE AB Depression is common among the elderly, and several factors need to be taken into account in selecting the appropriate antidepressant in this age group. Various physiologic changes occur in individuals as they age, potentially leading to changes in the pharmacodynamic and pharmacokinetic properties of drugs in elderly individuals. The efficacy of various medications, their side-effect profiles, and the potential for drug-drug interactions may differ in older patients compared to younger ones. The selective serotonin reuptake inhibitors (SSRIs), which are seen as being among the first-line agents for treatment of depression in elderly patients, have been shown to be effective but carry with them side effects and drug-drug interactions that warrant special attention when these medications are prescribed to older individuals. This review focuses on the pharmacology of SSRIs in elderly patients and on practical issues related to using these medications. C1 [Chemali, Zeina; Fricchione, Gregory] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Chahine, Lama M.] Cleveland Clin, Cleveland, OH 44106 USA. [Fricchione, Gregory] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Chemali, Zeina; Fricchione, Gregory] Brigham & Womens Hosp, Div Cognit & Behav Neurol, Boston, MA 02115 USA. RP Chemali, Z (reprint author), Brigham & Womens Hosp, Div Behav & Cognit Neurol, 221 Longwood Ave, Boston, MA 02115 USA. EM zchemali@hsph.harvard.edu NR 111 TC 10 Z9 10 U1 1 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PY 2009 VL 17 IS 4 BP 242 EP 253 AR PII 913448557 DI 10.1080/10673220903129798 PG 12 WC Psychiatry SC Psychiatry GA 475VW UT WOS:000268392400002 PM 19637073 ER PT J AU Schouten, R Brendel, RW AF Schouten, Ronald Brendel, Rebecca W. TI Common Pitfalls in Giving Medical-Legal Advice to Trainees and Supervisees SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE confidentially; forensic psychiatry; HIPAA; liability; malpractice; privacy; residency training; supervision C1 [Schouten, Ronald] Harvard Univ, Sch Med, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Schouten, R (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 4 TC 1 Z9 1 U1 1 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PY 2009 VL 17 IS 4 BP 291 EP 294 AR PII 913449344 DI 10.1080/10673220903129855 PG 4 WC Psychiatry SC Psychiatry GA 475VW UT WOS:000268392400005 PM 19637076 ER PT J AU Gross, A Altman, M Salvatore, P Baldessarini, RJ Chanoff, M Powers, JP AF Gross, Anne Altman, Matthew Salvatore, Paola Baldessarini, Ross J. Chanoff, Marni Powers, Joseph P. TI An Atypical, Chronic Psychotic Disorder in a 55-Year-Old Man SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE catatonia; psychodynamic; psychosis; social interaction model ID ELECTROCONVULSIVE-THERAPY; DEPRESSIVE ILLNESS; ELDERLY-PATIENTS; RATING-SCALE; SCHIZOPHRENIA; CATATONIA; DIMENSIONS; DIAGNOSIS; DRUGS; ECT C1 [Gross, Anne] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Salvatore, Paola; Baldessarini, Ross J.] Int Consortium Bipolar Disorder Res, Belmont, MA USA. [Gross, Anne; Chanoff, Marni; Powers, Joseph P.] McLean Hosp, Belmont, MA 02178 USA. [Altman, Matthew] Brigham & Womens Hosp, Boston, MA 02115 USA. [Salvatore, Paola] Univ Parma, Dept Neurosci, Psychiat Clin, I-43100 Parma, Italy. RP Gross, A (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, WACC 812,15 Parkman St, Boston, MA 02114 USA. EM afgross@partners.org NR 59 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PY 2009 VL 17 IS 5 BP 329 EP 343 DI 10.3109/10673220903299203 PG 15 WC Psychiatry SC Psychiatry GA 517LH UT WOS:000271614600004 PM 19832047 ER PT J AU Meyer, F Peteet, J Joseph, R AF Meyer, Fremonta Peteet, John Joseph, Robert TI Models of Care for Co-occurring Mental and Medical Disorders SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE anxiety; collaborative care; depression; primary care; telepsychiatry ID LATE-LIFE DEPRESSION; RANDOMIZED CONTROLLED-TRIAL; COLLABORATIVE CARE; HEALTH-SERVICES; UNITED-STATES; ANTIDEPRESSANT TREATMENT; PANIC DISORDER; HEPATITIS-C; TELEPSYCHIATRIC CONSULTATION; QUALITY IMPROVEMENT AB In this article we review practice models for treating common mental disorders in primary care. Novel treatment approaches by primary care providers and specialty providers, including collaborative care and telepsychiatric models, show considerable promise. An understanding of remaining barriers to improved care suggests several possible solutions and future directions for outpatient psychosomatic medicine. (HARV REV PSYCHIATRY 2009;17:353-360.) C1 [Meyer, Fremonta; Peteet, John] Dana Farber Canc Inst, Boston, MA 02115 USA. [Meyer, Fremonta; Peteet, John] Harvard Univ, Sch Med, Boston, MA USA. [Meyer, Fremonta; Peteet, John] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. [Joseph, Robert] Cambridge Hlth Alliance, Dept Psychiat, Cambridge, MA USA. RP Meyer, F (reprint author), Dana Farber Canc Inst, 44 Binney St,SW411, Boston, MA 02115 USA. EM fremonta_meyer@dfci.harvard.edu NR 66 TC 8 Z9 9 U1 2 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PY 2009 VL 17 IS 6 BP 353 EP 360 DI 10.3109/10673220903463325 PG 8 WC Psychiatry SC Psychiatry GA 548GB UT WOS:000273946900002 PM 19968450 ER PT J AU Nicolson, SE Caplan, JP Williams, DE Stern, TA AF Nicolson, Stephen E. Caplan, Jason P. Williams, Deldre E. Stern, Theodore A. TI Comorbid Pain, Depression, and Anxiety: Multifaceted Pathology Allows for Multifaceted Treatment SO HARVARD REVIEW OF PSYCHIATRY LA English DT Review DE analgesics; anxiety; depression; geriatrics; pain; psychiatry; psychosomatic medicine; psychotherapy; selective serotonin reuptake inhibitors ID IRRITABLE-BOWEL-SYNDROME; TENSION-TYPE HEADACHE; TORSADE-DE-POINTES; LOW-BACK-PAIN; NEUROPATHIC PAIN; FIBROMYALGIA SYNDROME; PLACEBO-RESPONSE; DOUBLE-BLIND; PROPHYLACTIC TREATMENT; PSYCHIATRIC-DISORDERS AB The care of patients who suffer from physical pain and a psychiatric illness is typically challenging because of the complex interplay of affective, behavioral, cognitive, and physical aspects of pain. Psychiatrists are often asked to evaluate patients with pain because of a concern for comorbid depression and anxiety, and fears of suicidality as a result of pain. This article reviews the pathophysiology of comorbid pain, anxiety, and depression, along with the treatment modalities (pharmacologic, psychotherapeutic, and "alternative") that may benefit all three conditions. (HARV REV PSYCHIATRY 2009;17:407-420.) C1 [Caplan, Jason P.] St Josephs Hosp, Dept Psychiat, Phoenix, AZ 85013 USA. [Nicolson, Stephen E.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Psychiat, Bronx, NY USA. [Caplan, Jason P.] Creighton Univ, Sch Med, Omaha, NE USA. [Williams, Deldre E.] Baylor Coll Med, Houston, TX 77030 USA. [Stern, Theodore A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Stern, Theodore A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Caplan, JP (reprint author), St Josephs Hosp, Dept Psychiat, 350 W Thomas Rd, Phoenix, AZ 85013 USA. EM jason.caplan@chw.edu NR 120 TC 22 Z9 23 U1 8 U2 13 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PY 2009 VL 17 IS 6 BP 407 EP 420 DI 10.3109/10673220903463226 PG 14 WC Psychiatry SC Psychiatry GA 548GB UT WOS:000273946900007 PM 19968455 ER PT J AU Jeyaretna, DS Whitfield, PC AF Jeyaretna, Deva S. Whitfield, Peter C. BE Whitfield, PC Thomas, EO Summers, F Whyte, M Hutchinson, PJ TI Clinical assessment of the head-injured patient: an anatomical approach SO HEAD INJURY: A MULTIDISCIPLINARY APPROACH LA English DT Article; Book Chapter ID SHAKEN BABY SYNDROME; PRESSURE-VOLUME CURVE; GLASGOW COMA SCALE; LOCALIZING SIGNS; BRAIN-INJURY; NEUROPATHOLOGY; INCISURA; PATTERNS; TRAUMA; FALSE C1 [Jeyaretna, Deva S.] Massachusetts Gen Hosp, Brain Tumour Res Ctr, Boston, MA 02114 USA. [Jeyaretna, Deva S.] Harvard Univ, Sch Med, Boston, MA USA. [Whitfield, Peter C.] Plymouth Hosp NHS Trust, Derriford Hosp, South West Neurosurg Ctr, Plymouth, Devon, England. RP Jeyaretna, DS (reprint author), Massachusetts Gen Hosp, Brain Tumour Res Ctr, Boston, MA 02114 USA. NR 21 TC 1 Z9 1 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-69762-0 PY 2009 BP 28 EP 35 D2 10.1017/CBO9780511576515 PG 8 WC Neurosciences SC Neurosciences & Neurology GA BFF00 UT WOS:000319565700005 ER PT J AU Maranhao-Filho, P Vincent, M AF Maranhao-Filho, Pericles Vincent, Maurice TI Professor Aristides Leao. Much More Than Spreading Depression SO HEADACHE LA English DT Review DE Leao; migraine; spreading depression ID CEREBRAL-CORTEX; DISCOVERY AB Professor Leao described cortical spreading depression (CSD) in 1944 and changed the way migraine pathophysiology is scientifically conceived. This Brazilian professor and researcher developed his career in Rio de Janeiro. Because of him, the city once became the CSD world capital, attracting scientists from many laboratories around the globe. Aristides Leao was first and foremost a naturalist, a man genuinely interested in birds, fishes, plants, shells, and neuroscience. He could easily fascinate whoever would come for a chat, leaving no question without answers. He was born in 1914 and died in 1993. This report focuses on his life, family, habits, and hobbies, describing a little of Leao apart from CSD and the year of 1944. C1 [Maranhao-Filho, Pericles] Univ Fed Ris Janeiro, Rio De Janeiro, Brazil. [Maranhao-Filho, Pericles] Inst Nacl Canc, Rio De Janeiro, Brazil. Univ Fed Rio de Janeiro, BR-21941 Rio De Janeiro, Brazil. Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP Vincent, M (reprint author), Avdas Amer 1155,Room 504, BR-22631000 Rio De Janeiro, Brazil. RI Vincent, Maurice/B-1415-2009 NR 28 TC 4 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-8748 J9 HEADACHE JI Headache PD JAN PY 2009 VL 49 IS 1 BP 110 EP 116 DI 10.1111/j.1526-4610.2008.01210.x PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 391IC UT WOS:000262226000015 PM 18647182 ER PT J AU Emmons, KM Lobb, R Puleo, E Bennett, G Stoffel, E Syngal, S AF Emmons, Karen M. Lobb, Rebecca Puleo, Elaine Bennett, Gary Stoffel, Elena Syngal, Sapna TI Colorectal Cancer Screening: Prevalence Among Low-Income Groups With Health Insurance SO HEALTH AFFAIRS LA English DT Article; Proceedings Paper CT AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved CY NOV 27-30, 2007 CL Atlanta, GA SP Amer Assoc Canc Res ID UNITED-STATES; DISPARITIES; POPULATION; KNOWLEDGE; COVERAGE; WOMEN; RACE AB We examined the prevalence of colorectal cancer (CRC) screening in a low-income, racial/ethnic minority sample, among whom 97 percent had health insurance that covered CRC screening. This is a model for examining the impact of health insurance on racial/ethnic disparities in screening. Screening rates (67 percent self-reported; 52 percent adjusted based on a validation substudy) were higher than among similar population-based samples who have lower levels of insurance coverage. There were no differences by race/ethnicity. This study suggests that insurance coverage for CRC screening should be considered as part of a comprehensive approach to address CRC disparities. [Health Affairs 28, no. 1 (2009): 169-177; 10.1377/hlthaff.28.1.169] C1 [Emmons, Karen M.; Bennett, Gary; Stoffel, Elena; Syngal, Sapna] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA. [Lobb, Rebecca] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Puleo, Elaine] Univ Massachusetts, Sch Publ Hlth, Amherst, MA 01003 USA. RP Emmons, KM (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA. EM karen_m_emmons@dfci.harvard.edu OI Lobb, Rebecca/0000-0003-3503-0675 FU NCI NIH HHS [R01 CA098864-05, R01CA098864, R01 CA098864, U01 CA114644-05, R01 CA098864-02S1, 1K05CA124415, K05 CA124415, K05 CA124415-03, 3R01CA098864-02S1, U01 CA114644, U01CA114644] NR 21 TC 9 Z9 10 U1 0 U2 1 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2009 VL 28 IS 1 BP 169 EP 177 DI 10.1377/hlthaff.28.1.169 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 390WM UT WOS:000262194400021 PM 19124867 ER PT J AU Volpp, KG Pauly, MV Loewenstein, G Bangsberg, D AF Volpp, Kevin G. Pauly, Mark V. Loewenstein, George Bangsberg, David TI P4P4P: An Agenda For Research On Pay-For-Performance For Patients SO HEALTH AFFAIRS LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-CARE; COST-EFFECTIVENESS; SMOKING-CESSATION; CONTINGENCY MANAGEMENT; MYOCARDIAL-INFARCTION; ECONOMIC INCENTIVES; UNITED-STATES; DRUG USERS; FOLLOW-UP AB Unhealthy behavior is a major cause of poor health outcomes and high health care costs. In this paper we describe an agenda for research to guide broader use of patient-targeted financial incentives, either in conjunction with provider-targeted financial incentives (pay-for-performance, or P4P) or in clinical contexts where provider-targeted approaches are unlikely to be effective. We discuss evidence of proven effectiveness and limitations of the existing evidence, reasons for underuse of these approaches, and options for achieving wider use. Patient-targeted incentives have great potential, and systematic testing will help determine how they can best be used to improve population health. [Health Affairs 28, no. 1 (2009): 206-214; 10.1377/hlthaff.28.1.206] C1 [Volpp, Kevin G.] Univ Penn, Wharton Sch, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Sch Med, Philadelphia Vet Affairs VA Med Ctr, Philadelphia, PA 19104 USA. [Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Bangsberg, David] Massachusetts Gen Hosp, Harvard Program Global Hlth, Cambridge, MA USA. [Bangsberg, David] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Volpp, KG (reprint author), Univ Penn, Wharton Sch, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA. EM volpp70@mail.med.upenn.edu FU NCCDPHP CDC HHS [R01 DP000100, R01 DP000100-01]; NIAAA NIH HHS [K24 AA015287, K24 AA015287-06]; NIMH NIH HHS [R01 MH064388, R01 MH054907, R01 MH054907-15, R01 MH054907-17, R01 MH064388-04, R03 MH066654, R03 MH066654-02]; PHS HHS [015287, 54907, 64388, 66654] NR 58 TC 61 Z9 62 U1 1 U2 8 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2009 VL 28 IS 1 BP 206 EP 214 DI 10.1377/hlthaff.28.1.206 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 390WM UT WOS:000262194400026 PM 19124872 ER PT J AU Lewis, N Gray, SW Freres, DR Hornik, RC AF Lewis, Nehama Gray, Stacy W. Freres, Derek R. Hornik, Robert C. TI Examining Cross-Source Engagement With Cancer-Related Information and Its Impact on Doctor-Patient Relations SO HEALTH COMMUNICATION LA English DT Article ID BREAST-CANCER; SOCIAL SUPPORT; INTERNET USE; SEEKING; HEALTH; ONCOLOGY; BEHAVIOR; MEDIA; WOMEN; NEEDS AB Patients may bring unreliable information to the physician, complicating the physician-patient relationship, or outside information seeking may complement physician information provision, reinforcing patients' responsibility for their health. The current descriptive evidence base is weak and focuses primarily on the Internet's effects on physician-patient relations. This study describes how cancer patients bring information to their physicians from a range of sources and are referred by physicians to these sources; the study also examines explanations for these behaviors. Patients with breast, prostate, and colon cancer diagnosed in 2005 (N = 1,594) were randomly drawn from the Pennsylvania Cancer Registry; participants returned mail surveys in Fall 2006 (response rate = 64%). There is evidence that both bringing information to physicians and being referred to other sources reflects patients' engagement with health information, preference for control in medical decision making, and seeking and scanning for cancer-related information. There is also evidence that patients who bring information from a source are referred back to that source. C1 [Lewis, Nehama; Freres, Derek R.; Hornik, Robert C.] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. [Gray, Stacy W.] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA USA. RP Lewis, N (reprint author), Univ Penn, Annenberg Sch Commun, 3620 Walnut St, Philadelphia, PA 19104 USA. EM nlewis@asc.upenn.edu OI Hornik, Robert/0000-0002-2148-8805 FU NCI NIH HHS [P20 CA095856, P20 CA095856-060001, P50 CA095856, P50 CA095856-05, P50-CA095856-05] NR 51 TC 21 Z9 21 U1 2 U2 10 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 1041-0236 J9 HEALTH COMMUN JI Health Commun. PY 2009 VL 24 IS 8 BP 723 EP 734 DI 10.1080/10410230903264030 PG 12 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA 557CA UT WOS:000274644600006 PM 20183381 ER PT J AU Safren, SA O'Cleirigh, C Tan, JY Raminani, SR Reilly, LC Otto, MW Mayer, KH AF Safren, Steven A. O'Cleirigh, Conall Tan, Judy Y. Raminani, Sudha R. Reilly, Laura C. Otto, Michael W. Mayer, Kenneth H. TI A Randomized Controlled Trial of Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD) in HIV-Infected Individuals SO HEALTH PSYCHOLOGY LA English DT Article DE HIV; adherence; cognitive behavioral therapy ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; SELF-REPORTED ADHERENCE; VIRAL LOAD; PSYCHIATRIC-DISORDERS; CLINICAL-SIGNIFICANCE; MEDICATION ADHERENCE; PSYCHOSOCIAL FACTORS; PROTEASE INHIBITORS; DISEASE PROGRESSION AB Objective: To evaluate cognitive-behavioral therapy to enhance medication adherence and reduce depression (CBT-AD) in individuals with HIV. Design: A two arm, randomized, controlled, cross-over trial comparing CBT-AD to enhanced treatment as usual only (ETAU). ETAU, which both groups received, included a single-session intervention for adherence and a letter to the patient's provider documenting her or his continued depression. The intervention group also received 10 to 12 sessions of CBT-AD. Main Outcome Measures: Adherence to antiretroviral therapy as assessed by Medication Event Monitoring Systems (MEMs) and depression as assessed by blinded structured evaluation. Results: At the acute outcome assessment (3-months), those who received CBT-AD evidenced significantly greater improvements in medication adherence and depression relative to the comparison group. Those who were originally assigned to the comparison group who chose to cross over to CBT-AD showed similar improvements in both depression and adherence outcomes. Treatment gains for those in the intervention group were generally maintained at 6-and 12-month follow-up assessments. By the end of the follow-up period, those originally assigned CBT-AD demonstrated improvements in plasma HIV RNA concentrations, though these differences did not emerge before the cross-over, and hence there were not between-groups differences. Conclusions: CBT-AD is a potentially efficacious approach for individuals with HIV struggling with depression and adherence. Replication and extension in larger efficacy trials are needed. C1 [Safren, Steven A.; O'Cleirigh, Conall] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA. [Otto, Michael W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Mayer, Kenneth H.] Brown Univ, Fenway Community Hlth & Infect Dis Div, Fenway Inst, Providence, RI 02912 USA. RP Safren, SA (reprint author), MGH Behav Med, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA. EM ssafren@partners.org FU National Institute of Mental Health [R21MH06660] FX This research was supported by the National Institute of Mental Health, grant number R21MH06660 to Dr. Steven A. Safren. NR 70 TC 153 Z9 155 U1 5 U2 26 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 J9 HEALTH PSYCHOL JI Health Psychol. PD JAN PY 2009 VL 28 IS 1 BP 1 EP 10 DI 10.1037/a0012715 PG 10 WC Psychology, Clinical; Psychology SC Psychology GA 394EA UT WOS:000262427200001 PM 19210012 ER PT S AU Akashi, K AF Akashi, Koichi BE Kanz, L Weisel, KC Dick, JE Fibbe, WE TI Lymphoid Lineage Fate Decision of Hematopoietic Stem Cells SO HEMATOPOIETIC STEM CELLS VII SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 7th Biennial International Symposium and Workshop on Hematopoietic Stem Cells CY SEP 18-20, 2008 CL Meersburg, GERMANY SP Univ Tubingen, Amgen DE hematopoietic stem cells (HSCs); hematopoiesis; myelo-lymphoid precursors ID BONE-MARROW; PROGENITOR CELLS; FLT3 LIGAND; RAG1 LOCUS; PU.1; GATA-1; TRANSCRIPTION; COMMITMENT; EXPRESSION; DIFFERENTIATION AB To understand the mechanism in lymphoid development, it is critical to identify developmental intermediates downstream of hematopoietic stem cells, including cells responsible for seeding the thymus. Although early studies showed that hematopoietic stem cells choose either the myeloid-erythroid or the lymphoid pathway, recent data suggest that myelo-lymphoid precursors lacking erythroid potential exist in early hematopoiesis before cells are fully committed to the lymphoid lineage. We here summarize the phenotype and functional properties of such progenitors and the current developmental map for the lymphoid lineage. C1 [Akashi, Koichi] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Akashi, Koichi] Kyushu Univ, Fac Med, Dept Med & Biosyst Sci, Fukuoka 812, Japan. RP Akashi, K (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM Koichi_akashi@dfci.harvard.edu NR 43 TC 4 Z9 4 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-761-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2009 VL 1176 BP 18 EP 25 DI 10.1111/j.1749-6632.2009.04570.x PG 8 WC Biotechnology & Applied Microbiology; Cell Biology; Hematology; Multidisciplinary Sciences SC Biotechnology & Applied Microbiology; Cell Biology; Hematology; Science & Technology - Other Topics GA BLX37 UT WOS:000271280000002 PM 19796229 ER PT S AU Krivtsov, AV Feng, ZH Armstrong, SA AF Krivtsov, Andrei V. Feng, Zhaohui Armstrong, Scott A. BE Kanz, L Weisel, KC Dick, JE Fibbe, WE TI Transformation from Committed Progenitor to Leukemia Stem Cells SO HEMATOPOIETIC STEM CELLS VII SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES LA English DT Article; Proceedings Paper CT 7th Biennial International Symposium and Workshop on Hematopoietic Stem Cells CY SEP 18-20, 2008 CL Meersburg, GERMANY SP Univ Tubingen, Amgen DE leukemia; stem cells; hematopoiesis ID MIXED-LINEAGE LEUKEMIA; TRANSCRIPTIONAL ELONGATION; MYELOID-LEUKEMIA; CHROMATIN; METHYLATION; MLL-AF9; MURINE; MAINTENANCE; RENEWAL; BMI-1 AB Leukemias are composed of a hierarchy of cells, only a fraction of which have stem cell-like properties and are capable of self-renewal. Mixed lineage leukemia (MLL) fusion proteins produced by translocations involving the MLL gene on chromosome 11q23 confer stem cell-like properties on committed hematopoietic progenitors. This provides an opportunity to assess changes in immunophenotype, gene expression, and epigenetic programs during the transition from a hematopoietic cell with minimal inherent self-renewal capability to cells capable of leukemic self-renewal. C1 [Armstrong, Scott A.] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Div Hematol Oncol,Karp Family Res Labs, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Armstrong, SA (reprint author), Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Div Hematol Oncol,Karp Family Res Labs, 1 Blackfan Circle, Boston, MA 02215 USA. EM scott.armstrong@childrens.harvard.edu OI Krivtsov, Andrei/0000-0002-5511-1686 NR 22 TC 12 Z9 12 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-761-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2009 VL 1176 BP 144 EP 149 DI 10.1111/j.1749-6632.2009.04966.x PG 6 WC Biotechnology & Applied Microbiology; Cell Biology; Hematology; Multidisciplinary Sciences SC Biotechnology & Applied Microbiology; Cell Biology; Hematology; Science & Technology - Other Topics GA BLX37 UT WOS:000271280000015 PM 19796242 ER PT J AU El-Serag, HB Engels, EA Landgren, O Chiao, E Henderson, L Amaratunge, HC Giordano, TP AF El-Serag, Hashem B. Engels, Eric A. Landgren, Ola Chiao, Elizabeth Henderson, Louise Amaratunge, Harshinie C. Giordano, Thomas P. TI Risk of Hepatobiliary and Pancreatic Cancers After Hepatitis C Virus Infection: A Population-Based Study of US Veterans SO HEPATOLOGY LA English DT Article ID ADMINISTRATION MEDICAL SYSTEM; UNITED-STATES; INTRAHEPATIC CHOLANGIOCARCINOMA; EXTRAHEPATIC CHOLANGIOCARCINOMA; LIVER; CIRRHOSIS; ASCERTAINMENT; PREVALENCE; CARCINOMA; AFFAIRS AB Hepatitis C virus (HCV) may increase the risk of hepatopancreaticobiliary tumors other than hepatocellular carcinoma (HCC). Previous case control studies indicated a possible association between HCV and intrahepatic cholangiocarcinoma (ICC). Little is known about the association between HCV and extrahepatic cholangiocarcinoma (ECC) or pancreatic cancer. We conducted a cohort study including 146,394 HCV-infected and 572,293 HCV-uninfected patients who received care at Veterans Affairs health care facilities. Patients with two visits between 1996 and 2004 with HCV infection were included, as were up to four matched HCV-uninfected subjects for each HCV-infected subject. Risks of ICC, ECC, pancreatic cancer, and HCC were assessed using proportional hazards regression. In the 1.37 million person-years of follow-up, which began 6 months after the baseline visit, there were 75 cases of ECC, 37 cases of ICC, 617 cases of pancreatic cancer, and 1679 cases of HCC. As expected, the risk of HCC associated with HCV was very high (hazard ratio [HR], 15.09; 95% confidence interval [95% CI], 13.44, 16.94). Risk for ICC was elevated with HCV infection 2.55; 1.31, 4.95), but risk for ECC was not significantly increased (1.50; 0.60, 1.85). Adjustments for cirrhosis, diabetes, inflammatory bowel disease, hepatitis B, alcoholism, and alcoholic liver disease did not reduce the risk for ICC below twofold. The risk of pancreatic cancer was slightly elevated (1.23; 1.02, 1.49), but was attenuated after adjusting for alcohol use, pancreatitis, and other variables. Conclusions. Findings indicated that HCV infection conferred a more than twofold elevated risk of ICC. Absence of an association with ECC was consistent in adjusted and unadjusted models. A significant association with pancreatic cancer was erased by alcohol use and other variables. (HEPATOLOGY 2009;49:116-123.) C1 [El-Serag, Hashem B.; Chiao, Elizabeth; Henderson, Louise; Amaratunge, Harshinie C.; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [El-Serag, Hashem B.; Chiao, Elizabeth; Henderson, Louise; Amaratunge, Harshinie C.; Giordano, Thomas P.] Dept Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. [Engels, Eric A.; Landgren, Ola] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA. RP El-Serag, HB (reprint author), Houston VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU National Cancer Institute, National Institutes of Health; Michael E. DeBakey Veterans Affairs Medical Center; Department of Veterans Affairs, Houston; NIH [K24 DK078154-01] FX Supported by the Intramural Program of the National Cancer Institute, National Institutes of Health, and the Michael E. DeBakey Veterans Affairs Medical Center, Department of Veterans Affairs, Houston, TX. Dr. El-Sang is supported by NIH grant K24 DK078154-01. NR 25 TC 134 Z9 141 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD JAN PY 2009 VL 49 IS 1 BP 116 EP 123 DI 10.1002/hep.22606 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 389WX UT WOS:000262127400016 PM 19085911 ER PT J AU Yuan, HX Zhang, H Wu, XW Zhang, Z Du, D Zhou, WC Zhou, SH Brakebusch, C Chen, ZJ AF Yuan, Haixin Zhang, Hong Wu, Xunwei Zhang, Zhe Du, Dan Zhou, Wenchao Zhou, Shuhua Brakebusch, Cord Chen, Zhengjun TI Hepatocyte-Specific Deletion of Cdc42 Results in Delayed Liver Regeneration After Partial Hepatectomy in Mice SO HEPATOLOGY LA English DT Article ID CYCLIN D1 EXPRESSION; P70 S6 KINASE; FARNESOID-X RECEPTOR; DIRECTED MIGRATION; RHO-GTPASES; ACTIVATION; RAC; PROLIFERATION; PATHWAY; GROWTH AB Cdc42, a member of the Rho guanosine triphosphatase (GTPase) family, plays important roles in the regulation of the cytoskeleton, cell proliferation, cell polarity, and cellular transport, but little is known about its specific function in mammalian liver. We investigated the function of Cdc42 in regulating liver regeneration. Using a mouse model with liver-specific knockout of Cdc42 (Cdc42LK), we studied liver regeneration after partial hepatectomy. Histological analysis, immunostaining, and western blot analysis were performed to characterize Cdc42LK livers and to explore the role of Cdc42 in liver regeneration. In control mouse livers, Cdc42 became activated between 3 and 24 hours after partial hepatectomy. Loss of Cdc42 led to a significant delay of liver recovery after partial hepatectomy, which was associated with reduced and delayed DNA synthesis indicated by 5-bromo-2'-deoxyuridine staining. Consistent with this, expression of cyclins D1, A, and E was markedly delayed or reduced in Cdc42LK livers during regeneration. As a potential effector of Cdc42, Rac1 activation was dramatically attenuated in Cdc42LK livers after partial hepatectomy, suggesting it is regulated in a Cdc42-dependent manner. Activation of certain proliferative signaling pathways, such as extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p70S6 kinase pathways, was delayed in Cdc42LK livers. In addition, dilated bile canaliculi and excessive lipid accumulation were observed in mutant livers during liver regeneration, which may result from impaired cytoskeletal organization and intracellular trafficking in hepatocytes. Conclusion: Our results revealed important roles of Cdc42 in the regulation of proliferative signaling during liver regeneration. (HEPATOLOGY 2009;49:240-249.) C1 [Yuan, Haixin; Zhang, Hong; Zhang, Zhe; Du, Dan; Zhou, Wenchao; Zhou, Shuhua; Chen, Zhengjun] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai, Peoples R China. [Yuan, Haixin; Zhang, Hong; Du, Dan; Zhou, Wenchao; Zhou, Shuhua] Chinese Acad Sci, Grad Sch, Shanghai, Peoples R China. [Wu, Xunwei] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA. [Brakebusch, Cord] Univ Copenhagen, BRIC, Inst Biomed, Copenhagen, Denmark. RP Chen, ZJ (reprint author), Shanghai Inst Biochem & Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China. EM zjchen@sibs.ac.cn RI Du, Dan/D-6106-2017 OI Du, Dan/0000-0002-3470-2890 FU National Natural Science Foundation of China [30730055, 30623002]; National Key Scientific Program of China [2007CB914504]; National High Technology Research and Development Program of China [2006AA02A308]; Chinese Academy of Sciences [ASCV2-YW-R-108] FX Supported by grants from the National Natural Science Foundation of China (No.30730055 and No. 30623002), the National Key Scientific Program of China (No. 2007CB914504), the National High Technology Research and Development Program of China (No. 2006AA02A308) and the grants from Chinese Academy of Sciences (ASCV2-YW-R-108). NR 43 TC 17 Z9 18 U1 1 U2 8 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD JAN PY 2009 VL 49 IS 1 BP 240 EP 249 DI 10.1002/hep.22610 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 389WX UT WOS:000262127400028 PM 19085966 ER PT J AU Giovanello, KS Schnyer, D Verfaellie, M AF Giovanello, Kelly Sullivan Schnyer, David Verfaellie, Mieke TI Distinct Hippocampal Regions Make Unique Contributions to Relational Memory SO HIPPOCAMPUS LA English DT Article DE hippocampus; declarative memory; relational memory; fMRI ID MEDIAL TEMPORAL-LOBE; MILD COGNITIVE IMPAIRMENT; ASSOCIATIVE RECOGNITION; ITEM RECOGNITION; RETRIEVAL; FMRI; PET; ACTIVATIONS; CORTEX; PAIRS AB Neuroscientific research has shown that the hippocampus is important for binding or linking together the various components of a learning event into an integrated memory. In a prior study, we demonstrated that the anterior hippocampus is involved in memory for the relations among informational elements to a greater extent that it is involved in memory for individual elements (Giovanello et al., 2004. Hippocampus 14:5-8). In the current study, we extend those findings by further specifying the role of anterior hippocampus during relational memory retrieval. Specifically, anterior hippocampal activity was observed during flexible retrieval of learned associations, whereas posterior hippocampal activity was detected during reinstatement of study episodes. These findings suggest a functional dissociation across the long axis of human hippocampus based on the nature of the mnemonic process rather than the stage of memory processing or type of stimulus. (C) 2008 Wiley-Liss, Inc. C1 [Giovanello, Kelly Sullivan] Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA. [Giovanello, Kelly Sullivan] Univ N Carolina, Biomed Res Imaging Ctr, Chapel Hill, NC 27599 USA. [Schnyer, David] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. [Verfaellie, Mieke] Boston Univ, Sch Med, Memory Disorders Res Ctr, Jamaica Plain, MA USA. [Verfaellie, Mieke] VA Boston Healthcare Syst, Jamaica Plain, MA USA. RP Giovanello, KS (reprint author), Univ N Carolina, Dept Psychol, Davie Hall 341,CB 3270, Chapel Hill, NC 27599 USA. EM kgio@unc.edu OI Verfaellie, Mieke/0000-0001-5535-4584; Schnyer, David/0000-0002-7472-2853 FU Medical Research Service of the Department of Veterans AffairsNIH [NIH MH57681] FX Medical Research Service of the Department of Veterans Affairs; Grant number: NIH MH57681. NR 26 TC 66 Z9 67 U1 1 U2 8 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2009 VL 19 IS 2 BP 111 EP 117 DI 10.1002/hipo.20491 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 410AH UT WOS:000263546700001 PM 18727049 ER PT J AU Dickerson, BC AF Dickerson, Bradford C. TI New Frontiers in Computational Analysis of Human Hippocampal Anatomy SO HIPPOCAMPUS LA English DT Editorial Material ID MEDIAL TEMPORAL-LOBE; ALZHEIMERS-DISEASE; MR CORRELATION; LIMBIC LOBE; SEVERITY; SECTIONS; MEMORY; MILD C1 [Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol,Athinoula A Martinos Ctr Biomed Imagi, MGH Memory Disorders & Frontotemporal Dementias U, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02114 USA. [Dickerson, Bradford C.] Harvard Univ, Sch Med, Boston, MA USA. RP Dickerson, BC (reprint author), MGH Frontotemporal Dementia Unit, 149 13th St,Suite 2691, Charlestown, MA 02129 USA. EM bradd@nmr.mgh.harvard.edu NR 19 TC 0 Z9 1 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2009 VL 19 IS 6 BP 507 EP 509 DI 10.1002/hipo.20624 PG 3 WC Neurosciences SC Neurosciences & Neurology GA 456EP UT WOS:000266824000001 PM 19405144 ER PT J AU Wang, L Khan, A Csernansky, JG Fischl, B Miller, MI Morris, JC Beg, MF AF Wang, Lei Khan, Ali Csernansky, John G. Fischl, Bruce Miller, Michael I. Morris, John C. Beg, M. Faisal TI Fully-Automated, Multi-Stage Hippocampus Mapping in Very Mild Alzheimer Disease SO HIPPOCAMPUS LA English DT Article; Proceedings Paper CT 1st Computational Hippocampal Anatomy and Physiology Workshop CY SEP 06, 2008 CL New York Univ, New York, NY HO New York Univ DE Computational anatomy; Automated segmentation; MR imaging; FreeSurfer ID BRAIN SEGMENTATION; DEMENTIA; VOLUME; RELIABILITY; ADULTS; ATLAS; SHAPE AB Landmark-based high-dimensional diffeomorphic maps of the hippocampus (although accurate) is highly-dependent on rater's anatomic knowledge of the hippocampus in the magnetic resonance images. It is therefore vulnerable to rater drift and errors if substantial amount of effort is not spent on quality assurance, training, and re-training. A fully-automated, FreeSurfer-initialized large-deformation diffeomorphic metric mapping procedure of small brain substructures, including the hippocampus, has been previously developed and validated in small samples. in this report, we demonstrate that this fully-automated pipeline can be used in place of the landmark-based procedure in a large-sample clinical study to produce similar statistical outcomes. Some direct comparisons of the two procedures are also presented. (C) 2009 Wiley-Liss, Inc. C1 [Wang, Lei; Csernansky, John G.] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA. [Wang, Lei] Northwestern Univ, Dept Radiol, Feinberg Sch Med, Chicago, IL 60611 USA. [Khan, Ali; Beg, M. Faisal] Simon Fraser Univ, Sch Engn Sci, Burnaby, BC V5A 1S6, Canada. [Fischl, Bruce] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Miller, Michael I.] Johns Hopkins Univ, Ctr Imaging Sci, Baltimore, MD USA. [Miller, Michael I.] Johns Hopkins Univ, Whiting Sch Engn, Baltimore, MD USA. [Morris, John C.] Washington Univ, Sch Med, Alzheimers Dis Res Ctr, St Louis, MO USA. [Morris, John C.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA. RP Wang, L (reprint author), Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, 710 N Lake Shore Dr,Suite 1312, Chicago, IL 60611 USA. EM leiwang1@northwestern.edu RI Miller, Michael I./A-3213-2010; Morris, John/A-1686-2012; Wang, Lei/I-7552-2013; Khan, Ali/P-1353-2014 OI Wang, Lei/0000-0003-3870-3388; Khan, Ali/0000-0002-0760-8647 FU NCRR NIH HHS [P41 RR015241, UL1 RR025741]; NIA NIH HHS [P01 AG003991, P01 AG003991-250013, P01 AG026276, P01 AG026276-050004, P50 AG005681, R01 AG025824]; NIMH NIH HHS [P50 MH071616, R01 MH060883, R01 MH060883-10] NR 20 TC 15 Z9 15 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2009 VL 19 IS 6 BP 541 EP 548 DI 10.1002/hipo.20616 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 456EP UT WOS:000266824000006 PM 19405129 ER PT J AU Van Leemput, K Bakkour, A Benner, T Wiggins, G Wald, LL Augustinack, J Dickerson, BC Golland, P Fischl, B AF Van Leemput, Koen Bakkour, Akram Benner, Thomas Wiggins, Graham Wald, Lawrence L. Augustinack, Jean Dickerson, Bradford C. Golland, Polina Fischl, Bruce TI Automated Segmentation of Hippocampal Subfields From Ultra-High Resolution In Vivo MRI SO HIPPOCAMPUS LA English DT Article; Proceedings Paper CT 1st Computational Hippocampal Anatomy and Physiology Workshop CY SEP 06, 2008 CL New York Univ, New York, NY HO New York Univ DE hippocampal subfields; segmentation; computational methods; MRI; statistical modeling ID MEDIAL TEMPORAL-LOBE; ALZHEIMERS-DISEASE; IMAGE REGISTRATION; UNIFIED FRAMEWORK; FUNCTIONAL MRI; BRAIN; ATLAS; MODEL; SUBREGIONS AB Recent developments in MRI data acquisition technology are starting to yield images that show anatomical features of the hippocampal formation at an unprecedented level of detail, providing the basis for hippocampal subfield measurement. However, a fundamental bottleneck in MRI studies of the hippocampus at the subfield level is that they currently depend on manual segmentation, a laborious process that severely limits the amount of data that can be analyzed. In this article, we present a computational method for segmenting the hippocampal subfields in ultra-high resolution MRI data in a fully automated fashion. Using Bayesian inference, we use a statistical model of image formation around the hippocampal area to obtain automated segmentations. We validate the proposed technique by comparing its segmentations to corresponding manual delineations in ultra-high resolution MRI scans of 10 individuals, and show that automated volume measurements of the larger subfields correlate well with manual volume estimates. Unlike manual segmentations, our automated technique is fully reproducible, and fast enough to enable routine analysis of the hippocampal subfields in large imaging studies. (C) 2009 Wiley-Liss, Inc. C1 [Van Leemput, Koen; Bakkour, Akram; Benner, Thomas; Wiggins, Graham; Wald, Lawrence L.; Augustinack, Jean; Dickerson, Bradford C.; Fischl, Bruce] Harvard Univ, Athinoula Martinos Ctr Biomed Imaging, Dept Radiol, Massachusetts Gen Hosp,Sch Med, Charlestown, MA 02129 USA. [Van Leemput, Koen; Golland, Polina; Fischl, Bruce] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA. [Bakkour, Akram; Dickerson, Bradford C.] Harvard Univ, Dept Neurol, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA. [Wald, Lawrence L.; Fischl, Bruce] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Van Leemput, K (reprint author), Harvard Univ, Athinoula Martinos Ctr Biomed Imaging, Dept Radiol, Massachusetts Gen Hosp,Sch Med, Bldg 149,Room 2301,13th St, Charlestown, MA 02129 USA. EM koen@nmr.mgh.harvard.edu RI Van Leemput, Koen/A-9197-2009; Wald, Lawrence/D-4151-2009; OI Van Leemput, Koen/0000-0001-6466-5309; Bakkour, Akram/0000-0002-6070-4945 FU NCRR NIH HHS [P41 RR013218, P41 RR013218-08, P41 RR014075, P41 RR014075-02, P41-RR13218, P41-RR14075, R01 RR016594, R01 RR016594-01A1, R01 RR16594-01A1, U24 RR021382, U24 RR021382-03]; NIA NIH HHS [R01 AG029411, R01 AG029411-02, R21 AG029840, R21 AG029840-02]; NIBIB NIH HHS [R01 EB001550, R01 EB001550-03, R01 EB006758, R01 EB006758-03, R01EB006758, U54 EB005149, U54 EB005149-010014, U54-EB005149]; NINDS NIH HHS [R01 NS051826, R01 NS051826-02, R01 NS052585, R01 NS052585-01, R01 NS052585-01A1] NR 28 TC 154 Z9 154 U1 0 U2 12 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2009 VL 19 IS 6 BP 549 EP 557 DI 10.1002/hipo.20615 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 456EP UT WOS:000266824000007 PM 19405131 ER PT J AU Mueller, SG Weiner, MW AF Mueller, Susanne G. Weiner, Michael W. TI Selective Effect of Age, Apo e4, and Alzheimer's Disease on Hippocampal Subfields SO HIPPOCAMPUS LA English DT Article; Proceedings Paper CT 1st Computational Hippocampal Anatomy and Physiology Workshop CY SEP 06, 2008 CL New York Univ, New York, NY HO New York Univ DE CA1; dentate; volumetry; neurodegeneration; MCI ID HIGH-RESOLUTION MRI; TRANSGENIC MICE; NEUROFIBRILLARY TANGLES; MULTIPLE-SCLEROSIS; DENTATE GYRUS; NEURONAL LOSS; NEUROGENESIS; BRAIN; CA1; MORPHOLOGY AB Histopathological studies and animal models suggest that different physiological and pathophysiological processes exert different subfield specific effects on the hippocampus. High-resolution images at 4T depict details of the internal structure of the hippocampus allowing for in vivo volumetry of hippocampal subfields. The aims of this study were (1) to determine patterns of hippocampal subfield volume loss due to normal aging and Apo e4 carrier state, (2) to determine subfield specific volume losses due to preclinical (MCI) and clinical Alzheimer's disease (AD) and their modification due to age and Apo e4 carrier state. One hundred fifty seven subjects (119 cognitively healthy elderly controls, 20 MCI and 18 AD) were studied with a high resolution T2 weighted imaging sequence obtained at 4T aimed at the hippocampus. Apo e4 carrier state was known in 95 subjects (66 controls, 14 MCI, 15 AD). Subiculum (SUB), CA1, CA1-CA2 transition zone (CA1-2 transition), CA3- dentate gyrus (CA3&DG) were manually marked. Multiple linear regression analysis was used to test for effects of age, Apo e4 carrier state and effects of MCI and AD on different hippocampal subfields. Age had a significant negative effect on CA1 and CA3&DG volumes in controls (P < 0.05). AD had significantly smaller volumes of SUB, CA1, CA1-2 transition, and MCI had smaller CA1-2 transition volumes than controls (P < 0.05). Apo e4 carrier state was associated with volume loss in CA3&DG compared to non-Apo e4 carriers in healthy controls and AD. Based on these findings, we conclude that subfield volumetry provides regional selective information that allows to distinguish between different normal and pathological processes affecting the hippocampus and thus for an improved differential diagnosis of neurodegenerative diseases affecting the hippocampus. (C) 2009 Wiley-Liss, Inc. C1 [Mueller, Susanne G.; Weiner, Michael W.] US Dept Vet Affairs, Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. RP Mueller, SG (reprint author), US Dept Vet Affairs, Med Ctr, Ctr Imaging Neurodegenerat Dis, Clement St 4150, San Francisco, CA 94121 USA. EM susanne.mueller@ucsf.edu FU NIA NIH HHS [P01 AG012435-139001, P01 AG012435, P01 AG12435, R01 AG010897, R01 AG010897-21] NR 43 TC 117 Z9 119 U1 0 U2 9 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2009 VL 19 IS 6 BP 558 EP 564 DI 10.1002/hipo.20614 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 456EP UT WOS:000266824000008 PM 19405132 ER PT J AU Yang, K Trepanier, CH Li, HB Beazely, MA Lerner, EA Jackson, MF MacDonald, JF AF Yang, Kai Trepanier, Catherine H. Li, Hongbin Beazely, Michael A. Lerner, Ethan A. Jackson, Michael F. MacDonald, John F. TI Vasoactive Intestinal Peptide Acts via Multiple Signal Pathways to Regulate Hippocampal NMDA Receptors and Synaptic Transmission SO HIPPOCAMPUS LA English DT Article DE VIP; NMDA receptor; cAMP/PKA; VPAC receptor; AKAP ID CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN-KINASE-A; LONG-TERM POTENTIATION; CA1 PYRAMIDAL CELLS; VPAC(2) RECEPTORS; COUPLED RECEPTORS; VIP; NEURONS; PACAP; METAPLASTICITY AB Vasoactive intestinal peptide (VIP) is a 28-amino acid peptide, which belongs to a superfamily of structurally related peptide hormones including pituitary adenylate cyclase-activating polypeptide (PACAP). Although several studies have identified the involvement of PACAP in learning and memory, little work has been done to investigate such a role for VIP. At least three receptors for VIP have been identified including the PACAP receptor (PAC1-R) and the two VIP receptors (VPAC receptors). VIP can activate the PAC1-R only if it is used at relatively high concentrations (e.g., 100 nM); however, at lower concentrations (e.g., 1 nM) it is selective for the VPAC receptors. Our lab has showed that PAC1-R activation signals through PKC/CAKP/Src pathway to regulate NMDA receptors; however, there is little known about the potential regulation of NMDA receptors by VPAC receptors. Our studies demonstrated that application of 1 nM VIP enhanced NMDA currents by stimulating the VPAC receptors as the effect was blocked by VPAC receptor antagonist [Ac-Tyr(1), D-Phe(2)]GRF (1-29). This enhancement of NMDA currents was blocked by both Rp-cAMPS and PK(14-22) (they are highly specific PKA inhibitors), but not by the specific PKC inhibitor, bisindolylmaleimide 1. In addition, the VIP-induced enhancement of NMDA currents was accentuated by inhibition of phosphodiesterase 4, which inhibits the degradation of cAMP. This regulation of NMDA receptors also required the scaffolding protein AKAP. In contrast, the potentiation induced by high concentration of VIP (e.g., 100 nM) was mediated by PAC1-R as well as by Src kinase. Overall, these results show that VIP can regulate NMDA receptors through different receptors and signaling pathways. (C) 2009 Wiley-Liss, Inc. C1 [Jackson, Michael F.; MacDonald, John F.] Univ Western Ontario, Robarts Res Inst, Mol Brain Res Grp, London, ON N6A 5K8, Canada. [Yang, Kai; Li, Hongbin] Univ Toronto, Dept Physiol, Toronto, ON, Canada. [Trepanier, Catherine H.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada. [Beazely, Michael A.] Univ Waterloo, Sch Pharm, Waterloo, ON N2L 3G1, Canada. [Lerner, Ethan A.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol, Chareleston, MA USA. RP MacDonald, JF (reprint author), Univ Western Ontario, Robarts Res Inst, Mol Brain Res Grp, 100 Perth Dr, London, ON N6A 5K8, Canada. EM j.macdonald@utoronto.ca RI Jackson, Mike/H-5573-2012 OI Jackson, Mike/0000-0002-4730-201X FU Canadian Institutes of Health Researc [15514, 44008]; National Institutes of Health [U01 A1061420] FX Grant sponsor: Canadian Institutes of Health Research; Grant numbers: 15514 and 44008; Grant sponsor: National Institutes of Health; Grant number: U01 A1061420. NR 50 TC 14 Z9 14 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2009 VL 19 IS 9 BP 779 EP 789 DI 10.1002/hipo.20559 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 494CN UT WOS:000269787100002 PM 19173226 ER PT J AU Ross, RS Brown, TI Stern, CE AF Ross, Robert S. Brown, Thackery I. Stern, Chantal E. TI The Retrieval of Learned Sequences Engages the Hippocampus: Evidence From fMRI SO HIPPOCAMPUS LA English DT Article DE disambiguation; memory; medial temporal lobe; fMRI; sequence ID MEDIAL TEMPORAL-LOBE; EPISODIC MEMORY; WORKING-MEMORY; OVERLAPPING SEQUENCES; SUBSEQUENT MEMORY; AMNESIC PATIENTS; CONTEXT; ORDER; EVENTS; ITEM AB Computational models suggest that the hippocampus plays an important role in the retrieval of sequences. However, empirical evidence supporting hippocampal involvement during sequence retrieval is lacking. The current study used functional magnetic resonance imaging (fMRI) to examine the role of the human hippocampus during the learning and retrieval of sequences. Participants were asked to learn four sequences comprised of six faces each. An overlapping condition, where sequences shared common elements, was comprised of two sequences in which two identical faces were shown as the middle images of both sequences. A nonoverlapping condition contained two sequences that did not share any faces between them. A third random condition contained two sets of six faces that were always presented in a random order. The fMRI data were split into a learning phase and an experienced phase based upon each individual's behavioral performance. Patterns of hippocampal activity during presentation, delay, and choice periods were assessed both during learning (learning phase) and after subjects learned the sequences to criteria (experienced phase). The results revealed hippocampal activation during sequence learning, consistent with previous findings in rats and humans. Critically, the current results revealed hippocampal activation during the retrieval of learned sequences. No difference in hippocampal activation was seen between the overlapping and nonoverlapping sequences during either sequence learning or retrieval of sequences. The results extend our current knowledge by providing evidence that the hippocampus is active during the retrieval of learned sequences, consistent with current computational models of sequence learning and retrieval. (C) 2009 Wiley-Liss, Inc. C1 [Ross, Robert S.; Brown, Thackery I.; Stern, Chantal E.] Boston Univ, Silvio O Conte Ctr Memory & Brain, Boston, MA 02215 USA. [Ross, Robert S.; Brown, Thackery I.; Stern, Chantal E.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP Ross, RS (reprint author), Boston Univ, Silvio O Conte Ctr Memory & Brain, 2 Cummington St, Boston, MA 02215 USA. EM bross@bu.edu OI Ross, Robert/0000-0002-3987-881X FU National Institutes of Health; National Center for Research Resources [P41 RR14075]; Cognitive Neuroimaging Laboratory; Silvio O. Conte Center for Memory and Brain; Boston University (Boston, MA); Athinoula A. Martinos Center for Biomedical Imaging, MGH/MIT/HMS (Charlestown, MA); [P50 MH071702] FX This work was conducted with the support of the Cognitive Neuroimaging Laboratory, Silvio O. Conte Center for Memory and Brain, Boston University (Boston, MA), and the Athinoula A. Martinos Center for Biomedical Imaging, MGH/MIT/HMS (Charlestown, MA). The authors thank Karin Schon and Michael Hasselmo for helpful discussion about the design of the study and helpful comments on this manuscript. NR 36 TC 37 Z9 38 U1 0 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1050-9631 J9 HIPPOCAMPUS JI Hippocampus PY 2009 VL 19 IS 9 BP 790 EP 799 DI 10.1002/hipo.20558 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 494CN UT WOS:000269787100003 PM 19219919 ER PT B AU Utikal, J Schadendorf, D Ugurel, S AF Utikal, Jochen Schadendorf, Dirk Ugurel, Selma BA Hellberg, D BF Hellberg, D TI Histological and Serological Tumor Markers and Their Clinical Usefulness in Skin Cancer SO HISTOLOGICAL AND SEROLOGICAL TUMOR MARKETS AND GENE EXPRESSION AND THEIR CLINICAL USEFULNESS IN CANCERS LA English DT Article; Book Chapter DE skin cancer; biomarker; prognosis; serum; immunohistochemistry ID CUTANEOUS MALIGNANT-MELANOMA; AMERICAN-JOINT-COMMITTEE; SQUAMOUS-CELL CARCINOMA; SERUM-LEVELS; METASTATIC MELANOMA; PROGNOSTIC-SIGNIFICANCE; LACTATE-DEHYDROGENASE; DISEASE PROGRESSION; POOR-PROGNOSIS; ADHESION MOLECULE-1 C1 [Utikal, Jochen] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Ctr Regenerat Med,Stem Cell Inst, Boston, MA 02114 USA. [Utikal, Jochen; Schadendorf, Dirk] German Canc Res Ctr, Skin Canc Unit, D-6900 Heidelberg, Germany. [Utikal, Jochen; Schadendorf, Dirk] Univ Heidelberg, Univ Med Ctr Mannheim, D-6800 Mannheim, Germany. [Ugurel, Selma] Univ Wurzburg, Dept Dermatol, D-8700 Wurzburg, Germany. RP Utikal, J (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Ctr Regenerat Med,Stem Cell Inst, Simches Res Bldg,CPZN 4200,4th Floor,185 Cambridg, Boston, MA 02114 USA. EM jutikal@mgh.harvard.edu NR 88 TC 0 Z9 0 U1 0 U2 0 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60741-382-0 PY 2009 BP 37 EP 51 PG 15 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA BNU55 UT WOS:000275598500003 ER PT J AU Young, RH AF Young, Robert H. TI The History of British Gynaecological Pathology SO HISTOPATHOLOGY LA English DT Review DE Matthew Baillie; Thomas Hodgkin; Richard Bright; Alban Doran; John Bland-Sutton; Cuthbert Lockyer; Elizabeth Hurdon; John Hammond Teacher; Magnus Haines; Claud Taylor; Frederick Langley; Wallace Park; Harold Fox AB The venerable tradition of British gynaecological pathology is honoured by brief comments on those who have pioneered work in this arena, using as the starting point the remarkable Scottish physician Dr Matthew Baillie who, with his uncles, the legendary William and John Hunter, can arguably be considered the founders of medicine in Great Britain. The impact of Baillie's great work 'The Morbid Anatomy of Some of the Most Important Parts of the Human Body' is noted. Because of the fame they achieved in working in other areas, the contributions to gynaecological pathology of Thomas Hodgkin and Richard Bright, particularly the former, are often overlooked and are noted herein as is a remarkable book on the ovary by Charles G. Ritchie, published in 1865. The middle years of the 19th century were notable because of the activities of pioneering surgeons such as Sir Spencer Wells and Lawson Tait which gradually led to a greater emphasis on pathologic examination of specimens removed at operation, as opposed to autopsy evaluation. The closing years of the 19th century and early years of the 20th century were dominated by five individuals, Alban Doran, John Bland-Sutton, Cuthbert Lockyer, Elizabeth Hurdon and John Hammond Teacher. Doran wrote an early study of tubal carcinoma and a book on that organ and the ovary. Bland-Sutton was a remarkably influential surgeon with a significant interest in pathology and also contributed a book on the ovary and fallopian tube as well as one of the early good papers on metastatic tumours to the ovary. Lockyer wrote an outstanding book on uterine fibroids and established, and funded, a museum at Charing Cross Hospital. Hurdon can be considered the first female gynaecological pathologist. She spent much of her active career in the United States working at Johns Hopkins Hospital. She co-authored a monumental book on the appendix, likely never to be equalled. Teacher worked in Glasgow for many years and was almost single-handedly responsible for the acceptance in Britain of the concepts of trophoblastic disease espoused by the German investigator Felix Marchand. Wallace Park of Dundee also contributed significantly on trophoblastic disease in later years. The years following the death of Dr Teacher were largely dominated by three individuals, Magnus Haines working in London, Claud Taylor in Birmingham, and Frederick Langley in Manchester. The first two individuals wrote an excellent textbook and Langley brought great fame to the Manchester School, ably assisted by Harold Fox, the latter being the doyen of British gynaecologic pathologists throughout the latter decades of the 20th century. With Langley he wrote an important book on ovarian tumours, an equally influential book on the placenta, and with Dr Hilary Buckley he authored a book on endometrial biopsy interpretation. Additionally, his countless entertaining and instructive lectures throughout the world represented a remarkable educational experience. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, James Homer Wright Pathol Labs,Dept Pathol, Boston, MA 02114 USA. RP Young, RH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, James Homer Wright Pathol Labs,Dept Pathol, 55 Fruit St, Boston, MA 02114 USA. EM rhyoung@partners.org NR 61 TC 1 Z9 1 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0309-0167 J9 HISTOPATHOLOGY JI Histopathology PD JAN PY 2009 VL 54 IS 2 BP 144 EP 155 DI 10.1111/j.1365-2559.2008.03194.x PG 12 WC Cell Biology; Pathology SC Cell Biology; Pathology GA 397CY UT WOS:000262640900002 PM 19207941 ER PT B AU Stone, VE AF Stone, Valerie E. BE Stone, V Ojikutu, B Rawlings, MK Smith, KY TI Overcoming Challenges to Successful Treatment Outcomes in Minority Patients with HIV/AIDS SO HIV/AIDS IN U.S. COMMUNITIES OF COLOR LA English DT Article; Book Chapter ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED DRUG-USERS; HIV-POSITIVE PATIENTS; HEALTH-CARE; UNITED-STATES; PROTEASE INHIBITORS; PHYSICIAN RELATIONSHIP; ADHERENCE; DISPARITIES C1 [Stone, Valerie E.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Div Infect Dis, Boston, MA 02114 USA. [Stone, Valerie E.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Div Gen Med, Boston, MA 02114 USA. RP Stone, VE (reprint author), Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Div Infect Dis, Boston, MA 02114 USA. EM vstone@partners.org NR 71 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-98151-2 PY 2009 BP 53 EP 67 DI 10.1007/978-0-387-98152-9_4 D2 10.1007/978-0-387-98152-9 PG 15 WC Ethnic Studies; Public, Environmental & Occupational Health; Infectious Diseases SC Ethnic Studies; Public, Environmental & Occupational Health; Infectious Diseases GA BKW34 UT WOS:000269460200004 ER PT B AU Ojikutu, BO Stone, VE Bardeguez, A AF Ojikutu, Bisola O. Stone, Valerie E. Bardeguez, Arlene BE Stone, V Ojikutu, B Rawlings, MK Smith, KY TI Women of Color and HIV/AIDS Epidemiology, Clinical Aspects, and Management SO HIV/AIDS IN U.S. COMMUNITIES OF COLOR LA English DT Article; Book Chapter ID HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; TRICHOMONAS-VAGINALIS INFECTION; GENITAL-TRACT INFECTIONS; SQUAMOUS INTRAEPITHELIAL LESIONS; PNEUMOCYSTIS-CARINII-PNEUMONIA; SEXUALLY-TRANSMITTED-DISEASES; CERVICAL-CANCER INCIDENCE; AFRICAN-AMERICAN WOMEN C1 [Ojikutu, Bisola O.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div AIDS,Off Int Programs, Boston, MA 02114 USA. [Stone, Valerie E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA. [Stone, Valerie E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Internal Med, Boston, MA 02114 USA. [Bardeguez, Arlene] Univ Med & Dent New Jersey, Newark, NJ 07103 USA. RP Ojikutu, BO (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div AIDS,Off Int Programs, Boston, MA 02114 USA. EM bojikutu@partners.org NR 123 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-98151-2 PY 2009 BP 83 EP 101 DI 10.1007/978-0-387-98152-9_6 D2 10.1007/978-0-387-98152-9 PG 19 WC Ethnic Studies; Public, Environmental & Occupational Health; Infectious Diseases SC Ethnic Studies; Public, Environmental & Occupational Health; Infectious Diseases GA BKW34 UT WOS:000269460200006 ER PT B AU Ojikutu, B Harris, J AF Ojikutu, Bisola Harris, Jamal BE Stone, V Ojikutu, B Rawlings, MK Smith, KY TI Moving Toward a Unified Global HIV/AIDS Agenda: Communities of Color in Crisis SO HIV/AIDS IN U.S. COMMUNITIES OF COLOR LA English DT Article; Book Chapter ID SUB-SAHARAN AFRICA; ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTION; MALE CIRCUMCISION; HIV-1-INFECTED PATIENTS; BEHAVIOR-CHANGE; SOUTH-AFRICA; WOMENS RISK; FOLLOW-UP; UGANDA C1 [Ojikutu, Bisola] Harvard Univ, Sch Med, Div AIDS, Off Int Programs,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Harris, Jamal] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA. RP Ojikutu, B (reprint author), Harvard Univ, Sch Med, Div AIDS, Off Int Programs,Massachusetts Gen Hosp, Boston, MA 02115 USA. EM bojikutu@partners.org; bojikutu@partners.org NR 80 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-98151-2 PY 2009 BP 283 EP 299 DI 10.1007/978-0-387-98152-9_15 D2 10.1007/978-0-387-98152-9 PG 17 WC Ethnic Studies; Public, Environmental & Occupational Health; Infectious Diseases SC Ethnic Studies; Public, Environmental & Occupational Health; Infectious Diseases GA BKW34 UT WOS:000269460200015 ER PT J AU Ciaranello, AL Walensky, RR Sax, PE Chang, YC Freedberg, KA Weissman, JS AF Ciaranello, Andrea L. Walensky, Rochelle R. Sax, Paul E. Chang, Yuchiao Freedberg, Kenneth A. Weissman, Joel S. TI Access to Medications and Medical Care After Participation in HIV Clinical Trials: A Systematic Review of Trial Protocols and Informed Consent Documents SO HIV CLINICAL TRIALS LA English DT Article DE clinical trials; HIV; posttrial services; trial protocols ID ANTIRETROVIRAL TREATMENT; POSTTRIAL ACCESS; INTERRUPTION; PROVISION; HIV/AIDS AB Background: Expectations regarding receipt of medications and medical care after clinical trials conclude may inform decisions about trial participation. We describe the frequency with which these posttrial services are described in the protocols and informed consent forms (ICFs) of antiretroviral drug (ARV) trials. Method: We systematically reviewed protocols and ICFs from Phase 3 and 4 antiretroviral trials in adults (>= 2 years) from 1987 to 2006. Pharmaceutical industry-sponsored trials were selected from US Food and Drug Administration (FDA) documentation and Clinicaltrials.gov. Trials administered by the AIDS Clinical Trials Group (ACTG) were selected from the ACTG online registry. ACTG- and industry-provided protocols and ICFs were reviewed in full. The primary outcome was any mention of posttrial services, defined as any text regarding posttrial medications or medical care. Results: Complete trial documents were available for 31 (48%) of 65 trials meeting inclusion criteria. Documents from 14 trials (45%) mentioned any posttrial service: 12 (39%) mentioned medications, and 5 (16%) mentioned medical care. Payment for trial participation (74%) and for care for trial-related injury (94%) were mentioned more often than were posttrial services. Conclusions: Posttrial medications or medical care was mentioned in the trial documents of <50% of reviewed antiretroviral trials. Improved efforts are needed to clearly describe posttrial services in clinical trial protocols and ICFs. C1 [Ciaranello, Andrea L.; Walensky, Rochelle R.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Walensky, Rochelle R.; Chang, Yuchiao; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Walensky, Rochelle R.; Sax, Paul E.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Walensky, Rochelle R.; Freedberg, Kenneth A.] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA. [Weissman, Joel S.] Univ Massachusetts, Sch Med, Dept Family & Community Med, Worcester, MA USA. RP Ciaranello, AL (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM aciaranello@partners.org FU National Institute of Allergy and Infectious Disease [T32 AI07433, R01 AI058736, R37 AI42006, P30 AI 60354]; Doris Duke Charitable Foundation; Adult AIDS Clinical Trials Group [U01 AI068636]; National Institute of Nursing Research [R01 NR009289-01] FX Funding for this work was provided by the National Institute of Allergy and Infectious Disease (T32 AI07433 [ALC], R01 AI058736 [KAF, RPW, ALCI, R37 AI42006 [KAF, RPW, ALC], and P30 AI 60354 [YC]; the Doris Duke Charitable Foundation (Clinical Scientist Development Award [RPWI); the Adult AIDS Clinical Trials Group (U01 AI068636 [ALC]); and the National Institute of Nursing Research (R01 NR009289-01 [JSW]). NR 29 TC 6 Z9 6 U1 0 U2 1 PU THOMAS LAND PUBLISHERS, INC PI ST LOUIS PA 255 JEFFERSON RD, ST LOUIS, MO 63119 USA SN 1528-4336 J9 HIV CLIN TRIALS JI HIV Clin. Trials PD JAN-FEB PY 2009 VL 10 IS 1 BP 13 EP 24 DI 10.1310/hct1001-13 PG 12 WC Infectious Diseases; Pharmacology & Pharmacy SC Infectious Diseases; Pharmacology & Pharmacy GA 436ZX UT WOS:000265456400002 PM 19362992 ER PT J AU Mimiaga, MJ Reisner, SL Reilly, L Soroudi, N Safren, SA AF Mimiaga, Matthew J. Reisner, Sari L. Reilly, Laura Soroudi, Nafisseh Safren, Steven A. BE Mayer, KH Pizer, HF TI Individual interventions SO HIV PREVENTION: A COMPREHENSIVE APPROACH LA English DT Article; Book Chapter ID SEXUAL RISK BEHAVIOR; HIV PREVENTION INTERVENTIONS; BASE-LINE DATA; UNITED-STATES; ANTIRETROVIRAL THERAPY; REDUCTION INTERVENTION; TRANSTHEORETICAL MODEL; CONTROLLED-TRIAL; PUERTO-RICO; DRUG-USERS C1 [Mimiaga, Matthew J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Safren, Steven A.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Safren, Steven A.] Massachusetts Gen Hosp, Behav Med Serv, Boston, MA 02114 USA. RP Mimiaga, MJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. NR 82 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-092129-7 PY 2009 BP 203 EP 239 DI 10.1016/B978-0-12-374235-3.00008-X PG 37 WC Public, Environmental & Occupational Health; Immunology; Infectious Diseases SC Public, Environmental & Occupational Health; Immunology; Infectious Diseases GA BEK32 UT WOS:000317059400010 ER PT J AU Chagin, AS Hirai, T Weinstein, LS Chen, M Kronenberg, HM AF Chagin, Andrei S. Hirai, Takao Weinstein, Lee S. Chen, Min Kronenberg, Henry M. TI Postnatal deletion of the G-protein subunit alpha (G(s)alpha) in epiphyseal chondrocytes inhibits longitudinal bone growth SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Chagin, Andrei S.; Hirai, Takao; Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Chagin, Andrei S.; Hirai, Takao; Kronenberg, Henry M.] Harvard Univ, Sch Med, Boston, MA USA. [Weinstein, Lee S.; Chen, Min] NIDDKD, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2009 VL 72 SU 3 BP 27 EP 27 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 502WB UT WOS:000270489900090 ER PT J AU Avbelj, M Romero, C Tziaferi, V McCabe, M Zhang, CK Sidis, Y Plummer, L Elting, M Martin, C Zou, QY Mohammadi, M Dattani, M Radovick, S Pitteloud, N AF Avbelj, Magdalena Romero, Christopher Tziaferi, Vaitsa McCabe, Mark Zhang, Chengkang Sidis, Yisrael Plummer, Lacey Elting, Mariet Martin, Cecilia Zou, Qun-Yong Mohammadi, Moosa Dattani, Mehul Radovick, Sally Pitteloud, Nelly TI New loci for congenital hypopituitarism: overlap with Kallmann syndrome SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Avbelj, Magdalena; Sidis, Yisrael; Plummer, Lacey; Martin, Cecilia; Pitteloud, Nelly] Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA. [Avbelj, Magdalena; Sidis, Yisrael; Plummer, Lacey; Martin, Cecilia; Pitteloud, Nelly] Massachusetts Gen Hosp, Dept Med, Reprod Endocrine Unit, Boston, MA 02114 USA. [Avbelj, Magdalena] Univ Childrens Hosp, Univ Med Ctr Ljubljana, Dept Diabet Endocrinol & Metab, Ljubljana, Slovenia. [Romero, Christopher; Radovick, Sally] Johns Hopkins Univ, Sch Med, Div Pediat Endocrinol, Baltimore, MD USA. [Tziaferi, Vaitsa; McCabe, Mark; Dattani, Mehul] UCL, Clin & Mol Genet Unit, Dev Endocrinol Res Grp, Inst Child Hlth, London, England. [Zhang, Chengkang; Zou, Qun-Yong] Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA. [Elting, Mariet] Emma Childrens Hosp, AMC Amsterdam, Dept Pediat, Amsterdam, Netherlands. [Mohammadi, Moosa] NYU, Sch Med, Dept Pharmacol, New York, NY USA. RI PITTELOUD, Nelly/K-2709-2014 NR 0 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2009 VL 72 BP 30 EP 31 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 502WB UT WOS:000270489900100 ER PT J AU Misra, M Russell, M Mendes, N Klibanski, A AF Misra, Madhusmita Russell, Melissa Mendes, Nara Klibanski, Anne TI Subcutaneous and visceral fat are determinants of bone density measures in obese adolescent girls SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Misra, Madhusmita; Russell, Melissa; Mendes, Nara; Klibanski, Anne] Massachusetts Gen Hosp, NeuroEndocrine Unit, Boston, MA 02114 USA. [Misra, Madhusmita; Russell, Melissa] Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA 02114 USA. RI Mendes Estella, Nara/E-4682-2013 NR 0 TC 0 Z9 0 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2009 VL 72 BP 55 EP 55 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 502WB UT WOS:000270489900169 ER PT J AU Lodish, MB Adams, KT Huynh, TT Prodanov, T Ling, A Shusterman, S Basu, E Jimenez, C Stratakis, CA Pacak, K AF Lodish, Maya B. Adams, Karen T. Huynh, Thanh T. Prodanov, Tamara Ling, Alex Shusterman, Suzanne Basu, Ellen Jimenez, Camilo Stratakis, Constantine A. Pacak, Karel TI Succinate dehydrogenase mutations are strongly associated with paraganglioma of the organ of Zuckerkandl in pediatric and adult patients SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Lodish, Maya B.; Stratakis, Constantine A.] NICHD, SEGEN, NIH, Bethesda, MD USA. [Adams, Karen T.; Huynh, Thanh T.; Prodanov, Tamara; Pacak, Karel] NICHD, DIR, RBMB, NIH, Bethesda, MD USA. [Ling, Alex] NIH, CC, DRD, Bethesda, MD 20892 USA. [Shusterman, Suzanne; Basu, Ellen] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Jimenez, Camilo] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2009 VL 72 BP 96 EP 96 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 502WB UT WOS:000270489900283 ER PT J AU Balhara, B Misra, M Levitsky, LL AF Balhara, Bharti Misra, Madhusmita Levitsky, Lynne L. TI Are current guidelines for monitoring infants with congenital hypothyroidism appropriate? SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Balhara, Bharti; Misra, Madhusmita; Levitsky, Lynne L.] MassGen Hosp Children, Pediat Endocrine Unit, Boston, MA USA. [Balhara, Bharti; Misra, Madhusmita; Levitsky, Lynne L.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2009 VL 72 BP 165 EP 165 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 502WB UT WOS:000270489900484 ER PT J AU Mamkin, I Purushothaman, R Martin, C Cole, L Jacobson-Dickman, E Ten, S Crowley, WF Pitteloud, N AF Mamkin, Irene Purushothaman, Radhika Martin, Cecilia Cole, Lindsay Jacobson-Dickman, Elka Ten, Svetlan Crowley, William F. Pitteloud, Nelly TI Phenotypic variability in patients carrying PROKR2 mutations SO HORMONE RESEARCH LA English DT Meeting Abstract C1 [Mamkin, Irene; Purushothaman, Radhika; Jacobson-Dickman, Elka; Ten, Svetlan] Infants & Childrens Hosp Brooklyn, Brooklyn, NY USA. [Mamkin, Irene; Purushothaman, Radhika; Jacobson-Dickman, Elka; Ten, Svetlan] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Martin, Cecilia; Cole, Lindsay; Crowley, William F.; Pitteloud, Nelly] Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA. [Martin, Cecilia; Cole, Lindsay; Crowley, William F.; Pitteloud, Nelly] Harvard Univ, Sch Med, Boston, MA USA. RI PITTELOUD, Nelly/K-2709-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2009 VL 72 BP 267 EP 268 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 502WB UT WOS:000270489900790 ER PT J AU Biller, BMK Ghigo, E AF Biller, Beverly M. K. Ghigo, Ezio TI KIMS/ACROSTUDY Highlights Introduction SO HORMONE RESEARCH LA English DT Editorial Material C1 [Biller, Beverly M. K.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Biller, Beverly M. K.] Massachusetts Gen Hosp, Neuroendocrine Clin Ctr, Boston, MA 02114 USA. [Ghigo, Ezio] Univ Turin, Dept Internal Med, Turin, Italy. RP Biller, BMK (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2009 VL 71 BP 28 EP 29 DI 10.1159/000178033 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 395UI UT WOS:000262548600007 ER PT J AU Chagin, AS Vannesjo, J Savendahl, L AF Chagin, Andrei S. Vannesjo, Johanna Savendahl, Lars TI Androgen Receptor Modulation Does Not Affect Longitudinal Growth of Cultured Fetal Rat Metatarsal Bones SO HORMONE RESEARCH LA English DT Article DE Testosterone; Oxandrolone; Growth plate cartilage and chondrocytes ID CONSTITUTIONAL DELAY; SEX STEROIDS; EPIPHYSEAL CHONDROCYTES; CARTILAGE CELLS; FACTOR-I; TESTOSTERONE; PLATE; DIHYDROTESTOSTERONE; OXANDROLONE; HORMONE AB Background: Systemic administration of the nonaromatizable androgen oxandrolone stimulates growth in girls with Turner syndrome and boys with a constitutional delay of growth and puberty. It is unknown if oxandrolone acts locally at the growth plate level to stimulate longitudinal bone growth. Methods: Metatarsal bones from female and male rat fetuses (day E20) were cultured for 14 days in the presence of oxandrolone, testosterone or the androgen receptor (AR) antagonist flutamide with/without insulin-like growth-factor-I (IGF-I) or charcoal-treated serum. Results: The AR was found to be expressed in both male and female fetal rat metatarsal bones. Neither oxandrolone nor testosterone had any effect on metatarsal bone growth when tested at a wide concentration range (1 nM to 10 mu M), not even in the presence of IGF-I (100 ng/ml) or charcoal-treated serum (10%). Bone growth was also unaffected when the AR was blocked by flutamide. Control experiments confirmed that metatarsal bone growth was significantly stimulated by IGF-I (p < 0.001). Conclusion: Modulation of AR activity in the fetal rat growth plate does not affect linear bone growth. Extrapolating from these in vitro data, it could be speculated that oxandrolone stimulates longitudinal bone growth in treated children by acting indirectly rather than directly through AR activation in growth plate chondrocytes. Copyright (C) 2009 S. Karger AG, Basel C1 [Chagin, Andrei S.; Vannesjo, Johanna; Savendahl, Lars] Karolinska Inst, Dept Woman & Child Hlth, Pediat Endocrinol Unit, Stockholm, Sweden. RP Chagin, AS (reprint author), Massachusetts Gen Hosp, Their 1101,Blossom St 50, Boston, MA 02114 USA. EM achagin@partners.org RI Chagin, Andrei/F-4080-2014; OI Chagin, Andrei/0000-0002-2696-5850; Vannesjo, Signe Johanna/0000-0003-2432-4192 FU Swedish Research Council [K2007-54X-15073-04-3]; Sallskapet Barnavard; Stiftelsen Frimurare Barnhuset i Stockholm; HKH Kronprinsessan Lovisas forening for Barnasjukvard; Wera Ekstroms Stiftelse; Pfizer AB FX This study was supported by the Swedish Research Council (K2007-54X-15073-04-3), Sallskapet Barnavard, Stiftelsen Frimurare Barnhuset i Stockholm, HKH Kronprinsessan Lovisas forening for Barnasjukvard, Wera Ekstroms Stiftelse and an unrestricted grant from Pfizer AB. NR 34 TC 5 Z9 6 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 J9 HORM RES JI Horm. Res. PY 2009 VL 71 IS 4 BP 219 EP 227 DI 10.1159/000201111 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 415DL UT WOS:000263914400006 PM 19258714 ER PT J AU Aalbers, AM Chin, D Pratt, KL Little, BM Frank, SJ Hwa, V Rosenfeld, RG AF Aalbers, Anna M. Chin, Daisy Pratt, Katherine L. Little, Brian M. Frank, Stuart J. Hwa, Vivian Rosenfeld, Ron G. TI Extreme Elevation of Serum Growth Hormone-Binding Protein Concentrations Resulting from a Novel Heterozygous Splice Site Mutation of the Growth Hormone Receptor Gene SO HORMONE RESEARCH LA English DT Article DE Growth hormone-binding protein; Growth hormone receptor defect; Short stature ID ACID-LABILE SUBUNIT; FAMILIAL SHORT STATURE; INTRACELLULAR DOMAIN; FACTOR DEFICIENCY; GH INSENSITIVITY; LARON-SYNDROME; I RECEPTOR; INTRAUTERINE; RETARDATION; FAILURE AB Background/Aims: Circulating growth hormone-binding protein (GHBP), in humans, is the proteolytic product of the growth hormone receptor (GHR). We investigated a prepubertal male subject who was of short stature, but who had a markedly elevated serum level of GHBP. Methods: Serum and DNA from the patient and his mother were analyzed. Results: Both the patient and mother had serum GHBP concentrations over 100-fold higher than normal, by assays, and Western and ligand blot analysis. Sequencing of the GHR gene revealed a novel heterozygous C>A transversion at position 785-3 in the acceptor splice site of intron 7. Conclusion: In silico analysis of the altered sequence suggested that 785-3(C>A) is a splicing mutation, with either retention of intron 7 or the skipping of exon 8. The consequence is a truncated GHR lacking the transmembrane domain (encoded by exon 8) and the cytoplasmic domain. We hypothesize that this GHR variant cannot anchor to the cell membrane, and the continual secretion into the circulation explains the elevated levels of serum GHBP detected in the patient and his mother. Despite this mutation, the presence of the wildtype GHR allele, presumably, permits some normality in GH-induced action. Copyright (C) 2009 S. Karger AG, Basel C1 [Aalbers, Anna M.; Pratt, Katherine L.; Little, Brian M.; Hwa, Vivian; Rosenfeld, Ron G.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA. [Aalbers, Anna M.] Leiden Univ, Med Ctr, Dept Pediat, Leiden, Netherlands. [Chin, Daisy] Atlantic Hlth Syst, Dept Pediat, Morristown, NJ USA. [Frank, Stuart J.] Univ Alabama Birmingham, Dept Med Cell Biol & Physiol, Birmingham, AL USA. [Frank, Stuart J.] Birmingham VAMC, Med Serv, Birmingham, AL USA. [Rosenfeld, Ron G.] Lucile Packard Fdn Childrens Hlth, Palo Alto, CA USA. [Rosenfeld, Ron G.] Stanford Univ, Stanford, CA 94305 USA. RP Hwa, V (reprint author), Oregon Hlth & Sci Univ, Dept Pediat, NRC5,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM hwav@ohsu.edu FU Tercica, Inc; National Institutes of Health [RO1 DK58259] FX We thank the family of the patient for participating in this study. This study was supported by Tercica, Inc. (R.G.R.), and by a grant from the National Institutes of Health, RO1 DK58259 (S.J.F.). R. G. R. is a consultant for Tercica, Inc. NR 30 TC 12 Z9 13 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-0163 EI 1663-2826 J9 HORM RES JI Horm. Res. PY 2009 VL 71 IS 5 BP 276 EP 284 DI 10.1159/000208801 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 428SF UT WOS:000264869200005 PM 19339792 ER PT J AU Rubin, RT Carroll, BJ AF Rubin, R. T. Carroll, B. J. BE Pfaff, DW Arnold, AP Etgen, AM Fahrbach, SE Rubin, RT TI The Neuroendocrinology of Mood Disorders SO HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION LA English DT Article; Book Chapter ID CORTICOTROPIN-RELEASING HORMONE; PITUITARY-ADRENAL AXIS; MAJOR DEPRESSIVE DISORDER; DEXAMETHASONE-SUPPRESSION TEST; PRIMARY ENDOGENOUS-DEPRESSION; MATCHED CONTROL SUBJECTS; LOW-DOSE PHYSOSTIGMINE; TREATMENT-RESISTANT DEPRESSION; 5-HT1A RECEPTOR RESPONSIVITY; GROWTH-HORMONE C1 [Rubin, R. T.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Carroll, B. J.] Pacific Behav Res Fdn, Carmel, CA USA. RP Rubin, RT (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 203 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-088783-8 PY 2009 BP 2899 EP 2926 PG 28 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA BCV83 UT WOS:000311627104007 ER PT J AU Lupien, SJ Lord, C Sindi, S Wilkinson, CW Fiocco, AJ AF Lupien, S. J. Lord, C. Sindi, S. Wilkinson, C. W. Fiocco, A. J. BE Pfaff, DW Arnold, AP Etgen, AM Fahrbach, SE Rubin, RT TI Aging and Alzheimer's Disease SO HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION LA English DT Article; Book Chapter ID MILD COGNITIVE IMPAIRMENT; CATECHOL-O-METHYLTRANSFERASE; ESTROGEN-RECEPTOR-ALPHA; APOLIPOPROTEIN-E GENOTYPE; AMYLOID-BETA PEPTIDE; AGE-RELATED-CHANGES; PITUITARY-ADRENOCORTICAL AXIS; RANDOMIZED CONTROLLED-TRIAL; INSULIN-DEGRADING ENZYME; HEALTHY POSTMENOPAUSAL WOMEN C1 [Lupien, S. J.] Univ Montreal, Montreal, PQ, Canada. [Lord, C.] McMaster Univ, Womens Hlth Concerns Clin, Hamilton, ON, Canada. [Sindi, S.] McGill Univ, Montreal, PQ, Canada. [Wilkinson, C. W.] Univ Washington, Seattle, WA 98195 USA. [Wilkinson, C. W.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Fiocco, A. J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Lupien, SJ (reprint author), Univ Montreal, Montreal, PQ, Canada. NR 371 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-088783-8 PY 2009 BP 3049 EP 3080 PG 32 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA BCV83 UT WOS:000311627104012 ER PT J AU Miyasaki, Y Goetz, MB Newton, TF AF Miyasaki, Y. Goetz, M. B. Newton, T. F. BE Pfaff, DW Arnold, AP Etgen, AM Fahrbach, SE Rubin, RT TI Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome SO HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION LA English DT Article; Book Chapter ID HIV-INFECTED PATIENTS; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE-DEFICIENCY-SYNDROME; QUALITY-OF-LIFE; RECONSTITUTION INFLAMMATORY SYNDROME; CHRONIC HEPATITIS-C; REVERSE-TRANSCRIPTASE INHIBITORS; PNEUMOCYSTIS-CARINII INFECTION; INTERFERON-INDUCED DEPRESSION; GROWTH-HORMONE-SECRETION C1 [Miyasaki, Y.; Goetz, M. B.; Newton, T. F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Miyasaki, Y (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 203 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-088783-8 PY 2009 BP 3267 EP 3285 PG 19 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA BCV83 UT WOS:000311627104018 ER PT J AU Yehuda, R Sarapas, C AF Yehuda, R. Sarapas, C. BE Pfaff, DW Arnold, AP Etgen, AM Fahrbach, SE Rubin, RT TI Neuroendocrine Aspects of Post-Traumatic Stress Disorder SO HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION LA English DT Article; Book Chapter ID DEXAMETHASONE-SUPPRESSION TEST; PITUITARY-ADRENAL AXIS; CORTICOTROPIN-RELEASING-FACTOR; URINARY CORTISOL EXCRETION; CHILDHOOD SEXUAL-ABUSE; BORDERLINE PERSONALITY-DISORDER; GLUCOCORTICOID-RECEPTOR NUMBER; HORMONE STIMULATION TEST; MOTOR-VEHICLE ACCIDENT; HOLOCAUST SURVIVORS C1 [Yehuda, R.; Sarapas, C.] James J Peters VA Med Ctr, Bronx, NY USA. RP Yehuda, R (reprint author), James J Peters VA Med Ctr, Bronx, NY USA. NR 103 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-088783-8 PY 2009 BP 3303 EP 3318 PG 16 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA BCV83 UT WOS:000311627104020 ER PT J AU Kong, J Kaptchuk, TJ Webb, JM Kong, JT Sasaki, Y Polich, GR Vangel, MG Kwong, K Rosen, B Gollub, RL AF Kong, Jian Kaptchuk, Ted J. Webb, Julia Megan Kong, Jiang-Ti Sasaki, Yuka Polich, Ginger R. Vangel, Mark G. Kwong, Kenneth Rosen, Bruce Gollub, Randy L. TI Functional Neuroanatomical Investigation of Vision-Related Acupuncture Point Specificity-A Multisession fMRI Study SO HUMAN BRAIN MAPPING LA English DT Article DE acupuncture; electroacupuncture; vision-related acupoint; acupoint specificity; fMRI; brain imaging ID IMPLICATED ACUPOINTS; HUMAN BRAIN; ELECTROACUPUNCTURE STIMULATION; CORTICAL ACTIVATIONS; SHAM ACUPUNCTURE; CORTEX; REAL; MRI; VARIABILITY; HUMANS AB The concept that specific acupuncture points have salubrious effects on distant target organ systems is a salient feature of Traditional Chinese Medicine (TCM). In this study, we used a multiple-session experiment to test whether electroacupuncture stimulation at two TCM vision-related acupoints, UB 60 and GB 37, located on the leg, could produce fMRI signal changes in the occipital regions of the brain, and the specificity of this effect when compared with stimulation at an adjacent non-acupoint (NAP). Six normal, acupuncture naive subjects completed the study. Each subject participated in six identical scanning sessions. Voxelwise group analysis showed that electroacupuncture stimulation at both vision-related acupoints and the NAP produced modest, comparable fMRI signal decreases in the occipital cortex, including the bilateral cuneus, calcarine fissure and surrounding areas, lingual gyrus, and lateral occipital gyrus. Further analysis of fMRI signal changes in occipital cortex showed no significant difference among the three points, UB 60, GB 37, and NAP. Our results thus do not support the view that acupuncture Stimulation at vision-related acupoints induces specific fMRI blood oxygen level dependent (BOLD) signal changes in the occipital cortex. We speculate that cross modal inhibition, produced by needling-evoked somatosensory stimulation, may account for our finding of BOLD signal decreases in the occipital cortex. Given the complexity of acupuncture systems and brain activity, additional work is required to determine whether functional neuroanatomical correlates of acupoint specificity can be validated by means of brain imaging tools. Hum Brain Mapp 30:38-46, 2009. (c) 2007 Wiley-Liss, Inc. C1 [Kong, Jian; Webb, Julia Megan; Polich, Ginger R.; Gollub, Randy L.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Kaptchuk, Ted J.] Harvard Univ, Sch Med, Osher Inst, Boston, MA USA. [Kong, Jiang-Ti] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Sasaki, Yuka; Vangel, Mark G.; Rosen, Bruce; Gollub, Randy L.] MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA. [Sasaki, Yuka] ERATO Shimojo Implicit Brain Funct Project, Pasadena, CA USA. [Vangel, Mark G.; Kwong, Kenneth; Gollub, Randy L.] MGH MIT GCRC Biomed Imaging Core, Charlestown, MA USA. RP Kong, J (reprint author), 149 13th St,Room 2661, Charlestown, MA 02129 USA. EM kongj@nmr.mgh.harvard.edu OI Gollub, Randy L./0000-0002-9434-4044 FU NIH (NCCAM) [R21AT00949, P01-AT002048, KOIAT003883, K24AT004095]; NIH (NCRR) [P4LRR74075, M01-RR-01066]; MIND Institute FX Contract grant sponsor: NIH (NCCAM); Contract grant numbers: R21AT00949, P01-AT002048, KOIAT003883, K24AT004095; Contract grant sponsor: NIH (NCRR); Contract grant number: P4LRR74075, M01-RR-01066; Contract grant sponsor: MIND Institute. NR 39 TC 55 Z9 66 U1 3 U2 8 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1065-9471 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD JAN PY 2009 VL 30 IS 1 BP 38 EP 46 DI 10.1002/hbm.20481 PG 9 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 393TW UT WOS:000262397000004 PM 17990299 ER PT J AU Caplan, D AF Caplan, David TI Experimental Design and Interpretation of Functional Neuroimaging Studies of Cognitive Processes SO HUMAN BRAIN MAPPING LA English DT Review DE functional neuroimaging inferences; experimental design; validity and soundness ID COMPUTATIONAL ACCOUNT; WORKING-MEMORY; HUMAN BRAIN; TOLD US; ACTIVATION; FMRI; SYSTEMS; SPEECH; OBJECT; CORTEX AB This article discusses how the relation between experimental and baseline conditions in functional neuroimaging studies affects the conclusions that can be drawn from a study about the neural correlates of components of the cognitive system and about the nature and organization of those components. I argue that certain designs in common use-in particular the contrast of qualitatively different representations that are processed at parallel stages of a functional architecture-can never identify the neural basis of a cognitive operation and have limited use in providing information about the nature of cognitive systems. Other types of designs-such as ones that contrast representations that are computed in immediately sequential processing steps and ones that contrast qualitatively similar representations that are parametrically related within a single processing stage-are more easily interpreted. Hurry Brain Mapp 30:59-77, 2009. (c) 2007 Wiley-Liss, Inc. C1 Massachusetts Gen Hosp, Dept Neurol, Neuropsychol Lab, Boston, MA 02114 USA. RP Caplan, D (reprint author), Massachusetts Gen Hosp, Dept Neurol, Neuropsychol Lab, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM dcaplan@partners.org FU NIDCD [DC02146] FX Contract grant sponsor: NIDCD; Contract grant number: DC02146. NR 76 TC 10 Z9 11 U1 6 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD JAN PY 2009 VL 30 IS 1 BP 59 EP 77 DI 10.1002/hbm.20489 PG 19 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 393TW UT WOS:000262397000006 PM 17979122 ER PT J AU Pankratz, N Wilk, JB Latourelle, JC DeStefano, AL Halter, C Pugh, EW Doheny, KF Gusella, JF Nichols, WC Foroud, T Myers, RH AF Pankratz, Nathan Wilk, Jemma B. Latourelle, Jeanne C. DeStefano, Anita L. Halter, Cheryl Pugh, Elizabeth W. Doheny, Kimberly F. Gusella, James F. Nichols, William C. Foroud, Tatiana Myers, Richard H. CA PSG PROGENI Investigators GenePD Investigators TI Genomewide association study for susceptibility genes contributing to familial Parkinson disease SO HUMAN GENETICS LA English DT Article ID ALPHA-SYNUCLEIN; LEWY BODY; TAU-GENE; MUTATION; SAMPLE; HAPLOTYPE; HETEROZYGOSITY; DUPLICATION; VARIABILITY; LINKAGE AB Five genes have been identified that contribute to Mendelian forms of Parkinson disease (PD); however, mutations have been found in fewer than 5% of patients, suggesting that additional genes contribute to disease risk. Unlike previous studies that focused primarily on sporadic PD, we have performed the first genomewide association study (GWAS) in familial PD. Genotyping was performed with the Illumina HumanCNV370Duo array in 857 familial PD cases and 867 controls. A logistic model was employed to test for association under additive and recessive modes of inheritance after adjusting for gender and age. No result met genomewide significance based on a conservative Bonferroni correction. The strongest association result was with SNPs in the GAK/DGKQ region on chromosome 4 (additive model: p = 3.4 x 10(-6); OR = 1.69). Consistent evidence of association was also observed to the chromosomal regions containing SNCA (additive model: p = 5.5 x 10(-5); OR = 1.35) and MAPT (recessive model: p = 2.0 x 10(-5); OR = 0.56). Both of these genes have been implicated previously in PD susceptibility; however, neither was identified in previous GWAS studies of PD. Meta-analysis was performed using data from a previous case-control GWAS, and yielded improved p values for several regions, including GAK/DGKQ (additive model: p = 2.5 x 10(-7)) and the MAPT region (recessive model: p = 9.8 x 10(-6); additive model: p = 4.8 x 10(-5)). These data suggest the identification of new susceptibility alleles for PD in the GAK/DGKQ region, and also provide further support for the role of SNCA and MAPT in PD susceptibility. C1 [Pankratz, Nathan; Halter, Cheryl; Foroud, Tatiana] Indiana Univ, Sch Med, Indianapolis, IN 46202 USA. [Wilk, Jemma B.; Latourelle, Jeanne C.; DeStefano, Anita L.; Myers, Richard H.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [DeStefano, Anita L.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA. [Pugh, Elizabeth W.; Doheny, Kimberly F.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA. [Gusella, James F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gusella, James F.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Nichols, William C.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA. RP Foroud, T (reprint author), Indiana Univ, Sch Med, Hlth Information & Translat Sci Bldg,HS 4000,410, Indianapolis, IN 46202 USA. EM npankrat@iupui.edu; tforoud@iupui.edu; rmyers@bu.edu RI Pramstaller, Peter/C-2357-2008; OI Latourelle, Jeanne/0000-0002-4218-9572; Myers, Richard/0000-0002-8365-2674 FU Robert P. & Judith N. Goldberg Foundation; Bumpus Foundation; Harvard NeuroDiscovery Center; Telethon [GTB07001]; National Institutes of Health [HHSN268200782096C]; [R01 NS37167]; [R01 NS036711] FX This project was supported by R01 NS37167, R01 NS036711, the Robert P. & Judith N. Goldberg Foundation, the Bumpus Foundation and the Harvard NeuroDiscovery Center. This study used samples from the NINDS Human Genetics Resource Center DNA and Cell Line Repository (http://ccr.coriell.org/ninds), as well as clinical data. DNA samples contributed by the Parkinson Institute-Istituti Clinici di Perfezionamento, Milan, Italy were from the "Human genetic bank of patients affected by PD and parkinsonisms", supported by Italian Telethon grant n. GTB07001 and by the "Fondazione Grigioni per il Morbo di Parkinson". Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. We particularly thank Justin Paschall from the NCBI dbGaP staff for his assistance in developing the dataset available at dbGaP. The data generated from this case-control study are available at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap through dbGaP accession number: phs000126.v1.p1. Data from the Fung et al. study were obtained from dbGaP. Funding support for "NINDS-Genome-Wide Genotyping in Parkinson's Disease: First Stage Analysis and Public Release of Data" was provided by intramural programs of the National Institute on Aging and the National Institute on Neurological Disorders and Stroke (NINDS) and the genotyping of samples was provided by NINDS. The dataset used for the meta-analyses described in this manuscript were obtained from the NINDS Database found at http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap through dbGaP accession number phs000089.v1.p1. The following are members of the PROGENI Steering Committee. University of Tennessee Health Science Center: R. F. Pfeiffer; University of Rochester: F. Marshall, D. Oakes, A. Rudolph, A. Shinaman; Columbia University Medical Center: K. Marder; Indiana University School of Medicine: P. M. Conneally, T. Foroud, C. Halter; University of Kansas Medical Center: K. Lyons; Eli Lilly & Company: E. Siemers; Medical College of Ohio: L. Elmers; University of California, Irvine: N. Hermanowicz. The following are members of the GenePD Steering Committee. University of Virginia Health System: G. F. Wooten; UMDNJ-Robert Wood Johnson Medical School: L. Golbe; Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School: J. F. Gusella; Boston University School of Medicine: R. H. Myers. We thank the subjects for their participation in this research study. NR 38 TC 238 Z9 240 U1 1 U2 18 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-6717 J9 HUM GENET JI Hum. Genet. PD JAN PY 2009 VL 124 IS 6 BP 593 EP 605 DI 10.1007/s00439-008-0582-9 PG 13 WC Genetics & Heredity SC Genetics & Heredity GA 387KV UT WOS:000261952000003 PM 18985386 ER PT J AU Adegbola, AA Gonzales, ML Chess, A LaSalle, JM Cox, GF AF Adegbola, Abidemi A. Gonzales, Michael L. Chess, Andrew LaSalle, Janine M. Cox, Gerald F. TI A novel hypomorphic MECP2 point mutation is associated with a neuropsychiatric phenotype SO HUMAN GENETICS LA English DT Article ID LINKED MENTAL-RETARDATION; X-CHROMOSOME INACTIVATION; RETT-SYNDROME MUTATIONS; CPG BINDING DOMAIN; CLINICAL SEVERITY; PROTEIN MECP2; GENE; LOCATION; VARIANTS; DISORDER AB The MECP2 gene on Xq28 encodes a transcriptional repressor, which binds to and modulates expression of active genes. Mutations in MECP2 cause classic or preserved speech variant Rett syndrome and intellectual disability in females and early demise or marked neurodevelopmental handicap in males. The consequences of a hypomorphic Mecp2 allele were recently investigated in a mouse model, which developed obesity, motor, social, learning, and behavioral deficits, predicting a human neurobehavioral syndrome. Here, we describe mutation analysis of a nondysmorphic female proband and her father who presented with primarily neuropsychiatric manifestations and obesity with relative sparing of intelligence, language, growth, and gross motor skills. We identified and characterized a novel missense mutation (c.454C > G; p.P152A) in the critical methyl-binding domain of MeCP2 that disrupts MeCP2 functional activity. We show that a gradient of impairment is present when the p.P152A mutation is compared with an allelic p.P152R mutation, which causes classic Rett syndrome and another Rett syndrome-causing mutation, such that protein-heterochromatin binding observed by immunofluorescence and immunoblotting is wild-type > P152A > P152R > T158 M, consistent with the severity of the observed phenotype. Our findings provide evidence for very mild phenotypes in humans associated with partial reduction of MeCP2 function arising from subtle variation in MECP2. C1 [Adegbola, Abidemi A.] Harvard Partners Ctr Genet & Gen, Boston, MA 02115 USA. [Adegbola, Abidemi A.; Chess, Andrew] Massachusetts Gen Hosp, Ctr Human Genet Res, Dept Med, Boston, MA 02114 USA. [Adegbola, Abidemi A.; Chess, Andrew; Cox, Gerald F.] Harvard Univ, Sch Med, Boston, MA USA. [Adegbola, Abidemi A.; Cox, Gerald F.] Childrens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA. [Gonzales, Michael L.; LaSalle, Janine M.] Univ Calif Davis, Sch Med, Rowe Program Human Genet, Davis, CA 95616 USA. [Cox, Gerald F.] Genzyme Corp, Dept Clin Res, Cambridge, MA USA. RP Adegbola, AA (reprint author), Harvard Partners Ctr Genet & Gen, 77 Ave Louis Pasteur,NRB 250, Boston, MA 02115 USA. EM abidemi.adegbola@childrens.harvard.edu RI LaSalle, Janine/A-4643-2008 OI LaSalle, Janine/0000-0002-3480-2031 FU NIH (NIGMS) [T32 GM007748]; NIH (NIMH) [T32MH073124]; NIH (NICHD) [R01HD041462, R01HD048799] FX We would like to thank Jennifer Gentile and Susan Waisbren for neuropsychological testing and Yiping Shen for his help with MECP2 controls. Abidemi Adegbola was supported by an NIH (NIGMS) grant (grant number T32 GM007748). Michael Gonzales was supported by an NIH (NIMH) grant (grant number T32MH073124). Janine Lasalle was supported by NIH (NICHD) grants (grants numbers R01HD041462 and R01HD048799). NR 46 TC 15 Z9 15 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-6717 J9 HUM GENET JI Hum. Genet. PD JAN PY 2009 VL 124 IS 6 BP 615 EP 623 DI 10.1007/s00439-008-0585-6 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 387KV UT WOS:000261952000005 PM 18989701 ER PT S AU Colvin, RB AF Colvin, Robert B. BE Remuzzi, G Chiaramonte, S Perico, N Ronco, C TI Pathology of Chronic Humoral Rejection SO HUMORAL IMMUNITY IN KIDNEY TRANSPLANTATION: WHAT CLINICIANS NEED TO KNOW SE CONTRIBUTIONS TO NEPHROLOGY LA English DT Article ID RENAL-ALLOGRAFT REJECTION; ANTIBODY-MEDIATED REJECTION; CAPILLARY C4D DEPOSITION; TRANSPLANT GLOMERULOPATHY; PERITUBULAR CAPILLARIES; KIDNEY ALLOGRAFTS; ALLOANTIBODY; NEPHROPATHY; EXPRESSION; INJURY AB Since its initial description in 2001, chronic humoral rejection (CHR, aka 'chronic antibody-mediated rejection') has been recognized as a distinct and common cause of late graft dysfunction and loss. The pathology is focused on the microvascular components of the kidney, manifested by endothelial 'activation', multilamination of glomerular and peritubular capillary basement membranes, interstitial fibrosis and tubular atrophy, and sometimes chronic transplant arteriopathy. Diagnosis requires a biopsy and demonstration of the complement degradation product, Cod in peritubular and/or glomerular capillaries. For definitive diagnosis, detection of donor-specific anti-endothelial antibodies is required (most commonly to class II MHC antigens). Here we review the diagnostic criteria, pathologic manifestations, new molecular markers and related studies in experimental animals. Copyright (C) 2009 S. Karger AG. Basel C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Colvin, RB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Thier 831, Boston, MA 02114 USA. EM colvin@helix.mgh.harvard.edu NR 44 TC 21 Z9 24 U1 1 U2 1 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0302-5144 BN 978-3-8055-8945-1 J9 CONTRIB NEPHROL JI Contrib.Nephrol. PY 2009 VL 162 BP 75 EP 86 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA BIP31 UT WOS:000261530300007 PM 19001815 ER PT J AU Carr, DB Newton, KM Utzschneider, KM Tong, J Gerchman, F Kahn, SE Easterling, TR Heckbert, SR AF Carr, D. B. Newton, K. M. Utzschneider, K. M. Tong, J. Gerchman, F. Kahn, S. E. Easterling, T. R. Heckbert, S. R. TI Preeclampsia and Risk of Developing Subsequent Diabetes SO HYPERTENSION IN PREGNANCY LA English DT Article DE Preeclampsia; Gestational diabetes; Diabetes; Epidemiology ID IMPAIRED GLUCOSE-TOLERANCE; ISCHEMIC-HEART-DISEASE; NECROSIS-FACTOR-ALPHA; LONG-TERM MORTALITY; VISCERAL ADIPOSITY; INSULIN-RESISTANCE; METABOLIC SYNDROME; JAPANESE-AMERICANS; REMOTE PROGNOSIS; FAMILY-HISTORY AB Objective: Determine whether preeclampsia is associated with developing diabetes. Methods: Subsequent diabetes was ascertained using ICD-9 codes, pharmacy and glucose data in a retrospective cohort study of 2,032 women with preeclampsia and 29,431 without preeclampsia. Results: During a median follow-up of 8.2 years, 342 women developed diabetes. Preeclampsia was associated with a higher risk of diabetes adjusting for age, primigravidity, and gestational diabetes (hazard ratio, HR 1.82, 95% CI 1.26, 2.62) and in women without gestational diabetes (n = 30,109; HR 1.86, 95% CI 1.22, 2.84). Conclusion: Women with preeclampsia have greater risk of developing diabetes, even in the absence of gestational diabetes. C1 [Carr, D. B.; Easterling, T. R.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Newton, K. M.; Heckbert, S. R.] Grp Hlth Ctr Hlth Studies, Seattle, WA USA. [Newton, K. M.; Heckbert, S. R.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Utzschneider, K. M.; Tong, J.; Gerchman, F.; Kahn, S. E.] Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Heckbert, S. R.] Cardiovasc Hlth Res Unit, Seattle, WA USA. RP Carr, DB (reprint author), Univ Washington, Dept Obstet & Gynecol, Box 356460, Seattle, WA 98195 USA. EM darcarr@u.washington.edu FU NCRR NIH HHS [K23RR16066, K30RR022293] NR 53 TC 25 Z9 25 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1064-1955 EI 1525-6065 J9 HYPERTENS PREGNANCY JI Hypertens. Pregnancy PY 2009 VL 28 IS 4 BP 435 EP 447 DI 10.3109/10641950802629675 PG 13 WC Obstetrics & Gynecology; Physiology; Peripheral Vascular Disease SC Obstetrics & Gynecology; Physiology; Cardiovascular System & Cardiology GA 569NR UT WOS:000275604500007 PM 19843005 ER PT J AU Frank, DA AF Frank, David A. TI Targeting transcription factors for cancer therapy SO IDRUGS LA English DT Review DE Cancer; chemotherapy; drug development; signal transduction; transcription factors AB Despite all of the advances in understanding the operations of cancer cells, cancer is on track to pass heart disease as the leading cause of death in the developed world. The primary treatment approach for advanced cancer remains chemotherapeutic drugs that kill cells, both normal and malignant, in a relatively indiscriminate manner. One recent advance in treatment has been the introduction of drugs that target kinases, which can undergo mutations and become activated inappropriately in cancer cells. However, the maximal benefit that can derive from this approach may soon be reached, and a clear need exists for identifying other therapeutic targets that will have broader applicability. Transcription factors, proteins that regulate the expression of genes within a cell and ultimately control cell behavior, are frequently locked in an 'on' position in cancer cells; when the transcription factors are shut off, a cancer cell will generally stop growing or begin to die. In contrast, normal cells tolerate a loss of transcription factor function with little consequence, as a result of redundancies that are present under normal conditions. Despite challenges involved in developing drugs to target transcription factors, increasing evidence indicates that this approach may be a highly promising strategy in the development of cancer treatments that are more effective and less toxic than existing options. C1 Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Frank, DA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Mayer 522B,44 Binney St, Boston, MA 02115 USA. EM david_frank@dfci.harvard.edu NR 6 TC 13 Z9 13 U1 0 U2 2 PU THOMSON REUTERS (SCIENTIFIC) LTD PI LONDON PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND SN 1369-7056 J9 IDRUGS JI IDrugs PD JAN PY 2009 VL 12 IS 1 BP 29 EP 33 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 394RJ UT WOS:000262464800010 PM 19127502 ER PT J AU Bilenca, A Lasser, T Bouma, BE Leitgeb, RA Tearney, GJ AF Bilenca, A. Lasser, T. Bouma, B. E. Leitgeb, R. A. Tearney, G. J. TI Information Limits of Optical Coherence Imaging Through Scattering Media SO IEEE PHOTONICS JOURNAL LA English DT Article DE Coherent imaging; optical coherent tomography; speckle ID MONTE-CARLO; MULTIPLE-SCATTERING; TURBID MEDIA; TOMOGRAPHY; CAPACITY; MICROSCOPY; CHANNELS; SPECKLE; SIGNAL AB We develop an information-theoretic framework for the quantitative assessment of the maximum amount of information provided by optical coherence imaging through scattering media. We use our approach to investigate the fundamental dependence of the extractable information on the nature of the coherent imaging process, such as on speckle formation. We present nontrivial predictions for the maximum amount of information detected by optical coherence tomography (OCT) from within homogeneous and heterogeneous scattering media and explore its behavior against coherence length and dimension of the detection array. Extension to additional coherent and incoherent light imaging approaches is also discussed. C1 [Bilenca, A.] Lehigh Univ, Biomed Photon Lab, Penn State Lehigh Ctr Opt Technol, Bethlehem, PA 18015 USA. [Bilenca, A.] Lehigh Univ, Dept Elect & Comp Engn, Bethlehem, PA 18015 USA. [Lasser, T.] Ecole Polytech Fed Lausanne, Lab Opt Biomed, CH-1015 Lausanne, Switzerland. [Bouma, B. E.; Tearney, G. J.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Bouma, B. E.; Tearney, G. J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Leitgeb, R. A.] Med Univ Vienna, Ctr Biomed Engn & Phys, A-1090 Vienna, Austria. RP Bilenca, A (reprint author), Lehigh Univ, Biomed Photon Lab, Penn State Lehigh Ctr Opt Technol, Bethlehem, PA 18015 USA. EM bilenca@lehigh.edu RI Lasser, Theo/A-1006-2013; OI Lasser, Theo/0000-0002-4948-7580; Leitgeb, Rainer/0000-0002-0131-4111 FU European Commission FX The work of A. Bilenca was supported by the European Commission under the Marie Curie Fellowship. NR 26 TC 0 Z9 0 U1 0 U2 7 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1943-0655 J9 IEEE PHOTONICS J JI IEEE Photonics J. PY 2009 VL 1 IS 2 BP 119 EP 127 DI 10.1109/JPHOT.2009.2026911 PG 9 WC Engineering, Electrical & Electronic; Optics; Physics, Applied SC Engineering; Optics; Physics GA 647RA UT WOS:000281635100005 ER PT J AU Pezaris, JS Reid, RC AF Pezaris, John S. Reid, R. Clay TI Simulations of Electrode Placement for a Thalamic Visual Prosthesis SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING LA English DT Article DE Foveal magnification; lateral geniculate nucleus; LGN; visual prosthesis ID LATERAL GENICULATE-NUCLEUS; ADVANCED PARKINSONS-DISEASE; DEEP BRAIN-STIMULATION; ELECTRICAL-STIMULATION; SUBTHALAMIC NUCLEUS; PIXELIZED VISION; CORTEX; RETINA; MICROSTIMULATION; PERFORMANCE AB In this paper, placement parameters for microstimulation electrodes in a visual prosthesis are evaluated based on retinotopic models of macaque and human lateral geniculate nucleus. Phosphene patterns were simulated for idealized microwire electrodes as well as for currently available clinical electrodes. For idealized microwire electrodes, spacing as large as 600 pin in three dimensions would allow for over 250 phosphenes per visual hemifield in macaques, and over 800 in humans. C1 [Pezaris, John S.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Reid, R. Clay] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. RP Pezaris, JS (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. EM john@pezaris.com FU Bushrod H. Campbell and Adah F. Hall Charity Fund. FX This work was supported by Grant from the Bushrod H. Campbell and Adah F. Hall Charity Fund. NR 38 TC 16 Z9 20 U1 1 U2 5 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0018-9294 J9 IEEE T BIO-MED ENG JI IEEE Trans. Biomed. Eng. PD JAN PY 2009 VL 56 IS 1 BP 172 EP 178 DI 10.1109/TBME.2008.2005973 PG 7 WC Engineering, Biomedical SC Engineering GA 411HR UT WOS:000263640900019 PM 19224730 ER PT J AU Fang, QQ Carp, SA Selb, J Boverman, G Zhang, Q Kopans, DB Moore, RH Miller, EL Brooks, DH Boas, DA AF Fang, Qianqian Carp, Stefan A. Selb, Juliette Boverman, Greg Zhang, Quart Kopans, Daniel B. Moore, Richard H. Miller, Eric L. Brooks, Dana H. Boas, David A. TI Combined Optical Imaging and Mammography of the Healthy Breast: Optical Contrast Derived From Breast Structure and Compression SO IEEE TRANSACTIONS ON MEDICAL IMAGING LA English DT Article DE Breast imaging; multimodality imaging; tomography ID DIFFUSION EQUATION; CALIBRATION METHOD; BLOOD-FLOW; TOMOGRAPHY; RECONSTRUCTION; SPECTROSCOPY; HEMOGLOBIN; SCATTERING; TISSUE; CANCER AB In this paper, we report new progress in developing the instrument and software platform of a combined X-ray mammography/diffuse optical breast imaging system. Particularly, we focus on system validation using a series of balloon phantom experiments and the optical image analysis of 49 healthy patients. Using the finite-element method for forward modeling and a regularized Gauss-Newton method for parameter reconstruction, we recovered the inclusions inside the phantom and the hemoglobin images of the human breasts. An enhanced coupling coefficient estimation scheme was also incorporated to improve the accuracy and robustness of the reconstructions. The recovered average total hemoglobin concentration (HbT) and oxygen saturation (SO(2)) from 68 breast measurements are 16.2 mu m and 71%, respectively, where the HbT presents a linear trend with breast density. The low HbT value compared to literature is likely due to the associated mammographic compression. From the spatially co-registered optical/X-ray images, we can identify the chest-wall muscle, fatty tissue, and fibroglandular regions with an average HbT of 20.1 +/- 6.1 mu m for fibroglandular tissue, 15.4 +/- 5.0 mu m for adipose, and 22.2 +/- 7.3 mu m for muscle tissue. The differences between fibroglandular tissue and the corresponding adipose tissue are significant (p < 0.0001). At the same time, we recognize that the optical images are influenced, to a certain extent, by mammographical compression. The optical images from a subset of patients show composite features from both tissue structure and pressure distribution. We present mechanical simulations which further confirm this hypothesis. C1 [Fang, Qianqian; Carp, Stefan A.; Selb, Juliette; Zhang, Quart; Boas, David A.] Massachusetts Gen Hosp, Charlestown, MA 02148 USA. [Boverman, Greg] Rensselaer Polytech Inst, Dept Biomed Engn, Troy, NY 12180 USA. [Kopans, Daniel B.; Moore, Richard H.] Massachusetts Gen Hosp, Avon Fdn Comprehens Breast Evaluat Ctr, Boston, MA 02114 USA. [Miller, Eric L.] Tufts Univ, Dept Elect & Comp Engn, Boston, MA 02115 USA. [Brooks, Dana H.] Northeastern Univ, Dept Elect & Comp Engn, Boston, MA 02115 USA. RP Fang, QQ (reprint author), Massachusetts Gen Hosp, Charlestown, MA 02148 USA. EM fangq@nmr.mgh.harvard.edu; carp@nmr.mgh.harvard.edu; juliette@nmr.mgh.harvard.edu; boverg@rpi.edu; qzhang@nmr.mgh.harvard.edu; dkopans@partnars.org; rmoore@partnars.org; elmiller@ece.tufts.edu; brooks@ece.neu.edu; dboas@nmr.mgh.harvard.edu RI Miller, Eric/B-2546-2008 OI Miller, Eric/0000-0002-3156-6002 FU National Institutes of Health (NIH) through the National Cancer Institute [R01-CA97305-01, U54-CA105480]; National Science Foundation [EEC-9986821] FX This work was supported in part by National Institutes of Health (NIH) through the National Cancer Institute under Grant R01-CA97305-01 and Grant U54-CA105480 (NTROI) and in part by the Center for Subsurface Sensing and Imaging System (CenSSIS) under the Engineering Research Centers Program of the National Science Foundation Award EEC-9986821. NR 62 TC 70 Z9 70 U1 0 U2 5 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA SN 0278-0062 J9 IEEE T MED IMAGING JI IEEE Trans. Med. Imaging PD JAN PY 2009 VL 28 IS 1 BP 30 EP 42 DI 10.1109/TMI.2008.925082 PG 13 WC Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Engineering, Electrical & Electronic; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Engineering; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA 391GB UT WOS:000262220700004 PM 19116186 ER PT B AU Yoon, SS Patel, D Chung, DC Lauwers, GY AF Yoon, S. S. Patel, D. Chung, D. C. Lauwers, G. Y. GP Int Gastric Canc Assoc TI Prophylactic total gastrectomy for hereditary diffuse gastric cancer: surgical and pathological results SO IGCC: PROCEEDINGS OF THE 8TH INTERNATIONAL GASTRIC CANCER CONGRESS LA English DT Proceedings Paper CT 8th International Gastric Cancer Congress (IGCC) CY JUN 10-13, 2009 CL Cracow, POLAND ID E-CADHERIN GENE; GERMLINE MUTATIONS; MANAGEMENT; CDH1 AB In this study, we examined the results of prophylactic total gastrectomy for patients with germline CDHI (E-cadherin) mutation. The 8 patients (3 male, 5 female) had a median age of 42 (range 38-51). All patients had an upper endoscopy or chromoendoscopy prior to surgery with only one patient identified as having a focus of diffuse gastric cancer. All patients underwent a total gastrectomy with Roux-en-Y esophagojejunostomy. For pathological analysis, the entire gastric mucosa was examined microscopically, which required up to 490 sections. Only one patient had unremarkable pathology. The other 7 patients had 1-77 foci of noninvasive cancer, and two of these patients had 4-12 foci of T1 invasive cancer. Thus, the majority of patients with germline CDHI mutation have foci of noninvasive or invasive gastric cancer by middle age. Serial endoscopy provides inadequate screening, and total prophylactic gastrectomy is the procedure of choice for definitive treatment. C1 [Yoon, S. S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA. RP Yoon, SS (reprint author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU MEDIMOND S R L PI 40128 BOLOGNA PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY BN 978-88-7587-510-7 PY 2009 BP 133 EP 136 PG 4 WC Oncology; Gastroenterology & Hepatology SC Oncology; Gastroenterology & Hepatology GA BKO70 UT WOS:000268806300030 ER PT S AU Cherkassky, V Cai, F Liang, LC AF Cherkassky, Vladimir Cai, Feng Liang, Lichen GP IEEE TI Predictive Learning with Sparse Heterogeneous Data SO IJCNN: 2009 INTERNATIONAL JOINT CONFERENCE ON NEURAL NETWORKS, VOLS 1- 6 SE IEEE International Joint Conference on Neural Networks (IJCNN) LA English DT Proceedings Paper CT International Joint Conference on Neural Networks CY JUN 14-19, 2009 CL Atlanta, GA SP Int Neural Network Soc, IEEE Computat Intelligence Soc AB many applications of machine learning involve sparse and heterogeneous data. For example, estimation of predictive (diagnostic) models using patients' data from clinical studies requires effective integration of genetic, clinical and demographic data. Typically all heterogeneous inputs are properly encoded and mapped onto a single feature vector, used for estimating (training) a predictive model. This approach, known as standard inductive learning, is used in most application studies. More recently, several new learning methodologies have emerged. In particular, when training data can be naturally separated into several groups (or structured), we can view learning (estimation) for each group as a separate task, leading to Multi-Task Learning framework. Similarly, a setting where training data is structured, but the objective is to estimate a single predictive model (for all groups), leads to Learning with Structured Data and SVM+ methodology recently proposed by Vapnik. This paper demonstrates advantages and limitations of these new data modeling approaches for modeling heterogeneous data (relative to standard inductive SVM) via empirical comparisons using several publicly available medical data sets. C1 [Cherkassky, Vladimir; Cai, Feng] Univ Minnesota, Dept Elect & Comp Engn, Minneapolis, MN 55455 USA. [Liang, Lichen] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Cherkassky, V (reprint author), Univ Minnesota, Dept Elect & Comp Engn, Minneapolis, MN 55455 USA. EM cherk001@umn.edu; caixx043@umn.edu; lian0064@umn.edu FU NSF [ECCS-0802056]; Richard Newton Breakthrough Research Award from Microsoft Research; BICB grant from the University of Minnesota, Rochester FX This work was supported, in part, by NSF grant ECCS-0802056, by the A. Richard Newton Breakthrough Research Award from Microsoft Research, and by the BICB grant from the University of Minnesota, Rochester. NR 13 TC 0 Z9 0 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 2161-4393 BN 978-1-4244-3549-4 J9 IEEE IJCNN PY 2009 BP 3155 EP + PG 2 WC Computer Science, Artificial Intelligence; Computer Science, Hardware & Architecture; Engineering, Electrical & Electronic SC Computer Science; Engineering GA BQB78 UT WOS:000280591601204 ER PT S AU Huang, AJ Willis, MH Kattapuram, SV Bredella, MA AF Huang, Ambrose J. Willis, Marc H. Kattapuram, Susan V. Bredella, Miriam A. BE Davies, AM Sundaram, M James, SLJ TI Surgical Staging 2: Metastatic Disease SO IMAGING OF BONE TUMORS AND TUMOR-LIKE LESIONS: TECHNIQUES AND APPLICATIONS SE Medical Radiology Diagnostic Imaging LA English DT Article; Book Chapter ID POSITRON-EMISSION-TOMOGRAPHY; PRIMARY BONE-TUMORS; WHOLE-BODY MRI; EXTRASKELETAL MYXOID CHONDROSARCOMA; PULMONARY METASTASES; OSTEOGENIC-SARCOMA; FDG-PET; PROGNOSTIC-FACTORS; 32-CHANNEL SYSTEM; SOFT-TISSUE C1 [Huang, Ambrose J.; Willis, Marc H.; Kattapuram, Susan V.; Bredella, Miriam A.] Massachusetts Gen Hosp, Dept Radiol, Musculoskeletal Div, Boston, MA 02114 USA. RP Huang, AJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, Musculoskeletal Div, 55 Fruit St,Yawkey 6E, Boston, MA 02114 USA. NR 71 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0942-5373 BN 978-3-540-77982-7 J9 MED RADIOL DIAGN IMA PY 2009 BP 183 EP 197 DI 10.1007/978-3-540-77984-1_10 D2 10.1007/978-3-540-77984-1 PG 15 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BLW75 UT WOS:000271231600010 ER PT S AU Willis, MH Huang, AJ Bredella, MA Kattapuram, SV AF Willis, Marc H. Huang, Ambrose J. Bredella, Miriam A. Kattapuram, Susan V. BE Davies, AM Sundaram, M James, SLJ TI Assessment of Locally Recurrent Disease SO IMAGING OF BONE TUMORS AND TUMOR-LIKE LESIONS: TECHNIQUES AND APPLICATIONS SE Medical Radiology Diagnostic Imaging LA English DT Article; Book Chapter ID GIANT-CELL TUMOR; ANEURYSMAL BONE-CYSTS; RADIOLOGIC-PATHOLOGICAL CORRELATION; LONG BONES; NEOADJUVANT CHEMOTHERAPY; SINGLE INSTITUTION; CHONDROSARCOMA; OSTEOSARCOMA; EXPERIENCE; MANAGEMENT C1 [Willis, Marc H.; Huang, Ambrose J.; Bredella, Miriam A.; Kattapuram, Susan V.] Massachusetts Gen Hosp, Dept Radiol, Musculoskeletal Div, Boston, MA 02114 USA. RP Willis, MH (reprint author), Massachusetts Gen Hosp, Dept Radiol, Musculoskeletal Div, 55 Fruit St,Yawkey 6E, Boston, MA 02114 USA. NR 46 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0942-5373 BN 978-3-540-77982-7 J9 MED RADIOL DIAGN IMA PY 2009 BP 211 EP 223 DI 10.1007/978-3-540-77984-1_12 D2 10.1007/978-3-540-77984-1 PG 13 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BLW75 UT WOS:000271231600012 ER PT J AU Pillai, S Cariappa, A AF Pillai, Shiv Cariappa, Annaiah TI The bone marrow perisinusoidal niche for recirculating B cells and the positive selection of bone marrow-derived B lymphocytes SO IMMUNOLOGY AND CELL BIOLOGY LA English DT Review DE perisinusoidal B cells; follicular B cells; positive selection; lymphocyte development; bone marrow; secondary lymphoid organ ID T-CELLS; INDEPENDENT RESPONSES; NEGATIVE REGULATOR; IMMUNE-RESPONSE; CD22; MICE; ACTIVATION; RECEPTOR; THYMUS; MATURATION AB A unique 'second' niche for follicular B cells has been described in the extravascular compartment of the bone marrow surrounding vascular sinusoids. The occupancy of this niche by B cells presumably evolved to facilitate humoral immune responses to blood-borne pathogens. B cells appear to be sustained in this niche by bone marrow dendritic cells and are lost from this compartment in certain mutant mice. We discuss here what is known regarding the mechanisms of entry and egress of B cells from the perisinusoidal niche and also consider the function of the bone marrow as a secondary lymphoid organ. Although immature B cells can mature into follicular B cells in this niche as well as in the spleen, the lineage commitment event that accompanies positive selection of B cells occurs only in the spleen. C1 [Pillai, Shiv] Massachusetts Gen Hosp, Canc Res Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Pillai, S (reprint author), Massachusetts Gen Hosp, Canc Res Ctr, 149,13th St, Boston, MA 02114 USA. EM pillai@helix.mgh.harvard.edu FU NIH [AI064930] FX This study was supported by a grant (AI064930) from the NIH. NR 31 TC 14 Z9 15 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0818-9641 J9 IMMUNOL CELL BIOL JI Immunol. Cell Biol. PD JAN PY 2009 VL 87 IS 1 BP 16 EP 19 DI 10.1038/icb.2008.89 PG 4 WC Cell Biology; Immunology SC Cell Biology; Immunology GA 392IT UT WOS:000262297100004 PM 19030017 ER PT S AU Huppert, TJ Franceschini, MA Boas, DA AF Huppert, Theodore J. Franceschini, Maria Angela Boas, David A. BE Frostig, RD TI Noninvasive Imaging of Cerebral Activation with Diffuse Optical Tomography SO IN VIVO OPTICAL IMAGING OF BRAIN FUNCTION, SECOND EDITION SE Frontiers in Neuroscience LA English DT Article; Book Chapter ID NEAR-INFRARED SPECTROSCOPY; HUMAN VISUAL-CORTEX; HIGHLY SCATTERING TISSUES; BLOOD OXYGENATION CHANGES; HUMAN BRAIN ACTIVITY; EVENT-RELATED FMRI; BEER-LAMBERT LAW; HEMODYNAMIC-RESPONSE; HEMOGLOBIN OXYGENATION; NEWBORN-INFANTS C1 [Huppert, Theodore J.] Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA 15260 USA. [Franceschini, Maria Angela; Boas, David A.] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP Huppert, TJ (reprint author), Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA 15260 USA. NR 181 TC 3 Z9 3 U1 0 U2 3 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA SN 2154-5723 BN 978-1-4200-7684-4 J9 FRONT NEUROSCI JI Front. Neurosci. PY 2009 BP 393 EP 433 D2 10.1201/9781420076851 PG 41 WC Neurosciences SC Neurosciences & Neurology GA BKK00 UT WOS:000268336500014 ER PT J AU Osborn, PM Smith, WR Moore, EE Cothren, CC Morgan, SJ Williams, AE Stahel, PF AF Osborn, Patrick M. Smith, Wade R. Moore, Ernest E. Cothren, C. Clay Morgan, Steven J. Williams, Allison E. Stahel, Philip F. TI Direct retroperitoneal pelvic packing versus pelvic angiography: A comparison of two management protocols for haemodynamically unstable pelvic fractures SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED LA English DT Article DE Pelvic fracture; Retroperitoneal approach; Pelvic packing; Angiography; Embolisation; Traumatic haemorrhage ID MULTIPLE ORGAN FAILURE; BLOOD-TRANSFUSION; RING DISRUPTIONS; ARTERIAL EMBOLIZATION; MORTALITY; TRAUMA; HEMORRHAGE; INJURIES; RESUSCITATION; PREDICTORS AB Objective: To evaluate the outcomes of haemodynamically unstable cases of pelvic ring injury treated with a protocol focused on either direct retroperitoneal pelvic packing or early pelvic angiography and embolisation. Methods: A retrospective review of a prospectively collected database in an academic level 1 trauma centre, treating matched haemodynamically unstable cases of pelvic fracture with either pelvic packing (PACK group, n = 20) or early pelvic angiography (ANGIO group, n = 20). Physiological markets of haemorrhage, time to intervention, transfusion requirements, complications and early mortality were recorded. Results: The PACK group underwent operative packing at a median of 45 min from admission; the median time to angiography in the ANGIO group was 130 min. The PACK group, but not the ANGIO group, demonstrated a significant decrease in blood transfusions over the next 24 h post intervention. In the ANGIO group, ten people required embolisation and six died, two from acute haemorrhage; in the PACK group, three people required embolisation; four died, none due to uncontrolled haemorrhage. Conclusions: Pelvic packing is as effective as pelvic angiography for stabilising haemodynamically unstable casualties with pelvic fractures, decreases need for pelvic embolisation and post-procedure blood transfusions, and may reduce early mortality due to exsanguination from pelvic haemorrhage. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Osborn, Patrick M.; Smith, Wade R.; Morgan, Steven J.; Williams, Allison E.; Stahel, Philip F.] Univ Colorado, Denver Hlth Med Ctr, Dept Orthopaed Surg, Sch Med, Denver, CO 80204 USA. [Moore, Ernest E.; Cothren, C. Clay] Univ Colorado, Denver Hlth Med Ctr, Dept Surg, Sch Med, Denver, CO 80204 USA. [Williams, Allison E.] Denver Vet Affairs Med Ctr, Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA. RP Stahel, PF (reprint author), Univ Colorado, Denver Hlth Med Ctr, Dept Orthopaed Surg, Sch Med, 777 Bannock St, Denver, CO 80204 USA. EM philip.stahel@dhha.org FU Jourdan Block Trauma Research Foundation; Society of Military Orthopaedic Surgeons, Honolulu, December 2006; Orthopaedic Trauma Association, Boston, USA FX This study was funded in part by a grant from the Jourdan Block Trauma Research Foundation. The project was previously presented at the Society of Military Orthopaedic Surgeons, Honolulu, December 2006, and. at the annual meeting of the Orthopaedic Trauma Association, Boston, USA, October 2007. NR 33 TC 78 Z9 86 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-1383 J9 INJURY JI Injury-Int. J. Care Inj. PD JAN PY 2009 VL 40 IS 1 BP 54 EP 60 DI 10.1016/j.injury.2008.08.038 PG 7 WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery GA 407TA UT WOS:000263386000009 PM 19041967 ER PT J AU Irimia, D Mindrinos, M Russom, A Xiao, WZ Wilhelmy, J Wang, SL Heath, JD Kurn, N Tompkins, RG Davis, RW Toner, M AF Irimia, Daniel Mindrinos, Michael Russom, Aman Xiao, Wenzhong Wilhelmy, Julie Wang, Shenglong Heath, Joe Don Kurn, Nurith Tompkins, Ronald G. Davis, Ronald W. Toner, Mehmet TI Genome-wide transcriptome analysis of 150 cell samples SO INTEGRATIVE BIOLOGY LA English DT Article ID GENE-EXPRESSION PATTERNS; EMBRYONIC STEM-CELLS; SINGLE-CELL; MICROARRAY ANALYSIS; RNA ISOLATION; HUMAN BREAST; CANCER; DNA; DIFFERENTIATION; ARRAYS AB A major challenge in molecular biology is interrogating the human transcriptome on a genome wide scale when only a limited amount of biological sample is available for analysis. Current methodologies using microarray technologies for simultaneously monitoring mRNA transcription levels, require nanogram amounts of total RNA. To overcome the sample size limitation of Current technologies, we have developed a method to probe the global gene expression ill biological samples as small as 150 cells, or the equivalent of approximately 300 pg total RNA. The new method employs microfluidic devices for the purification of total RNA from mammalian cells and ultra-sensitive whole transcriptome amplification techniques. We verified that the RNA integrity is preserved through the isolation process, accomplished highly reproducible whole transcriptome analysis, and established high correlation between repeated isolations of 150 cells and the same cell culture sample. We validated the technology by demonstrating that the combined microfluidic and amplification protocol is capable of identifying biological pathways perturbed by Stimulation, which are consistent with the information recognized in bulk-isolated samples. C1 [Irimia, Daniel; Russom, Aman; Tompkins, Ronald G.; Toner, Mehmet] Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02114 USA. [Irimia, Daniel; Russom, Aman; Tompkins, Ronald G.; Toner, Mehmet] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Mindrinos, Michael; Xiao, Wenzhong; Wilhelmy, Julie; Davis, Ronald W.] Stanford Univ, Stanford Genome Technol Ctr, Stanford, CA 94305 USA. [Mindrinos, Michael; Xiao, Wenzhong; Wilhelmy, Julie; Davis, Ronald W.] Stanford Univ, Dept Biochem, Stanford, CA 94305 USA. [Wang, Shenglong; Heath, Joe Don; Kurn, Nurith] NuGEN Technol Inc, San Carlos, CA 94070 USA. RP Irimia, D (reprint author), Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02114 USA. EM dirimia@hms.harvard.edu; mindrinos@stanford.edu RI Russom, Aman/B-1675-2012; OI xiao, wenzhong/0000-0003-4944-6380; Irimia, Daniel/0000-0001-7347-2082; Russom, Aman/0000-0002-0242-358X FU National Human Genome Research Institute [P01HG000205]; National Institutes of General Medical Sciences [U54GM62119]; National Institute of Biomedical Imaging and Bioengineering [P41 EB002503] FX This work was supported by grants from the National Human Genome Research Institute (P01HG000205) to RWD, National Institutes of General Medical Sciences (U54GM62119) to RGT, and National Institute of Biomedical Imaging and Bioengineering (P41 EB002503) to MT. NR 43 TC 11 Z9 11 U1 0 U2 4 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1757-9694 J9 INTEGR BIOL JI Integr. Biol. PD JAN PY 2009 VL 1 IS 1 BP 99 EP 107 DI 10.1039/b814329c PG 9 WC Cell Biology SC Cell Biology GA 457ZL UT WOS:000266978200011 PM 20023796 ER PT J AU Irimia, D Toner, M AF Irimia, Daniel Toner, Mehmet TI Spontaneous migration of cancer cells under conditions of mechanical confinement SO INTEGRATIVE BIOLOGY LA English DT Article ID IN-VITRO; CHEMOATTRACTANT GRADIENTS; MULTIPHOTON MICROSCOPY; MICROFLUIDIC PLATFORM; NEUTROPHIL CHEMOTAXIS; METASTASIS; INVASION; TUMOR; 3D; MOTILITY AB When cancer cells spread away from the primary tumor, they often follow the trajectories of lymphatic vessels, nerves, white matter tracts, or other heterogeneous structures in tissues. To better understand this form of guided cell migration we designed a series of microfluidic devices that mechanically constrain migrating cancer cells inside microchannels with cross-section comparable to cell size. We observed unexpectedly fast and persistent movement in one direction for several hours of cancer cells of different types. The persistent motility occurs spontaneously, in the absence of external gradients, suggesting the presence of intrinsic mechanisms driving cancer cell motility that are induced in conditions of mechanical confinement. To probe the mechanisms responsible for this behavior, we exposed cancer cells inside channels to drugs targeting the microtubules, and measured a significant reduction in the average migration speed. Surprisingly, a small number of cells appeared not to be affected by the treatment and displayed fast and persistent migration, comparable to the untreated cells. The new matrix-free, 3D-confined motility assay replicates critical interactions that cancer cells would normally have inside tissues, is compatible with high-content, high-throughput analysis of cellular motility at single cell level, and could provide useful insights into the biology of cancer cell migratory phenotype. C1 [Irimia, Daniel] Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02129 USA. Harvard Univ, Sch Med, Boston, MA 02129 USA. RP Irimia, D (reprint author), Massachusetts Gen Hosp, Shriners Hosp Children, Ctr Engn Med & Surg Serv, BioMEMS Resource Ctr, Boston, MA 02129 USA. EM dirimia@hms.harvard.edu OI Irimia, Daniel/0000-0001-7347-2082 FU National Institutes of Health [P41 EB002503] FX This work was supported in part by National Institutes of Health under grant P41 EB002503. Confocal microscopy was performed with help from Mr Igor Bagayev, at the Microscopy Core Facility at the Neuroscience Center at the Massachusetts General Hospital. NR 55 TC 92 Z9 93 U1 3 U2 56 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1757-9694 J9 INTEGR BIOL JI Integr. Biol. PY 2009 VL 1 IS 8-9 BP 506 EP 512 DI 10.1039/b908595e PG 7 WC Cell Biology SC Cell Biology GA 492TE UT WOS:000269681600002 PM 20023765 ER PT J AU Hough, CL Steinberg, KP Thompson, BT Rubenfeld, GD Hudson, LD AF Hough, Catherine L. Steinberg, Kenneth P. Thompson, B. Taylor Rubenfeld, Gordon D. Hudson, Leonard D. TI Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS SO INTENSIVE CARE MEDICINE LA English DT Article DE Acute lung injury; Acute respiratory distress syndrome; Critical illness; Glucocorticoids/therapeutic use; Paresis; Critica`l illness polyneuropathy ID RESPIRATORY-DISTRESS-SYNDROME; CRITICAL ILLNESS POLYNEUROPATHY; CRITICALLY-ILL PATIENTS; ACUTE LUNG INJURY; QUALITY-OF-LIFE; RISK-FACTORS; MECHANICAL VENTILATION; INSULIN THERAPY; RAT SOLEUS; MYOPATHY AB To determine the incidence and outcomes of intensive care unit-acquired neuromyopathy and to investigate the role of methylprednisolone in survivors of persistent acute lung injury. Secondary analysis of completed randomized placebo-controlled trial. Twenty-five hospitals in the NHLBI ARDS Network. Patients enrolled in the ARDS Network study of methylprednisolone versus placebo for persistent ARDS who survived 60 days or to hospital discharge. One hundred and twenty-eight study patients survived 60 days. Forty-three (34%) of these patients had evidence by chart review of ICU-acquired neuromyopathy, which was associated with prolonged mechanical ventilation, return to mechanical ventilation, and delayed return to home after critical illness. Treatment with methylprednisolone was not significantly associated with an increase in risk of neuromyopathy (OR 1.5; 95% CI 0.7-3.2). ICU-acquired-neuromyopathy is common among survivors of persistent ARDS and is associated with poorer clinical outcomes. We did not find a significant association between methylprednisolone treatment and neuromyopathy. Limitations of this study preclude definitive conclusions about the causal relationship between corticosteroids and ICU-acquired neuromuscular dysfunction. C1 Univ Washington, NHLBI ARDS Network, Seattle, WA 98104 USA. [Thompson, B. Taylor] Massachusetts Gen Hosp, Dept Med, Boston, MA USA. [Rubenfeld, Gordon D.] Univ Toronto, Dept Med, Toronto, ON, Canada. [Thompson, B. Taylor] Massachusetts Gen Hosp, NHLBI ARDS Network, Boston, MA 02114 USA. [Hough, Catherine L.] Univ Washington, Dept Med, Seattle, WA 98104 USA. RP Hough, CL (reprint author), Univ Washington, Dept Med, 325 9th Ave,Mailstop 359762, Seattle, WA 98104 USA. EM cterrlee@u.washington.edu; steinkp@u.washington.edu; tthompson1@partners.org; gordon.rubenfeld@sunnybrook.ca; lhudson@u.washington.edu FU Francis Family Foundation; National Heart Lung and Blood Institute; Mentored Career Development Award [K23HL74294] FX Support for this work was provided by the Francis Family Foundation and the National Heart Lung and Blood Institute through the ARDS Network and Mentored Career Development Award (K23HL74294). NR 33 TC 51 Z9 55 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0342-4642 J9 INTENS CARE MED JI Intensive Care Med. PD JAN PY 2009 VL 35 IS 1 BP 63 EP 68 DI 10.1007/s00134-008-1304-4 PG 6 WC Critical Care Medicine SC General & Internal Medicine GA 395UN UT WOS:000262549100008 PM 18946661 ER PT J AU Papakostas, GI Cooper-Kazaz, R Appelhof, BC Posternak, MA Johnson, DP Klibanski, A Lerer, B Fava, M AF Papakostas, George I. Cooper-Kazaz, Rena Appelhof, Bente C. Posternak, Michael A. Johnson, Daniel P. Klibanski, Anne Lerer, Bernard Fava, Maurizio TI Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE analysis; augmentation; depressive; disorder; major; meta; rapidity; remission; selective serotonin reuptake inhibitor; thyroid ID STAR-ASTERISK-D; PLACEBO-CONTROLLED TRIAL; THYROID-HORMONE; ANTIDEPRESSANT RESPONSE; METAANALYSIS; AUGMENTATION; IMIPRAMINE; POTENTIATION; ENHANCEMENT; MIRTAZAPINE AB To examine the efficacy and overall tolerability of the simultaneous initiation of treatment (coinitiation) with triiodothyronine (T3) and a selective serotonin reuptake inhibitor (SSRI) for major depressive disorder (MDD). Sources of date were Medline/Pubmed, EMBASE, the Cochrane database, and program syllabi from major psychiatric meetings held since 1995. The study selection comprised double-blind, randomized clinical trials comparing T3-SSRI coinitiation therapy versus SSRI monotherapy for MDD. Data were extracted with the use of a precoded form. Data from four clinical trials involving a total of 444 patients with MDD were identified and combined using a random effects model. There was no statistically significant difference in terms of remission rates or response rates at week 1, week 2, or at endpoint between the two treatment groups (SSRI+T3 coinitiation therapy vs. SSRI monotherapy). Pooled response and remission rates at endpoint for the SSRI+T3 versus SSRI monotherapy groups were 64.6 versus 58.5% and 46.8 versus 44.8%, respectively. In addition, there was no statistically significant difference in overall rates of premature discontinuation of treatment, or in the rate of premature discontinuation of treatment owing to inefficacy or intolerance between the two treatment groups. Notwithstanding important methodological differences between the studies included in the meta-analysis in terms of patient characteristics and treatment protocols, these results do not support the notion that simultaneous initiation of treatment of MDD with an SSRI and T3 is more effective than SSRI monotherapy. However, given the etiologically diverse and clinically heterogeneous nature of MDD, it is at least plausible that T3-SSRIs coinitiation therapy may be effective for a particular subgroup of patients including patients with atypical depression or patients with a functional polymorphism of the D-1 deiodinase gene. Clearly, further work is needed to help determine whether there are specific MDD populations that can, indeed, benefit from T3-SSRI coinitiation therapy. Int Clin Psychopharmacol 24:19-25 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Papakostas, George I.; Posternak, Michael A.; Johnson, Daniel P.; Fava, Maurizio] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Depress Clin & Res Program, Boston, MA 02114 USA. [Appelhof, Bente C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Neuroendocrine Unit, Boston, MA 02114 USA. [Klibanski, Anne] Hadassah Hebrew Univ Med Ctr, Dept Psychiat, Biol Psychiat Lab, Jerusalem, Israel. [Cooper-Kazaz, Rena; Lerer, Bernard] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, NL-1012 WX Amsterdam, Netherlands. RP Papakostas, GI (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Depress Clin & Res Program, 15 Parkman St,WAC 812, Boston, MA 02114 USA. EM gpapakostas@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 FU National Institute for Psychobiology in Israel FX This study was supported in part by grants to R.C.K. from the National Institute for Psychobiology in Israel and the Professor Milton Rosenbaum Endowment Fund for Research in the Psychiatric Sciences (Hebrew University, Jerusalem, Israel). NR 26 TC 20 Z9 21 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0268-1315 J9 INT CLIN PSYCHOPHARM JI Int. Clin. Psychopharmacol. PD JAN PY 2009 VL 24 IS 1 BP 19 EP 25 DI 10.1097/YIC.0b013e328314dfaf PG 7 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 393OD UT WOS:000262381700002 PM 19092448 ER PT J AU Gurcan, HM Keskin, DB Stern, JNH Nitzberg, MA Shekhani, H Ahmed, AR AF Guercan, Hakan M. Keskin, Derin B. Stern, Joel N. H. Nitzberg, Matthew A. Shekhani, Haris Ahmed, A. Razzaque TI A review of the current use of rituximab in autoimmune diseases SO INTERNATIONAL IMMUNOPHARMACOLOGY LA English DT Review DE Rituximab; B cell depletion; Autoimmune diseases ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTI-CD20 MONOCLONAL-ANTIBODY; B-CELL DEPLETION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; CHRONIC LYMPHOCYTIC-LEUKEMIA; INTRAVENOUS IMMUNE GLOBULIN; COLD AGGLUTININ DISEASE; VERSUS-HOST-DISEASE; REMITTING MULTIPLE-SCLEROSIS; T-REGULATORY-CELLS AB Rituximab is a human/murine chimeric monoclonal antibody primarily used for treating non-Hodgkin's B-cell lymphoma. Recently it has also been used in the treatment of several autoimmune diseases. A literature review was conducted to determine the efficacy of rituximab in the treatment of some of these autoimmune diseases. Multiple mechanisms proposed for the rituximab mediated B cell depletion are also discussed. The efficacy of rituximab is well-established and it is FDA approved for treatment of Rheumatoid arthritis. In this review, data on the use of rituximab is presented from 92 studies involving 1197 patients with the following diseases: systemic lupus erythematosus, idiopathic thrombocytopenic purpura, anti-neutrophil cytoplasmic antibody associated vasculitis, Grave's disease, autoimmune hemolytic anemia, pemphigus vulgaris, hemophilia A. cold agglutinin disease. Sjogren's syndrome, graft vs. host disease, thrombotic thrombocytopenic purpura, cryoglobulinemia, IgM mediated neuropathy, multiple sclerosis, neuromyelitis optica, idiopathic membranous nephropathy, dermatomyositis, and opsoclonus myoclonus. The efficacy varies among different autoimmune diseases. The cumulative data would suggest that in the vast majority of studies in this review, RTX has a beneficial role in their treatment. While rituximab is very effective in the depletion of B cells, current research suggests it may also influence other cells of the immune system by reestablishing immune homeostasis and tolerance. The safety profile of RTX reveals that most reactions are infusion related. In patients with autoimmune diseases the incidence of serious and severe side effects is low. Systemic infection still remains a major concern and may result in death. (C) 2008 Published by Elsevier B.V. C1 [Guercan, Hakan M.; Nitzberg, Matthew A.; Shekhani, Haris; Ahmed, A. Razzaque] New England Baptist Hosp, Ctr Blistering Dis, Boston, MA 02120 USA. [Keskin, Derin B.; Stern, Joel N. H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Ahmed, AR (reprint author), New England Baptist Hosp, Ctr Blistering Dis, 70 Parker Hill Ave,Suite 208, Boston, MA 02120 USA. EM aramanuscript@msn.com RI Shekhani, Haris/E-3757-2016; OI Stern, Joel N.H./0000-0002-1259-2256 NR 188 TC 154 Z9 159 U1 0 U2 37 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-5769 EI 1878-1705 J9 INT IMMUNOPHARMACOL JI Int. Immunopharmacol. PD JAN PY 2009 VL 9 IS 1 BP 10 EP 25 DI 10.1016/j.intimp.2008.10.004 PG 16 WC Immunology; Pharmacology & Pharmacy SC Immunology; Pharmacology & Pharmacy GA 404IF UT WOS:000263144300002 PM 19000786 ER PT J AU Siev, J AF Siev, Jedidiah TI Attitude and Behavior in (Classic) Social Psychology and Rabbinic Thought: Implications for Psychology of Religion Research SO INTERNATIONAL JOURNAL FOR THE PSYCHOLOGY OF RELIGION LA English DT Article ID IN-DOOR TECHNIQUE; SELF-PERCEPTION; CONSISTENCY; HYPOTHESIS; DISSONANCE; PRESSURE; CHILDREN; LIKING; REWARD AB Certainly attitudes influence behavior; however, less intuitively obvious is the empirical literature revealing that external behavior affects internal attitudes sometimes even more powerfully. This article explores the parallel literatures about the relationship between attitude and behavior in social psychology and the rabbinic tradition. Judaism, characterized by orthopraxy, has considerably more emphasis on legislated behavior than belief, doctrine, or attitude. Moreover, rabbinic text is replete with observations that complement the empirical demonstrations of social psychology. These relate to the causal influence of behavior on attitude, behavioral factors leading to internalization or externalization, and the relationship between effort and satisfaction. C1 [Siev, Jedidiah] Univ Penn, Philadelphia, PA 19104 USA. RP Siev, J (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Simches Res Bldg,185 Cambridge St,2nd Floor, Boston, MA 02114 USA. EM jsiev@partners.org NR 44 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1050-8619 J9 INT J PSYCHOL RELIG JI Int. J. Psychol. Relig. PY 2009 VL 19 IS 3 BP 187 EP 199 DI 10.1080/10508610902880097 PG 13 WC Psychology, Multidisciplinary; Religion SC Psychology; Religion GA 499UP UT WOS:000270252000004 ER PT J AU Nunes, RA Li, XC Kang, SP Burstein, H Roberts, L Carney, W Blackwell, K Ryan, P Borges, V Iglehart, JD Friedman, P Harris, LN AF Nunes, Raquel A. Li, Xiaochun Kang, Soonmo Peter Burstein, Harold Roberts, Lisa Carney, Walter Blackwell, Kimberly Ryan, Paula Borges, Virginia Iglehart, J. Dirk Friedman, Paula Harris, Lyndsay N. TI Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS LA English DT Article DE Circulating tumor cells; HER-2/ECD; Cytokeratin 19; Metastatic breast cancer; Trastuzumab ID POLYMERASE-CHAIN-REACTION; BONE-MARROW MICROMETASTASES; PERIPHERAL-BLOOD; PROGNOSTIC-SIGNIFICANCE; STAGE-I; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; SYSTEMIC THERAPY; C-ERBB-2 PROTEIN; PROGRESSION-FREE AB The detection of circulating tumor cells (CTCs) in peripheral blood may have important prognostic and predictive implications in breast cancer treatment. A limitation in this field has been the lack of a validated method of accurately measuring CTCs. While sensitivity has improved using RT-PCR, specificity remains a major challenge. The goal of this paper is to present a sensitive and specific methodology of detecting CTCs in women with HER-2-positive metastatic breast cancer, and to examine its role as a marker that tracks disease response during treatment with trastuzumab-containing regimens. The study included patients with HER-2-positive metastatic breast cancer enrolled on two different clinical protocols using a trastuzumab-containing regimen. Serial CTCs were measured at planned time points and clinical correlations were made. Immunomagnetic selection of circulating epithelial cells was used to address the specificity of tumor cell detection using cytokeratin 19 (CK19). In addition, the extracellular domain of the HER-2 protein (HER-2/ECD) was measured to determine if CTCs detected by CK19 accurately reflect tumor burden. The presence of CTCs at first restaging was associated with disease progression. We observed an association between CK19 and HER-2/ECD. The association of HER-2/ECD with clinical response followed a similar pattern to that seen with CK19. Finally, the absence of HER-2/ECD at best overall response and a change of HER-2/ECD from positive at baseline to negative at best overall response was associated with favorable treatment response. Our study supports the prognostic and predictive role of the detection of CTCs in treatment of HER-2-positive metastatic breast cancer patients. The association between CK19 and markers of disease burden is in line with the concept that CTCs may be a reliable measure of tumor cells in the peripheral blood of patients with metastatic breast cancer. The association of CTCs at first restaging with treatment failure indicates that CTCs may have a role as surrogate markers to monitor treatment response. (Int J Biol Markers 2009; 24: 1-10) C1 [Kang, Soonmo Peter; Harris, Lyndsay N.] Yale Univ, Yale Canc Ctr, Sch Med, Sect Med Oncol, New Haven, CT 06520 USA. [Nunes, Raquel A.; Li, Xiaochun; Burstein, Harold; Carney, Walter; Blackwell, Kimberly; Ryan, Paula; Borges, Virginia; Iglehart, J. Dirk] Dana Farber Canc Inst, Dept Canc Biol Adult Oncol, Boston, MA 02115 USA. [Roberts, Lisa; Friedman, Paula] Abbott Mol, Des Plaines, IL USA. [Iglehart, J. Dirk] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. RP Harris, LN (reprint author), Yale Univ, Yale Canc Ctr, Sch Med, Sect Med Oncol, 333 Cedar St,POB 208032, New Haven, CT 06520 USA. EM lyndsay.harris@yale.edu FU Dana-Farber Harvard Cancer Center [DAMD17-01-1-0220]; Portuguese-American Foundation for Development FX This work was supported by Dana-Farber Harvard Cancer Center SPORE in Breast Cancer USAMRDC Grant # DAMD17-01-1-0220 and the Portuguese-American Foundation for Development. NR 50 TC 4 Z9 4 U1 1 U2 4 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 0393-6155 J9 INT J BIOL MARKER JI Int. J. Biol. Markers PD JAN-MAR PY 2009 VL 24 IS 1 BP 1 EP 10 PG 10 WC Biotechnology & Applied Microbiology; Oncology SC Biotechnology & Applied Microbiology; Oncology GA 613GK UT WOS:000278967200001 PM 19404916 ER PT J AU Yi, J Horky, LL Friedlich, AL Shi, Y Rogers, JT Huang, XD AF Yi, Jing Horky, Laura L. Friedlich, Avi L. Shi, Ying Rogers, Jack T. Huang, Xudong TI L-Arginine and Alzheimer's Disease SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY LA English DT Review DE L-arginine; nitric oxide synthase; nitric oxide; arginase; polyamines; neurogenesis; stem cells; Alzheimer's disease ID NITRIC-OXIDE SYNTHASE; DIETARY L-ARGININE; EMBRYONIC STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; NEURONAL INSULIN-RECEPTOR; APOLIPOPROTEIN-E GENOTYPE; BRAIN GLUCOSE-METABOLISM; CENTRAL-NERVOUS-SYSTEM; ORAL L-ARGININE AB Alzheimer's disease (AD), the most common form of dementia, is characterized by progressive neurodegeneration and loss of cognitive and memory functions. Although the exact causes of AD are still unclear, evidence suggests that atherosclerosis, redox stress, inflammation, neurotransmitter dysregulation, and impaired brain energy metabolism may all be associated with AD pathogenesis. Herein, we explore a possible role for L-arginine (L-arg) in AD, taking into consideration known functions for L-arg in atherosclerosis, redox stress and the inflammatory process, regulation of synaptic plasticity and neurogenesis, and modulation of glucose metabolism and insulin activity. L-arg, a precursor of nitric oxide and polyamine, exhibits multiple functions in human health and may play a prominent role in age-related degenerative diseases such as AD. C1 [Shi, Ying; Huang, Xudong] Harvard Univ, Brigham & Womens Hosp, Conjugate & Med Chem Lab, Div Nucl Med & Mol Imaging,Dept Radiol, Boston, MA 02115 USA. [Horky, Laura L.; Shi, Ying; Huang, Xudong] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Yi, Jing; Friedlich, Avi L.; Rogers, Jack T.; Huang, Xudong] Harvard Univ, Massachusetts Gen Hosp, Neurochem Lab, Dept Psychiat, Charlestown, MA 02129 USA. [Yi, Jing; Friedlich, Avi L.; Rogers, Jack T.; Huang, Xudong] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Huang, XD (reprint author), Harvard Univ, Brigham & Womens Hosp, Conjugate & Med Chem Lab, Div Nucl Med & Mol Imaging,Dept Radiol, Boston, MA 02115 USA. EM xhuang3@partners.org FU NIH/NIA [5R21AG028850]; Alzheimer's Association [IIRG-07-60397] FX The authors wish to thank Ms. Kimberly Lawson for her wonderful help with manuscript editing. This work was supported by grants from NIH/NIA (5R21AG028850) and Alzheimer's Association (IIRG-07-60397). NR 374 TC 20 Z9 21 U1 4 U2 9 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 1936-2625 J9 INT J CLIN EXP PATHO JI Int. J. Clin. Exp. Pathol. PY 2009 VL 2 IS 3 BP 211 EP 238 PG 28 WC Oncology; Pathology SC Oncology; Pathology GA V18RM UT WOS:000208021900002 PM 19079617 ER PT J AU Zhao, W Liu, YY Cahill, CM Yang, WL Rogers, JT Huang, XD AF Zhao, Wen Liu, Yuying Cahill, Catherine M. Yang, Wenlu Rogers, Jack T. Huang, Xudong TI The Role of T Cells in Osteoporosis, an Update SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY LA English DT Review DE Osteoporosis; T cells; osteoclast; osteoclastogenesis; cytokine; chemokine AB Emerging evidence highlights the importance of the interplay between the bone and immune systems. That evidence bolsters a longstanding recognition that estrogen deficiency, infection, inflammation, and autoimmune disorders are associated with systemic and local bone loss. Yet, only recently has an understanding emerged that T lymphocytes and their products act as key regulators of osteoclast formation, life span, and activity. This review presents this understanding of the process of T lymphocytes and their products mediating osteoporosis and explores some of the most recent findings and hypotheses to explain their action in bone. A more complete appreciation of the interactions between immune and bone cells should lead to targeted therapeutic strategies for diseases that affect either or both systems. C1 [Yang, Wenlu; Huang, Xudong] Brigham & Womens Hosp, Conjugate & Med Chem Lab, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02115 USA. [Yang, Wenlu; Huang, Xudong] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Zhao, Wen] Beijing Aerosp Gen Hosp, Dept Orthoped, Beijing, Peoples R China. [Liu, Yuying] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Cahill, Catherine M.; Rogers, Jack T.; Huang, Xudong] Harvard Univ, Sch Med, Charlestown, MA USA. [Cahill, Catherine M.; Rogers, Jack T.; Huang, Xudong] Massachusetts Gen Hosp, Dept Psychiat, Neurochem Lab, Charlestown, MA USA. [Yang, Wenlu] Shanghai Maritime Univ, Dept Elect Engn, Informat Engn Coll, Shanghai, Peoples R China. RP Huang, XD (reprint author), Brigham & Womens Hosp, Conjugate & Med Chem Lab, Dept Radiol, Div Nucl Med & Mol Imaging, 75 Francis St, Boston, MA 02115 USA. EM xhuang3@partners.org FU Beijing Aerospace General Hospital; Radiology Department of Brigham and Women's Hospital (BWH) FX WZ would like to express his gratitude for the supports from the Beijing Aerospace General Hospital. XH is partially supported by the research funds from Radiology Department of Brigham and Women's Hospital (BWH). We thank Ms. Kimberly Lawson at BWH Radiology Department for her editing of our manuscript. NR 72 TC 9 Z9 10 U1 0 U2 1 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 1936-2625 J9 INT J CLIN EXP PATHO JI Int. J. Clin. Exp. Pathol. PY 2009 VL 2 IS 6 BP 544 EP 552 PG 9 WC Oncology; Pathology SC Oncology; Pathology GA V18RP UT WOS:000208022200004 PM 19636401 ER PT J AU Zeng, XQ Li, GZ Wu, GF Yang, JY Yang, MQ AF Zeng, Xue-Qiang Li, Guo-Zheng Wu, Geng-Feng Yang, Jack Y. Yang, Mary Qu TI Irrelevant gene elimination for Partial Least Squares based Dimension Reduction by using feature probes SO INTERNATIONAL JOURNAL OF DATA MINING AND BIOINFORMATICS LA English DT Article CT 22nd ACM Symposium on Applied Computing CY MAR 11-15, 2007 CL Seoul, SOUTH KOREA SP ACM DE PLS; partial least squares; dimension reduction; gene selection; microarray analysis; data mining; bioinformatics ID EXPRESSION MICROARRAY DATA; TUMOR CLASSIFICATION; CANCER; PREDICTION; REGRESSION; PATTERNS AB It is hard to analyse gene expression data which has only a few observations but with thousands of measured genes. Partial Least Squares based Dimension Reduction (PLSDR) is superior for handling such high dimensional problems, but irrelevant features will introduce errors into the dimension reduction process. Here, feature selection is applied to filter the data and an algorithm named PLSDR(g) is described by integrating PLSDR with gene elimination, which is performed by the indication of t-statistic scores on standardised probes. Experimental results on six microarray data sets show that PLSDR(g) is effective and reliable to improve generalisation performance of classifiers. C1 [Li, Guo-Zheng] Tongji Univ, Dept Control Sci & Engn, Shanghai 201804, Peoples R China. [Zeng, Xue-Qiang; Wu, Geng-Feng] Shanghai Univ, Sch Comp Engn & Sci, Shanghai 200072, Peoples R China. [Yang, Jack Y.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Yang, Jack Y.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Yang, Mary Qu] NHGRI, NIH, US Dept Hlth & Human Serv, Bethesda, MD 20852 USA. [Yang, Mary Qu] US DOE, Oak Ridge, TN USA. RP Li, GZ (reprint author), Tongji Univ, Dept Control Sci & Engn, Shanghai 201804, Peoples R China. EM stamina_zeng@shu.edu.cn; drgzli@gmail.com; gfwu@shu.edu.cn; yang@hadron.mgh.Harvard.edu; yangma@mail.NIH.GOV RI Li, Guo-Zheng /D-5744-2011 OI Li, Guo-Zheng /0000-0001-5568-0347 NR 27 TC 8 Z9 9 U1 0 U2 2 PU INDERSCIENCE ENTERPRISES LTD PI GENEVA PA WORLD TRADE CENTER BLDG, 29 ROUTE DE PRE-BOIS, CASE POSTALE 896, CH-1215 GENEVA, SWITZERLAND SN 1748-5673 J9 INT J DATA MIN BIOIN JI Int. J. Data Min. Bioinform. PY 2009 VL 3 IS 1 BP 85 EP 103 PG 19 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA 438FN UT WOS:000265541400007 PM 19432378 ER PT J AU Rabban, JT Lerwill, MF McCluggage, WG Grenert, JP Zaloudek, CJ AF Rabban, Joseph T. Lerwill, Melinda F. McCluggage, W. Glenn Grenert, James P. Zaloudek, Charles J. TI Primary Ovarian Carcinoid Tumors may Express CDX-2: A Potential Pitfall in Distinction From Metastatic Intestinal Carcinoid Tumors Involving the Ovary SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY LA English DT Article DE Ovary; Carcinoid tumor; CDX-2 ID CLINICOPATHOLOGIC ANALYSIS; IMMUNOHISTOCHEMICAL SURVEY; NEUROENDOCRINE TUMORS; PULMONARY; MARKER; TISSUE; ORIGIN; SITES; GENE AB Carcinoid tumors of the ovary are rare neoplasms that may be primary or metastatic. Clinicopathologic features Such as unilaterality and early stage favor a primary ovarian neoplasm but in the absence of other teratomatous elements it may be difficult or impossible to determine whether an ovarian carcinoid is primary or metastatic. CDX-2 is a marker of intestinal differentiation that has been proposed as a marker of midgut Origin for Metastatic carcinoids. Its expression has not been tested in ovarian carcinoids, Additional markers of potential help in defining the origin of a carcinoid include cytokeratin (CK) 20, CK7, and thyroid transcription factor (TTF-1), none of which have been studied in Ovarian carcinoids. We evaluated the diagnostic utility of CDX-2. CK20, CK7, and TTF-1 as well as conventional clinicopathologic features in determining the site of origin in 26 Ovarian carcinoids (16 primary and 10 metastatic from midgut). Non-neoplastic premenopausal ovaries (n = 10) served as controls. All primary ovarian carcinoids were unilateral whereas only 3/10 metastatic carcinoids were unilateral. Multinodular growth occurred in 6/10 metastatic carcinoids but not in any primary carcinoid. The average size of primary Ovarian carcinoids was 3.4 cm (range: 0.2-13.5 cm) versus 10.2 cm for metastatic carcinoids (range: 4-32 cm). Of the primary Ovarian carcinoids, 12/16 were 3 cm or smaller whereas all metastatic carcinoids were 4 cm or larger. Teratomatous elements were present in association with 10/16 primary Ovarian carcinoids, whereas none were present in any metastatic carcinoid. The primary ovarian carcinoid types were insular (n = 6), trabecular (n = 3), strumal (n = 6, of which 5 were trabecular pattern and I was insular pattern) or mucinous (it = 1). CDX-2 was not expressed in any cells in normal ovaries. Among primary Ovarian neoplasms, there was diffuse nuclear CDX-2 expression in 4/6 insular, 0/3 trabecular, 116 strumal (1/1 insular pattern and 015 trabecular pattern strumal carcinoids), and 1/1 mucinous carcinoids. All metastatic carcinoids, except for two of mucinous type, were insular. CDX-2 was diffusely and strongly expressed in all 8 metastatic insular carcinoids and in both metastatic mucinous carcinoids. None of the metastases was trabecular in type but 12 primary hindgut or foregut trabecular carcinoids were evaluated and all were negative for CDX-2. None of the Ovarian carcinoids expressed TTF-1, CK7, or CK20, except for the primary and metastatic mucinous carcinoids, all of which were CK20-positive. These results demonstrate that CDX-2 cannot be used to determine if a carcinoid is primary in the ovary or metastatic from the intestine as insular and mucinous types of either origin express this marker. Trabecular carcinoids of either origin lack CDX-2 expression. CK20, CK7, or TTF-1 do not have diagnostic utility in this context. Conventional clinicopathologic features (unilaterality, lack of multinodular growth, early stage, presence of teratomatous elements, and size 3 cm or smaller) are the most helpful findings in Suggesting a primary origin for an ovarian carcinoid tumor. C1 [Rabban, Joseph T.; Grenert, James P.; Zaloudek, Charles J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA. [Lerwill, Melinda F.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [McCluggage, W. Glenn] Royal Grp Hosp Trust, Dept Pathol, Belfast, Antrim, North Ireland. RP Rabban, JT (reprint author), Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave,M-551, San Francisco, CA 94143 USA. EM joseph.rabban@ucsf.edu NR 23 TC 19 Z9 23 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-1691 J9 INT J GYNECOL PATHOL JI Int. J. Gynecol. Pathol. PD JAN PY 2009 VL 28 IS 1 BP 41 EP 48 DI 10.1097/PGP.0b013e31817a8f51 PG 8 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA 389MA UT WOS:000262095600007 PM 19047909 ER PT J AU Behbod, F Kittrell, FS LaMarca, H Edwards, D Kerbawy, S Heestand, JC Young, E Mukhopadhyay, P Yeh, HW Allred, DC Hu, M Polyak, K Rosen, JM Medina, D AF Behbod, Fariba Kittrell, Frances S. LaMarca, Heather Edwards, David Kerbawy, Sofia Heestand, Jessica C. Young, Evetin Mukhopadhyay, Purna Yeh, Hung-Wen Allred, D. Craig Hu, Min Polyak, Kornelia Rosen, Jeffrey M. Medina, Daniel TI An intra-ductal human-in-mouse (HIM) transplantation model mimics the subtypes of ductal carcinoma in situ SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE LA English DT Meeting Abstract C1 [Behbod, Fariba; Kerbawy, Sofia] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA. [Kittrell, Frances S.; LaMarca, Heather; Edwards, David; Heestand, Jessica C.; Young, Evetin; Rosen, Jeffrey M.; Medina, Daniel] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Mukhopadhyay, Purna; Yeh, Hung-Wen] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66160 USA. [Allred, D. Craig] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA. [Hu, Min; Polyak, Kornelia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Hu, Min; Polyak, Kornelia] Harvard Univ, Sch Med, Boston, MA 02115 USA. RI Mukhopadhyay, Purna/J-3690-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1107-3756 J9 INT J MOL MED JI Int. J. Mol. Med. PY 2009 VL 24 MA 123 BP S10 EP S10 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 502YQ UT WOS:000270497500024 ER PT J AU Kim, DS Park, SH Jeong, YM Kwon, SB Miller, AJ Fisher, DE Kim, MK Park, KC AF Kim, Dong-Seok Park, Seo-Hyoung Jeong, Yun-Mi Kwon, Sun-Bang Miller, Arlo J. Fisher, David E. Kim, Myo-Kyoung Park, Kyoung-Chan TI Sphingosine-1-phosphate decreases melanin synthesis via MITF phosphorylation through the SIP3 receptor subtype SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE LA English DT Meeting Abstract C1 [Kim, Dong-Seok; Jeong, Yun-Mi] Chung Ang Univ, Coll Med, Dept Biochem, Seoul 156756, South Korea. Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 110744, South Korea. [Miller, Arlo J.; Fisher, David E.] Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Charlestown, MA USA. [Miller, Arlo J.; Fisher, David E.] Harvard Univ, Sch Med, Charlestown, MA USA. [Kim, Myo-Kyoung] Univ Pacific, Thomas J Long Sch Pharm, Stockton, CA 95211 USA. RI Park, Kyoung Chan/J-5474-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1107-3756 J9 INT J MOL MED JI Int. J. Mol. Med. PY 2009 VL 24 SU 1 MA 399 BP S79 EP S79 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 502YQ UT WOS:000270497500300 ER PT J AU Shammas, MA AF Shammas, Masood A. TI Molecular mechanisms underlying genomic instability and the development of drug resistance in cancer SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE LA English DT Meeting Abstract C1 [Shammas, Masood A.] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA. [Shammas, Masood A.] VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1107-3756 J9 INT J MOL MED JI Int. J. Mol. Med. PY 2009 VL 24 MA 206 BP S31 EP S31 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 502YQ UT WOS:000270497500107 ER PT J AU Neville, CM Huang, AY Shyu, JY Snyder, EY Hadlock, TA Sundback, CA AF Neville, Craig M. Huang, Albert Y. Shyu, Jeffrey Y. Snyder, Evan Y. Hadlock, Tessa A. Sundback, Cathryn A. TI NEURAL PRECURSOR CELL LINES PROMOTE NEURITE BRANCHING SO INTERNATIONAL JOURNAL OF NEUROSCIENCE LA English DT Article DE dorsal root ganglia; neural progenitor cells; neuroma; peripheral nerve regeneration; rat sciatic nerve; Schwann cells ID PERIPHERAL-NERVE REGENERATION; ADULT SENSORY NEURONS; GROWTH-FACTOR-I; ROOT GANGLION NEURONS; MARROW STROMAL CELLS; SPINAL-CORD-INJURY; RAT SCIATIC-NERVE; STEM-CELLS; SCHWANN-CELLS; NEUROTROPHIC FACTOR AB Schwann cells and primary progenitor cells improve regeneration across peripheral nerve defects. This study examined the impact of immortalized neural precursor cells on regeneration of rat nerve defects. Across 10-mm gaps, neuromas formed without neural cables with C17.2- or RN33B-transplanted cells, but neural cables formed across 5-mm gaps seeded with RN33B cells. In vitro, dorsal root ganglia neurites elongated across Schwann and RN33B cells; RN33B cells induced neurite branching with shorter total outgrowth. Neural cable formation in vivo was likely determined by the balance of guidance and branch-inducing factors secreted by Schwann and transplanted precursor cells. C1 [Neville, Craig M.; Huang, Albert Y.; Shyu, Jeffrey Y.; Sundback, Cathryn A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Hadlock, Tessa A.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Snyder, Evan Y.] Burnham Inst, La Jolla, CA 92037 USA. RP Sundback, CA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Regenerat Med, Simches Res Bldg CPZN 4809,185 Cambridge St, Boston, MA 02114 USA. EM csundback@partners.org FU Amelia Peabody Charitable FX The authors gratefully acknowledge Dr. Scott Whittemore for supplying the RN33B cells, Dr. David Scadden for supplying the plasmids and cell line for producing the GFP-expressing murine leukemia virus, and Dr. Jonathan Winograd for sharing his unpublished results. The avian-specific anti-neurofilament NF-160 and the anti-chicken cell marker antibodies developed by W. Halfster were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA 52242. This work was funded by an Amelia Peabody Charitable Grant (MEEI, TAH) NR 50 TC 4 Z9 6 U1 0 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0020-7454 J9 INT J NEUROSCI JI Int. J. Neurosci. PY 2009 VL 119 IS 1 BP 15 EP 39 DI 10.1080/00207450802480218 PG 25 WC Neurosciences SC Neurosciences & Neurology GA 389KB UT WOS:000262090200002 PM 19116829 ER PT J AU Feil, DG Pearman, A Victor, T Harwood, D Weinreb, J Kahle, K Unutzer, J AF Feil, Denise G. Pearman, Ann Victor, Tara Harwood, Dylan Weinreb, Jane Kahle, Kristin Unuetzer, Juergen TI THE ROLE OF COGNITIVE IMPAIRMENT AND CAREGIVER SUPPORT IN DIABETES MANAGEMENT OF OLDER OUTPATIENTS SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE cognitive impairment; dementia; diabetes mellitus; self-care; caregivers ID MEDICATION ADHERENCE; ALZHEIMERS-DISEASE; CORNELL SCALE; SELF-CARE; DEMENTIA; DEPRESSION; MELLITUS; HEALTH; IMPACT; RISK AB Objectives: To examine the role of cognitive impairment and caregiver support in diabetes care adherence and glycemic control. Methods: Fifty-one veteran male outpatients (27 with caregivers) aged 60 years and older with type 2 diabetes were evaluated for cognitive impairment with the Cognitive Abilities Screening Instrument. Patients or caregivers completed diabetes self-care and depression scales. Medical morbidity information and HbA(1c) plasma levels at baseline and 1 year later were obtained from electronic medical records. Results: Greater cognitive impairment (F= 5.1, p < .05), and presence of a caregiver (F = 5.3, p < .05), were independently associated with worse diabetes care adherence (adjusting for age, education, medical comorbidity, and depression). In addition, Mean HbA(1c) levels were worse in the cognitively impaired group with caregivers relative to the three other groups (F = 4.10, p <.05, eta(2) = .09). One year later, mean HbA(1c) levels rose from 7.7 to 8.2% in the cognitively impaired group with caregivers. Conclusion: Cognitive impairment is associated with worse diabetes care management. Surprisingly, the presence of a caregiver is not protective. Further research is necessary to examine the healthcare needs of cognitively impaired, diabetic patients and their caregivers. (Int'l. J. Psychiatry in Medicine 2009;39:199-214) C1 [Feil, Denise G.; Weinreb, Jane; Kahle, Kristin] W Los Angeles VA Med Ctr, Los Angeles, CA USA. [Feil, Denise G.; Harwood, Dylan; Weinreb, Jane] Univ Calif Los Angeles, Los Angeles, CA USA. [Pearman, Ann] Georgia State Univ, Atlanta, GA 30303 USA. [Victor, Tara] Cal State Northridge, Northridge, CA USA. [Unuetzer, Juergen] Univ Washington, Seattle, WA 98195 USA. RP Feil, DG (reprint author), W Los Angeles Vet Hlth Care Ctr, 11301 Wilshire Blvd Bldg 500,3 South 116-AE, Los Angeles, CA 90073 USA. EM denise.feil@va.gov FU Career Development Award FX Institutional Support: West Los Angeles VA Geriatric Research and Education Clinical Care (G.R.E.C.C.), Special Fellow in Advanced Geriatrics, and Career Development Award in Health Services Research and Development, Veterans Affairs. NR 37 TC 20 Z9 21 U1 1 U2 5 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2009 VL 39 IS 2 BP 199 EP 214 DI 10.2190/PM.39.2.h PG 16 WC Psychiatry SC Psychiatry GA 503XZ UT WOS:000270576800008 PM 19860078 ER PT J AU Somer, E Maguen, S Or-Chen, K Litz, BT AF Somer, Eli Maguen, Shira Or-Chen, Keren Litz, Brett T. TI Managing terror: Differences between Jews and Arabs in Israel SO INTERNATIONAL JOURNAL OF PSYCHOLOGY LA English DT Article DE Coping-behavior; PTSD; Arab; Israel ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH SYMPTOMS; REPRESENTATIVE SAMPLE; EXPOSURE; ADJUSTMENT; DISASTER; STUDENTS AB Using telephone surveys, we examined exposure to terror, coping, and mental health response in randomly selected Jewish-Israelis (n=100) and Arab-Israelis (n=100) living in five Israeli cities affected by terrorism. Jewish-Israelis and Arab-Israelis were randomly selected for study participation and completed telephone surveys in May 2002, following an extended string of terror attacks and hostilities. Although terrorism is designed to target Jewish-Israelis, the rates of exposure were similar in the two groups. Arab-Israelis reported using a wider array of coping strategies, yet also endorsed more frequent PTSD and more severe depression symptoms than Jewish-Israelis. We examined a variety of demographic, ethnic, and religious predictors of different coping styles and found varying results. For example, acceptance coping was best predicted by Arab-Israeli ethnicity, being female, greater religiosity, and lower education. Predictors of mental health response to terror were also examined, with Arab-Israeli ethnicity, being female, adaptation coping and collaborative coping best predicting PTSD and depression symptoms. Arab-Israelis may not have the same access to overarching sources of patriotic support that are readily available to their Jewish compatriots, and civilian and economic inequity experienced by the Arab minority may add to a sense of diminished resources. Our findings justify outreach efforts to overlooked minorities at risk for posttraumatic distress. Women seem to be at particular risk for the development of mental health symptoms following terrorism, which should also be noted for outreach purposes. C1 [Somer, Eli; Or-Chen, Keren] Univ Haifa, IL-31905 Haifa, Israel. [Somer, Eli] Israel Inst Treatment & Study Stress, Haifa, Israel. [Maguen, Shira] San Francisco VA Med Ctr, San Francisco, CA USA. [Maguen, Shira] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Litz, Brett T.] Vet Affairs Hlth Care Syst, Boston Dept, Boston, MA USA. [Litz, Brett T.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Somer, E (reprint author), Univ Haifa, IL-31905 Haifa, Israel. EM somer@research.haifa.ac.il NR 25 TC 19 Z9 20 U1 0 U2 0 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0020-7594 J9 INT J PSYCHOL JI Int. J. Psychol. PY 2009 VL 44 IS 2 BP 138 EP 146 AR PII 783095206 DI 10.1080/00207590701609076 PG 9 WC Psychology, Multidisciplinary SC Psychology GA 420DJ UT WOS:000264268300006 PM 22029455 ER PT J AU Held, KD AF Held, Kathryn D. TI Effects of low fluences of radiations found in space on cellular systems SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY LA English DT Review DE Space radiation; heavy ions; high LET radiation; bystander effects; adaptive responses ID DOUBLE-STRAND BREAKS; TRANSFORMATION IN-VITRO; HEAVY-ION IRRADIATION; HIGH-LET IRRADIATION; MEDIATED INTERCELLULAR COMMUNICATION; ANCHORAGE-INDEPENDENT GROWTH; NORMAL HUMAN FIBROBLASTS; HZE-PARTICLE RADIATION; HUMAN EPITHELIAL-CELLS; HUMAN SKIN FIBROBLASTS AB Purpose: In recent years, there has been a large increase in the amount of space-related radiation biology research being conducted. This review will discuss selected issues related to cellular responses to the types of radiations found in space, with emphasis on comparison of cellular effects from high versus low linear energy transfer (LET) radiations and on effects that might be expected to predominate at the low radiation fluences characteristic of space, e. g., bystander effects and adaptive responses. Conclusions: Space radiation is unique and complex, being composed of galactic cosmic rays and solar particles. Not surprisingly, space radiation biology is also unique and complex. Responses in cells traversed by high atomic number, high energy (HZE) particles are different, at least in part, from the responses of cells exposed to low LET photons not just quantitatively but also qualitatively. This is illustrated by discussion of four sets of data - clustering of DNA damages, foci of DNA repair-related proteins, chromosome aberrations and gene expression. 'Non-targeted' effects, particularly bystander responses, may have increased importance in cellular responses to space radiation because of the very low fluences and fluence rates as well as the non-homogeneous dose distributions from HZE particles compared to the more homogeneous distributions of the photon radiations usually encountered on Earth. Likewise adaptive responses could be expected to play a role in cellular damages at the low particle fluences characteristic of space. The growing number of ground-based studies being performed with energetic protons and heavy ions should lead to greatly expanded knowledge of the impact of the space radiation environment on astronauts. C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Held, KD (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Cox 302,55 Fruit St, Boston, MA 02114 USA. EM kheld@partners.org FU NASA [NNX07AE40G] FX Space-related radiation biology research in the author's laboratory is supported by NASA grant NNX07AE40G. NR 121 TC 35 Z9 36 U1 4 U2 17 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0955-3002 J9 INT J RADIAT BIOL JI Int. J. Radiat. Biol. PY 2009 VL 85 IS 5 BP 379 EP 390 DI 10.1080/09553000902838558 PG 12 WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 448SA UT WOS:000266281100001 PM 19382021 ER PT J AU Kuhnert, VM Kachnic, LA Li, L Purschke, M Gheorghiu, L Lee, R Held, KD Willers, H AF Kuhnert, Verena M. Kachnic, Lisa A. Li, Li Purschke, Martin Gheorghiu, Liliana Lee, Richard Held, Kathryn D. Willers, Henning TI FANCD2-deficient human fibroblasts are hypersensitive to ionising radiation at oxygen concentrations of 0% and 3% but not under normoxic conditions SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY LA English DT Article DE Fanconi Anemia; FANCD2; radiation sensitivity; hypoxia ID FANCONI ANEMIA/BRCA PATHWAY; MARKED CLINICAL RADIOSENSITIVITY; DNA-REPAIR; HOMOLOGOUS RECOMBINATION; MONOUBIQUITINATED FANCD2; OXIDATIVE STRESS; STRAND BREAKS; CELL STRAINS; DAMAGE; PROTEINS AB Purpose: Individuals suffering from Fanconi Anemia (FA) exhibit a pronounced hypersensitivity to agents that cause DNA inter-strand crosslinks and frequently also to ionising radiation. However, fibroblast lines derived from FA patients generally show little or no radiosensitivity invitro. Here, we sought to elucidate the role of the central FA protein D2 (FANCD2) in determining cellular radioresistance. Material and methods: Clonogenic radiation survival was assessed in an isogenic pair of human fibroblasts with or without wild-type FANCD2 under varying oxygen concentrations. Additional endpoints included single-cell gel electrophoresis, RAD51 foci formation, and apoptosis. Results: At 20% oxygen, there was no reduction in the survival of FANCD2-deficient fibroblasts compared to wild-type complemented cells. However, at 0% oxygen FANCD2-deficient cells were more radiosensitive than wild-type cells. Interestingly, at 3% oxygen, which more closely resembles the physiological environment in human tissues, the difference in radiosensitivity was maintained. Our data also suggest that the increased radiosensitivity of FANCD2-deficient cells seen under conditions of reduced oxygen is associated with apoptotic cell death, but not secondary to a defect in the homologous recombination repair pathway that is required for crosslink repair. Conclusions: Our data may help explain the previously described discrepancy between the clinical and cellular radiosensitivity of FA patients. C1 [Kachnic, Lisa A.; Li, Li; Purschke, Martin; Gheorghiu, Liliana; Lee, Richard; Held, Kathryn D.; Willers, Henning] Massachusetts Gen Hosp, Dept Radiat Oncol, Ctr Canc, Lab Cellular & Mol Radiat Oncol, Boston, MA 02114 USA. [Kuhnert, Verena M.] Med Univ Lubeck, Dept Radiat Oncol, D-23538 Lubeck, Germany. RP Willers, H (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Ctr Canc, Lab Cellular & Mol Radiat Oncol, Cox 3,55 Fruit St, Boston, MA 02114 USA. EM hwillers@partners.org FU Susan G. Komen for the Cure; NIH [P01 CA095227] FX The excellent technical assistance of Chake Tokadjian is acknowledged. This research was supported in part by grants from Susan G. Komen for the Cure (to LAK and HW) and NIH P01 CA095227 (to KDH). NR 47 TC 15 Z9 16 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0955-3002 J9 INT J RADIAT BIOL JI Int. J. Radiat. Biol. PY 2009 VL 85 IS 6 BP 523 EP 531 AR PII 911666010 DI 10.1080/09553000902883810 PG 9 WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 448SH UT WOS:000266281800007 PM 19466639 ER PT J AU Abi-Raad, RF Boutrus, R Goldberg, S Niemierko, A Taghian, A AF Abi-Raad, R. F. Boutrus, R. Goldberg, S. Niemierko, A. Taghian, A. TI Patterns and Risk Factors of Locoregional Recurrence in T1-T2 Node Negative Breast Cancer Patients Treated with Mastectomy: Implications for Postmastectomy Radiotherapy (PMRT) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Abi-Raad, R. F.; Boutrus, R.; Goldberg, S.; Niemierko, A.; Taghian, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S52 EP S52 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600111 ER PT J AU Albuquerque, KV Beall, N Shah, K Niemierko, A Bova, D AF Albuquerque, K. V. Beall, N. Shah, K. Niemierko, A. Bova, D. TI Incidence and Predictors of Thyroid Dysfunction following Three-Dimensional Conformal Radiation Therapy (3D-CRT) to Low Neck as Component of Adjuvant Radiation in Women with Breast Cancer: Prospective Long Term Follow-Up SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Albuquerque, K. V.; Beall, N.; Shah, K.; Bova, D.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Niemierko, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S499 EP S499 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602016 ER PT J AU Alcorn, SR Mauch, PM Ng, A Oppenheimer, AKE Webber, BT Balboni, TA AF Alcorn, S. R. Mauch, P. M. Ng, A. Oppenheimer, A. K. E. Webber, B. T. Balboni, T. A. TI Predictors of Symptomatic Failure after Palliative Radiation Therapy for Multiple Myeloma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Alcorn, S. R.; Mauch, P. M.; Ng, A.; Oppenheimer, A. K. E.; Webber, B. T.; Balboni, T. A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Alcorn, S. R.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S503 EP S504 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602025 ER PT J AU Arvold, ND Mamon, HJ Sahani, D Fernandez-del Castillo, C Hong, TS AF Arvold, N. D. Mamon, H. J. Sahani, D. Fernandez-del Castillo, C. Hong, T. S. TI Pancreatic Cancer Primary Tumor Size on Multidetector Row CT vs. Pathologic Specimen: Implications for Radiation Treatment Planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Arvold, N. D.] Harvard Radiat Oncol Program, Boston, MA USA. [Mamon, H. J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Sahani, D.; Fernandez-del Castillo, C.; Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S55 EP S55 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600117 ER PT J AU Boutrus, R Raad, RA Niemierko, A Brachtel, E Rizk, L Kelada, A Taghian, A AF Boutrus, R. Raad, R. Abi Niemierko, A. Brachtel, E. Rizk, L. Kelada, A. Taghian, A. TI Does Lymphovascular Invasion Predict Regional Nodal Failure in Stage I/II Breast Cancer Patients Treated with Conserving Surgery and Radiation Therapy? Implications for Regional Radiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Boutrus, R.; Raad, R. Abi; Niemierko, A.; Brachtel, E.; Rizk, L.; Kelada, A.; Taghian, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S8 EP S8 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600017 ER PT J AU Bradley, JD Bae, K Choi, N Forster, K Siegel, BA Brunetti, J Purdy, JA Faria, S Vu, T Choy, H AF Bradley, J. D. Bae, K. Choi, N. Forster, K. Siegel, B. A. Brunetti, J. Purdy, J. A. Faria, S. Vu, T. Choy, H. TI A Phase II Comparative Study of Gross Tumor Volume Definition with or without PET/CT Fusion in Dosimetric Planning for Non-small-cell Lung Cancer (NSCLC): Primary Analysis of Radiation Therapy Oncology Group (RTOG) 0515 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Bradley, J. D.; Siegel, B. A.] Washington Univ, Sch Med, St Louis, MO USA. [Bae, K.] RTOG Dept Stat, Philadelphia, PA USA. [Choi, N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Forster, K.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Brunetti, J.] Holy Name Hosp, Teaneck, NJ USA. [Purdy, J. A.] Univ Calif Davis, Davis, CA 95616 USA. [Faria, S.] McGill Univ, Montreal, PQ, Canada. [Vu, T.] Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada. [Choy, H.] Univ Texas SW, Dallas, TX USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S2 EP S2 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600005 ER PT J AU Chakravarthy, A Catalano, PJ Martenson, JA Mondschein, JK Wagner, H Schuchter, LM Mansour, EG Talamonti, MS Benson, AB AF Chakravarthy, A. Catalano, P. J. Martenson, J. A. Mondschein, J. K. Wagner, H. Schuchter, L. M. Mansour, E. G. Talamonti, M. S. Benson, A. B. TI Long-term Follow-up of ECOG E4292: A Phase II Trial of High Dose Radiation with Concurrent 5-Fluorouracil and Cisplatin in Patients with Anal Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Chakravarthy, A.; Mondschein, J. K.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Catalano, P. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Martenson, J. A.] Mayo Clin, Rochester, MN USA. [Wagner, H.] Penn State Hershey Canc Inst, Hershey, PA USA. [Schuchter, L. M.] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA. [Mansour, E. G.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Talamonti, M. S.; Benson, A. B.] Northwestern Univ, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S27 EP S27 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600057 ER PT J AU Chen, G Hong, TS Hallman, J Sharp, GC Wolfgang, JA Lu, H Mori, S AF Chen, G. Hong, T. S. Hallman, J. Sharp, G. C. Wolfgang, J. A. Lu, H. Mori, S. TI 4D Proton Treatment Planning for Liver Tumors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Chen, G.; Hong, T. S.; Hallman, J.; Sharp, G. C.; Wolfgang, J. A.; Lu, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mori, S.] Natl Inst Radiol Sci, Chiba 260, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S698 EP S698 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602458 ER PT J AU Chen, RC Punglia, RS Sher, DJ AF Chen, R. C. Punglia, R. S. Sher, D. J. TI Stereotactic Radiosurgery (SRS) vs. Whole Brain Radiation Therapy (WBRT) vs. Combined Treatment (SRS & WBRT) for Brain Metastases: A Decision Analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Chen, R. C.] Harvard Radiat Oncol Program, Boston, MA USA. [Punglia, R. S.; Sher, D. J.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Punglia, R. S.; Sher, D. J.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S89 EP S89 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600190 ER PT J AU Chen, Y Ciernik, F Niemierko, A Kobayashi, W Torunn, Y Ebb, D Harmon, D Raskin, K Hornicek, F DeLaney, T AF Chen, Y. Ciernik, F. Niemierko, A. Kobayashi, W. Torunn, Y. Ebb, D. Harmon, D. Raskin, K. Hornicek, F. DeLaney, T. TI Treatment of Unresectable Osteosarcoma with Proton Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Chen, Y.; Niemierko, A.; Kobayashi, W.; Torunn, Y.; Ebb, D.; Harmon, D.; Raskin, K.; Hornicek, F.; DeLaney, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ciernik, F.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland. NR 0 TC 0 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S528 EP S528 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602080 ER PT J AU Cheung, AK Chen, M Moran, BJ Braccioforte, MH Dosoretz, DE Salenius, S Katin, M Ross, R D'Amico, AV AF Cheung, A. K. Chen, M. Moran, B. J. Braccioforte, M. H. Dosoretz, D. E. Salenius, S. Katin, M. Ross, R. D'Amico, A. V. TI Use of Supplemental External Beam Radiotherapy in Men with Low-risk Prostate Cancer undergoing Brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Cheung, A. K.; D'Amico, A. V.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Cheung, A. K.; D'Amico, A. V.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, M.] Univ Connecticut, Storrs, CT USA. [Moran, B. J.; Braccioforte, M. H.] Prostate Canc Fdn Chicago, Westmont, IL USA. [Dosoretz, D. E.; Salenius, S.; Katin, M.; Ross, R.] 21st Century Oncol, Ft Myers, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S494 EP S494 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602004 ER PT J AU Clancy, PE Schuller, BW Sroczinski, LM Hirsch, AE AF Clancy, P. E. Schuller, B. W. Sroczinski, L. M. Hirsch, A. E. TI Assessment of Patient Setup Error in Prostate Radiation Therapy using Fiducial-based Image Guided Radiation Therapy with kV Onboard Imaging and Conebeam CT SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Clancy, P. E.; Schuller, B. W.; Sroczinski, L. M.; Hirsch, A. E.] Boston Med Ctr, Boston, MA USA. [Schuller, B. W.; Hirsch, A. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S579 EP S580 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602198 ER PT J AU Coen, J Talcott, JA Houlihan, RL Rodrigues, AE Zietman, AL AF Coen, J. Talcott, J. A. Houlihan, R. L. Rodrigues, A. E. Zietman, A. L. TI Correlating Patient Reported Symptoms after High Dose Proton Irradiation for Localized Prostate Cancer with Dose Volume Histogram Parameters SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Coen, J.; Talcott, J. A.; Houlihan, R. L.; Rodrigues, A. E.; Zietman, A. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S304 EP S305 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573601142 ER PT J AU Cotter, SE Herrup, DA Adams, J Friedmann, AM MacDonald, SM Chen, YL Tarbell, NJ Yock, TI AF Cotter, S. E. Herrup, D. A. Adams, J. Friedmann, A. M. MacDonald, S. M. Chen, Y. L. Tarbell, N. J. Yock, T. I. TI Clinical Outcomes of Proton Radiotherapy for Pediatric Bladder/Prostate Rhabdomyosarcoma and a Dosimetric Comparison with Intensity Modulated Radiotherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Cotter, S. E.] Harvard Radiat Oncol Program, Boston, MA USA. [Herrup, D. A.; Adams, J.; Friedmann, A. M.; MacDonald, S. M.; Chen, Y. L.; Tarbell, N. J.; Yock, T. I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S511 EP S511 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602042 ER PT J AU DeLaney, TF Kim, B Chen, YE Kirsch, DG Goldberg, SI Kobayashi, W Kung, JH Doppke, K Rosenberg, AE Hornicek, FJ AF DeLaney, T. F. Kim, B. Chen, Y. E. Kirsch, D. G. Goldberg, S. I. Kobayashi, W. Kung, J. H. Doppke, K. Rosenberg, A. E. Hornicek, F. J. TI An Effective 3D Target Volume for Preoperative Radiotherapy in Extremity Soft Tissue Sarcoma and the Effect of Margin Width on Local Control SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [DeLaney, T. F.; Chen, Y. E.; Goldberg, S. I.; Kobayashi, W.; Kung, J. H.; Doppke, K.; Rosenberg, A. E.; Hornicek, F. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kim, B.] Dankook Univ, Cheonan, South Korea. [Kirsch, D. G.] Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 SU S BP S527 EP S528 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602079 ER PT J AU Dennis, ER Bussiere, M Niemierko, A Lu, M Loeffler, JS Shih, HA AF Dennis, E. R. Bussiere, M. Niemierko, A. Lu, M. Loeffler, J. S. Shih, H. A. TI A Comparison of Critical Structure Dose and Toxicity Risks in Patients with Low Grade Gliomas Treated with IMRT versus Proton Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Dennis, E. R.; Bussiere, M.; Niemierko, A.; Lu, M.; Loeffler, J. S.; Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S232 EP S233 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600498 ER PT J AU Efstathiou, JA Coen, JJ Spiegel, DY Niemierko, A Kaufman, DS Heney, NM McDougal, WS McGovern, FJ Zietman, AL Shipley, WU AF Efstathiou, J. A. Coen, J. J. Spiegel, D. Y. Niemierko, A. Kaufman, D. S. Heney, N. M. McDougal, W. S. McGovern, F. J. Zietman, A. L. Shipley, W. U. TI Fifteen-year Outcomes of Selective Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer: The Long-term MGH Experience SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Efstathiou, J. A.; Coen, J. J.; Spiegel, D. Y.; Niemierko, A.; Kaufman, D. S.; Heney, N. M.; McDougal, W. S.; McGovern, F. J.; Zietman, A. L.; Shipley, W. U.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S10 EP S11 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600022 ER PT J AU Engelsman, M Delaney, TF Hong, TS AF Engelsman, M. Delaney, T. F. Hong, T. S. TI Proton Radiotherapy: The Biologic Effect of Treating Alternating Subsets of Fields for Different Fractions SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Engelsman, M.; Delaney, T. F.; Hong, T. S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S50 EP S50 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600106 ER PT J AU Garzotto, M Hung, A Beer, TM Farris, P AF Garzotto, M. Hung, A. Beer, T. M. Farris, P. TI Phase I Study of Preoperative Radiation and Docetaxel for High-risk Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Garzotto, M.; Hung, A.; Beer, T. M.; Farris, P.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Garzotto, M.; Farris, P.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S13 EP S13 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600027 ER PT J AU Gokhale, AS Epperly, MW Glowacki, J Wang, H Wipf, P Patrene, K Dixon, T Greenberger, JS AF Gokhale, A. S. Epperly, M. W. Glowacki, J. Wang, H. Wipf, P. Patrene, K. Dixon, T. Greenberger, J. S. TI Small Molecule GS-nitroxide Ameliorates the Ionizing Irradiation-induced Delay in Bone Wound Healing Measured in a Novel Murine Model SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Gokhale, A. S.; Epperly, M. W.; Wang, H.; Dixon, T.; Greenberger, J. S.] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA USA. [Glowacki, J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Patrene, K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S551 EP S551 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602133 ER PT J AU Hacker, FL Weiss, SE Marcus, KJ Ramakrishna, N AF Hacker, F. L. Weiss, S. E. Marcus, K. J. Ramakrishna, N. TI Implementation and Initial Experience with a Non-invasive Image Guided Radiosurgery System for Intra-Cranial Lesions SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Hacker, F. L.; Weiss, S. E.; Marcus, K. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hacker, F. L.; Weiss, S. E.; Marcus, K. J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Hacker, F. L.; Weiss, S. E.; Marcus, K. J.] Harvard Univ, Sch Med, Boston, MA USA. [Ramakrishna, N.] MD Anderson Canc Ctr, Orlando, FL USA. [Marcus, K. J.] Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S693 EP S694 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602448 ER PT J AU Haglund, KE Raut, CP Nascimento, AF Wang, Q George, S Baldini, EH AF Haglund, K. E. Raut, C. P. Nascimento, A. F. Wang, Q. George, S. Baldini, E. H. TI Recurrence Patterns and Survival in Patients with Intermediate and High-grade Myxofibrosarcoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Haglund, K. E.] Harvard Radiat Oncol Program, Boston, MA USA. [Raut, C. P.; Nascimento, A. F.; George, S.; Baldini, E. H.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Raut, C. P.; Wang, Q.; George, S.; Baldini, E. H.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S525 EP S525 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602073 ER PT J AU Hattangadi, JA Wo, JY Nguyen, PL Raad, RFA Sreedhara, M Freer, PE Georgian-Smith, D Harris, JR Taghian, AG AF Hattangadi, J. A. Wo, J. Y. Nguyen, P. L. Raad, R. F. Abi Sreedhara, M. Freer, P. E. Georgian-Smith, D. Harris, J. R. Taghian, A. G. TI Basal (or Triple Negative) Subtype of Invasive Breast Cancer (IBC) is Associated with a Higher Risk of True Recurrence/Marginal Miss (TR/MM) after Conventional Breast-conserving Therapy (BCT) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Hattangadi, J. A.; Wo, J. Y.; Nguyen, P. L.; Taghian, A. G.] Massachusetts Gen Hosp, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S7 EP S7 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600014 ER PT J AU Hirsch, AE Janicek, MJ Mui, K Lee, RJ Wang, DS Babayan, RK Zumwalt, AC Ozonoff, A Zietman, AL AF Hirsch, A. E. Janicek, M. J. Mui, K. Lee, R. J. Wang, D. S. Babayan, R. K. Zumwalt, A. C. Ozonoff, A. Zietman, A. L. TI Anatomical Differences after Robotic-assisted Radical Prostatectomy (RARP) and Open Prostatectomy (OP): Implications for Radiation Field Design SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Hirsch, A. E.; Janicek, M. J.; Wang, D. S.; Babayan, R. K.; Zumwalt, A. C.] Boston Univ, Med Ctr, Boston, MA USA. [Hirsch, A. E.; Zietman, A. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mui, K.; Lee, R. J.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Ozonoff, A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S298 EP S299 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573601130 ER PT J AU Hoffman, KE Chen, M Nguyen, PL D'Amico, AV AF Hoffman, K. E. Chen, M. Nguyen, P. L. D'Amico, A. V. TI The use of Postprostatectomy Radiation Therapy in the United States: Patterns of Care SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Hoffman, K. E.; Nguyen, P. L.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, M.] Univ Connecticut, Storrs, CT USA. [D'Amico, A. V.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S90 EP S90 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600192 ER PT J AU Hong, TS DeLaney, TF Mamon, HJ Niemierko, A Adams, J Yeap, B Blaszkowsky, LS Ryan, DP Willett, CG Zhu, AX AF Hong, T. S. DeLaney, T. F. Mamon, H. J. Niemierko, A. Adams, J. Yeap, B. Blaszkowsky, L. S. Ryan, D. P. Willett, C. G. Zhu, A. X. TI Pilot of Respiratory Gated Proton Beam Therapy for Liver Tumors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Hong, T. S.; DeLaney, T. F.; Niemierko, A.; Adams, J.; Yeap, B.; Blaszkowsky, L. S.; Ryan, D. P.; Zhu, A. X.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mamon, H. J.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Willett, C. G.] Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S166 EP S166 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600354 ER PT J AU Igdem, S Spiegel, D Efstathiou, J Zietman, A Miller, R Poortmans, P Unsal, D AF Igdem, S. Spiegel, D. Efstathiou, J. Zietman, A. Miller, R. Poortmans, P. Unsal, D. TI Prostatic Duct Adenocarcinoma: Clinical Characteristics, Treatment Options and Outcomes: A Rare Cancer Network Study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Igdem, S.] Istanbul Bilim Univ, Istanbul, Turkey. [Spiegel, D.; Efstathiou, J.; Zietman, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Miller, R.] Mayo Clin, Rochester, MN USA. [Poortmans, P.] Dr Bernard Verbeeten Inst, Tilburg, Netherlands. [Unsal, D.] Gazi Univ, Ankara, Turkey. RI Poortmans, P.M.P./L-4581-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S300 EP S301 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573601134 ER PT J AU Landry, JC Catalano, P Cohen, SJ Staley, C Sigurdson, E Feng, Y Benson, AB AF Landry, J. C. Catalano, P. Cohen, S. J. Staley, C. Sigurdson, E. Feng, Y. Benson, A. B. TI Phase II Study of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin and Bevacizumab followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients with Locally Advanced Rectal Cancer: ECOG 3204 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Landry, J. C.; Staley, C.] Emory Univ, Atlanta, GA 30322 USA. [Catalano, P.; Feng, Y.] Dana Farber Canc Inst, Dept Stat, Boston, MA 02115 USA. [Cohen, S. J.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA. [Sigurdson, E.] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA. [Benson, A. B.] Northwestern Univ, Dept Med Oncol, Chicago, IL 60611 USA. NR 0 TC 3 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S27 EP S28 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600058 ER PT J AU Lee, LJ Schultz, D Tanaka, C Viswanathan, AN AF Lee, L. J. Schultz, D. Tanaka, C. Viswanathan, A. N. TI The Percentage of Positive Lymph Nodes is a Predictor of Survival in Uterine Papillary Serous Carcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Lee, L. J.] Harvard Radiat Oncol Program, Boston, MA USA. [Schultz, D.] Millersville Univ, Wickersham, PA USA. [Tanaka, C.; Viswanathan, A. N.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S372 EP S372 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573601293 ER PT J AU MacDonald, S Trofimov, A Safai, S Jordan, RC Ramesh, J Fullerton, B Adams, J Ebb, D Tarbell, NJ Yock, TI AF MacDonald, S. Trofimov, A. Safai, S. Jordan, R. C. Ramesh, J. Fullerton, B. Adams, J. Ebb, D. Tarbell, N. J. Yock, T. I. TI Proton Radiotherapy for Pediatric Central Nervous System Germ Cell Tumors: Early Clinical Outcomes SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [MacDonald, S.; Trofimov, A.; Safai, S.; Jordan, R. C.; Ramesh, J.; Fullerton, B.; Adams, J.; Ebb, D.; Tarbell, N. J.; Yock, T. I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S509 EP S510 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602038 ER PT J AU Mak, KS Lee, LK Mak, RH Wang, S Pile-Spellman, J Balboni, TA AF Mak, K. S. Lee, L. K. Mak, R. H. Wang, S. Pile-Spellman, J. Balboni, T. A. TI Underlying Cancer Diagnoses, Treatment Patterns, and Mortality in Hospitalizations for Malignant Spinal Cord Compression in the United States, 1998-2006 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Mak, K. S.] Harvard Univ, Sch Med, Boston, MA USA. [Lee, L. K.; Pile-Spellman, J.] Columbia Univ, Med Ctr, Div Intervent Neuroradiol, New York, NY USA. [Mak, R. H.] Harvard Radiat Oncol Residency Program, Boston, MA USA. [Wang, S.] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY USA. [Balboni, T. A.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S132 EP S132 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600282 ER PT J AU Mak, RH Halasz, LM Schultz, DJ Tanaka, C Ancukiewicz, M Russell, AH Viswanathan, AN AF Mak, R. H. Halasz, L. M. Schultz, D. J. Tanaka, C. Ancukiewicz, M. Russell, A. H. Viswanathan, A. N. TI Weekly Platinum or 5-Fluorouracil-containing Chemotherapy with Radiation Therapy for Squamous Cell Carcinoma of the Vulva SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Mak, R. H.; Halasz, L. M.] Harvard Radiat Oncol Program, Boston, MA USA. [Schultz, D. J.] Millersville Univ Pennsylvania, Dept Math, Millersville, PA 17551 USA. [Tanaka, C.; Viswanathan, A. N.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA USA. [Tanaka, C.; Ancukiewicz, M.; Russell, A. H.; Viswanathan, A. N.] Harvard Univ, Sch Med, Boston, MA USA. [Ancukiewicz, M.; Russell, A. H.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S152 EP S152 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600324 ER PT J AU Makrigiorgos, M Sridhar, S Suh, W D'Amico, A Cormack, R AF Makrigiorgos, M. Sridhar, S. Suh, W. D'Amico, A. Cormack, R. TI Biological In Situ Dose-painting for Image-guided Radiation Therapy using Drug-loaded Implantable Devices SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Makrigiorgos, M.; Sridhar, S.; Suh, W.; D'Amico, A.; Cormack, R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S711 EP S712 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602487 ER PT J AU Mamon, HJ Killoran, JH Blake, MA Hong, TS AF Mamon, H. J. Killoran, J. H. Blake, M. A. Hong, T. S. TI Impact of F-18-Fluoro-3 '-Deoxy-3 '-L-Fluorothymidine (FLT) PET/CT on GTV Identification and Definition for Pancreatic Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-09, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Mamon, H. J.; Killoran, J. H.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Blake, M. A.; Hong, T. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 SU S BP S266 EP S266 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573601058 ER PT J AU Martin, NE Ng, AK Luthy, SK Webber, BT Freedman, AS Mauch, PM AF Martin, N. E. Ng, A. K. Luthy, S. K. Webber, B. T. Freedman, A. S. Mauch, P. M. TI Local Progression after Low-dose Involved-field Radiation for Non-Hodgkin Lymphoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Martin, N. E.] Harvard Radiat Oncol Program, Boston, MA USA. [Ng, A. K.; Luthy, S. K.; Webber, B. T.; Mauch, P. M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. RI Martin, Neil/E-2193-2014 OI Martin, Neil/0000-0002-8164-8516 NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S481 EP S481 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573601532 ER PT J AU Nanda, A Chen, M Braccioforte, MH Moran, BJ D'Amico, AV AF Nanda, A. Chen, M. Braccioforte, M. H. Moran, B. J. D'Amico, A. V. TI Cardiac Comorbidity and Mortality in Men with Prostate Cancer Treated with Brachytherapy with or without Neoadjuvant Hormonal Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Nanda, A.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, M.] Univ Connecticut, Storrs, CT USA. [Braccioforte, M. H.; Moran, B. J.] Prostate Canc Fdn Chicago, Westmont, IL USA. [D'Amico, A. V.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S88 EP S88 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600188 ER PT J AU Nguyen, PL Chen, MH Beard, CJ Suh, WW Choueiri, TK Efstathiou, JA Hoffman, KE Loffredo, M Kantoff, PW D'Amico, AV AF Nguyen, P. L. Chen, M. H. Beard, C. J. Suh, W. W. Choueiri, T. K. Efstathiou, J. A. Hoffman, K. E. Loffredo, M. Kantoff, P. W. D'Amico, A. V. TI Comorbidity, Body Mass Index, and Age and the Risk of Non-prostate Cancer-specific Mortality following a Postradiation PSA Recurrence SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Nguyen, P. L.; Beard, C. J.; Suh, W. W.; Choueiri, T. K.; Loffredo, M.; Kantoff, P. W.; D'Amico, A. V.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, M. H.] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA. [Efstathiou, J. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hoffman, K. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S495 EP S495 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602007 ER PT J AU Parmar, KM Raad, RA Niemierko, A Specht, M Smith, B Taghian, A AF Parmar, K. M. Raad, R. A. Niemierko, A. Specht, M. Smith, B. Taghian, A. TI Decision-making in Early Breast Cancer Patients with Positive Margins after Re-excision: Continue Re-excisions or Convert to Mastectomy? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Raad, R. A.; Niemierko, A.; Taghian, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. [Specht, M.; Smith, B.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Div Surg Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S193 EP S193 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600411 ER PT J AU Quon, H Langer, CJ Lee, J Patel, UA Shin, DM Argiris, A Ridge, JA Forastiere, AA AF Quon, H. Langer, C. J. Lee, J. Patel, U. A. Shin, D. M. Argiris, A. Ridge, J. A. Forastiere, A. A. TI E3303: A Phase II Study of Cetuximab (C225) in Combination with Cisplatin (DDP) and Definitive Radiation (XRT) in Unresectable Squamous Cell Carcinoma of the Head and Neck (U-SCCHN) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Quon, H.; Langer, C. J.] Univ Penn, Philadelphia, PA 19104 USA. [Lee, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Patel, U. A.] John H Stroger Hosp Cook Cty, Chicago, IL USA. [Shin, D. M.] Emory Univ, Atlanta, GA 30322 USA. [Argiris, A.] Univ Pittsburgh, Pittsburgh, PA USA. [Ridge, J. A.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Forastiere, A. A.] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 2 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S15 EP S15 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600031 ER PT J AU Russell, TA O'Toole, J Ancukiewicz, M Singer, M Raad, RA Specht, M Smith, BL Taghian, AG AF Russell, T. A. O'Toole, J. Ancukiewicz, M. Singer, M. Raad, R. Abi Specht, M. Smith, B. L. Taghian, A. G. TI Prospective Analysis of Breast Cancer Associated Lymphedema: Utilizing Natural History to Inform Volumetric Thresholds for Intervention SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Russell, T. A.; O'Toole, J.; Ancukiewicz, M.; Singer, M.; Raad, R. Abi; Specht, M.; Smith, B. L.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S111 EP S111 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600238 ER PT J AU Schuller, BW Wolfgang, J Truong, M Hirsch, AE Nawaz, AO Willins, JD Chen, GTY Kachnic, LA AF Schuller, B. W. Wolfgang, J. Truong, M. Hirsch, A. E. Nawaz, A. O. Willins, J. D. Chen, G. T. Y. Kachnic, L. A. TI Assessment of Image Guidance Techniques for Tumor Bed Localization in Accelerated Partial Breast Irradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Schuller, B. W.; Truong, M.; Hirsch, A. E.; Willins, J. D.; Kachnic, L. A.] Boston Med Ctr, Boston, MA USA. [Schuller, B. W.; Wolfgang, J.; Truong, M.; Hirsch, A. E.; Willins, J. D.; Chen, G. T. Y.; Kachnic, L. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nawaz, A. O.] Paoli Mem Hosp, Paoli, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S576 EP S576 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602190 ER PT J AU Shah, MM Czito, B Duda, DG Mantyh, C Yea, JW Jain, RK Willett, CG AF Shah, M. M. Czito, B. Duda, D. G. Mantyh, C. Yea, J. W. Jain, R. K. Willett, C. G. TI Neoadjuvant Bevacizumab Does Not Appear to Contribute to Postoperative Complications after Surgery of Rectal Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Shah, M. M.; Czito, B.; Mantyh, C.; Yea, J. W.; Willett, C. G.] Duke Univ, Med Ctr, Durham, NC USA. [Duda, D. G.; Jain, R. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S264 EP S264 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573601054 ER PT J AU Sher, DJ Tishler, RB Annino, D Punglia, RS AF Sher, D. J. Tishler, R. B. Annino, D. Punglia, R. S. TI Cost-effectiveness of CT and PET-CT for Determining the Need for Adjuvant Neck Dissection in Locally Advanced Head and Neck Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Sher, D. J.; Tishler, R. B.; Annino, D.; Punglia, R. S.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S89 EP S89 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600189 ER PT J AU Sperduto, PW Chao, ST Sneed, PK Luo, X Roberge, D Bhatt, A Jensen, A Shih, H Kirkpatrick, J Schwer, A AF Sperduto, P. W. Chao, S. T. Sneed, P. K. Luo, X. Roberge, D. Bhatt, A. Jensen, A. Shih, H. Kirkpatrick, J. Schwer, A. TI Diagnosis-specific Prognostic Factors, Indices, and Treatment Outcomes for Patients with Newly-diagnosed Brain Metastases: A Multi-institutional Analysis of over 5000 Patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Sperduto, P. W.] Univ Minnesota, Gamma Knife Ctr, Minneapolis, MN USA. [Chao, S. T.] Cleveland Clin, Cleveland, OH 44106 USA. [Sneed, P. K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Luo, X.] Univ Minnesota, Div Biostat, Minneapolis, MN USA. [Roberge, D.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. [Bhatt, A.] Univ Wisconsin, Madison, WI USA. [Jensen, A.] Mayo Clin, Rochester, MN USA. [Shih, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kirkpatrick, J.] Duke Univ, Med Ctr, Durham, NC USA. [Schwer, A.] Univ Colorado, Denver, CO 80202 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S225 EP S225 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600482 ER PT J AU Tejwani, A Kobayashi, W Chen, Y Nielsen, GP Rosenberg, AL Yoon, SS Springfield, D Rosenthal, DI Homicek, FJ DeLaney, TF AF Tejwani, A. Kobayashi, W. Chen, Y. Nielsen, G. P. Rosenberg, A. L. Yoon, S. S. Springfield, D. Rosenthal, D. I. Homicek, F. J. DeLaney, T. F. TI Radiation Therapy in the Management of Acral Myxoinflammatory Fibroblastic Sarcoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Tejwani, A.] Tufts Univ, Lemuel Shattuck Hosp, Jamaica Plain, MA USA. [Chen, Y.; DeLaney, T. F.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Nielsen, G. P.; Rosenberg, A. L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Yoon, S. S.] Dept Surg, Sect Surg Oncol, Boston, MA USA. [Springfield, D.; Homicek, F. J.] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA. [Rosenthal, D. I.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S524 EP S525 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602072 ER PT J AU Trofimov, A Nguyen, PL Lu, MW Unkelbach, J Kang, J Bortfeld, T Zietman, AL AF Trofimov, A. Nguyen, P. L. Lu, M. W. Unkelbach, J. Kang, J. Bortfeld, T. Zietman, A. L. TI Feasibility of Hemi-prostate Dose Escalation to 91 Gy with 3D-conformal vs. Intensity-modulated Proton Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Trofimov, A.; Nguyen, P. L.; Lu, M. W.; Unkelbach, J.; Kang, J.; Bortfeld, T.; Zietman, A. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nguyen, P. L.] Harvard Radiat Oncol Program, Boston, MA USA. [Unkelbach, J.] Dalle Molle Inst Artificial Intelligence, Lugano, Switzerland. NR 0 TC 1 Z9 1 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S703 EP S704 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573602470 ER PT J AU Wang, JJ Adams, JG Liebsch, NJ McIntyre, JF Chan, AW Chan, AW AF Wang, J. J. Adams, J. G. Liebsch, N. J. McIntyre, J. F. Chan, A. W. Chan, A. W. TI Proton Beam Therapy for Unresectable Sinonasal Squamous Cell Carcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Wang, J. J.; Adams, J. G.; Liebsch, N. J.; McIntyre, J. F.; Chan, A. W.; Chan, A. W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S382 EP S383 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573601315 ER PT J AU Wear, C Wang, J Truong, M Liebsch, N Busse, P Clark, J Chan, A AF Wear, C. Wang, J. Truong, M. Liebsch, N. Busse, P. Clark, J. Chan, A. TI Preliminary Results of a Phase II Trial with Proton Beam Therapy for Nasopharyngeal Carcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Wear, C.; Wang, J.; Truong, M.; Liebsch, N.; Busse, P.; Clark, J.; Chan, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S422 EP S423 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573601404 ER PT J AU Willers, H Taghian, AG Luo, C Treszezamsky, A Sgroi, DC Powell, SN AF Willers, H. Taghian, A. G. Luo, C. Treszezamsky, A. Sgroi, D. C. Powell, S. N. TI Utility of Repair Protein Foci for the Detection of BRCA1 Defects in Breast Cancer Biopsies Ex Vivo SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Willers, H.; Taghian, A. G.; Luo, C.; Treszezamsky, A.; Sgroi, D. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Powell, S. N.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S20 EP S20 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600042 ER PT J AU Wo, JY Taghian, AG Nguyen, PL Raad, RA Sreedhara, M Bellon, JR Wong, JS Gadd, MA Smith, BL Harris, JR AF Wo, J. Y. Taghian, A. G. Nguyen, P. L. Raad, R. A. Sreedhara, M. Bellon, J. R. Wong, J. S. Gadd, M. A. Smith, B. L. Harris, J. R. TI The Association between Biologic Subtype and Isolated Regional Nodal Failure after Breast-conserving Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Wo, J. Y.; Nguyen, P. L.] Harvard Radiat Oncol Program, Boston, MA USA. [Taghian, A. G.; Raad, R. A.; Gadd, M. A.; Smith, B. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sreedhara, M.; Bellon, J. R.; Wong, J. S.; Harris, J. R.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S9 EP S9 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600019 ER PT J AU Zietman, AL Bae, K Rossi, C Slater, JD Efstathiou, JA Coen, JJ Lunt, M Spiegel, DY Skowronski, RY Shipley, WU AF Zietman, A. L. Bae, K. Rossi, C. Slater, J. D. Efstathiou, J. A. Coen, J. J. Lunt, M. Spiegel, D. Y. Skowronski, R. Y. Shipley, W. U. TI A Phase III Trial Employing Conformal Photons with Proton Boost in Early-stage Prostate Cancer: Conventional Dose (70.2 GyE) Compared to High-dose Irradiation (79.2 GyE): Long-term Updated Analysis of Proton Radiation Oncology Group (PROG)/American College of Radiology (ACR) 95-09 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-for-Radiation-Oncology CY NOV 01-05, 2009 CL Chicago, IL SP Amer Soc Radiat Oncol C1 [Zietman, A. L.; Efstathiou, J. A.; Coen, J. J.; Spiegel, D. Y.; Skowronski, R. Y.; Shipley, W. U.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bae, K.] Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Rossi, C.; Slater, J. D.; Lunt, M.] Loma Linda Univ, Med Ctr, Loma Linda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2009 VL 75 IS 3 BP S11 EP S11 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 503WW UT WOS:000270573600023 ER PT J AU El-Din, MAA Hughes, KS Finkelstein, DM Betts, KA Yock, TI Tarbell, NJ Aisenberg, AC Taghian, AG AF El-Din, Mohamed A. Alm Hughes, Kevin S. Finkelstein, Dianne M. Betts, Keith A. Yock, Torunn I. Tarbell, Nancy J. Aisenberg, Alan C. Taghian, Alphonse G. TI BREAST CANCER AFTER TREATMENT OF HODGKIN'S LYMPHOMA: RISK FACTORS THAT REALLY MATTER SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article; Proceedings Paper CT 49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY OCT 28-NOV 01, 2007 CL Los Angeles, CA SP Amer Soc Therapeut Radiol & Oncol DE Breast cancer; Risk; Hodgkin's lymphoma; Radiation ID ATOMIC-BOMB SURVIVORS; 2ND MALIGNANT-TUMORS; LONG-TERM SURVIVORS; RADIATION-THERAPY; YOUNG-WOMEN; DISEASE; IRRADIATION; CHEMOTHERAPY; RADIOTHERAPY; CHILDHOOD AB Purpose: To evaluate the risk of breast cancer (BC) and the contributing risk factors in women after supradiaphragmatic irradiation (SDI) for Hodgkin's lymphoma (HL). Subjects and Methods: Medical records of 248 women 60 years of age or less who received SDI for stage I/II HL between 1964 and 2001 at Massachusetts General Hospital were retrospectively reviewed. Results: The median age at SDI was 26 years (range, 5.7-59.3). The median follow-up was 15.2 years (range, 0.1=41.3). In 36 patients, BC developed (bilaterally in 11 patients) at a median interval of 18.4 years (range, 4.3-33.8) after SDI. Based on data from the National Cancer Institute Surveillance, Epidemiology, and End Results program, the standardized morbidity ratio (SMR) for the first BC after SDI was 9.78 (95% confidence interval [CI, 4.64-18.11, p < 0.0001). The SMR of patients who received radiation before age of 30 years was 19.05 (95% CI, 12.33-28.13) compared with 4.64 (95% CI, 2.31-8.30) for patients aged 30 years or more at the time of treatment (p < 0.00003). Risk for BC was significantly higher 15 years or more after SDI compared with the risk during the first 15 years (p = 0.0026). None of HL characteristics or treatment details was associated with higher risk of BC after adjusting for age and calendar time. Conclusions: Age at irradiation and time since therapy appear to be the only significant risk factors for development of BC after treatment of HL. The risk is significantly higher 15 years or more after radiation and for women treated before age 30 years. Long-term surveillance strategies are indicated for women at risk. (C) 2009 Elsevier Inc. C1 [El-Din, Mohamed A. Alm; Yock, Torunn I.; Tarbell, Nancy J.; Taghian, Alphonse G.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Hughes, Kevin S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA. [Finkelstein, Dianne M.; Betts, Keith A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. [Aisenberg, Alan C.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA. RP Taghian, AG (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox Bldg 302, Boston, MA 02114 USA. OI Betts, Keith/0000-0002-3088-7453; Hughes, Kevin/0000-0003-4084-6484 NR 45 TC 22 Z9 22 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2009 VL 73 IS 1 BP 69 EP 74 DI 10.1016/j.ijrobp.2008.03.066 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 385NF UT WOS:000261820200012 ER PT J AU Drappatz, J Wong, ET Schiff, D Kesari, S Batchelor, TT Doherty, L LaFrankie, DC Ramakrishna, N Weiss, S Smith, ST Ciampa, A Zimmerman, J Ostrowsky, L David, K Norden, A Barron, L Sceppa, C Black, PM Wen, PY AF Drappatz, Jan Wong, Eric T. Schiff, David Kesari, Santosh Batchelor, Tracy T. Doherty, Lisa LaFrankie, Debra Conrad Ramakrishna, Naren Weiss, Stephanie Smith, Sharon T. Ciampa, Abigail Zimmerman, Jennifer Ostrowsky, Louis David, Karly Norden, Andrew Barron, Loretta Sceppa, Christine Black, Peter M. Wen, Patrick Y. TI A PILOT SAFETY STUDY OF LENALIDOMIDE AND RADIOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Lenalidomide; Glioblastoma; Angiogenesis; Radiotherapy; Immunomodulatory ID ENDOTHELIAL-CELL MIGRATION; HIGH-GRADE GLIOMAS; PHASE-II TRIAL; PLUS DEXAMETHASONE; MULTIPLE-MYELOMA; COMBINATION THERAPY; MALIGNANT GLIOMA; THALIDOMIDE; TUMOR; BRAIN AB Purpose: To define the maximum tolerated dose (MTD) of lenalidomide, an analogue of thalidomide with enhanced immunomodulatory and antiangiogenic properties and a more favorable toxicity profile, in patients with newly diagnosed glioblastoma multiforme (GBM) when given concurrently with radiotherapy. Patients and Methods: Patients with newly diagnosed GBM received radiotherapy concurrently with lenalidomide given for 3 weeks followed by a 1-week rest period and continued lenalidomide until tumor progression or unacceptable toxicity. Dose escalation occurred in groups of 6. Determination of the MTD was based on toxicities during the first 12 weeks of therapy. The primary end point was toxicity. Results: Twenty-three patients were enrolled, of whom 20 were treated and evaluable for both toxicity and tumor response and 2 were evaluable for toxicity only. Common toxicities included venous thromboembolic disease, fatigue, and nausea. Dose-limiting toxicities were eosinophilic pneumonitis and transaminase elevations. The MTD for lenalidomide was determined to be 15 mg/m(2)/d. Conclusion: The recommended dose for lenalidomide with radiotherapy is 15 mg/m2/d for 3 weeks followed by a 1-week rest period. Venous thromboembolic complications occurred in 4 patients, and prophylactic anticoagulation should be considered. (C) 2009 Elsevier Inc. C1 [Drappatz, Jan; Kesari, Santosh; Doherty, Lisa; LaFrankie, Debra Conrad; Smith, Sharon T.; Ciampa, Abigail; Zimmerman, Jennifer; Ostrowsky, Louis; David, Karly; Norden, Andrew; Sceppa, Christine; Wen, Patrick Y.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dana Farber Brigham & Womens Canc Ctr,Ctr Neuroon, Boston, MA 02115 USA. [Drappatz, Jan; Kesari, Santosh; Norden, Andrew; Wen, Patrick Y.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Div Canc Neurol, Boston, MA 02115 USA. [Wong, Eric T.; Barron, Loretta] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA. [Schiff, David] Univ Virginia, Dept Neurol, Neurooncol Ctr, Charlottesville, VA USA. [Batchelor, Tracy T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Boston, MA 02115 USA. [Ramakrishna, Naren; Weiss, Stephanie] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA. [Black, Peter M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA. RP Drappatz, J (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dana Farber Brigham & Womens Canc Ctr,Ctr Neuroon, SW460,44 Binney St, Boston, MA 02115 USA. EM jdrappatz@partners.org RI Kesari, Santosh/E-8461-2013 NR 31 TC 24 Z9 25 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2009 VL 73 IS 1 BP 222 EP 227 DI 10.1016/j.ijrobp.2008.03.046 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 385NF UT WOS:000261820200034 PM 18513880 ER PT J AU Wagner, TD Kobayashi, W Dean, S Goldberg, SI Kirsch, DG Suit, HD Hornicek, FJ Pedlow, FX Raskin, KA Springfield, DS Yoon, SS Gebhardt, MC Mankin, HJ DeLaney, TF AF Wagner, Timothy D. Kobayashi, Wendy Dean, Susan Goldberg, Saveli I. Kirsch, David G. Suit, Herman D. Hornicek, Francis J. Pedlow, Francis X. Raskin, Kevin A. Springfield, Dempsey S. Yoon, Sam S. Gebhardt, Marc C. Mankin, Henry J. DeLaney, Thomas F. TI COMBINATION SHORT-COURSE PREOPERATIVE IRRADIATION, SURGICAL RESECTION, AND REDUCED-FIELD HIGH-DOSE POSTOPERATIVE IRRADIATION IN THE TREATMENT OF TUMORS INVOLVING THE BONE SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Radiotherapy; Chordoma; Chondrosarcoma; Proton therapy; Tumor seeding ID OSTEOSARCOMA STUDY-GROUP; PROGNOSTIC-FACTORS; RADIATION-THERAPY; CERVICAL-SPINE; CHORDOMA; EXPERIENCE; SARCOMA; CHONDROSARCOMA; RADIOTHERAPY; TISSUE AB Purpose: To assess the feasibility and outcomes of combination short-course preoperative radiation, resection, and reduced-field (tumor bed without operative field coverage) high-dose postoperative radiation for patients with solid tumors mainly involving the spine and pelvis. Methods and Materials: Between 1982 and 2006, a total of 48 patients were treated using this treatment strategy for solid tumors involving bone. Radiation treatments used both photons and protons. Results: Of those treated, 52% had chordoma, 31% had chondrosarcoma, 8% had osteosarcoma, and 4% had Ewing's sarcoma, with 71% involving the pelvis/sacrum and 21% elsewhere in the spine. Median preoperative dose was 20 Gy, with a median of 50.4 Gy postoperatively. With 31.8-month median follow-up, the 5-year overall survival (OS) rate is 65%; 5-year disease-free survival (DFS) rate, 53.8%; and 5-year local control (LC) rate, 72%. There were no significant differences in OS, DFS, and LC according to histologic characteristics. Between primary and recurrent disease, there was no significant difference in OS rates (74.4% vs. 51.4%, respectively; p = 0.128), in contrast to DFS (71.5% vs. 18.3%; p = 0.0014) and LC rates (88.9% vs. 30.9%; p = 0.0011) favoring primary disease. After resection, 10 patients experienced delayed wound healing that did not significantly impact on OS, DFS, or LC. Conclusion: This approach is promising for patients with bone sarcomas in which resection will likely yield close/ positive margins. It appears to inhibit tumor seeding with an acceptable rate of wound-healing complications. Dose escalation is accomplished without high-dose preoperative radiation (likely associated with higher rates of acute wound healing delays) or large-field postoperative radiation only (likely associated with late normal tissue toxicity). The LC and DFS rates are substantially better for patients with primary than recurrent sarcomas. Published by Elsevier Inc. C1 [Wagner, Timothy D.] Brooke Army Med Ctr, Dept Radiat Oncol, Ft Sam Houston, TX 78234 USA. [Kobayashi, Wendy; Dean, Susan; Goldberg, Saveli I.; Suit, Herman D.; DeLaney, Thomas F.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Hornicek, Francis J.; Pedlow, Francis X.; Raskin, Kevin A.; Springfield, Dempsey S.; Mankin, Henry J.] Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA. [Yoon, Sam S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Kirsch, David G.] Duke Univ, Sch Med, Dept Radiat Oncol, Durham, NC USA. [Gebhardt, Marc C.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Wagner, TD (reprint author), Brooke Army Med Ctr, Dept Radiat Oncol, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM timothy.wagner@amedd.army.mil NR 34 TC 26 Z9 27 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2009 VL 73 IS 1 BP 259 EP 266 DI 10.1016/j.ijrobp.2008.03.074 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 385NF UT WOS:000261820200039 PM 19100921 ER PT J AU Hui, ZG Tretiakova, M Zhang, ZF Li, Y Wang, XZ Xiaohong, JL Gao, YH Mai, WY Furge, K Qian, CN Amato, R Butler, EB Teh, BT Ten, BS AF Hui, Zhouguang Tretiakova, Maria Zhang, Zhongfa Li, Yan Wang, Xiaozhen Xiaohong, Julie Gao, Yuanhong Mai, Weiyuan Furge, Kyle Qian, Chao-Nan Amato, Robert Butler, E. Brian Teh, Bin Tean Ten, Bin S. TI RADIOSENSITIZATION BY INHIBITING STAT1 IN RENAL CELL CARCINOMA SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article; Proceedings Paper CT 48th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology CY NOV 05-09, 2006 CL Philadelphia, PA SP Amer Soc Therapeut Radiol & Oncol DE Renal cell carcinoma; Signal transducer and activator of transcription 1; STAT1; Gene expression; siRNA; Radiosensitization ID SIGNAL TRANSDUCERS; DNA-DAMAGE; GROWTH; ACTIVATION; RADIATION; TUMORS; APOPTOSIS; P53; EXPRESSION; RESISTANCE AB Purpose: Renal cell carcinoma (RCC) has been historically regarded as a radioresistant malignancy, but the molecular mechanism underlying its radioresistance is not understood. This study investigated the role of signal transducer and activator of transcription 1 (STAT1), a transcription factor downstream of the interferon-signaling pathway, in radioresistant RCC. Methods and Materials: The expressions of STAT1 and STAT3 in 164 human clear cell RCC samples, 47 papillary RCC samples, and 15 normal kidney tissue samples were examined by microarray expression profiling and immunohistochemistry. Western blotting was performed to evaluate the total and phosphorylated STAT1 expression in CRL-1932 (786-0) (human clear cell RCC), SKRC-39 (human papillary RCC), CCL-116 (human fibroblast), and CRL-1441 (G-401) (human Wilms tumor). STAT1 was reduced or inhibited by fludarabine and siRNA, respectively, and the effects on radiation-induced cell death were investigated using clonogenic assays. Results: STAT1 expression, but not STAT3 expression, was significantly greater in human RCC samples (p = 1.5 x 10(-8) for clear cell; and p = 3.6 x 10(-4) for papillary). Similarly, the expression of STAT1 was relatively greater in the two RCC cell lines. STAT1 expression was reduced by both fludarabine and siRNA, significantly increasing the radiosensitivity in both RCC cell lines. Conclusion: This is the first study reporting the overexpression of STAT1 in human clear cell and papillary RCC tissues. Radiosensitization in RCC cell lines was observed by a reduction or inhibition of STAT1 signaling, using fludarabine or siRNA. Our data suggest that STAT1 may play a key role in RCC radioresistance and manipulation of this pathway may enhance the efficacy of radiotherapy. (C) 2009 Elsevier Inc. C1 [Butler, E. Brian; Ten, Bin S.] Methodist Hosp, Dept Radiat Oncol, Houston, TX 77030 USA. [Hui, Zhouguang; Wang, Xiaozhen; Xiaohong, Julie; Gao, Yuanhong; Mai, Weiyuan] Baylor Coll Med, Dept Radiol, Div Radiat Oncol, Houston, TX 77030 USA. [Hui, Zhouguang; Wang, Xiaozhen] Chinese Acad Med Sci, Peking Union Med Coll, Canc Inst Hosp, Dept Radiat Oncol, Beijing 100037, Peoples R China. [Tretiakova, Maria] Univ Chicago, Pritzker Sch Med, Dept Pathol, Chicago, IL 60637 USA. [Zhang, Zhongfa; Li, Yan; Qian, Chao-Nan; Teh, Bin Tean] Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI USA. [Furge, Kyle] Van Andel Res Inst, Lab Computat Biol, Grand Rapids, MI USA. [Gao, Yuanhong; Qian, Chao-Nan] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou 510275, Guangdong, Peoples R China. [Amato, Robert] Methodist Hosp, Dept Genitourinary Oncol, Houston, TX 77030 USA. [Butler, E. Brian] Methodist Hosp, Res Inst, Houston, TX 77030 USA. [Ten, Bin S.] Michael E DeBakey Vet Affairs Med Ctr, Lab Radiat Biol Res, Houston, TX USA. RP Ten, BS (reprint author), Methodist Hosp, Dept Radiat Oncol, 6565 Fannin St, Houston, TX 77030 USA. EM bteh@tmhs.org NR 31 TC 23 Z9 27 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2009 VL 73 IS 1 BP 288 EP 295 DI 10.1016/j.ijrobp.2008.08.043 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 385NF UT WOS:000261820200043 PM 19100922 ER PT J AU Wroe, A Clasie, B Kooy, H Flanz, J Schulte, R Rosenfeld, A AF Wroe, Andrew Clasie, Ben Kooy, Hanne Flanz, Jay Schulte, Reinhard Rosenfeld, Anatoly TI OUT-OF-FIELD DOSE EQUIVALENTS DELIVERED BY PASSIVELY SCATTERED THERAPEUTIC PROTON BEAMS FOR CLINICALLY RELEVANT FIELD CONFIGURATIONS SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Proton therapy; Dose equivalent; Neutrons; Microdosimetry ID SOLID-STATE MICRODOSIMETRY; BIOL-PHYS 2006/65/1-7; RADIATION-THERAPY; SECONDARY NEUTRON; MONTE-CARLO; RADIOTHERAPY; DOSIMETRY; PHANTOMS; MOTHER; CANCER AB Purpose: Microdosimetric measurements were performed at Massachusetts General Hospital, Boston, MA, to assess the dose equivalent external to passively delivered proton fields for various clinical treatment scenarios. Methods and Materials: Treatment fields evaluated included a prostate cancer field, cranial and spinal medulloblastoma fields, ocular melanoma field, and a field for an intracranial stereotactic treatment. Measurements were completed with patient-specific configurations of clinically relevant treatment settings using a silicon-on-insulator microdosimeter placed on the surface of and at various depths within a homogeneous Lucite phantom. The dose equivalent and average quality factor were assessed as a function of both lateral displacement from the treatment field edge and distance downstream of the beam's distal edge. Results: Dose-equivalent value range was 8.3-0.3 mSv/Gy (2.5-60-cm lateral displacement) for a typical prostate cancer field, 10.8-0.58 mSv/Gy (2.5-40-cm lateral displacement) for the cranial medulloblastoma field, 2.5-0.58 mSv/Gy (5-20-cm lateral displacement) for the spinal medulloblastoma field, and 0.5-0.08 mSv/Gy (2.5-10-cm lateral displacement) for the ocular melanoma field. Measurements of external field dose equivalent for the stereotactic field case showed differences as high as 50% depending on the modality of beam collimation. Average quality factors derived from this work ranged from 2-7, with the value dependent on the position within the phantom in relation to the primary beam. Conclusions: This work provides a valuable and clinically relevant comparison of the external field dose equivalents for various passively scattered proton treatment fields. (C) 2009 Elsevier Inc. C1 [Wroe, Andrew; Schulte, Reinhard] Loma Linda Univ, Med Ctr, Dept Radiat Med, Loma Linda, CA USA. [Wroe, Andrew; Rosenfeld, Anatoly] Univ Wollongong, Ctr Med Radiat Phys, Wollongong, NSW 2522, Australia. [Clasie, Ben; Kooy, Hanne; Flanz, Jay] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Clasie, Ben; Kooy, Hanne; Flanz, Jay] Harvard Univ, Sch Med, Boston, MA USA. RP Wroe, A (reprint author), B121 11234 Anderson St, Loma Linda, CA 92354 USA. EM awroe@dominion.llumc.edu RI Rosenfeld, Anatoly/D-1989-2014 NR 34 TC 32 Z9 32 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JAN 1 PY 2009 VL 73 IS 1 BP 306 EP 313 DI 10.1016/j.ijrobp.2008.09.030 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 385NF UT WOS:000261820200045 PM 19100924 ER PT J AU Walsh, ME Wieneke, KM AF Walsh, Mary E. Wieneke, Kristin M. BE Deslandes, R TI Evaluation of comprehensive prevention-intervention partnership programmes for school children SO INTERNATIONAL PERSPECTIVES ON CONTEXTS, COMMUNITIES AND EVALUATED INNOVATIVE PRACTICES - FAMILY-SCHOOL-COMMUNITY PARTNERSHIPS SE Contexts of Learning LA English DT Article; Book Chapter ID PARENTAL INVOLVEMENT; ACADEMIC-ACHIEVEMENT; METAANALYSIS; BEHAVIOR C1 [Walsh, Mary E.; Wieneke, Kristin M.] Boston Coll, Dept Counseling Dev & Educ Psychol, Lynch Sch Educ, Chestnut Hill, MA 02167 USA. [Walsh, Mary E.] Boston Coll, Ctr Child Family & Community Partnerships, Chestnut Hill, MA 02167 USA. [Wieneke, Kristin M.] Massachusetts Gen Hosp, Dept Child Psychiat, Boston, MA 02114 USA. [Walsh, Mary E.; Wieneke, Kristin M.] Boston Connects, Boston, MA USA. RP Walsh, ME (reprint author), Boston Coll, Dept Counseling Dev & Educ Psychol, Lynch Sch Educ, Chestnut Hill, MA 02167 USA. NR 31 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-87566-7 J9 CONTEXTS LEARN PY 2009 BP 189 EP 203 PG 15 WC Education & Educational Research SC Education & Educational Research GA BND98 UT WOS:000274250300014 ER PT J AU Davis, MD Sheetz, MJ Aiello, LP Milton, RC Danis, RP Zhi, X Girach, A Jimenez, MC Vignati, L AF Davis, Matthew D. Sheetz, Matthew J. Aiello, Lloyd P. Milton, Roy C. Danis, Ronald P. Zhi, Xin Girach, Aniz Jimenez, Maria C. Vignati, Louis CA PKC DRS2 Study Grp TI Effect of Ruboxistaurin on the Visual Acuity Decline Associated with Long-standing Diabetic Macular Edema SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID PROTEIN-KINASE-C; PKC-BETA; RETINOPATHY; GROWTH; NEOVASCULARIZATION; INHIBITION; ACTIVATION; ISOFORMS AB PURPOSE. To compare relationships between severity and duration of diabetic macular edema (DME) and visual acuity (VA) observed in the PKC-DRS2 with those from the Early Treatment Diabetic Retinopathy Study (ETDRS) and to assess the effect of the orally administered PKC beta inhibitor ruboxistaurin (RBX) on these parameters. METHODS. In the PKC-DRS2, patients with moderately severe to very severe nonproliferative diabetic retinopathy (n = 685) were randomly assigned to 32 mg/d RBX or placebo and followed up for 36 months with ETDRS VA measurements and fundus photographs (FP) every 3 to 6 months. Mean VA was calculated across all FP visits for eyes in each level of the ETDRS DME severity scale at those visits. For eyes with baseline VA >= 20/40, relationships between change in VA from baseline to last visit and duration of severe DME were analyzed with linear regression. RESULTS. Mean VA decreased by approximately 22 letters between the mildest and most severe levels of the DME scale in the PKC-DRS2, compared with 27 letters in the ETDRS. In the placebo group, the rate of decrease in VA over time associated with duration of severe DME was 0.67 letters per month (24 letters over 36 months, compared with 20 letters over 28-36 months in the ETDRS). This rate was 30% less in the RBX group (0.47 letter per month, P = 0.022). CONCLUSIONS. The VA decrease in the PKC-DRS2 associated with long-standing DME agrees well with estimates from the ETDRS. RBX appears to ameliorate this decrease, an effect that could be important clinically. (ClinicalTrials.gov number, NCT00604383.) (Invest Ophthalmol Vis Sci. 2009; 50: 1-4) DOI: 10.1167/iovs.08-2473 C1 [Sheetz, Matthew J.] Eli Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA. [Davis, Matthew D.; Danis, Ronald P.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA. [Aiello, Lloyd P.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02115 USA. [Aiello, Lloyd P.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Milton, Roy C.] EMMES Corp, Rockville, MD USA. [Girach, Aniz] Lilly Res Labs, Windlesham, Surrey, England. RP Sheetz, MJ (reprint author), Eli Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA. EM msheetz@lilly.com FU Eli Lilly Company FX Supported by Eli Lilly & Company. NR 16 TC 42 Z9 46 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JAN PY 2009 VL 50 IS 1 BP 1 EP 4 DI 10.1167/iovs.08-2473 PG 4 WC Ophthalmology SC Ophthalmology GA 390YP UT WOS:000262199900001 PM 18708615 ER PT J AU Osborn, EA Jaffer, FA AF Osborn, Eric A. Jaffer, Farouc A. TI The Year in Molecular Imaging SO JACC-CARDIOVASCULAR IMAGING LA English DT Article DE molecular imaging; atherosclerosis; myocardial infarction; heart failure; thrombosis ID POSITRON-EMISSION-TOMOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; IN-VIVO; ATHEROSCLEROTIC LESIONS; NONINVASIVE DETECTION; CONTRAST AGENT; PLAQUE INFLAMMATION; VULNERABLE PLAQUE; IRON-OXIDE; PET C1 [Jaffer, Farouc A.] Harvard Univ, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Cardiol Div,Med Sch, Boston, MA 02114 USA. [Jaffer, Farouc A.] Harvard Univ, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Sch Med, Boston, MA 02114 USA. [Osborn, Eric A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Beth Israel Deaconess Med Ctr, Boston, MA 02114 USA. RP Jaffer, FA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Cardiol Div,Med Sch, 185 Cambridge St,Simches Res Bldg 3206, Boston, MA 02114 USA. EM fjaffer@mgh.harvard.edu OI Jaffer, Farouc/0000-0001-7980-384X FU Howard Hughes Medical Institute; American Heart Association; Donald W. Reynolds Foundation FX Dr. Jaffer is a consultant for VisEn Medical and has received financial support from Howard Hughes Medical Institute Early Career Award, American Heart Association Scientist Development Grant, and the Donald W. Reynolds Foundation. NR 40 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD JAN PY 2009 VL 2 IS 1 BP 97 EP 113 DI 10.1016/j.jcmg.2008.11.001 PG 17 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 725NJ UT WOS:000287651900017 PM 19356541 ER PT J AU Joyce, VR Barnett, PG Bayoumi, AM Griffin, SC Kyriakides, TC Yu, W Sundaram, V Holodniy, M Brown, ST Cameron, W Youle, M Sculpher, M Anis, AH Owens, DK AF Joyce, Vilija R. Barnett, Paul G. Bayoumi, Ahmed M. Griffin, Susan C. Kyriakides, Tassos C. Yu, Wei Sundaram, Vandana Holodniy, Mark Brown, Sheldon T. Cameron, William Youle, Mike Sculpher, Mark Anis, Aslam H. Owens, Douglas K. TI Health-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 26th Annual Meeting of the Society-for-Medical-Decision-Making CY OCT 17-20, 2004 CL Atlanta, GA SP Soc Med Decis Making DE AIDS; highly active antiretroviral therapy; health status indicators; highly active; HIV; quality of life ID HUMAN-IMMUNODEFICIENCY-VIRUS; 2 NUCLEOSIDE ANALOGS; CD4 CELL COUNTS; MENTAL-HEALTH; CYTOMEGALOVIRUS RETINITIS; POSITIVE PATIENTS; INFECTED PATIENTS; CUBIC MILLIMETER; MEDICAL OUTCOMES; CLINICAL-TRIAL AB Objective: To assess and compare alternative approaches of measuring preference-based health-related quality of life (HRQoL) in treatment-experienced HIV patients and evaluate their association with health status and clinical variables. Design: Cross-sectional study. Setting: Twenty-eight Veterans Affairs hospitals in the United States, 13 hospitals in Canada. and 8 hospitals in the United Kingdom. Patients: Three hundred sixty-eight treatment-experienced HIV-infected patients enrolled in the Options in Management with Antiretrovirals randomized trial. Measurements: Baseline sociodemographic and clinical indicators and baseline HRQoL using the Medical Outcome Study HIV Health Survey (MOS-HIV), the EQ-5D, the EQ-5D visual analog scale (EQ-5D VAS), the Health Utilities Index Mark 3 (HUI3), and standard gamble (SG) and time trade-off (TTO) techniques. Results: The mean (SD) baseline HRQoL scores were as follows: MOS-HIV physical health summary score 41.70 (11.16), MOS-HIV mental health summary score 44.76 (11.38), EQ-5D 0.77 (0.19), HUI3 0.59 (0.32), EQ-5D VAS 65.94 (21.71), SG 0.75 (0.29), and TTO 0.80 (0.31). Correlations between MOS-HIV summary scores and EQ-5D, EQ-5D VAS, and HUI3 ranged from 0.60 to 0.70; the correlation between EQ-5D and HUI3 was 0.73; and the correlation between SG and TTO was 0.43. Preference-based HRQoL scores were related to physical, mental, social, and overall health as measured by MOS-HIV Concomitant medication use, CD4(+) cell count, and HIV viral load were related to some instruments' scores. Conclusions: On average, preference-based HRQoL for treatment-experienced HIV patients was decreased relative to national norms but also highly variable. Health status and clinical variables were related to HRQoL. C1 [Joyce, Vilija R.; Barnett, Paul G.; Yu, Wei] Hlth Econ Resource Ctr, Vet Affairs Cooperat Studies Program Coordinating, Vet Affairs Hlth Serv,Res & Dev Serv, Vet Affairs Palo Alto Hlth Care Syst, Menlo Pk, CA 94025 USA. [Bayoumi, Ahmed M.] Univ Toronto, Ctr Res Inner City Hlth, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5S 1A1, Canada. [Bayoumi, Ahmed M.] Univ Toronto, St Michaels Hosp, Div Gen Internal Med, Toronto, ON M5S 1A1, Canada. [Bayoumi, Ahmed M.] Univ Toronto, Dept Med & Hlth Policy, Toronto, ON M5S 1A1, Canada. [Bayoumi, Ahmed M.] Univ Toronto, Dept Management, Toronto, ON M5S 1A1, Canada. [Bayoumi, Ahmed M.] Univ Toronto, Dept Evaluat, Toronto, ON M5S 1A1, Canada. [Griffin, Susan C.; Sculpher, Mark] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England. [Kyriakides, Tassos C.] Vet Affairs Cooperat Studies Program Coordinating, Vet Affairs Connecticut Hlth Care Syst, West Haven, CT USA. [Sundaram, Vandana; Holodniy, Mark; Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Sundaram, Vandana; Owens, Douglas K.] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA. [Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Cameron, William] Univ Ottawa, Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada. [Youle, Mike] Royal Free Hosp, London NW3 2QG, England. [Anis, Aslam H.] Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada. [Anis, Aslam H.] Canadian HIV Trials Network, Vancouver, BC, Canada. RP Joyce, VR (reprint author), Hlth Econ Resource Ctr, Vet Affairs Cooperat Studies Program Coordinating, Vet Affairs Hlth Serv,Res & Dev Serv, Vet Affairs Palo Alto Hlth Care Syst, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA. EM vilija.joyce@va.gov RI Joyce, Vilija/A-2578-2013; OI Joyce, Vilija/0000-0002-2484-4625; Cameron, Bill/0000-0002-0090-3539 FU Medical Research Council NR 44 TC 14 Z9 14 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2009 VL 50 IS 1 BP 27 EP 36 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 388KQ UT WOS:000262019100004 PM 19295332 ER PT J AU Mimiaga, MJ Case, P Johnson, CV Safren, SA Mayer, KH AF Mimiaga, Matthew J. Case, Patricia Johnson, Carey V. Safren, Steven A. Mayer, Kenneth H. TI Preexposure Antiretroviral Prophylaxis Attitudes in High-Risk Boston Area Men Who Report Having Sex With Men: Limited Knowledge and Experience but Potential for Increased Utilization After Education SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV/AIDS; MSM; nPEP; preexposure prophylaxis; prevention ID GAY PRIDE EVENTS; POSTEXPOSURE PROPHYLAXIS; CAGE QUESTIONNAIRE; HIV PREVENTION; BISEXUAL MEN; CHEMOPROPHYLAXIS; ALCOHOLISM; ATTENDEES; BEHAVIOR; EXPOSURE AB Background: Preexposure prophylaxis (PrEP) Could protect individuals engaging in repeated high-risk behaviors from HIV infection. Understanding the demographic and behavioral predictors of intent-to-use PrEP may prove useful to identify clinical trial participants. Methods: In 2007, 227 HIV uninfected men who report having sex with men (MSM) recruited through modified respondent-driven sampling completed an interviewer-administered survey assessing prior PrEP use and awareness, future intent-to-use PrEP, demographics, Sexual risk, psychosocial variables, and drug/alcohol use. Bivariate and multivariable logistic regression procedures examined predictors of intent-to-use PrEP. Results: Mean age of participants was 41 (SD = 9.1); 54% were nonwhite. One participant reported prior off-label PrEP use (medication obtained from his HIV infected brother). Nineteen percent had previously heard of PrEP, whereas 74% reported intent-to-use PrEP if available after being educated about its potential. In multivariable analysis controlling for age and race/ethnicity, significant predictors of intent-to-use PrEP included the following: less education [odds ratio (OR) = 7.7; P = 0.04], moderate income (OR = 13.0; P = 0.04), no perceived side effects from taking PrEP (OR = 3.5; P = 0.001), and not having to pay for PrEP (OR 4.2; P = 0.05). Discussion: Many New England MSM indicated an interest in using PrEP after learning about its potential, particularly if they could obtain PrEP at no expense and if PrEP had no side effects. Less educated MSM and those who knew less about PrEP and antiretroviral therapy before entering the study were more open to using antiretroviral therapy for prevention once they had received some information suggesting its potential value. Findings suggest that careful educational messages are necessary to ensure appropriate PrEP use if clinical trials reveal partial efficacy. C1 [Mimiaga, Matthew J.; Case, Patricia; Johnson, Carey V.; Safren, Steven A.; Mayer, Kenneth H.] Fenway Community Hlth, Fenway Inst, Boston, MA 02119 USA. [Mimiaga, Matthew J.; Safren, Steven A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Case, Patricia] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Mayer, Kenneth H.] Miriam Hosp, Brown Med Sch, Providence, RI 02906 USA. RP Mimiaga, MJ (reprint author), Fenway Community Hlth, Fenway Inst, Prudential Tower,4th Floor,800 Boylston St, Boston, MA 02119 USA. EM mmimiaga@fenwayhealth.org FU National Institute of Mental Health [R01MH068746]; Lifespan-Tufts-Brown Center for AIDS Research [P30AI42853] FX Supported by an Office of AIDS Research supplement to grant number R01MH068746, from the National Institute of Mental Health to Dr. K.H.M., and from the Lifespan-Tufts-Brown Center for AIDS Research grant number P30AI42853 (Principal Investigator Dr. Charles C. J. Carpenter). NR 30 TC 115 Z9 127 U1 3 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2009 VL 50 IS 1 BP 77 EP 83 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 388KQ UT WOS:000262019100009 PM 19295337 ER PT J AU Freeman, MP AF Freeman, Marlene P. TI Complementary and alternative medicine for perinatal depression SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Review DE Pregnant; Postpartum; Perinatal; Depression; Omega-3; Exercise; Acupuncture; S-adenosyl-methionine; St. John's Wort; Light therapy ID ST-JOHNS-WORT; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL; BRIGHT LIGHT TREATMENT; ADENOSYL-L-METHIONINE; HYPERICUM-PERFORATUM; POSTPARTUM DEPRESSION; MAJOR DEPRESSION; NATIONAL-SURVEY; DOUBLE-BLIND AB Introduction: Perinatal Major Depressive Disorder (MDD) is common and poses particular treatment dilemmas. Complementary and Alternative Medicine (CAM) treatments are widely used, accessible, and understudied for well-defined psychiatric indications, Women are more likely than men to both suffer from MDD and use CAM. Methods: A PubMed/Medline search was conducted to assess the evidence base for commonly utilized CAM treatments, MDD, and perinatal depression. Results: Among CAM treatments, omega-3 fatty acids have received the most specific Study in terms of epidemiological, preclinical, and clinical research for perinatal depression. Three randomized placebo-controlled trials have been conducted in which investigators assessed omega-3 fatty acids vs. placebo for perinatal depression, with conflicting results. CAM interventions that call be easily added to a treatment plan with little risk and general health benefits for most women include omega-3 fatty acids, exercise, and folate, although data are insufficient at this time to recommend any of these as monotherapy for perinatal depression. S-adenosyl-methionine (SAMe) and bright light therapy may be reasonable to consider based on the evidence in MDD. St. John's Wort requires further Study with regard to safety in pregnancy, and drug interactions can be a potential problem. Discussion: Further study is required to elucidate the role of CAM treatments for perinatal depression, and the clinical context of perinatal depression requires safe, effective, and accessible treatment options. (c) 2008 Elsevier B.V. All rights reserved. C1 [Freeman, Marlene P.] Univ Texas SW Med Ctr Dallas, Womens Mental Hlth Ctr, Dallas, TX 75235 USA. RP Freeman, MP (reprint author), Massachusetts Gen Hosp, Simches Res Bldg,Floor 2 185 Cambridge St, Boston, MA 02114 USA. EM marlene.freeman@utsouthwestern.edu NR 95 TC 22 Z9 22 U1 6 U2 19 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN PY 2009 VL 112 IS 1-3 BP 1 EP 10 DI 10.1016/j.jad.2008.06.017 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 385UW UT WOS:000261840100001 PM 18692251 ER PT J AU Kilboume, AM Biswas, K Pirraglia, PA Sajatovic, M Williford, WO Bauer, MS AF Kilboume, Amy M. Biswas, Kousick Pirraglia, Paul A. Sajatovic, Martha Williford, William O. Bauer, Mark S. TI Is the collaborative chronic care model effective for patients with bipolar disorder and co-occurring conditions? SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article; Proceedings Paper CT International Conference of the World-Psychiatric-Association on Mental Health Policy and Economics CY MAR 09-14, 2007 CL Venice, ITALY SP World Psychiat Assoc DE Mood disorders-bipolar; Cardiovascular disease; Substance use disorders; Collaborative care; Interaction ID RANDOMIZED EFFECTIVENESS TRIAL; COGNITIVE-BEHAVIORAL THERAPY; EFFICACY; PROGRAM; DISEASE; INTERVENTION; COMORBIDITY; DEPRESSION; SUBSTANCE; ANXIETY AB Background: The effectiveness of bipolar collaborative chronic care models (B-CCMs) among those with co-occurring Substance use, psychiatric, and/or medical conditions has not specifically been assessed. We assessed whether B-CCM effects are equivalent comparing those with and without co-occurring conditions. Methods: We reanalyzed data from the VA Cooperative Study #430 (n = 290), an 11-site randomized controlled trial of the B-CCM compared to usual care. Moderators included common co-occurring conditions observed in patients with bipolar disorder, including substance use disorders (SUD), anxiety, psychosis; medical comorbidities (total number), and cardiovascular disease-related conditions (CVD). Mixed-effects regression models were used to determine interactive effects between moderators and 3-year primary Outcomes. Results: Treatment effects were comparable for those with and without co-occurring substance use and psychiatric conditions, although possibly less effective in improving physical quality of life in those with CVD-related conditions (Beta = -6.11; p = 0.04). Limitations: Limitations included multiple comparisons and underpowered analyses of moderator effects. Conclusions: B-CCM effects were comparable in patients with co-occurring conditions, indicating that the intervention may be generally applied. Specific attention to physical quality of life in those with CVD maybe warranted. Published by Elsevier B.V. C1 [Kilboume, Amy M.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Kilboume, Amy M.] Univ Michigan, VA Ann Arbor Serious Mental Illness Treatment Res, Ann Arbor, MI 48109 USA. [Biswas, Kousick; Williford, William O.] VA Maryland Hlth Care Syst, Coordinating Ctr, Cooperat Studies Program, Perry Point, MD USA. [Pirraglia, Paul A.] Providence VA Med Ctr, Providence, RI USA. [Pirraglia, Paul A.] Brown Univ, Providence, RI 02912 USA. [Sajatovic, Martha] Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Cleveland, OH 44106 USA. [Bauer, Mark S.] VA Boston Healthcare Syst, Boston, MA USA. RP Kilboume, AM (reprint author), VA Ann Arbor SMITREC 11H, 2215 Fuller Rd, Ann Arbor, MI 48105 USA. EM amykilbo@umich.edu RI Sajatovic, Martha/I-8001-2014 NR 29 TC 15 Z9 15 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN PY 2009 VL 112 IS 1-3 BP 256 EP 261 DI 10.1016/j.jad.2008.04.010 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 385UW UT WOS:000261840100031 PM 18504059 ER PT J AU Hedrick, SC Sullivan, JH Sales, AEB Gray, SL AF Hedrick, Susan C. Sullivan, Jean H. Sales, Anne E. B. Gray, Shelly L. TI Mom and Pop Versus the Big Boys: Adult Family Homes as Providers of Medicaid-Funded Residential Care SO JOURNAL OF AGING & SOCIAL POLICY LA English DT Article DE long-term care; residential care; assisted living; adult family homes ID ASSISTED LIVING FACILITIES; PROGRAM; OUTCOMES; OREGON AB This paper compares assisted living apartments (ALs), adult residential care facilities (ARCs), and small adult family homes (AFHs) for Medicaid residents in Washington State, with particular emphasis on the settings, staffing, services, and policies of AFHs. We targeted for enrollment all residents entering an AFH, ARC, or AL setting on Medicaid/state funding in a three-county area of Washington State. We obtained information on 199 settings, interviewing administrative and direct care providers. AFHs are smaller than ARCs and ALs and less likely to be part of a chain, with no significant difference in staffing ratios of registered nurses and licensed practical nurses. Sixty-four percent of AFH residents were receiving public funds compared to 32% of AL residents. AFHs report admitting residents with more activities of daily living needs, health conditions, and behavior problems. They are less likely to have autonomy-related policies, and they provide more services and fewer activities. While attention should continue to be paid to staff supports, policy and practice should support the continued role of AFHs, which are of special interest because of their potential to provide more homelike, less costly care but with possible trade-offs compared to larger facilities. C1 [Hedrick, Susan C.; Sullivan, Jean H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA. [Hedrick, Susan C.] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA. [Sales, Anne E. B.] Univ Alberta, Fac Nursing, Calgary, AB, Canada. [Gray, Shelly L.] Univ Washington, Sch Pharm, Pharm Program Geriatr, Seattle, WA 98195 USA. RP Hedrick, SC (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM susan.hedrick@va.gov RI Sales, Anne/D-9678-2012; OI Sales, Anne/0000-0001-9360-3334 NR 34 TC 1 Z9 1 U1 1 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0895-9420 J9 J AGING SOC POLICY JI J. Aging Soc. Policy PY 2009 VL 21 IS 1 BP 31 EP 51 DI 10.1080/08959420802523153 PG 21 WC Gerontology SC Geriatrics & Gerontology GA 669BN UT WOS:000283321500003 PM 19197607 ER PT J AU Mikhak, Z Fukui, M Farsidjani, A Medoff, BD Tager, AM Luster, AD AF Mikhak, Zamaneh Fukui, Mieko Farsidjani, Alireza Medoff, Benjamin D. Tager, Andrew M. Luster, Andrew D. TI Contribution of CCR4 and CCR8 to antigen-specific T(H)2 cell trafficking in allergic pulmonary inflammation SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE CCR4; CCR8; CXCR3; asthma; chemokine; T-cell trafficking ID CHEMOKINE RECEPTORS CCR4; T-CELLS; AIRWAY INFLAMMATION; CUTTING EDGE; TH2 CELLS; ATOPIC ASTHMATICS; MOUSE MODEL; RECRUITMENT; EXPRESSION; MICE AB Background: Recruitment of antigen-specific T(H)2 cells into the lung is critical for the development of allergic airway inflammation. Although CCR4 and CCR8 are preferentially expressed on T(H)2 cells and CCR4, CCR8, and CXCR3 ligands are increased in asthma, the specific relative contribution of these receptors to antigen-specific T(H)2 cell trafficking into the allergic lung is not known. Objective: To determine the relative contribution of the chemokine receptors CCR4, CCR8, and CXCR3 to antigen-specific T(H)2 cell trafficking in a murine model of allergic pulmonary inflammation. Methods: We used adoptive transfer experiments to compare the trafficking of wild-type antigen-specific T(H)2 cells with antigen-specific T(H)2 cells deficient in CCR4, CCR8, or CXCR3. Results: CCR4-deficient antigen-specific T(H)2 cells failed to traffic efficiently into the lung and the airways. In contrast, CCR8-deficient antigen-specific T(H)2 cells accumulated in these sites. Trafficking of CXCR3-deficient antigen-specific T(H)2 cells and CCR4-deficient and CCR8-deficient antigen-specific Till cells were comparable to their wild-type counterparts. Approximately 60% of IL-4-producing antigen-specific T cells expressed CCR4. Disruption of CCR4-mediated antigen-specific T(H)2 cell trafficking decreased the levels of T(H)2-type cytokines in the airways and reduced airway eosinophilia and mucus production. Conclusions: Our study demonstrates that CCR4 is required for file efficient entry of antigen-specific T(H)2 cells into the lung and the airways in a murine model of allergic pulmonary inflammation. (J Allergy Clin Immunol 2009;123:67-73.) C1 [Mikhak, Zamaneh; Fukui, Mieko; Farsidjani, Alireza; Medoff, Benjamin D.; Tager, Andrew M.; Luster, Andrew D.] Harvard Univ, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Sch Med,Div Rheumatol Allergy & Immunol, Charlestown, MA 02129 USA. [Medoff, Benjamin D.; Tager, Andrew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit, Charlestown, MA 02129 USA. RP Luster, AD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Sch Med,Div Rheumatol Allergy & Immunol, 149 13th St,Room 8301, Charlestown, MA 02129 USA. EM aluster@mgh.harvard.edu FU National Institutes of Health [R37-AI40618, K08AI67519] FX supported by the National Institutes of Health (R37-AI40618 to A.D.L. and K08AI67519 to Z.M.). NR 36 TC 49 Z9 49 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD JAN PY 2009 VL 123 IS 1 BP 67 EP 73 DI 10.1016/j.jaci.2008.09.049 PG 7 WC Allergy; Immunology SC Allergy; Immunology GA 399IP UT WOS:000262793900010 PM 19062085 ER PT J AU Ferruzzi, MG Lobo, JK Janle, EM Cooper, B Simon, JE Wu, QL Welch, C Ho, L Weaver, C Pasinetti, GM AF Ferruzzi, Mario G. Lobo, Jessica K. Janle, Elsa M. Cooper, Bruce Simon, James E. Wu, Qing-Li Welch, Cara Ho, Lap Weaver, Connie Pasinetti, Giulio M. TI Bioavailability of Gallic Acid and Catechins from Grape Seed Polyphenol Extract is Improved by Repeated Dosing in Rats: Implications for Treatment in Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; Bioavailability; brain; catechins; gallic acid; grape seed extract; pharmacokinetics ID LIQUID-CHROMATOGRAPHY; TEA CATECHINS; MOUSE MODEL; METABOLITES; ABSORPTION; (-)-EPICATECHIN; MEMORY; BRAIN; GUT; PROANTHOCYANIDINS AB The present study explored the bioavailability and brain deposition of a grape seed polyphenolic extract (GSPE) previously found to attenuate cognitive deterioration in a mouse model of Alzheimer's disease (AD). Plasma pharmacokinetic response of major GSPE phenolic components was measured following intragastric gavage of 50, 100, and 150 mg GSPE per kg body weight. Liquid chromatography-mass spectrometry (LC-MS) analysis identified gallic acid (GA), catechin (C), and epicatechin (EC) in plasma of rats gavaged acutely with GSPE. Additionally, 4-methylgallic acid (4-OMeGA), 3'-methylcatechin (3'-OMeC), and 3'-methylepicatechin (3'-OMeEC) were identified as circulating metabolites of GSPE phenolic constituents. C(max) for individual GSPE constituents and their metabolites increased in a dose-dependent fashion (with increasing GSPE oral dose). Repeated daily exposure to GSPE was found to significantly increase bioavailability (defined as plasma AUC(0-8h)) of GA, C, and EC by 198, 253, and 282% relative to animals receiving only a single acute GSPE dose. EC and C were not detectable in brain tissues of rats receiving a single GSPE dose but reached levels of 290.7 +/- 45.9 and 576.7 +/- 227.7 pg/g in brain tissues from rats administered GSPE for 10 days. This study suggests that brain deposition of GA, C, and EC is affected by repeated dosing of GSPE. C1 [Ferruzzi, Mario G.; Lobo, Jessica K.] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA. [Ferruzzi, Mario G.; Janle, Elsa M.; Weaver, Connie] Purdue Univ, Dept Food & Nutr, W Lafayette, IN 47907 USA. [Cooper, Bruce] Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA. [Simon, James E.; Wu, Qing-Li; Welch, Cara] Rutgers State Univ, Dept Plant Biol & Plant Pathol, NUANPP, New Brunswick, NJ 08903 USA. [Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. [Ho, Lap; Pasinetti, Giulio M.] James J Peters VA Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY USA. RP Ferruzzi, MG (reprint author), Purdue Univ, Dept Food Sci, 745 Agr Mall Dr, W Lafayette, IN 47907 USA. EM mferruzz@purdue.edu FU NIH-NCCAM [P01AT004511-01] FX Grape Seed Extract used in this study was generously provided by Polyphenolics (Madera, CA). The authors wish to thank Pamela Lachcik and Michael Grannan for technical assistance. Funding for these studies was provided by NIH-NCCAM grant P01AT004511-01 as part of the Mount Sinai School of Medicine Center of Excellence in Complimentary and Alternative Medicine for Alzheimer's Disease. NR 39 TC 99 Z9 103 U1 0 U2 18 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 18 IS 1 BP 113 EP 124 DI 10.3233/JAD-2009-1135 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 492BQ UT WOS:000269629500012 PM 19625746 ER PT J AU Carrion-Baralt, JR Melendez-Cabrero, J Rodriguez-Ubinas, H Schmeidler, J Beeri, MS Angelo, G Sano, M Silverman, JM AF Carrion-Baralt, Jose R. Melendez-Cabrero, Josefina Rodriguez-Ubinas, Heide Schmeidler, James Beeri, Michal Schnaider Angelo, Gary Sano, Mary Silverman, Jeremy M. TI Impact of APOE epsilon 4 on the Cognitive Performance of a Sample of Non-Demented Puerto Rican Nonagenarians SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE APOE; cognition; Hispanic; nonagenarian ID APOLIPOPROTEIN-E GENOTYPE; NEUROPSYCHOLOGICAL BATTERY; ALZHEIMERS-DISEASE; OLDEST-OLD; COMPENSATORY MECHANISM; METABOLIC SYNDROME; BLOOD-PRESSURE; RISK; POPULATION; DEMENTIA AB APOE epsilon 4 is a major risk factor for Alzheimer's disease. It has also been associated with cognitive impairment and cognitive decline in young-olds, but the impact of the epsilon 4 allele on cognitive function in very late life is still unclear. The object of this study was to evaluate the association of the epsilon 4 allele of APOE with the cognitive performance of a sample of non-demented oldest-olds. Eighty-seven Spanish-speaking Puerto Rican non-demented nonagenarians were administered a complete neuropsychological assessment and provided a blood sample used for APOE genotyping. A factor analysis generated two factors: 1) verbal memory; and 2) visuo-spatial, naming and attention tasks, accounting for 43.6% of the overall variance in the 13 original neuropsychological variables. The multivariate analysis reflected, after controlling for gender, education, and age, the APOE epsilon 4 carriers performed better in overall cognition (both factors analyzed together) than non-carriers (T(2) = 0.082, F(2, 80) = 3.289, p = 0.042). Neither gender nor the gender by APOE epsilon 4 status interaction was associated with differences in cognition. In conclusion, the results of this study suggest that, among these Puerto Rican non-demented nonagenarians, being an APOE epsilon 4 allele carrier is associated with better cognition. C1 [Carrion-Baralt, Jose R.; Melendez-Cabrero, Josefina; Rodriguez-Ubinas, Heide; Schmeidler, James; Beeri, Michal Schnaider; Angelo, Gary; Sano, Mary; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Carrion-Baralt, Jose R.; Melendez-Cabrero, Josefina; Rodriguez-Ubinas, Heide] San Juan Vet Affairs Med Ctr, San Juan, PR USA. [Sano, Mary; Silverman, Jeremy M.] Bronx Vet Affairs Med Ctr, Bronx, NY USA. RP Carrion-Baralt, JR (reprint author), VA Caribbean Healthcare Syst, Res & Dev Serv 151, 10 Casia St, San Juan, PR 00921 USA. EM jose.carrion-baralt@mssm.edu NR 41 TC 8 Z9 8 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 18 IS 3 BP 533 EP 540 DI 10.3233/JAD-2009-1160 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 533XS UT WOS:000272860100006 PM 19584451 ER PT J AU Watson, GS Baker, LD Cholerton, BA Rhoads, KW Merriam, GR Schellenberg, GD Asthana, S Cherrier, M Craft, S AF Watson, G. Stennis Baker, Laura D. Cholerton, Brenna A. Rhoads, Kristoffer W. Merriam, George R. Schellenberg, Gerard D. Asthana, Sanjay Cherrier, Monique Craft, Suzanne TI Effects of Insulin and Octreotide on Memory and Growth Hormone in Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Acetylcholine; Alzheimer's disease (AD); apolipoprotein E (APOE); growth hormone (GH); insulin; memory; mild cognitive impairment (MCI); octreotide; somatostatin ID APOLIPOPROTEIN-E GENOTYPE; SOMATOSTATIN-LIKE IMMUNOREACTIVITY; MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; LONG-TERM POTENTIATION; CEREBROSPINAL-FLUID; CEREBRAL-CORTEX; IN-VIVO; GLUCOSE; HYPOGLYCEMIA AB Both insulin alone and the somatostatin analogue octreotide alone facilitate memory in patients with Alzheimer's disease (AD). Since octreotide inhibits endogenous insulin secretion, the cognitive effects of insulin and octreotide may not be independent. This study tested the individual and interactive effects of insulin and octreotide on memory and plasma growth hormone (GH) levels in older adults. Participants were 16 memory-impaired (AD = 7, amnestic mild cognitive impairment = 9; apolipoprotein E [APOE] epsilon 4- [no epsilon 4 alleles] = 9, epsilon 4+ [1-2 epsilon 4 alleles] = 7), and 19 cognitively-intact older adults (APOE epsilon 4- = 17, epsilon 4+ = 1). On separate days, fasting participants received counterbalanced infusions of: 1) insulin (1 mU.kg(-1).min(-1)) and dextrose to maintain euglycemia; 2) octreotide (150 mu g/h); 3) insulin, dextrose, and octreotide; or 4) saline. Story recall was the principal endpoint. Insulin alone facilitated delayed recall for epsilon 4- patients, relative to epsilon 4+ patients (P = 0.0012). Furthermore, epsilon 4- patients with higher Mattis Dementia Rating Scale (DRS) scores had greater octreotide-induced memory facilitation (P = 0.0298). For healthy adults, octreotide facilitated memory (P = 0.0122). Unexpectedly, hyperinsulinemia with euglycemia increased GH levels in healthy controls (P = 0.0299). Thus, insulin and octreotide appear to regulate memory in older adults. APOE epsilon 4 genotype modulates responses to insulin and octreotide. Finally, insulin may regulate GH levels during euglycemia. C1 [Watson, G. Stennis; Baker, Laura D.; Cholerton, Brenna A.; Rhoads, Kristoffer W.; Schellenberg, Gerard D.; Craft, Suzanne] VAPSHCS, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. [Watson, G. Stennis; Baker, Laura D.; Cholerton, Brenna A.; Rhoads, Kristoffer W.; Cherrier, Monique; Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Rhoads, Kristoffer W.] Virginia Mason Med Ctr, Phys Med & Rehabil PMR G2, Seattle, WA 98101 USA. [Merriam, George R.] VA Puget Sound Healthcare Syst, Med Serv, Seattle, WA USA. [Merriam, George R.; Schellenberg, Gerard D.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Schellenberg, Gerard D.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Schellenberg, Gerard D.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA. [Schellenberg, Gerard D.] Univ Penn, Philadelphia, PA 19104 USA. [Asthana, Sanjay] Univ Wisconsin, Sch Med, GRECC, William S Middleton Mem Vet Hosp, Madison, WI USA. [Asthana, Sanjay] Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA. [Cherrier, Monique] VA Puget Sound Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. RP Craft, S (reprint author), VAPSHCS, Ctr Geriatr Res Educ & Clin, S-182 GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM scraft@u.washington.edu FU Department of Veterans Affairs; National Institutes of Health [5 R37 AG010880, 1 K01 AG023650] FX This work was supported by the Department of Veterans Affairs and by National Institutes of Health grants 5 R37 AG010880 (SC) and 1 K01 AG023650 (GSW). Dr. Craft and Dr. Watson had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The authors thank the following persons for their excellent technical help: Pam Asberry, Darla Chapman, Donna Davis, Karen Enstrom, Karen Hyde, Tracia Clark, Dana Belongia, Jaime Tdwell, Michelle Keeling, Amy Morgan, Margaret Pagoria, and Monica Kletke. NR 33 TC 8 Z9 9 U1 0 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 18 IS 3 BP 595 EP 602 DI 10.3233/JAD-2009-1165 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 533XS UT WOS:000272860100011 PM 19625744 ER PT J AU Sonnen, JA Larson, EB Haneuse, S Woltjer, R Li, G Crane, PK Craft, S Montine, TJ AF Sonnen, Joshua A. Larson, Eric B. Haneuse, Sebastien Woltjer, Randy Li, Ge Crane, Paul K. Craft, Suzanne Montine, Thomas J. TI Neuropathology in the Adult Changes in Thought Study: A Review SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Aging; community-based; microinfarct; longitudinal; neuropathology ID VASCULAR COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; ELDERLY-PEOPLE; OLDER PERSONS; DEMENTIA; PATHOLOGY; RISK; AUTOPSY; PREVALENCE; DIAGNOSIS AB The neuropathology underlying dementia syndromes in older populations is complex. The contributions of Alzheimer's and Lewy body pathology are well appreciated. Recent studies with brain autopsies have highlighted the high prevalence of vascular disease as an independent, but often co-morbid contributor to dementia. The Adult Changes in Thought Study is a community-based, longitudinal study of brain aging and cognitive decline which has recently confirmed cerebral microinfarcts as a strong correlate of cognitive impairment and dementia. This study examines correlations between clinical characteristics including extensive, longitudinal medication histories, and longitudinal cognitive testing against structural and biochemical features of disease. C1 [Sonnen, Joshua A.; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98104 USA. [Larson, Eric B.; Haneuse, Sebastien] Grp Hlth Cooperat Puget Sound, Grp Hlth Ctr Hlth Studies, Seattle, WA USA. [Woltjer, Randy] Hlth Sci Univ Oregon, Dept Pathol, Portland, OR USA. [Li, Ge; Craft, Suzanne] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA USA. [Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. RP Sonnen, JA (reprint author), Univ Washington, Dept Pathol, Seattle, WA 98104 USA. EM jsonnen@u.washington.edu RI Crane, Paul/C-8623-2014; Sonnen, 37382016/H-3738-2016; OI Sonnen, 37382016/0000-0001-9267-8705; Crane, Paul/0000-0003-4278-7465 FU NIA NIH HHS [R01 AG023801, U01 AG006781]; NINDS NIH HHS [R01 NS048595] NR 41 TC 19 Z9 19 U1 1 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 18 IS 3 BP 703 EP 711 DI 10.3233/JAD-2009-1180 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 533XS UT WOS:000272860100021 PM 19661627 ER PT J AU Atwood, C Brewer, G Herrup, K Khurana, V Kim, D Lamb, B Langley, B Leitner, M Muresan, V Neve, R Park, K Patzke, H Strobel, G Tsai, LH Yankner, B AF Atwood, Craig Brewer, Greg Herrup, Karl Khurana, Vikram Kim, Dohoon Lamb, Bruce Langley, Brett Leitner, Melanie Muresan, Virgil Neve, Rachael Park, Kevin Patzke, Holger Strobel, Gabrielle Tsai, Li-Huei Yankner, Bruce TI Alzheimer Research Forum Live Discussion: Meet New Players, Histone Deacetylase and Sirtuin - Will They Help the Cell Cycle, DNA Repair, and Gene Expression Break Into Alzheimerology's Major League? Discussion SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Editorial Material C1 [Atwood, Craig] Univ Wisconsin, Madison, WI 53706 USA. [Brewer, Greg] So Illinois Univ, Sch Med, Carbondale, IL 62901 USA. [Herrup, Karl] Rutgers State Univ, Piscataway, NJ 08855 USA. [Khurana, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kim, Dohoon; Neve, Rachael; Tsai, Li-Huei] MIT, Picower Inst, Cambridge, MA 02139 USA. [Lamb, Bruce] Cleveland Clin, Cleveland, OH USA. [Muresan, Virgil] Univ Med & Dent New Jersey, Newark, NJ USA. [Park, Kevin] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Yankner, Bruce] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Atwood, C (reprint author), Univ Wisconsin, Madison, WI 53706 USA. OI Herrup, Karl/0000-0001-7786-5844 NR 5 TC 0 Z9 0 U1 0 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 17 IS 1 BP 233 EP 238 DI 10.3233/JAD-2009-1084 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 461RS UT WOS:000267289200022 ER PT J AU Zhao, W Wang, J Ho, L Ono, K Teplow, DB Pasinetti, GM AF Zhao, Wei Wang, Jun Ho, Lap Ono, Kenjiro Teplow, David B. Pasinetti, Giulio M. TI Identification of Antihypertensive Drugs Which Inhibit Amyloid-beta Protein Oligomerization SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; hypertension; oligomerization ID ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; BLOOD-PRESSURE; CROSS-LINKING; ASSEMBLIES; DEMENTIA AB Recent studies suggest that certain cardiovascular antihypertensive agents decrease the incidence of Alzheimer's disease. Based on this evidence and the fact that A beta aggregation into high-molecular-weight-soluble oligomeric A beta species is known to directly induce cognitive impairment, we tested the possibility that certain antihypertensive compounds may affect the progression of Alzheimer's disease, at least in part by influencing the formation of A beta oligomers. High throughput screening of 55 commercially available antihypertensive drugs identified four compounds that significantly reduced A beta(1-42) oligomerization in a dose dependent manner. These four compounds, furosemide (diuretic), nitrendipine (calcium channel blocker), candesartan cilextil (angiotensin II receptor antagonist) and diazoxide (vasodilator) showed no detectable A beta lowering activities in primary neuron cultures generated from Tg2576 mouse embryos. However, furosemide, nitrendipine and candesartan cilextil prevented oligomerization of both A beta(1-40) and A beta(1-42) in vitro. Furosemide also dissociated pre-aggregated A beta(1-42) oligomers. Furthermore, short term furosemide treatment resulted in decreased amount of A beta oligomers in the brain of Tg2576 mice. Our studies suggest that certain antihypertensive compounds may prevent AD-type neuropathology through inhibition of A beta oligomer formation. C1 [Pasinetti, Giulio M.] Mt Sinai Sch Med, Ichan Res Inst, Dept Psychiat, New York, NY 10029 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. [Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Ichan Res Inst, Dept Psychiat, 1425 Madison Ave,Box 1230, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu RI Zhao, Wei/B-3220-2010; Zhao, Wei/A-2206-2010 FU Altschul Foundation; Dr. Robert C. Atkins Foundation; James J. Peters VA Geriatrics, Research, Education and Clinical Center Program; National Institute of Aging [AG02219] FX This work was supported by the Altschul Foundation, the Dr. Robert C. Atkins Foundation, the James J. Peters VA Geriatrics, Research, Education and Clinical Center Program and National Institute of Aging grant AG02219 to G. M. Pasinetti. NR 21 TC 26 Z9 26 U1 2 U2 7 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 16 IS 1 BP 49 EP 57 DI 10.3233/JAD-2009-0925 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 405ZF UT WOS:000263262000006 PM 19158421 ER PT J AU Ho, L Chen, LH Wang, J Zhao, W Talcott, ST Ono, K Teplow, D Humala, N Cheng, A Percival, SS Ferruzzi, M Janle, E Dickstein, DL Pasinetti, GM AF Ho, Lap Chen, Ling Hong Wang, Jun Zhao, Wei Talcott, Stephen T. Ono, Kenjiro Teplow, David Humala, Nelson Cheng, Alice Percival, Susan S. Ferruzzi, Mario Janle, Elsa Dickstein, Dara L. Pasinetti, Giulio Maria TI Heterogeneity in Red Wine Polyphenolic Contents Differentially Influences Alzheimer's Disease-type Neuropathology and Cognitive Deterioration SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease dementia; amyloid-beta protein precursor (A beta PP); high-molecular-weight amyloid-beta oligomer species; polyphenols ID PHOTOINDUCED CROSS-LINKING; MOUSE MODEL; UNMODIFIED PROTEINS; TRANSGENIC MOUSE; ELLAGIC ACID; IN-VITRO; BETA; OLIGOMERS; DEFICITS; PLAQUES AB We recently found that moderate consumption of two unrelated red wines generate from different grape species, a Cabernet Sauvignon and a muscadine wine that are characterized by distinct component composition of polyphenolic compounds, significantly attenuated the development of Alzheimer's disease (AD)-type brain pathology and memory deterioration in a transgenic AD mouse model. Interestingly, our evidence suggests that the two red wines attenuated AD phenotypes through independent mechanisms. In particular, we previously found that treatment with Cabernet Sauvignon reduced the generation of AD-type amyloid-beta (A beta) peptides. In contrast, evidence from our present study suggests that muscadine treatment attenuates A beta neuropathology and A beta-related cognitive deterioration in Tg2576 mice by interfering with the oligomerization of A beta molecules to soluble high-molecular-weight A beta oligomer species that are responsible for initiating a cascade of cellular events resulting in cognitive decline. Collectively, our observations suggest that distinct polyphenolic compounds from red wines may be bioavailable at the organism level and beneficially modulate AD phenotypes through multiple A beta-related mechanisms. Results from these studies suggest the possibility of developing a "combination" of dietary polyphenolic compounds for AD prevention and/or therapy by modulating multiple A beta-related mechanisms. C1 [Ho, Lap; Chen, Ling Hong; Wang, Jun; Zhao, Wei; Humala, Nelson; Cheng, Alice; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10019 USA. [Ho, Lap; Pasinetti, Giulio Maria] James J Peters VA Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY USA. [Dickstein, Dara L.; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10019 USA. [Talcott, Stephen T.] Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX USA. [Ono, Kenjiro; Teplow, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Percival, Susan S.] Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA. [Ferruzzi, Mario; Janle, Elsa] Purdue Univ, Dept Foods & Nutr, W Lafayette, IN 47907 USA. RP Ho, L (reprint author), Mt Sinai Sch Med, Dept Psychiat, New York, NY 10019 USA. EM Lap.Ho@mssm.edu RI Zhao, Wei/B-3220-2010; Zhao, Wei/A-2206-2010; Dickstein, Dara/F-3036-2013 FU Dept. of Veterans Affairs; James J. Peters VA GRECC Program; [1P01AT004511-01]; [1P01 AT004511-01] FX These studies were supported by 1P01AT004511-01 Project 1 to LH and 1P01 AT004511-01 Project 3 to GMP, MERIT Review grant from Dept. of Veterans Affairs, and James J. Peters VA GRECC Program to GMP. NR 38 TC 57 Z9 57 U1 2 U2 8 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 16 IS 1 BP 59 EP 72 DI 10.3233/JAD-2009-0916 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 405ZF UT WOS:000263262000007 PM 19158422 ER PT J AU Okereke, OI Xia, WM Irizarry, MC Sun, XY Qiu, WQ Fagan, AM Mehta, PD Hyman, BT Selkoe, DJ Grodstein, F AF Okereke, Olivia I. Xia, Weiming Irizarry, Michael C. Sun, Xiaoyan Qiu, Wei Q. Fagan, Anne M. Mehta, Pankaj D. Hyman, Bradley T. Selkoe, Dennis J. Grodstein, Francine TI Performance Characteristics of Plasma Amyloid-beta 40 and 42 Assays SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid; assay reliability; biomarker; quality control ID ALZHEIMER-DISEASE; CEREBROSPINAL-FLUID; RISK; STANDARDIZATION; BIOMARKERS; DEMENTIA; AGE AB Identifying biomarkers of Alzheimer's disease (AD) risk will be critical to effective AD prevention. Levels of circulating amyloid-beta (A beta) 40 and 42 may be candidate biomarkers. However, properties of plasma A beta assays must be established. Using five different protocols, blinded samples were used to assess: intra-assay reproducibility; impact of EDTA vs. heparin anticoagulant tubes; and effect of time-to-blood processing. In addition, percent recovery of known A beta concentrations in spiked samples was assessed. Median intra-assay coefficients of variation for the assay protocols ranged from 6-24% for A beta(40), and 8-14% for A beta(42). There were no systematic differences in reproducibility by collection method. Plasma concentrations of A beta (particularly A beta(42)) appeared stable in whole blood kept in ice packs and processed as long as 24 hours after collection. Recovery of expected concentrations was modest, ranging from-24% to 44% recovery of A beta(40), and 17% to 61% of A beta(42). In conclusion, across five protocols, plasma A beta(40) and A beta(42) levels were measured with generally low error, and measurements appeared similar in blood collected in EDTA versus heparin. While these preliminary findings suggest that measuring plasma A beta(40) and A beta(42) may be feasible in varied research settings, additional work in this area is necessary. C1 [Okereke, Olivia I.; Grodstein, Francine] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. [Okereke, Olivia I.; Xia, Weiming; Selkoe, Dennis J.; Grodstein, Francine] Harvard Univ, Sch Med, Boston, MA USA. [Okereke, Olivia I.; Grodstein, Francine] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA. [Xia, Weiming; Selkoe, Dennis J.] Brigham & Womens Hosp, Ctr Neurol Dis, Dept Neurol, Boston, MA 02115 USA. [Irizarry, Michael C.; Hyman, Bradley T.] Massachusetts Gen Hosp, Dept Neurol, Alzheimers Dis Res Unit, Boston, MA 02114 USA. [Sun, Xiaoyan; Qiu, Wei Q.] Tufts Univ, Sch Med, Tufts New England Med Ctr, Dept Psychiat, Boston, MA 02111 USA. [Fagan, Anne M.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA. [Mehta, Pankaj D.] New York State Inst Basic Res Dev Disabil, Dept Immunol, Staten Isl, NY 10314 USA. [Grodstein, Francine] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Okereke, OI (reprint author), Brigham & Womens Hosp, Dept Med, Channing Lab, 3rd Floor,181 Longwood Ave, Boston, MA 02115 USA. EM ookereke@partners.org RI xia, weiming/E-5465-2016; Okereke, Olivia/R-9934-2016; OI xia, weiming/0000-0002-7463-3295; Qiu, Wendy/0000-0002-2082-2410 FU National Institutes of Health [AG24215, CA49449, CA87969] FX Dr. Hyman is, or was, a paid consultant/advisory board member for Takeda, Pfizer, and FoldRx. NR 21 TC 12 Z9 13 U1 1 U2 7 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 16 IS 2 BP 277 EP 285 DI 10.3233/JAD-2009-0948 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 420KN UT WOS:000264288800005 PM 19221417 ER PT J AU Zhou, DW Zambrano, N Russo, T D'Adamio, L AF Zhou, Dawang Zambrano, Nicola Russo, Tommaso D'Adamio, Luciano TI Phosphorylation of a Tyrosine in the Amyloid-beta Protein Precursor Intracellular Domain Inhibits Fe65 Binding and Signaling SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Amyloid-beta protein precursor; Fe65; phosphorylation; threonine; tyrosine ID ALZHEIMERS-DISEASE; CYTOPLASMIC DOMAIN; APP; ASSOCIATION; BRAIN; JNK; TRANSCRIPTION; METABOLISM; FRAGMENTS; CELLS AB The phosphorylation of Tyr-682 residue in the intracellular domain (AID) of amyloid-beta protein precursor (A beta PP) is significantly enhanced in Alzheimer's disease patients' brain. The role of this phosphotyrosine, however, remains elusive. Here we report that phosphorylation of Tyr-682 inhibits the interactions between A beta PP and Fe65, which is the main regulatory mechanism controlling Fe65 nuclear signaling. Furthermore, we show that tyrosine phosphorylation of A beta PP also inhibits interaction of the two other Fe65 family members, Fe65L1 and Fe65L2. Likewise, docking of Fe65, Fe65L1 and Fe65L2 to APLP1 and APLP2, the two other members of the A beta PP-gene family, is abolished by analogous phosphorylation events. Our results indicate that phosphorylation of the cytoplasmic tail of A beta PP on Tyr-682 represents a second mechanism, alternative to A beta PP processing by secretases, that regulates A beta PP/Fe65 downstream signaling pathways. C1 [D'Adamio, Luciano] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA. [Zambrano, Nicola; Russo, Tommaso] Univ Naples Federico 2, Dipartimento Biochim & Biotecnol Med, CEINGE Biotecnol Avanzate, Naples, Italy. [Zhou, Dawang] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP D'Adamio, L (reprint author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA. EM ldadamio@aecom.yu.edu RI Zambrano, Nicola/B-9352-2014; Russo, Tommaso/K-1331-2016; OI Zambrano, Nicola/0000-0001-9395-3481; Russo, Tommaso/0000-0003-4426-0106; Zhou, Dawang/0000-0002-9053-5249; D'Adamio, Luciano/0000-0002-9820-4882 FU Alzheimer Disease Research [A2003-076]; National Institutes of Health [R01 AG22024, R01 AG21588]; Alzheimer's Association [IIRG-04- 1310]; VI FP-APOPIS Consortium FX This work was supported in part by Alzheimer Disease Research Grant A2003-076; National Institutes of Health Grants R01 AG22024 and R01 AG21588 (to L. D.) and by the Alzheimer's Association IIRG-04- 1310 and VI FP-APOPIS Consortium (to T. R.). We wish to thank Dr. Huiyong Chen for assistance in Biacore assay and Caterina Schemidt for editing the manuscript. Dr. D'Adamio owns equity or stock options in Remegenix. NR 36 TC 24 Z9 24 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 16 IS 2 BP 301 EP 307 DI 10.3233/JAD-2009-0970 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 420KN UT WOS:000264288800007 PM 19221419 ER PT J AU Marques, MA Kulstad, JJ Savard, CE Green, PS Lee, SP Craft, S Watson, GS Cook, DG AF Marques, Marcos A. Kulstad, J. Jacob Savard, Christopher E. Green, Pattie S. Lee, Sum P. Craft, Suzanne Watson, G. Stennis Cook, David G. TI Peripheral Amyloid-beta Levels Regulate Amyloid-beta Clearance from the Central Nervous System SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; blood-brain-barrier; hepatic clearance; liver; passive immunization; peripheral sink ID BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; PEPTIDE; TRANSPORT; EFFLUX AB Amyloid-beta (A beta) is cleared from the brain by both proteolytic digestion and transport across the blood-brain-barrier into the peripheral circulatory system. To investigate the role peripheral A beta levels play in regulating A beta brain clearance, we measured the clearance of [(125)I]-A beta(1-40) injected into the brains of liver-ligated rats that allowed peripheral A beta levels to be maintained at elevated levels for approximately one hour with/without a single peripheral bolus of unlabeled A beta(1-40). We found that elevating peripheral A beta levels significantly decreased [(125)I]-A beta(1-40) brain clearance, thus supporting the hypothesis that peripheral A beta levels regulate A beta clearance from the central nervous system. C1 [Marques, Marcos A.; Kulstad, J. Jacob; Savard, Christopher E.; Green, Pattie S.; Craft, Suzanne; Watson, G. Stennis; Cook, David G.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Marques, Marcos A.; Kulstad, J. Jacob; Craft, Suzanne; Watson, G. Stennis; Cook, David G.] Univ Washington, Ctr Geriatr Res Educ & Clin, Sch Med, Seattle, WA 98108 USA. [Marques, Marcos A.; Craft, Suzanne; Watson, G. Stennis] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA. [Kulstad, J. Jacob] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Savard, Christopher E.; Green, Pattie S.; Cook, David G.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Cook, David G.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA. [Lee, Sum P.] Univ Hong Kong, Fac Med, LKS, Hong Kong, Hong Kong, Peoples R China. RP Cook, DG (reprint author), Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM dgcook@u.washington.edu RI Lee, Sum Ping/C-4333-2009 FU Veterans Affairs Office of Research and Development Medical Research Serve; NIH [T32 AG000258] FX This work was supported by a grant to DGC from the Veterans Affairs Office of Research and Development Medical Research Serve and an NIH fellowship to MAM (T32 AG000258). NR 16 TC 24 Z9 24 U1 1 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 16 IS 2 BP 325 EP 329 DI 10.3233/JAD-2009-0964 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 420KN UT WOS:000264288800010 PM 19221422 ER PT J AU Amadio, M Pascale, A Wang, J Ho, L Quattrone, A Gandy, S Haroutunian, V Racchi, M Pasinetti, GM AF Amadio, Marialaura Pascale, Alessia Wang, Jun Ho, Lap Quattrone, Alessandro Gandy, Sam Haroutunian, Vahram Racchi, Marco Pasinetti, Giulio Maria TI nELAV Proteins Alteration in Alzheimer's Disease Brain: A Novel Putative Target for Amyloid-beta Reverberating on A beta PP Processing SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE ADAM10; Alzheimer's disease; amyloid-beta; amyloid-beta protein precursor processing; nELAV ID RNA-BINDING PROTEIN; NEURONAL ELAV PROTEINS; PRECURSOR PROTEIN; TRANSGENIC MICE; MESSENGER-RNA; UP-REGULATION; GENE; HUD; ACCUMULATION; TRANSLATION AB Neuronal ELAV (nELAV) proteins are RNA-binding proteins which play a physiological role in controlling gene expression in memory formation, and their alteration may contribute to cognitive impairment associated with neurodegenerative pathologies such as Alzheimer's disease (AD). Indeed, we found that the content of nELAV proteins is significantly decreased along with clinical dementia progression in the hippocampi of AD brains, where it inversely correlates with the amount of amyloid-beta (A beta). To check the direct influence of A beta on nELAV, we performed in vitro experiments using human SH-SY5Y cells, finding that A beta(1-42) specifically determines nELAV proteins reduction. Since ADAM10 mRNA has the predicted sequences targeted by nELAV, we investigated whether A beta, through nELAV proteins, could originate a vicious circle affecting amyloid-beta protein precursor (A beta PP) processing. Immunoprecipitation experiments showed that indeed nELAV proteins bind to ADAM10 mRNA and that this binding is disrupted by A beta(1-42) exposure, resulting in a decreased ADAM10 protein expression. ADAM10 protein diminution was also found in AD hippocampi. These data show for the first time the involvement of nELAV in AD pathology and suggest that their alteration may affect genes implicated in A beta PP processing. C1 [Amadio, Marialaura; Pascale, Alessia; Racchi, Marco] Univ Pavia, Dept Expt & Appl Pharmacol, I-27100 Pavia, Italy. [Amadio, Marialaura; Pascale, Alessia; Racchi, Marco] Univ Pavia, Ctr Excellence Appl Biol, I-27100 Pavia, Italy. [Amadio, Marialaura; Wang, Jun; Ho, Lap; Haroutunian, Vahram; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Wang, Jun; Ho, Lap; Haroutunian, Vahram; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA. [Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Amadio, Marialaura; Wang, Jun; Gandy, Sam; Haroutunian, Vahram; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Quattrone, Alessandro] Univ Trent, Ctr Integrat Biol, Mattarello, TN, Italy. [Quattrone, Alessandro] Univ Trent, Engn & Informat Sci Dept, Mattarello, TN, Italy. RP Amadio, M (reprint author), Univ Pavia, Dept Expt & Appl Pharmacol, Via Taramelli 14, I-27100 Pavia, Italy. EM amadio@unipv.it FU Fondo Sociale Europeo - Regione Lombardia FX The authors wish to thank Prof. Schinelli and Dr. Paolillo for their help and kindness for the performance of real-time RT-PCR experiments. M. A. has been partially supported by a fellowship from the Fondo Sociale Europeo - Regione Lombardia. NR 33 TC 30 Z9 30 U1 0 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 16 IS 2 BP 409 EP 419 DI 10.3233/JAD-2009-0967 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 420KN UT WOS:000264288800018 PM 19221430 ER PT J AU Ho, L Yemul, S Wang, J Pasinettia, GM AF Ho, Lap Yemul, Shrishailam Wang, Jun Pasinettia, Giulio Maria TI Grape Seed Polyphenolic Extract as a Potential Novel Therapeutic Agent in Tauopathies SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Neurodegeneration; neurofibrillary tangles; polyphenols; tauopathies ID ALZHEIMERS-DISEASE; TAU AB Abnormal misfoldings of the microtubule-associated protein tau, leading to the aggregation of tau into paired helical filaments that are ultimately deposited as neurofibrillary tangles, is a key neuropathologic feature of a number of neurodegenerative disorders collectively referred to as tauopathies. We recently observed that a particular grape seed polyphenolic extract (GSPE), namely, Meganatural-Az (R) may attenuate the generation and stability of misfolded proteins. We hypothesized that Meganatural-Az (R) GSPE might also attenuate tau protein misfolding that leads to the generation of tau filamentary aggregates that are critical for the initiation and progression of neurodegeneration and/or cognitive dysfunctions in tauopathies. In this study, we used in vitro aggregations of synthetic Ac-(306)VQIVYK(311) tau peptide as a model system to explore whether Meganatural-Az (R) GSPE might modulate aggregations of tau protein. We demonstrate that this GSPE is capable of inhibiting tau peptide aggregations, as well as dissociating preformed tau peptide aggregates. Results from this study suggest that this GSPE might provide beneficial disease-modifying bioactivities in tau-associated neurodegenerative disorders by modulating tau-mediated neuropathologic mechanisms. Our observation, in conjunction with the demonstrated bioavailability, as well as safety and tolerability, of this GSPE, supports the development of Meganatural-Az (R) GSPE for the prevention and/or treatment of tau-associated neurodegenerative disorders. C1 [Ho, Lap; Yemul, Shrishailam; Wang, Jun; Pasinettia, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Pasinettia, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Ho, Lap; Pasinettia, Giulio Maria] James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Pasinettia, GM (reprint author), Mt Sinai Sch Med, Dept Psychiat, Annenberg Bldg,Room 14-94C,1468 Madison Ave,100 S, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Polyphenolics, Inc [1PO1 AT004511-01] FX These studies were supported by Research Funding from Polyphenolics, Inc. to GMP, 1PO1 AT004511-01 Project 1 to LH and 1PO1 AT004511-01 Project 3 to GMP, MERIT Review grant from Dept. of Veterans Affairs to GMP, and James J. Peters VA GRECC Program to GMP. We thank Drs. Hanna Ksiezak-Reding and Don Scott for their editorial comments in the preparation of this manuscript. NR 12 TC 26 Z9 27 U1 1 U2 6 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 16 IS 2 BP 433 EP 439 DI 10.3233/JAD-2009-0969 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 420KN UT WOS:000264288800020 PM 19221432 ER PT J AU Tan, ZS Vasan, RS AF Tan, Zaldy S. Vasan, Ramachandran S. TI Thyroid Function and Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Alzheimer's disease; dementia; hyperthyroidism; hypothyroidism; thyroid ID INDEPENDENT RISK-FACTOR; PRECURSOR PROTEIN GENE; MEDIAL TEMPORAL-LOBE; SUBCLINICAL HYPOTHYROIDISM; CARDIOVASCULAR-DISEASE; STIMULATING HORMONE; FETAL BRAIN; RAT-BRAIN; OLD-AGE; DEMENTIA AB Thyroid dysfunction has been implicated as a cause of reversible cognitive impairment and as such, the thyroid stimulating hormone has long been part of the screening laboratory test for dementia. Recently, several population-based studies demonstrated an association between hypo- or hyperthyroidism and Alzheimer's disease. This review discusses the role of thyroid hormone in the normal development and regulation of central nervous system functions and summarizes the studies that have linked thyroid function and dementia risk. Finally, it explores possible biological mechanisms to explain this association, including the direct effects of thyroid hormone on cerebral amyloid processing, neurodegeneration and thyrotropin-mediated mechanisms and vascular mediated enhancement of Alzheimer's disease risk. C1 [Tan, Zaldy S.] Brigham & Womens Hosp, Div Aging, Boston, MA 02160 USA. [Tan, Zaldy S.] Harvard Univ, Sch Med, GRECC, VA Boston Healthcare Syst, Boston, MA USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. RP Tan, ZS (reprint author), Brigham & Womens Hosp, Div Aging, 1620 Tremont St,3rd Flr, Boston, MA 02160 USA. EM ztan@hms.harvard.edu OI Ramachandran, Vasan/0000-0001-7357-5970 FU NIH/NHLBI [N01-HC-25195, 2K24 HL04334]; NIH [RO1 AR/AG 41398]; NIH/NIA [5 R01 AG08122] FX This work was supported in part by NIH/NHLBI contract N01-HC-25195, 2K24 HL04334 [Dr. Vasan]. The Framingham Heart Study of the National Heart, Lung, and Blood Institute (Supported by NIH/NHLBI Contract N01-HC-25195); NIH grant (RO1 AR/AG 41398); NIH/NIA, Epidemiology of Dementia in the Framingham Study Grant 5 R01 AG08122. NR 49 TC 30 Z9 33 U1 0 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 16 IS 3 BP 503 EP 507 DI 10.3233/JAD-2009-0991 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 420KP UT WOS:000264289000005 PM 19276542 ER PT J AU Foskett, K Bacskai, B Kuchibhotla, K Fagan, T Bezprozvanny, I Moyer, J Stutzmann, B Green, K Villalobos, C Michno, K Goussakov, I Atwood, C Rybalchenko, V Chakroborty, S AF Foskett, Kevin Bacskai, Brian Kuchibhotla, Kishore Fagan, Tom Bezprozvanny, Ilya Moyer, James Stutzmann, Beth Green, Kim Villalobos, Carlos Michno, Kinga Goussakov, Ivan Atwood, Craig Rybalchenko, Volodymyr Chakroborty, Shreaya TI Alzheimer Research Forum Live Discussion: Calcium in AD Pathogenesis SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Editorial Material ID APOLIPOPROTEIN-E; ENDOPLASMIC-RETICULUM; DISEASE; PEPTIDE; NEUROTOXICITY; MUTATIONS; TOXICITY; NEURONS; CELLS C1 [Foskett, Kevin] Univ Penn, Philadelphia, PA 19104 USA. [Atwood, Craig] Univ Wisconsin, Madison, WI 53706 USA. [Bacskai, Brian; Kuchibhotla, Kishore] Massachusetts Gen Hosp, Charlestown, MA USA. [Bezprozvanny, Ilya] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Green, Kim] Univ Calif Irvine, Irvine, CA USA. [Goussakov, Ivan] Rosalind Franklin Univ Med & Sci, Chicago, IL USA. [Moyer, James; Michno, Kinga] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Rybalchenko, Volodymyr] Univ N Texas, Denton, TX 76203 USA. [Stutzmann, Beth] Rosalind Franklin Univ, Chicago Med Sch, Chicago, IL USA. [Villalobos, Carlos] Univ Valladolid, IBGM, E-47002 Valladolid, Spain. [Villalobos, Carlos] CSIC, Spanish Res Council, Madrid, Spain. RP Foskett, K (reprint author), Univ Penn, Philadelphia, PA 19104 USA. OI Foskett, J. Kevin/0000-0002-8854-0268; Villalobos, Carlos/0000-0002-0429-3846 NR 19 TC 1 Z9 1 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2009 VL 16 IS 4 BP 909 EP 917 DI 10.3233/JAD-2009-1026 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 448PV UT WOS:000266275400020 ER PT J AU Court, LE Ching, D Schofield, D Czerminska, M Allen, AM AF Court, Laurence E. Ching, David Schofield, Deborah Czerminska, Maria Allen, Aaron M. TI Evaluation of the dose calculation accuracy in intensity-modulated radiation therapy for mesothelioma, focusing on low doses to the contralateral lung SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE mesothelioma; Monte Carlo; IMRT ID TREATMENT PLANNING SYSTEM; MALIGNANT PLEURAL MESOTHELIOMA; MONTE-CARLO CODE; CLINICAL IMPLEMENTATION; CANCER PATIENTS; AIR CAVITIES; PHASE-I; RADIOTHERAPY; BEAM; IMRT AB This study compares Monte Carlo (MC) with conventional treatment planning system (TPS) calculations. The EGS4nrc MC code, BEAMnrc, was commissioned to simulate a Varian 21Ex Linac. The accuracy of the simulations, including points blocked by the jaws, was evaluated by comparing MC with ion chamber and MOSFET measurements. Eight mesothelioma IMRT cases were planned using Eclipse ( pencil beam and superposition convolution algorithms). Dose distributions were recalculated using BEAMnrc/DOSxyz, and compared with TPS. MC agreed with experimental results for IMRT fields within 3% (96% of points). For regions blocked by the jaws, average agreement between MC and experiment was better than 5% up to 20 cm from isocenter. The pencil beam algorithm underestimated lung MLD, V20, and V5, compared with MC, by a mean ( range) of 16% (11-22%), 9.0% (2.4-30.1%), and 11.8% (2-30%), respectively. The superposition convolution algorithm gave better agreement of 8.5% (0-17%), 4% (0-12%) and 0% (-6- 6%). Mean dose to the targets was better than +/- 5% in all cases. In conclusion, there is excellent correlation between TPS and MC calculations for the target doses. The pencil beam algorithm and superposition convolution algorithms both underestimate lung dose parameters, but the superposition convolution dose offers improvements in dose calculation accuracy for these patients. C1 [Court, Laurence E.; Ching, David; Schofield, Deborah; Czerminska, Maria; Allen, Aaron M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. RP Court, LE (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM lcourt@lroc.harvard.edu NR 29 TC 4 Z9 4 U1 0 U2 1 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2009 VL 10 IS 2 BP 34 EP 42 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 482BR UT WOS:000268859100005 ER PT J AU Chin, DWH Treister, N Friedland, B Cormack, RA Tishler, RB Makrigiorgos, GM Court, LE AF Chin, David W. H. Treister, Nathaniel Friedland, Bernard Cormack, Robert A. Tishler, Roy B. Makrigiorgos, G. Mike Court, Laurence E. TI Effect of dental restorations and prostheses on radiotherapy dose distribution: a Monte Carlo study SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE Monte Carlo; radiotherapy; backscatter; dental work; mucositis ID THERAPEUTIC RADIATION; ELECTRON-TRANSPORT; X-RAY; BEAMS; SIMULATIONS; TUMORS; METAL; HEAD AB Dental restorations, fixed prosthodontics, and implants affect dose distribution in head and neck radiation therapy due to the high atomic number of the materials utilized. The backscatter of electrons from metallic materials due to the impinging treatment x-ray results in localized dose enhancements. These dose enhancements cause localized mucositis in patients who have dental work, a significant clinical complication. We investigated the backscatter effect of 23 configurations of dental work using the EGS4nrc Monte Carlo (MC) simulation system. We found that all-metal fixed partial dentures caused the highest amount of dose enhancement-up to 33%-while amalgam restorations did not cause a significant amount. Restorations with a ceramic veneer caused up to 8% enhancement. Between 3 mm and 5 mm of water-equivalent material almost completely absorbed the backscatter. MC simulations provide an accurate estimate of backscatter dose, and may provide patient-specific estimates in future. C1 [Chin, David W. H.; Cormack, Robert A.; Tishler, Roy B.; Makrigiorgos, G. Mike; Court, Laurence E.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA. [Chin, David W. H.; Cormack, Robert A.; Tishler, Roy B.; Makrigiorgos, G. Mike; Court, Laurence E.] Harvard Univ, Sch Med, Boston, MA USA. [Treister, Nathaniel; Friedland, Bernard] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. RP Chin, DWH (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, 25 Shattuck St, Boston, MA 02115 USA. EM dwchin@lroc.harvard.edu OI Cormack, Robert/0000-0001-5553-9984 NR 21 TC 13 Z9 13 U1 0 U2 1 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2009 VL 10 IS 1 BP 80 EP 89 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 441BM UT WOS:000265744300009 ER PT J AU Camargo, C AF Camargo, Carlos A., Jr. TI Update on Acute Asthma SO JOURNAL OF ASTHMA LA English DT Article CT 3rd Annual Nemacolin Asthma Conference CY SEP 19-21, 2008 CL Farmington, PA DE Acute asthma; exacerbation; emergency department; guideline; heliox; intravenous magnesium sulfate; anticholinergic; inhaled corticosteroid; education AB There have been several important changes in the updated NIH asthma guidelines regarding the management of acute asthma. At home during an exacerbation, doubling the dose of inhaled corticosteroids is not recommended. Pre-hospital, a standing order for albuterol is important in implementation of protocols such as the CDC model protocol. There are new cut points of 40% and 70% predicted peak expiratory flow rates. When someone presents to the emergency department with a flow rate less than 40% predicted (approximately 200 L/min for typical adult woman and 250 L/min for typical adult man), there are several adjunct treatments that merit consideration, such as heliox and intravenous magnesium sulfate. Consider initiating inhaled corticosteroids at discharge from the emergency department. Inhaled anticholinergics can be used in the first hours of presentation to the emergency department, but are not recommended during inpatient hospitalization. C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, EMNet Coordinating Ctr,Dept Emergency Med, Boston, MA 02114 USA. RP Camargo, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, EMNet Coordinating Ctr,Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA. EM ccamargo@partners.org NR 0 TC 1 Z9 1 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PY 2009 VL 46 BP 3 EP 9 AR PII 908822022 DI 10.1080/02770900802664982 PG 7 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 423XX UT WOS:000264531200002 ER PT J AU Gibbs-Strauss, SL O'Hara, JA Hoopes, PJ Hasan, T Pogue, BW AF Gibbs-Strauss, Summer L. O'Hara, Julia A. Hoopes, P. Jack Hasan, Tayyaba Pogue, Brian W. TI Noninvasive measurement of aminolevulinic acid-induced protoporphyrin IX fluorescence allowing detection of murine glioma in vivo SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE aminolevulinic acid; protoporphyrin IX; glioma; fluorescence; spectroscopy ID 5-AMINOLEVULINIC ACID; PHOTODYNAMIC THERAPY; RESECTION; GLIOBLASTOMA; CELLS; MODEL AB Aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) fluorescence is studied as a contrast agent for noninvasive detection of murine glioma, using the fluorescence-to-transmission ratio measured through the cranium. Signals measured prior to administration of ALA are very similar between control animals, 9L-GFP, and U251 tumor-bearing animals. However, 2 h after ALA administration, the PpIX signal from both tumor-bearing groups is significantly higher than the control group (9L-GFP group p-value=0.016, and U251 group p-value=0.004, relative to the control group). The variance in signal from the 9L-GFP group is much larger than either the control group or the U251 group, which is consistent with higher intrinsic PpIX fluorescence heterogeneity as seen in situ at ex vivo analysis. Decreasing the skin PpIX fluorescence via intentional photobleaching using red light (635 nm) is examined as a tool for increasing PpIX contrast between the tumor-bearing and control groups. The red light bleaching is found to increase the ability to accurately quantify PpIX fluorescence in vivo, but decreases the specificity of detection between tumor-bearing and nontumor-bearing groups. (c) 2009 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3065543] C1 [Gibbs-Strauss, Summer L.; O'Hara, Julia A.; Hoopes, P. Jack; Pogue, Brian W.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. [Hoopes, P. Jack] Dartmouth Coll, Dept Surg, Hanover, NH 03755 USA. [Hasan, Tayyaba] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Gibbs-Strauss, SL (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. EM sgibbs@bidmc.harvard.edu; Brian.W.Pogue@Dartmouth.edu FU NCI [RO1CA109558, PO1CA84203]; Norris Cotton Cancer Center Shared Resources FX The authors are grateful to Nathan Watson and Mark Israel for use of the U251 tumor cell line and for informative discussions about the glioma lines and data. This work has been funded by NCI grants RO1CA109558 and PO1CA84203, as well as the Norris Cotton Cancer Center Shared Resources. NR 20 TC 12 Z9 13 U1 0 U2 4 PU SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2009 VL 14 IS 1 AR 014007 DI 10.1117/1.3065543 PG 8 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 424FW UT WOS:000264551900012 PM 19256695 ER PT J AU Guze, K Short, M Sonis, S Karimbux, N Chan, J Zeng, HS AF Guze, Kevin Short, Michael Sonis, Stephen Karimbux, Nadeem Chan, Jimmy Zeng, Haishan TI Parameters defining the potential applicability of Raman spectroscopy as a diagnostic tool for oral disease SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE Raman spectroscopy; Oral mucosal disease; ethnic groups; diagnostic tool ID IN-VIVO; NECK-CANCER; OPTICAL DIAGNOSIS; TISSUE; AUTOFLUORESCENCE; FLUORESCENCE; MUCOSA; HEAD; DISCRIMINATION; SPECTRA AB Raman spectroscopy can provide information about the molecular composition of tissues, with potential to be applied as a diagnostic tool in lieu of histopathology. Our objectives are to determine if laser Raman spectra (RS) can be acquired reliably from the oral mucosa of patients, and to determine if the RS signature of normal oral mucosa is reproducible among anatomic oral sites and among subjects of different races and gender. 25 Caucasian and 26 Asian subjects are studied using RS with a signal acquisition time of 1 s at seven specified sites within the mouth. Multivariate analysis is used to determine the variability between tissue types and between races and gender. Unique spectra are defined for various sites in the mouth and are likely related to the degree of keratinization. However, spectral concordance by site is not greatly influenced by subject ethnicity or gender. We demonstrate, for the first time, the potential in-vivo application of RS for oral mucosal disease and demonstrate its specificity for particular mucosal types in the mouth. RS offers the potential to provide a diagnosis of disease using a noninvasive, convenient, sensitive technology that provides immediate results. (c) 2009 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3076195] C1 [Guze, Kevin; Short, Michael; Karimbux, Nadeem] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02114 USA. [Short, Michael; Zeng, Haishan] British Columbia Canc Res Ctr, Canc Imaging Dept, Vancouver, BC V5Z 1L3, Canada. [Sonis, Stephen] Brigham & Womens Hosp, Harvard Farber Canc Ctr, Div Oral Med, Boston, MA 02115 USA. RP Guze, K (reprint author), Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, 188 Longwood Ave, Boston, MA 02114 USA. EM Kevin_Guze@hsdm.harvard.edu NR 34 TC 33 Z9 34 U1 0 U2 4 PU SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2009 VL 14 IS 1 AR 014016 DI 10.1117/1.3076195 PG 9 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 424FW UT WOS:000264551900021 PM 19256704 ER PT J AU Krishnaswamy, V Hoopes, PJ Samkoe, KS O'Hara, JA Hasan, T Pogue, BW AF Krishnaswamy, Venkataramanan Hoopes, P. Jack Samkoe, Kimberley S. O'Hara, Julia A. Hasan, Tayyaba Pogue, Brian W. TI Quantitative imaging of scattering changes associated with epithelial proliferation, necrosis, and fibrosis in tumors using microsampling reflectance spectroscopy SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE scattering; spectroscopy; imaging; reflectance; tissue structure; microscopic ID PATH-LENGTH SPECTROSCOPY; LOCAL OPTICAL-PROPERTIES; LIGHT-SCATTERING; POLARIZED-LIGHT; PHOTODYNAMIC THERAPY; TURBID MEDIA; TISSUE; BACKSCATTERING; DESIGN; BRAIN AB Highly localized reflectance measurements can be used to directly quantify scatter changes in tissues. We present a microsampling approach that is used to raster scan tumors to extract parameters believed to be related to the tissue ultrastructure. A confocal reflectance imager was developed to examine scatter changes across pathologically distinct regions within tumor tissues. Tissue sections from two murine tumors, AsPC-1 pancreas tumor and the Mat-LyLu Dunning prostate tumor, were imaged. After imaging, histopathology-guided region-of-interest studies of the images allowed analysis of the variations in scattering resulting from differences in tissue ultrastructure. On average, the median scatter power of tumor cells with high proliferation index (HPI) was about 26% less compared to tumor cells with low proliferation index (LPI). Necrosis exhibited the lowest scatter power signature across all the tissue types considered, with about 55% lower median scatter power than LPI tumor cells. Additionally, the level and maturity of the tumor's fibroplastic response was found to influence the scatter signal. This approach to scatter visualization of tissue ultrastructure in situ could provide a unique tool for guiding surgical resection, but this kind of interpretation into what the signal means relative to the pathology is required before proceeding to clinical studies. c 2009 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.3065540] C1 [Krishnaswamy, Venkataramanan; Samkoe, Kimberley S.; O'Hara, Julia A.; Pogue, Brian W.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. [Hoopes, P. Jack; Pogue, Brian W.] Dartmouth Med Sch, Dept Surg, Lebanon, NH 03756 USA. [Hoopes, P. Jack] Dartmouth Med Sch, Dept Med, Lebanon, NH 03756 USA. [O'Hara, Julia A.] Dartmouth Med Sch, Dept Radiol, Hanover, NH 03755 USA. [Hasan, Tayyaba; Pogue, Brian W.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Hasan, Tayyaba] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. RP Krishnaswamy, V (reprint author), Dartmouth Coll, Thayer Sch Engn, 8000 Cummings Hall, Hanover, NH 03755 USA. EM venkat@dartmouth.edu FU NIH [P01CA80139, P01CA84203] FX The authors thank Dr. Xiaodong Zhou, Rendall R. Strawbridge, Imran Rizvi, Summer L. Gibbs- Strauss, and Timothy Monahan for their help with the tumor models, sample preparation, and histopathology- related work. This work has been funded through NIH Grant Nos. P01CA80139 and P01CA84203. NR 49 TC 34 Z9 34 U1 0 U2 4 PU SPIE-SOC PHOTOPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN-FEB PY 2009 VL 14 IS 1 AR 014004 DI 10.1117/1.3065540 PG 10 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 424FW UT WOS:000264551900009 PM 19256692 ER PT J AU Shomron, N Levy, C AF Shomron, Noam Levy, Carmit TI MicroRNA-Biogenesis and Pre-mRNA Splicing Crosstalk SO JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY LA English DT Article ID POSTTRANSCRIPTIONAL REGULATION; MICROPROCESSOR COMPLEX; CURRENT PERSPECTIVES; POLYMERASE-II; HOST GENES; TRANSCRIPTION; SPLICEOSOME; EXPRESSION; MACHINE; CELL AB MicroRNAs (miRNAs) are often hosted in introns of protein-coding genes. Given that the same transcriptional unit can potentially give rise to both miRNA and mRNA transcripts raises the intriguing question of the level of interaction between these processes. Recent studies from transcription, pre-mRNA splicing, and miRNA-processing perspectives have investigated these relationships and yielded interesting, yet somewhat controversial findings. Here we discuss major studies in the field. Copyright (C) 2009 N. Shomron and C. Levy. C1 [Shomron, Noam] Tel Aviv Univ, Sackler Fac Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel. [Levy, Carmit] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA. RP Shomron, N (reprint author), Tel Aviv Univ, Sackler Fac Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel. EM nshomron@post.tau.ac.il NR 57 TC 34 Z9 37 U1 0 U2 3 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1110-7243 J9 J BIOMED BIOTECHNOL JI J. Biomed. Biotechnol. PY 2009 AR 594678 DI 10.1155/2009/594678 PG 6 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA 472LG UT WOS:000268132200001 ER PT J AU Jupiter, JB Marent-Huber, M AF Jupiter, Jesse B. Marent-Huber, M. CA LCP Study Grp TI Operative Management of Distal Radial Fractures with 2.4-Millimeter Locking Plates A Multicenter Prospective Case Series SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID FRAGMENT-SPECIFIC FIXATION; ANGLE VOLAR PLATE; INTERNAL-FIXATION; EXTERNAL FIXATION; INTRAARTICULAR FRACTURES; OPEN REDUCTION; RADIOGRAPHIC EVALUATION; PERCUTANEOUS FIXATION; HAND QUESTIONNAIRE; HEALTH SURVEY AB Background: In the past decade, there has been a trend toward open reduction and internal fixation of unstable distal radial fractures. There are now more than thirty different implant designs specific for the fixation of distal radial fractures. A multicenter prospective study of a case series was conducted to determine the efficacy of the operative management of distal radial fractures stabilized with 2.4-mm locking plates. Methods: One hundred and fifty patients were entered into the study over a two-year period. The mean age of these patients was fifty-one years, and the cohort included eighty-eight women and sixty-two men. Eighty-six patients sustained a low-energy injury. Seventy-one percent of the fractures in the series were intra-articular and were Type C according to the Muller-AO Comprehensive Classification. The follow-up evaluations, which were conducted at six weeks, six months, one year, and two years, included assessments of pain, motion, grip strength, and standard radiographs. Gartland and Werley scores were recorded at six months and one and two years, and Disabilities of the Arm, Shoulder and Hand (DASH) scores were recorded at one and two years. Results: One hundred and twenty-five patients (83%) had a complete follow-up at six months; 121 (81%), atone year; and 117 (78%), at two years. Significant improvements in motion, grip strength, and patient satisfaction were observed between six months and one year, but further improvements were not seen at the two-year follow-up examination. The mean DASH score changed from a preinjury baseline of 2 points to 8 points at one year and 7 points at two years (p < 0.0001). The mean Gartland and Werley score improved significantly from 4 points at six months to 2 points at two years. Of the 102 intra-articular fractures examined in the immediate postoperative period, twenty had a step-off of <= 2 mm and seven had a step-off of >2 mm. Of the seventy-one intra-articular fractures seen at two years, sixty-one had no step-off, five had a step-off of <= 2 mm, and five had a step-off of >2 mm. Twenty-seven percent of the patients showed an increase of at least one grade in radiographic signs of arthritis at two years. There were twenty-eight complications, twenty of which were considered minor. Tendon inflammation occurred in nine patients. There were two tendon ruptures, one of which was due to a prominent dorsal screw tip placed through a volar plate and one of which was due to a prominent volar plate. Loss of reduction occurred in two patients, and screw loosening occurred in two patients. Conclusion: Internal fixation of displaced distal radial fractures with implants featuring locking screw fixation can result in good-to-excel lent outcomes with a limited number of complications. C1 [Jupiter, Jesse B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Marent-Huber, M.] AO Clin Invest & Documentat, CH-8600 Dubendorf, Switzerland. RP Jupiter, JB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 2100 Yawkey Bldg,55 Fruit St, Boston, MA 02114 USA. EM jjupiter1@partners.org; marta.marent@aofoundation.org RI AOCID, AO Foundation/R-6455-2016 NR 44 TC 75 Z9 85 U1 0 U2 1 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD JAN PY 2009 VL 91A IS 1 BP 55 EP 65 DI 10.2106/JBJS.G.01498 PG 11 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 394CH UT WOS:000262422400008 PM 19122079 ER PT J AU Van de Velde, SK Bingham, JT Gill, TJ Li, GA AF Van de Velde, Samuel K. Bingham, Jeffrey T. Gill, Thomas J. Li, Guoan TI Analysis of Tibiofemoral Cartilage Deformation in the Posterior Cruciate Ligament-Deficient Knee SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID SIMULATED MUSCLE LOADS; FINITE-ELEMENT MODEL; IN-SITU FORCES; TERM-FOLLOW-UP; CONTACT DEFORMATION; ARTICULAR-CARTILAGE; JOINT; INJURIES; KINEMATICS; STABILITY AB Background: Degeneration of the tibiofemoral articular cartilage often develops inpatients with posterior cruciate ligament deficiency, yet little research has focused on the etiology of this specific type of cartilage degeneration. In this study, we hypothesized that posterior cruciate ligament deficiency changes the location and magnitude of cartilage deformation in the tibiofemoral joint. Methods: Fourteen patients with a posterior cruciate ligament injury in one knee and the contralateral side intact participated in the study. First, both knees were imaged with use of a specific magnetic resonance imaging sequence to create three-dimensional knee models of the surfaces of the bone and cartilage. Next, each patient performed a single leg lunge as images were recorded with a dual fluoroscopic system at 0 degrees, 30 degrees, 60 degrees, 75 degrees, 90 degrees, 105 degrees, and 120 degrees of knee flexion. Finally, the three-dimensional knee models and fluoroscopic images were used to reproduce the in vivo knee position at each flexion angle with use of a previously described image-matching method. With use of these series of knee models, the location and magnitude of peak tibiofemoral cartilage deformation at each flexion angle were compared between the intact contralateral and posterior cruciate ligament-deficient knees. Results: In the medial compartment of the posterior cruciate ligament-deficient knees, the location and magnitude of peak cartilage deformation were significantly changed, compared with those in the intact contralateral knees, between 75 degrees and 120 degrees of flexion, with a more anterior and medial location of peak cartilage deformation on the tibial plateau as well as increased deformation of the cartilage. In the lateral compartment, no significant differences in the location or magnitude of peak cartilage deformation were found between the intact and posterior cruciate ligament-deficient knees. Conclusions: The altered kinematics associated with posterior cruciate ligament deficiency resulted in a shift of the tibiofemoral contact location and an increase in cartilage deformation in the medial compartment beyond 75 degrees of knee flexion. The magnitude of the medial contact shift in the posterior cruciate ligament-deficient knee was on the same order as that of the anterior contact shift. C1 [Van de Velde, Samuel K.; Bingham, Jeffrey T.; Gill, Thomas J.; Li, Guoan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Bioengn Lab, Boston, MA 02114 USA. RP Van de Velde, SK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Bioengn Lab, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA. EM glil@partners.org RI Bingham, Jeffrey/I-6901-2012 OI Bingham, Jeffrey/0000-0002-9590-8526 FU National Institutes of Health [R01 AR052408-02]; National Football League Charities Foundation; Belgian American Educational Foundation FX In support of their research for or preparation of this work, one or more of the authors received, in any one year, outside funding or grants in excess of $10,000 from the National Institutes of Health (Grant R01 AR052408-02), the National Football League Charities Foundation, and the Belgian American Educational Foundation. Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which the authors, or a member oftheir immediate families. are affiliated or associated. NR 43 TC 29 Z9 30 U1 0 U2 2 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD JAN PY 2009 VL 91A IS 1 BP 167 EP 175 DI 10.2106/JBJS.H.00177 PG 9 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 394CH UT WOS:000262422400021 PM 19122092 ER PT J AU DeFranco, MJ Bach, BR AF DeFranco, Michael J. Bach, Bernard R., Jr. TI A Comprehensive Review of Partial Anterior Cruciate Ligament Tears SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Review ID CONSERVATIVELY TREATED TEARS; FOLLOW-UP EVALUATION; POSTEROLATERAL BUNDLE; RADIOFREQUENCY ENERGY; ACTIVE INDIVIDUALS; THERMAL SHRINKAGE; NATURAL-HISTORY; PATELLAR TENDON; PARTIAL RUPTURE; KNEE LOCKING C1 [DeFranco, Michael J.] Harvard Univ, Shoulder Serv, Massachusetts Gen Hosp, Yawkey Ctr Outpatient Care, Boston, MA 02114 USA. [Bach, Bernard R., Jr.] Rush Univ, Med Ctr, Div Sports Med, Chicago, IL 60612 USA. RP DeFranco, MJ (reprint author), Harvard Univ, Shoulder Serv, Massachusetts Gen Hosp, Yawkey Ctr Outpatient Care, 3G,55 Fruit St, Boston, MA 02114 USA. EM brbachmd@comcast.net NR 78 TC 45 Z9 47 U1 0 U2 6 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 USA SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD JAN PY 2009 VL 91A IS 1 BP 198 EP 208 DI 10.2106/JBJS.H.00819 PG 11 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 394CH UT WOS:000262422400025 PM 19122096 ER PT J AU Martin, TJ Potts, J Raisz, L Zaidi, M AF Martin, T. John Potts, John Raisz, Lawrence Zaidi, Mone TI Iain MacIntyre 1924-2008 IN MEMORIAM SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Biographical-Item C1 [Martin, T. John] St Vincents Inst Med Res, Melbourne, Vic, Australia. [Potts, John] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Raisz, Lawrence] Univ Connecticut, Ctr Hlth, Farmington, CT USA. [Zaidi, Mone] Mt Sinai Med Ctr, New York, NY 10029 USA. RP Martin, TJ (reprint author), St Vincents Inst Med Res, Melbourne, Vic, Australia. NR 0 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD JAN PY 2009 VL 24 IS 1 BP 1 EP 2 DI 10.1359/JBMR.0901IMM PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 386QG UT WOS:000261897100001 ER PT J AU Palmieri, TL Warner, P Mlcak, RP Sheridan, R Kagan, RJ Herndon, DN Tompkins, R Greenhalgh, DG AF Palmieri, Tina L. Warner, Petra Mlcak, Ronald P. Sheridan, Robert Kagan, Richard J. Herndon, David N. Tompkins, Ronald Greenhalgh, David G. TI Inhalation Injury in Children: A 10 Year Experience at Shriners Hospitals for Children SO JOURNAL OF BURN CARE & RESEARCH LA English DT Article ID PEDIATRIC-PATIENTS; VENTILATION; MORTALITY AB Inhalation injury remains a significant source of morbidity, and mortality in children with burn injury. The purpose of this study is to analyze the incidence, demographic characteristics, and outcomes for children who have sustained burn injury at one of four regional pediatric burn centers. A retrospective review of children aged 0 to 18 years admitted to one of four pediatric burn centers from 1997 to 2007 with a diagnosis of inhalation injury was performed. Factors analyzed included demographics, injury severity, treatment duration, and outcomes. A total of 850 patients with a mean age of 7.9 +/- 0.2 years and a mean total body surface area burn of 48.6 +/- 0.9% were admitted with a diagnosis of inhalation injury. Mean interval between injury and hospital admission was 4.2 +/- 0.3 days. Inhalation injury was diagnosed by bronchoscopy in 71%, via elevated carboxyhemoglobin in 4%, and by clinical signs/history alone in 25%. Hospital length of stay averaged 44.8 +/- 1.7 days, and patients required mechanical ventilation for a mean of 15.2 +/- 0.8 days. Mortality was 16.4%. Inhalation injury in children is associated with significant morbidity and mortality, and diagnosis of inhalation injury does not follow consistent guidelines. Further studies are required to standardize diagnostic criteria for inhalation injury and to optimize the treatment of children with inhalation injury. (J Burn Care Res 2009;30:206-208) C1 [Palmieri, Tina L.; Greenhalgh, David G.] Shriners Hosp Children, Dept Burn Surg, No Calif, CA USA. [Palmieri, Tina L.; Greenhalgh, David G.] Univ Calif Davis, Dept Surg, Sacramento, CA 95817 USA. [Warner, Petra] Shriners Hosp Children, Dept Burn Surg, Cincinnati, OH USA. [Warner, Petra; Kagan, Richard J.] Univ Cincinnati, Dept Surg, Cincinnati, OH 45221 USA. [Mlcak, Ronald P.; Herndon, David N.] Shriners Hosp Children, Dept Burn Surg, Galveston, TX 77550 USA. [Mlcak, Ronald P.; Herndon, David N.] Univ Texas Med Branch, Dept Surg, Galveston, TX USA. [Sheridan, Robert; Tompkins, Ronald] Shriners Hosp Children, Dept Burn Surg, Boston, MA USA. [Sheridan, Robert; Tompkins, Ronald] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Palmieri, TL (reprint author), 2425 Stockton Blvd,Suite 718, Sacramento, CA 95817 USA. FU Shriners Hospitals [8431] FX This study was supported by a Grant 8431 from Shriners Hospitals for Children. NR 7 TC 20 Z9 21 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1559-047X J9 J BURN CARE RES JI J. Burn Care Res. PD JAN-FEB PY 2009 VL 30 IS 1 BP 206 EP 208 DI 10.1097/BCR.0b013e3181923ea4 PG 3 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA 393QX UT WOS:000262388900049 PM 19060756 ER PT J AU Dougherty, CM Hunziker, J AF Dougherty, Cynthia M. Hunziker, Jim TI Predictors of Implantable Cardioverter Defibrillator Shocks During the First Year SO JOURNAL OF CARDIOVASCULAR NURSING LA English DT Article DE heart failure; ICD; logistic regression; predictors; shocks; sudden cardiac arrest ID QUALITY-OF-LIFE; VENTRICULAR-ARRHYTHMIAS; ELECTRICAL STORM; DEVICE THERAPY; TRIAL; ANTIARRHYTHMICS; ADJUSTMENT; PREVENTION; RECIPIENTS; DISCHARGE AB The purpose of this study was to predict implantable cardioverter defibrillator (ICD) shocks using demographic and clinical characteristics in the first year after implantation for secondary prevention of cardiac arrest. A prospective design was used to follow 168 first-time ICD recipients over 12 months. Demographic and clinical data were obtained from medical records at the time of ICD insertion. Implantable cardioverter defibrillator shock data were obtained from ICD interrogation reports at hospital discharge, 3, 6, and 12 months. Logistic regression was used to predict ever receiving an ICD shock using background characteristics. Patients received an ICD for secondary prevention of sudden cardiac arrest, they were 64.1 years old, 89% were white, 77% were male, with a mean (SD) ejection fraction of 33.7% (14.1 %). The cumulative percentage of ever receiving an ICD shock was 33.3% over 1 year. Three variables predicted shocks in the first year: history of chronic obstructive pulmonary disease (COPD) (odds ratio [OR], 4,42; 95% confidence interval [CI], 1.2-16.4; P = .03), history of congestive heart failure (OR, 3.55; 95% CI, 1.4-9.3; P = .01), and documented ventricular tachycardia (VT) at the time of ICD implant (OR, 10.05; 95% CI, 1.8-55.4; P = .01). High levels of anxiety approached significance (OR = 2.82; P = .09). The presence of COPD, congestive heart failure, or VT at ICD implant was a significant predictor of receiving an ICD shock in the first year after ICD implantation. Because ICD shocks are distressing, painful, and associated with greater mortality, healthcare providers should focus attention on prevention of shocks by controlling VT, careful management of HF symptoms, reduction of the use of short acting p agonist medications in COPD, and perhaps recognizing and treating high levels of anxiety. C1 [Dougherty, Cynthia M.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Hunziker, Jim] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Dougherty, CM (reprint author), Univ Washington, Sch Nursing, Box 357266, Seattle, WA 98195 USA. EM cindyd@u.washington.edu FU NINR NIH HHS [R01 NR004766-01A1, R01NR04766, R01 NR004766] NR 39 TC 9 Z9 9 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0889-4655 J9 J CARDIOVASC NURS JI J. Cardiovasc. Nurs. PD JAN-FEB PY 2009 VL 24 IS 1 BP 21 EP 28 PG 8 WC Cardiac & Cardiovascular Systems; Nursing SC Cardiovascular System & Cardiology; Nursing GA 389TR UT WOS:000262117900008 PM 19114797 ER PT J AU Tu, QS Zhang, J Fix, A Brewer, E Li, YP Zhang, ZY Chen, J AF Tu, Qisheng Zhang, Jin Fix, Amanda Brewer, Erika Li, Yi-Ping Zhang, Zhi-Yuan Chen, Jake TI Targeted Overexpression of BSP in Osteoclasts Promotes Bone Metastasis of Breast Cancer Cells SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID IN-VITRO; VISCERAL METASTASES; SIALOPROTEIN BSP; TRANSGENIC MICE; MOUSE MODEL; EXPRESSION; RESORPTION; MIGRATION; ADHESION; DIFFERENTIATION AB Bone is one of the most common sites of breast cancer metastasis while bone sialoprotein (BSP) is thought to play an important role in bone metastasis of malignant tumors. The objective of this study is to determine the role of BSP overexpression in osteolytic metastasis using two homozygous transgenic mouse lines in which BSP expression is elevated either in all the tissues (CMV-BSP mice) or only in the osteoclasts (CtpsK-BSP mice). The results showed that skeletal as well as systemic metastases of 4T1 murine breast cancer cells were dramatically increased in CMV-BSP mice. In CtpsK-BSP mice, it was found that targeted BSP overexpression in osteoclasts promoted in vitro osteoclastogenesis and activated osteoclastic differentiation markers such as Cathepsin K, TRAP and NFAT2. MicroCT scan demonstrated that CtpsK/BSP mice had reduced trabecular bone volume and bone mineral density (BMD). The real-time IVIS Imaging System showed that targeted BSP overexpression in osteoclasts promoted bone metastasis of breast cancer cells. The osteolytic lesion area was significantly larger in CtpsK/BSP mice than in the controls as demonstrated by both radiographic and histomorphometric analyses. TRAP staining demonstrated a twofold increase in the number of osteoclasts in the bone lesion area from CtpsK/BSP mice compared with that from wild type mice. We conclude that host tissue-derived BSP also plays important roles in breast cancer metastasis through inducing tumor cell seeding into the remote host tissues. Furthermore, osteoclast-derived BSP promotes osteoclast differentiation in an autocrine manner and consequently promotes osteolytic bone metastasis of breast cancer. C1 [Tu, Qisheng; Zhang, Jin; Fix, Amanda; Brewer, Erika; Chen, Jake] Tufts Univ, Sch Dent Med, Div Oral Biol, Boston, MA 02111 USA. [Zhang, Jin] Shandong Univ, Sch Dent, Jinan 250100, Shandong, Peoples R China. [Li, Yi-Ping] Harvard Univ, Sch Dent Med, Dept Cytokine Biol, Forsyth Inst, Boston, MA 02115 USA. [Li, Yi-Ping] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA. [Zhang, Zhi-Yuan] Shanghai Jiao Tong Univ, Coll Stomatol, Shanghai 200030, Peoples R China. RP Tu, QS (reprint author), Tufts Univ, Sch Dent Med, Div Oral Biol, 1 Kneeland St, Boston, MA 02111 USA. EM qisheng.tu@tufts.edu; jk.chen@tufts.edu FU NIH [DE14537, DE16710] FX Contract grant numbers: DE14537, DE16710. NR 44 TC 22 Z9 25 U1 0 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD JAN PY 2009 VL 218 IS 1 BP 135 EP 145 DI 10.1002/jcp.21576 PG 11 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 383FV UT WOS:000261660400017 PM 18756497 ER PT J AU Jameel, NM Thirunavukkarasu, C Wu, T Watkins, SC Friedman, SL Gandhi, CR AF Jameel, Noor Mohamed Thirunavukkarasu, Chinnasamy Wu, Tong Watkins, Simon C. Friedman, Scott L. Gandhi, Chandrashekhar R. TI p38-MAPK- and Caspase-3-Mediated Superoxide-Induced Apoptosis of Rat Hepatic Stellate Cells: Reversal by Retinoic Acid SO JOURNAL OF CELLULAR PHYSIOLOGY LA English DT Article ID FAT-STORING CELLS; OXIDATIVE STRESS; CARBON-TETRACHLORIDE; LIVER FIBROSIS; GLUTATHIONE DEPLETION; LIPID-PEROXIDATION; COMET ASSAY; PROLIFERATION; HEPATOCYTES; EXPRESSION AB Reactive oxygen species (ROS) activate retinoid-containing quiescent hepatic stellate cells (qHSCs) to retinoid-deficient fibrogenic myofibroblast-like cells (aHSCs). However, ROS also cause apoptosis of aHSCs, and apoptotic aHSCs are observed in inflammatory fibrotic liver. Here, we investigated mechanisms of the effects of oxidative stress on the survival of qHSCs and aHSCs. HSCs from normal rat liver were used after overnight culture (qHSCs), or in 3-5 passages (aHSCs). For in vivo induction of oxidative stress, tert-butylhydroperoxide was injected into control and CC14-induced cirrhotic rats. Spontaneous caspase-3 activation and apoptosis, observed in cultured qHSCs, decreased with time and were unaffected by superoxide. In contrast, superoxide caused caspase-3 and p38-MAPK activation, reduction in Bcl-xL expression, and apoptosis in aHSCs. Inhibition of caspase-3 and p38-MAPK did not affect the viability of qHSCs in the absence or presence of superoxide, but inhibited superoxide-induced death of aHSCs. Glutathione (GSH) level and activities of superoxide dismutase (SOD), catalase and glutathione peroxidase (GPx) were lower in aHSCs than qHSCs. Superoxide increased GSH content,and activities of SOD, catalase and GPx in qHSCs but not in aHSCs. Incubation of 13-cis-retinoic acid (RA)-treated aHSCs with superoxide increased their GSH content significantly, and prevented superoxide-induced p38-MAPK and caspase-3 activation while dramatically reducing the extent of apoptosis. Finally, oxidative stress induced in vivo caused apoptosis of aHSCs in cirrhotic but not of qHSCs in control rats. These results suggest that the absence of retinoids render aHSCs susceptible to superoxide-induced apoptosis via caspase-3 and p38-MAPK activation. C1 [Jameel, Noor Mohamed; Thirunavukkarasu, Chinnasamy; Gandhi, Chandrashekhar R.] Univ Pittsburgh, Dept Surg, Thomas E Starzi Transplantat Inst, Pittsburgh, PA 15213 USA. [Wu, Tong; Gandhi, Chandrashekhar R.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA. [Watkins, Simon C.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15213 USA. [Friedman, Scott L.] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA. [Gandhi, Chandrashekhar R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Gandhi, CR (reprint author), Univ Pittsburgh, Dept Surg, Thomas E Starzi Transplantat Inst, E-1518 BST,200 Lothrop St, Pittsburgh, PA 15213 USA. EM gandhics@upmc.edu OI Thirunavukkarasu, Chinnasamy/0000-0002-2339-997X FU VA Merit award; NIH [DK 54411, DK37320, DK56621, CA 102325, CA 106280] FX We thank Ms. Holly Grunebach, Mr. Mark Ross, Mr. Sean Alber and Mr. Adam Kichler for excellent technical assistance. This work was supported by VA Merit award (CRG), and NIH grants DK 54411 (CRG), DK37320 and DK56621 (SLF) and CA 102325 and CA 106280 (TW). NR 43 TC 28 Z9 33 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9541 J9 J CELL PHYSIOL JI J. Cell. Physiol. PD JAN PY 2009 VL 218 IS 1 BP 157 EP 166 DI 10.1002/jcp.21581 PG 10 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 383FV UT WOS:000261660400019 PM 18792915 ER PT J AU Lok, J Sardi, SP Guo, S Besancon, E Ha, DM Rosell, A Kim, WJ Corfas, G Lo, EH AF Lok, Josephine Sardi, S. Pablo Guo, Shuzhen Besancon, Elaine Ha, Duy M. Rosell, Anna Kim, Woo Jean Corfas, Gabriel Lo, Eng H. TI Neuregulin-1 signaling in brain endothelial cells SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE blood-brain barrier; erbB; neuregulin; neuroprotection; neurovascular unit; oxidative stress ID ERBB RECEPTORS AB Neuregulin-1 (NRG1) signaling has multiple functions in neurons and glia. The data in this study show that NRG1 may also possess significant signaling and cytoprotective properties in human brain microvascular endothelial cells (BMECs). Neuregulin-1 mRNA and protein expression are present in these cells, and NRG1 receptors erbB2 and erbB3 are phosphorylated in response to NRG1. Neuregulin-1 triggers clear biologic responses in BMECs-elevated phospho-Akt levels, increased ring formation in a Matrigel assay, and decreased cell death after oxidative injury with H(2)O(2). These data suggest that NRG1 signaling is functional and cytoprotective in BMECs. C1 [Lok, Josephine; Guo, Shuzhen; Besancon, Elaine; Ha, Duy M.; Rosell, Anna; Kim, Woo Jean; Lo, Eng H.] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Boston, MA 02114 USA. [Lok, Josephine; Guo, Shuzhen; Besancon, Elaine; Ha, Duy M.; Rosell, Anna; Kim, Woo Jean; Lo, Eng H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Lok, Josephine; Guo, Shuzhen; Besancon, Elaine; Ha, Duy M.; Rosell, Anna; Kim, Woo Jean; Lo, Eng H.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA. [Lok, Josephine] Massachusetts Gen Hosp, Dept Pediat Pediat Crit Care Med, Boston, MA 02114 USA. [Sardi, S. Pablo; Corfas, Gabriel] Harvard Univ, Sch Med, Neurobiol Program, Childrens Hosp, Boston, MA USA. RP Lok, J (reprint author), Neuroprotect Res Lab, MGH E 149-2401, Charlestown, MA 02129 USA. EM jlok1@partners.org FU NIH [R01-NS37074, R01-NS48422, R01-NS53560, R01-NS35884, P50-NS10828, P01-NS55104, P30-NS045776] FX The study was supported by NIH Grants R01-NS37074, R01-NS48422, R01-NS53560, R01-NS35884, P50-NS10828, P01-NS55104, and P30-NS045776. NR 15 TC 19 Z9 19 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD JAN PY 2009 VL 29 IS 1 BP 39 EP 43 DI 10.1038/jcbfm.2008.94 PG 5 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 389QS UT WOS:000262110200006 PM 18728681 ER PT J AU Kuban, KCK Allred, EN O'Shea, TM Paneth, N Pagano, M Dammann, O Leviton, A Du Plessis, A Westra, SJ Miller, CR Bassan, H Krishnamoorthy, K Junewick, J Olomu, N Romano, E Seibert, J Engelke, S Karna, P Batton, D O'Connor, SE Keller, CE AF Kuban, Karl C. K. Allred, Elizabeth N. O'Shea, T. Michael Paneth, Nigel Pagano, Marcello Dammann, Olaf Leviton, Alan Du Plessis, Adre Westra, Sijirk J. Miller, Cindy R. Bassan, Haim Krishnamoorthy, Kalpathy Junewick, Joseph Olomu, Nicholas Romano, Elaine Seibert, Joanna Engelke, Steve Karna, Padmani Batton, Daniel O'Connor, Sunila E. Keller, Cecelia E. CA ELGAN Study Investigators TI Cranial Ultrasound Lesions in the NICU Predict Cerebral Palsy at Age 2 Years in Children Born at Extremely Low Gestational Age SO JOURNAL OF CHILD NEUROLOGY LA English DT Article DE cerebral palsy; extremely low gestational age; cranial ultrasound ID LOW-BIRTH-WEIGHT; WHITE-MATTER INJURY; PERIVENTRICULAR HEMORRHAGIC INFARCTION; EXTREMELY PRETERM INFANTS; PREMATURE-INFANTS; NEURODEVELOPMENTAL OUTCOMES; CEREBELLAR INJURY; INTRAVENTRICULAR HEMORRHAGE; MOTOR FUNCTION; BRAIN-INJURY AB Our prospective cohort study of extremely low gestational age newborns evaluated the association of neonatal head ultrasound abnormalities with cerebral palsy at age 2 years. Cranial ultrasounds in 1053 infants were read with respect to intraventricular hemorrhage, ventriculopathy, and echolucency, by multiple sonologists. Standardized neurological examinations classified cerebral palsy, and functional impairment was assessed. Forty-four percent with ventriculomegaly and 52% with echolucency developed cerebral palsy. Compared with no ultrasound abnormalities, children with echolucency were 24 times more likely to have quadroparesis and 29 times more likely to have hemiparesis. Children with ventriculomegaly were 17 dimes more likely to have quadriparesis or hemiparesis. Forty-three percent of children with cerebral palsy had normal head ultrasound. Focal white matter damage (echolucency) and diffuse damage (late ventriculomegaly) are associated with it high probability of cerebral palsy, especially quadriparesis. Nearly half the cerebral palsy identified at 2 years is not preceded by a neonatal brain ultrasound abnormality. C1 [Kuban, Karl C. K.] Boston Univ, Div Pediat Neurol, Dept Pediat, Boston Med Ctr, Boston, MA 02215 USA. [Allred, Elizabeth N.; Pagano, Marcello; Dammann, Olaf; Leviton, Alan] Harvard Univ, Neuroepidemiol Unit, Dept Neurol, Childrens Hosp Boston, Boston, MA 02115 USA. [Allred, Elizabeth N.; Pagano, Marcello] Harvard Univ, Dept Biostat, Sch Publ Hlth, Boston, MA 02115 USA. [O'Shea, T. Michael] Wake Forest Univ, Dept Neonatol, Winston Salem, NC 27109 USA. [Paneth, Nigel; Olomu, Nicholas; Karna, Padmani] Michigan State Univ, Coll Human Med, Dept Epidemiol, E Lansing, MI 48824 USA. [Dammann, Olaf; Keller, Cecelia E.] Tufts Med Ctr, Floating Hosp Children, Div Newborn Med, Boston, MA USA. [Du Plessis, Adre; Bassan, Haim] Harvard Univ, Childrens Hosp Boston, Dept Neurol, Boston, MA 02115 USA. [Du Plessis, Adre] Brigham & Womens Med Ctr, Boston, MA USA. [Westra, Sijirk J.; Krishnamoorthy, Kalpathy] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Westra, Sijirk J.] Harvard Univ, Sch Med, Boston, MA USA. [Miller, Cindy R.; Romano, Elaine] Yale Univ, Sch Med, New Haven, CT USA. [Junewick, Joseph] DeVos Childrens Hosp, Grand Rapids, MI USA. [Seibert, Joanna] Arkansas Childrens Hosp, Little Rock, AR 72202 USA. [Seibert, Joanna] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Engelke, Steve] E Carolina Univ, Greenville, NC USA. [Batton, Daniel] William Beaumont Hosp, Royal Oak, MI 48072 USA. [O'Connor, Sunila E.] Med Coll Wisconsin, Dept Neurol, Sect Pediat Neurol, Milwaukee, WI 53226 USA. RP Kuban, KCK (reprint author), 1 Boston Med Ctr Pl,Dowling 3 S, Boston, MA 02118 USA. EM karl.kuban@bmc.org FU National Institute of Neurological Disorders and Stroke FX Financial Support for this research was provided by the National Institute of Neurological Disorders and Stroke. NR 55 TC 52 Z9 53 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0883-0738 J9 J CHILD NEUROL JI J. Child Neurol. PD JAN PY 2009 VL 24 IS 1 BP 63 EP 72 DI 10.1177/0883073808121048 PG 10 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 388KV UT WOS:000262019600011 PM 19168819 ER PT J AU Cohen, RA Poppas, A Forman, DE Hoth, KF Haley, AP Gunstad, J Jefferson, AL Tate, DF Paul, RH Sweet, LH Ono, M Jerskey, BA Gerhard-Herman, M AF Cohen, Ronald A. Poppas, Athena Forman, Daniel E. Hoth, Karin F. Haley, Andreana P. Gunstad, John Jefferson, Angela L. Tate, David F. Paul, Robert H. Sweet, Lawrence H. Ono, Mokato Jerskey, Beth A. Gerhard-Herman, Marie TI Vascular and cognitive functions associated with cardiovascular disease in the elderly SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE Cardiovascular disease; Cerebrovascular disease; White matter hyperintensities; Magnetic resonance imaging; Flow mediated dilatation intima lamina thickness; Blood pressure variability; Cardiac output; Cognition; Attention; Executive function; Psychomotor function ID WHITE-MATTER LESIONS; CEREBRAL-BLOOD-FLOW; ENDOTHELIUM-DEPENDENT DILATION; SMOOTH-MUSCLE RELAXATION; SILENT BRAIN INFARCTS; RISK-FACTORS; OLDER-ADULTS; BRACHIAL-ARTERY; GENERAL-POPULATION; ROTTERDAM SCAN AB This study examines the relationship between systemic vascular function, neurocognitive performance, and structural brain abnormalities on magnetic resonance imaging (MRI) among geriatric outpatients with treated, stable cardiovascular disease and no history of neurological illness (n = 88, ages 56-85 years). Vascular function was assessed by cardiac ejection fraction and output, sequential systolic and diastolic blood pressures, flow mediated brachial artery reactivity (BAR), and carotid intima media thickness (IMT). White matter hyperintensities (WMH) on MRI were quantified and examined relative to cognitive and vascular function. Principal component analysis revealed two primary vascular components: one associated with cardiac function, the other with atherosclerotic burden/endothelial dysfunction. Both factors were significantly associated with cognitive function and WMH volume. Reduced systolic variability and increased IMT were most strongly related to reduced attention, executive function, and information-processing speed. These findings suggest the possibility that systemic vascular indices may provide proxy measures of cerebrovascular dysfunction and reinforce the importance of achieving greater understanding of interaction between systemic vascular disease and brain dysfunction among elderly people with cardiovascular disease. C1 [Cohen, Ronald A.; Tate, David F.; Paul, Robert H.; Sweet, Lawrence H.; Ono, Mokato; Jerskey, Beth A.] Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Poppas, Athena] Brown Univ, Warren Alpert Med Sch, Dept Cardiol, Rhode Isl Hosp, Providence, RI 02912 USA. [Forman, Daniel E.; Gerhard-Herman, Marie] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol,VA Boston Hlth Care Syst, Boston, MA 02115 USA. [Haley, Andreana P.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. [Gunstad, John] Kent State Univ, Dept Psychol, Kent, OH 44242 USA. [Jefferson, Angela L.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Paul, Robert H.] Univ Missouri, Dept Psychol Behav Neurosci, St Louis, MO 63121 USA. [Hoth, Karin F.] Univ Colorado, Dept Med, Natl Jewish Med & Res Ctr, Denver, CO USA. [Hoth, Karin F.] Univ Colorado, Dept Psychiat, Denver, CO USA. RP Cohen, RA (reprint author), Ctr Behav & Prevent Med, CORO Bldg,5th Floor,1 Hoppin St, Providence, RI 02903 USA. EM RCohen@lifespan.org RI Tate, David/G-5166-2011; Tate, David/I-3963-2013 OI Tate, David/0000-0003-0213-1920; FU National Institute of Health [R01-AG017975] FX This work was supported in part by Grant R01-AG017975 (R. A. C.) from the National Institute of Health. NR 83 TC 38 Z9 38 U1 3 U2 9 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1380-3395 J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PY 2009 VL 31 IS 1 BP 96 EP 110 AR PII 794118156 DI 10.1080/13803390802014594 PG 15 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 384IT UT WOS:000261739200010 PM 18608677 ER PT J AU McCauley, JL Conoscenti, LM Ruggiero, KJ Resnick, HS Saunders, BE Kilpatrick, DG AF McCauley, Jenna L. Conoscenti, Lauren M. Ruggiero, Kenneth J. Resnick, Heidi S. Saunders, Benjamin E. Kilpatrick, Dean G. TI Prevalence and Correlates of Drug/Alcohol-Facilitated and Incapacitated Sexual Assault in a Nationally Representative Sample of Adolescent Girls SO JOURNAL OF CLINICAL CHILD AND ADOLESCENT PSYCHOLOGY LA English DT Article ID SUBSTANCE USE; RISK; RAPE; DEPRESSION; VIOLENCE; TRAUMA; WOMEN AB Incapacitated/drug-alcohol facilitated sexual assault (IS/DAFS) is rapidly gaining recognition as a distinct form of assault with unique public health implications. This study reports the prevalence, case characteristics, and associated health risks of IS/DAFS using a large, nationally representative sample of 1,763 adolescent girls. Results indicate that 11.8% of girls experienced at least one form of sexual assault; 2.1% of the total sample experienced IS/DAFS. Thus IS/DAFS accounted for 18% of all reported sexual assaults, with a prevalence of 4.0% among girls 15 to 17 years of age and 0.7% among girls 12 to 14 years of age. Girls with a history of IS/DAFS were significantly more likely than girls with other sexual assault histories to report past-year substance abuse but not significantly more likely than girls with other sexual assault histories to report past-year depression or posttraumatic stress disorder. C1 [McCauley, Jenna L.; Ruggiero, Kenneth J.; Resnick, Heidi S.; Saunders, Benjamin E.; Kilpatrick, Dean G.] Med Univ S Carolina, Dept Psychiat, Natl Crime Victims Ctr, Charleston, SC USA. [Conoscenti, Lauren M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. RP McCauley, JL (reprint author), Natl Crime Victims Res & Treatment Ctr, 165 Cannon St,POB 250852, Charleston, SC 29425 USA. EM mccaule@musc.edu FU NICHD NIH HHS [R01 HD046830-01, R01 HD046830] NR 21 TC 24 Z9 25 U1 2 U2 5 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 1537-4416 J9 J CLIN CHILD ADOLESC JI J. Clin. Child Adolesc. Psychol. PY 2009 VL 38 IS 2 BP 295 EP 300 DI 10.1080/15374410802698453 PG 6 WC Psychology, Clinical; Psychology, Developmental SC Psychology GA 427FK UT WOS:000264765000011 PM 19283607 ER PT J AU Brown, WW Juppner, H Langman, CB Price, H Farrow, EG White, KE McCormick, KL AF Brown, Whitney W. Jueppner, Harald Langman, Craig B. Price, Heather Farrow, Emily G. White, Kenneth E. McCormick, Kenneth L. TI Hypophosphatemia with Elevations in Serum Fibroblast Growth Factor 23 in a Child with Jansen's Metaphyseal Chondrodysplasia SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID PRIMARY HYPERPARATHYROIDISM; PARATHYROID-HORMONE; FIBROBLAST-GROWTH-FACTOR-23; EXPRESSION; FGF-23; METABOLISM; CELLS; FGF23; BONE AB Context: Previous studies have suggested a regulatory relationship between serum phosphorus, vitamin D, and fibroblast growth factor 23 (FGF23), a hormone that promotes renal excretion of phosphate. Despite these associations, the identity of the primary regulator of serum FGF23 is unresolved. Jansen's metaphyseal chondrodysplasia is a rare autosomal dominant disorder associated with short-limbed dwarfism and other characteristic skeletal abnormalities. This condition is caused by mutations in the PTH/PTHrP receptor that result in ligand-independent cAMP accumulation, thus rendering the receptor constitutively active. These patients typically exhibit asymptomatic hypercalcemia and hypophosphatemia despite low or undetectable serum levels of PTH and PTHrP. Evidence Acquisition: A literature search revealed that serum FGF23 levels had not been studied in patients with Jansen's syndrome, a disorder in which the biochemical features present a unique opportunity to study the possible relationship between FGF23 and calcium-phosphorus-vitamin D metabolism. A case of Jansen's syndrome is presented in which serum FGF23 concentrations, along with serum phosphorus and 1,25(OH) 2 vitamin D levels, were measured and compared with those of age-matched controls. Evidence Synthesis: Serum FGF23 concentrations in the patient with Jansen's syndrome were found to be markedly and persistently elevated, compared with values in healthy, age-matched controls, despite hypophosphatemia and normal 1,25(OH) 2 vitamin D levels. Conclusion: Together, our findings indicate that serum FGF23 could be governed by factor(s) other than serum phosphorus, potentially by activation of the PTH/PTHrP receptor in bone. (J Clin Endocrinol Metab 94: 17-20, 2009) C1 [Brown, Whitney W.; McCormick, Kenneth L.] Univ Alabama, Sch Med, Dept Pediat Endocrinol, Birmingham, AL 35233 USA. [Jueppner, Harald] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Jueppner, Harald] Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA. [Jueppner, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Langman, Craig B.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60614 USA. [Price, Heather] Childrens Mem Hosp, Chicago, IL 60614 USA. [Farrow, Emily G.; White, Kenneth E.] Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA. RP Brown, WW (reprint author), Univ Alabama, Sch Med, Dept Pediat Endocrinol, Childrens Pk Pl Suite 230,1600 7th Ave S, Birmingham, AL 35233 USA. EM dr.whitneyw.brown@erlanger.org FU National Institutes of Health [R01AG032227]; Zell Family Foundation; McNulty Family Foundation FX This work was supported in parts by grants from the National Institutes of Health (R01AG032227), and from the Zell Family Foundation and the McNulty Family Foundation. NR 15 TC 60 Z9 60 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2009 VL 94 IS 1 BP 17 EP 20 DI 10.1210/jc.2008-0220 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 391UR UT WOS:000262260200005 PM 18854401 ER PT J AU Boscaro, M Ludlam, WH Atkinson, B Glusman, JE Petersenn, S Reincke, M Snyder, P Tabarin, A Biller, BMK Findling, J Melmed, S Darby, CH Hu, K Wang, Y Freda, PU Grossman, AB Frohman, LA Bertherat, J AF Boscaro, M. Ludlam, W. H. Atkinson, B. Glusman, J. E. Petersenn, S. Reincke, M. Snyder, P. Tabarin, A. Biller, B. M. K. Findling, J. Melmed, S. Darby, C. H. Hu, K. Wang, Y. Freda, P. U. Grossman, A. B. Frohman, L. A. Bertherat, J. TI Treatment of Pituitary-Dependent Cushing's Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID PPAR-GAMMA RECEPTOR; NELSONS-SYNDROME; CONSENSUS STATEMENT; ACTH-SECRETION; ADENOMAS; THERAPY; SMS-201-995; EXPRESSION; RELEASE; TUMORS AB Context: There is currently no medical therapy for Cushing's disease that targets the pituitary adenoma. Availability of such a medical therapy would be a valuable therapeutic option for the management of this disorder. Objective: Our objective was to evaluate the short-term efficacy of the novel multireceptor ligand somatostatin analog pasireotide in patients with de novo, persistent, or recurrent Cushing's disease. Design: We conducted a phase II, proof-of-concept, open-label, single-arm, 15-d multicenter study. Patients: Thirty-nine patients with either de novo Cushing's disease who were candidates for pituitary surgery or with persistent or recurrent Cushing's disease after surgery without having received prior pituitary irradiation. Intervention: Patients self-administered sc pasireotide 600 mu g twice daily for 15 d. Main Outcome Measure: Normalization of urinary free cortisol (UFC) levels after 15 d treatment was the main outcome measure. Results: Of the 29 patients in the primary efficacy analysis, 22 (76%) showed a reduction in UFC levels, of whom five (17%) had normal UFC levels (responders), after 15 d of treatment with pasireotide. Serum cortisol levels and plasma ACTH levels were also reduced. Steady-state plasma concentrations of pasireotide were achieved within 5 d of treatment. Responders appeared to have higher pasireotide exposure than nonresponders. Conclusions: Pasireotide produced a decrease in UFC levels in 76% of patients with Cushing's disease during the treatment period of 15 d, with direct effects on ACTH release. These results suggest that pasireotide holds promise as an effective medical treatment for this disorder. (J Clin Endocrinol Metab 94: 115-122, 2009) C1 [Bertherat, J.] Paris Descartes Univ, Hop Cochin, AP HP,Inst Cochin, INSERM,Ctr Rare Adrenal Dis,Dept Endocrinol,U567, F-75014 Paris, France. [Boscaro, M.] Polytech Univ Marche, Div Endocrinol, I-60126 Ancona, Italy. [Ludlam, W. H.] Swedish Neurosci Inst, Seattle Pituitary Ctr, Seattle, WA 98122 USA. [Atkinson, B.] Royal Victoria Hosp, Reg Ctr Endocrinol & Diabet, Belfast BT12 6BA, Antrim, North Ireland. [Glusman, J. E.; Darby, C. H.; Hu, K.; Wang, Y.] Novartis Pharmaceut, Oncol Clin Dev, E Hanover, NJ 07932 USA. [Petersenn, S.] Univ Essen Gesamthsch, Med Ctr, Div Endocrinol, D-45122 Essen, Germany. [Reincke, M.] Univ Munich, Klinikum Innenstadt, Med Klin, D-80336 Munich, Germany. [Snyder, P.] Univ Penn, Philadelphia, PA 19104 USA. [Tabarin, A.] CHU Bordeaux, Serv Endocrinol, F-33075 Pessac, France. [Biller, B. M. K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Findling, J.] Midwest Endocrinol Associates, Milwaukee, WI 53215 USA. [Melmed, S.] Cedars Sinai Pituitary Ctr, Los Angeles, CA 90048 USA. [Freda, P. U.] Columbia Univ, Dept Med, Div Endocrinol, New York, NY 10027 USA. [Grossman, A. B.] St Bartholomews Hosp, Dept Endocrinol, London EC1M 6BQ, England. [Frohman, L. A.] Univ Illinois, Dept Med, Sect Endocrinol Diabet & Metab, Chicago, IL 60637 USA. RP Bertherat, J (reprint author), Paris Descartes Univ, Hop Cochin, AP HP,Inst Cochin, INSERM,Ctr Rare Adrenal Dis,Dept Endocrinol,U567, 27 Rue Faubourg St Jacques, F-75014 Paris, France. EM jerome.bertherat@cch.aphp.fr OI BOSCARO, MARCO/0000-0003-2596-1652 FU Novartis FX Disclosure Statement: M.B., J.F., and A.T.have nothing to declare. B.A., B.M.K.B., A.B.G., S.M., and M.R.have received consulting fees from Novartis.B.A.and B.M.K.B.have been expert witnesses for Novartis. J.B., B.M.K.B., L.A.F., A.B.G., P.U.F., W.H.L., S.M., S.P., and M.R.have received lecture fees from Novartis.B.A., B.M.K.B., P.U.F., S.M., and P.S.have received grant support from Novartis. C.H.D., J.E.G., K.H., and Y.W.are employed by Novartis.J.E.G.and Y.W.have equity interests in Novartis. NR 26 TC 170 Z9 173 U1 0 U2 6 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2009 VL 94 IS 1 BP 115 EP 122 DI 10.1210/jc.2008-1008 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 391UR UT WOS:000262260200020 PM 18957506 ER PT J AU Prudente, S Scarpelli, D Chandalia, M Zhang, YY Morini, E Del Guerra, S Perticone, F Li, R Powers, C Andreozzi, F Marchetti, P Dallapiccola, B Abate, N Doria, A Sesti, G Trischitta, V AF Prudente, Sabrina Scarpelli, Daniela Chandalia, Manisha Zhang, Yuan-Yuan Morini, Eleonora Del Guerra, Silvia Perticone, Francesco Li, Rong Powers, Christine Andreozzi, Francesco Marchetti, Piero Dallapiccola, Bruno Abate, Nicola Doria, Alessandro Sesti, Giorgio Trischitta, Vincenzo TI The TRIB3 Q84R Polymorphism and Risk of Early-Onset Type 2 Diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID INSULIN-RECEPTOR SUBSTRATE-1; GENOME-WIDE ASSOCIATION; AGE-OF-ONSET; TRIBBLES HOMOLOG; GLUCOSE-HOMEOSTASIS; RESISTANCE; VARIANT; YOUNG; TRB3; SENSITIVITY AB Context: The prevalence of type 2 diabetes (T2D), particularly among young adults, has been rising steadily during the past 2 decades. T2D, especially in its early-onset subtype, is under genetic control. TRIB3 inhibits insulin-stimulated Akt phosphorylation and subsequent insulin action. A TRIB3 gain-of-function polymorphism, Q84R (rs2295490), impairs insulin signaling. Objective: The objective of the study was to verify the association of TRIB3Q84Rwith: 1) T2D, either subtyped or not according to age at diagnosis (early-onset, <45 yr, or >= 45 yr); 2) insulin secretion and sensitivity in nondiabetic individuals; or 3) in vitro insulin secretion from isolated human islets. Design: Four different case-control samples comprising a total of 5469 whites were examined. Insulinogenic and insulin sensitivity indexes and their interplay (disposition index) were assessed in 645 nondiabetic individuals at oral glucose tolerance test, glucose (16.7 mmol/liter)-induced in vitro insulin secretion was assessed in islets isolated from 54 nondiabetic donors. Results: In the whole sample, the R84 variant was nominally associated with T2D (odds ratio 1.17,95% confidence interval 1.00-1.36, P = 0.04). When stratifying according to age of diabetes onset, R84 carriers had an increased risk of early-onset T2D (odds ratio 1.32, 95% confidence interval 1.10-1.58, P = 0.002). Among 645 nondiabetic subjects, R84 carriers had higher glucose levels (P = 0.005) and lower insulinogenic (P = 0.03) and disposition index (P = 0.02) during the oral glucose tolerance test. R84 islets were more likely to display relatively low glucose-stimulated insulin release (P = 0.04). Conclusions: The TRIB3 R84 variant is associated with early-onset T2D in whites. Alteration in the insulin secretion/insulin sensitivity interplay appears to underlie this association. (J Clin Endocrinol Metab 94: 190-196, 2009) C1 [Prudente, Sabrina; Morini, Eleonora; Dallapiccola, Bruno; Trischitta, Vincenzo] CSS Mendel Inst, I-00198 Rome, Italy. [Prudente, Sabrina; Trischitta, Vincenzo] CSS Sci Inst, Res Unit Diabet & Endocrine Dis, I-71013 San Giovanni Rotondo, Italy. [Trischitta, Vincenzo] CSS Sci Inst, Unit Endocrinol, I-71013 San Giovanni Rotondo, Italy. [Scarpelli, Daniela; Perticone, Francesco; Andreozzi, Francesco; Sesti, Giorgio] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy. [Chandalia, Manisha; Li, Rong; Abate, Nicola] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [Chandalia, Manisha; Li, Rong; Abate, Nicola] Univ Texas SW Med Ctr Dallas, Ctr Human Nutr, Dallas, TX 75390 USA. [Zhang, Yuan-Yuan; Powers, Christine; Doria, Alessandro] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. [Zhang, Yuan-Yuan; Doria, Alessandro] Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA. [Morini, Eleonora; Trischitta, Vincenzo] Univ Roma La Sapienza, Dept Clin Sci, I-00161 Rome, Italy. [Dallapiccola, Bruno] Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy. [Del Guerra, Silvia; Marchetti, Piero] Univ Pisa, Dept Endocrinol & Metab, Metab Unit, Osped Cisanello, I-56127 Pisa, Italy. RP Trischitta, V (reprint author), CSS Mendel Inst, Viale Regina Margherita 261, I-00198 Rome, Italy. EM vincenzo.trischitta@uniroma1.it RI Sesti, Giorgio/B-1509-2012; Marchetti, Piero/J-7439-2013; Prudente, Sabrina/H-2886-2016; Trischitta, Vincenzo/K-1487-2016; Dallapiccola, Bruno/K-8692-2016; OI Marchetti, Piero/0000-0003-4907-0635; Prudente, Sabrina/0000-0001-9220-8981; Trischitta, Vincenzo/0000-0003-1174-127X; Andreozzi, Francesco/0000-0001-9375-1513; Dallapiccola, Bruno/0000-0002-5031-1013; Sesti, Giorgio/0000-0002-1618-7688 FU Italian Ministry of Health; European Community's FP6 EUGENE 2 [LSHM-CT-2004-512013]; National Institutes of Health [HL073168, DK055523, DK036836]; The European Union [LSHM-CT-2006-518153]; [DK072158] FX This work was partly supported by the Italian Ministry of Health (Ricerca Corrente 2006 and 2008, to S. P.); European Community's FP6 EUGENE 2 (Grant LSHM-CT-2004-512013, to G. S); National Institutes of Health Grants HL073168, DK055523, and DK036836 (to A. D. and the Genetics Core of the Diabetes and Endocrinology Research Center at the Joslin Diabetes Center) and DK072158 (to N. A.); and The European Union (Integrated Project EuroDia LSHM-CT-2006-518153, to P. M.). NR 33 TC 41 Z9 43 U1 1 U2 7 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2009 VL 94 IS 1 BP 190 EP 196 DI 10.1210/jc.2008-1365 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 391UR UT WOS:000262260200030 PM 18984671 ER PT J AU Ernst, ME Carter, BL Basile, JN AF Ernst, Michael E. Carter, Barry L. Basile, Jan N. TI All Thiazide-Like Diuretics Are Not Chlorthalidone: Putting the ACCOMPLISH Study Into Perspective SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Editorial Material ID HIGH BLOOD-PRESSURE; ISOLATED SYSTOLIC HYPERTENSION; CONVERTING ENZYME-INHIBITOR; CALCIUM-CHANNEL BLOCKER; RESISTANT HYPERTENSION; NIFEDIPINE GITS; TRIAL; HYDROCHLOROTHIAZIDE; AMLODIPINE; MORTALITY C1 [Ernst, Michael E.; Carter, Barry L.] Univ Iowa, Coll Pharm, Div Clin & Adm Pharm, Iowa City, IA 52242 USA. [Ernst, Michael E.; Carter, Barry L.] Univ Iowa, Carver Coll Med, Dept Family Med, Iowa City, IA USA. [Basile, Jan N.] Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC USA. [Basile, Jan N.] Med Univ S Carolina, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA. RP Ernst, ME (reprint author), Univ Iowa Hosp & Clin, Dept Family Med, 01291-A PFP,200 Hawkins Dr, Iowa City, IA 52242 USA. EM michael-ernst@uiowa.edu NR 34 TC 21 Z9 22 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JAN PY 2009 VL 11 IS 1 BP 5 EP 10 DI 10.1111/j.1751-7176.2008.00009.x PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 408KA UT WOS:000263432700002 PM 19125852 ER PT J AU Wu, HJ Bondada, S AF Wu, Hsin-Jung Bondada, Subbarao TI CD72, a Coreceptor with Both Positive and Negative Effects on B Lymphocyte Development and Function SO JOURNAL OF CLINICAL IMMUNOLOGY LA English DT Article DE B cell; autoimmunity; CD72; B cell receptor; proliferation; antibody response; differentiation; apoptosis; protein tyrosine kinase; protein tyrosine phosphatase; ITIM motifs; CD100 ID CELL ANTIGEN-RECEPTOR; MONOCLONAL ANTI-LYB-2 ANTIBODY; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TYROSINE-PHOSPHATASE SHP-1; REGULATORY MOLECULE CD72; STIMULATORY FACTOR-I; IGM CROSS-LINKING; C-TYPE LECTINS; SIGNAL-TRANSDUCTION; DIFFERENTIAL REGULATION AB B lymphocytes remain in a resting state until activated by antigenic stimuli through interaction with the B cell receptor (BCR). Coreceptors on B cells can modulate the thresholds for signaling through the BCR for growth and differentiation. CD72 is a B cell coreceptor that has been shown to interact with CD100, a semaphorin, and to enhance BCR signaling. CD72 ligation induces a variety of early signaling events such as activation of the Src kinases Blk and Lyn and the non-src kinase Btk leading to activation of the mitogen-activated protein (MAP) kinases, events usually associated with positive signaling. CD72 signals can enable Btk-deficient B cells to overcome their unresponsiveness to BCR signaling. On the other hand, BCR-mediated signals are enhanced in CD72-deficient cells but are reduced in CD100 null cells. The dual effects of CD72 on B cells can be explained by its association with positive and negative signaling molecules. Thus, CD72 interacts with SHP-1, an SH2-domain containing protein tyrosine phosphatase, a negative regulator of signaling, and Grb2, an adaptor protein associated with the Ras/MAPK pathway. Ligation of CD72 also triggered its association with CD19, a positive modulator of B cell receptor signaling. We propose a dual signaling hypothesis to explain the growth and differentiation promoting properties of CD72. Deficiency in either CD72 or CD100 leads to autoimmunity in mouse models. CD72 expression and polymorphisms exhibit some association with autoimmune diseases such as lupus, Sjogren's syndrome, and type 1 diabetes. C1 [Bondada, Subbarao] Univ Kentucky, Lucille P Markey Canc Ctr, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA. [Wu, Hsin-Jung] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Immunol & Immunogenet, Boston, MA 02115 USA. RP Bondada, S (reprint author), Univ Kentucky, Lucille P Markey Canc Ctr, Dept Microbiol Immunol & Mol Genet, Room 303 Combs Canc Bldg, Lexington, KY 40536 USA. EM bondada@email.uky.edu FU NIH [AI21490, AG05731, CA92372]; Markey Cancer Center FX This work is supported by NIH grants AI21490, AG05731, and CA92372 and funds from the Markey Cancer Center to SB. NR 71 TC 23 Z9 25 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0271-9142 J9 J CLIN IMMUNOL JI J. Clin. Immunol. PD JAN PY 2009 VL 29 IS 1 BP 12 EP 21 DI 10.1007/s10875-008-9264-6 PG 10 WC Immunology SC Immunology GA 402AR UT WOS:000262987100002 PM 19067131 ER PT J AU Eikermann-Haerter, K Dilekoz, E Kudo, C Savitz, SI Waeber, C Baum, MJ Ferrari, MD van den Maagdenberg, AMJM Moskowitz, MA Ayata, C AF Eikermann-Haerter, Katharina Dilekoz, Ergin Kudo, Chiho Savitz, Sean I. Waeber, Christian Baum, Michael J. Ferrari, Michel D. van den Maagdenberg, Arn M. J. M. Moskowitz, Michael A. Ayata, Cenk TI Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1 SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID MINOR HEAD TRAUMA; DELAYED CEREBRAL EDEMA; CALCIUM-CHANNELS; NMDA-RECEPTOR; ESTROGEN-RECEPTORS; REPLACEMENT THERAPY; ANTERIOR-PITUITARY; CAUDATE-NUCLEUS; CURRENT-DENSITY; FUNCTIONAL MRI AB Familial hemiplegic migraine type 1 (FHM1) is an autosomal dominant subtype of migraine with aura that is associated with hemiparesis. As with other types of migraine, it affects women more frequently than men. FHM1 is caused by mutations in the CACNA1A gene, which encodes the alpha(1A) subunit of Ca(v)2.1 channels; the R192Q mutation in CACNA1A causes a mild form of FHM1, whereas the S218L mutation causes a severe, often lethal phenotype. Spreading depression (SD), a slowly propagating neuronal and glial cell depolarization that leads to depression of neuronal activity, is the most likely cause of migraine aura. Here, we have shown that transgenic mice expressing R192Q or S218L FHM1 mutations have increased SD frequency and propagation speed; enhanced corticostriatal propagation; and, similar to the human FHM1 phenotype, more severe and prolonged post-SD neurological deficits. The susceptibility to SD and neurological deficits is affected by allele dosage and is higher in S218L than R192Q mutants. Further, female S218L and R192Q mutant mice were more susceptible to SD and neurological deficits than males. This sex difference was abrogated by ovariectomy and senescence and was partially restored by estrogen replacement, implicating ovarian hormones in the observed sex differences in humans with FHM1. These findings demonstrate that genetic and hormonal factors modulate susceptibility to SD and neurological deficits in FHM1 mutant mice, providing a potential mechanism for the phenotypic diversity of human migraine and aura. C1 [Eikermann-Haerter, Katharina; Dilekoz, Ergin; Kudo, Chiho; Waeber, Christian; Moskowitz, Michael A.; Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab,Dept Radiol, Charlestown, MA 02129 USA. [Eikermann-Haerter, Katharina] Univ Duisburg Essen, Dept Neurol, Essen, Germany. [Savitz, Sean I.] Univ Texas Med Sch Houston, Dept Neurol, Houston, TX USA. [Baum, Michael J.] Boston Univ, Dept Biol, Boston, MA 02215 USA. [Ferrari, Michel D.; van den Maagdenberg, Arn M. J. M.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands. [van den Maagdenberg, Arn M. J. M.] Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands. [Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Stroke Serv & Neurosci Intens Care Unit,Dept Neur, Charlestown, MA 02129 USA. RP Ayata, C (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab,Dept Radiol, 149 13th St,Room 6403, Charlestown, MA 02129 USA. EM cayata@partners.org RI Waeber, Christian/A-8333-2009 OI Waeber, Christian/0000-0001-6078-0027 FU Deutsche Forschungsgemeinschaft [HaS085/1-1]; National Institute of Neurological Disorders and Stroke [1ROINS061S05, 2P01NS35611]; Netherlands Organization for Scientific Research [903-52-291, 918.56.602]; EU "EUROHEAD" [LSHM-CT-2004-504837]; Centre for Medical Systems Biology (CMSB) in the framework of the Netherlands Genomics Initiative (NGI) FX This work was supported by the Deutsche Forschungsgemeinschaft (HaS085/1-1 to K. Eikermann-Haerter), National Institute of Neurological Disorders and Stroke (1ROINS061S05 to C. Ayata; 2P01NS35611 to M.A. Moskowitz), Netherlands Organization for Scientific Research (903-52-291 and Vici 918.56.602 to M.D. Ferrari), EU "EUROHEAD" grant (LSHM-CT-2004-504837 to M.D. Ferrari, A.M.J.M. van den Maagdenberg), and the Centre for Medical Systems Biology (CMSB) in the framework of the Netherlands Genomics Initiative (NGI). We would like to thank Elkan Halpern and Tobias Kurth for statistical guidance, Lynda Banzi for assistance with videos, Mike Whalen and Zerong You for assistance with neurological deficit assessment, and Jianhua Qiu for histological imaging. NR 97 TC 119 Z9 120 U1 2 U2 11 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2009 VL 119 IS 1 BP 99 EP 109 DI 10.1172/JCI36059 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 390BS UT WOS:000262139900014 PM 19104150 ER PT J AU Kim, KK Wei, Y Szekeres, C Kugler, MC Wolters, PJ Hill, ML Frank, JA Brumwell, AN Wheeler, SE Kreidberg, JA Chapman, HA AF Kim, Kevin K. Wei, Ying Szekeres, Charles Kugler, Matthias C. Wolters, Paul J. Hill, Maria L. Frank, James A. Brumwell, Alexis N. Wheeler, Sarah E. Kreidberg, Jordan A. Chapman, Harold A. TI Epithelial cell alpha 3 beta 1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID GROWTH-FACTOR-BETA; MESENCHYMAL TRANSITION; TGF-BETA; FIBROBLASTS DERIVE; RENAL FIBROSIS; RECEPTOR; MICE; ACTIVATION; ADHESION; PHOSPHORYLATION AB Pulmonary fibrosis, in particular idiopathic pulmonary fibrosis (IPF), results from aberrant wound healing and scarification. One population of fibroblasts involved in the fibrotic process is thought to originate from lung epithelial cells via epithelial-mesenchymal transition (EMT). Indeed, alveolar epithelial cells (AECs) undergo EMT in vivo during experimental fibrosis and ex vivo in response to TGF-beta 1. As the ECM critically regulates AEC responses to TGF-beta 1, we explored the role of the prominent epithelial integrin alpha 3 beta 1 in experimental fibrosis by generating mice with lung epithelial cell-specific loss of alpha 3 integrin expression. These mice had a normal acute response to bleomycin injury, but they exhibited markedly decreased accumulation of lung myofibroblasts and type I collagen and did not progress to fibrosis. Signaling through beta-catenin has been implicated in EMT; we found that in primary AECs, alpha 3 integrin was required for beta-catenin phosphorylation at tyrosine residue 654 (Y654), formation of the pY654-beta-catenin/pSmad2 complex, and initiation of EMT, both in vitro and in vivo during the fibrotic phase following bleomycin injury. Finally, analysis of lung tissue from IPF patients revealed the presence of pY654-beta-catenin/pSmad2 complexes and showed accumulation of pY654-beta-catenin in myofibroblasts. These findings demonstrate epithelial integrin-dependent profibrotic crosstalk between beta-catenin and Smad signaling and support the hypothesis that EMT is an important contributor to pathologic fibrosis. C1 [Kim, Kevin K.; Wei, Ying; Kugler, Matthias C.; Wolters, Paul J.; Hill, Maria L.; Frank, James A.; Brumwell, Alexis N.; Wheeler, Sarah E.; Chapman, Harold A.] Univ Calif San Francisco, Div Pulm & Crit Care, Dept Med, San Francisco, CA 94143 USA. [Kim, Kevin K.; Wei, Ying; Kugler, Matthias C.; Wolters, Paul J.; Hill, Maria L.; Brumwell, Alexis N.; Wheeler, Sarah E.; Chapman, Harold A.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [Szekeres, Charles; Kreidberg, Jordan A.] Childrens Hosp, Boston, MA 02115 USA. [Szekeres, Charles; Kreidberg, Jordan A.] Harvard Univ, Sch Med, Boston, MA USA. [Frank, James A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Chapman, HA (reprint author), Univ Calif San Francisco, Div Pulm & Crit Care, Dept Med, Box 0111, San Francisco, CA 94143 USA. EM hal.chapman@ucsf.edu RI Wolters, Paul/A-7181-2009 FU Parker B. Francis Foundation; NIH [K08HL085290, HL88440, RO1 H L44712] FX The authors thank Jonathon Alexander, Chi-Hui Tang, Michael Galvez, and Liliane Robillard for technical assistance. This work was supported by the Parker B. Francis Foundation (to K.K. Kim) and NIH grants K08HL085290 (to K.K. Kim), HL88440 (to J.A. Frank), and RO1 H L44712 (to H.A. Chapman). NR 49 TC 216 Z9 230 U1 5 U2 33 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2009 VL 119 IS 1 BP 213 EP 224 DI 10.1172/JCI36940 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 390BS UT WOS:000262139900024 PM 19104148 ER PT J AU Sheikh, SI Nijhawan, A Basgoz, N Venna, N AF Sheikh, Sarah I. Nijhawan, Ank Basgoz, Nesh Venna, Nagagopal TI Reversible Cogan's syndrome in a patient with human immunodeficiency virus (HIV) infection SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Cogan's syndrome; Human immunodeficiency virus; Parainfectious immunopathogenesis AB Cogan's syndrome is a rare, immune-mediated disorder characterized by chronic, bilateral vestibular-cochlear dysfunction and interstitial keratitis. We describe the first case of Cogan's syndrome that resolved with antiretroviral therapy in a patient with human immunodeficiency virus infection. Plausible disease mechanisms are discussed. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Sheikh, Sarah I.; Venna, Nagagopal] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Nijhawan, Ank; Basgoz, Nesh] Massachusetts Gen Hosp, Dept Infect Dis, Boston, MA 02114 USA. RP Sheikh, SI (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. EM sisheikh@partners.org NR 8 TC 2 Z9 3 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD JAN PY 2009 VL 16 IS 1 BP 154 EP 156 DI 10.1016/j.jocn.2008.04.013 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 393CM UT WOS:000262348500040 PM 19013805 ER PT J AU Tarhini, AA Stuckert, J Lee, S Sander, C Kirkwood, JM AF Tarhini, Ahmad A. Stuckert, Joseph Lee, Sandra Sander, Cindy Kirkwood, John M. TI Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID COOPERATIVE-ONCOLOGY-GROUP; METASTATIC MALIGNANT-MELANOMA; STAGE-IV MELANOMA; LACTATE-DEHYDROGENASE; III MELANOMA; DOSE INTERFERON-ALPHA-2B; INHIBITING ACTIVITY; CUTANEOUS MELANOMA; POOLED ANALYSIS; TUMOR-MARKERS AB Purpose We evaluated adjuvant trial E1694 to more precisely define the prognostic significance of serum S100B in patients with high-risk resected melanoma. Patients and Methods Sera from 670 E1694 patients banked at baseline and three additional time points were tested for S100B protein using chemiluminescence. Results S100B testing results showed that the higher the S100B level is, the higher the risk of relapse and death, regardless of the cutoff value. Univariate analysis showed that baseline S100B >= 0.15 mu g/L is significantly correlated with overall survival ( OS; P = .01). Multivariate analysis was performed adjusting for significant prognostic factors ( ulceration and lymph node status) and treatment. Baseline S100B was a significant prognostic factor for survival ( hazard ratio = 1.39; 95% CI, 1.01 to 1.92; P = .043). S100B values measured at later time points over 1 year were also demonstrated to be significant prognostic factors for relapse-free survival (RFS) and OS. Lower S100B values at baseline and during follow-up were associated with longer survival. A changing S100B from low at baseline to high on follow-up seemed to be associated with the worst RFS and OS. Conclusion For patients with high-risk surgically resected melanoma, a high baseline or increasing serum S100B is an independent prognostic marker of risk for mortality that may allow us to refine the application of adjuvant therapy in the future. C1 [Kirkwood, John M.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RP Kirkwood, JM (reprint author), Univ Pittsburgh, Inst Canc, 5117 Ctr Ave,Ste 1-32, Pittsburgh, PA 15213 USA. EM kirkwoodjm@upmc.edu FU NCI NIH HHS [P50CA121973, U24 CA114737] NR 42 TC 55 Z9 55 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2009 VL 27 IS 1 BP 38 EP 44 DI 10.1200/JCO.2008.17.1777 PG 7 WC Oncology SC Oncology GA 388SC UT WOS:000262038500009 PM 19047287 ER PT J AU Emmons, KM Puleo, E Mertens, A Gritz, ER Diller, L Li, FP AF Emmons, Karen M. Puleo, Elaine Mertens, Ann Gritz, Ellen R. Diller, Lisa Li, Frederick P. TI Long-Term Smoking Cessation Outcomes Among Childhood Cancer Survivors in the Partnership for Health Study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ADULT SURVIVORS; SELF-EFFICACY; SHORT-FORM; POPULATION; RELAPSE; COHORT; MAINTENANCE; PREDICTORS; PREVENTION AB Purpose Partnership for Health (PFH) was found to increase smoking cessation among smokers in the Childhood Cancer Survivors Study (CCSS) at the 8- and 12-month postbaseline follow-up. This report provides outcomes at 2 to 6 years postbaseline; the primary outcome is a four-category smoking status variable ( quit at all follow-ups, quit at final follow-up only, smoker at all follow-ups, and smoker at final follow-up only); quit attempts among those who reported smoking at the final follow-up is a secondary outcome. Methods PFH was a randomized control trial with two conditions, peer phone counseling ( PC) and self-help (SH), that involved smokers (n = 796) enrolled in the CCSS cohort. Results Long-term quit rates were higher in PC versus SH participants. Long-term smoking cessation outcomes were lower among those who were nicotine dependent, of lower educational levels, and among men, and were higher among those who used nicotine replacement therapy and who had higher levels of situational self-efficacy. There were no significant differences in relapse rates between conditions or in quit attempts among continued smokers. Conclusion Cessation rates continue to be significantly higher among participants in the PC condition versus SH, although the differences were not large. This article highlights differences in long-term engagement with smoking cessation among those who received the intervention. C1 [Emmons, Karen M.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Massachusetts, Amherst, MA 01003 USA. Univ Minnesota, Minneapolis, MN USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Emmons, KM (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM Karen_M_Emmons@dfci.harvard.edu FU National Institutes of Health [U24-CA55727, RO1-CA77780, R01CA106914-04]; University of Minnesota by the Children's Cancer Research; Dana-Farber Cancer Institute by Liberty Mutual FX Supported by Grants no. U24-CA55727, RO1-CA77780, and R01CA106914-04 from the National Institutes of Health; support provided to the University of Minnesota by the Children's Cancer Research Fund; and support provided to the Dana-Farber Cancer Institute by Liberty Mutual, the Patterson Fellowship Fund, and the Harry and Elsa Jiler American Cancer Society Research Professorship ( F. P. L.). Smith Kline Beecham donated nicotine patches. NR 46 TC 24 Z9 24 U1 2 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2009 VL 27 IS 1 BP 52 EP 60 DI 10.1200/JCO.2007.13.0880 PG 9 WC Oncology SC Oncology GA 388SC UT WOS:000262038500011 PM 19047296 ER PT J AU Efstathiou, JA Bae, K Shipley, WU Hanks, GE Pilepich, MV Sandler, HM Smith, MR AF Efstathiou, Jason A. Bae, Kyounghwa Shipley, William U. Hanks, Gerald E. Pilepich, Miljenko V. Sandler, Howard M. Smith, Matthew R. TI Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; PHASE-III TRIAL; RADIATION-THERAPY; HORMONE AGONISTS; BODY-COMPOSITION; DEFINITIVE RADIOTHERAPY; METABOLIC SYNDROME; COMPETING RISK; MEN; SUPPRESSION AB Purpose Gonadotropin-releasing hormone ( GnRH) agonists are associated with greater risk of coronary heart disease and myocardial infarction in men with prostate cancer, but little is known about potential impact on cardiovascular mortality. We assessed the relationship between GnRH agonists and cardiovascular mortality in a large randomized phase III trial of men treated with or without adjuvant goserelin after radiation therapy (RT) for locally advanced prostate cancer. Patients and Methods Between 1987 and 1992, 945 men with locally advanced prostate cancer were randomly assigned to RT and adjuvant goserelin or RT alone. Fine and Gray's regression was used to evaluate treatment effect on cardiovascular mortality. Covariates included age, prevalent cardiovascular disease (CVD), hypertension, diabetes mellitus (DM), body mass index, race, Gleason score, stage, acid phosphatase level, prostatectomy history, and nodal involvement. Results After a median follow-up of 8.1 years, there were 117 cardiovascular-related deaths but no treatment-related increase in cardiovascular mortality. At 9 years, cardiovascular mortality for men receiving adjuvant goserelin was 8.4% v 11.4% for men treated without adjuvant goserelin ( Gray's P = .17). In multiple regression analyses, treatment arm was not significantly associated with increased risk of cardiovascular mortality ( adjusted hazard ratio [HR] = 0.73; 95% CI, 0.47 to 1.15; P = .16; when censoring at time of salvage goserelin therapy, HR = 0.99; 95% CI, 0.58 to 1.69; P = .97). Traditional cardiac risk factors, including prevalent CVD and DM, were significantly associated with greater cardiovascular mortality. Conclusion GnRH agonists do not seem to increase cardiovascular mortality in men with locally advanced prostate cancer. Further studies are warranted to evaluate adverse effects of GnRH agonists in men with lower cancer-specific mortality. C1 [Smith, Matthew R.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA. Radiat Therapy Oncol Grp, Dept Stat, Philadelphia, PA USA. Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA. Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles Sch Med, Los Angeles, CA 90024 USA. Univ Michigan, Dept Radiat Oncol, Sch Med, Ann Arbor, MI 48109 USA. RP Smith, MR (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Yawkey 7038,55 Fruit St, Boston, MA 02114 USA. EM smith.matthew@mgh.harvard.edu FU NIH [5K24CA121990-02]; Prostate Cancer Foundation FX Supported in part by an NIH K24 Midcareer Investigator Award ( 5K24CA121990-02; M. R. S.) and grants from the Prostate Cancer Foundation ( M. R. S.). NR 42 TC 143 Z9 146 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2009 VL 27 IS 1 BP 92 EP 99 DI 10.1200/JCO.2007.12.3752 PG 8 WC Oncology SC Oncology GA 388SC UT WOS:000262038500016 PM 19047297 ER PT J AU Dimopoulos, MA Gertz, MA Kastritis, E Garcia-Sanz, R Kimby, EK LeBlond, V Fermand, JP Merlini, G Morel, P Morra, E Ocio, EM Owen, R Ghobrial, IM Seymour, J Kyle, RA Treon, SP AF Dimopoulos, Meletios Athanasios Gertz, Morie A. Kastritis, Efstathios Garcia-Sanz, Ramon Kimby, Eva K. LeBlond, Veronique Fermand, Jean-Paul Merlini, Giampaolo Morel, Pierre Morra, Enrica Ocio, Enrique M. Owen, Roger Ghobrial, Irene M. Seymour, John Kyle, Robert A. Treon, Steven P. TI Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Review ID CONSENSUS PANEL RECOMMENDATIONS; PHASE-II; RITUXIMAB; BORTEZOMIB; THERAPY; ALEMTUZUMAB; LYMPHOMA AB Waldenstrom macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder characterized by lymphoplasmacytic bone marrow infiltration along with an immunoglobulin M (IgM) monoclonal gammopathy. Patients with disease-related cytopenias, bulky adenopathy or organomegaly, symptomatic hyperviscosity, severe neuropathy, amyloidosis, cryoglobulinemia, cold agglutinin disease, or evidence of disease transformation should be considered for immediate therapy. Initiation of therapy should not be based on serum IgM levels alone, and asymptomatic patients should be observed. Individual patient considerations should be considered when deciding on a first-line agent including the presence of cytopenias, need for rapid disease control, age, and candidacy for autologous transplantation. Therapeutic outcomes should be evaluated using updated criteria. As part of the Fourth International Workshop on Waldenstrom's Macroglobulinemia, a consensus panel updated its recommendations on both first-line and salvage therapy in view of recently published and ongoing clinical trials. The panel considered encouraging results from recent studies of first-line combinations such as rituximab with nucleoside analogs with or without alkylating agents or with cyclophosphamide-based therapies (eg, cyclophosphamide, doxorubicin, vincristine, and prednisone or cyclophosphamide and dexamethasone) or the combination of rituximab with thalidomide. Such therapeutic approaches are likely to yield responses at least as good as, if not better than, monotherapy with any of the alkylating agents, nucleoside analogs, or rituximab. In the salvage setting, reuse of a first-line regimen or use of a different regimen should be considered along with bortezomib, alemtuzumab, autologous transplantation, and, in selected circumstances, allogeneic transplantation. Finally, the panel reaffirmed its encouragement of the active enrollment of patients with WM onto innovative clinical trials whenever possible. C1 Univ Athens, Sch Med, Athens 11528, Greece. Hosp Univ Salamanca, Salamanca, Spain. Karolinska Inst, Stockholm, Sweden. Hop St Louis, Hop La Pitie Salpetriere, Paris, France. Hosp Schaffner, Lens, France. Policlin San Matteo, Ist Ricovero & Cura Carattere Sci, Inst Sci, I-27100 Pavia, Italy. Osped Niguarda Ca Granda, Milan, Italy. Leeds Gen Infirm, Leeds, W Yorkshire, England. Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Hematol, Rochester, MN 55905 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. Peter MacCallum Canc Inst, Dept Hematol, Melbourne, Vic 3000, Australia. Univ Melbourne, Melbourne, Vic, Australia. RP Dimopoulos, MA (reprint author), Univ Athens, Dept Clin Therapeut, Sch Med, Alexandra Hosp, 80 Vas Sofias, Athens 11528, Greece. EM mdimop@med.uoa.gr RI 2009, Secribsal/A-1266-2012; Garcia-Sanz, Ramon/B-7986-2017; OI Garcia-Sanz, Ramon/0000-0003-4120-2787; Merlini, Giampaolo/0000-0001-7680-3254 NR 33 TC 111 Z9 120 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 1 PY 2009 VL 27 IS 1 BP 120 EP 126 DI 10.1200/JCO.2008.17.7865 PG 7 WC Oncology SC Oncology GA 388SC UT WOS:000262038500020 PM 19047284 ER PT J AU Freeman, MP AF Freeman, Marlene P. TI Complementary and Alternative Medicine (CAM): Considerations for the Treatment of Major Depressive Disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID TRENDS AB The use of complementary and alternative medicine (CAM) has increased among patients with psychiatric disorders, as it has in the general population, over recent decades. Psychiatrists, therefore, need to inquire about and discuss the use of these treatments with patients and offer up-to-date information about risks and benefits. However, evidence-based information is limited. To address the needs of practicing psychiatrists and the public, the American Psychiatric Association has set up a task force on CAM to review the evidence for the efficacy and safety of CAM treatments in major depressive disorder (MDD). Some CAM treatments have known general health benefits but currently equivocal evidence of benefit in MDD. Exercise, folate, and omega-3 fatty acids can be recommended to most patients with MDD for their general health benefits, and St John's wort and S-adenosyl-L-methionine (SAM-e) may be appropriate to treat depression in some patients. In all instances, use of CAM therapies should not take the place of diagnostic assessment and evaluation for MDD and consideration of standard treatment use. Patients should receive advice about all available treatment options, including risks, benefits, and possible drug interactions, as well as full evaluations and regular monitoring. (J Clin Psychiatry 2009;70[suppl 5]:4-6) C1 Massachusetts Gen Hosp, Ctr Womens Mental Hlth, Boston, MA 02114 USA. RP Freeman, MP (reprint author), Massachusetts Gen Hosp, Ctr Womens Mental Hlth, Simches Res Bldg,Floor 2,185 Cambridge St, Boston, MA 02114 USA. EM mfreeman@partners.org FU Forest; GlaxoSmithKline; Eli Lilly; US Food and Drug Administration FX During the past 3 years, Dr Freeman has received research funding from Forest, GlaxoSmithKline, Eli Lilly, and the US Food and Drug Administration, and has received CME/honorarium from KV Pharmaceuticals, AstraZeneca, Forest (APA Industry-Supported Symposium at annual meeting), DSM Nutritionals (for medical editing), Consulting-Reliant, Ther-Rx, and Pamlab. NR 10 TC 10 Z9 10 U1 2 U2 6 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2009 VL 70 BP 4 EP 6 DI 10.4088/JCP.8157su1c.01 PG 3 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 521IK UT WOS:000271914100001 PM 19909686 ER PT J AU Thase, ME AF Thase, Michael E. TI Update on Partial Response in Depression SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID STAR-ASTERISK-D; DOUBLE-BLIND; AUGMENTATION; DISORDER; OUTPATIENTS; ANTIDEPRESSANTS; MULTICENTER; REMISSION; SYMPTOMS; OUTCOMES AB Full symptomatic remission is the optimal outcome for patients with major depression. Unfortunately, antidepressant efficacy is limited to partial response for a significant minority of patients. Incomplete remission of depressive symptoms is associated with increased risk of relapse, decreased functioning in work and social settings, and increased risk of eventual suicide. Factors that increase the likelihood of incomplete remission include chronicity, severe symptomatology, and comorbid illnesses. Strategies to manage incomplete remission include "watchful waiting" (ie, continuing the original medication for another 4 to 8 weeks to see if complete remission will develop), switching antidepressants, or adding a second, adjunctive treatment (ie, either beginning psychotherapy or a second medication to augment the original antidepressant). Augmentation strategies may well prove to be the preferred strategy for improving response if tolerability is not an issue. Although studies on predictive factors have not yielded definitive results, clinicians in practice often select adjunctive agents that target patients' persistent symptoms. (J Clin Psychiatry 2009;70[suppl 6]:04-09) C1 [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Thase, Michael E.] Pittsburgh Med Ctr, Dept Psychiat, Philadelphia, PA USA. [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia Vet Affairs Med Ctr, Pittsburgh, PA USA. [Thase, Michael E.] Pittsburgh Med Ctr, Dept Psychiat, Pittsburgh, PA USA. RP Thase, ME (reprint author), Univ Pittsburgh, Sch Med, 3535 Market St,Suite 670, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu FU American Psychiatric Publishing, Inc; Guilford Publications; Herald House; W W Norton Company; Eli Lilly; Forest; GlaxoSmithKline; Sepracor; National Institute of Mental Health FX Dr Thase is a consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, MedAvante, Neuronetics, Novartis, Pfizer, Schering-Plough, Sepracor Shire US, Supernus, Transcept, and Wyeth; currently is a member of the speakers' bureaus for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Wyeth; has equity holdings in MedAvante; receives royalties from American Psychiatric Publishing, Inc, Guilford Publications, Herald House, and W W Norton & Company; has provided expert testimony for Jones Day (Wyeth litigation), Philips Lyttle, LLP (GlaxoSmithKline litigation), and Pepper Hamilton, LLP (Eli Lilly litigation), has received research funding (during the past 3 years) from Eli Lilly, Forest, GlaxoSmithKline, Sepracor and the National Institute of Mental Health; and his spouse is an employee of Advogent, which does business with Bristol-Myers Squibb and Wyeth. NR 20 TC 19 Z9 19 U1 1 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2009 VL 70 BP 4 EP 9 DI 10.4088/JCP.8133su1c.01 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 531CG UT WOS:000272639700001 PM 19922738 ER PT J AU Freeman, MP AF Freeman, Marlene P. TI Omega-3 Fatty Acids in Major Depressive Disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID POLYUNSATURATED FATTY-ACIDS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; FISH CONSUMPTION; CARDIOVASCULAR-DISEASE; DOCOSAHEXAENOIC ACID; SEAFOOD CONSUMPTION; MERCURY LEVELS; PREGNANCY; MECHANISMS AB Patients with major depressive disorder have high rates of cardiovascular disease and other medical comorbidity. Omega-3 fatty acids, particularly those found in fish and seafood, have cardiovascular health benefits and may play an adjunctive role in the treatment of mood disorders. However, existing studies on omega-3 fatty acids in depression have limitations such as small sample sizes and a wide variance in study design, and results regarding efficacy are mixed. The preponderance of data from placebo-controlled treatment studies suggests that omega-3 fatty acids are a reasonable augmentation strategy for the treatment of major depressive disorder. More research is necessary before omega-3 supplements can be recommended as monotherapy for the treatment of depression. For many individuals with major depressive disorder, augmentation with omega-3 fatty acids should be considered, as general health benefits are well established and adjunctive use is low risk. (J Clin Psychiatry 2009;70[suppl 5]:7-11) C1 Massachusetts Gen Hosp, Ctr Womens Mental Hlth, Boston, MA 02114 USA. RP Freeman, MP (reprint author), Massachusetts Gen Hosp, Ctr Womens Mental Hlth, Simches Res Bldg,Floor 2,185 Cambridge St, Boston, MA 02114 USA. EM mfreeman@partners.org FU Forest; GlaxoSmithKline; Eli Lilly; US Food and Drug Administration FX During the past 3 years, Dr Freeman has received research funding from Forest, GlaxoSmithKline, Eli Lilly, and the US Food and Drug Administration, and has received CME/honorarium from KV Pharmaceuticals, AstraZeneca, Forest (APA Industry-Supported Symposium at annual meeting), DSM Nutritionals (for medical editing), Consulting-Reliant, Ther-Rx, and Pamlab. NR 37 TC 26 Z9 26 U1 4 U2 10 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2009 VL 70 BP 7 EP 11 DI 10.4088/JCP.8157su1c.02 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 521IK UT WOS:000271914100002 PM 19909687 ER PT J AU Simon, NM AF Simon, Naomi M. TI Generalized Anxiety Disorder and Psychiatric Comorbidities Such as Depression, Bipolar Disorder, and Substance Abuse SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID MAJOR DEPRESSION; NATIONAL-COMORBIDITY; DSM-IV; SURVEY REPLICATION; STEP-BD; PREVALENCE; RECOGNITION; OUTPATIENTS; POPULATION; PREDICTION AB Generalized anxiety disorder (GAD) has a high rate of comorbidity with other psychiatric disorders, including major depressive disorder (MDD), bipolar disorder, other anxiety disorders, and substance use disorders. The similarities between GAD and MDD have led some to suggest that GAD should be reclassified as a mood disorder. The concurrence of GAD with another disorder heightens a patient's risk for impairment, disability, and suicidality. Clinical trials for GAD and disorders that are most likely to occur with GAD have generally not taken comorbidity into account, and there is a paucity of data guiding how comorbidity should inform treatment selection. Research into the biology and psychopathology underlying the high rate of comorbidity of GAD and into efficacious interventions for GAD with comorbidity is needed. (J Clin Psychiatry 2009,70[suppl 2]:10-14) C1 [Simon, Naomi M.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Anxiety & Traumat Stress Disorders, Boston, MA 02114 USA. [Simon, Naomi M.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Simon, NM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Anxiety & Traumat Stress Disorders, Simches 2200,185 Cambridge St, Boston, MA 02114 USA. EM nsimon@partners.org FU AstraZeneca Pharmaceuticals LP FX This article is derived from the planning teleconference series "Insights Into Generalized Anxiety Disorder," which was held June-August 2008, and supported by an educational grant from AstraZeneca Pharmaceuticals LP NR 30 TC 40 Z9 43 U1 0 U2 7 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2009 VL 70 BP 10 EP 14 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 435TR UT WOS:000265366700002 PM 19371501 ER PT J AU Fava, M Mischoulon, D AF Fava, Maurizio Mischoulon, David TI Folate in Depression: Efficacy, Safety, Differences in Formulations, and Clinical Issues SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID CONTROLLED-TRIAL; L-METHYLFOLATE; SERUM FOLATE; FOLIC-ACID; FLUOXETINE; DISORDER; HOMOCYSTEINE; VITAMIN-B-12; ENHANCEMENT; PREDICTORS AB Supplementation with folate may help reduce depressive symptoms. Folate, a naturally occurring B vitamin, is needed in the brain for the synthesis of norepinephrine, serotonin, and dopamine. Three forms of folate are commonly used: folic acid, 5-methyltetrahydrofolate (5-MTHF) (also known as methylfolate and L-methylfolate), and folinic acid. Some forms may be more bioavailable than others in patients with a genetic polymorphism and in those who take particular medications or use alcohol. Folic acid augmentation in depressed patients may reduce residual symptoms. The 5-MTHF formulation indicated efficacy as adjunctive therapy or monotherapy in reducing depressive symptoms in patients with normal and low folate levels, improving cognitive function and reducing depressive symptoms in elderly patients with dementia and folate deficiency, and reducing depressive and somatic symptoms in patients with depression and alcoholism. Adjunctive folinic acid reduced depressive symptoms in patients who were partially responsive or nonresponsive to a selective serotonin reuptake inhibitor. Evidence for the efficacy of folate in improving cognitive symptoms is equivocal, but most studies used folic acid. Although the studies reviewed have limitations and, historically, concerns have been raised about the role of folate in increasing cancer risk, masking B(12) deficiency, and worsening depressive symptoms, folate is generally well tolerated, and 5-MTHF may be less likely to incur some of these risks. Several forms of folate appear to be safe and efficacious in some individuals with major depressive disorder, but more information is needed about dosage and populations most suited to folate therapy. (J Clin Psychiatry 2009;70[suppl 5]:12-17) C1 [Fava, Maurizio] Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Mischoulon, David] Bristol Myers Squibb Co, New York, NY 10154 USA. RP Fava, M (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Bulfinch 351, Boston, MA 02114 USA. EM mfava@partners.org FU Abbott; Alkermes; Aspect Medical Systems; AstraZeneca; Bio Research; BrainCells Inc; Bristol-Myers Squibb; Cephalon; Clinical Trial Solutions; Eli Lilly; Forest; Ganeden; GlaxoSmithKline; Johnson Johnson; Lichtwer Pharma GmbH; Lorex; NARSAD; National Center for Complementary and Alternative Medicine; National Institute on Drug Abuse; National Institute of Mental Health; Novartis; Organon; Pamlab; Pfizer; Pharmavite; Roche; Sanofi-Aventis; Shire; Solvay; Synthelabo; Wyeth-Ayerst; Nordic Naturals; Amarin; Swiss Medica; MGH Psychiatry Academy FX Dr Fava reported the following lifetime financial disclosures as of August 11, 2009: he has received research support from Abbott, Alkermes, Aspect Medical Systems, AstraZeneca, Bio Research, BrainCells Inc, Bristol-Myers Squibb, Cephalon, Clinical Trial Solutions, Eli Lilly, Forest, Ganeden, GlaxoSmithKline, Johnson & Johnson, Lichtwer Pharma GmbH, Lorex, NARSAD, National Center for Complementary and Alternative Medicine, National Institute on Drug Abuse, National Institute of Mental Health, Novartis, Organon, Pamlab, Pfizer, Pharmavite, Roche, Sanofi-Aventis, Shire, Solvay, Synthelabo, and Wyeth-Ayerst; is an advisor/consultant for Abbott, Amarin, Aspect Medical Systems, AstraZeneca, Auspex, Bayer AG, Best Practice Project Management, Biovail, BrainCells Inc, Bristol-Myers Squibb, Cephalon, Clinical Trial Solutions, CNS Response, Compellis, Cypress, DOV, Eli Lilly, EPLX, Fabre-Kramer, Forest, GlaxoSmithKline, Grunenthal GmBH, Janssen, Jazz, Johnson & Johnson, Knoll, Labopharm, Lorex, Lundbeck, MedAvante, Merck, Methylation Sciences, Neuronetics, Novartis, Nutrition 21, Organon, Pamlab, Pfizer, PharmaStar, Pharmavite, Precision Human Biolaboratory PsychoGenics, Roche, Sanofi-Aventis, Sepracor, Schering-Plough, Solvay, Somaxon, Somerset, Synthelabo, Takeda, Tetragenex, Transcept, Vanda, and Wyeth-Ayerst; is a member of the speakers bureau for or has published with Advanced Meeting Partners, the American Psychiatric Association, AstraZeneca, Belvoir, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Imedex, Novartis, Organon, Pfizer, PharmaStar, MGH Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed-Elsevier, UBC, and Wyeth-Ayerst has equity holdings in Compellis; has submitted patent applications for SPCD and for a combination of azapirones and bupropion in major depressive disorder; and receives copyright royalties for the NIGH CPFQ, SFI, ATRQ, DESS, and the SAFER criteria. Dr Mischoulon is a consultant for Pamlab and Bristol-Myers Squibb; has received grant/research support from Nordic Naturals, Amarin, and Swiss Medica; has received honoraria from Pamlab, Virbac, and Nordic Naturals; and has received royalties from Back Bay Scientific. Dr Mischoulon has also received honoraria from Reed Medical Education (a company working as a logistics collaborator for the NIGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education grants from pharmaceutical companies cosupporting programs along with participant tuition. Commercial entities currently supporting the MGH Psychiatry Academy are listed on the Academy's website, www.mghcme.org/organization/supporters. NR 28 TC 45 Z9 47 U1 2 U2 14 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2009 VL 70 BP 12 EP 17 DI 10.4088/JCP.8157su1c.03 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 521IK UT WOS:000271914100003 PM 19909688 ER PT J AU Papakostas, GI AF Papakostas, George I. TI Managing Partial Response or Nonresponse: Switching, Augmentation, and Combination Strategies for Major Depressive Disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID PLACEBO-CONTROLLED TRIAL; TREATMENT-RESISTANT-DEPRESSION; SEROTONIN REUPTAKE INHIBITORS; STAR-ASTERISK-D; TREATMENT-REFRACTORY DEPRESSION; FAILED MEDICATION TREATMENTS; PRELIMINARY DOUBLE-BLIND; LITHIUM AUGMENTATION; OLANZAPINE/FLUOXETINE COMBINATION; EXTENDED-RELEASE AB Despite the multitude of agents approved for the treatment of major depressive disorder, approximately 50% of patients experience no response to treatment with a first-line antidepressant. Clinicians have 4 broad pharmacologic strategies to choose from for treating antidepressant nonresponders: increasing the dose of the antidepressant, switching to a different antidepressant, augmenting the treatment regimen with a nonantidepressant agent, and combining the original antidepressant with a second antidepressant. TO date, the most comprehensively studied treatment strategy for nonresponse or partial response to antidepressants is augmentation with atypical antipsychotic agents, including aripiprazole, olanzapine, quetiapine, and risperidone. However, augmentation or combination with other agents such as mirtazapine, mianserin, and omega-3 fatty acids is also supported by considerable efficacy data. Lithium, desipramine, triiodothyronine, and modafinil have mixed data. While more studies are needed, agents such as bupropion, desipramine, mecamylamine, and testosterone look promising. Switching antidepressants, especially to the newer agents, including selective serotonin reuptake inhibitors, bupropion, mirtazapine, and venlafaxine, is also supported by considerable efficacy data. Clinicians should carefully reevaluate patients with major depressive disorder who are nonresponders to treatment, particularly those who have had several adequate trials. When choosing the best treatment strategy for antidepressant nonresponders, clinicians should take into account the efficacy and tolerability of treatment as well as patient preference and treatment history. Finally, the risk of potential loss of partial therapeutic benefit from the first-line antidepressant, as well as the risk of withdrawal symptoms, should be taken into account when considering switching antidepressants, while the risk of drug interactions and poor adherence should be taken into account when considering combination and augmentation treatments. (J Clin Psychiatry 2009;70[suppl 6]:16-25) C1 [Papakostas, George I.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 01224 USA. [Papakostas, George I.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Papakostas, GI (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St WACC 812, Boston, MA 01224 USA. EM gpapakostas@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 FU National Institute of Mental Health; Pamlab; Plizer Forest; Ridge Diagnostics; Bristol-Myers Squibb FX Lifetime financial disclosure as of September 23, 2009: Dr Papakostas has served as an advisor/consultant for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Evotec, Inflabloc, Jazz, Shire, Otsuka, Plizer Pierre Fabre, Wyeth, and Pamlab; has received grant/research support from the National Institute of Mental Health, Pamlab, Plizer Forest, Ridge Diagnostics, and Bristol-Myers Squibb; has received honoraria from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Evotec, Inflabloc, Jazz, Shire, Otsuka, Pierre Fabre, Plizer Pamlab, Titan, Wyeth, and Lundbeck; and has been a member of the speaker's bureau for Bristol-Myers Squibb and Plizer. NR 91 TC 66 Z9 68 U1 3 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2009 VL 70 BP 16 EP 25 DI 10.4088/JCP.8133su1c.03 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 531CG UT WOS:000272639700003 PM 19922740 ER PT J AU Papakostas, GI AF Papakostas, George I. TI Evidence for S-Adenosyl-L-Methionine (SAM-e) for the Treatment of Major Depressive Disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; MONOAMINE METABOLISM; CELL FOLATE; FOLIC-ACID; ADENOSYLMETHIONINE; ANTIDEPRESSANT; IMIPRAMINE; EFFICACY; ENHANCEMENT AB Despite the increasingly large array of antidepressants available to treat major depressive disorder, patients continue to experience relatively modest response and remission rates. In addition, patients may experience adverse side effects from pharmacotherapy that not only hinder treatment compliance and adherence but, in some cases, may also contribute to increased disability, patient suffering, morbidity, and mortality. In order to enhance treatment efficacy and tolerability, patients and clinicians have become increasingly interested in nonpharmaceutical supplements for treating depression. One of the best-studied of these supplements is S-adenosyl-L-methionine (SAM-e), a naturally occurring molecule present in all living cells and a major methyl group donor in the human body. Controlled trials have found SAM-e to be more efficacious than placebo and equal in efficacy to the tricyclic antidepressants for treating major depressive disorder (MDD) when administered parenterally (either intravenously or intramuscularly). Less evidence supports the use of oral SAM-e, although some trials have demonstrated its efficacy as well. In addition, there is a paucity of evidence examining whether oral forms of SAM-e can be safe, well tolerated, and efficacious when used as adjunctive treatment for antidepressant nonresponders with MDD. Although preliminary data suggest SAM-e may be useful as an adjunctive therapy to antidepressants, controlled studies are needed to confirm or refute these preliminary findings. (J Clin Psychiatry 2009; 70[suppl 5]:18-22) C1 [Papakostas, George I.] Massachusetts Gen Hosp, Boston, MA 01224 USA. [Papakostas, George I.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. RP Papakostas, GI (reprint author), Massachusetts Gen Hosp, 15 Parkman St WACC 812, Boston, MA 01224 USA. EM gpapakostas@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 FU National Institute of Mental Health; Pamlab; Pfizer; Forest; Precision Human Biolaboratories; Bristol-Myers Squibb FX Lifetime financial disclosure as of July 14, 2009: Dr Papakostas has served as an advisor/consultant for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Evotec, Inflabloc, Jazz, Shire, Titan, Otsuka, Pfizer, Pierre Fabre, Wyeth, and Pamlab; has received grant/research support from the National Institute of Mental Health, Pamlab, Pfizer, Forest, Precision Human Biolaboratories, and Bristol-Myers Squibb; and has received honoraria from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Evotec, Inflabloc, Jazz, Shire, Otsuka, Pierre Fabre, Pfizer, Pamlab, Titan, Wyeth, and Lundbeck. NR 44 TC 49 Z9 53 U1 0 U2 11 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2009 VL 70 BP 18 EP 22 DI 10.4088/JCP.8157su1c.04 PG 5 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 521IK UT WOS:000271914100004 PM 19909689 ER PT J AU Pollack, MH AF Pollack, Mark H. TI Refractory Generalized Anxiety Disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID NATIONAL-COMORBIDITY-SURVEY; MAJOR DEPRESSIVE DISORDER; PLACEBO-CONTROLLED TRIAL; OPEN-LABEL TRIAL; DOUBLE-BLIND; SURVEY REPLICATION; BIPOLAR DISORDER; PANIC DISORDER; TERM TREATMENT; AUGMENTATION AB Generalized anxiety disorder (GAD) has a lifetime prevalence in the US population of about 5.7%. Typically, GAD begins in early adulthood and tends to have a chronic and persistent course. The disorder frequently presents comorbidly with other conditions, and about 90% of patients with GAD have at least 1 comorbid lifetime psychiatric disorder. Patients with GAD tend to be high users of medical services; the disorder is associated with significant physical as well as psychological symptomatology and impacts health, family relationships, and employment. Pharmacologic and psychosocial treatments are available for GAD. Different side effect profiles, speed of onset of action, and discontinuation requirements of individual drugs need to be taken into account when selecting treatment. Treatment selection should include consideration of comorbidity, psychological function, social impairment, and refractoriness, as well as the need for ongoing intervention for many individuals. Innovative treatments, including anticonvulsants, atypical antipsychotics, and others, as well as treatment targeting concomitant insomnia, may help improve outcomes for affected individuals. (J Clin Psychiatry 2009;70[suppl 2]:32-38) C1 [Pollack, Mark H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Anxiety & Traumat Stress Disorders, Boston, MA USA. RP Pollack, MH (reprint author), 185 Cambridge St,Suite 2200,2nd Floor, Boston, MA 02114 USA. EM mpollack@partners.org FU AstraZeneca Pharmaceuticals LP FX This article is derived from the planning teleconference series "Insights Into Generalized Anxiety Disorder," which was held June-August 2008, and supported by an educational grant from AstraZeneca Pharmaceuticals LP NR 55 TC 28 Z9 31 U1 2 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2009 VL 70 BP 32 EP 38 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 435TR UT WOS:000265366700006 PM 19371505 ER PT J AU Guo, C Stella, SL Hirano, AA Brecha, NC AF Guo, Chenying Stella, Salvatore L., Jr. Hirano, Arlene A. Brecha, Nicholas C. TI Plasmalemmal and Vesicular gamma-Aminobutyric Acid Transporter Expression in the Developing Mouse Retina SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Review DE GAT; VGAT; amacrine cells; horizontal cells; retina; visual system ID GABA-LIKE IMMUNOREACTIVITY; NEONATAL RABBIT RETINA; OUTER PLEXIFORM LAYER; PROTEIN-KINASE-C; RAT RETINA; POSTNATAL-DEVELOPMENT; SYNAPTIC VESICLES; NEUROTRANSMITTER TRANSPORTERS; MEMBRANE TRANSPORTER; VERTEBRATE RETINA AB Plasmalemmal and vesicular gamma-aminobutyric acid (GABA) transporters influence neurotransmission by regulating high-affinity GABA uptake and GABA release into the synaptic cleft and extracellular space. Postnatal expression of the plasmalemmal GABA transporter-1 (GAT-1), GAT-3, and the vesicular GABA/glycine transporter (VGAT) were evaluated in the developing mouse retina by using immunohistochemistry with affinity-purified antibodies. Weak transporter immunoreactivity was observed in the inner retina at postnatal day 0 (P0). GAT-1 immunostaining at P0 and at older ages was in amacrine and displaced amacrine cells in the inner nuclear layer (INL) and ganglion cell layer (GCL), respectively, and in their processes in the inner plexiform layer (IPL). At P10, weak GAT-1 immunostaining was in Muller cell processes. GAT-3 immunostaining at P0 and older ages was in amacrine cells and their processes, as well as in Muller cells and their processes that extended radially across the retina. At P10, Muller cell somata were observed in the middle of the INL. VGAT immunostaining was present at P0 and older ages in amacrine cells in the INL as well as processes in the IPL. At P5, weak VGAT immunostaining was also observed in horizontal cell somata and processes. By P15, the GAT and VGAT immunostaining patterns appear similar to the adult immunostaining patterns; they reached adult levels by about P20. These findings demonstrate that GABA uptake and release are initially established in the inner retina during the first postnatal week and that these systems subsequently mature in the outer retina during the second postnatal week. J. Comp. Neurol. 512: 6-26,2009. Published 2008 Wiley-Liss, Inc. C1 [Guo, Chenying; Stella, Salvatore L., Jr.; Hirano, Arlene A.; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Brecha, NC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM nbrecha@ucla.edu OI Stella Jr., Salvatore/0000-0003-1971-2537 FU National Institutes of Health [EY 04067, 15573] FX Grant sponsor: National Institutes of Health; Grant number: EY 04067; Grant number: EY 15573. NR 113 TC 31 Z9 31 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0021-9967 J9 J COMP NEUROL JI J. Comp. Neurol. PD JAN 1 PY 2009 VL 512 IS 1 BP 6 EP 26 DI 10.1002/cne.21846 PG 21 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA 383EY UT WOS:000261658100002 PM 18975268 ER PT J AU Cunnane, ME Platt, M Caruso, PA Metson, R Curtin, HD AF Cunnane, Mary Elizabeth Platt, Michael Caruso, Paul A. Metson, Ralph Curtin, Hugh D. TI Medialization of the Lamina Papyracea After Endoscopic Ethmoidectomy: Comparison of Preprocedure and Postprocedure Computed Tomographic Scans SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE functional endoscopic sinus surgery; ethmoidectomy; enophthalmos AB Objective: The purpose of this article is to report computed tomography demonstration of medial bowing of the lamina papyracea in 5 patients after internal ethmoidectomy. Methods: We identified 5 patients who had apparent medial bowing of the lamina papyracea after functional endoscopic sinus surgery (FESS) and who had preoperative scans available. Preoperative and postoperative scans were reviewed using a 3-dimensional workstation to ensure similar angulation of the slices before measurement. Measurements of the interorbital distance and also the position of the posterior margin of the globe relative to a line connecting the lateral orbital walls were performed. Results: Each of the patients demonstrated a decrease in the interorbital distance on the postoperative scan. Measurement of globe position showed that 9 of the 10 globes lay in a more posterior position within the orbit on postoperative examination. Conclusions: Medial bowing of the lamina papyracea may occur as a result of FESS and may lead to relative enophthalmos in comparison. The incidence of this phenomenon is unknown because most patients are not reimaged after FESS. C1 [Cunnane, Mary Elizabeth; Platt, Michael; Caruso, Paul A.; Metson, Ralph; Curtin, Hugh D.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Cunnane, ME (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM Mary_Beth_Cunnane@meei.harvard.edu NR 3 TC 3 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-8715 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD JAN-FEB PY 2009 VL 33 IS 1 BP 79 EP 81 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 404FH UT WOS:000263135900014 PM 19188790 ER PT J AU Nagle, BM McHale, JM Alexander, GA French, BM AF Nagle, Beth M. McHale, Jeanne M. Alexander, Gail A. French, Brian M. TI Incorporating Scenario-Based Simulation Into a Hospital Nursing Education Program SO JOURNAL OF CONTINUING EDUCATION IN NURSING LA English DT Article ID REALITY AB Nurse educators are challenged to provide meaningful and effective learning opportunities for both new and experienced nurses. Simulation as a teaching and learning methodology is being embraced by nursing in academic and practice settings to provide innovative educational experiences to assess and develop clinical competency, promote teamwork, and improve care processes. This article provides an overview of the historical basis for using simulation in education, simulation methodologies, and perceived advantages and disadvantages. It also provides a description of the integration of scenario-based programs using a full-scale patient simulator into nursing education programming at a large academic medical center. J Contin Educ Nurs 2009;40(1):18-25. C1 [Nagle, Beth M.] Massachusetts Gen Hosp, Inst Patient Care, Boston, MA 02114 USA. [Alexander, Gail A.] Massachusetts Gen Hosp, Surg ICU, Boston, MA 02114 USA. RP Nagle, BM (reprint author), Massachusetts Gen Hosp, Inst Patient Care, 275 Cambridge St, Boston, MA 02114 USA. NR 18 TC 30 Z9 33 U1 1 U2 6 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0022-0124 J9 J CONTIN EDUC NURS JI J. Contin. Educ. Nursing PD JAN PY 2009 VL 40 IS 1 BP 18 EP 25 PG 8 WC Nursing SC Nursing GA 700HJ UT WOS:000285728400005 PM 19226995 ER PT J AU Baran, J Kroshinsky, D Duncan, L Hoang, M AF Baran, J. Kroshinsky, D. Duncan, L. Hoang, M. TI LYMPHOMATOID DRUG REACTION IMITATING MYCOSIS FUNGOIDES SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Baran, J.; Kroshinsky, D.; Duncan, L.; Hoang, M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2009 VL 36 IS 1 BP 116 EP 116 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 389XT UT WOS:000262129600069 ER PT J AU Mandal, R Duncan, L Nielsen, G AF Mandal, R. Duncan, L. Nielsen, G. TI INTRAMUSCULAR SPINDLE CELL LIPOMA OF THE FACE SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Mandal, R.; Duncan, L.; Nielsen, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2009 VL 36 IS 1 BP 124 EP 124 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 389XT UT WOS:000262129600101 ER PT J AU Kolman, O Chang, C Kim, J Duncan, L AF Kolman, O. Chang, C. Kim, J. Duncan, L. TI LARGE ABDOMINAL BASAL CELL CARCINOMA WITH WIDESPREAD METASTASIS SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Kolman, O.; Chang, C.; Kim, J.; Duncan, L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2009 VL 36 IS 1 BP 128 EP 128 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 389XT UT WOS:000262129600118 ER PT J AU Baran, J Hoang, M AF Baran, J. Hoang, M. TI APOCRINE MIXED TUMOR OF THE SKIN WITH A PROMINENT PILOMATRICOMAL COMPONENT SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Baran, J.; Hoang, M.] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2009 VL 36 IS 1 BP 130 EP 130 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 389XT UT WOS:000262129600126 ER PT J AU Johnson, M Nielsen, G Stemmer-Rachamimov, A Kreshock, A Mihm, M AF Johnson, M. Nielsen, G. Stemmer-Rachamimov, A. Kreshock, A. Mihm, M. TI SOX-9 EXPRESSION IN BENIGN AND MALIGNANT MELANOCYTIC TUMORS SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Johnson, M.; Nielsen, G.; Stemmer-Rachamimov, A.; Kreshock, A.; Mihm, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2009 VL 36 IS 1 BP 140 EP 140 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 389XT UT WOS:000262129600166 ER PT J AU Nazarian, R Mihm, M AF Nazarian, R. Mihm, M. TI INFLAMMATORY MYXOHYALINE TUMOR: A DIAGNOSTIC PITFALL FOR A DECADE SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Nazarian, R.; Mihm, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2009 VL 36 IS 1 BP 146 EP 146 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 389XT UT WOS:000262129600192 ER PT J AU Sepehr, A Kroshinsky, D AF Sepehr, A. Kroshinsky, D. TI ACUTE NECROTIZING NEUTROPHILIC DERMATOSIS (ANND): A NEW VARIANT OF SWEET'S SYNDROME MIMICKING NECROTIZING FASCIITIS SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [Sepehr, A.; Kroshinsky, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2009 VL 36 IS 1 BP 155 EP 155 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 389XT UT WOS:000262129600229 ER PT J AU King, R Hayzen, B Page, R Mihm, M AF King, R. Hayzen, B. Page, R. Mihm, M., Jr. TI RECURRENT NEVUS PHENOMENON (PSEUDOMELANOMA) AND MELANOMA WITH REGRESSION: A COMPARATIVE HISTOLOGIC STUDY SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Meeting Abstract C1 [King, R.; Hayzen, B.; Page, R.] Knoxville Dermatopathol Lab, Knoxville, TN USA. [Mihm, M., Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD JAN PY 2009 VL 36 IS 1 BP 162 EP 162 PG 1 WC Dermatology; Pathology SC Dermatology; Pathology GA 389XT UT WOS:000262129600259 ER PT J AU McRae-Clark, AL Verduin, ML Tolliver, BK Carter, RE Wahlquist, AE Brady, KT Cluver, JS Anderson, S AF McRae-Clark, Aimee L. Verduin, Marcia L. Tolliver, Bryan K. Carter, Rickey E. Wahlquist, Amy E. Brady, Kathleen T. Cluver, Jeffrey S. Anderson, Samantha TI An Open-Label Trial of Aripiprazole Treatment in Dual Diagnosis Individuals: Safety and Efficacy SO JOURNAL OF DUAL DIAGNOSIS LA English DT Article; Proceedings Paper CT 69th Annual Meeting of the College-of-Problems-on-Drug-Dependence CY JUN 19, 2007 CL Quebec City, CANADA SP Coll Problems Drug Dependence DE Aripiprazole; dual diagnosis; alcohol; cocaine; marijuana ID QUINOLINONE DERIVATIVE OPC-14597; SUBSTANCE USE DISORDER; TARDIVE-DYSKINESIA; MENTAL-DISORDERS; ANIMAL-MODEL; SCHIZOPHRENIA; ALCOHOL; ABUSE; BUSPIRONE; DEPENDENCE AB This open-label study evaluated the safety and efficacy of aripiprazole in the treatment of 20 patients with co-morbid schizophrenia, schizoaffective disorder, or bipolar disorder and alcohol, cocaine, and/or marijuana use disorders. Primary outcomes were substance use, measured by the Timeline Followback, and score on the Clinical Global Impression scale for psychiatric and substance use symptoms. The data suggest that aripiprazole may reduce substance use and improve psychiatric symptoms in patients with co-morbid disorders; however, limitations are noted. Subsequent randomized studies are needed to further explore these findings. C1 [McRae-Clark, Aimee L.; Tolliver, Bryan K.; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Verduin, Marcia L.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. [Carter, Rickey E.; Wahlquist, Amy E.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Cluver, Jeffrey S.] Ralph H Johnson VAMC, Mental Hlth Serv Line, Charleston, SC USA. RP McRae-Clark, AL (reprint author), Med Univ S Carolina, Dept Psychiat, 67 President St, Charleston, SC 29425 USA. EM mcraeal@musc.edu RI McRae-Clark, Aimee/I-3341-2013 OI McRae-Clark, Aimee/0000-0002-9774-318X NR 42 TC 2 Z9 2 U1 1 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1550-4263 EI 1550-4271 J9 J DUAL DIAGN JI J. Dual Diagn. PY 2009 VL 5 IS 1 BP 83 EP 96 DI 10.1080/15504260802620210 PG 14 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA 668WE UT WOS:000283303200007 ER PT J AU Kline, A Callahan, L Butler, M St Hill, L Losonczy, MF Smelson, DA AF Kline, Anna Callahan, Lanora Butler, Mark St Hill, Lauren Losonczy, Miklos F. Smelson, David A. TI The Relationship Between Military Service Eras and Psychosocial Treatment Needs Among Homeless Veterans With a Co-Occurring Substance Abuse and Mental Health Disorder SO JOURNAL OF DUAL DIAGNOSIS LA English DT Article DE Veterans; psychosocial treatment needs; homelessness; mental health; substance abuse; era served ID POSTTRAUMATIC-STRESS-DISORDER; WAR VETERANS; US VETERANS; DRUG-USE; SUICIDE; IRAQ; AFGHANISTAN; SYMPTOMS; ILLNESS; WOMEN AB This article will examine baseline assessment data from consecutive admissions to the MISSION Program, a transitional case management program for homeless veterans, to better understand the differences across military service eras that impact the psychosocial treatment needs of homeless, mentally ill, substance-abusing veterans. In all, 373 homeless veterans with a co-occurring mental illness and substance abuse disorder received the Structured Clinical Interview for DSM-IV Diagnosis, a modified Addiction Severity Index, the BASIS-32, and a comprehensive assessment battery focusing on other psychosocial treatment needs. Chi-square analysis and ANOVA were used to measure differences in mental health, substance use, physical health status, and homelessness across service eras, broken down by Vietnam era, post-Vietnam era, and Persian Gulf/Middle East era. Persian Gulf/Middle East era veterans were significantly more likely to have mental health problems than other veteran cohorts, especially problems with post-traumatic stress disorder (p <= .001), and reported more days of mental health problems in the last month (p = .01). Mideast veterans also became homeless at a significantly earlier age than other veterans (p <= .001), were more likely to report housing instability in their families of origin (p <= .05) and to attribute their homelessness to mental health problems (p = .01). Service providers need to be aware of the diversity of homeless veterans' service needs by period of military service in order to develop well-targeted, effective interventions. C1 [Kline, Anna; Callahan, Lanora; Butler, Mark; St Hill, Lauren; Losonczy, Miklos F.] US Dept Vet Affairs, New Jersey Hlth Care Syst, Lyons, NJ 07939 USA. [Kline, Anna; Callahan, Lanora; Butler, Mark; St Hill, Lauren; Losonczy, Miklos F.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA. [Smelson, David A.] US Dept Vet Affairs, Bedford, MA USA. [Smelson, David A.] Univ Massachusetts, Sch Med, Bedford, MA USA. RP Kline, A (reprint author), US Dept Vet Affairs, New Jersey Hlth Care Syst, Lyons Campus,Mental Hlth & Behav Sci Bldg 143,151, Lyons, NJ 07939 USA. EM anna.kline@va.gov NR 47 TC 2 Z9 2 U1 3 U2 22 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1550-4263 J9 J DUAL DIAGN JI J. Dual Diagn. PY 2009 VL 5 IS 3-4 BP 357 EP 374 DI 10.1080/15504260903175882 PG 18 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA 668XB UT WOS:000283306900007 ER PT J AU Brown, EL Brown, DFM Nadel, ES AF Brown, Emily L. Brown, David F. M. Nadel, Eric S. TI PEDIATRIC ABDOMINAL PAIN SO JOURNAL OF EMERGENCY MEDICINE LA English DT Editorial Material ID ACUTE OVARIAN TORSION C1 [Nadel, Eric S.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Brown, Emily L.; Brown, David F. M.; Nadel, Eric S.] Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA. [Brown, David F. M.; Nadel, Eric S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Nadel, ES (reprint author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA. NR 7 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD JAN PY 2009 VL 36 IS 1 BP 72 EP 75 DI 10.1016/j.jemermed.2008.10.010 PG 4 WC Emergency Medicine SC Emergency Medicine GA 401WA UT WOS:000262972000017 PM 19038517 ER PT J AU Shah, S Thomas, S Gibb, E AF Shah, Sachita Thomas, Stephen Gibb, Elizabeth TI PNEUMOMEDIASTINUM AFTER SHALLOW WATER DIVING SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article C1 [Shah, Sachita; Thomas, Stephen; Gibb, Elizabeth] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Shah, S (reprint author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA. NR 5 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD JAN PY 2009 VL 36 IS 1 BP 76 EP 77 DI 10.1016/j.jemermed.2007.05.011 PG 2 WC Emergency Medicine SC Emergency Medicine GA 401WA UT WOS:000262972000018 PM 17976822 ER PT J AU Ricchiuti, V Lian, CG Oestreicher, EM Tran, L Stone, JR Yao, T Seely, EW Williams, GH Adler, GK AF Ricchiuti, Vincent Lian, Christine G. Oestreicher, Eveline M. Tran, Loc Stone, James R. Yao, Tham Seely, Ellen W. Williams, Gordon H. Adler, Gail K. TI Estradiol increases angiotensin II type 1 receptor in hearts of ovariectomized rats SO JOURNAL OF ENDOCRINOLOGY LA English DT Article ID ESTROGEN PLUS PROGESTIN; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE-CELLS; POSTMENOPAUSAL WOMEN; HYPERTENSIVE-RATS; MESSENGER-RNA; SEX-HORMONES; IN-VITRO; ALDOSTERONE; DISEASE AB We tested the hypothesis that 17 beta-estradiol (E(2)) has dual effects on the heart, increasing levels of proteins thought to have beneficial cardiovascular effects (e.g. endothelial nitric oxide (NO) synthase (eNOS)) as well as those thought to have detrimental cardiovascular effects (e.g. type 1 angiotensin II (Ang II) receptor (AT(1)R)). Ovariectomized Wistar rats consuming a high-sodium diet received one of four treatments (n=7 per group): group 1, placebo pellets; group 2, E(2) (0-5 mg/pellet, 21-day release); group 3, NOS inhibitor, N(omega)-nitro-L-arginine-methyl-ester (L-NAME; 40 mg/kg per day for 14 days)plus AngII(0.225 mg/kg per day on days 11-14); group 4, E, plus L-NAME/Ang II. E, increased cardiac levels of estrogen receptors ESR1 and ESR2, an ESR-associated membrane protein caveolin-3, eNOS, and phosphorylated (p)eNOS, thus, exerting potentially beneficial cardiovascular effects oil NO. However, E(2) also increased cardiac levels of proteins associated with cardiovascular injury and inflammation including, AT(1)R, protein kinase C delta (PRKCD), phosphorylated PRKC, and phosphorylated extracellular signal regulated kinase (pMAPK)3/1, plasminogen activator inhabitor-1 (PAI-1), osteopontin and ED-1, a monocyte/macrophage-specific protein. E(2) treatment led to similar protein changes in the hearts of L-NAME/Ang II-treated rats except that the increase in peNOS was prevented, and L-NAME/Ang II and E(2) had additive effects in increasing cardiac PRKCD and PAI-1. Thus, the highest levels of cardiac PAI-1 and PRKCD Occurred in L-NAME/Ang II-treated rats receiving E(2). In summary, E(2) treatment increased cardiac expression of AT, R as well as the expression of pro-inflammatory and prothrombotic factors. C1 [Ricchiuti, Vincent; Lian, Christine G.; Oestreicher, Eveline M.; Tran, Loc; Yao, Tham; Seely, Ellen W.; Williams, Gordon H.; Adler, Gail K.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. [Stone, James R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA. RP Ricchiuti, V (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Endocrinol Diabet & Hypertens, 221 Longwood Ave, Boston, MA 02115 USA. EM vricchiuti@partners.org FU NIH [5T32HL007609, DK07529, HL-63423, HL-69208, HL-67332K24, RR018613, R01 HL67332, HL-07718] FX This work was supported by NIH training grants 5T32HL007609 and DK07529, and NIH research grants HL-63423, HL-069208, HL-67332K24, RR018613, It01 HL67332, and HL-07718. NR 44 TC 16 Z9 19 U1 1 U2 3 PU BIOSCIENTIFICA LTD PI BRISTOL PA 22 APEX COURT, WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0022-0795 J9 J ENDOCRINOL JI J. Endocrinol. PD JAN PY 2009 VL 200 IS 1 BP 75 EP 84 DI 10.1677/JOE-08-0199 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 395IB UT WOS:000262516700007 PM 18931023 ER PT J AU Kwolek, CJ Crawford, RS AF Kwolek, Christopher J. Crawford, Robert S. TI Training the Next Generation of Vascular Specialists: Current Status and Future Perspectives SO JOURNAL OF ENDOVASCULAR THERAPY LA English DT Review DE vascular surgery; vascular medicine; endovascular surgery; training; residency programs; simulators; vascular laboratory; imaging ID MULTISPECIALTY CONSENSUS RECOMMENDATIONS; CLINICAL COMPETENCE STATEMENT; SURGERY; SIMULATION; GUIDELINES; REPAIR AB Several challenges exist with respect to training the current and next generation of vascular specialists. Current advances in technology have led to changes in the length and type of training required to master new endovascular techniques. At the same time, the number of open surgical cases being provided to trainees may not be sufficient to allow them to manage complex open procedures. This growth is occurring at a time when increased external pressures are being applied to shorten training programs. Finally, the next generation of vascular specialists will come from medical students who are accruing a large educational debt during their course of training. Vascular specialists outside the US have already begun to successfully deal with many of these issues, and insight can be gained from their successes and difficulties. In this article, we review the current status of training for vascular and endovascular specialists and discuss the need for changes in current US training paradigms. While this will touch on initiatives in other specialties, including cardiology, vascular medicine, and interventional and neuroradiology, we will focus primarily on changes that are occurring with respect to the training of surgical specialists who manage vascular disease. J Endovasc Ther. 2009; 16(Suppl I):I42-I52 C1 [Kwolek, Christopher J.; Crawford, Robert S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp Ctr, Div Vasc & Endovasc Surg, Boston, MA 02115 USA. RP Kwolek, CJ (reprint author), Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, 15 Parkman St,WAC 440, Boston, MA 02114 USA. EM ckwolek@partners.org NR 21 TC 5 Z9 5 U1 0 U2 0 PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 1526-6028 J9 J ENDOVASC THER JI J. Endovascular Ther. PY 2009 VL 16 SU 1 BP 42 EP 52 PG 11 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 680VG UT WOS:000284263400004 ER PT J AU Bansal, S Harber, P Yun, D Liu, D Liu, YH Wu, S Ng, D Santiago, S AF Bansal, Siddharth Harber, Philip Yun, David Liu, David Liu, Yihang Wu, Samantha Ng, David Santiago, Silverio TI Respirator Physiological Effects under Simulated Work Conditions SO JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART A-TOXIC/HAZARDOUS SUBSTANCES & ENVIRONMENTAL ENGINEERING LA English DT Article DE physiology; plethysmography; pulmonary ventilation; respirator; terrorism ID PROTECTIVE DEVICES; INSPIRATORY RESISTANCE; INDUCTIVE PLETHYSMOGRAPHY; INDUSTRIAL RESPIRATORS; EXHALATION RESISTANCES; EXERCISE PERFORMANCE; DEMAND RESPIRATOR; LUNG-DISEASE; FACE MASKS; DEAD SPACE AB This study compared the physiological impacts of two respirator types in simulated work conditions. Fifty-six subjects included normal volunteers and persons with mild respiratory impairments (chronic rhinitis, mild COPD, and mild asthma). Respiratory parameters and electrocardiogram were measured using respiratory inductive plethysmography while performing eight work tasks involving low to moderate exertion using two respirators: (1) a dual cartridge half face mask (HFM) respirator, and (2) the N95. Mixed model regression analyses evaluating the effect of task and respirator type showed that task affected tidal volume, minute ventilation, breathing frequency and heart rate; all were greater in heavier tasks. Although respirator type did not affect respiratory volume parameters and flow rates, the HFM led to increase in the inspiratory time, reduction of the expiratory time, and increase in the duty cycle in comparison with the N95. The magnitude of differences was relatively small. The results suggest that most individuals, including persons with mild respiratory impairments, will physiologically tolerate either type of respirator at low to moderate exertion tasks. However, because effective protection depends on proper use, differences in subjective effect may have greater impact than physiological differences. Using respirators may be feasible on a widespread basis if necessary for maintaining essential services in the face of widespread concern about an infectious or terrorist threat. C1 [Bansal, Siddharth; Harber, Philip; Yun, David; Liu, David; Liu, Yihang; Wu, Samantha] Univ Calif Los Angeles, Dept Family Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Harber, Philip; Ng, David; Santiago, Silverio] VA Greater Angeles Healthcare Syst, Dept Med, Div Pulm Med, Los Angeles, CA USA. RP Harber, P (reprint author), Univ Calif Los Angeles, Dept Family Med, David Geffen Sch Med, 10880 Wilshire,1800, Los Angeles, CA 90024 USA. EM pharber@mednet.ucla.edu FU CDC/NIOSH [R01 OH-8119] FX This study was supported by grant # R01 OH-8119 from CDC/NIOSH. NR 46 TC 1 Z9 1 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1093-4529 J9 J ENVIRON SCI HEAL A JI J. Environ. Sci. Health Part A-Toxic/Hazard. Subst. Environ. Eng. PY 2009 VL 44 IS 3 BP 221 EP 227 DI 10.1080/15459620902729218 PG 7 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 402LT UT WOS:000263015900001 ER PT J AU Keil, DE Peden-Adams, MM Wallace, S Ruiz, P Gilkeson, GS AF Keil, Deborah E. Peden-Adams, Margie M. Wallace, Stacy Ruiz, Phillip Gilkeson, Gary S. TI Assessment of trichloroethylene (TCE) exposure in murine strains genetically-prone and non-prone to develop autoimmune disease SO JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART A-TOXIC/HAZARDOUS SUBSTANCES & ENVIRONMENTAL ENGINEERING LA English DT Article DE Trichloroethylene; autoimmune disease; NZBWF1; B6C3F1 ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTI-DNA ANTIBODIES; T-CELL-ACTIVATION; MRL+/+ MICE; ANTINUCLEAR ANTIBODIES; RISK-ASSESSMENT; B6C3F1 MICE; DSDNA; WATER; IMMUNOTOXICITY AB There is increasing laboratory and epidemiologic evidence relating exposure to trichloroethylene (TCE) with autoimmune disease including scleroderma and lupus. New Zealand Black/New Zealand White (NZBWF1) and B6C3F1 mice were exposed to TCE (0, 1, 400 or 14,000 ppb) via drinking water for 27 or 30 weeks, respectively. NZBWF1 mice spontaneously develop autoimmune disease while B6C3F1 mice, a standard strain used in immunotoxicology testing, are not genetically prone to develop autoimmune disease. During the TCE exposure period, serum levels of total IgG, and autoantibodies (anti-ssDNA, -dsDNA, and -glomerular antigen [GA]) were monitored. At the termination of the study, renal pathology, natural killer (NK) cell activity, total IgG levels, autoantibody production, T-cell activation, and lymphocytic proliferative responses were evaluated. TCE did not alter NK cell activity, or T- and B-cell proliferation in either strain. Numbers of activated T-cells (CD4+/CD44+) were increased in the B6C3F1 mice but not in the NZBWF1 mice. Renal pathology, as indicated by renal score, was significantly increased in the B6C3F1, but not in the NZBWF1 mice. Serum levels of autoantibodies to dsDNA and ssDNA were increased at more time points in B6C3F1, as compared to the NZBWF1 mice. Anti-GA autoantibodies were increased by TCE treatment in early stages of the study in NZBWF1 mice, but by 23 weeks of age, control levels were comparable to those of TCE-exposed animals. Serum levels anti-GA autoantibodies in B6C3F1 were not affected by TCE exposure. Overall, these data suggest that TCE did not contribute to the progression of autoimmune disease in autoimmune-prone mice during the period of 11-36 weeks of age, but rather lead to increased expression of markers associated with autoimmune disease in a non-genetically prone mouse strain. C1 [Keil, Deborah E.] Univ Nevada, Clin Lab Sci Program, Las Vegas, NV 89154 USA. [Peden-Adams, Margie M.; Wallace, Stacy; Gilkeson, Gary S.] Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Peden-Adams, Margie M.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Peden-Adams, Margie M.] Med Univ S Carolina, Marine Biomed & Environm Sci Ctr, Charleston, SC 29425 USA. [Ruiz, Phillip] Univ Miami, Dept Pathol & Surg, Miami, FL USA. [Gilkeson, Gary S.] Ralph Johnson VAMC, Med Res Serv, Charleston, SC USA. RP Keil, DE (reprint author), Univ Nevada, Clin Lab Sci Program, Las Vegas, NV 89154 USA. EM deborah.keil@unlv.edu FU Medical Research Service; Department of Energy [DE-FC09-02CH11109] FX The authors thank Dr. Chris Reilly, Keisha Redmond, and Jackie EuDaly for their technical assistance and Raymond Kivi for assistance in manuscript preparation. This research was supported by the Medical Research Service, Ralph H. Johnson VAMC and by Contract DE-FC09-02CH11109 from the Department of Energy to the MUSC Environmental Biosciences Program. The authors have no conflict of interest to declare. NR 51 TC 9 Z9 9 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1093-4529 J9 J ENVIRON SCI HEAL A JI J. Environ. Sci. Health Part A-Toxic/Hazard. Subst. Environ. Eng. PY 2009 VL 44 IS 5 BP 443 EP 453 AR PII 909036764 DI 10.1080/10934520902719738 PG 11 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 412HM UT WOS:000263715900002 PM 19241258 ER PT J AU Greenberg, CC AF Greenberg, Caprice C. TI Learning from Adverse Events and Near Misses SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article CT 49th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract/Digestive Disease Week CY MAY 17-21, 2008 CL San Diego, CA SP Soc Surg Alimentary Tract DE Adverse events; Near misses; Patient safety; Operating room; Malpractice claims C1 [Greenberg, Caprice C.] Brigham & Womens Hosp, Div Breast Surg Oncol, Boston, MA 02215 USA. [Greenberg, Caprice C.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02215 USA. [Greenberg, Caprice C.] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA. RP Greenberg, CC (reprint author), Brigham & Womens Hosp, Div Breast Surg Oncol, 75 Francis St, Boston, MA 02215 USA. EM ccgreenberg@partners.org NR 5 TC 9 Z9 9 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD JAN PY 2009 VL 13 IS 1 BP 3 EP 5 DI 10.1007/s11605-008-0693-6 PG 3 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 387LB UT WOS:000261952600002 PM 18797974 ER PT J AU Weiser, SD Frongillo, EA Ragland, K Hogg, RS Riley, ED Bangsberg, DR AF Weiser, Sheri D. Frongillo, Edward A. Ragland, Kathleen Hogg, Robert S. Riley, Elise D. Bangsberg, David R. TI Food Insecurity is Associated with Incomplete HIV RNA Suppression Among Homeless and Marginally Housed HIV-infected Individuals in San Francisco SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 15th Conference on Retroviruses and Opportunistic Infections CY FEB 03-06, 2008 CL Boston, MA DE HIV/AIDS; food insecurity; homeless; HIV viral load suppression; adherence; San Francisco ID ACTIVE ANTIRETROVIRAL THERAPY; LESS-THAN 95-PERCENT; WELFARE RECIPIENTS; VIRAL SUPPRESSION; MENTAL-HEALTH; WEIGHT-LOSS; ADHERENCE; INSUFFICIENCY; PREVALENCE; PREDICTORS AB There is growing international concern that food insecurity may negatively impact antiretroviral (ARV) treatment outcomes, but no studies have directly evaluated the effect of food insecurity on viral load suppression and antiretroviral adherence. We hypothesized that food insecurity would be associated with poor virologic response among homeless and marginally housed HIV-positive ARV-treated patients. This is a cross-sectional study. Participants were ARV-treated homeless and marginally housed persons receiving adherence monitoring with unannounced pill counts in the Research on Access to Care in the Homeless (REACH) Cohort. Food insecurity was measured by the Household Food Insecurity Access Scale (HFIAS). The primary outcome was suppression of HIV viral RNA to < 50 copies/ml. We used multivariate logistic regression to assess whether food insecurity was associated with viral suppression. Among 104 participants, 51% were food secure, 24% were mildly or moderately food insecure and 25% were severely food insecure. Severely food insecure participants were less likely to have adherence >=80%. In adjusted analyses, severe food insecurity was associated with a 77% lower odds of viral suppression (95% CI = 0.06-0.82) when controlling for all covariates. In analyses stratified by adherence level, severe food insecurity was associated with an 85% lower odds of viral suppression (95% CI = 0.02-0.99) among those with <=80% adherence and a 66% lower odds among those with > 80% adherence (95% CI = 0.06-1.81). Food insecurity is present in half of the HIV-positive urban poor in San Francisco, one of the best resourced settings for HIV-positive individuals in the United States, and is associated with incomplete viral suppression. These findings suggest that ensuring access to food should be an integral component of public health HIV programs serving impoverished populations. C1 [Weiser, Sheri D.; Riley, Elise D.] Univ Calif San Francisco, San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94143 USA. [Weiser, Sheri D.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA. [Frongillo, Edward A.] Univ S Carolina, Arnold Sch Publ Hlth, Dept Hlth Promot Educ & Behav, Columbia, SC 29208 USA. [Ragland, Kathleen] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Gen Internal Med, San Francisco, CA 94143 USA. [Hogg, Robert S.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada. [Hogg, Robert S.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Bangsberg, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Harvard Initiat Global Hlth, Boston, MA USA. RP Weiser, SD (reprint author), Univ Calif San Francisco, Posit Hlth Program, POB 0874, San Francisco, CA 94143 USA. EM Sheri.Weiser@ucsf.edu RI Hogg, Robert/B-2783-2012; OI Hogg, Robert/0000-0003-3463-5488 FU NCRR NIH HHS [UL1 RR024131]; NIAAA NIH HHS [AA 015287]; NIMH NIH HHS [K24 MH087227, MH 54907, MH 79713-01, R01 MH054907] NR 55 TC 93 Z9 94 U1 0 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2009 VL 24 IS 1 BP 14 EP 20 DI 10.1007/s11606-008-0824-5 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 387RS UT WOS:000261969900003 PM 18953617 ER PT J AU Chen, JY Malin, J Ganz, PA Ko, C Tisnado, D Tao, ML Timmer, M Adams, JL Kahn, KL AF Chen, Judy Y. Malin, Jennifer Ganz, Patricia A. Ko, Clifford Tisnado, Diana Tao, May Lin Timmer, Martha Adams, John L. Kahn, Katherine L. TI Variation in Physician-patient Discussion of Breast Reconstruction SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE breast reconstruction; decision-making; low income ID CANCER CARE QUALITY; DECISION-MAKING; OF-LIFE; OUTCOMES; MASTECTOMY; IMMEDIATE; SURGERY; PARTICIPATION; COMPLICATIONS; RADIOTHERAPY AB For women with early stage breast cancer, physician-patient discussion of breast reconstruction is an essential step in their participation in the decision-making process for their treatments. This study examines sociodemographic variation of physician-patient discussion of breast reconstruction and explores the impact of this discussion on the use of breast reconstruction. We used data from the Los Angeles Women's Study, a population-based study of women 50 years and older with breast cancer. Bivariate and multivariate logistic regression models were used to estimate the impact of patient and hospital characteristics on self-reported receipt of physician-patient discussion and use of breast reconstruction. Of 315 post-mastectomy women, 81% and 27% reported physician-patient discussion and use of breast reconstruction, respectively. In multivariable analysis, women with an annual income <$20,000 were less likely to have physician-patient discussion than women with annual income a parts per thousand yen$40,000 (OR = 0.23, 95% CI 0.07-0.82). Among the subset of women with physician-patient discussion, chest wall radiation, a known characteristic associated with higher rates of reconstruction complications, became an additional significant negative predictor of reconstruction. Lower income women are at risk of not receiving physician-patient discussion of breast reconstruction. Physician-patient discussion of breast reconstruction appears to decrease the use of breast reconstruction among women with clinical characteristics associated with higher rates of reconstruction complications and failure. This highlights the need for interventions to increase physician-patient discussion of breast reconstruction among lower income women. C1 [Timmer, Martha; Adams, John L.; Kahn, Katherine L.] RAND Corp, Santa Monica, CA 90401 USA. [Chen, Judy Y.; Ganz, Patricia A.; Ko, Clifford; Tisnado, Diana; Tao, May Lin] Univ Calif Los Angeles, Los Angeles, CA USA. [Malin, Jennifer] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Tao, May Lin] Valley Radiotherapy Associates Med Grp, El Segundo, CA USA. [Kahn, Katherine L.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. RP Kahn, KL (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM kahn@rand.org FU National Cancer Institute (NCI) [R01 CA81338-01A1] FX Funding is from the National Cancer Institute (NCI) grant no. R01 CA81338-01A1. NR 42 TC 19 Z9 20 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2009 VL 24 IS 1 BP 99 EP 104 DI 10.1007/s11606-008-0855-y PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 387RS UT WOS:000261969900017 PM 19023629 ER PT J AU Yu, ASL Cheng, MH Angelow, S Gunzel, D Kanzawa, SA Schneeberger, EE Fromm, M Coalson, RD AF Yu, Alan S. L. Cheng, Mary H. Angelow, Susanne Guenzel, Dorothee Kanzawa, Sanae A. Schneeberger, Eveline E. Fromm, Michael Coalson, Rob D. TI Molecular Basis for Cation Selectivity in Claudin-2-based Paracellular Pores: Identification of an Electrostatic Interaction Site SO JOURNAL OF GENERAL PHYSIOLOGY LA English DT Article ID EPITHELIAL-CELLS; ION-TRANSPORT; DIELECTRIC-PROPERTIES; RABBIT GALLBLADDER; GLYCINE RECEPTOR; TIGHT JUNCTIONS; EXPRESSION; CHANNELS; PERMEATION; CONDUCTANCE AB Paracellular ion transport in epithelia is mediated by pores formed by members of the claudin family. The degree of selectivity and the molecular mechanism of ion permeation through claudin pores are poorly understood. By expressing a high-conductance claudin isoform, claudin-2, in high-resistance Madin-Darby canine kidney cells under the control of an inducible promoter, we were able to quantitate claudin pore permeability. Claudin-2 pores were found to be narrow, fluid filled, and cation selective. Charge selectivity was mediated by the electrostatic interaction of partially dehydrated permeating cations with a negatively charged site within the pore that is formed by the side chain carboxyl group of aspartate-65. Thus, paracellular pores use intrapore electrostatic binding sites to achieve a high conductance with a high degree of charge selectivity. C1 [Yu, Alan S. L.; Angelow, Susanne; Kanzawa, Sanae A.] Univ So Calif, Keck Sch Med, Dept Med, Div Nephrol, Los Angeles, CA 90089 USA. [Yu, Alan S. L.] Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90089 USA. [Cheng, Mary H.; Coalson, Rob D.] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA. [Guenzel, Dorothee; Fromm, Michael] Charite, Inst Clin Physiol, D-12200 Berlin, Germany. [Schneeberger, Eveline E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Yu, ASL (reprint author), Univ So Calif, Keck Sch Med, Dept Med, Div Nephrol, Los Angeles, CA 90089 USA. EM alanyu@usc.edu RI Fromm, Michael/K-6203-2013; OI Fromm, Michael/0000-0003-4497-7983; Yu, Alan/0000-0002-1776-2533 FU National Institutes of Health [DK062283, HL25822, DK48522]; National Science Foundation [CHE-0518044] FX We thank Drs. Alicia McDonough and Kwang Kim for sharing their equipment, and Dr. Robert Chow for reading an early version of the manuscript. We also wish to thank the reviewers, who played a collaborative role in revising aspects of this manuscript, particularly with regard to the method of correcting for liquid junction potentials. This turned out to be critical in arriving at quantitatively accurate data and changed our conclusions signifi cantly, and has also led to a signifi cant change in the way we now perform diffusion potential experiments in our laboratories.; This work was supported by National Institutes of Health grants DK062283 (to A. S. L. Yu), HL25822 (to E. E. Schneeberger), and DK48522 (to the USC Center for Liver Diseases, for the Confocal Microscopy Sub-Core). The work of M. H. Cheng and R. D. Coalson was supported in part by the National Science Foundation (grant CHE-0518044). NR 51 TC 119 Z9 120 U1 0 U2 11 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA SN 0022-1295 EI 1540-7748 J9 J GEN PHYSIOL JI J. Gen. Physiol. PD JAN PY 2009 VL 133 IS 1 BP 111 EP 127 DI 10.1085/jgp.200810154 PG 17 WC Physiology SC Physiology GA 454NU UT WOS:000266690000009 PM 19114638 ER PT J AU Belanger, HG Uomoto, JM Vanderploeg, RD AF Belanger, Heather G. Uomoto, Jay M. Vanderploeg, Rodney D. TI The Veterans Health Administration System of Care for Mild Traumatic Brain Injury: Costs, Benefits, and Controversies SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE screening; TBI; Veterans Health Administration ID POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSION-LIKE SYMPTOMS; OIF/OEF SERVICE MEMBERS; GULF-WAR VETERANS; MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL OUTCOMES; COGNITIVE PERFORMANCE; CLINICAL MANAGEMENT; EXPLOSION INJURIES; MAJOR DEPRESSION AB The Veterans Health Administration's (VHA!s) Polytrauma System of Care, developed in response to a new cohort of patients back from Iraq and Afghanistan, is described with particular focus on the assessment and treatment of Mild traumatic bra-In Injury (mild TBI). The development of systemwide TBI screening within the VHA has been an ambitious and historic undertaking. As with any population-wide screening tool, there are benefits and costs associated with it. The purpose of this article is to identify and discuss the strengths and weaknesses of the VHA's TBI clinical reminder and subsequent evaluation and treatment processes. Complicating factors such as increased media attention and other contextual factors are discussed. C1 [Belanger, Heather G.; Vanderploeg, Rodney D.] James A Haley VA, Dept Mental Hlth & Behav Sci, Tampa, FL USA. [Belanger, Heather G.; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA. [Uomoto, Jay M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Uomoto, Jay M.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. RP Belanger, HG (reprint author), James A Haley Vet Hosp, Dept Psychol, 13000 Bruce B Downs Blvd 117, Tampa, FL 33612 USA. EM Heather.Belanger@va.gov FU Department of Veterans Affairs; Veterans Health Administration (VHA) FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA). Further support was provided by the James A. Haley Veterans' Hospital. The views expressed herein are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs. NR 62 TC 84 Z9 84 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD JAN-FEB PY 2009 VL 24 IS 1 BP 4 EP 13 PG 10 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 427GT UT WOS:000264768500003 PM 19158591 ER PT J AU Ancker, JS Carpenter, KM Greene, P Hoffman, R Kukafka, R Marlow, LAV Prigerson, HG Quillin, JM AF Ancker, Jessica S. Carpenter, Kristen M. Greene, Paul Hoffman, Randi Kukafka, Rita Marlow, Laura A. V. Prigerson, Holly G. Quillin, John M. TI Peer-to-Peer Communication, Cancer Prevention, and the Internet SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID BREAST-CANCER; HEALTH INFORMATION; EMOTIONAL EXPRESSION; SUPPORT GROUPS; WOMEN; COMMUNITY; NETWORK; IMPACT; LIST AB Online communication among patients and consumers through support groups, discussion boards, and knowledge resources is becoming more common. In this article, the summary of a workgroup discussion, we discuss key methods through which such web-based peer-to-peer communication may affect health promotion and disease prevention behavior (exchanges of information, emotional and instrumental support, and establishment of group norms and models). We also discuss several theoretical models for studying online peer communication, including social theory, health communication models, and health behavior models. Although online peer communication about health and disease is very common, research evaluating effects on health behaviors, mediators, and outcomes is still relatively sparse. We suggest that future research in this field should include formative evaluation and studies of effects on mediators of behavior change, behaviors, and outcomes. It also will be important to examine spontaneously emerging peer communication efforts to see how they can be integrated with theory-based efforts initiated by researchers. C1 [Ancker, Jessica S.] Columbia Univ, Dept Biomed Informat, New York, NY 10032 USA. [Carpenter, Kristen M.] Univ Calif Los Angeles, Los Angeles, CA USA. [Greene, Paul] Univ Arkansas Med Sci, Coll Publ Hlth, Little Rock, AR 72205 USA. [Hoffman, Randi] Mayo Clin, Rochester, NY USA. [Kukafka, Rita] Columbia Univ, New York, NY USA. [Marlow, Laura A. V.] UCL, London, England. [Prigerson, Holly G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Quillin, John M.] Virginia Commonwealth Univ, Richmond, VA USA. RP Ancker, JS (reprint author), Columbia Univ, Dept Biomed Informat, 622 W 168th St,VC5, New York, NY 10032 USA. EM jsa2002@columbia.edu RI Carpenter, Kristen/I-1569-2013; OI Marlow, Laura/0000-0003-1709-2397; Ancker, Jessica/0000-0002-3859-9130 FU NLM NIH HHS [LM007079, T15 LM007079] NR 37 TC 12 Z9 13 U1 0 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 J9 J HEALTH COMMUN JI J. Health Commun. PY 2009 VL 14 BP 38 EP 46 DI 10.1080/10810730902806760 PG 9 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 473YQ UT WOS:000268248900006 PM 19449267 ER PT J AU Eggly, SS Albrecht, TL Kelly, K Prigerson, HG Sheldon, LK Studts, J AF Eggly, Susan S. Albrecht, Terrance L. Kelly, Kimberly Prigerson, Holly G. Sheldon, Lisa Kennedy Studts, Jamie TI The Role of the Clinician in Cancer Clinical Communication SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID PATIENT-CENTERED COMMUNICATION; OF-LIFE CARE; PHYSICIANS COMMUNICATION; DECISION-MAKING; BREAST-CANCER; BAD-NEWS; CONSOLIDATION WORKSHOPS; PATIENTS PERCEPTIONS; RACIAL-DIFFERENCES; FOLLOW-UP AB Clinician communication is critical to positive outcomes for patients and families in most health contexts. Researchers have investigated areas such as defining and teaching effective communication and identifying specific outcomes that can be improved through more effective communication. In the area of cancer care, advances in detection and treatment require that clinicians develop new skills to adapt to the evolving needs of patients, families, and other members of the health care team. Some areas that require the attention of researchers are defining, assessing, and teaching effective communication in the context of the specific desires and preferences of individual patients and special populations; and meeting the needs of patients across the cancer continuum from screening, diagnosis, treatment to palliative care and survivorship. This report highlights three areas of research in cancer clinician communication including key areas of current and emerging research and theories and approaches for future research. C1 [Eggly, Susan S.; Albrecht, Terrance L.] Wayne State Univ, Karmanos Canc Inst, Sch Med, Detroit, MI 48201 USA. [Kelly, Kimberly] Ohio State Univ, Columbus, OH 43210 USA. [Prigerson, Holly G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sheldon, Lisa Kennedy] St Joseph Hosp, Nashua, NH USA. [Studts, Jamie] Univ Kentucky, Coll Med, Lexington, KY USA. RP Eggly, SS (reprint author), Wayne State Univ, Karmanos Canc Inst, Sch Med, 4100 John R St, Detroit, MI 48201 USA. EM eggly@karmanos.org OI Sheldon, Lisa Kennedy/0000-0002-5958-8529; Eggly, Susan/0000-0002-8137-6098 NR 61 TC 4 Z9 4 U1 0 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 J9 J HEALTH COMMUN JI J. Health Commun. PY 2009 VL 14 BP 66 EP 75 DI 10.1080/10810730902806778 PG 10 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 473YQ UT WOS:000268248900009 PM 19449270 ER PT J AU Trice, ED Prigerson, HG AF Trice, Elizabeth D. Prigerson, Holly G. TI Communication in End-Stage Cancer: Review of the Literature and Future Research SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID DOCTOR-PATIENT COMMUNICATION; TERMINALLY-ILL PATIENTS; LIFE DECISION-MAKING; BLACK-AND-WHITE; TREATMENT PREFERENCES; PHYSICIAN COMMUNICATION; POOR COMMUNICATION; RACIAL-DIFFERENCES; INFORMATION NEEDS; HEALTH-SERVICES AB Concerns have been raised about the quality of life and health care received by cancer patients at the end of life (EOL). Many patients die with pain and other distressing symptoms inadequately controlled, receiving burdensome, aggressive care that worsens quality of life and limits patient exposure to palliative care, such as hospice. Patient-physician communication is likely a very important determinate of EOL care. Discussions of EOL with physicians are associated with an increased likelihood of the following (1) acknowledgment of terminal illness, (2) preferences for comfort care over life extension, and (3) receipt of less intensive, life-prolonging and more palliative EOL care; while this appears to hold for White patients, it is less clear for Black, advanced cancer patients. These results highlight the importance Of communication in determining EOL cancer care and suggest that communication disparities may contribute to Black-While differences in EOL care. We review the pertinent literature and discuss areas for future research. C1 [Trice, Elizabeth D.; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, Boston, MA 02114 USA. [Trice, Elizabeth D.; Prigerson, Holly G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02114 USA. [Prigerson, Holly G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Prigerson, Holly G.] Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA. RP Trice, ED (reprint author), Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, 44 Binney St,Suite G530E, Boston, MA 02114 USA. EM etrice@partners.org FU NCI NIH HHS [CA 106370, P30 CA006516, P30CA06516-43, R01 CA106370, T32 CA009172, U56 CA118641, U56CA118641]; NIMH NIH HHS [MH63892, R01 MH063892] NR 82 TC 28 Z9 29 U1 6 U2 17 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 J9 J HEALTH COMMUN JI J. Health Commun. PY 2009 VL 14 BP 95 EP 108 DI 10.1080/10810730902806786 PG 14 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 473YQ UT WOS:000268248900012 PM 19449273 ER PT J AU Primack, BA Sidani, J Carroll, MV Fine, MJ AF Primack, Brian A. Sidani, Jaime Carroll, Mary V. Fine, Michael J. TI Associations Between Smoking and Media Literacy in College Students SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID FLORIDA TRUTH CAMPAIGN; ADOLESCENT SMOKING; TOBACCO USE; UNITED-STATES; CIGARETTE USE; NORMATIVE BELIEFS; RESPONSE RATES; PUBLIC-HEALTH; YOUTH SMOKING; PAPER SURVEYS AB Organizations recommend media literacy to reduce tobacco use, and higher media literacy has been associated with lower smoking among high school students. The relationship between smoking media literacy and tobacco use, however, has not been systematically studied among college students. The purpose of this study was to determine the association between smoking and smoking media literacy among college students. We conducted the National College Health Assessment (NCHA) at a large, urban university, adding six items measuring smoking media literacy. A total of 657 students responded to this random sample e-mail survey. We used multiple logistic regression to determine independent associations between smoking media literacy items and current smoking. The media literacy scale was internally consistent (=0.79). Of the respondents, 21.5% reported smoking cigarettes over the past 30 days. In a fully adjusted multivariate model, participants with medium media literacy had an odds ratio (OR) for current smoking of 0.45 (95% CI=0.29, 0.70), and those with high media literacy had an OR for current smoking of 0.38 (95% CI=0.20, 0.70). High smoking media literacy is independently associated with lower odds of smoking. Smoking media literacy may be a valuable construct to address in college populations. C1 [Primack, Brian A.] Univ Pittsburgh, Dept Med, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Primack, Brian A.] Univ Pittsburgh, Dept Pediat, Sch Med, Pittsburgh, PA 15213 USA. [Sidani, Jaime] Univ Pittsburgh, Student Hlth Serv, Pittsburgh, PA 15213 USA. [Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Sch Med, Pittsburgh, PA 15213 USA. [Fine, Michael J.] VA Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Primack, BA (reprint author), Univ Pittsburgh, Dept Med, Sch Med, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu FU NCI NIH HHS [K07 CA114315-03, K07 CA114315] NR 62 TC 17 Z9 17 U1 2 U2 14 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 J9 J HEALTH COMMUN JI J. Health Commun. PY 2009 VL 14 IS 6 BP 541 EP 555 AR PII 914457135 DI 10.1080/10810730903089598 PG 15 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 490YL UT WOS:000269543900004 PM 19731126 ER PT J AU Mathurin, P O'Grady, J Carithers, RL Phillips, M Ramond, MJ Louvet, A Castel, H Naveau, S Morgan, T Maddrey, WC Mendenhall, CL AF Mathurin, P. O'Grady, J. Carithers, R. L. Phillips, M. Ramond, M. -J. Louvet, A. Castel, H. Naveau, S. Morgan, T. Maddrey, W. C. Mendenhall, C. L. TI CORTICOSTEROIDS IMPROVE 28-DAY SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS: INDIVIDUAL DATA ANALYSIS OF THE LAST 5 RANDOMIZED CONTROLLED TRIALS SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 22-26, 2009 CL Copenhagen, DENMARK SP European Assoc Study Liver C1 [Mathurin, P.; Louvet, A.; Castel, H.] Chru Lille, Serv Malad Appareil Digestif, Lille, France. [O'Grady, J.; Phillips, M.] Kings Coll London, Inst Liver Studies, Sch Med, London WC2R 2LS, England. [Carithers, R. L.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA USA. [Ramond, M. -J.] Hop Beaujon, Serv Hepatol, Clichy, France. [Naveau, S.] Hop Antoine Beclere, Serv Hepatogastroenterol, F-92141 Clamart, France. [Morgan, T.] VA Med Ctr, Gastroenterol Sect, Long Beach, CA USA. [Maddrey, W. C.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [Mendenhall, C. L.] Univ Cincinnati, Med Ctr, Dept Vet Affairs, Cincinnati, OH 45267 USA. [Mendenhall, C. L.] Univ Cincinnati, Med Ctr, Dept Med, Cincinnati, OH 45267 USA. EM castel_h@hotmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2009 VL 50 MA 201 BP S82 EP S83 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 450EV UT WOS:000266384700202 ER PT J AU Moro, N Gassler, N Nevzorova, YA Sicinski, P Trautwein, C Liedtke, C AF Moro, N. Gassler, N. Nevzorova, Y. A. Sicinski, P. Trautwein, C. Liedtke, C. TI INACTIVATION OF CYCLIN E1 INHIBITS CHEMICAL HEPATOCARCINOGENESIS IN MICE SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 22-26, 2009 CL Copenhagen, DENMARK SP European Assoc Study Liver C1 [Moro, N.; Nevzorova, Y. A.; Trautwein, C.; Liedtke, C.] Univ Hosp Aachen, Dept Med 3, Aachen, Germany. [Gassler, N.] Univ Hosp Aachen, Inst Pathol, Aachen, Germany. [Sicinski, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. EM nmoro@ukaachen.de NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2009 VL 50 MA 112 BP S46 EP S46 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 450EV UT WOS:000266384700113 ER PT J AU Carley, WK AF Carley, Willie K. TI Far from Home: Deficiencies in Federal Disaster Housing Assistance after Hurricanes Katrina and Rita and Recommendations for Improvement SO JOURNAL OF HOMELAND SECURITY AND EMERGENCY MANAGEMENT LA English DT Book Review C1 James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Carley, WK (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. NR 2 TC 0 Z9 0 U1 0 U2 3 PU BERKELEY ELECTRONIC PRESS PI BERKELEY PA 2809 TELEGRAPH AVENUE, STE 202, BERKELEY, CA 94705 USA SN 1547-7355 J9 J HOMEL SECUR EMERG JI J. Homel. Secur. Emerg. Manag. PY 2009 VL 6 IS 1 AR 52 PG 5 WC Public Administration SC Public Administration GA 478MG UT WOS:000268591800008 ER PT J AU Campbell, ML Happ, MB Hultman, T Kirchhoff, KT Mahon, MM Mayo, MM McMillan, S Raudonis, B AF Campbell, Margaret L. Happ, Mary Beth Hultman, Todd Kirchhoff, Karin T. Mahon, Margaret M. Mayo, M. Murray McMillan, Susan Raudonis, Barbara TI The HPNA Research Agenda for 2009-2012 SO JOURNAL OF HOSPICE & PALLIATIVE NURSING LA English DT Article DE HPNA; research; research agenda ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; OPIOID-INDUCED CONSTIPATION; CANCER-RELATED FATIGUE; RESPIRATORY-DISTRESS; PALLIATIVE CARE; SYMPTOM PREVALENCE; RELEASE OXYCODONE; ASPHYXIAL THREAT; POSTURAL RELIEF AB The research committee of the Hospice and Palliative Nurses Association engaged in an iterative process to develop a research agenda for the association that is expected to provide a focus for graduate students and junior and senior researchers and guide our organization's research funding. In addition, this agenda will illustrate to stakeholders the importance of these research foci. The focus of this article is twofold: to describe the process for developing the agenda and describe the agenda itself with rationale for the foci. C1 [Campbell, Margaret L.] Wayne State Univ, Coll Nursing, Ctr Hlth Res, Detroit, MI 48202 USA. [Happ, Mary Beth] Univ Pittsburgh, Ctr Bioeth & Hlth Law, Sch Nursing, Pittsburgh, PA 15260 USA. [Hultman, Todd] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kirchhoff, Karin T.] Univ Wisconsin Madison, Sch Nursing, Madison, WI USA. [Mahon, Margaret M.] George Mason Univ, Coll Hlth & Human Serv, Sch Nursing, Fairfax, VA 22030 USA. [Mayo, M. Murray] Ursuline Coll, Breen Sch Nursing, Pepper Pike, OH USA. [McMillan, Susan] Univ S Florida, Coll Nursing, Tampa, FL USA. [Raudonis, Barbara] Univ Texas Arlington, Sch Nursing, Arlington, TX USA. RP Campbell, ML (reprint author), Wayne State Univ, Coll Nursing, Ctr Hlth Res, 5557 Cass Ave, Detroit, MI 48202 USA. EM m.campbell@wayne.edu OI Campbell, Margaret/0000-0003-4517-690X NR 73 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1522-2179 J9 J HOSP PALLIAT NURS JI J. Hosp. Palliat. Nurs. PD JAN-FEB PY 2009 VL 11 IS 1 BP 10 EP 18 PG 9 WC Nursing SC Nursing GA 544CK UT WOS:000273629500003 ER PT J AU Ginde, AA Savaser, DJ Camargo, CA AF Ginde, Adit A. Savaser, Davut J. Camargo, Carlos A., Jr. TI Limited Communication and Management of Emergency Department Hyperglycemia in Hospitalized Patients SO Journal of Hospital Medicine LA English DT Article DE communication; diabetes; emergency medicine; hyperglycemia; public health ID COMMUNITY-ACQUIRED PNEUMONIA; MYOCARDIAL-INFARCTION; MORTALITY; RISK; ASSOCIATION; DEATH AB BACKGROUND: Hyperglycemia is often overlooked and unaddressed in hospitalized patients, and early and intensive management may improve outcomes. OBJECTIVE: To evaluate communication and early management of emergency department (ED) hyperglycemia. METHODS: This was a retrospective cohort study of patients with an initial serum glucose >= 140 mg/dL at an urban, academic institution. We randomly selected cases from a consecutive sample of ED visits with at least I serum glucose result during a 1-year period. We recorded clinical data and compared the content of inpatient and ED-written discharge instructions. RESULTS: Of the 27,688 initial ED glucose results during the study period, 3517 (13%) were 140-199 mg/dL, and 2304 (8%) values were >= 200 mg/dL. In our sample of 385 patients, 293 (76%) patients were hospitalized. Inpatient or ED discharge instructions informed 36 (10%) patients of their hyperglycemia and 23 (6%) of a plan for further evaluation and management. There was no difference between inpatient and ED instructions for either of these variables (P = 0.73 and 0.16, respectively). Overall, 107 (55%) patients with glucose values 140-199 mg/dL and 31 (16%) patients with glucose >= 200 mg/dL had no prior diabetes diagnosis. Only 61 (16%) received insulin in the ED for their hyperglycemia, and hyperglycemia was charted as a diagnosis in 36 (9%) cases. CONCLUSIONS: Most ED patients with even mild hyperglycemia were hospitalized. Recognition, Communication, and management of ED hyperglycemia were suboptimal and represent a missed opportunity to identify undiagnosed diabetes and to initiate early glycemic control for hospitalized patients. Journal of Hospital Medicine 2009;4:45-49. (c) 2009 Society of Hospital Medicine. C1 [Ginde, Adit A.] Univ Colorado, Denver Sch Med, Dept Emergency Med, Aurora, CO 80045 USA. [Ginde, Adit A.] Beth Israel Deaconess Med Ctr, Med Ctr, Dept Emergency Med, Boston, MA 02215 USA. [Savaser, Davut J.] Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY USA. [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Ginde, AA (reprint author), Univ Colorado, Denver Sch Med, Dept Emergency Med, 12401 E 17th Ave,B-215, Aurora, CO 80045 USA. EM adit.ginde@ucdenver.edu RI Siry, Bonnie/D-7189-2017 FU Emergency Medicine Foundation Research FX A.A.G. was supported by an Emergency Medicine Foundation Research Fellowship grant (Dallas, TX). NR 18 TC 6 Z9 6 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2009 VL 4 IS 1 BP 45 EP 49 DI 10.1002/jhm.400 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 395XP UT WOS:000262557100006 PM 19140193 ER PT J AU Chauhan, SK Saban, DR Lee, HK Dana, R AF Chauhan, Sunil K. Saban, Daniel R. Lee, Hyung K. Dana, Reza TI Levels of Foxp3 in Regulatory T Cells Reflect Their Functional Status in Transplantation SO JOURNAL OF IMMUNOLOGY LA English DT Article ID RENAL-ALLOGRAFTS; ACUTE REJECTION; EXPRESSION; TOLERANCE; DONOR AB Foxp3 expressing CD4(+)CD25(+) regulatory T cells (Tregs) have been shown to prevent allograft rejection in clinical and animal models of transplantation. However, the role of Foxp3 in regulating Treg function, and the kinetics and mechanism of action of Tregs in inducing allograft tolerance in transplantation, are still not fully understood. Thus, we investigated the kinetics and function of Tregs in a mouse model of orthotopic corneal transplantation, the most common form of tissue grafting worldwide. In this study, using in vitro functional assays and in vivo Treg adoptive transfer assays, we show that far more relevant than Treg frequency is their level of Foxp3 expression, which is directly associated with the potential of Tregs to prevent allograft rejection by producing regulatory cytokines and suppressing effector T cell activation. In addition, our data clearly demonstrate that Tregs primarily suppress the induction of alloimmunity in regional draining lymph nodes rather than suppressing the effector phase of the immune response in the periphery. These findings provide new insights on Treg dynamics in transplantation, which are crucial for designing therapeutic strategies to modulate Treg function and to optimize Treg-based cell therapies for clinical translation. The Journal of Immunology, 2009, 182: 148-153. C1 [Chauhan, Sunil K.; Saban, Daniel R.; Lee, Hyung K.; Dana, Reza] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA. [Dana, Reza] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. RP Dana, R (reprint author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM reza.dana@schepens.harvard.edu FU National Institutes of Health [NEI R01-12963]; Eye Bank Association of America FX This work was supported by National Institutes of Health (NEI R01-12963) and the Eye Bank Association of America. NR 25 TC 112 Z9 117 U1 1 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2009 VL 182 IS 1 BP 148 EP 153 PG 6 WC Immunology SC Immunology GA 388YU UT WOS:000262057200022 PM 19109145 ER PT J AU Camargo, JF Quinones, MP Mummidi, S Srinivas, S Gaitan, AA Begum, K Jimenez, F VanCompernolle, S Unutmaz, D Ahuja, SS Ahuja, SK AF Camargo, Jose F. Quinones, Marlon P. Mummidi, Srinivas Srinivas, Sowmya Gaitan, Alvaro A. Begum, Kazi Jimenez, Fabio VanCompernolle, Scott Unutmaz, Derya Ahuja, Seema S. Ahuja, Sunil K. TI CCR5 Expression Levels Influence NFAT Translocation, IL-2 Production, and Subsequent Signaling Events during T Lymphocyte Activation SO JOURNAL OF IMMUNOLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CCR5; CELL-MEDIATED-IMMUNITY; BETA-CHEMOKINES; HIV-1 INFECTION; CHEMOTACTIC RESPONSIVENESS; RHEUMATOID-ARTHRITIS; ALLOGRAFT-REJECTION; AIDS PATHOGENESIS; KAWASAKI-DISEASE AB Ligands of CCR5, the major coreceptor of HIV-1, costimulate T lymphocyte activation. However, the full impact of CCR5 expression on T cell responses remains unknown. Here, we show that compared with CCR5(+/+), T cells from CCR5(-/-) mice secrete lower amounts of IL-2, and a similar phenotype is observed in humans who lack CCR5 expression (CCR5-Delta 32/Delta 32 homozygotes) as well as after Ab-mediated blockade of CCR5 in human T cells genetically intact for CCR5 expression. Conversely, overexpression of CCR5 in human T cells results in enhanced IL-2 production. CCR5 surface levels correlate positively with IL-2 protein and mRNA abundance, suggesting that CCR5 affects IL-2 gene regulation. Signaling via CCR5 resulted in NFAT transactivation in T cells that was blocked by Abs against CCR5 agonists, suggesting a link between CCR5 and downstream pathways that influence IL-2 expression. Furthermore, murine T cells lacking CCR5 had reduced levels of intranuclear NFAT following activation. Accordingly, CCR5 expression also promoted IL-2-dependent events, including CD25 expression, STAT5 phosphorylation, and T cell proliferation. We therefore suggest that by influencing a NFAT-mediated pathway that regulates IL-2 production and IL-2-dependent events, CCR5 may play a critical role in T cell responses. In accord with our prior inferences from genetic-epidemiologic studies, such CCR5-dependent responses might constitute a viral entry-independent mechanism by which CCR5 may influence HIV-AIDS pathogenesis. The Journal of Immunology, 2009, 182: 171-182. C1 [Camargo, Jose F.; Quinones, Marlon P.; Mummidi, Srinivas; Srinivas, Sowmya; Gaitan, Alvaro A.; Begum, Kazi; Jimenez, Fabio; Ahuja, Seema S.; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Camargo, Jose F.; Quinones, Marlon P.; Mummidi, Srinivas; Srinivas, Sowmya; Gaitan, Alvaro A.; Begum, Kazi; Jimenez, Fabio; Ahuja, Seema S.; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV1 Infect, San Antonio, TX USA. [Quinones, Marlon P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Quinones, Marlon P.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Bipolar Illness Intervent Hispan Communities, San Antonio, TX 78229 USA. [VanCompernolle, Scott] Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37201 USA. [Unutmaz, Derya] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA. NYU, Sch Med, Dept Pathol, New York, NY 10016 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Immunol, San Antonio, TX 78229 USA. [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. RP Ahuja, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,Room 5-009R, San Antonio, TX 78229 USA. EM ahujas@uthscsa.edu RI Mummidi, Srinivas/C-1004-2008 OI Mummidi, Srinivas/0000-0002-4068-6380 FU National Institutes of Health [R37046326, AI043279, MH069270, RO1-A149131]; Department of Veterans Affairs; Elizabeth Glaser Scientist Burroughs Wellcome Clinical Scientist; Stanley Research Foundation; Young Investigator NARSAD FX This work was supported by the Veterans Administration Center on AIDS and HIV infection of the South Texas Veterans Health Care System, a MERIT (R37046326) and other awards (AI043279 and MH069270) from the National Institutes of Health to S.K.A., and separate Merit Review grants from the Department of Veterans Affairs to S.K.A., S.S.A., and S.M. This work was also supported by a National Institutes of Health grant to D.U. (RO1-A149131). S.K.A. is a recipient of the Elizabeth Glaser Scientist Award and the Burroughs Wellcome Clinical Scientist Award in Translational Research. M.P.Q. acknowledges support by the Stanley Research Foundation and a Young Investigator NARSAD award. NR 90 TC 48 Z9 50 U1 2 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2009 VL 182 IS 1 BP 171 EP 182 PG 12 WC Immunology SC Immunology GA 388YU UT WOS:000262057200025 PM 19109148 ER PT J AU Babbe, H McMenamin, J Hobeika, E Wang, J Rodig, SJ Reth, M Leder, P AF Babbe, Holger McMenamin, Jennifer Hobeika, Elias Wang, Jing Rodig, Scott J. Reth, Michael Leder, Philip TI Genomic Instability Resulting from Blm Deficiency Compromises Development, Maintenance, and Function of the B Cell Lineage SO JOURNAL OF IMMUNOLOGY LA English DT Article ID CLASS-SWITCH RECOMBINATION; BLOOMS-SYNDROME HELICASE; SYNDROME GENE-PRODUCT; MOUSE BONE-MARROW; HOMOLOGOUS RECOMBINATION; RECQ HELICASES; ATAXIA-TELANGIECTASIA; REPLICATION FORKS; DNA-REPAIR; G4 DNA AB The RecQ family helicase BLM is critically involved in the maintenance of genomic stability, and BLM mutation causes the heritable disorder Bloom's syndrome. Affected individuals suffer from a predisposition to a multitude of cancer types and an ill-defined immunodeficiency involving low serum Ab titers. To investigate its role in B cell biology, we inactivated murine Blm specifically in B lymphocytes in vivo. Numbers of developing B lymphoid cells in the bone marrow and mature B cells in the periphery were drastically reduced upon Blm inactivation. Of the major peripheral B cell subsets, Bla cells were most prominently affected. In the sera of Blm-deficient naive mice, concentrations of all Ig isotypes were low, particularly IgG3. Specific IgG Ab responses upon immunization were poor and mutant B cells exhibited a generally reduced Ab class switch capacity in vitro. We did not find evidence for a crucial role of Blm in the mechanism of class switch recombination. However, a modest shift toward microhomology-mediated switch junction formation was observed in Blm-deficient B cells. Finally, a cohort of p53-deficient, conditional Blm knockout mice revealed an increased propensity for B cell lymphoma development. Impaired cell cycle progression and survival as well as high rates of chromosomal structural abnormalities in mutant B cell blasts were identified as the basis for the observed effects. Collectively, our data highlight the importance of BLM-dependent genome surveillance for B cell immunity by ensuring proper development and function of the various B cell subsets while counteracting lymphomagenesis. The Journal of Immunology, 2009, 182: 347-360. C1 [Babbe, Holger; McMenamin, Jennifer; Leder, Philip] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Hobeika, Elias; Reth, Michael] Univ Freiburg, Fac Biol, Max Planck Inst Immunbiol, Freiburg, Germany. [Hobeika, Elias; Reth, Michael] Univ Freiburg, Fac Biol, Ctr Biol Signalling Studies, Freiburg, Germany. [Wang, Jing] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA. [Rodig, Scott J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Babbe, H (reprint author), Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA. EM hbabbe@genetics.med.harvard.edu FU Deutsche Forschungsgemeinschaft [SFB620, Teilprojekt 135]; National Institutes of Health FX This work was supported in part by the Deutsche Forschungsgemeinschaft (SFB620, Teilprojekt 135) to M.R. and grants from the National Institutes of Health (to J.W.). NR 73 TC 11 Z9 11 U1 1 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2009 VL 182 IS 1 BP 347 EP 360 PG 14 WC Immunology SC Immunology GA 388YU UT WOS:000262057200043 PM 19109166 ER PT J AU Mayoral, RJ Pipkin, ME Pachkov, M van Nimwegen, E Rao, A Monticelli, S AF Mayoral, Ramon J. Pipkin, Matthew E. Pachkov, Mikhail van Nimwegen, Erik Rao, Anjana Monticelli, Silvia TI MicroRNA-221-222 Regulate the Cell Cycle in Mast Cells SO JOURNAL OF IMMUNOLOGY LA English DT Article ID ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR GATA-2; NF-KAPPA-B; IMMUNE-RESPONSES; MICE LACKING; GENOMIC DNA; DIFFERENTIATION; EXPRESSION; MICRORNAS; PROTEIN AB MicroRNAs (miRNAs) constitute a large family of small noncoding RNAs that have emerged as key posttranscriptional regulators in a wide variety of organisms. Because any one miRNA can potentially regulate expression of a distinct set of genes, differential miRNA expression can shape the repertoire of proteins that are actually expressed during development and differentiation or disease. Here, we have used mast cells as a model to investigate the role of miRNAs in differentiated innate immune cells and found that miR-221-222 are significantly up-regulated upon mast cell activation. Using both bioinformatics and experimental approaches, we identified some signaling pathways, transcription factors, and potential cis-regulatory regions that control MiR-221-222 transcription. Overexpression of miR-221-222 in a model mast cell line perturbed cell morphology and cell cycle regulation without altering viability. While in stimulated cells miR-221-222 partially counteracted expression of the cell-cycle inhibitor p27(kip1), we found that in the mouse alternative splicing results in two p27(kip1) mRNA isoforms that differ in their 3' untranslated region, only one of which is subject to miR-221-222 regulation. Additionally, transgenic expression of miR-221-222 from bacterial artificial chromosome clones in embryonic stem cells dramatically reduced cell proliferation and severely impaired their accumulation. Our study provides further insights on miR-221-222 transcriptional regulation as well as evidences that miR-221-222 regulate cell cycle checkpoints in mast cells in response to acute activation stimuli. The Journal of Immunology, 2009, 182: 433-445. C1 [Mayoral, Ramon J.; Monticelli, Silvia] Inst Res Biomed, CH-6500 Bellinzona, Switzerland. [Pipkin, Matthew E.; Rao, Anjana] Immune Dis Inst, Boston, MA 02115 USA. [Pipkin, Matthew E.; Rao, Anjana] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Pachkov, Mikhail; van Nimwegen, Erik] Univ Basel, Biozentrum, Basel, Switzerland. RP Monticelli, S (reprint author), Inst Res Biomed, Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland. EM silvia.monticelli@irb.unisi.ch FU Institute for Research in Biomedicine Foundation; National Institutes of Health [AI44432, AI070788]; National Cancer Institute [F32 CA 126247-01]; Ceresio Foundation; San Raffaele "Vita e Salute" University FX This work was supported by a start-up grant from the Institute for Research in Biomedicine Foundation to S.M. and National Institutes of Health Grants AI44432 and AI070788 to A.R. M.E.P. is supported by a fellowship from the National Cancer Institute F32 CA 126247-01. R.J.M. was temporarily supported by a fellowship from the Ceresio Foundation and is now a recipient of a San Raffaele "Vita e Salute" University predoctoral fellowship. NR 55 TC 53 Z9 60 U1 1 U2 4 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2009 VL 182 IS 1 BP 433 EP 445 PG 13 WC Immunology SC Immunology GA 388YU UT WOS:000262057200052 PM 19109175 ER PT J AU Liu, YJ Yuan, YZ Li, YH Zhang, J Xiao, GZ Vodovotz, Y Billiar, TR Wilson, MA Fan, J AF Liu, Yujian Yuan, Youzhong Li, Yuehua Zhang, Jian Xiao, Guozhi Vodovotz, Yoram Billiar, Timothy R. Wilson, Mark A. Fan, Jie TI Interacting Neuroendocrine and Innate and Acquired Immune Pathways Regulate Neutrophil Mobilization from Bone Marrow following Hemorrhagic Shock SO JOURNAL OF IMMUNOLOGY LA English DT Article ID COLONY-STIMULATING FACTOR; MOBILITY GROUP BOX-1; NF-KAPPA-B; KLEBSIELLA-PNEUMONIAE INFECTION; MEDIATES HEPATIC-INJURY; TOLL-LIKE RECEPTOR-2; ACUTE LUNG INJURY; CUTTING EDGE; INFLAMMATORY RESPONSE; ISCHEMIA-REPERFUSION AB Polymorphonuclear neutrophils (PMN) are critical innate immune effector cells that either protect the host or exacerbate organ dysfunction by migrating to injured or inflamed tissues. Resuscitated hemorrhagic shock following major trauma promotes the development of organ inflammation by priming PMN migration and activation in response to a second, often trivial, stimulus (a so-called "two hit" phenomenon). PMN mobilization from bone marrow supports a sustained, hemorrhagic shock/resuscitation (HS/R)-primed migration of PMN. We addressed the role and mechanism of HS/R in regulating PMN egress from bone marrow. We demonstrate that HS/R through the alarmin HMGB1 induces IL-23 secretion from macrophages in an autocrine and TLR4 signaling-dependent manner. In turn IL-23, through an IL-17 G-CSF-mediated mechanism, induces PMN egress from bone marrow. We also show that beta-adrenergic receptor activation by catecholamine of macrophages mediates the HS/R-induced release of HMGB1. These data indicate that HS/R, a global ischemia/reperfusion stimulus, regulates PMN mobilization through a series of interacting pathways that include neuroendocrine and innate and acquired immune systems. Blocking this novel signaling axis may present a novel therapeutic target for posttrauma inflammation. The Journal of Immunology, 2009, 182: 572-580. C1 [Liu, Yujian; Yuan, Youzhong; Li, Yuehua; Vodovotz, Yoram; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Dept Surg, Sch Med, Pittsburgh, PA 15260 USA. [Zhang, Jian; Xiao, Guozhi] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15260 USA. [Wilson, Mark A.; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. RP Fan, J (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Bldg 1,Room 2W109 151L-U,Univ Dr C, Pittsburgh, PA 15240 USA. EM jif7@pitt.edu FU National Institutes of Health [R01-HL-079669, P50-GM-53799]; Veterans Affairs Merit Award FX This work was supported by Grant R01-HL-079669 from the National Institutes of Health (to IT.), by Grant P50-GM-53799 from the National Institutes of Health Center (to T.R.B. and Y.V.), and by a Veterans Affairs Merit Award (to IT.). NR 70 TC 25 Z9 27 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2009 VL 182 IS 1 BP 572 EP 580 PG 9 WC Immunology SC Immunology GA 388YU UT WOS:000262057200067 PM 19109190 ER PT J AU Medoff, BD Seung, E Hong, S Thomas, SY Sandall, BP Duffield, JS Kuperman, DA Erle, DJ Luster, AD AF Medoff, Benjamin D. Seung, Edward Hong, Sandra Thomas, Seddon Y. Sandall, Barry P. Duffield, Jeremy S. Kuperman, Douglas A. Erle, David J. Luster, Andrew D. TI CD11b(+) Myeloid Cells Are the Key Mediators of Th2 Cell Homing into the Airway in Allergic Inflammation SO JOURNAL OF IMMUNOLOGY LA English DT Article ID ACTIVATION-REGULATED CHEMOKINE; THYMIC STROMAL LYMPHOPOIETIN; EPITHELIAL-CELLS; LUNG INFLAMMATION; DENDRITIC CELL; EXPERIMENTAL ASTHMA; EOTAXIN EXPRESSION; SIGNAL TRANSDUCER; MUCUS PRODUCTION; TYPE-2 IMMUNITY AB STAT6-mediated chemokine production in the lung is required for Th2 lymphocyte and eosinophil homing into the airways in allergic pulmonary inflammation, and thus is a potential therapeutic target in asthma. However, the critical cellular source of STAT6-mediated chemokine production has not been defined. In this study, we demonstrate that STAT6 in bone marrow-derived myeloid cells was sufficient for the production of CCL17, CCL22, CCL11, and CCL24 and for Th2 lymphocyte and eosinophil recruitment into the allergic airway. In contrast, STAT6 in airway-lining cells did not mediate chemokine production or support cellular recruitment. Selective depletion of CD11b(+) myeloid cells in the lung identified these cells as the critical cellular source for the chemokines CCL17 and CCL22. These data reveal that CD11b(+) myeloid cells in the lung help orchestrate the adaptive immune response in asthma, in part, through the production of STAT6-inducible chemokines and the recruitment of Th2 lymphocytes into the airway. The Journal of Immunology, 2009, 182: 623-635. C1 [Medoff, Benjamin D.; Seung, Edward; Hong, Sandra; Thomas, Seddon Y.; Sandall, Barry P.; Luster, Andrew D.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Charlestown, MA 02129 USA. [Medoff, Benjamin D.; Seung, Edward; Hong, Sandra; Thomas, Seddon Y.; Sandall, Barry P.; Luster, Andrew D.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Medoff, Benjamin D.; Sandall, Barry P.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Medoff, Benjamin D.; Sandall, Barry P.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Duffield, Jeremy S.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. [Duffield, Jeremy S.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Duffield, Jeremy S.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Kuperman, Douglas A.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA. [Erle, David J.] Univ Calif San Francisco, Lung Biol Ctr, Dept Med, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [Erle, David J.] Univ Calif San Francisco, Program Immunol, San Francisco, CA 94143 USA. RP Luster, AD (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, CNY 8301,149 13th St, Charlestown, MA 02129 USA. EM aluster@mgh.harvard.edu OI Thomas, Seddon/0000-0003-0075-0744 FU National Institutes of Health [K08 HL072775, R37 AI40618] FX This work was supported by National Institutes of Health Grants K08 HL072775 (to B.D.M.) and R37 AI40618 (to A.D.L.). NR 66 TC 49 Z9 49 U1 1 U2 2 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2009 VL 182 IS 1 BP 623 EP 635 PG 13 WC Immunology SC Immunology GA 388YU UT WOS:000262057200073 PM 19109196 ER PT J AU Jukkola-Vuorinen, A Rahko, E Vuopala, KS Desmond, R Lehenkari, PP Harris, KW Selander, KS AF Jukkola-Vuorinen, Arja Rahko, Eeva Vuopala, Katri S. Desmond, Renee Lehenkari, Petri P. Harris, Kevin W. Selander, Katri S. TI Toll-Like Receptor-9 Expression Is Inversely Correlated with Estrogen Receptor Status in Breast Cancer SO JOURNAL OF INNATE IMMUNITY LA English DT Article DE Breast cancer; Estrogen receptor; Toll-like receptor 9 ID PROSTATIC INTRAEPITHELIAL NEOPLASIA; PLASMACYTOID DENDRITIC CELLS; IFN-ALPHA PRODUCTION; SUBCELLULAR-LOCALIZATION; HELICOBACTER-PYLORI; EPITHELIAL-CELLS; SELF-DNA; TLR9; RECOGNITION; AGONISTS AB Toll-like receptor 9 (TLR9) recognizes microbial and vertebrate DNA. We previously demonstrated TLR9 expression in human breast cancer cell lines and showed that TLR9 ligands stimulate their in vitro invasion. The aim of this study was to characterize TLR9 expression in clinical breast cancer specimens. Immunohistochemical staining intensity was compared with known baseline prognostic factors and distant metastasis-free survival. TLR9 expression was detected in 98% of the tumors studied (n = 141). The mean TLR9 staining intensity was higher in ER- than in the highly ER+ breast cancers (p = 0.039). High-grade tumors had significantly increased TLR9 expression (p = 0.027) compared with lower-grade tumors. The highest TLR9 expression was detected in the mucinous and the lowest in the tubular breast cancers (p = 0.034). Distant metastasis-free survival was higher in the lower TLR9-expressing half of the cohort than in the higher TLR9-expressing group (p = 0.118). TLR9 expression did not correlate with menopausal, PgR or Her2 status, patient age, tumor proliferative or invasive characteristics. Copyright (C) 2008 S. Karger AG, Basel C1 [Harris, Kevin W.; Selander, Katri S.] Univ Alabama, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. [Jukkola-Vuorinen, Arja; Rahko, Eeva] Univ Hosp Oulu, Dept Oncol, Oulu, Finland. [Lehenkari, Petri P.] Univ Hosp Oulu, Dept Surg, Oulu, Finland. [Vuopala, Katri S.] Lapland Cent Hosp, Dept Pathol, Rovaniemi, Finland. [Desmond, Renee] Univ Alabama, Biostat & Bioinformat Unit, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Harris, Kevin W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Selander, KS (reprint author), Univ Alabama, Dept Med, Div Hematol Oncol, WT1 T558,1824 6th Ave S, Birmingham, AL 35294 USA. EM Katri.Selander@ccc.uab.edu RI Lehenkari, Petri/O-3009-2016 OI Lehenkari, Petri/0000-0002-0055-5183 FU Northern Finnish Duodecim Foundation; Finnish Cancer Foundation; Comprehensive Cancer Center at the University of Alabama at Birmingham FX The authors Wish to thank Kari Mononen (RN) and Markku Yli-Pyky (RN) at the Department of Oncology, University Hospital of Oulu, and Paivi Sortti (RN) and Taru Kahkonen (RN) at the Department of Pathology, Lapland Central Hospital, Rovaniemi, Finland, for skillful technical assistance. This study was funded by grants from the Northern Finnish Duodecim Foundation ( T-V.), the Finnish Cancer Foundation (K.S.S.) and the Comprehensive Cancer Center at the University of Alabama at Birmingham (K.S.S.). NR 43 TC 15 Z9 18 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1662-811X J9 J INNATE IMMUN JI J. Innate Immun. PY 2009 VL 1 IS 1 BP 59 EP 68 DI 10.1159/000151602 PG 10 WC Immunology SC Immunology GA 471AS UT WOS:000268024800006 PM 20375566 ER PT J AU Wang, LJ Cherayil, BJ AF Wang, Lijian Cherayil, Bobby J. TI Ironing Out the Wrinkles in Host Defense: Interactions between Iron Homeostasis and Innate Immunity SO JOURNAL OF INNATE IMMUNITY LA English DT Review DE Iron homeostasis; Macrophage; Inflammation ID NF-KAPPA-B; REGULATES HEPCIDIN EXPRESSION; ENDOTHELIAL-CELL ACTIVATION; SLC11A1 FORMERLY NRAMP1; PATHOGEN INTERACTIONS; HEREDITARY HEMOCHROMATOSIS; MYCOBACTERIUM-TUBERCULOSIS; TRANSCRIPTIONAL REGULATION; INFLAMMATORY RESPONSES; SALMONELLA-TYPHIMURIUM AB Iron is an essential micronutrient for both microbial pathogens and their mammalian hosts. Changes in iron availability and distribution have significant effects on pathogen virulence and on the immune response to infection. Recent advances in our understanding of the molecular regulation of iron metabolism have shed new light on how alterations in iron homeostasis both contribute to and influence innate immunity. In this article, we review what is currently known about the role of iron in the response to infection. Copyright (C) 2009 S. Karger AG, Basel C1 [Cherayil, Bobby J.] Massachusetts Gen Hosp, Pediat Gastroenterol Unit, Mucosal Immunol Lab, Charlestown, MA 02129 USA. [Cherayil, Bobby J.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Wang, Lijian] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. RP Cherayil, BJ (reprint author), Massachusetts Gen Hosp, Pediat Gastroenterol Unit, Mucosal Immunol Lab, Bldg 114,16th St, Charlestown, MA 02129 USA. EM cherayil@helix.mgh.harvard.edu FU NIDDK NIH HHS [P30 DK040561, P30 DK040561-12] NR 88 TC 28 Z9 28 U1 0 U2 9 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1662-811X EI 1662-8128 J9 J INNATE IMMUN JI J. Innate Immun. PY 2009 VL 1 IS 5 BP 455 EP 464 DI 10.1159/000210016 PG 10 WC Immunology SC Immunology GA 480MD UT WOS:000268738000008 PM 20375603 ER PT J AU Alter, G Altfeld, M AF Alter, G. Altfeld, M. TI NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection SO JOURNAL OF INTERNAL MEDICINE LA English DT Article DE HIV; innate immunity; Natural killer cells; viral immunity ID NATURAL-KILLER-CELLS; CLASS-I MOLECULES; MHC CLASS-I; IMMUNODEFICIENCY VIRUS-INFECTION; DEPENDENT CELLULAR CYTOTOXICITY; HLA-B; DENDRITIC CELLS; INHIBITORY RECEPTORS; SELF-TOLERANCE; BINDING-SITE AB Increasing evidence supports the notion that the innate immune response, and in particular, natural killer cells play a central role in determining the quality of the host immune response to infection. In this review we highlight recent evidence that suggests that NK cells influence the clinical fate of HIV-infected individuals. C1 [Alter, G.; Altfeld, M.] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA. RP Altfeld, M (reprint author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Bldg 149,13th St,6th Floor, Charlestown, MA 02129 USA. EM maltfeld@partners.org FU NIAID NIH HHS [R01 AI067031, R01 AI067031-04] NR 80 TC 97 Z9 101 U1 0 U2 9 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0954-6820 J9 J INTERN MED JI J. Intern. Med. PD JAN PY 2009 VL 265 IS 1 BP 29 EP 42 DI 10.1111/j.1365-2796.2008.02045.x PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 381IM UT WOS:000261529400005 PM 19093958 ER PT J AU Liu, P Figoni, S Kunkel, C AF Liu, P. Figoni, S. Kunkel, C. TI RELATIONSHIPS BETWEEN PHYSIOLOGICAL AND FUNCTIONAL VARIABLES IN PERIPHERAL ARTERIAL DISEASE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-31, 2009 CL Carmel, CA SP Amer Federat Med Res, Western Reg, Western Soc Clin Invest, Western Assoc Phys, Western Soc Pediat Res, Western Student Med Res Forum C1 [Liu, P.; Kunkel, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Figoni, S.; Kunkel, C.] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 99 EP 99 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400015 ER PT J AU Brar, M Knaub, L Reusch, JE AF Brar, M. Knaub, L. Reusch, J. E. TI COBALT MIMICS HYPOXIA MEDIATED CREB DOWN-REGULATION IN VASCULAR SMOOTH MUSCLE CELLS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-31, 2009 CL Carmel, CA SP Amer Federat Med Res, Western Reg, Western Soc Clin Invest, Western Assoc Phys, Western Soc Pediat Res, Western Student Med Res Forum C1 [Brar, M.; Knaub, L.; Reusch, J. E.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Brar, M.; Knaub, L.; Reusch, J. E.] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 123 EP 123 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400101 ER PT J AU Lee, CG Fujimoto, WY Brunzell, JD Kahn, SE McNeely, MJ Leonetti, DL Boyko, EJ AF Lee, C. G. Fujimoto, W. Y. Brunzell, J. D. Kahn, S. E. McNeely, M. J. Leonetti, D. L. Boyko, E. J. TI Adiposity Accumulation is Greatest at Younger Ages in Japanese-American Adults SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-31, 2009 CL Carmel, CA SP Amer Federat Med Res, Western Reg, Western Soc Clin Invest, Western Assoc Phys, Western Soc Pediat Res, Western Student Med Res Forum C1 [Lee, C. G.; Fujimoto, W. Y.; Brunzell, J. D.; Kahn, S. E.; McNeely, M. J.; Leonetti, D. L.; Boyko, E. J.] Univ Washington, Seattle, WA 98195 USA. [Kahn, S. E.; Boyko, E. J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 124 EP 124 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400106 ER PT J AU Adochio, RL Moriarty, M Leitner, JW Gray, K Draznin, B Cornier, MA AF Adochio, R. L. Moriarty, M. Leitner, J. W. Gray, K. Draznin, B. Cornier, M. A. TI EARLY ADAPTIVE CHANGES IN INSULIN SENSITIVITY DEPEND UPON INITIAL STATE OF INSULIN SENSITIVITY SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-31, 2009 CL Carmel, CA SP Amer Federat Med Res, Western Reg, Western Soc Clin Invest, Western Assoc Phys, Western Soc Pediat Res, Western Student Med Res Forum C1 [Adochio, R. L.; Moriarty, M.; Gray, K.; Draznin, B.; Cornier, M. A.] Univ Colorado Denver, Aurora, CO USA. [Adochio, R. L.; Leitner, J. W.; Draznin, B.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 125 EP 125 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400108 ER PT J AU Bayomy, AF Aubin, PM Sangeorzan, BJ Ledoux, WR AF Bayomy, A. F. Aubin, P. M. Sangeorzan, B. J. Ledoux, W. R. TI ARTHRODESIS OF THE FIRST METATARSOPHALANGEAL JOINT: A ROBOTIC CADAVERIC STUDY OF DORSIFLEXION ANGLE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-31, 2009 CL Carmel, CA SP Amer Federat Med Res, Western Reg, Western Soc Clin Invest, Western Assoc Phys, Western Soc Pediat Res, Western Student Med Res Forum C1 [Bayomy, A. F.; Aubin, P. M.; Sangeorzan, B. J.; Ledoux, W. R.] VA Puget Sound, Seattle, WA USA. [Bayomy, A. F.; Aubin, P. M.; Sangeorzan, B. J.; Ledoux, W. R.] Univ Washington, Seattle, WA 98195 USA. RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 140 EP 141 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400162 ER PT J AU Otto, ME Dominitz, JA Larson, M Wu, PC AF Otto, M. E. Dominitz, J. A. Larson, M. Wu, P. C. TI IMPACT OF DELAYED RECTAL CANCER SURGERY FOLLOWING NEOADJUVANT CHEMORADIOTHERAPY SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-31, 2009 CL Carmel, CA SP Amer Federat Med Res, Western Reg, Western Soc Clin Invest, Western Assoc Phys, Western Soc Pediat Res, Western Student Med Res Forum C1 [Otto, M. E.] Univ Washington, Seattle, WA 98195 USA. [Dominitz, J. A.; Larson, M.; Wu, P. C.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 185 EP 185 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400320 ER PT J AU Liu, P Figoni, S Kunkel, C AF Liu, P. Figoni, S. Kunkel, C. TI RELATIONSHIPS BETWEEN PHYSIOLOGICAL AND FUNCTIONAL VARIABLES IN PERIPHERAL ARTERIAL DISEASE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-31, 2009 CL Carmel, CA SP Amer Federat Med Res, Western Reg, Western Soc Clin Invest, Western Assoc Phys, Western Soc Pediat Res, Western Student Med Res Forum C1 [Liu, P.; Kunkel, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Figoni, S.; Kunkel, C.] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 188 EP 188 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400333 ER PT J AU U'Ren, B Gil, S Farnand, A Matute-Bello, G AF U'Ren, B. Gil, S. Farnand, A. Matute-Bello, G. TI LIPOPOLYSACCHARIDE-INDUCED LUNG INJURY IS INDEPENDENT OF ALVEOLAR EPITHELIAL CASPASE ACTIVATION IN MECHANICALLY VENTILATED MICE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-31, 2009 CL Carmel, CA SP Amer Federat Med Res, Western Reg, Western Soc Clin Invest, Western Assoc Phys, Western Soc Pediat Res, Western Student Med Res Forum C1 [U'Ren, B.; Matute-Bello, G.] Univ Washington, Sch Med, Seattle, WA USA. [Matute-Bello, G.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [U'Ren, B.; Gil, S.; Farnand, A.; Matute-Bello, G.] UW Med Res, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 224 EP 224 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400460 ER PT J AU Bluth, B Eagan, M Zhao, K Wu, B McAllister, D AF Bluth, B. Eagan, M. Zhao, K. Wu, B. McAllister, D. TI PROLIFERATIVE EFFECTS OF MULTIPLE GROWTH FACTORS ON MOUSE BONE MARROW MESENCHYMAL STEM CELLS: IMPLICATIONS FOR ENGINEERING ANTERIOR CRUCIATE LIGAMENT GRAFTS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-31, 2009 CL Carmel, CA SP Amer Federat Med Res, Western Reg, Western Soc Clin Invest, Western Assoc Phys, Western Soc Pediat Res, Western Student Med Res Forum C1 [Bluth, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Zhao, K.] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 230 EP 231 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400483 ER PT J AU Gandhi, NM Sham, C Chen, L Yang, X Sharpe, AH Freeman, G Braun, J Gordon, L AF Gandhi, N. M. Sham, C. Chen, L. Yang, X. Sharpe, A. H. Freeman, G. Braun, J. Gordon, L. TI PROGRAMMED CELL DEATH-1 INTERACTION WITH PROGRAMMED CELL DEATH LIGAND REGULATES NEURONAL CELL DEATH IN THE MOUSE RETINA SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-31, 2009 CL Carmel, CA SP Amer Federat Med Res, Western Reg, Western Soc Clin Invest, Western Assoc Phys, Western Soc Pediat Res, Western Student Med Res Forum C1 [Gandhi, N. M.; Sham, C.; Chen, L.; Yang, X.; Braun, J.; Gordon, L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Chen, L.; Sharpe, A. H.; Freeman, G.] Harvard Univ, Sch Med, Boston, MA USA. [Gordon, L.] Greater Los Angeles VA Healthcare, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 237 EP 237 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400507 ER PT J AU Patel, D Martin, JL Alessi, C AF Patel, D. Martin, J. L. Alessi, C. TI CHARACTERISTICS OF SLEEP DISTURBANCE AMONG ORTHOPEDIC PATIENTS DURING POST-ACUTE REHABILITATION SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 28-31, 2009 CL Carmel, CA SP Amer Federat Med Res, Western Reg, Western Soc Clin Invest, Western Assoc Phys, Western Soc Pediat Res, Western Student Med Res Forum C1 [Patel, D.] Western Univ Hlth Sci, Coll Osteopath Med Pacific, Pomona, CA USA. [Martin, J. L.; Alessi, C.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Martin, J. L.; Alessi, C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 237 EP 238 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400509 ER PT J AU Mataria, M Bland, A Janech, M Lewis, E Arthur, J AF Mataria, M. Bland, A. Janech, M. Lewis, E. Arthur, J. TI VARIABILITY OF INDIVIDUAL URINE PROTEINS ASSOCIATED WITH BLOOD PRESSURE AND MEDICATIONS DIFFERENCES IN DIABETIC NEPHROPATHY SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2009 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Mataria, M.; Bland, A.; Janech, M.; Lewis, E.; Arthur, J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Mataria, M.; Janech, M.; Lewis, E.; Arthur, J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 359 EP 359 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400737 ER PT J AU Mashmoushi, AK Hofbauer, AF Komlosi, P Bell, PD Oates, JC AF Mashmoushi, A. K. Hofbauer, A. F. Komlosi, P. Bell, P. D. Oates, J. C. TI ROLE OF REACTIVE INTERMEDIATES IN LUPUS NEPHRITIS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2009 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Mashmoushi, A. K.; Hofbauer, A. F.; Komlosi, P.; Bell, P. D.; Oates, J. C.] Med Univ S Carolina, Charleston, SC 29425 USA. [Hofbauer, A. F.; Oates, J. C.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 369 EP 370 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400776 ER PT J AU Salanitro, AH Castiglioni, A Willett, LL Shewchuk, RM Qu, H Heudebert, GR Centor, RM AF Salanitro, A. H. Castiglioni, A. Willett, L. L. Shewchuk, R. M. Qu, H. Heudebert, G. R. Centor, R. M. TI USING COGNITIVE MAPPING TO IDENTIFY FACULTY PERSPECTIVES FOR SUCCESSFUL WARD ATTENDING ROUNDS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2009 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Salanitro, A. H.; Castiglioni, A.; Heudebert, G. R.; Centor, R. M.] Birmingham VAMC, Birmingham, AL USA. [Salanitro, A. H.; Castiglioni, A.; Willett, L. L.; Shewchuk, R. M.; Qu, H.; Heudebert, G. R.; Centor, R. M.] Univ Alabama, Birmingham, AL USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 382 EP 383 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400822 ER PT J AU Ramirez, P Al-Shahrouri, H Fanti, P Abboud, H Lorenzo, C Haffner, S AF Ramirez, P. Al-Shahrouri, H. Fanti, P. Abboud, H. Lorenzo, C. Haffner, S. TI ATHEROGENIC LIPOPROTEIN ABNORMALITIES ASSOCIATED WITH MILD ELEVATIONS IN URINE ALBUMIN EXCRETION AND IMPAIRMENT IN KIDNEY FUNCTION IN TYPE 2 DIABETIC SUBJECTS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2009 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Ramirez, P.; Al-Shahrouri, H.; Fanti, P.; Abboud, H.; Lorenzo, C.; Haffner, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Al-Shahrouri, H.; Fanti, P.; Abboud, H.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 413 EP 413 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400931 ER PT J AU Estrada, C Krishnamoorthy, P Smith, A Staton, L Houston, T AF Estrada, C. Krishnamoorthy, P. Smith, A. Staton, L. Houston, T. TI WEB-ANALYTICS: CHANGES OF PARTICIPATION MEASUREMENT SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2009 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Estrada, C.; Houston, T.] Birmingham VAMC, Birmingham, AL USA. [Estrada, C.; Krishnamoorthy, P.; Smith, A.; Houston, T.] Univ Alabama, Birmingham, AL USA. [Staton, L.] Univ Tennessee, Coll Med Chattanooga, Chattanooga, TN USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 421 EP 421 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400958 ER PT J AU Snyder, ED Castiglioni, A Salanitro, A Estrada, C AF Snyder, E. D. Castiglioni, A. Salanitro, A. Estrada, C. TI PREPARING FOR SCIENTIFIC PRESENTATIONS: HOW DO YOU PRACTICE? SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2009 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Snyder, E. D.; Castiglioni, A.; Salanitro, A.; Estrada, C.] Univ Alabama, Birmingham, AL USA. [Snyder, E. D.; Castiglioni, A.; Salanitro, A.; Estrada, C.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 421 EP 422 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400960 ER PT J AU Depuy, P Cherrington, A Boohaker, E Snyder, E AF DePuy, P. Cherrington, A. Boohaker, E. Snyder, E. TI PATTERNS OF CERVICAL CANCER SCREENING AMONG INTERNAL MEDICINE RESIDENTS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2009 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [DePuy, P.; Cherrington, A.; Boohaker, E.; Snyder, E.] Univ Alabama, Birmingham, AL USA. [Snyder, E.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 422 EP 422 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400963 ER PT J AU Salanitro, AH Funkhouser, E Allison, JJ Halanych, JH Houston, TK Litaker, MS Levine, DA Safford, MM AF Salanitro, A. H. Funkhouser, E. Allison, J. J. Halanych, J. H. Houston, T. K. Litaker, M. S. Levine, D. A. Safford, M. M. TI MULTIPLE UNCONTROLLED COMORBID CONDITIONS AND MEDICATION INTENSIFICATION SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 12-14, 2009 CL New Orleans, LA SP Amer Federat Med Res, So Reg C1 [Salanitro, A. H.; Funkhouser, E.; Allison, J. J.; Houston, T. K.; Litaker, M. S.] Birmingham VA Med Ctr, Birmingham, AL USA. [Levine, D. A.] Ohio State Univ, Columbus, OH 43210 USA. [Salanitro, A. H.; Funkhouser, E.; Allison, J. J.; Halanych, J. H.; Houston, T. K.; Litaker, M. S.; Safford, M. M.] Univ Alabama, Birmingham, AL USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2009 VL 57 IS 1 BP 423 EP 423 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 497VU UT WOS:000270092400966 ER PT J AU Grierson, JR Stekhova, SA Minoshima, S Petrie, EC AF Grierson, J. R. Stekhova, S. A. Minoshima, S. Petrie, E. C. TI DEVELOPING A RADIOLABELING STRATEGY FOR 2-[F-18]FLUORO-HEAT SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS LA English DT Meeting Abstract C1 [Grierson, J. R.; Stekhova, S. A.; Minoshima, S.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Petrie, E. C.] Vet Affairs Puget Sound Healthcare Syst, MIRECC, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0362-4803 J9 J LABELLED COMPD RAD JI J. Label. Compd. Radiopharm. PY 2009 VL 52 BP S169 EP S169 PG 1 WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry, Analytical SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry GA 480HQ UT WOS:000268724900170 ER PT J AU Nakase, K Cheng, JH Zhu, Q Marasco, WA AF Nakase, Koichi Cheng, Jihua Zhu, Quan Marasco, Wayne A. TI Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE DNA methylation; adult T cell leukemia; leukemogenesis ID PROTEIN-TYROSINE-PHOSPHATASE; ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; ABERRANT METHYLATION; NEGATIVE REGULATORS; JAK/STAT PATHWAY; GENE-EXPRESSION; LYMPHOMA-CELLS; CANCER; LYMPHOMAS/LEUKEMIAS AB The Src homology-2-containing protein-tyrosine phosphatase 1 (SHP-1), is a negative regulator of cell signaling. It is also considered a tumor suppressor gene because of its ability to antagonize the action of tyrosine kinases. Although SHP-1 is expressed strongly in hematopoietic cells, decreased expression has been observed in various hematological malignancies, which suggests a central involvement of SHP-1 in leukemogenesis. We have shown previously that human T cell lymphotropic virus type-1 (HTLV-1) Tax-induced promoter silencing ( TIPS) is an early event causing down-regulation of SHP-1 expression, which is dependent on NF-kappa B. In this study, DNase I footprinting and EMSA also revealed binding of transcription factors, specificity protein 1 (Sp1) and octamer-binding transcription factor 1 (Oct-1) to the P2 promoter, and site-directed mutagenesis confirmed that these factors contribute to the basal P2 promoter activity. Chromatin immunoprecipitation ( CHIP) assays showed that Sp1, Oct-1, NF-kappa B, CREB-1, and RNA polymerase II interacted with the core SHP-1 P2 promoter in CD4(+) T cells and Jurkat cells but not in HTLV-1-transformed MT-2 and HUT102 cells when HTLV-1 Tax is present. Furthermore, bisulfite sequencing of the SHP-1 P2 core region revealed heavy CpG methylation in HTLV-1-transformed cells compared with freshly isolated CD4(+) T cells and HTLV-1-noninfected T cell lines. A significant inverse correlation between degree of CpG methylation and expression of SHP-1 mRNA or protein was observed. Taken together, our data support the notion that in HTLV-1-transformed CD4(+) T cells, TIPS causes dissociation of transcription factors from the core SHP-1 P2 promoter, which in turn leads to subsequent DNA methylation, an important early step for leukemogenesis. J. Leukoc. Biol. 85: 165-174; 2009. C1 [Nakase, Koichi; Cheng, Jihua; Zhu, Quan; Marasco, Wayne A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. RP Marasco, WA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM wayne_marasco@dfci.harvard.edu FU NIH [CA104936, AI058804]; National Foundation for Cancer Research FX Grant support is from NIH grants CA104936 ( W. A. M.) and AI058804 ( Q. Z.). This work was also supported by the National Foundation for Cancer Research ( W. A. M). NR 36 TC 16 Z9 17 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD JAN 1 PY 2009 VL 85 IS 1 BP 165 EP 174 DI 10.1189/jlb.0608383 PG 10 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 385YG UT WOS:000261848900020 PM 18948549 ER PT J AU Schmidt, EJ Yoneyama, R Dumoulin, CL Darrow, RD Klein, E Kiruluta, AJM Hayase, M AF Schmidt, Ehud J. Yoneyama, Ryuichi Dumoulin, Charles L. Darrow, Robert D. Klein, Eric Kiruluta, Andrew J. M. Hayase, Motoya TI 3D Coronary Motion Tracking in Swine Models With MR Tracking Catheters SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE coronary arteries; intervention; motion; MRI image artifacts ID MAGNETIC-RESONANCE ANGIOGRAPHY; RESPIRATORY MOTION; IMAGING GUIDANCE; VESSEL WALL; CAROTID ARTERIES; CARDIAC CYCLE; POSITION; DEVICES; FEASIBILITY; TRANSFORM AB Purpose: To develop MR-tracked catheters to delineate the three-dimensional motion of coronary arteries at high spatial and temporal resolution. Materials and Methods: Catheters with three tracking microcoils were placed into nine swine. During breath-holds, electrocardiographic (ECG)-synchronized 3D motion was measured at varying vessel depths. 3D motion was measured in American Heart Association left anterior descending (LAD) segments 6-7, left circumflex (LCX) segments 11-15, and right coronary artery (RCA) segments 2-3, at 60-115 beats/min heart rates. Similar-length cardiac cycles were averaged. Intercoil cross-correlation identified early systolic phase (ES) and determined segment motion delay. Results: Translational and rotational motion, as a function of cardiac phase, is shown, with directionality and amplitude varying along the vessel length. Rotation (peak-to-peak solid-angle RCA approximate to 0.10, LAD approximate to 0.06, LCX approximate to 0.18 radian) occurs primarily during fast translational motion and increases distally. LCX displacement increases with heart rate by 18%. Phantom simulations of motion effects on high-resolution images, using RCA results, show artifacts due to translation and rotation. Conclusion: Magnetic resonance imaging (MRI) tracking catheters quantify motion at 20 fps and 1 mm(3) resolution at multiple vessel depths, exceeding that available with other techniques. Imaging artifacts due to rotation are demonstrated. Motion-tracking catheters may provide physiological information during interventions and improve imaging spatial resolution. C1 [Schmidt, Ehud J.; Yoneyama, Ryuichi; Kiruluta, Andrew J. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Schmidt, Ehud J.] GE Healthcare Appl Sci Lab, Boston, MA USA. [Dumoulin, Charles L.; Darrow, Robert D.; Klein, Eric] GE Global Res Ctr, Niskayuna, NY USA. [Hayase, Motoya] Jack N Skirball Ctr Cardiovasc Res, Orangeburg, NY USA. RP Schmidt, EJ (reprint author), Brigham & Womens Hosp, Room LM-10C,221 Longwood Ave, Boston, MA 02116 USA. EM eschmidt3@partners.org NR 33 TC 10 Z9 11 U1 1 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD JAN PY 2009 VL 29 IS 1 BP 86 EP 98 DI 10.1002/jmri.21468 PG 13 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 390MK UT WOS:000262168200011 PM 19097093 ER PT J AU Chen, SL Reynolds, F Yu, LT Weissleder, R Josephson, L AF Chen, Suelin Reynolds, Fred Yu, Lingtau Weissleder, Ralph Josephson, Lee TI A screening paradigm for the design of improved polymer-coated superparamagnetic iron oxide nanoparticles SO JOURNAL OF MATERIALS CHEMISTRY LA English DT Article ID MR CONTRAST AGENTS; MAGNETIC NANOPARTICLES; DEXTRAN; PEPTIDE; FERUMOXIDES; FERUMOXTRAN; CANCER; CELLS AB Polymer-coated superparamagnetic iron oxide nanoparticles (NPs) have been used for a variety of biomedical applications, including as MRI contrast agents, for the treatment of iron anemias, and for ex vivo labeling of the cells used in cell-based therapies so that they can be tracked by MRI. Here we describe a three-stage screening paradigm to develop high potency (i.e., high relaxivity), stable, polymer-coated superparamagnetic iron oxide NPs. Each screen examined different facets of the interaction between iron oxides and polymers. First, an Ion Challenge Screen assessed whether a polymer interacted with the surface of the iron oxide. Second, a Synthesis Optimization Screen examined whether polymers that passed the Ion Challenge Screen were compatible with the synthetic method used to make NPs, and optimized the synthetic method for each polymer. Finally, a Heat Stress/Stability Screen assessed the stability of the optimized polymer-coated superparamagnetic iron oxides that passed the Synthesis Optimization Screen. A carboxymethyl dextran-coated superparamagnetic iron oxide nanoparticle (CMD-NP) with a transverse relaxivity (R(2)) of 271 mM(-1) s(-1) and a diameter of 47 nm by dynamic light scattering was obtained. A second NP, a carboxymethyl polyvinyl alcohol-coated nanoparticle (CMPVA-NP) had an R(2) of 119 and diameter of 37 nm, but was less stable to heat stress than the CMD- NP. The CMD- NP is a polymer-coated superparamagnetic iron oxide NP with improved relaxivity and high stability achieved without the crosslinking procedure used in our cross-linked iron oxide (CLIO) NP. C1 [Reynolds, Fred; Yu, Lingtau; Weissleder, Ralph; Josephson, Lee] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA. [Chen, Suelin] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA. RP Josephson, L (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, 149 13th St, Charlestown, MA 02129 USA. EM suelin@mit.edu; ljosephson@mgh.harvard.edu FU NIH [R01-EB0004626, U01-HL080731, P50-CA86355, U54-119349] FX This work was supported by R01-EB0004626, U01-HL080731, P50-CA86355 and U54-119349 from the NIH. NR 27 TC 12 Z9 12 U1 0 U2 14 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 0959-9428 J9 J MATER CHEM JI J. Mater. Chem. PY 2009 VL 19 IS 35 BP 6387 EP 6392 DI 10.1039/b902170a PG 6 WC Chemistry, Physical; Materials Science, Multidisciplinary SC Chemistry; Materials Science GA 487QG UT WOS:000269289300020 ER PT J AU Rauh-Hain, JA Rana, S Tamez, H Wang, A Cohen, B Cohen, A Brown, F Ecker, JL Karumanchi, SA Thadhani, R AF Rauh-Hain, Jose A. Rana, Sarosh Tamez, Hector Wang, Alice Cohen, Bruce Cohen, Allison Brown, Florence Ecker, Jeffrey L. Karumanchi, S. Ananth Thadhani, Ravi TI Risk for developing gestational diabetes in women with twin pregnancies SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE LA English DT Article DE Gestational diabetes; twin pregnancy; singleton pregnancy ID RESPIRATORY-DISTRESS; NEWBORN-INFANTS; UNITED-STATES; PREVALENCE; MELLITUS; RACE; ADIPONECTIN; MANAGEMENT; MOTHERS; AGE AB Objective. To examine the risk of developing gestational diabetes mellitus (GDM) in women with twin compared with singleton pregnancies. Research design and methods. We examined a cohort of 23,056 pregnant women who gave birth to a live infant between 1 September 1998 and 31 December 2006, 553 of whom had twin pregnancy. The primary exposure was twin versus singleton pregnancy, and the primary outcome was the development of GDM. Standard univariate analyses were performed, as were multivariable analysis with logistic regression to control for potential confounding variables. GDM was diagnosed using criteria of the National Diabetes Data Group. Results. Patients with twin pregnancies had a higher rate of GDM when compared with singleton pregnancies (3.98%vs. 2.32%; p=0.01). In a multiple regression analysis after adjusting for age, race/ethnicity, body mass index, maximal systolic and diastolic blood pressure, smoking and parity, twin pregnancy was associated with an approximately two-fold increase in risk for developing GDM (OR 2.2, 95% CI 1.4-3.6). In a stratified analysis, women between the ages of 25 and 30 years and African-American women had the highest risk of developing GDM in twin pregnancies. When compared with twins of non-diabetic mothers, twins of gestational diabetics had a higher rate of admission to the neonatal intensive care unit (37%vs. 52%; p=0.05), had longer hospitalisation (80.5 vs. 164 days; p=0.01) and higher rate for respiratory distress syndrome (7%vs. 27%; p=0.001). Conclusion. There is a significant increase in the incidence of GDM in twin pregnancies versus singleton pregnancies. The risk is highest in African-American and young women. C1 [Rauh-Hain, Jose A.; Tamez, Hector; Ecker, Jeffrey L.; Thadhani, Ravi] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Rana, Sarosh; Wang, Alice; Cohen, Bruce; Cohen, Allison; Brown, Florence; Karumanchi, S. Ananth] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02114 USA. [Rana, Sarosh; Wang, Alice; Cohen, Bruce; Cohen, Allison; Brown, Florence; Karumanchi, S. Ananth] Harvard Univ, Sch Med, Joslin Clin, Boston, MA 02114 USA. RP Thadhani, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bulfinch 127,55 Fruit St, Boston, MA 02114 USA. EM rthadhani@partners.org FU American Diabetes Association; Howard Hughes Medical Institute FX R. T. is supported by N. I. H grants and a grant from the American Diabetes Association. S. A. K. is an investigator of the Howard Hughes Medical Institute. NR 30 TC 35 Z9 35 U1 0 U2 4 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1476-7058 J9 J MATERN-FETAL NEO M JI J. Matern.-Fetal Neonatal Med. PY 2009 VL 22 IS 4 BP 293 EP 299 AR PII 910154222 DI 10.1080/14767050802663194 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 438VG UT WOS:000265583100002 PM 19340713 ER PT J AU Kern, NI Majewski, TJ Triolo, RJ Kobetic, R Quinn, RD AF Kern, Nicole I. Majewski, Thomas J. Triolo, Ronald J. Kobetic, Rudi Quinn, Roger D. TI A Locking Compliant Device Inspired by the Anatomy of the Spine SO JOURNAL OF MECHANICAL DESIGN LA English DT Article DE robotic spine; body flexion; object manipulation; variable stiffness AB A device reminiscent of the mammalian spine has been designed and built with the ability to lock each individual joint in a string of ball joints. The assembly may be controlled in a manner similar to other hyper-redundant robots, with the added advantage of locking in a straight or axial position. Locking is achieved by orienting two mating collars in a singular configuration that forces compression against neighboring collars and prohibits bending or rotation. Locking is desirable for added strength in supporting objects, as well as for stabilization and power efficiency when bending is not necessary. The split locking mechanism represents a biologically inspired structure with added strength and stability for use in robotics. [DOI: 10.1115/1.2991143] C1 [Kern, Nicole I.; Majewski, Thomas J.; Quinn, Roger D.] Case Western Reserve Univ, Dept Mech & Aerosp Engn, Cleveland, OH 44106 USA. [Triolo, Ronald J.] Case Western Reserve Univ, Dept Orthopaed, Cleveland, OH 44106 USA. [Triolo, Ronald J.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA. [Triolo, Ronald J.; Kobetic, Rudi] US Dept Vet Affairs, Rehabil Res & Dev Serv, Cleveland, OH 44106 USA. RP Kern, NI (reprint author), Case Western Reserve Univ, Dept Mech & Aerosp Engn, 10900 Euclid Ave, Cleveland, OH 44106 USA. EM roger.quinn@case.edu FU Army Medical Research and Material Command of the U. S. Department of Defense [PR043074]; U.S. Department of Veterans Affairs [B3463R] FX The authors would like to acknowledge funding provided by Grant No. PR043074 from the Army Medical Research and Material Command of the U. S. Department of Defense and by Merit Review Grant No. B3463R from the Rehabilitation R&D Service of the U.S. Department of Veterans Affairs. NR 5 TC 1 Z9 1 U1 0 U2 4 PU ASME-AMER SOC MECHANICAL ENG PI NEW YORK PA THREE PARK AVE, NEW YORK, NY 10016-5990 USA SN 1050-0472 J9 J MECH DESIGN JI J. Mech. Des. PD JAN PY 2009 VL 131 IS 1 AR 014501 DI 10.1115/1.2991143 PG 3 WC Engineering, Mechanical SC Engineering GA 404QF UT WOS:000263167400018 ER PT J AU Huttunen, HJ Puglielli, L Ellis, BC Ingano, LAM Kovacs, DM AF Huttunen, Henri J. Puglielli, Luigi Ellis, Blake C. Ingano, Laura A. MacKenzie Kovacs, Dora M. TI Novel N-terminal Cleavage of APP Precludes A beta Generation in ACAT-Defective AC29 Cells SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE Alzheimer's disease; Amyloid; Cholesterol ID APOLIPOPROTEIN-E POLYMORPHISM; TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; AMYLOID-BETA; CHOLESTEROL ACYLTRANSFERASE; IN-VIVO; DENSITY-LIPOPROTEIN; E GENOTYPE; PROTEIN; PRECURSOR AB A common pathogenic event that occurs in all forms of Alzheimer's disease is the progressive accumulation of amyloid beta-peptide (A beta) in brain regions responsible for higher cognitive functions. Inhibition of acyl-coenzyme A: cholesterol acyltransferase (ACAT), which generates intracellular cholesteryl esters from free cholesterol and fatty acids, reduces the biogenesis of the A beta from the amyloid precursor protein (APP). Here we have used AC29 cells, defective in ACAT activity, to show that ACAT activity steers APP either toward or away from a novel proteolytic pathway that replaces both alpha and the amyloidogenic beta cleavages of APP. This alternative pathway involves a novel cleavage of APP holoprotein at Glu281, which correlates with reduced ACAT activity and A beta generation in AC29 cells. This sterol-dependent cleavage of APP occurs in the endosomal compartment after internalization of cell surface APP. The resulting novel C-terminal fragment APP-C470 is destined to proteasomal degradation limiting the availability of APP for the A beta generating system. The proportion of APP molecules that are directed to the novel cleavage pathway is regulated by the ratio of free cholesterol and cholesteryl esters in cells. These results suggest that subcellular cholesterol distribution may be an important regulator of the cellular fate of APP holoprotein and that there may exist several competing proteolytic systems responsible for APP processing within the endosomal compartment. C1 [Huttunen, Henri J.; Puglielli, Luigi; Ellis, Blake C.; Ingano, Laura A. MacKenzie; Kovacs, Dora M.] MIND, Neurobiol Dis Lab, Genet & Aging Res Unit, Charlestown, MA 02129 USA. [Huttunen, Henri J.; Puglielli, Luigi; Ellis, Blake C.; Ingano, Laura A. MacKenzie; Kovacs, Dora M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA. RP Kovacs, DM (reprint author), MIND, Neurobiol Dis Lab, Genet & Aging Res Unit, Charlestown, MA 02129 USA. EM Dora_Kovacs@hms.harvard.edu OI Huttunen, Henri/0000-0002-9867-4438 FU NIH-NINDS; Alzheimer's Association; Helsingin Sanomat Centennial Foundation; Maud Kuistila Foundation FX We thank T.Y. Chang and C.C.Y. Chang ( Dartmouth Medical School, Hanover, NH, USA) for the gift of cholesterol mutant cell lines, J.H. Harwood (Pfizer, Groton, CT, USA) for providing us with the ACAT inhibitor CP-113,818, and D.J. Selkoe and W. Xia (Center for Neurological Diseases, Brigham and Women's Hospital, Boston, MA, USA) for A beta determinations. This work was supported by grants from the NIH-NINDS (D.M.K.), the Alzheimer's Association (L.P.), Helsingin Sanomat Centennial Foundation (H.J.H.) and Maud Kuistila Foundation (H.J.H.). NR 45 TC 17 Z9 20 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD JAN PY 2009 VL 37 IS 1 BP 6 EP 15 DI 10.1007/s12031-008-9088-0 PG 10 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 387SE UT WOS:000261971100002 PM 18618086 ER PT J AU Eddy, KT Crosby, RD Keel, PK Wonderlich, SA le Grange, D Hill, L Powers, P Mitchell, JE AF Eddy, Kamryn T. Crosby, Ross D. Keel, Pamela K. Wonderlich, Stephen A. le Grange, Daniel Hill, Laura Powers, Pauline Mitchell, James E. TI Empirical Identification and Validation of Eating Disorder Phenotypes in a Multisite Clinical Sample SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Eating disorders; diagnostic classification; latent profile analysis; anorexia nervosa; bulimia nervosa ID DEPRESSIVE SYMPTOMATOLOGY IDS; SELF-REPORT QUESTIONNAIRE; MULTIPLE PURGING METHODS; LATENT PROFILE ANALYSIS; HEALTH SURVEY SF-36; QUALITY-OF-LIFE; BULIMIA-NERVOSA; ANOREXIA-NERVOSA; EDE-Q; DIAGNOSTIC CROSSOVER AB Identified problems with the classification system of eating disorders (EDs), including its imperfect application to clinical samples, challenge its validity and limit its utility. The present study aimed to empirically identify and validate ED phenotypes in a multisite clinical sample using latent profile analysis (LPA). ED symptom data collected from 687 individuals were included in LPA. Identified latent profiles (LPs) were compared on clinical validators. Five LPs were identified: LPI (n = 178), objective bingeing and multiple purging methods; LP2 (n = 172), objective bingeing without purging; LP3 (n = 130), objective bingeing and vomiting; LP4 (n = 108), low/normal weight and excessive exercise; LP5 (n = 99), low/normal weight and absence of ED symptoms. Validation analyses demonstrated the most extreme psychopathology/medical morbidity in LPI and the least in LP5. LPI and LP3 were most likely to report medication treatment for EDs. Identified LPs imperfectly resembled diagnostic and statistical manual of mental disorders IV-TR EDs. Multiple purging methods and the absence of ED cognitions marked differences in severity across groups, whereas low weight did not. Clinical differences in psychopathology, medical morbidity, and treatment utilization validated groups. Future research should examine longitudinal stability of empirically-derived phenotypes and incremental validity of alternative classification schema to inform DSM-V. C1 [Eddy, Kamryn T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02214 USA. [Crosby, Ross D.; Wonderlich, Stephen A.; Mitchell, James E.] Neuropsychiat Res Inst, Fargo, ND USA. [Crosby, Ross D.; Wonderlich, Stephen A.; Mitchell, James E.] Univ N Dakota, Sch Med & Hlth Sci, Dept Clin Neurosci, Fargo, ND USA. [Keel, Pamela K.] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA. [le Grange, Daniel] Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA. [Hill, Laura] Ctr Balanced Living, Worthington, OH USA. [Powers, Pauline] Univ S Florida, Dept Psychiat, Tampa, FL USA. RP Eddy, KT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, 2 Longfellow Pl,St 200, Boston, MA 02214 USA. EM keddy@partners.org RI Le Grange, Daniel/A-2649-2011; OI Crosby, Ross/0000-0001-9131-1629 NR 68 TC 42 Z9 42 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD JAN PY 2009 VL 197 IS 1 BP 41 EP 49 DI 10.1097/NMD.0b013e3181927389 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 394KS UT WOS:000262446200007 PM 19155809 ER PT J AU Stein, MB Hilsenroth, M Pinsker-Aspen, JH Primavera, L AF Stein, Michelle B. Hilsenroth, Mark Pinsker-Aspen, Janet H. Primavera, Louis TI Validity of DSM-IV Axis V Global Assessment of Relational Functioning Scale A Multimethod Assessment SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article; Proceedings Paper CT Annual Meeting Society-for-Personality-Assessment CY MAR, 2007 CL Arlington, VA SP Soc Personal Assessment DE multimethod assessment; relational functioning; SCORS; GARF; IIP ID TERM PSYCHODYNAMIC PSYCHOTHERAPY; CONFIRMATORY FACTOR-ANALYSIS; RELIABILITY; GARF; TAT; PERSONALITY; RORSCHACH; MODEL; FIT AB We investigate the convergent validity of the DSM-IV Axis V Global Assessment of Relational Functioning Scale (GARF: American Psychiatric Association, 1994). This study included 79 patients at a university-based outpatient treatment clinic. We examined clinician-rated GARF and the relationship to self-reported (Inventory of Interpersonal Problems; IIP-C; Horowitz et al. 2000) and free response themes [Social Cognition and Object Relations Scale: SCORS; Hilsenroth, Stein & Pinsker, 2004; Westen, 1995] of interpersonal functioning. Clinician ratings of the GARF scale and SCORS variables were highly reliable and internally consistent. Convergent Validity among the GARF, SCORS, and HP scores was calculated using a Principal Components Analysis and Confirmatory Factor Analysis (CFA). Results of the Principal Components Analysis revealed that the GARF, SCORS, and HP scores converged on a single factor, although findings of the CFA did not fully confirm the I factor model originally proposed. Intercorrelations among the GAR-F, SCORS, and HP variables were analyzed and a pattern of significant relationships was found between the GARF and SCORS variables. This study helps support the convergent validity GARF as a relational functioning measure and is one of the first investigations to examine this scale multidimensionally. C1 [Stein, Michelle B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Stein, Michelle B.] Harvard Univ, Sch Med, Psychol Assessment Ctr, Boston, MA USA. [Hilsenroth, Mark; Pinsker-Aspen, Janet H.] Adelphi Univ, Derner Inst Adv Psychol Studies, Garden City, NY 11530 USA. [Primavera, Louis] Touro Coll, Grad Sch Psychol, New York, NY USA. RP Stein, MB (reprint author), Massachusetts Gen Hosp, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA. EM mstein@partners.org NR 38 TC 14 Z9 14 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD JAN PY 2009 VL 197 IS 1 BP 50 EP 55 DI 10.1097/NMD.0b013e3181923ca1 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 394KS UT WOS:000262446200008 PM 19155810 ER PT J AU Blakeley, JO Olson, J Grossman, SA He, XY Weingart, J Supko, JG AF Blakeley, Jaishri O. Olson, Jeffrey Grossman, Stuart A. He, Xiaoying Weingart, Jon Supko, Jeffrey G. CA NABTT Consortium TI Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Glioma; Microdialysis; Drug delivery; Pharmacokinetics ID INTRACEREBRAL MICRODIALYSIS; IN-VIVO; INTRAVENOUS-INFUSION; CONTRAST ENHANCEMENT; MALIGNANT GLIOMAS; PROTEIN-BINDING; DRUG TRANSPORT; SOLID TUMORS; DELIVERY; CHEMOTHERAPY AB Purpose: Determining whether potentially therapeutic drug exposure is achieved within brain tumors in an exploratory clinical investigation would provide a rational basis for selecting agents for evaluation in phase II trials. This study investigated the use of microdialysis to assess intratumoral drug distribution in patients with recurrent high grade gliomas (HGG). Patients and Methods: Microdialysis catheters were placed during surgery for residual HGG 1-day before giving methotrexate (MTX) 12g/m 2 by 4-h i.v. infusion. MTX was measured by Liquid Chromatography/Mass Spectrometry (LC/MS) in plasma and microdialysate during the infusion and for 24-h thereafter. Blood brain barrier (BBB) permeability of tissue in which the microdialysis probe was located was determined by digitally fusing brain CT and contrast enhanced MRI images. Results: The microdialysis probe was located in contrast enhancing tumor in two patients and nonenhancing tissue in two others. Cerebral drug penetration, as indicated by the ratio of the area under the MTX concentration-time curves in brain extracellular fluid and plasma, was considerably greater in contrast enhancing tumor (0.28-0.31) than nonenhancing tissue (0.032-0.094). Nevertheless, MTX concentrations in ECF exceeded 2-mu M, the average concentration for 50% cell kill against glioma cell lines in vitro, for 20-26 h in both regions of the tumor. Conclusions: Microdialysis is a very informative technique for characterizing the intratumoral pharmacokinetics of drugs, such as MTX, that do not freely penetrate the BBB. Establishing the catheter probe location relative to areas of BBB disruption is required to properly assess the significance of microdialysis data in this context. C1 [Blakeley, Jaishri O.; Grossman, Stuart A.; Weingart, Jon] Johns Hopkins Univ, Sch Med, Baltimore, MD 21231 USA. [Olson, Jeffrey] Emory Univ, Sch Med, Atlanta, GA USA. [He, Xiaoying; Supko, Jeffrey G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Blakeley, JO (reprint author), Johns Hopkins Univ, Sch Med, Canc Res Bldg 2,1550 Orleans St,Suite 1M16, Baltimore, MD 21231 USA. EM jblake13@jhmi.edu FU National Cancer Institute [U01-CA62475]; National Institutes of Health [U01-CA105689]; Department of Health and Human Services, Bethesda, Maryland [P30-CA0516] FX Grant support: This study was supported by grants U01-CA62475, U01-CA105689, and P30-CA0516 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland. Microdialysis catheters were generously donated by CMA Microdialysis AB (North Chelmsford, MA). NR 35 TC 59 Z9 61 U1 0 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2009 VL 91 IS 1 BP 51 EP 58 DI 10.1007/s11060-008-9678-2 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 376JR UT WOS:000261180400009 PM 18787762 ER PT J AU Ulmer, S Liess, C Kesari, S Otto, N Straube, T Jansen, O AF Ulmer, Stephan Liess, Carsten Kesari, Santosh Otto, Nadine Straube, Torsten Jansen, Olav TI Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Glioblastoma; DSC-MRI; Brain parenchyma; Blood supply; Pathophysiology; Perfusion ID CEREBRAL BLOOD-VOLUME; ENDOTHELIAL GROWTH-FACTOR; HIGH-GRADE GLIOMA; ENHANCED MR; MICROVASCULAR PERMEABILITY; MALIGNANT GLIOMAS; HISTOLOGIC GRADE; TUMOR GRADE; MAPS; RCBV AB Introduction We investigated the effect of increased tumor perfusion using dynamic susceptibility-contrast magnetic resonance imaging (DSC-MRI) in glioblastoma (GBM) patients on the surrounding ipsilateral brain tissue with respect to perfusion of the normal, unaffected contralateral brain and of the tumor. Material and methods DSC-MRI was performed in 11 patients with glioblastoma using a multislice T2*-weighed EPI sequence (TR/TE = 2,000/62 ms; FOV 240 mm; matrix 128 x 128; slice thickness 6 mm) on a standard clinical 1.5 Tesla scanner during intravenous injection of 40 cc Gadolinium-DTPA at a flow rate of 5 cc/s. Maps for relative regional cerebral blood volume (rCBV) and relative regional cerebral blood flow (rCBF) were created and relative values analyzed in relation to the arterial input. Results Relative CBV and CBF were significantly higher in gray matter than in the respective white matter (paired t-test; P < 0.001) with a high correlation for both perfusion parameters between the gray and the white matter in both ipsilateral and contralateral brain (P < 0.001). The highest values for rCBV and rCBF were found in solid tumor tissue with a significant positive correlation between tumor and the adjacent gray matter (for both rCBV and rCBF; P < 0.001). Conclusion In GBM patients there is increased metabolism and thus increased rCBV and rCBF within the tumor. This increased perfusion of the tumor is not at the expense of perfusion of the ipsilateral normal brain parenchyma and in fact, the rCBV and rCBF values are linked to tumor-induced changes in rCBV and rCBF. C1 [Ulmer, Stephan; Otto, Nadine; Straube, Torsten; Jansen, Olav] Univ Hosp Schleswig Holstein, Inst Neuroradiol, D-24105 Kiel, Germany. [Liess, Carsten] Univ Hosp Schleswig Holstein, Div Med Phys, Dept Radiol, D-24105 Kiel, Germany. [Kesari, Santosh] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Kesari, Santosh] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Ulmer, S (reprint author), Univ Hosp Schleswig Holstein, Inst Neuroradiol, Schittenhelmstr 10, D-24105 Kiel, Germany. EM ulmer@email.com RI Jansen, Olav/D-2547-2010; Kesari, Santosh/E-8461-2013 NR 40 TC 7 Z9 7 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD JAN PY 2009 VL 91 IS 2 BP 213 EP 220 DI 10.1007/s11060-008-9701-7 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 379DG UT WOS:000261375800012 PM 18807224 ER PT J AU Uemura, K Lill, CM Banks, M Asada, M Aoyagi, N Ando, K Kubota, M Kihara, T Nishimoto, T Surimoto, H Takahashi, R Hyman, BT Shimohama, S Berezovska, O Kinoshita, A AF Uemura, Kengo Lill, Christina M. Banks, Mary Asada, Megumi Aoyagi, Nobuhisa Ando, Koichi Kubota, Masakazu Kihara, Takeshi Nishimoto, Takaaki Surimoto, Hachiro Takahashi, Ryosuke Hyman, Bradley T. Shimohama, Shun Berezovska, Oksana Kinoshita, Ayae TI N-cadherin-based adhesion enhances A beta release and decreases A beta(42/40) ratio SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE Alzheimer's disease; amyloid beta; N-cadherin; presenilin 1; synapse ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; GAMMA-SECRETASE; IN-VIVO; INTRACELLULAR DOMAIN; SIGNALING PATHWAY; TRANSGENIC MICE; PRESENILIN-1; CLEAVAGE; CONFORMATION AB In neurons, Presenilin 1(PS1)/gamma-secretase is located at the synapses, bound to N-cadherin. We have previously reported that N-cadherin-mediated cell-cell contact promotes cell-surface expression of PS1/gamma-secretase. We postulated that N-cadherin-mediated trafficking of PS1 might impact synaptic PS1-amyloid precursor protein interactions and A beta generation. In the present report, we evaluate the effect of N-cadherin-based contacts on A beta production. We demonstrate that stable expression of N-cadherin in Chinese hamster ovary cells, expressing the Swedish mutant of human amyloid precursor protein leads to enhanced secretion of A beta in the medium. Moreover, N-cadherin expression decreased A beta(42/40) ratio. The effect of N-cadherin expression on A beta production was accompanied by the enhanced accessibility of PS1/gamma-secretase to amyloid precursor protein as well as a conformational change of PS1, as demonstrated by the fluorescence lifetime imaging technique. These results indicate that N-cadherin-mediated synaptic adhesion may modulate A beta secretion as well as the A beta(42/40) ratio via PS1/N-cadherin interactions. C1 [Kinoshita, Ayae] Kyoto Univ, Grad Sch Med, Sch Hlth Sci, Sakyo Ku, Kyoto 6068507, Japan. [Uemura, Kengo; Aoyagi, Nobuhisa; Ando, Koichi; Takahashi, Ryosuke] Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto, Japan. [Lill, Christina M.; Banks, Mary; Hyman, Bradley T.; Berezovska, Oksana] Massachusetts Gen Hosp, Alzheimer Res Unit, Charlestown, MA USA. [Kihara, Takeshi; Nishimoto, Takaaki; Surimoto, Hachiro] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Neurosci Drug Discovery, Kyoto, Japan. [Shimohama, Shun] Sapporo Med Univ, Dept Neurol, Sapporo, Hokkaido, Japan. RP Kinoshita, A (reprint author), Kyoto Univ, Grad Sch Med, Sch Hlth Sci, Sakyo Ku, 53 Shogoinkawahara Cho, Kyoto 6068507, Japan. EM akinoshita@hs.med.kyoto-u.ac.jp RI Lill, Christina/J-9449-2015 OI Lill, Christina/0000-0002-2805-1307 FU Philip Morris USA Inc; Philip Morris International; NIH [AG026593]; Ministry of Education, Science, Sportsand Culture (Japan) [18023021, 18059019] FX Research described in this article was supported by Philip Morris USA Inc., Philip Morris International (OB, SS) and NIH AG026593 (OB) and by the Ministry of Education, Science, Sportsand Culture (Japan), Grant-in-Aid for 18023021, 18059019 (AK). We thank Dr Kaether (Ludwig-Maximilians University, Germany) for generously providing original PS1-GFP construct. NR 30 TC 13 Z9 13 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD JAN PY 2009 VL 108 IS 2 BP 350 EP 360 DI 10.1111/j.1471-4159.2008.05760.x PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 382QH UT WOS:000261620000004 PM 19046403 ER PT J AU Xing, CH Lee, S Kim, WJ Jin, G Yang, YG Ji, XM Wang, XY Lo, EH AF Xing, Changhong Lee, Sunryung Kim, Woo Jean Jin, Guang Yang, Yong-Guang Ji, Xunming Wang, Xiaoying Lo, Eng H. TI Role of oxidative stress and caspase 3 in CD47-mediated neuronal cell death SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE caspase 3; CD47; cell death; reactive oxygen species; thrombospondin ID PROTEIN-KINASE-A; DENDRITIC CELLS; POLY(ADP-RIBOSE) POLYMERASE-1; DEPENDENT INHIBITION; LEUKEMIC-CELLS; CD47; APOPTOSIS; THROMBOSPONDIN-1; MITOCHONDRIA; ERYTHROPOIETIN AB CD47 or integrin-associated protein promotes cell death in blood and tumor cells. Recently, CD47 signaling has been identified in neurons as well. In this study, we investigated the role of CD47 in neuronal cell death. Exposure of primary mouse cortical neurons to the CD47 ligand thrombospondin-1 or the specific CD47-activating peptide 4N1K induced cell death. Activation of CD47 elevated levels of active caspase 3 and increased the generation of reactive oxygen species (ROS) in a time-dependent manner. Both ROS scavengers and caspase inhibitors attenuated cell death. But ROS scavenging did not reduce the activation of caspase 3, and combination treatments with a caspase inhibitor plus free radical scavenger did not yield additive protection. Taken together, these data suggest that parallel and redundant pathways of oxidative stress and caspase-mediated cell death are involved. We conclude that CD47 mediates neuronal cell death through caspase-dependent and caspase-independent pathways. C1 [Xing, Changhong; Lee, Sunryung; Kim, Woo Jean; Jin, Guang; Wang, Xiaoying; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Radiol & Neurol, Boston, MA 02129 USA. [Xing, Changhong; Ji, Xunming] Capital Med Univ, Xuan Wu Hosp, Beijing, Peoples R China. [Lee, Sunryung] Cheju Natl Univ, Dept Biol, Cheju, South Korea. [Yang, Yong-Guang] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Transplantat Biol Res Ctr, Boston, MA 02129 USA. RP Lo, EH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neuroprotect Res Lab,Dept Radiol & Neurol, Boston, MA 02129 USA. EM Lo@helix.mgh.harvard.edu FU [R01-NS37074]; [R01-NS48422]; [R01-NS53560]; [P50-NS10828]; [P01-NS55104]; [R01-AI064569] FX This study is supported in part by R01-NS37074, R01-NS48422, R01-NS53560, P50-NS10828, P01-NS55104, and R01-AI064569. NR 33 TC 15 Z9 15 U1 1 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD JAN PY 2009 VL 108 IS 2 BP 430 EP 436 DI 10.1111/j.1471-4159.2008.05777.x PG 7 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 382QH UT WOS:000261620000011 PM 19012741 ER PT J AU Neema, M Arora, A Healy, BC Guss, ZD Brass, SD Duan, Y Buckle, GJ Glanz, BI Stazzone, L Khoury, SJ Weiner, HL Guttmann, CRG Bakshi, R AF Neema, Mohit Arora, Ashish Healy, Brian C. Guss, Zachary D. Brass, Steven D. Duan, Yang Buckle, Guy J. Glanz, Bonnie I. Stazzone, Lynn Khoury, Samia J. Weiner, Howard L. Guttmann, Charles R. G. Bakshi, Rohit TI Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple Sclerosis SO JOURNAL OF NEUROIMAGING LA English DT Article DE MRI; multiple sclerosis; neurologic disability; iron; T2 hypointensity; T2 hyperintense lesions; brain atrophy ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; T2 HYPOINTENSITY; AUTOIMMUNE ENCEPHALOMYELITIS; IRON DEPOSITS; WHITE-MATTER; SJL MICE; ATROPHY; DISABILITY; IMPAIRMENT; ABNORMALITIES AB Conventional brain MRI lesion measures have unreliable associations with clinical progression in multiple sclerosis (MS). Gray matter imaging may improve clinical-MRI correlations. We tested if gray matter MRI measures and conventional measures of lesions/atrophy predicted clinical progression in a 4-year longitudinal study of 97 patients with MS. Baseline and follow-up brain MRI were analyzed for basal ganglia and thalamic normalized T2 signal intensity, whole brain T2-hyperintense lesion volume, and whole brain atrophy. Logistic regression tested the ability of baseline or on-study change in MRI to predict disability progression, as reported by area under the receiver operator characteristics curve (AUC). Lower caudate T2-intensity at baseline (P = .04; AUC = .69) and on-study decreasing T2-intensity in the putamen (P = .03; AUC = .70) and thalamus (P = .01; AUC = .71) were the MRI variables associated with clinical progression when regression modeling was adjusted for length of follow-up interval, baseline EDSS, disease duration, age, and sex. Gray matter T2-hypointensity, suggestive of excessive iron deposition is associated with worsening disability in patients with MS. Gray matter MRI assessment may be able to capture neurodegenerative aspects of the disease, with more clinical relevance than derived from conventional MRI measures. J Neuroimaging 2009;19:3-8. C1 [Neema, Mohit; Arora, Ashish; Healy, Brian C.; Guss, Zachary D.; Brass, Steven D.; Buckle, Guy J.; Glanz, Bonnie I.; Stazzone, Lynn; Khoury, Samia J.; Weiner, Howard L.; Guttmann, Charles R. G.; Bakshi, Rohit] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Partners MS Ctr, Boston, MA 02115 USA. [Duan, Yang; Guttmann, Charles R. G.; Bakshi, Rohit] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol,Partners MS Ctr, Boston, MA 02115 USA. [Healy, Brian C.; Brass, Steven D.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Bakshi, R (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Partners MS Ctr, 77 Ave Louis Pasteur,HIM 730, Boston, MA 02115 USA. EM rbakshi@bwh.harvard.edu OI khoury, samia/0000-0003-3198-6063 FU National Institutes of Health [NIH-NINDS K23 NS42379-01, R01 NS055083-01]; National Multiple Sclerosis Society [RG3705A1, RG3798A2] FX This work was supported by research grants to Dr. Bakshi from the National Institutes of Health (NIH-NINDS K23 NS42379-01 and R01 NS055083-01) and National Multiple Sclerosis Society (RG3705A1; RG3798A2). We thank Ms. Sophie Tamm for assistance with manuscript preparation. NR 32 TC 63 Z9 70 U1 1 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1051-2284 J9 J NEUROIMAGING JI J. Neuroimaging PD JAN PY 2009 VL 19 IS 1 BP 3 EP 8 DI 10.1111/j.1552-6569.2008.00296.x PG 6 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 392DS UT WOS:000262283700002 PM 19192042 ER PT J AU Alcalay, RN Smith, EE AF Alcalay, Roy N. Smith, Eric E. TI MRI Showing White Matter Lesions and Multiple Lobar Microbleeds in a Patient with Reversible Encephalopathy SO JOURNAL OF NEUROIMAGING LA English DT Article DE Inflammatory; amyloid; angiopathy; corticosteroids; encephalopathy; microbleeds ID CEREBRAL AMYLOID ANGIOPATHY; INFLAMMATION AB Cerebral amyloid angiopathy (CAA) can rarely be complicated by vascular and perivascular inflammation. Patients typically present with subacute cognitive decline, seizures, headaches, and hyperintensities on T2-weighted or fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) sequences. Little is known about the cause and natural history of inflammatory CAA, but recent case series show that some patients respond well to steroids. Here, we describe a patient who presented with severe subacute encephalopathy and was diagnosed with probable CAA-related inflammation based on characteristic MRI, showing subcortical FLAIR hyperintensities with mass effect and multiple cortical microbleeds, after excluding other possible causes of subacute delirium. Mental status examination markedly improved after a course of intravenous methylprednisolone, initially without significant change in MRI appearance. An MRI 4 months later, however, showed marked reduction in the volume of white matter T2 hyperintensities. Mental status remained improved with mild residual retrograde and anterograde amnesia. We propose that the diagnosis of CAA-related inflammation should be considered in patients with profound subacute mental status changes and typical MRI findings. In steroid-responsive patients, clinical improvement can precede radiographic improvement. J Neuroimaging 2009;19:89-91. C1 [Smith, Eric E.] Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, Boston, MA 02114 USA. RP Alcalay, RN (reprint author), Columbia Univ, Neurol Inst, 3rd Floor,710 W,168th St, New York, NY 10032 USA. EM royalcalay@gmail.com OI Smith, Eric/0000-0003-3956-1668 NR 8 TC 7 Z9 7 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1051-2284 J9 J NEUROIMAGING JI J. Neuroimaging PD JAN PY 2009 VL 19 IS 1 BP 89 EP 91 DI 10.1111/j.1552-6569.2008.00241.x PG 3 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 392DS UT WOS:000262283700019 PM 18494780 ER PT J AU Wuethrich, C Cheng, YM Joseph, JT Kesari, S Beckwith, C Stopa, E Bell, JE Koralnik, IJ AF Wuethrich, Christian Cheng, Yi Min Joseph, Jeffrey T. Kesari, Santosh Beckwith, Curt Stopa, Edward Bell, Jeanne E. Koralnik, Igor J. TI Frequent Infection of Cerebellar Granule Cell Neurons by Polyomavirus JC in Progressive Multifocal Leukoencephalopathy SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE Cerebellum; Granule cell neurons; HIV; JC virus; Progressive multifocal leukoencephalopathy ID SIMIAN IMMUNODEFICIENCY VIRUS; CD8(+) T-CELLS; IMMUNE RECONSTITUTION; GLIAL-CELLS; HUMAN BRAIN; AIDS; DISEASE; NEURONOPATHY; PATIENT; TISSUE AB Progressive multifocal leukoencephalopathy (PML) occurs, most often in immunosuppressed individuals. The lesions of PML result from astrocyte and oligodendrocyte infection by the polyomavirus JC (JCV): JCV has also been shown to infect and destroy cerebellar granule cell neurons (GCNs) in 2 human immunodeficiency virus (HIV)-positive patients. To determine the prevalence and pattern of JCV infection in GCNs, we immunostained formalin-fixed paraffin-embedded cerebellar samples from 40 HIV-positive and 3 HIV-negative PML patients for JCV, and glial and neuronal markers. The JCV infection was detected in 30 patients (70%); 28 (93%) of them had JCV-infected cells in the GC layer: JCV-infected GCNs were demonstrated in 15 (79%) of 19 tested cases, The JCV regulatory T antigen was expressed more frequently and abundantly in GCNs than JCV VP1 capsid protein. None of 37 HIV-negative controls but 1 (3%) of 35 HIV-positive subjects without PML had distinct foci of JCV-intected GCNs. Thus, JCV infection of GCNs is frequent in PML patients and may occur in the absence of cerebellar white matter demyelinating lesions. The predominance of T antigen over VP1 expression in GCNs suggests that they may be the site of early or latent central nervous system JCV infection. These results indicate that infection of GCNs is all important, previously overlooked. aspect of JCV pathogenesis in immunosuppressed individuals. C1 [Wuethrich, Christian; Cheng, Yi Min; Koralnik, Igor J.] Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02215 USA. [Joseph, Jeffrey T.; Koralnik, Igor J.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. [Kesari, Santosh] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Kesari, Santosh] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Stopa, Edward] Brown Univ, Alpert Med Sch, Rhode Isl Hosp, Providence, RI 02912 USA. [Beckwith, Curt] Miriam Hosp, Div Infect Dis, Providence, RI 02906 USA. [Bell, Jeanne E.] Univ Edinburgh, Western Gen Hosp, Neuropathol Unit, Edinburgh, Midlothian, Scotland. RP Koralnik, IJ (reprint author), Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, E-CLS-1005,330 Brookline Ave, Boston, MA 02215 USA. EM ikoralni@bidmc.harvard.edu RI Kesari, Santosh/E-8461-2013 FU National Institutes of Health to Igor Koralnik. MD [R21 NS 051124, ROI NS 047029, 041198, K24 NS 060950] FX This study was supported in part by Grant No. R21 NS 051124, ROI NS 047029 and 041198 and K24 NS 060950 from the National Institutes of Health to Igor Koralnik. MD. NR 28 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3069 EI 1554-6578 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD JAN PY 2009 VL 68 IS 1 BP 15 EP 25 PG 11 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 390YY UT WOS:000262200800002 PM 19104450 ER PT J AU Liu, JX Yu, ZY Guo, SZ Lee, SR Xing, CH Zhang, CG Gao, Y Nicholls, DG Lo, EH Wang, XY AF Liu, Jianxiang Yu, Zhanyang Guo, Shuzhen Lee, Sun-Ryung Xing, Changhong Zhang, Chenggang Gao, Yan Nicholls, David G. Lo, Eng H. Wang, Xiaoying TI Effects of Neuroglobin Overexpression on Mitochondrial Function and Oxidative Stress Following Hypoxia/Reoxygenation in Cultured Neurons SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE neuroglobin; oxidative stress; hypoxia; mitochondria; neuroprotection ID CELL-DEATH; CORTICAL-NEURONS; NERVOUS-SYSTEM; PROTEIN-KINASE; NITRIC-OXIDE; OXYGEN; HYPOXIA; BRAIN; HEMOGLOBIN; GLOBIN AB Neuroglobin (Ngb) is a recently discovered tissue globin with a high affinity for oxygen that is widely and specifically expressed in neurons of vertebrate central and peripheral nervous systems. Our laboratory and others have shown Ngb overexpression can protect neurons against hypoxic/ischemic insults, but the underlying mechanisms remain poorly understood. In this study, we examined the effects of Ngb overexpression on mitochondrial function, oxidative stress, and neurotoxicity in primary cortical neurons following hypoxia/reoxygenation (H/R). Ngb-overexpressing transgenic neurons (Ngb-Tg) were significantly protected against H/R-induced cell death. Rates of decline in ATP levels, MTT reduction, and mitochondrial membrane potential were significantly ameliorated in Ngb-Tg neurons. Furthermore, Ngb overexpression reduced superoxide anion generation after H/R, whereas glutathione levels were significantly improved compared with WT controls. Taken together, these data suggest that Ngb is neuroprotective against hypoxia, in part by improving mitochondria function and decreasing oxidative stress. (C) 2008 Wiley-Liss, Inc. C1 [Liu, Jianxiang; Yu, Zhanyang; Guo, Shuzhen; Lee, Sun-Ryung; Xing, Changhong; Lo, Eng H.; Wang, Xiaoying] Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, Charlestown, MA 02129 USA. [Liu, Jianxiang; Yu, Zhanyang; Guo, Shuzhen; Lee, Sun-Ryung; Xing, Changhong; Lo, Eng H.; Wang, Xiaoying] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA. [Liu, Jianxiang; Yu, Zhanyang; Guo, Shuzhen; Lee, Sun-Ryung; Xing, Changhong; Lo, Eng H.; Wang, Xiaoying] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA. [Liu, Jianxiang] China CDC, Natl Inst Radiol Protect, Beijing, Peoples R China. [Lee, Sun-Ryung] Cheju Natl Univ, Dept Life Sci, Cheju, South Korea. [Zhang, Chenggang; Gao, Yan] Beijing Inst Radiat Med, Dept Mol Neurobiol, Beijing, Peoples R China. [Nicholls, David G.] Buck Inst Age Res, Novato, CA USA. RP Wang, XY (reprint author), Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, 149 13th St,Room 2411A, Charlestown, MA 02129 USA. EM wangxi@helix.mgh.harvard.edu RI Zhang, Chenggang/B-1480-2009; NICHOLLS, DAVID/K-4300-2012 OI Zhang, Chenggang/0000-0002-4521-3304; FU NIH [R01-NS049476, R01-NS48422, R01-NS53560, P01-NS55104]; American Heart Association [0435087N] FX NIH; Contract grant number: R01-NS049476; Contract grant number: R01-NS48422 (to E.H.L.); Contract grant number: R01-NS53560 (to E.H.L.): Contract grant number: P01-NS55104 (to E.H.L.); Contract grant sponsor: American Heart Association; Contract grant number: 0435087N (to X.W.). NR 41 TC 72 Z9 83 U1 1 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD JAN PY 2009 VL 87 IS 1 BP 164 EP 170 DI 10.1002/jnr.21826 PG 7 WC Neurosciences SC Neurosciences & Neurology GA 397QX UT WOS:000262678300017 PM 18711728 ER PT J AU Campbell, JH Burdo, TH Autissier, P Ratai, EM Bombardier, JP Westmoreland, SV Soulas, C Gonzaz, RG Williams, KC AF Campbell, Jennifer H. Burdo, Tricia H. Autissier, Patrick Ratai, Eva-Maria Bombardier, Jeffery P. Westmoreland, Susan V. Soulas, Caroline Gonzaz, Ramon G. Williams, Kenneth C. TI The tetracycline antibiotic minocycline prevents the activation of CD14/CD16 monocytes in blood and accumulation in the brain, as well as the development of SIV encephalitis in rhesus macaques SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 9th International Symposium on NeuroVirology CY JUN 02-06, 2009 CL Miami Beach, FL C1 [Campbell, Jennifer H.; Burdo, Tricia H.; Autissier, Patrick; Soulas, Caroline; Williams, Kenneth C.] Boston Coll, Dept Biol, Boston, MA USA. [Ratai, Eva-Maria; Bombardier, Jeffery P.; Gonzaz, Ramon G.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Ratai, Eva-Maria; Bombardier, Jeffery P.; Gonzaz, Ramon G.] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Ratai, Eva-Maria; Bombardier, Jeffery P.; Westmoreland, Susan V.; Gonzaz, Ramon G.] Harvard Univ, Sch Med, Boston, MA USA. [Westmoreland, Susan V.] New England Reg Primate Res Ctr, Southborough, MA 01772 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 MA P30 BP 14 EP 14 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DT UT WOS:000270278700031 ER PT J AU Clarke, P Leser, S Tyler, KL AF Clarke, Penny Leser, Smith Tyler, Kenneth L. TI Gene Expression in the Brain During Virus-Induced Encephalitis SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 9th International Symposium on NeuroVirology CY JUN 02-06, 2009 CL Miami Beach, FL C1 [Clarke, Penny; Leser, Smith; Tyler, Kenneth L.] Univ Colorado Denver, Denver, CO USA. [Tyler, Kenneth L.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 MA P38 BP 17 EP 18 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DT UT WOS:000270278700039 ER PT J AU Cowley, D Gray, L Chiavaroli, L Gorry, PR Gabuzda, D Wesselingh, S Churchill, M AF Cowley, Daniel Gray, Lachlan Chiavaroli, Lisa Gorry, Paul R. Gabuzda, Dana Wesselingh, Steve Churchill, Melissa TI Genetic and functional analysis of HIV-1 Tat derived from central nervous system isolates of patients with HIV-1 associated dementia SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 9th International Symposium on NeuroVirology CY JUN 02-06, 2009 CL Miami Beach, FL C1 [Cowley, Daniel; Gray, Lachlan; Chiavaroli, Lisa; Gorry, Paul R.; Wesselingh, Steve; Churchill, Melissa] Macfarlane Burnet Inst Med Res & Publ Hlth, Ctr Virol, Melbourne, Vic, Australia. [Cowley, Daniel; Gorry, Paul R.; Wesselingh, Steve; Churchill, Melissa] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia. [Gray, Lachlan; Gorry, Paul R.] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic, Australia. [Gabuzda, Dana] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Gabuzda, Dana] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 MA P40 BP 18 EP 19 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DT UT WOS:000270278700041 ER PT J AU Gray, LR Roche, M Churchill, MJ Sterjovski, J Ellett, A Poumbourios, P Sherrief, S Wang, B Saksena, N Purcell, DFJ Wesselingh, S Cunningham, AL Brew, BJ Gabuzda, D Gorry, PR AF Gray, Lachlan R. Roche, Michael Churchill, Melissa J. Sterjovski, Jasminka Ellett, Anne Poumbourios, Pantelis Sherrief, Shameem Wang, Bin Saksena, Nitin Purcell, Damian F. J. Wesselingh, Steven Cunningham, Anthony L. Brew, Bruce J. Gabuzda, Dana Gorry, Paul R. TI Tissue-specific sequence alterations in the HIV-1 envelope favoring CCR5-usage contribute to persistence of dual-tropic virus in brain SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 9th International Symposium on NeuroVirology CY JUN 02-06, 2009 CL Miami Beach, FL C1 [Gray, Lachlan R.; Roche, Michael; Churchill, Melissa J.; Sterjovski, Jasminka; Ellett, Anne; Poumbourios, Pantelis; Gorry, Paul R.] Macfarlane Burnet Inst Med Res & Publ Hlth, Melbourne, Vic, Australia. [Gray, Lachlan R.; Purcell, Damian F. J.; Wesselingh, Steven; Gorry, Paul R.] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic, Australia. [Roche, Michael; Churchill, Melissa J.; Sterjovski, Jasminka; Wesselingh, Steven; Gorry, Paul R.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia. [Sherrief, Shameem; Wang, Bin; Saksena, Nitin; Cunningham, Anthony L.] Westmead Millennium Inst, Retroviral Genet Div, Westmead, NSW, Australia. [Brew, Bruce J.] St Vincents Ctr Appl Med Res, Dept Neurol, Darlinghurst, NSW, Australia. [Gabuzda, Dana] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Gabuzda, Dana] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA. RI Cunningham, Tony/B-7011-2013; Brew, Bruce/J-6513-2012 NR 0 TC 0 Z9 0 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 MA P67 BP 31 EP 32 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DT UT WOS:000270278700068 ER PT J AU Killebrew, DA Poulton, W Longo, FM Massa, SM Meeker, RB AF Killebrew, D. A. Poulton, W. Longo, F. M. Massa, S. M. Meeker, R. B. TI Neurotrophin Mimetics reverse effects of HIV gp120 on Macrophages and Microglia SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 9th International Symposium on NeuroVirology CY JUN 02-06, 2009 CL Miami Beach, FL C1 [Killebrew, D. A.; Poulton, W.; Meeker, R. B.] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA. [Longo, F. M.] Stanford Univ, Sch Med, Dept Neurol, Stanford, CA 94305 USA. [Massa, S. M.] San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 MA P91 BP 42 EP 43 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DT UT WOS:000270278700092 ER PT J AU Lentz, MR Mohamed, MA Degaonkar, MN Lee, V Kim, H Halpern, EF Sacktor, N Selnes, O Barker, PB Pomper, MG AF Lentz, Margaret R. Mohamed, Mona A. Degaonkar, Mahaveer N. Lee, Vallent Kim, Hyun Halpern, Elkan F. Sacktor, Ned Selnes, Ola Barker, Peter B. Pomper, Martin G. TI NAA factor scores suggest neuronal recovery during antiretroviral therapy: an MRSI study SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 9th International Symposium on NeuroVirology CY JUN 02-06, 2009 CL Miami Beach, FL C1 [Lentz, Margaret R.; Lee, Vallent; Kim, Hyun; Halpern, Elkan F.] Massachusetts Gen Hosp, Dept Neuroradiol, Charlestown, MA 02129 USA. [Lentz, Margaret R.; Lee, Vallent; Kim, Hyun; Halpern, Elkan F.] AA Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Mohamed, Mona A.; Degaonkar, Mahaveer N.; Barker, Peter B.; Pomper, Martin G.] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21231 USA. [Sacktor, Ned; Selnes, Ola] Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21231 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 MA P99 BP 46 EP 47 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DT UT WOS:000270278700100 ER PT J AU Lentz, MR Mohamed, MA Degaonkar, MN Kim, H Halpern, EF Sacktor, N Conant, K Barker, PB Pomper, MG AF Lentz, Margaret R. Mohamed, Mona A. Degaonkar, Mahaveer N. Kim, Hyun Halpern, Elkan F. Sacktor, Ned Conant, Katherine Barker, Peter B. Pomper, Martin G. TI Neuronal metabolism in HIV plus subjects lacking immune control correlates to M-CSF levels in cerebrospinal fluid SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 9th International Symposium on NeuroVirology CY JUN 02-06, 2009 CL Miami Beach, FL C1 [Lentz, Margaret R.; Kim, Hyun; Halpern, Elkan F.] Massachusetts Gen Hosp, Dept Neuroradiol, Charlestown, MA 02129 USA. [Lentz, Margaret R.; Kim, Hyun; Halpern, Elkan F.] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Mohamed, Mona A.; Degaonkar, Mahaveer N.; Barker, Peter B.; Pomper, Martin G.] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21231 USA. [Sacktor, Ned; Conant, Katherine] Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21231 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 MA P100 BP 47 EP 48 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DT UT WOS:000270278700101 ER PT J AU Mohamed, MA Lentz, MR Lee, V Halpern, EF Sacktor, N Selnes, O Barker, PB Pomper, MG AF Mohamed, Mona A. Lentz, Margaret R. Lee, Vallent Halpern, Elkan F. Sacktor, Ned Selnes, Ola Barker, Peter B. Pomper, Martin G. TI Neuronal factor analysis of proton MR spectroscopic imaging data in HIV infection: Regional patterns of involvement and relationship to cognitive status SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 9th International Symposium on NeuroVirology CY JUN 02-06, 2009 CL Miami Beach, FL C1 [Mohamed, Mona A.; Barker, Peter B.; Pomper, Martin G.] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21231 USA. [Lentz, Margaret R.; Lee, Vallent; Halpern, Elkan F.] Massachusetts Gen Hosp, Dept Neuroradiol, Charlestown, MA 02129 USA. [Lentz, Margaret R.; Lee, Vallent; Halpern, Elkan F.] AA Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Sacktor, Ned; Selnes, Ola] Johns Hopkins Med Inst, Dept Neurol, Baltimore, MD 21231 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 MA P127 BP 61 EP 62 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DT UT WOS:000270278700128 ER PT J AU Ratai, EM Bombardier, JP Joo, CG Lentz, MR He, JL Annamalai, L Burdot, T Westmoreland, SV Williams, KC Masliah, E Gonzalez, G AF Ratai, Eva-Maria Bombardier, Jeffrey P. Joo, Chan-Gyu Lentz, Margaret R. He, Julian Annamalai, Lakshmanan Burdot, Tricia Westmoreland, Susan V. Williams, Kenneth C. Masliah, Eliezer Gonzalez, Gilberto TI Combined antiretroviral therapy (CART) results in decreased astrocytosis and reversal of neuronal injury in SIV-infected CD8-depleted rhesus macaques SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 9th International Symposium on NeuroVirology CY JUN 02-06, 2009 CL Miami Beach, FL C1 [Ratai, Eva-Maria; Bombardier, Jeffrey P.; Joo, Chan-Gyu; Lentz, Margaret R.; He, Julian; Gonzalez, Gilberto] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Ratai, Eva-Maria; Bombardier, Jeffrey P.; Joo, Chan-Gyu; Lentz, Margaret R.; He, Julian; Gonzalez, Gilberto] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Ratai, Eva-Maria; Joo, Chan-Gyu; Lentz, Margaret R.; He, Julian; Annamalai, Lakshmanan; Westmoreland, Susan V.; Gonzalez, Gilberto] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Burdot, Tricia; Williams, Kenneth C.] Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA. [Masliah, Eliezer] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 MA P156 BP 75 EP 76 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DT UT WOS:000270278700157 ER PT J AU Ratai, EM Bombardier, JP Joo, CG Lentz, MR He, JL Annamalai, L Burdot, T Campbell, J Masliah, E Westmoreland, SV Williams, K Gonzalez, G AF Ratai, Eva-Maria Bombardier, Jeffrey P. Joo, Chan-Gyu Lentz, Margaret R. He, Julian Annamalai, Lakshmanan Burdot, Tricia Campbell, Jennifer Masliah, Eliezer Westmoreland, Susan V. Williams, Kenneth Gonzalez, Gilberto TI Brain Creatine Elevation and NAA Reduction detected by 3T 1H MR Spectroscopy Indicates Neuronal Dysfunction in the Setting of Enhanced Glial High Energy Metabolism in a macaque model of neuroAIDS SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 9th International Symposium on NeuroVirology CY JUN 02-06, 2009 CL Miami Beach, FL C1 [Ratai, Eva-Maria; Bombardier, Jeffrey P.; Joo, Chan-Gyu; Lentz, Margaret R.; He, Julian; Gonzalez, Gilberto] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Ratai, Eva-Maria; Bombardier, Jeffrey P.; Joo, Chan-Gyu; Lentz, Margaret R.; He, Julian; Gonzalez, Gilberto] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Ratai, Eva-Maria; Bombardier, Jeffrey P.; Joo, Chan-Gyu; Lentz, Margaret R.; He, Julian; Annamalai, Lakshmanan; Westmoreland, Susan V.; Gonzalez, Gilberto] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Burdot, Tricia; Campbell, Jennifer; Williams, Kenneth] Boston Coll, Dept Biol, Boston, MA USA. [Masliah, Eliezer] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 MA P157 BP 76 EP 77 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DT UT WOS:000270278700158 ER PT J AU Ratai, EM Joo, CG Bombardier, JP He, JL Burdot, T Campbell, J Autissier, P Annamalai, L Williams, K Westmoreland, SV Gonzalez, G AF Ratai, Eva-Maria Joo, Chan-Gyu Bombardier, Jeffrey P. He, Julian Burdot, Tricia Campbell, Jennifer Autissier, Patrick Annamalai, Lakshmanan Williams, Kenneth Westmoreland, Susan V. Gonzalez, Gilberto TI 1H MR Spectroscopy reveals neuroprotection by minocycline in an accelerated rhesus macaque model of neuroAIDS SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 9th International Symposium on NeuroVirology CY JUN 02-06, 2009 CL Miami Beach, FL C1 [Ratai, Eva-Maria; Joo, Chan-Gyu; Bombardier, Jeffrey P.; He, Julian; Gonzalez, Gilberto] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Ratai, Eva-Maria; Joo, Chan-Gyu; Bombardier, Jeffrey P.; He, Julian; Gonzalez, Gilberto] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Burdot, Tricia; Campbell, Jennifer; Autissier, Patrick; Williams, Kenneth] Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA. [Ratai, Eva-Maria; Joo, Chan-Gyu; He, Julian; Gonzalez, Gilberto] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 MA P158 BP 77 EP 77 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DT UT WOS:000270278700159 ER PT J AU Cardenas, VA Meyerhoff, DJ Studholme, C Kornak, J Rothlind, J Lampiris, H Neuhaus, J Grant, RM Chao, LL Truran, D Weiner, MW AF Cardenas, V. A. Meyerhoff, D. J. Studholme, C. Kornak, J. Rothlind, J. Lampiris, H. Neuhaus, J. Grant, R. M. Chao, L. L. Truran, D. Weiner, M. W. TI Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy SO JOURNAL OF NEUROVIROLOGY LA English DT Article DE ART; brain; brain MRI; deformation morphometry; HIV; segmentation ID CEREBRAL VOLUME LOSS; STRUCTURAL ABNORMALITIES; ALCOHOL DEPENDENCE; HIV-INFECTION; INDIVIDUALS; ABSTINENT; COCAINE; PERFORMANCE; PREVALENCE; HIV/AIDS AB Treatment with antiretroviral therapy (ART) has greatly reduced the incidence of dementia. The goal of this longitudinal study was to determine if there are ongoing macrostructural brain changes in human immunodeficiency virus-positive (HIV+) individuals treated with ART. To quantify brain structure, three-dimensional T1-weighted magnetic resonance imaging (MRI) scans were performed at baseline and again after 24 months in 39 HIV + patients on ART and 30 HIV- controls. Longitudinal changes in brain volume were measured using tissue segmentation within regions of interest and deformation morphometry. Measured by tissue segmentation, HIV + patients on ART had significantly (all P <. 05) greater rates of white matter volume loss than HIV- control individuals. Compared with controls, the subgroup of HIV+ individuals on ART with viral suppression also had significantly greater rates of white matter volume loss. Deformation morphometry confirmed these results with more specific spatial localization. Deformation morphometry also detected greater rates of gray matter and white matter loss in the subgroup of HIV+ individuals with detectable viral loads. These results provide evidence of ongoing brain volume loss in HIV+ individuals on stable ART, possibly suggesting ongoing cerebral injury. The presence of continuing injury raises the possibility that HIV+ individuals-even in the presence of viral suppression in the periphery-are at greater risk for future cognitive impairments and dementia and possibly faster cognitive decline. Therefore, HIV+ individuals on ART should be monitored for cognitive decline, and treatments that reduce ongoing neurological injury should be considered. Journal of NeuroVirology (2009) 15, 324-333. C1 [Cardenas, V. A.; Meyerhoff, D. J.; Studholme, C.; Rothlind, J.; Lampiris, H.; Chao, L. L.; Weiner, M. W.] San Francisco VA Med Ctr, San Francisco, CA USA. [Kornak, J.; Rothlind, J.; Lampiris, H.; Neuhaus, J.; Grant, R. M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94121 USA. [Cardenas, V. A.; Meyerhoff, D. J.; Studholme, C.; Chao, L. L.; Truran, D.; Weiner, M. W.] No Calif Inst Res & Educ, San Francisco, CA USA. [Grant, R. M.] Gladstone Inst Virol & Immunol, San Francisco, CA USA. RP Cardenas, VA (reprint author), Univ Calif San Francisco, Dept Vet Affairs Med Ctr, 4150 Clement St,114M, San Francisco, CA 94121 USA. EM valerie.cardenas-nicolson@ucsf.edu FU NIAAA NIH HHS [P01 AA011493, P01 AA011493-03]; NIBIB NIH HHS [R03 EB008136-01, R03 EB 008136, R03 EB008136]; NIMH NIH HHS [R01 MH065392, R01 MH065392-01, R01 MH65392] NR 45 TC 48 Z9 50 U1 0 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PY 2009 VL 15 IS 4 BP 324 EP 333 DI 10.1080/13550280902973960 PG 10 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 500DU UT WOS:000270278800004 PM 19499454 ER PT J AU Bansal, S Harber, P Yun, D Liu, D Liu, YH Wu, S Ng, D Santiago, S AF Bansal, Siddharth Harber, Philip Yun, David Liu, David Liu, Yihang Wu, Samantha Ng, David Santiago, Silverio TI Respirator Physiological Effects under Simulated Work Conditions SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE physiology; plethysmography; pulmonary ventilation; respirator; terrorism ID PROTECTIVE DEVICES; INSPIRATORY RESISTANCE; INDUCTIVE PLETHYSMOGRAPHY; INDUSTRIAL RESPIRATORS; EXHALATION RESISTANCES; EXERCISE PERFORMANCE; DEMAND RESPIRATOR; LUNG-DISEASE; FACE MASKS; DEAD SPACE AB This study compared the physiological impacts of two respirator types in simulated work conditions. Fifty-six subjects included normal volunteers and persons with mild respiratory impairments (chronic rhinitis, mild COPD, and mild asthma). Respiratory parameters and electrocardiogram were measured using respiratory inductive plethysmography while performing eight work tasks involving low to moderate exertion using two respirators: (1) a dual cartridge half face mask (HFM) respirator, and (2) the N95. Mixed model regression analyses evaluating the effect of task and respirator type showed that task affected tidal volume, minute ventilation, breathing frequency and heart rate; all were greater in heavier tasks. Although respirator type did not affect respiratory volume parameters and flow rates, the HFM led to increase in the inspiratory time, reduction of the expiratory time, and increase in the duty cycle in comparison with the N95. The magnitude of differences was relatively small. The results suggest that most individuals, including persons with mild respiratory impairments, will physiologically tolerate either type of respirator at low to moderate exertion tasks. However, because effective protection depends on proper use, differences in subjective effect may have greater impact than physiological differences. Using respirators may be feasible on a widespread basis if necessary for maintaining essential services in the face of widespread concern about an infectious or terrorist threat. C1 [Bansal, Siddharth; Harber, Philip; Yun, David; Liu, David; Liu, Yihang; Wu, Samantha] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Los Angeles, CA 90095 USA. [Harber, Philip; Ng, David; Santiago, Silverio] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Pulm Med, Los Angeles, CA USA. RP Harber, P (reprint author), UCLA Occupat & Environm Med, 10880 Wilshire,1800, Los Angeles, CA 90024 USA. EM pharber@mednet.ucla.edu FU CDC/NIOSH [R01 OH-8119] FX This study was supported by grant # R01 OH-8119 from CDC/NIOSH. NR 46 TC 12 Z9 12 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PY 2009 VL 6 IS 4 BP 221 EP 227 DI 10.1080/15459620902729218 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 402JX UT WOS:000263011100002 PM 19180375 ER PT J AU Harber, P Bansal, S Santiago, S Liu, D Yun, D Ng, D Liu, YH Wu, S AF Harber, Philip Bansal, Siddharth Santiago, Silverio Liu, David Yun, David Ng, David Liu, Yihang Wu, Samantha TI Multidomain Subjective Response to Respirator Use During Simulated Work SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID LUNG-DISEASE; NEW-ORLEANS; PREVALENCE; EXERCISE; POPULATION; PROTECTION; RESISTANCE; HEALTH; FACE; APPARATUS AB Objective: Evaluate subjective tolerance to respirator use outside of traditional industrial settings by users including persons with mild respiratory impairment. Methods: The response to respirator use (half face mask dual cartridge and N95) was measured during eight types of work activities as well as in an exercise laboratory setting. The 43 research subjects included persons with mild respiratory impairments. Multiple domains of subjective response were evaluated. Results: Mixed model regression analyses assessing the effect of respirator type and task type showed: 1) most tolerated respirator use well; 2) half face mask respirators typically had greater adverse impact than N95 types; 3) multiple subjective outcomes, rather than only comfort/breathing impact, should be measured; and 4) rated subjective impact during work activities is less than in exercise laboratory settings. Conclusions: The results suggest that respirator use may be feasible on a widespread basis if necessary in the face of epidemic or terror concerns. (J Occup Environ Med. 2009;51:38-45) C1 [Harber, Philip; Bansal, Siddharth; Liu, David; Yun, David; Liu, Yihang; Wu, Samantha] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Los Angeles, CA 90095 USA. [Santiago, Silverio; Ng, David] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Pulm Med, Los Angeles, CA USA. RP Harber, P (reprint author), UCLA Occupat Med, 10880 Wilshire 1800, Los Angeles, CA 90024 USA. EM pharber@mednet.ucla.edu FU CDC/NIOSH [R01 OH-8119] FX Supported by Grant # R01 OH-8119 from CDC/NIOSH. NR 28 TC 18 Z9 18 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD JAN PY 2009 VL 51 IS 1 BP 38 EP 45 DI 10.1097/JOM.0b013e31817f458b PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 394NB UT WOS:000262452300007 PM 19136872 ER PT J AU Sorensen, G Quintiliani, L Pereira, L Yang, M Stoddard, A AF Sorensen, Glorian Quintiliani, Lisa Pereira, Lesley Yang, May Stoddard, Anne TI Work Experiences and Tobacco Use: Findings From the Gear Up for Health Study SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CARDIOVASCULAR RISK-FACTORS; SMOKING-CESSATION; CIGARETTE-SMOKING; QUITTING SMOKING; SLEEP DURATION; SOCIAL-CONTEXT; HEART-DISEASE; UNITED-STATES; JOB STRAIN; ENVIRONMENT AB Objective: To examine the relationships between the work environment and amount smoked, intention to quit, and participation in a health Promotion intervention. Methods: cross-sectional data were collected from unionized truck drivers and dockworkers (N = 542; response rate = 78%) employed in eight trucking terminals as part of a. larger intervention study targeting tobacco use cessation and weight management. Results: Prevalence of tobacco use was 40% (n = 216). Multivariable analyses of amount smoked and coworker norms encouraging cessation found significant associations with intention to quit and negative social consequences of tobacco use. Program participation was significantly associated with concern about job exposures, working the day shift, and intention to quit. Conclusions: Work experiences represented in the social contextual model may help explain how the work environment affects tobacco-use behaviors and interest in quitting, and maybe guide interventions among blue-collar workers. (J Occup Environ Med. 2009:51:87-94) C1 [Sorensen, Glorian; Quintiliani, Lisa; Pereira, Lesley] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Sorensen, Glorian; Quintiliani, Lisa] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Yang, May; Stoddard, Anne] New England Res Inst, Watertown, MA 02172 USA. RP Sorensen, G (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 44 Binney St, Boston, MA 02115 USA. EM glorian_sorensen@dfci.harvard.edu OI Quintiliani, Lisa/0000-0002-3328-6768 FU Centers for Disease Control and Prevention [5 R01 DP000099-03] FX This work was conducted with the support of a Grant from the Centers for Disease Control and Prevention (grant number 5 R01 DP000099-03). NR 47 TC 12 Z9 12 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD JAN PY 2009 VL 51 IS 1 BP 87 EP 94 DI 10.1097/JOM.0b013e31818f69f8 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 394NB UT WOS:000262452300012 PM 19136877 ER PT J AU Porter, RM Liu, FJ Pilapil, C Betz, OB Vrahas, MS Harris, MB Evans, CH AF Porter, Ryan M. Liu, Fangjun Pilapil, Carmencita Betz, Oliver B. Vrahas, Mark S. Harris, Mitchel B. Evans, Christopher H. TI Osteogenic Potential of Reamer Irrigator Aspirator (RIA) Aspirate Collected from Patients Undergoing Hip Arthroplasty SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE intramedullary reaming; reamer irrigator aspirator; hemiarthroplasty; bone regeneration; mesenchymal stem cells ID MESENCHYMAL STEM-CELLS; HUMAN BONE-MARROW; ILIAC CREST; OSTEOPROGENITOR CELLS; SITE MORBIDITY; STROMAL CELLS; DIFFERENTIATION; REPAIR; FEMUR; ECHOCARDIOGRAPHY AB Intramedullary nailing preceded by canal reaming is the current standard of treatment for long-bone fractures requiring stabilization. However, conventional reaming methods can elevate intramedullary temperature and pressure, potentially resulting in necrotic bone, systemic embolism, and pulmonary complications. To address this problem, a reamer irrigator aspirator (RIA) has been developed that combines irrigation and suction for reduced-pressure reaming with temperature modulation. Osseous particles aspirated by the RIA can be recovered by filtration for use as an autograft, but the flow-through is typically discarded. The purpose of this study was to assess whether this discarded filtrate has osteogenic properties that could be used to enhance the total repair potential of aspirate. RIA aspirate was collected from five patients (ages 71-78) undergoing hip hemiarthroplasty. Osseous particles were removed using an open-pore filter, and the resulting filtrate (230 +/- 200 mL) was processed by Ficoll-gradient centrifugation to isolate mononuclear cells (6.2 +/- 5.2 x 10(6) cells/mL). The aqueous supernatant contained FGF-2, IGF-I, and latent TGF-beta 1, but BMP-2 was below the limit of detection. The cell fraction included culture plastic-adherent, fibroblastic cells that displayed a surface marker profile indicative of mesenchymal stem cells and that could be induced along the osteogenic, adipogenic, and chondrogenic lineages in vitro, When compared to outgrowth cells from the culture of osseous particles, filtrate cells were more sensitive to seeding density during osteogenic Culture but had similar capacity for chondrogenesis. These results suggest using RIA aspirate to develop improved, clinically expeditious, cost-effective technologies for accelerating the healing of bone and other musculoskeletal tissues. (C) 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27:42-49, 2009 C1 [Porter, Ryan M.; Liu, Fangjun; Pilapil, Carmencita; Betz, Oliver B.; Evans, Christopher H.] Harvard Univ, Sch Med, Ctr Mol Orthoped, Boston, MA 02115 USA. [Vrahas, Mark S.; Harris, Mitchel B.; Evans, Christopher H.] Harvard Univ, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA. [Porter, Ryan M.; Liu, Fangjun; Pilapil, Carmencita; Betz, Oliver B.; Vrahas, Mark S.; Harris, Mitchel B.; Evans, Christopher H.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Vrahas, Mark S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Evans, CH (reprint author), Harvard Univ, Sch Med, Ctr Mol Orthoped, 221 Longwood Ave BLI-152, Boston, MA 02115 USA. EM cevans@rics.bwh.harvard.edu RI Liu, Fangjun/B-1012-2012 FU AO Research Fund [04-B86]; National Institute of Biomedical Imaging and Bioengineering [F32 EB005566] FX We would like to thank James Green (Synthes USA) for providing invaluable insight into the RIA system as well as meticulous commentary on this manuscript. This study was supported by the AO Research Fund (project no. 04-B86) of the AO Foundation (Davos, Switzerland). R.M.P. was supported by a postdoctoral Ruth L. Kirschstein National Research Service Award (F32 EB005566) from the National Institute of Biomedical Imaging and Bioengineering (Bethesda, MD). Synthes donated the RIA system and accessories needed for the purposes of this study. NR 38 TC 55 Z9 59 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD JAN PY 2009 VL 27 IS 1 BP 42 EP 49 DI 10.1002/jor.20715 PG 8 WC Orthopedics SC Orthopedics GA 384XW UT WOS:000261778500007 PM 18655129 ER PT J AU Gallagher, MF Flavin, RJ Elbaruni, SA McInerney, JK Smyth, PC Salley, YM Vencken, SF O'Toole, SA Laios, A Lee, MYC Denning, K Li, JH Aherne, ST Lao, KQ Martin, CM Sheils, OM O'Leary, JJ AF Gallagher, Michael F. Flavin, Richard J. Elbaruni, Salah A. McInerney, Jamie K. Smyth, Paul C. Salley, Yvonne M. Vencken, Sebastian F. O'Toole, Sharon A. Laios, Alexandros Lee, Mathia Y. C. Denning, Karen Li, Jinghuan Aherne, Sinead T. Lao, Kai Q. Martin, Cara M. Sheils, Orla M. O'Leary, John J. TI Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients SO JOURNAL OF OVARIAN RESEARCH LA English DT Article ID BREAST-CANCER CELLS; GASTRIC-CANCER; PROSTATE-CANCER; LUNG-CANCER; PROSPECTIVE IDENTIFICATION; PANCREATIC-CANCER; ESTROGEN-RECEPTOR; TUMOR-SUPPRESSOR; DOWN-REGULATION; GROWTH AB Background: Tumours with high proportions of differentiated cells are considered to be of a lower grade to those containing high proportions of undifferentiated cells. This property may be linked to the differentiation properties of stem cell-like populations within malignancies. We aim to identify molecular mechanism associated with the generation of tumours with differing grades from malignant stem cell populations with different differentiation potentials. In this study we assessed microRNA (miRNA) regulation in two populations of malignant Embryonal Carcinoma (EC) stem cell, which differentiate (NTera2) or remain undifferentiated (2102Ep) during tumourigenesis, and compared this to miRNA regulation in ovarian serous carcinoma (OSC) patient samples. Methods: miRNA expression was assessed in NTera2 and 2102Ep cells in the undifferentiated and differentiated states and compared to that of OSC samples using miRNA qPCR. Results: Our analysis reveals a substantial overlap between miRNA regulation in 2102Ep cells and OSC samples in terms of miRNA biosynthesis and expression of mature miRNAs, particularly those of the miR-17/92 family and clustering to chromosomes 14 and 19. In the undifferentiated state 2102Ep cells expressed mature miRNAs at up to 15,000 fold increased levels despite decreased expression of miRNA biosynthesis genes Drosha and Dicer. 2102Ep cells avoid differentiation, which we show is associated with consistent levels of expression of miRNA biosynthesis genes and mature miRNAs while expression of miRNAs clustering to chromosomes 14 and 19 is deemphasised. OSC patient samples displayed decreased expression of miRNA biosynthesis genes, decreased expression of mature miRNAs and prominent clustering to chromosome 14 but not 19. This indicates that miRNA biosynthesis and levels of miRNA expression, particularly from chromosome 14, are tightly regulated both in progenitor cells and in tumour samples. Conclusion: miRNA biosynthesis and expression of mature miRNAs, particularly the miR-17/92 family and those clustering to chromosomes 14 and 19, are highly regulated in both progenitor cells and tumour samples. Strikingly, 2102Ep cells are not simply malfunctioning but respond to differentiation specifically, a mechanism that is highly relevant to OSC samples. Our identification and future manipulation of these miRNAs may facilitate generation of lower grade malignancies from these high-grade cells. C1 [Gallagher, Michael F.; Elbaruni, Salah A.; McInerney, Jamie K.; Smyth, Paul C.; Salley, Yvonne M.; Vencken, Sebastian F.; Denning, Karen; Li, Jinghuan; Aherne, Sinead T.; Martin, Cara M.; Sheils, Orla M.; O'Leary, John J.] Univ Dublin Trinity Coll, Inst Mol Med, St Jamess Hosp, Dept Histopathol, Dublin 8, Ireland. [Gallagher, Michael F.; Elbaruni, Salah A.; McInerney, Jamie K.; Salley, Yvonne M.; Vencken, Sebastian F.; Martin, Cara M.; O'Leary, John J.] Coombe Women & Infants Univ Hosp, Dept Pathol, Dublin 8, Ireland. [O'Toole, Sharon A.; Laios, Alexandros] Univ Dublin Trinity Coll, Inst Mol Med, St Jamess Hosp, Dept Obstet & Gynaecol, Dublin 8, Ireland. [Flavin, Richard J.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA. [Lee, Mathia Y. C.] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117456, Singapore. [Lao, Kai Q.] Appl Biosyst Inc, Foster City, CA 94404 USA. RP Gallagher, MF (reprint author), Univ Dublin Trinity Coll, Inst Mol Med, St Jamess Hosp, Dept Histopathol, Dublin 8, Ireland. EM gallagmi@tcd.ie; richard_flavin@dfci.harvard.edu; elbaruns@tcd.ie; mcinerjk@tcd.ie; pasmyth@tcd.ie; salleyy@tcd.ie; venckens@tcd.ie; shotoole@tcd.ie; alxlaios2000@yahoo.com; leeycm@gis.a-star.edu.sg; denningk@tcd.ie; jinghual@tcd.ie; ahernesi@tcd.ie; lao@lifetech.com; cmartin3@tcd.ie; osheils@tcd.ie; olearyjj@tcd.ie RI Sheils, Orla Sheils/B-8461-2015; OI Sheils, Orla Sheils/0000-0002-4493-9496; Vencken, Sebastian/0000-0003-1427-5657; o toole, sharon/0000-0002-9260-3225 FU Applied Biosystems; Cultural Affairs Dept, Libyan People's Bureau, London, UK; HRB Clinical Research Fellowship [CRT/2006/010]; Emer Casey Foundation and Cancer Research Ireland FX We thank Professor Peter Andrews, University of Sheffield, for the kind gift of EC cells. We acknowledge financial support from Applied Biosystems. SAE is supported by funding from the Cultural Affairs Dept, Libyan People's Bureau, London, UK. RJF is funded by a HRB Clinical Research Fellowship (Grant No: CRT/2006/010). The authors wish to acknowledge support from The Emer Casey Foundation and Cancer Research Ireland. NR 100 TC 14 Z9 14 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1757-2215 J9 J OVARIAN RES JI J. Ovarian Res. PY 2009 VL 2 IS 1 AR 19 DI 10.1186/1757-2215-2-19 PG 16 WC Reproductive Biology SC Reproductive Biology GA V19NX UT WOS:000208080200019 PM 20015364 ER PT J AU Dussel, V Kreicbergs, U Hilden, JM Watterson, J Moore, C Turner, BG Weeks, JC Wolfe, J AF Dussel, Veronica Kreicbergs, Ulrika Hilden, Joanne M. Watterson, Jan Moore, Caron Turner, Brian G. Weeks, Jane C. Wolfe, Joanne TI Looking Beyond Where Children Die: Determinants and Effects of Planning a Child's Location of Death SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Children; cancer; palliative care; terminal care; hospice; home care; location of death; quality of care; attitude to death; death ID COMPLEX CHRONIC CONDITIONS; TERMINALLY-ILL PATIENTS; OF-LIFE CARE; PALLIATIVE CARE; CANCER-PATIENTS; END; PLACE; HOME; PARENTS; PERSPECTIVES AB While dying at home may be the choice of many, where people die may be less important than argued. We examined factors associated with parental planning of a child's location, of death (LOD) and its effects on patterns of care and parent's experience. In a cross-sectional study of 140 parents who lost a child to cancer at one of two tertiary-level US. pediatric hospitals, 88 (63%) planned the child's LOD and 97% accomplished their plan. After adjusting for disease and family characteristics, families whose primary oncologist clearly explained treatment options during the child's end of life and who had home care involved were more likely to plan LOD. Planning LOD was associated With more home deaths (72% vs. 8% among those who did not. plan, P < 0.001) and fever hospital admissions (54% vs.. 98%, P < 0.001). Parents who planned were more likely to feel very prepared for the child's end of life (33 % vs. 12%, P = 0.007) and very comfortable with LOD (84 % vs. 40% P < 0.001). and less likely to have preferred a different LOD (2 % vs. 46 %, P < 0.001). Among the 73 nonhome deaths, planning was associated with more deaths occurring in the ward Man in the intensive care unit or other hospital (92% vs. 33%, P < 0.001), and fewer children being intubated (21 % vs. 48 %, P = 0.029). Comprehensive Physician communication. and home care involvement increase the likelihood of planning a child's LOD. Opportunity to plan LOD is associated with outcomes consistent with high-quality palliative Core, even. among nonhome deaths, and thus may represent a more. relevant outcome than actual LOD. J Pain Symptom Manage 2009;37:33-43. (c) 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Dussel, Veronica; Kreicbergs, Ulrika; Weeks, Jane C.; Wolfe, Joanne] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA. [Dussel, Veronica; Kreicbergs, Ulrika; Wolfe, Joanne] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Weeks, Jane C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Hilden, Joanne M.] St Vincent Childrens Hosp, Indianapolis, IN USA. [Hilden, Joanne M.] Childrens Hosp Boston, Boston, MA USA. [Watterson, Jan; Moore, Caron] Childrens Hosp & Clin, St Paul, MN USA. [Turner, Brian G.; Weeks, Jane C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. RP Wolfe, J (reprint author), Dana Farber Canc Inst, Ctr Outcomes & Policy Res, 44 Binney St SM-206, Boston, MA 02115 USA. EM joanne_wolf@dfci.harvard.edu FU Agency for Health Research and Quality [T32HP10018]; National Cancer Institute and a Child Health Research [NCI 5 K07 CA096746]; Charles H. Hood Foundation; Pine Tree Apple Tennis Classic Oncology Research Fund FX Authors' work, was independent, of funders. V. Dussel is the recipient of a fellowship from the Agency for Health Research and Quality (T32HP10018).J. Wolfe was the recipient of Grant No. NCI 5 K07 CA096746 from the National Cancer Institute and a Child Health Research Grant. from the Charles H. Hood Foundation. J. Watterson was supported in part by the Pine Tree Apple Tennis Classic Oncology Research Fund. NR 46 TC 69 Z9 71 U1 3 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JAN PY 2009 VL 37 IS 1 BP 33 EP 43 DI 10.1016/j.jpainsymman.2007.12.017 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 396FT UT WOS:000262578300005 PM 18538973 ER PT J AU Carlson, MDA Morrison, S AF Carlson, Melissa D. A. Morrison, Sean TI Study Design, Precision, and Validity in Observational Studies SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID TERMINALLY-ILL PATIENTS; CRITICAL-APPRAISAL; PALLIATIVE CARE; READERS GUIDE; HOSPICE CARE; COHORT C1 [Carlson, Melissa D. A.] Mt Sinai Sch Med, Hertzberg Palliat Care Inst Brookdale, Dept Geriatr, New York, NY 10029 USA. [Carlson, Melissa D. A.; Morrison, Sean] Natl Palliat Care Res Ctr, New York, NY USA. [Morrison, Sean] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Carlson, MDA (reprint author), Mt Sinai Sch Med, Hertzberg Palliat Care Inst Brookdale, Dept Geriatr, Box 1070, New York, NY 10029 USA. EM melissa.carlson@mssm.edu FU National Institute for Nursing [K99NR10495]; National Institute on Aging [K24AG022345] FX Dr. Morrison is the recipient of a Mid-Career Investigator Award in Patient Oriented Research from the National Institute on Aging (K24AG022345). NR 14 TC 56 Z9 61 U1 2 U2 14 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD JAN PY 2009 VL 12 IS 1 BP 77 EP 82 DI 10.1089/jpm.2008.9690 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 399VR UT WOS:000262827900019 PM 19284267 ER PT J AU Perner, S Wagner, PL Soltermann, A LaFargue, C Tischler, V Weir, BA Weder, W Meyerson, M Giordano, TJ Moch, H Rubin, MA AF Perner, S. Wagner, P. L. Soltermann, A. LaFargue, C. Tischler, V. Weir, B. A. Weder, W. Meyerson, M. Giordano, T. J. Moch, H. Rubin, M. A. TI TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival SO JOURNAL OF PATHOLOGY LA English DT Article DE TTF1; amplification; non-small cell lung cancer; biomarker; thyroid cancer ID TRANSCRIPTION FACTOR-I; TISSUE MICROARRAY; PROSTATE-CANCER; ADENOCARCINOMA; FACTOR-1; FUSION; ONCOGENE; PREDICTS AB Acquired chromosomal aberrations play an important role in tumour development and progression. Such genetic alterations occur in a significant proportion of non-small cell lung carcinomas (NSCLCs) and include amplification of 14q13.3, which contains the TTF1 gene. We asked whether TTF1 amplification is associated with increased TTF1 protein expression in NSCLCs, and whether TTF1 is associated with clinicopathological features, including patient survival. We used a FISH assay and quantitative immunohistochemical staining to interrogate a population-based cohort of 538 NSCLCs from Swiss patients for TTF1 amplification and protein expression. We found TTF1 amplification in similar to 13% of adenocarcinomas (ACs) and in similar to 9% of squamous cell carcinomas (SCCs) and TTF1 amplification was associated with increased TTF1 protein expression. High-level TTF1 expression was significantly associated with smaller tumour size, female gender and longer overall survival only among ACs (median survival 82 versus 28 months; p = 0.002). On multivariate analysis, high TTF1 expression was an independent predictor of favourable prognosis in patients with AC [hazard ratio, 0.56 (95% CI 0.38-0.83); p = 0.008]. We conclude that TTF1 amplification is a mechanism of high-level TTF1 expression in a subset of NSCLCs. When expressed at high levels, this routinely used diagnostic marker is also an independent biomarker of favourable prognosis in AC. Copyright (C) 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. C1 [Perner, S.; Wagner, P. L.; LaFargue, C.; Rubin, M. A.] Weill Cornell Med Ctr, Dept Pathol & Lab Med, New York, NY USA. [Soltermann, A.; Tischler, V.; Moch, H.] Univ Zurich Hosp, Dept Pathol, Inst Surg Pathol, CH-8091 Zurich, Switzerland. [Weder, W.] Univ Zurich Hosp, Div Thorac Surg, CH-8091 Zurich, Switzerland. [Giordano, T. J.] Univ Michigan, Sch Med, Dept Pathol, Ctr Comprehens Canc, Ann Arbor, MI USA. [Weir, B. A.; Meyerson, M.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Dept Med Oncol, Boston, MA 02115 USA. [Weir, B. A.; Meyerson, M.] Harvard Univ, Broad Inst, Cambridge, MA 02138 USA. [Weir, B. A.; Meyerson, M.] MIT, Cambridge, MA 02139 USA. [Meyerson, M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Rubin, MA (reprint author), Weill Cornell Med Ctr, Dept Pathol & Lab Med, New York, NY USA. EM rubinma@med.cornell.edu RI Meyerson, Matthew/E-7123-2012 NR 24 TC 52 Z9 55 U1 0 U2 2 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0022-3417 J9 J PATHOL JI J. Pathol. PD JAN PY 2009 VL 217 IS 1 BP 65 EP 72 DI 10.1002/path.2443 PG 8 WC Oncology; Pathology SC Oncology; Pathology GA 389LQ UT WOS:000262094500008 PM 18932182 ER PT J AU Hait, EJ Barendse, RM Arnold, JH Valim, C Sands, BE Korzenik, JR Fishman, LN AF Hait, Elizabeth J. Barendse, Renee M. Arnold, Janis H. Valim, Clarissa Sands, Bruce E. Korzenik, Joshua R. Fishman, Laurie N. TI Transition of Adolescents With Inflammatory Bowel Disease From Pediatric to Adult Care: A Survey of Adult Gastroenterologists SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION LA English DT Article DE Inflammatory bowel disease; Pediatric to adult transition; Patient education ID HEALTH-CARE; YOUNG-ADULTS; RECOMMENDATIONS; SOCIETY; YOUTH; NEEDS AB Objectives: Transition of patients with inflammatory bowel disease IBD from pediatric to adult providers requires preparation. Gastroenterologists for adult patients ("adult gastroenterologists") may have expectations of patients that are different from those of pediatric patients. We sought to explore the perspectives of adult gastroenterologists caring for adolescents and young adults with IBD, to improve preparation for transition. Materials and Methods: A survey sent to IBD adult gastroenterologists caring for patients with IBD asked physicians to rank the importance of patient competencies thought necessary in successful transition to an adult practice. Providers reported which problems occurred in patients with IBD transitioning to their own practice. Adult gastroenterologists were asked about medical and developmental issues that are unique to adolescence. Results: A response rate of 34% was achieved. Adult gastroenterologists reported that young adults with IBD often demonstrated deficits in knowledge of their medical history (55%) and medication regimens (69%). In addition, 51% of adult gastroenterologists reported receiving inadequate medical history from pediatric providers. Adult providers were less concerned about the ability of patients to identify previous and current health care providers (19%), or attend office visits by themselves (15%). Knowledge of adolescent medical and developmental issues was perceived as important by adult gastroenterologists; however, only 46% felt competent addressing the developmental aspects of adolescents. Conclusions: For successful transition, adolescents and young adults with IBD need improved education about their medical history and medications. Pediatric providers need to improve communication with the receiving physicians. In addition, adult providers may benefit from further training in adolescent issues. Formal transition checklists and programs may improve the transition of patients with IBD from pediatric to adult care. JPGN 48:61-65, 2009. C1 [Hait, Elizabeth J.; Arnold, Janis H.; Fishman, Laurie N.] Childrens Hosp, Div Gastroenterol & Nutr, Boston, MA 02115 USA. [Hait, Elizabeth J.; Arnold, Janis H.; Fishman, Laurie N.] Childrens Hosp, Ctr Inflammatory Bowel Dis, Boston, MA 02115 USA. [Valim, Clarissa] Childrens Hosp, Clin Res Program, Div Biostat, Boston, MA 02115 USA. [Sands, Bruce E.; Korzenik, Joshua R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Crohns & Colitis Ctr, Boston, MA 02114 USA. [Barendse, Renee M.] Univ Amsterdam, Amsterdam, Netherlands. RP Fishman, LN (reprint author), Childrens Hosp, Div Gastroenterol & Nutr, 300 Longwood Ave, Boston, MA 02115 USA. EM laurie.fishman@childrens.harvard.edu FU Wolpow Family Fund FX Study supported by the Wolpow Family Fund. NR 22 TC 52 Z9 53 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0277-2116 J9 J PEDIATR GASTR NUTR JI J. Pediatr. Gastroenterol. Nutr. PD JAN PY 2009 VL 48 IS 1 BP 61 EP 65 PG 5 WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics GA 390MH UT WOS:000262167900010 PM 19172125 ER PT J AU Nansel, TR Rovner, AJ Haynie, D Iannotti, RJ Simons-Morton, B Wysocki, T Anderson, B Weissberg-Benchell, J Laffel, L AF Nansel, Tonja R. Rovner, Alisha J. Haynie, Denise Iannotti, Ronald J. Simons-Morton, Bruce Wysocki, Timothy Anderson, Barbara Weissberg-Benchell, Jill Laffel, Lori TI Development and Validation of the Collaborative Parent Involvement Scale for Youths with Type 1 Diabetes SO JOURNAL OF PEDIATRIC PSYCHOLOGY LA English DT Article ID QUALITY-OF-LIFE; METABOLIC-CONTROL; SELF-MANAGEMENT; LONGITUDINAL ANALYSIS; HEALTH-STATUS; ADOLESCENTS; FAMILY; ADHERENCE; MELLITUS; SUPPORT AB Objective To develop and test a youth-report measure of collaborative parent involvement in type 1 diabetes management. Methods Initial item development and testing were conducted with 81 youths; scale refinement and validation were conducted with 122 youths from four geographic regions. Descriptive statistics, Cronbachs , and factor analyses were conducted to select items comprising the scale. Correlations with parenting style and parent diabetes responsibility were examined. Multiple regression analyses examining associations with quality of life, adherence, and glycemic control were conducted to assess concurrent validity. Results The measure demonstrated strong internal consistency. It was modestly associated with parenting style, but not with parent responsibility for diabetes management. A consistent pattern of associations with quality of life and adherence provide support for the measures concurrent validity. Conclusions This brief youth-report measure of parent collaborative involvement assesses a unique dimension of parent involvement in diabetes management associated with important youth outcomes. C1 [Nansel, Tonja R.; Rovner, Alisha J.; Haynie, Denise; Iannotti, Ronald J.; Simons-Morton, Bruce] Eunice Kennedy Shriver NICHHD, Div Epidemiol Stat & Prevent Res, NIH, DHHS, Bethesda, MD 20892 USA. [Anderson, Barbara] Baylor Coll Med, Houston, TX 77030 USA. [Weissberg-Benchell, Jill] Childrens Mem Hosp, Chicago, IL 60614 USA. [Laffel, Lori] Joslin Diabet Ctr, Boston, MA 02215 USA. RP Nansel, TR (reprint author), 6100 Execut Blvd,Rm 7B13R,MSC 7510, Bethesda, MD 20892 USA. EM nanselt@mail.nih.gov OI Nansel, Tonja/0000-0002-8298-7595; Simons-Morton, Bruce/0000-0003-1099-6617; Haynie, Denise/0000-0002-8270-6079 FU Intramural NIH HHS [Z01 HD008741-06]; NICHD NIH HHS [N01-HD-4-3361, N01-HD-4-3362, N01 HD003364, N01-HD-4-3363, N01-HD-4-3364, N01-HD-3-3360] NR 42 TC 24 Z9 26 U1 7 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0146-8693 J9 J PEDIATR PSYCHOL JI J. Pediatr. Psychol. PD JAN-FEB PY 2009 VL 34 IS 1 BP 30 EP 40 DI 10.1093/jpepsy/jsn058 PG 11 WC Psychology, Developmental SC Psychology GA 392WW UT WOS:000262333900006 PM 18567926 ER PT J AU Duro, D Duggan, C Valim, C Bechard, L Fitzgibbons, S Jaksic, T Yu, YM AF Duro, Debora Duggan, Christopher Valim, Clarissa Bechard, Lori Fitzgibbons, Shimae Jaksic, Tom Yu, Yong-Ming TI Novel intravenous C-13-methionine breath test as a measure of liver function in children with short bowel syndrome SO JOURNAL OF PEDIATRIC SURGERY LA English DT Article; Proceedings Paper CT 39th Annual Meeting of the American-Pediatric-Surgical-Association CY MAY 27-JUN 01, 2008 CL Phoenix, AZ SP Amer Pediat Surg Assoc DE C-13-methionine; Stable isotope; Breath test; Short bowel syndrome; Parenteral nutrition-associated liver disease; Liver function ID PARENTERAL-NUTRITION; MANAGEMENT; STEATOSIS; RESECTION; INFANCY; TRACER AB Monitoring hepatic function in children with short bowel syndrome (SBS) and parenteral nutrition-associated liver disease (PNALD) is currently limited to conventional blood testing or liver biopsy. Metabolism of the stable isotope L[1-C-13]methionine occurs exclusively in liver mitochondria and can be noninvasively quantified in expired breath samples. We hypothesized that the, 3 C-methionine breath test (C-13-MBT) could be a safe, noninvasive, and valid measure of hepatic mitochondrial function in children with SBS and PNALD. Methods: Baseline breath samples were collected in 8 children with SBS before intravenous administration of 2 mg/kg of L[1-C-13]methionine. Six paired breath samples were obtained at 20-minute intervals. The (CO2)-C-13, enrichment was analyzed using isotope ratio mass spectrometry. Results: All 8 patients (5 males;, mean age, 8.9 months) tolerated the C-13-MIBT without adverse events. Two patients underwent serial testing. One patient, tested before and after resolution of cholestasis, demonstrated increased Cumulative percentage dose (4.7% to 6.6%) and area under the curve (AUC) (270-303). A second patient with progressive PNALD demonstrated decreased cumulative percentage dose (from 7.8% to 5.9%) and AUC (from 335 to 288). Conclusion: The C-13-MBT is a feasible, safe, and potentially clinically relevant measure of hepatic mitochondrial function in children with SBS and PNALD. (c) 2009 Elsevier Inc. All rights reserved. C1 [Duro, Debora; Duggan, Christopher; Bechard, Lori] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Gastroenterol & Nutr, Boston, MA 02115 USA. [Valim, Clarissa] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Surg,Clin Res Program, Boston, MA 02115 USA. [Yu, Yong-Ming] Shriners Burns Hosp Children, Tampa, FL USA. [Yu, Yong-Ming] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Duro, D (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Div Gastroenterol & Nutr, Boston, MA 02115 USA. EM debora.duro@childrens.harvard.edu FU NCRR NIH HHS [M01 RR002172, MO1-RR02172]; NICHD NIH HHS [K24 HD058795, T32 HD043034, T32-HD43034-05A1]; NIDDK NIH HHS [P30 DK040561, NIH P30DK040561, P30 DK040561-13] NR 18 TC 13 Z9 13 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0022-3468 J9 J PEDIATR SURG JI J. Pediatr. Surg. PD JAN PY 2009 VL 44 IS 1 BP 236 EP 240 DI 10.1016/j.jpedsurg.2008.10.046 PG 5 WC Pediatrics; Surgery SC Pediatrics; Surgery GA 404LR UT WOS:000263154300048 PM 19159749 ER PT J AU Chang, HL Patel, VI Brewster, DC Masiakos, PT AF Chang, Henry L. Patel, Virendra I. Brewster, David C. Masiakos, Peter T. TI Endovascular stenting of a penetrating axillary artery injury in a 14-year-old with 1-year follow-up SO JOURNAL OF PEDIATRIC SURGERY LA English DT Article DE Pediatric vascular trauma; Endovascular therapy; Vascular stent ID TRAUMA AB In the management of pediatric trauma, certain principles that are practiced in children who have sustained injuries more commonly seen in adults are extrapolated from the adult trauma literature. The increased use of computer tomography angiograms in the diagnosis of penetrating vascular trauma and endovascular therapy in treating vascular trauma in the adult population is being extended to the pediatric Population. We present a case of a 14-year-old male with an axillary artery injury that was diagnosed by computer tomography angiogram and treated with an endovascular Stent graft with 1-year follow-up. (C) 2009 Published by Elsevier Inc. C1 [Chang, Henry L.; Masiakos, Peter T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Surg, Boston, MA 02114 USA. [Patel, Virendra I.; Brewster, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Vasc Surg, Boston, MA 02114 USA. RP Masiakos, PT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat Surg, Boston, MA 02114 USA. EM pmasiakos@partners.org NR 10 TC 3 Z9 3 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0022-3468 J9 J PEDIATR SURG JI J. Pediatr. Surg. PD JAN PY 2009 VL 44 IS 1 BP 294 EP 297 DI 10.1016/j.jpedsurg.2008.08.024 PG 4 WC Pediatrics; Surgery SC Pediatrics; Surgery GA 404LR UT WOS:000263154300059 PM 19159760 ER PT J AU Shaker, M Jenkins, P Ullrich, C Brugnara, C Nghiem, BT Bernstein, H AF Shaker, Marcus Jenkins, Pamela Ullrich, Christina Brugnara, Carlo Nghiem, Bao Tram Bernstein, Henry TI An Economic Analysis of Anemia Prevention during Infancy SO JOURNAL OF PEDIATRICS LA English DT Article ID RETICULOCYTE HEMOGLOBIN CONTENT; IRON-DEFICIENT INFANTS; UNITED-STATES; ERYTHROPOIETIN; CHILDREN; THERAPY; PAY AB Objective To compare the cost-benefit profile of reticulocyte hemoglobin content (CHr) with hemoglobin (Hb) alone and Hb as a component of the complete blood count I for detection and treatment of iron deficiency in 9- to 12-month-old infants. Study design Cohort simulations were used to compare CHr with Hb from a societal perspective. Assumptions included a 9% prevalence of iron deficiency and testing characteristies/costs of CHr, Hb. and CBC (CHr <27.5 pg: sensitivity 83%, specificity 72%, $11; Hb < 11 g/dL: sensitivity 26%. speeificity 95%, $5, CBC Hb < 11 g/dL, as well as cost of iron therapy ($61 for established anemia). Sensitivity analyses were performed. Results Under current market conditions, the incremental cost to diagnose and treat iron deficiency, compared with diagnosing and treating anemia by Hb, was only $22 per patient screened I per case of anemia prevented: number needed to treat = 20). With a 10-year time horizon incorporating risks and costs of neurocognitive delays associated with untreated iron deficiency. the cost of the CHr strategy was $280 per case of anemia prevented. Conclusions CHr is an affordable strategy to prevent anemia in infants with possible iron deficiency. (J Pediatr 2009:154:44-9) C1 Dartmouth Hitchcock Med Ctr, Dept Pediat, Lebanon, NH 03756 USA. [Shaker, Marcus; Jenkins, Pamela; Bernstein, Henry] Childrens Hosp Dartmouth, Hanover, NH USA. [Shaker, Marcus; Jenkins, Pamela] Ctr Evaluat Clin Sci, Hanover, NH USA. [Nghiem, Bao Tram] Dartmouth Coll, Hanover, NH 03755 USA. [Brugnara, Carlo; Bernstein, Henry] Childrens Hosp, Boston, MA 02115 USA. [Ullrich, Christina] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Shaker, M (reprint author), Dartmouth Hitchcock Med Ctr, Dept Pediat, 1 Med Ctr Dr, Lebanon, NH 03756 USA. EM marcus.shaker@dartmouth.edu RI Brugnara, Carlo/A-8041-2010 OI Brugnara, Carlo/0000-0001-8192-8713 NR 19 TC 9 Z9 10 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD JAN PY 2009 VL 154 IS 1 BP 44 EP 49 DI 10.1016/j.jpeds.2008.06.038 PG 6 WC Pediatrics SC Pediatrics GA 391ZK UT WOS:000262272500012 PM 18760421 ER PT J AU Svoren, BM Volkening, LK Wood, JR Laffel, LMB AF Svoren, Britta M. Volkening, Lisa K. Wood, Jamie R. Laffel, Lori M. B. TI Significant Vitamin D Deficiency in Youth with Type 1 Diabetes Mellitus SO JOURNAL OF PEDIATRICS LA English DT Article ID BONE-MINERAL DENSITY; YOUNG-ADULTS; RISK-FACTORS; 25-HYDROXYVITAMIN-D; OSTEOPOROSIS; ADOLESCENTS; CHILDREN AB Serum 25-hydroxyvitamin D was measured in 128 youth with type 1 diabetes mellitus. Less than 25% of the patients were vitamin D sufficient. Because individuals with type 1 diabetes mellitus possess multiple risk factors for skeletal fragility, ensuring,vitamin D sufficiency throughout childhood and adolescence in this population seems especially warranted. C1 [Svoren, Britta M.; Volkening, Lisa K.; Wood, Jamie R.; Laffel, Lori M. B.] Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Genet & Epidemiol Sect, Boston, MA 02215 USA. [Svoren, Britta M.; Wood, Jamie R.; Laffel, Lori M. B.] Harvard Univ, Childrens Hosp, Sch Med, Dept Med,Div Endocrinol, Boston, MA 02115 USA. RP Svoren, BM (reprint author), Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Genet & Epidemiol Sect, 1 Joslin Pl, Boston, MA 02215 USA. EM Britta.Svoren@joslin.harvard.edu FU National Institutes of Health [ROIDK046887, K12DK63696]; Charles H. Hood Foundation; Eli Lilly and Company FX Supported by grants from the National Institutes of Health (ROIDK046887 to L.L. and K12DK63696 to B.S.). Support was also received from the Charles H. Hood Foundation and Eli Lilly and Company. The authors declare no affiliations, financial agreements. or other involvements that would constitute a conflict of interest. NR 18 TC 83 Z9 88 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD JAN PY 2009 VL 154 IS 1 BP 132 EP 134 DI 10.1016/j.jpeds.2008.07.015 PG 3 WC Pediatrics SC Pediatrics GA 391ZK UT WOS:000262272500028 PM 19187735 ER PT J AU Fukumura, D Kashiwagi, S Tsukada, K Jain, RK AF Fukumura, Dai Kashiwagi, Satoshi Tsukada, Kosuke Jain, Rakesh K. TI PERIVASCULAR NITRIC OXIDE GRADIENTS NORMALIZE TUMOR VASCULATURE SO JOURNAL OF PHYSIOLOGICAL SCIENCES LA English DT Meeting Abstract C1 Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Edwin L Steele Lab, Dept Radiat Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 1880-6546 J9 J PHYSIOL SCI JI J. Physiol. Sci. PY 2009 VL 59 SU 1 BP 26 EP 26 PG 1 WC Physiology SC Physiology GA 509MX UT WOS:000271023100075 ER PT J AU Gukovskaya, A AF Gukovskaya, Anna TI AUTOPHAGY IN PANCREATITIS SO JOURNAL OF PHYSIOLOGICAL SCIENCES LA English DT Meeting Abstract C1 [Gukovskaya, Anna] Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Med Ctr, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 1880-6546 J9 J PHYSIOL SCI JI J. Physiol. Sci. PY 2009 VL 59 SU 1 BP 81 EP 81 PG 1 WC Physiology SC Physiology GA 509MX UT WOS:000271023100402 ER PT J AU Nguyen, TD AF Nguyen, Toan D. TI PURINERGIC REGULATION OF PANCREATIC DUCTAL SECRETION SO JOURNAL OF PHYSIOLOGICAL SCIENCES LA English DT Meeting Abstract C1 [Nguyen, Toan D.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Washington, DC USA. [Nguyen, Toan D.] VA Puget Sound Hlth Care Syst, Div Gastroenterol, Washington, DC USA. [Nguyen, Toan D.] Univ Washington, Sch Med, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 1880-6546 J9 J PHYSIOL SCI JI J. Physiol. Sci. PY 2009 VL 59 SU 1 BP 83 EP 83 PG 1 WC Physiology SC Physiology GA 509MX UT WOS:000271023100413 ER PT J AU Sorensen, AG AF Sorensen, A. Gregory TI SIMULTANEOUS MR-PET ENABLES MECHANISTIC HUMAN NEUROIMAGING SO JOURNAL OF PHYSIOLOGICAL SCIENCES LA English DT Meeting Abstract C1 [Sorensen, A. Gregory] Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging,Med Sch, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 1880-6546 J9 J PHYSIOL SCI JI J. Physiol. Sci. PY 2009 VL 59 SU 1 BP 103 EP 103 PG 1 WC Physiology SC Physiology GA 509MX UT WOS:000271023100534 ER PT J AU Slaugenhaupt, S Curcio-Morelli, C Charles, F Micsenyi, MC Cao, Y Venugopal, B Browning, MF Dobrenis, K Cotman, SL Walkley, SU AF Slaugenhaupt, Susan Curcio-Morelli, Cyntia Charles, Florie Micsenyi, Matthew C. Cao, Yi Venugopal, Bhuvarahamurthy Browning, Marsha F. Dobrenis, Konstantin Cotman, Susan L. Walkley, Steven U. TI MACROAUTOPHAGY IS DEFECTIVE IN MUCOLIPIN 1-DEFICIENT MOUSE NEURONS SO JOURNAL OF PHYSIOLOGICAL SCIENCES LA English DT Meeting Abstract C1 [Slaugenhaupt, Susan; Curcio-Morelli, Cyntia; Charles, Florie; Cao, Yi; Venugopal, Bhuvarahamurthy; Browning, Marsha F.; Cotman, Susan L.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Micsenyi, Matthew C.; Dobrenis, Konstantin; Walkley, Steven U.] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10467 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 1880-6546 J9 J PHYSIOL SCI JI J. Physiol. Sci. PY 2009 VL 59 SU 1 BP 104 EP 104 PG 1 WC Physiology SC Physiology GA 509MX UT WOS:000271023100539 ER PT J AU Sakata, S Sakata, N Sakata, Y Lebeche, D Hanaoka, T Chemaly, ER Takaki, M Hajjar, RJ AF Sakata, Susumu Sakata, Naoya Sakata, Yuri Lebeche, Djamel Hanaoka, Tomoko Chemaly, Elie R. Takaki, Miyako Hajjar, Roger J. TI DYNAMIC CHANGES IN LEFT VENTRICULAR MECHANOENERGETICS DURING DEVELOPMENT OF CARDIAC HYPERTROPHY AND FAILURE SO JOURNAL OF PHYSIOLOGICAL SCIENCES LA English DT Meeting Abstract C1 [Sakata, Naoya; Sakata, Yuri] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Lebeche, Djamel; Chemaly, Elie R.; Hajjar, Roger J.] Mt Sinai Sch Med, New York, NY USA. [Takaki, Miyako] Nara Med Univ, Sch Med, Dept Physiol 2, Nara, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 1880-6546 J9 J PHYSIOL SCI JI J. Physiol. Sci. PY 2009 VL 59 SU 1 BP 362 EP 362 PG 1 WC Physiology SC Physiology GA 509MX UT WOS:000271023102427 ER PT J AU Iwaki, S Belliveau, JW AF Iwaki, Sunao Belliveau, John W. TI 3-D STRUCTURE PERCEPTION FROM 2-D MOTION REQUIRES INTERACTIVE INVOLVEMENT OF BOTH DORSAL AND VENTRAL VISUAL SYSTEMS SO JOURNAL OF PHYSIOLOGICAL SCIENCES LA English DT Meeting Abstract C1 [Iwaki, Sunao] Natl Inst Adv Ind Sci & Technol, Inst Human Sci & Biomed Engn, Tsukuba, Ibaraki, Japan. [Belliveau, John W.] Massachusetts Gen Hosp, NMR Ctr, Boston, MA 02114 USA. RI Iwaki, Sunao/B-1079-2011 OI Iwaki, Sunao/0000-0002-7123-7203 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 1880-6546 J9 J PHYSIOL SCI JI J. Physiol. Sci. PY 2009 VL 59 SU 1 BP 426 EP 426 PG 1 WC Physiology SC Physiology GA 509MX UT WOS:000271023102812 ER PT J AU Warren, Z Etcoff, N Wood, B Taylor, C Marci, CD AF Warren, Zachary Etcoff, Nancy Wood, Benjamin Taylor, Chris Marci, Carl D. TI Preservation of differences in social versus non-social positive affect in children exposed to war SO JOURNAL OF POSITIVE PSYCHOLOGY LA English DT Article DE positive affect; display rules; social contagion; laughter; smiles; Afghanistan; well-being; war; cross-cultural research strategies AB No research to date has supported the 'social contagion' effect of laughter and smiles in a non-Western context, nor among children. Expressions of positive affect were here compared according to social and non-social conditions among 163 children between the ages of 5-12 while playing in a park in Afghanistan. Independent observers coded laugh and smile responses using published criteria and identified 147 laugh responses and 697 smile responses. Children in the social play condition demonstrated significantly more laughs than children in the non-social play condition, and the number of peer observers present in the social play condition significantly increased the number of participant smile responses, but not laugh responses. Findings supported the idea in Western research that laughter and smiles may function in moderating social relationships and communicating affect. The authors recommend future research to investigate the relationship between positive affect and wellbeing across cultures, with consideration for practical interventions. C1 [Warren, Zachary; Taylor, Chris] Harvard Univ, Cambridge, MA 02138 USA. [Etcoff, Nancy; Marci, Carl D.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Wood, Benjamin] Virginia Commonwealth Univ, Richmond, VA USA. RP Warren, Z (reprint author), Harvard Univ, Cambridge, MA 02138 USA. EM zach.warren@gmail.com NR 62 TC 1 Z9 1 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1743-9760 J9 J POSIT PSYCHOL JI J. Posit. Psychol. PY 2009 VL 4 IS 3 BP 234 EP 242 DI 10.1080/17439760902819576 PG 9 WC Psychology, Multidisciplinary SC Psychology GA V17RC UT WOS:000207953300007 ER PT J AU Qian, WJ Liu, T Petyuk, VA Gritsenko, MA Petritis, BO Polpitiya, AD Kaushal, A Xiao, W Finnerty, CC Jeschke, MG Jaitly, N Monroe, ME Moore, RJ Moldawer, LL Davis, RW Tompkins, RG Herndon, DN Camp, DG Smith, RD AF Qian, Wei-Jun Liu, Tao Petyuk, Vladislav A. Gritsenko, Marina A. Petritis, Brianne O. Polpitiya, Ashoka D. Kaushal, Amit Xiao, Wenzhong Finnerty, Celeste C. Jeschke, Marc G. Jaitly, Navdeep Monroe, Matthew E. Moore, Ronald J. Moldawer, Lyle L. Davis, Ronald W. Tompkins, Ronald G. Herndon, David N. Camp, David G., II Smith, Richard D. CA Inflammat & Host Response Injury L TI Large-Scale Multiplexed Quantitative Discovery Proteomics Enabled by the Use of an O-18-Labeled "Universal" Reference Sample SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE human plasma; proteomics; O-18 labeling; Reference; LC-MS; accurate mass and time tag; label-free quantitation isotope-labeling ID CHROMATOGRAPHY-MASS SPECTROMETRY; HIGH-THROUGHPUT PROTEOMICS; TIME TAG APPROACH; LIQUID-CHROMATOGRAPHY; ACCURATE MASS; PROTEIN EXPRESSION; MOUSE-BRAIN; PHOSPHORYLATION; REPRODUCIBILITY; QUANTIFICATION AB The quantitative comparison of protein abundances across a large number of biological or patient samples represents an important proteomics challenge that needs to be addressed for proteomics discovery applications. Herein, we describe a strategy that incorporates a stable isotope O-18-labeled "universal" reference sample as a comprehensive set of internal standards for analyzing large sample sets quantitatively. As a pooled sample, the O-18-labeled "universal" reference sample is spiked into each individually processed unlabeled biological sample and the peptide/protein abundances are quantified based on O-16/O-18 isotopic peptide pair abundance ratios that compare each unlabeled sample to the identical reference sample. This approach also allows for the direct application of label-free quantitation across the sample set simultaneously along with the labeling-approach (i.e., dual-quantitation) since each biological sample is unlabeled except for the labeled reference sample that is used as internal standards. The effectiveness of this approach for large-scale quantitative proteomics is demonstrated by its application to a set of 18 plasma samples from severe burn patients. When immunoaffinity depletion and cysteinyl-peptide enrichment-based fractionation with high resolution LC-MS measurements were combined, a total of 312 plasma proteins were confidently identified and quantified with a minimum of two unique peptides per protein. The isotope labeling data was directly compared with the label-free O-16-MS intensity data extracted from the same data sets. The results showed that the O-18 reference-based labeling approach had significantly better quantitative precision compared to the label-free approach. The relative abundance differences determined by the two approaches also displayed strong correlation, illustrating the complementary nature of the two quantitative methods. The simplicity of including the O-18-reference for accurate quantitation makes this strategy especially attractive when a large number of biological samples are involved in a study where label-free quantitation may be problematic, for example, due to issues associated with instrument platform robustness. The approach will also be useful for more effectively discovering subtle abundance changes in broad systems biology studies. C1 [Qian, Wei-Jun; Liu, Tao; Petyuk, Vladislav A.; Gritsenko, Marina A.; Petritis, Brianne O.; Polpitiya, Ashoka D.; Jaitly, Navdeep; Monroe, Matthew E.; Moore, Ronald J.; Camp, David G., II; Smith, Richard D.] Pacific NW Natl Lab, Environm Mol Sci Lab, Richland, WA 99352 USA. [Qian, Wei-Jun; Liu, Tao; Petyuk, Vladislav A.; Gritsenko, Marina A.; Petritis, Brianne O.; Polpitiya, Ashoka D.; Jaitly, Navdeep; Monroe, Matthew E.; Moore, Ronald J.; Camp, David G., II; Smith, Richard D.] Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA. [Kaushal, Amit; Xiao, Wenzhong; Davis, Ronald W.] Stanford Univ, Sch Med, Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA. [Finnerty, Celeste C.; Jeschke, Marc G.; Herndon, David N.] Univ Texas Med Branch, Shriners Burns Hosp, Dept Surg, Galveston, TX 77550 USA. [Moldawer, Lyle L.] Univ Florida, Coll Med, Dept Surg, Gainesville, FL 32610 USA. [Tompkins, Ronald G.] Harvard Univ, Sch Med, Shriners Burn Ctr, Dept Surg, Boston, MA 02114 USA. [Tompkins, Ronald G.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Smith, RD (reprint author), Pacific NW Natl Lab, Environm Mol Sci Lab, POB 999,MSIN K8-98, Richland, WA 99352 USA. EM rds@pnl.gov RI Qian, Weijun/C-6167-2011; Smith, Richard/J-3664-2012; Liu, Tao/A-9020-2013; OI Smith, Richard/0000-0002-2381-2349; Liu, Tao/0000-0001-9529-6550; Petyuk, Vladislav/0000-0003-4076-151X FU National Institute of General Medical Sciences [U54 GM-62119-02, T32 GM-008256]; NIH National Center for Research Resources [RR18522]; Entertainment Industry Foundation (EIF); EIF Women's Cancer Research Fund to the Breast Cancer Biomarker Discovery Consortium; Environmental Molecular Science Laboratory; Battelle Memorial Institute for the DOE [DE-AC06-76RLO-1830] FX Portions of this research were supported by the National Institute of General Medical Sciences (NIGMS, Large Scale Collaborative Research Grants U54 GM-62119-02 and T32 GM-008256), the NIH National Center for Research Resources (RR18522), the Entertainment Industry Foundation (EIF), and the EIF Women's Cancer Research Fund to the Breast Cancer Biomarker Discovery Consortium, and the Environmental Molecular Science Laboratory [a national scientific user facility sponsored by the U.S. Department of Energy (DOE) Office of Biological and Environmental Research and located at Pacific Northwest National Laboratory (PNNL)]. PNNL is operated by Battelle Memorial Institute for the DOE under contract DE-AC06-76RLO-1830. NR 35 TC 38 Z9 39 U1 1 U2 3 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 J9 J PROTEOME RES JI J. Proteome Res. PD JAN PY 2009 VL 8 IS 1 SI SI BP 290 EP 299 DI 10.1021/pr800467r PG 10 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 390NN UT WOS:000262171100030 PM 19053531 ER PT J AU Sylvia, LG Kopeski, LM Mulrooney, C Reid, J Jacob, K Neuhaus, EC AF Sylvia, Louisa G. Kopeski, Lynne M. Mulrooney, Catherine Reid, James Jacob, Karen Neuhaus, Edmund C. TI Does Exercise Impact Mood? Exercise Patterns of Patients in a Psychiatric Partial Hospital Program SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Editorial Material DE exercise; depressive symptoms; mood disorders; partial hospital; obesity; body mass index ID AUTOMATIC THOUGHTS QUESTIONNAIRE; MAJOR DEPRESSION; AEROBIC EXERCISE; DOSE-RESPONSE; DISORDER; PREVALENCE; EFFICACY AB Objective. To examine the exercise patterns of patients in a partial hospital (PH) program and to determine whether these patterns are associated with mood symptoms and body mass index (BMI). Methods. Eighty-six participants completed self-report questionnaires upon entry to the PH program. We conducted regression analyses to determine the association of exercise, mood, and BMI. Results. We found that the participants' exercise history did not predict automatic thoughts or depressive symptoms. Current exercise did predict fewer depressive symptoms and lower BMI, but not automatic thoughts. A majority of participants were overweight and reported not exercising, despite acknowledging that they were not physically fit and that exercise is beneficial. Conclusion. We recommend that exercise programs be piloted in PH settings to improve patients' mental as well as physical health. Future research should further examine obstacles to exercising in clinical populations. (Journal of Psychiatric Practice 2009;15:70-78) C1 [Sylvia, Louisa G.; Kopeski, Lynne M.; Mulrooney, Catherine; Reid, James; Jacob, Karen; Neuhaus, Edmund C.] McLean Hosp, Belmont, MA 02178 USA. [Sylvia, Louisa G.; Reid, James; Jacob, Karen; Neuhaus, Edmund C.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Sylvia, Louisa G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. EM lsylvia2@partners.org NR 25 TC 8 Z9 8 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1527-4160 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD JAN PY 2009 VL 15 IS 1 BP 70 EP 78 PG 9 WC Psychiatry SC Psychiatry GA 400OS UT WOS:000262878400011 PM 19182569 ER PT J AU Petty, CR Monuteaux, MC Mick, E Hughes, S Small, J Faraone, SV Biederman, J AF Petty, Carter R. Monuteaux, Michael C. Mick, Eric Hughes, Samantha Small, Jacqueline Faraone, Stephen V. Biederman, Joseph TI Parsing the familiality of oppositional defiant disorder from that of conduct disorder: A familial risk analysis SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE ADHD; Oppositional defiant; Conduct; Family risk ID ATTENTION-DEFICIT-HYPERACTIVITY; LA-TOURETTES SYNDROME; BIPOLAR DISORDER; ANXIETY DISORDERS; DEFICIT/HYPERACTIVITY DISORDER; GENETIC-RELATIONSHIP; CHILDHOOD-ONSET; CHILDREN; COMORBIDITY; SUBTYPE AB Background: Family risk analysis can provide an improved understanding of the association between attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD), attending to the comorbidity with conduct disorder (CD). Methods: We compared rates of psychiatric disorders in relatives of 78 control probands without ODD and CD (Control, N = 265), relatives of 10 control probands with ODD and without CD (ODD, N = 37), relatives of 19 ADHD probands without ODD and CD (ADHD, N = 71), relatives of 38 ADHD probands with ODD and without CD (ADHD + ODD, N = 130), and relatives of 50 ADHD probands with ODD and CD (ADHD + ODD + CD, N = 170). Results: Rates of ADHD were significantly higher in all three ADHD groups compared to the Control group, while rates of ODD were significantly higher in all three ODD groups compared to the Control group. Evidence for co-segregation was found in the ADHD + ODD group. Rates of mood disorders, anxiety disorders, and addictions in the relatives were significantly elevated only in the ADHD + ODD + CD group. Conclusions: ADHD and ODD are familial disorders, and ADHD plus ODD outside the context of CD may mark a familial subtype of ADHD. ODD and CD confer different familial risks, providing further support for the hypothesis that ODD and CD are separate disorders. (C) 2008 Elsevier Ltd. All rights reserved. C1 [Petty, Carter R.; Monuteaux, Michael C.; Mick, Eric; Hughes, Samantha; Small, Jacqueline; Biederman, Joseph] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. [Monuteaux, Michael C.; Mick, Eric; Biederman, Joseph] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat & Behav Sci, Syracuse, NY 13210 USA. RP Petty, CR (reprint author), Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Warren 705,55 Fruit St, Boston, MA 02114 USA. EM cpetty@partners.org OI Mick, Eric/0000-0001-8505-8145; Faraone, Stephen/0000-0002-9217-3982 FU NICHD NIH HHS [R01 HD036317, R01 HD036317-10, R01HD036317-10] NR 46 TC 7 Z9 7 U1 2 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JAN PY 2009 VL 43 IS 4 BP 345 EP 352 DI 10.1016/j.jpsychires.2008.03.010 PG 8 WC Psychiatry SC Psychiatry GA 406QF UT WOS:000263309300001 PM 18455189 ER PT J AU Rohan, E Bausch, J AF Rohan, Elizabeth Bausch, Jane TI Climbing Everest: Oncology Work as an Expedition in Caring SO JOURNAL OF PSYCHOSOCIAL ONCOLOGY LA English DT Article DE oncology clinicians; multidisciplinary team; teamwork; compassion fatigue; coping strategies; expedition; metaphor ID PSYCHOSOCIAL ISSUES; SOCIAL-WORK; STAFF DIALOGUE; CANCER-PATIENTS; TRAUMA WORK; STRESS; BURNOUT; CAREGIVERS; FAMILIES; EXPERIENCES AB This study reports findings from 21 in-depth interviews with oncology clinicians (social workers, physicians, and nurses). Interviews addressed clinicians' overall experiences of their work, including professional roles, teamwork, challenges and rewards of the work, and thoughts about whether oncology work changed their worldview. Researchers used an expedition metaphor to understand oncology clinicians' experiences. An expedition and oncology work have in common a clear division of labor, the necessity of collaboration, intense work, significant obstacles, great rewards, and work that the world at large cannot tolerate undertaking. Understanding the experiences of oncology health professionals is essential in attracting and retaining dedicated clinicians and in helping them mitigate the potential deleterious effects of their work, such as compassion fatigue. Additionally, the expedition metaphor itself is compelling; it highlights the breadth of experiences of oncology clinicians, particularly that successful multidisciplinary teamwork in itself can ameliorate compassion fatigue. C1 [Rohan, Elizabeth] 31 Stories LLC, Counseling Serv, Atlanta, GA 30326 USA. [Bausch, Jane] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. RP Rohan, E (reprint author), 31 Stories LLC, Counseling Serv, 3390 Peachtree Rd NE, Atlanta, GA 30326 USA. EM Elizabeth.rohan@gmail.com NR 82 TC 12 Z9 12 U1 5 U2 9 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 0734-7332 J9 J PSYCHOSOC ONCOL JI J. Psychosoc. Oncol. PY 2009 VL 27 IS 1 BP 84 EP 118 AR PII 908117490 DI 10.1080/07347330802616043 PG 35 WC Psychology, Social SC Psychology GA 428BU UT WOS:000264823800005 PM 19197680 ER PT J AU Fobair, P Stearns, N Christ, G Dozier-Hall, D Newman, NW Zabora, J Schnipper, HH Kennedy, V Loscalzo, M Stensland, S Hedlund, S Lauria, M Fife, M Herschl, J Marcusen, C Vaitones, V BrintzenhofeSzoc, K Walsh, K Lawson, K DeSonier, M AF Fobair, Patricia Stearns, Naomi 'Noni' Christ, Grace Dozier-Hall, Deborah Newman, Nancy W. Zabora, James Schnipper, Hester Hill Kennedy, Vicki Loscalzo, Matthew Stensland, Susan M. Hedlund, Susan Lauria, Marie M. Fife, Michael Herschl, Joyce Marcusen, Carol P. Vaitones, Virginia Brintzenhofeszoc, Karlynn Walsh, Katherine Lawson, Kimberly Desonier, Marcia TI Historical Threads in the Development of Oncology Social Work SO JOURNAL OF PSYCHOSOCIAL ONCOLOGY LA English DT Article ID SURVIVING ADULT CANCERS; BREAST-CANCER; RADICAL-MASTECTOMY; HODGKINS-DISEASE; GROUP-THERAPY; PERSPECTIVE; HEALTH; ADAPTATION; BARRIERS; OUTCOMES AB As the Association of Oncology Social Work celebrates its 25th year, we pause to reflect on the many historical threads that contributed to its development and hear from each of the presidents who helped create the organization, as we know it today. Set within hospitals, medical social work was born in the early 20th century. In the 1940s medical social work became necessary for hospital accreditation. Two additional historical shifts, one in medical improvements in treating cancer, the other a shift to a consumer-oriented American Cancer Society, contributed to the push for a greater role for the federal government in funding cancer research. Oncology social work came to full blossom in the 1970s, a result of the physicians' need for a member of the health care team who understood cancer, its treatment, and the patient's need to address his or her psychosocial needs resulting from cancer. Today, oncology social work is a fully developed profession with a national organization providing education and support to oncology social workers' in their use of psychosocial interventions and research in behalf of cancer patients and their families. C1 [Fobair, Patricia] Stanford Univ Hosp, Supportive Care program, Ctr Canc, Stanford, CA 94305 USA. [Stearns, Naomi 'Noni'] Dana Farber Canc Inst, Boston, MA 02115 USA. [Christ, Grace] Columbia Univ, Sch Social Work, New York, NY USA. [Dozier-Hall, Deborah] NIH, Dept Social Work, Bethesda, MD 20892 USA. [Newman, Nancy W.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Schnipper, Hester Hill] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Kennedy, Vicki] Wellness Community Natl, Program Dev & Qual Assurance, Indianapolis, IN USA. [Loscalzo, Matthew] Sheri & Les Biller Patient & Family Resource Ctr, Duarte, CA USA. [Stensland, Susan M.] Nebraska Med Ctr, Omaha, NE USA. [Hedlund, Susan] Hosp & Palliat Care Washington Cty, Hillsboro, OR USA. [Lauria, Marie M.] Univ N Carolina, Chapel Hill, NC USA. [Fife, Michael] Univ Texas MD Anderson Canc Ctr, Dept Social Work, Houston, TX 77030 USA. [Herschl, Joyce] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Vaitones, Virginia] Penobscot Bay Med Ctr, Rockport, ME USA. [Brintzenhofeszoc, Karlynn] Catholic Univ Amer, Natl Catholic Sch Social Serv, Washington, DC 20064 USA. [Walsh, Katherine] Springfield Coll, Sch Social Work, Springfield, MA USA. [Lawson, Kimberly] Siteman Canc Ctr, Dept Educ & Qual, St Louis, MO USA. [Desonier, Marcia] Baptist Hosp, Canc Support Serv, Pensacola, FL USA. [Loscalzo, Matthew] Dept Populat Sci, Dept Support Care Med, Duarte, CA USA. [Hedlund, Susan] Oregon Hlth & Sci Univ, Sch Med, Hillsboro, OR USA. [Hedlund, Susan] Portland State Univ, Grad Sch Social Work, Hillsboro, OR USA. RP Fobair, P (reprint author), 1943 Mt Vernon Court,203, Mountain View, CA 94040 USA. EM fobair@sbcglobal.net FU Intramural NIH HHS [Z99 CL999999] NR 78 TC 4 Z9 4 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0734-7332 EI 1540-7586 J9 J PSYCHOSOC ONCOL JI J. Psychosoc. Oncol. PY 2009 VL 27 IS 2 BP 155 EP 215 AR PII 910064540 DI 10.1080/07347330902775301 PG 61 WC Psychology, Social SC Psychology GA 428BV UT WOS:000264823900001 PM 19337929 ER PT J AU Crane, JN AF Crane, Jacquelyn N. TI Religion and Cancer: Examining the Possible Connections SO JOURNAL OF PSYCHOSOCIAL ONCOLOGY LA English DT Article DE cancer; religion; mental health ID LONG-TERM ADJUSTMENT; QUALITY-OF-LIFE; BREAST-CANCER; SOCIAL RELATIONSHIPS; SPIRITUAL BELIEFS; PROSTATE-CANCER; PHYSICAL HEALTH; MENTAL-HEALTH; INVOLVEMENT; ATTENDANCE AB Numerous sound scientific studies (cross-sectional and longitudinal) have found a positive correlation between religion and physical and mental health. In particular, there is evidence that demonstrates that religion helps cancer patients better adjust to and cope with their disease, at least psychologically. However, some research suggests that mediating factors associated with religion may explain the positive effects of religion on health. This article argues that even if this is the case, there is still intrinsic value to religion in that the mediators themselves are strongly connected to religion, and therefore religion is important to the patient in terms of coping, support, hope, and meaning. This has possible important implications for clinical practice. C1 Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02114 USA. RP Crane, JN (reprint author), Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, 185 Cambridge St,Room 6300, Boston, MA 02114 USA. EM Jcrane@pngu.mgh.harvard.edu NR 81 TC 5 Z9 5 U1 2 U2 5 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 0734-7332 J9 J PSYCHOSOC ONCOL JI J. Psychosoc. Oncol. PY 2009 VL 27 IS 4 BP 469 EP 486 DI 10.1080/07347330903182010 PG 18 WC Psychology, Social SC Psychology GA 504CZ UT WOS:000270592800006 PM 19813136 ER PT J AU Kupersmith, J Lew, HL Ommaya, AK Jaffee, M Koroshetz, WJ AF Kupersmith, Joel Lew, Henry L. Ommaya, Alex K. Jaffee, Michael Koroshetz, Walter J. TI Traumatic brain injury research opportunities: Results of Department of Veterans Affairs Consensus Conference SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; BLAST INJURY; INDUCED NEUROTRAUMA; SEVERITY; POPULATION; PREVALENCE; PLASTICITY; DAMAGE; RISK; IRAQ C1 [Kupersmith, Joel; Ommaya, Alex K.] US EPA, Off Res & Dev, Dept Vet Affairs VA, Washington, DC 20460 USA. [Lew, Henry L.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Jaffee, Michael] VA Boston Healthcare Syst, Boston, MA USA. [Jaffee, Michael] Walter Reed Army Med Ctr, Def & Vet Brain injury Ctr, Washington, DC 20307 USA. [Koroshetz, Walter J.] NINDS, NIH, Bethesda, MD 20892 USA. RP Kupersmith, J (reprint author), US EPA, Off Res & Dev, Dept Vet Affairs VA, Washington, DC 20460 USA. EM henry.lew@va.gou NR 33 TC 3 Z9 3 U1 0 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 6 BP VII EP XV DI 10.1682/JRRD.2009.06.0079 PG 9 WC Rehabilitation SC Rehabilitation GA 531BQ UT WOS:000272638100001 PM 20104393 ER PT J AU Kupersmith, J Ommaya, AK Selzer, ME Ruff, RL Lew, HL AF Kupersmith, Joel Ommaya, Alex K. Selzer, Michael E. Ruff, Robert L. Lew, Henry L. TI Traumatic brain injury research state-of-the-art conference SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material C1 [Kupersmith, Joel; Ommaya, Alex K.; Ruff, Robert L.] ORD, VA, Washington, DC USA. [Selzer, Michael E.] Vet Hlth Adm, Rehabil Res & Dev Serv, Washington, DC USA. [Lew, Henry L.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Lew, Henry L.] VA Boston Healthcare Syst, Boston, MA USA. RP Kupersmith, J (reprint author), ORD, VA, Washington, DC USA. EM henry.lew@va.gov NR 2 TC 3 Z9 3 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 6 BP XVII EP XVIII DI 10.1682/JRRD.2009.06.0085 PG 2 WC Rehabilitation SC Rehabilitation GA 531BQ UT WOS:000272638100002 PM 20104394 ER PT J AU Dicianno, BE Sibenaller, S Kimmich, C Cooper, RA Pyo, J AF Dicianno, Brad E. Sibenaller, Sara Kimmich, Claire Cooper, Rory A. Pyo, Jay TI Joystick use for virtual power wheelchair driving in individuals with tremor: Pilot study SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE computer-user interface; filtering system; isometric joystick; movement-sensing joystick; multiple sclerosis; Parkinson's disease; rehabilitation; tremor; wheelchair driving performance; wheelchairs ID HAND TREMOR; ISOMETRIC JOYSTICKS; FREQUENCY; POSITION AB People with disabilities such as Multiple sclerosis and Parkinson's disease have difficulty operating conventional movement-sensing joysticks (MSJs) because of varying levels of tremor. We developed an isometric joystick (IJ) that has performed as well as a conventional MSJ when used by persons with tipper-limb impairments in real and virtual wheelchair driving tasks. The Weighted-Frequency Fourier Linear Combiner (WFLC) filter has been used to cancel tremor effectively in microsurgery. In this study, we compared an MSJ, IJ, and IJ with the WFLC filter in individuals performing a virtual driving task. Although the WFLC filter did not improve driving performance in this study, the IJ Without a filter yielded better results than the conventional MSJ and thus may be a potential alternative to the MSJ in minimizing the effects of tremor. C1 [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Dicianno, Brad E.; Sibenaller, Sara; Kimmich, Claire; Cooper, Rory A.] Dept Vet Affairs Pittsburg Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.; Sibenaller, Sara; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Kimmich, Claire] Univ Virginia, Dept Biomed Engn, Charlottesville, VA USA. [Pyo, Jay] Walter Reed Army Med Ctr, Dept Orthoped & Rehabil, PM&R Serv, Washington, DC 20307 USA. RP Dicianno, BE (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr,Bldg 4,2D Floor E 151R1-H, Pittsburgh, PA 15206 USA. EM dicianno@pitt.edu OI Dicianno, Brad/0000-0003-0738-0192 FU Department of Veterans Affairs Center of Excellence for Wheelchairs and Associated Rehabilitation Engineering [B4132C]; National Science Foundation [EEC 0552351] FX This material was based on work supported by the Department of Veterans Affairs Center of Excellence for Wheelchairs and Associated Rehabilitation Engineering (grant B4132C) and the National Science Foundation (project EEC 0552351). NR 24 TC 7 Z9 7 U1 2 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 2 BP 269 EP 275 DI 10.1682/JRRD.2008.02.0022 PG 7 WC Rehabilitation SC Rehabilitation GA 455EA UT WOS:000266739100013 PM 19533540 ER PT J AU Moy, ML Matthess, K Stolzmann, K Reilly, J Garshick, E AF Moy, Marilyn L. Matthess, Kirby Stolzmann, Kelly Reilly, John Garshick, Eric TI Free-living physical activity in COPD: Assessment with accelerometer and activity checklist SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE accelerometer; ambulation; COPD; dyspnea; exercise capacity; free-living physical activity; health-related quality of life; physical activity checklist; pulmonary; wearable sensor ID OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; DAILY-LIFE; OLDER-ADULTS; QUESTIONNAIRE; DYSPNEA; HEALTH; MORTALITY; STATEMENT; EMPHYSEMA AB To assess physical activity and disability in chronic obstructive pulmonary disease (COPD), we evaluated the use of an accelerometer and checklist to measure free-living physical activity. Seventeen males with stable COPD completed a daily activity checklist for 14 days. Ten subjects concurrently wore an Actiped accelerometer (FitSense, Southborough, Massachussetts) that records steps per day. Regression models assessed relationships between steps per day, number of daily checklist activities performed, and clinical measures of COPD status. The average steps per day ranged from 406 to 4,856. The median intrasubject coefficient of variation for steps per day was 0.52 (interquartile range [IQR] 0.41-0.58) and for number of daily checklist activities performed was 0.28 (IQR 0.22-0.32). A higher number of steps per day was associated with a greater distance walked on the 6-minute walk test and better health-related quality of life. A higher number of daily checklist activities performed was associated with a higher force expiratory volume in 1 s percent predicted and lowerbody mass index, airflow obstruction, dyspnea, exercise capacity (BODE) index. Prospectively measuring free-living physical activity in COPD using an unobtrusive accelerometer and simple activity checklist is feasible. Low intrasubject variation was found in free-living physical activity, which is significantly associated with clinical measures of COPD status. C1 [Moy, Marilyn L.] Rehabil Res & Dev Serv, Vet Hlth Adm, Dept Vet Affairs, Boston, MA USA. [Moy, Marilyn L.; Garshick, Eric] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA USA. [Moy, Marilyn L.; Reilly, John] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Matthess, Kirby; Stolzmann, Kelly; Reilly, John; Garshick, Eric] Harvard Univ, Sch Med, Boston, MA USA. [Moy, Marilyn L.; Matthess, Kirby; Stolzmann, Kelly; Garshick, Eric] VA Boston Healthcare Syst, Res & Dev Serv, Boston, MA USA. [Garshick, Eric] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. RP Moy, ML (reprint author), VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, 1400 VFW Pkwy,Mail Code 111PI, W Roxbury, MA 02132 USA. EM marilyn.moy@va.gov FU Veterans Health Administration, Rehabilitation Research and Development Service; National Institutes of Health (NIH); NIH/National Institute of Child Health grant [RO1 HD42141] FX This material was based on work supported in part by the VA, Veterans Health Administration, Rehabilitation Research and Development Service, and by the National Institutes of Health (NIH) through a VA Career Development Award (Dr. Moy); and by the NIH/National Institute of Child Health grant RO1 HD42141 (Dr. Garshick). The work was performed at VA Boston Healthcare System, Boston, MA. NR 40 TC 36 Z9 36 U1 0 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 2 BP 277 EP 286 DI 10.1682/JRRD.2008.07.0083 PG 10 WC Rehabilitation SC Rehabilitation GA 455EA UT WOS:000266739100014 PM 19533541 ER PT J AU Klute, GK Kantor, C Darrouzet, C Wild, H Wilkinson, S Iveljic, S Creasey, G AF Klute, Glenn K. Kantor, Carole Darrouzet, Chris Wild, Helga Wilkinson, Susann Iveljic, Suzana Creasey, Graham TI Lower-limb amputee needs assessment using multistakeholder focus-group approach SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE amputation; amputee; artificial limb; diabetes; focus group; lower limb; needs assessment; prosthesis; rehabilitation; trauma ID AMPUTATIONS; HEALTH AB To assess the needs of lower-limb amputees and identify differences between diabetic dysvascular amputees and traumatic amputees, we held a multistakeholder focus-group workshop whose participants included veteran lower-limb amputees, clinicians, researchers, and prosthetic device manufacturers. We conducted the initial workshop sessions as traditional focus-group meetings with homogeneous participant groups generating lists of issues relevant to the individual groups. Subsequent sessions assembled heterogeneous participant groups for a two-phase approach: Discovery and Codesign. The Discovery phase used observation and discussion to elicit specific needs. The Codesign phase focused on emergent topics and explored potential Solutions. The participants identified needs associated with desired improvements to the socket system, foot and ankle components, and alignment with the residual limb. One need was a comprehensive understanding of the recovery path following amputation that could be addressed through enhanced education and communication. Another need was remote monitoring systems that could potentially improve quality of care. No dichotomy of needs between diabetic dysvascular amputees and traumatic amputees was evident among the participants of this workshop. The lively, open-ended discussions produced numerous suggestions for improving amputee quality of life that are listed to facilitate future research and development. C1 [Klute, Glenn K.] Puget Sound Hlth Care Syst, Dept Vet Affairs, Ctr Excellence Limb Loss Prevent & Prosthet Engn, Seattle, WA USA. [Klute, Glenn K.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Kantor, Carole; Iveljic, Suzana; Creasey, Graham] Louis Stokes Cleveland VA Med Ctr, Adv Platform Technol Ctr, Cleveland, OH USA. [Darrouzet, Chris; Wild, Helga; Wilkinson, Susann] Water Cooler Log Inc, Menlo Pk, CA USA. RP Klute, GK (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,MS 151, Seattle, WA 98108 USA. EM gklute@u.washington.edu FU VA Rehabilitation Research and Development [A2661C, A4843C, C3819C] FX This material was based on work supported by VA Rehabilitation Research and Development grants A2661C, A4843C, and C3819C. NR 17 TC 16 Z9 18 U1 3 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 3 BP 293 EP 304 DI 10.1682/JRRD.2008.02.0031 PG 12 WC Rehabilitation SC Rehabilitation GA 483OC UT WOS:000268975600003 PM 19675983 ER PT J AU Karmarkar, AM Collins, DM Wichman, T Franklin, A Fitzgerald, SG Dicianno, BE Pasquina, PF Cooper, RA AF Karmarkar, Amol M. Collins, Diane M. Wichman, Todd Franklin, Allison Fitzgerald, Shirley G. Dicianno, Brad E. Pasquina, Paul. F. Cooper, Rory A. TI Prosthesis and wheelchair use in veterans with lower-limb amputation SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE function; health characteristics; lower-limb amputation; mobility device; outcome; prostheses; rehabilitation; satisfaction; veterans; wheelchairs ID LOWER-EXTREMITY AMPUTATION; TRANSFEMORAL AMPUTATION; ELDERLY AMPUTEES; SATISFACTION; DEVICES; PEOPLE; RISK AB We determined the demographic, health, functional, and satisfaction factors related to lower-limb prosthesis or wheelchair use among veterans with lower-limb amputation. Forty-two veterans were recruited from the 20th National Disabled Veterans Winter Sports Clinic and the 26th National Veterans Wheelchair Games. Participants were at least 18 years of age, had a lower-limb amputation, and were either prosthesis or wheelchair users. Level of amputation was the most significant health-related characteristic determining the veterans' use of a prosthesis versus a wheelchair (p = 0.02). Veterans who had a higher level of amputation and used a prosthesis reported significantly greater difficulty navigating a ramp (p = 0.03), getting in and out of cars and buses (p = 0.03), carrying 10 lb of groceries (p = 0.02), and participating in sports and leisure activities) = 0.03). The parameter "satisfaction related to prosthesis" did not determine selection of mobility device type. The interaction of demographics, health-related characteristics, and mobility device characteristics affects functional performance and influences the use of prostheses, wheelchairs, or both in persons with lower-limb amputation. Long-term outcome assessments may help determine factors associated with either transition from one device to another or combined use of the devices over time. C1 [Karmarkar, Amol M.; Collins, Diane M.; Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. [Karmarkar, Amol M.; Collins, Diane M.; Dicianno, Brad E.; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Dept Vet Affairs, Human Engn Res Labs, Pittsburgh, PA USA. [Wichman, Todd; Franklin, Allison; Pasquina, Paul. F.] Walter Reed Army Med Ctr, Dept Phys Med & Rehabil, Washington, DC 20307 USA. [Fitzgerald, Shirley G.] James A Haley Vet Hosp, Patient Safety Ctr Inquiry, Tampa, FL USA. RP Collins, DM (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, 5044 Forbes Tower,3600 Forbes Atwood, Pittsburgh, PA 15260 USA. EM dmcst84@pitt.edu RI Karmarkar, Amol/E-6030-2011; OI Karmarkar, Amol/0000-0001-8355-1585; Dicianno, Brad/0000-0003-0738-0192 FU Armed Forces Amputees Care Program (DOD); Telemedicine and Advanced Technology Research Center [06053001]; VA Center for Excellence in Wheelchairs and Associated Rehabilitation Engineering [B3142C] FX This material was based on work supported by the Armed Forces Amputees Care Program (DOD), Telemedicine and Advanced Technology Research Center (grant 06053001), and VA Center for Excellence in Wheelchairs and Associated Rehabilitation Engineering (grant B3142C). NR 27 TC 30 Z9 30 U1 2 U2 19 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 5 BP 567 EP 575 DI 10.1682/JRRD.2008.08.0102 PG 9 WC Rehabilitation SC Rehabilitation GA 513BJ UT WOS:000271296700003 PM 19882491 ER PT J AU Henry, JA James, KE Owens, K Zaugg, T Porsov, E Silaski, G AF Henry, James A. James, Kenneth E. Owens, Kimberly Zaugg, Tara Porsov, Edward Silaski, Grayson TI Auditory test result characteristics of subjects with and without tinnitus SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE compensation; hearing disorders; loudness matching; loudness perception; malingering; pitch matching; pitch perception; rehabilitation; reliability of results; tinnitus; tinnitus diagnosis ID HEARING THRESHOLDS; PREVALENCE; RELIABILITY; MECHANISMS; MANAGEMENT; EARPHONES AB Tinnitus is the perception Of sound that does not have an acoustic source in the environment. Ascertaining the presence of tinnitus in individuals who claim tinnitus for compensation purposes is very difficult and increasingly becoming a problem. This study examined the potential to observe differences in loudness and pitch matches between individuals who experience tinnitus versus those who do not. This Study follows a previous pilot study we completed that included 12 subjects with and 12 subjects without tinnitus. The current study included 36 subjects with and 36 without tinnitus. Results of this study revealed no significant differences between groups with regard to decibel sensation level (SL) loudness matches and within-session loudness-match reliability. Between-group differences revealed that the tinnitus subjects had (1) greater decibel sound pressure level loudness matches, (2) better between-session loudness-match reliability, (3) better pitch-match reliability, and (4) higher frequency pitch matches. These findings support the data from our pilot study with the exception that decibel SL loudness matches were greater for the tinnitus subjects in the pilot Study. Tinnitus loudness and pitch matching may have some value in an overall battery of tests for evaluating tinnitus claims. C1 [Henry, James A.; James, Kenneth E.; Owens, Kimberly; Zaugg, Tara; Silaski, Grayson] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Dept Vet Affairs, VA Rehabil Res & Dev Serv, Portland, OR 97207 USA. [James, Kenneth E.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Henry, James A.; Porsov, Edward] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. RP Henry, JA (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Dept Vet Affairs, VA Rehabil Res & Dev Serv, POB 1034, Portland, OR 97207 USA. EM james.henry@va.gov FU VHA; VA Rehabilitation Research and Development Service [C2300R] FX This material was based oil work Supported by the VHA and VA Rehabilitation Research and Development Service (grant C2300R). NR 36 TC 7 Z9 7 U1 0 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 5 BP 619 EP 632 DI 10.1682/JRRD.2008.11.0157 PG 14 WC Rehabilitation SC Rehabilitation GA 513BJ UT WOS:000271296700007 PM 19882495 ER PT J AU Moy, ML Reilly, JJ Ries, AL Mosenifar, Z Kaplan, RM Lew, R Garshick, E AF Moy, Marilyn L. Reilly, John J. Ries, Andrew L. Mosenifar, Zab Kaplan, Robert M. Lew, Robert Garshick, Eric CA Natl Emphysema Treatment TI Multivariate models of determinants of health-related quality of life in severe chronic obstructive pulmonary disease SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE chronic obstructive pulmonary disease; COPD; disability; dyspnea; emphysema; exercise capacity; health-related quality of life; multivariate regression models; National Emphysema Treatment Trial; pulmonary rehabilitation ID EMPHYSEMA TREATMENT TRIAL; VOLUME-REDUCTION SURGERY; AIR-FLOW LIMITATION; LUNG-VOLUME; EXERCISE CAPACITY; RANDOMIZED-TRIAL; MORTALITY; COPD; QUESTIONNAIRE; DEPRESSION AB Persons with severe chronic obstructive pulmonary disease (COPD) and similar levels of forced expiratory volume in 1 second (FEV(1)), exercise capacity, and dyspnea have a wide range of health-related quality of life (HRQL). We identified the independent determinants of HRQL in persons with COPD. Comprehensive assessments of physiological, psychosocial, and clinical variables from the National Ernphysema Treatment Trial were used. HRQL was assessed by the Medical Outcomes Study 36-Item Short Form Physical Component Summary (PCS) and Mental Component Summary (MCS) scores and the St. George's Respiratory Questionnaire total score (SGRQ-TS). In multivariate linear regression models, exercise capacity, dyspnea, age, single-breath diffusing capacity of the lung for carbon monoxide percent predicted, and self-report of being disabled were significant determinants of PCS score. Dyspnea, depression, antidepressant use, daytime sleepiness, and education were significant determinants of MCS score. Prior participation in pulmonary rehabilitation, Supplemental oxygen use, and oral corticosteroid use were significant determinants of SGRQ-TS. Although FEV(1), 6-minute walk test distance, and dyspnea significantly correlated with HRQL, their effects on HRQL were reduced when other variables were considered. Greater exercise capacity, prior participation in pulmonary rehabilitation, and use of supplemental oxygen were significantly associated with better HRQL. Self-perception of being disabled, depression, dyspnea, oral corticosteroid use, and daytime sleepiness were associated with worse HRQL. To optimize HRQL, clinicians should pay attention to a number of clinical and physiological factors. C1 [Moy, Marilyn L.; Reilly, John J.; Garshick, Eric] Harvard Univ, Sch Med, Boston, MA USA. [Moy, Marilyn L.; Reilly, John J.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Moy, Marilyn L.; Garshick, Eric] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA USA. [Moy, Marilyn L.] Vet Hlth Adm Rehabil Res & Dev Serv, Dept Vet Affairs VA, Boston, MA USA. [Ries, Andrew L.] Univ Calif San Diego, Dept Med, Div Pulm & Crit Care Med, San Diego, CA 92103 USA. [Ries, Andrew L.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Mosenifar, Zab] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Kaplan, Robert M.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA. [Lew, Robert] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. [Garshick, Eric] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA. RP Moy, ML (reprint author), VA Boston Healthcare Syst Pulm & Crit Care Med Se, 1400 VFW Pkwy, W Roxbury, MA 02132 USA. EM marilyn.moy@va.gov FU Department of Veterans Affairs (VA); Veterans Health Administration, Rehabilitation Research and Development Service; National Institutes of Health (NIH); National Institute of Child Health and Human Development [NIH/NICHD RO1 HD42141]; NIH National Heart, Lung, and Blood Institute [N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, N01HR76119]; Centers for Medicare and Medicaid Services; Agency for Healthcare Research and Quality FX This material was based on work supported by the Department of Veterans Affairs (VA), Veterans Health Administration, Rehabilitation Research and Development Service through a VA Career Development Award to Dr. Moy and by the National Institutes of Health (NIH) National Institute of Child Health and Human Development (grant NIH/NICHD RO1 HD42141 to Dr. Garshick). The NETT was supported by the NIH National Heart, Lung, and Blood Institute (grants N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, and N01HR76119); the Centers for Medicare and Medicaid Services; and the Agency for Healthcare Research and Quality. NR 29 TC 23 Z9 23 U1 0 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 5 BP 643 EP 654 DI 10.1682/JRRD.2008.09.0127 PG 12 WC Rehabilitation SC Rehabilitation GA 513BJ UT WOS:000271296700009 PM 19882497 ER PT J AU Kocsis, JD Tessler, A AF Kocsis, Jeffery D. Tessler, Alan TI Pathology of blast-related brain injury SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE barotrauma; blast injury; blast overpressure; blast-related; brain injury; blast underpressure; central nervous system; closed head injury; improvised explosive devices; neuropathology; traumatic brain injury ID CENTRAL-NERVOUS-SYSTEM; INDUCED NEUROTRAUMA; INVOLVEMENT AB Blasts are responsible for about two-thirds of the combat injuries in Operation Iraqi Freedom and Operation Enduring Freedom, which include at least 1,200 traumatic brain injuries. Blasts inflict damage to the brain directly and by causing injuries to other organs, resulting in air emboli, hypoxia, and shock. Direct injuries to the brain result from rapid shifts in air pressure (primary blast injury), from impacts with munitions fragments and other objects propelled by the explosion (secondary blast injury), and from collisions with objects and rapid acceleration of individuals propelled by the explosion (tertiary blast injury). Tertiary injury can occur from a building or other structure collapsing and from an individual being thrown by the blast wind. The pathological consequences of secondary and tertiary blast injuries are very likely to be similar to those of other types of mechanical trauma seen in civilian life. The damage attributable to the specific effects of a blast, however, has received little study, although it has been assumed to include the focal and diffuse lesions characteristic of closed head injuries. Available clinical studies of blast injuries show focal damage similar to that found in other types of closed head injuries but have not determined whether diffuse axonal injury also occurs. In this article, we will try to reach a better understanding of the specific pathology of blast-related brain injury by reviewing the available experimental studies and the autopsy reports of victims of terrorist attacks and military casualties dating back to World War I. C1 [Kocsis, Jeffery D.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. [Kocsis, Jeffery D.] Yale Univ, Sch Med, Ctr Neurosci & Regenerat Res, New Haven, CT 06510 USA. [Kocsis, Jeffery D.] Dept Vet Affairs VA Connecticut Healthcare Syst, Rehabil Res Ctr, West Haven, CT USA. [Tessler, Alan] Philadelphia VA Med Ctr, Dept Neurol, Philadelphia, PA USA. RP Kocsis, JD (reprint author), Yale Univ, Sch Med, Neurosci Res Ctr 127A, VA CT Healthcare Syst, West Haven, CT 06516 USA. EM jeffery.kocsis@yale.edu FU Department of Veterans Affairs FX This material was supported by the Department of Veterans Affairs. NR 24 TC 36 Z9 38 U1 0 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 6 BP 667 EP 671 DI 10.1682/JRRD.2008.08.0100 PG 5 WC Rehabilitation SC Rehabilitation GA 531BQ UT WOS:000272638100004 PM 20104396 ER PT J AU Chen, JWY Ruff, RL Eavey, R Wasterlain, CG AF Chen, James W. Y. Ruff, Robert L. Eavey, Roland Wasterlain, Claude G. TI Posttraumatic epilepsy and treatment SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE anticonvulsants; brain imaging; posttraumatic epilepsy; posttraumatic stress disorder; refractory seizures; rehabilitation; seizures; traumatic brain injury; unprovoked seizures; veterans ID POST-TRAUMATIC EPILEPSY; HEAD-INJURY; SEIZURES; PROPHYLAXIS; PHENYTOIN; RISK; ANTICONVULSANT; AGENTS AB Posttraumatic epilepsy (PTE) is a major long-term complication of traumatic brain injury (TBI). PTE usually develops within 5 years of head injury. The risk for developing PTE varies with TBI type. Both Korean and Vietnam war veterans with penetrating TBI had a 53% risk of developing PTE. The risk of developing PTE is between 10% and 25% in combat-associated closed-head trauma with positive brain imaging and about 5% in moderately severe closed-head injury without imaging finding. We do not know the risk of PTE among Operation Iraqi Freedom/Operation Enduring Freedom veterans with minimal TBI because of blast exposure. Partial seizures may manifest with subtle behavioral alterations that can be mistaken for manifestations of posttraumatic stress disorder and improperly treated. Accidents and medical complications commonly occur during seizures. Sudden unexpected death in epilepsy is most frequent among 20- to 40-year-olds. Seizures increase the likelihood of refractory seizures years after TBI. Seizures are also a social stigma that compromise veterans' reintegration into society. People with uncontrolled epilepsy are not allowed to drive and have difficulty obtaining or maintaining employment. Optimal seizure control is essential to the physical and emotional health of veterans with TBI and to their ability to lead productive lives. C1 [Chen, James W. Y.; Eavey, Roland; Wasterlain, Claude G.] VA Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA USA. [Chen, James W. Y.; Eavey, Roland; Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Ruff, Robert L.] Louis Stokes Cleveland VA Med Ctr, Neurol Serv, Cleveland, OH USA. [Ruff, Robert L.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. RP Chen, JWY (reprint author), W Los Angeles VA Healthcare Ctr, Neurol MC 127,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jwychen@ucla.edu FU BLRD VA [I01 BX000273] NR 21 TC 29 Z9 32 U1 0 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 6 BP 685 EP 695 DI 10.1682/JRRD.2008.09.0130 PG 11 WC Rehabilitation SC Rehabilitation GA 531BQ UT WOS:000272638100006 PM 20104398 ER PT J AU Lew, HL Otis, JD Tun, C Kerns, RD Clark, ME Cifu, DX AF Lew, Henry L. Otis, John D. Tun, Carlos Kerns, Robert D. Clark, Michael E. Cifu, David X. TI Prevalence of chronic pain, posttraumatic stress disorder, and persistent postconcussive symptoms in OIF/OEF veterans: Polytrauma clinical triad SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE brain injuries; explosions; Iraq; military personnel; pain; posttraumatic stress disorder; rehabilitation; veterans; war; wounds and injuries ID TRAUMATIC BRAIN-INJURY; OPERATIONS ENDURING FREEDOM; IRAQI FREEDOM; AFGHANISTAN; MILITARY; SOLDIERS AB This study examines the prevalence and coprevalence with which returning Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) veterans were reporting symptoms consistent with chronic pain, posttraumatic stress disorder (PTSD), and persistent postconcussive symptoms (PPCS). The medical records of 340 OIF/OEF veterans seen at a Department of Veterans Affairs Polytrauma Network Site were comprehensively reviewed. Analyses indicated a high prevalence of all three conditions in this population, with chronic pain, PTSD, and PPCS present in 81.5%, 68.2%, and 66.8%, respectively. Only 12 of the veterans (3.5%) had no chronic pain, PTSD, or PPCS. The frequency at which these three conditions were present in isolation (10.3%, 2.9%, and 5.3%, respectively) was significantly lower than the frequency at which they were present in combination with one another, with 42.1% of the sample being diagnosed with all three conditions simultaneously. The most common chronic pain locations were the back (58%) and head (55%). These results underscore the complexity of the presenting complaints in OIF/OEF veterans and support the importance of a multidisciplinary team approach to assessment and treatment. C1 [Lew, Henry L.; Tun, Carlos] VA Boston Healthcare Syst, PM&R Serv, Dept Vet Affairs, Boston, MA 02130 USA. [Lew, Henry L.; Tun, Carlos] Harvard Univ, Sch Med, Boston, MA USA. [Lew, Henry L.] DVBIC Site, Boston, MA USA. [Otis, John D.] VA Boston Healthcare Syst, Pain Res Program, Boston, MA USA. [Kerns, Robert D.] VA Connecticut Healthcare Syst, PRIME Ctr, West Haven, CT USA. [Clark, Michael E.] James A Haley Vet Hosp, Chron Pain Rehabil Program, Tampa, FL USA. [Cifu, David X.] Richmond VA Med Ctr, PM&R Serv, Richmond, VA USA. RP Lew, HL (reprint author), VA Boston Healthcare Syst, PM&R Serv, Dept Vet Affairs, 150 S Huntington Ave, Boston, MA 02130 USA. EM henry.lew@va.gov OI Otis, John/0000-0002-5441-7421 FU VA Rehabilitation Research and Development Service [B5008R] FX This material was based on work supported by the VA Rehabilitation Research and Development Service, Merit Review Project B5008R. NR 21 TC 210 Z9 211 U1 1 U2 20 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 6 BP 697 EP 702 DI 10.1682/JRRD.2009.01.0006 PG 6 WC Rehabilitation SC Rehabilitation GA 531BQ UT WOS:000272638100007 PM 20104399 ER PT J AU Van Boven, RW Harrington, GS Hackney, DB Ebel, A Gauger, G Bremner, JD D'Esposito, M Detre, JA Haacke, EM Jack, CR Jagust, WJ Le Bihan, D Mathis, CA Mueller, S Mukherjee, P Schuff, N Chen, A Weiner, MW AF Van Boven, Robert W. Harrington, Greg S. Hackney, David B. Ebel, Andreas Gauger, Grant Bremner, J. Douglas D'Esposito, Mark Detre, John A. Haacke, E. Mark Jack, Clifford R., Jr. Jagust, William J. Le Bihan, Denis Mathis, Chester A. Mueller, Susanne Mukherjee, Pratik Schuff, Norbert Chen, Anthony Weiner, Michael W. TI Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE diagnosis; diffusion tensor imaging; fMRI; neuroimaging; OIF/OEF; posttraumatic stress disorder; PTSD; TBI; traumatic brain injury; veterans ID PROTON-MAGNETIC-RESONANCE; DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; CHILDHOOD SEXUAL-ABUSE; POSITRON-EMISSION-TOMOGRAPHY; SMALLER HIPPOCAMPAL VOLUME; CONTROLLED CORTICAL IMPACT; INTIMATE PARTNER VIOLENCE; MEDIAL PREFRONTAL CORTEX; APPEARING WHITE-MATTER AB Improved diagnosis and treatment of traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) are needed for our military and veterans, their families, and society at large. Advances in brain imaging offer important biomarkers of structural, functional, and metabolic information concerning the brain. This article reviews the application of various imaging techniques to the clinical problems of TBI and PTSD. For TBI, we focus on findings and advances in neuroimaging that hold promise for better detection, characterization, and monitoring of objective brain changes in symptomatic patients with combat-related, closed-head brain injuries not readily apparent by standard computed tomography or conventional magnetic resonance imaging techniques. C1 [Van Boven, Robert W.; Harrington, Greg S.] Cent Texas Dept Vet Affairs VA Hlth Care Syst, Brain Imaging & Recovery Lab, Austin, TX USA. [Hackney, David B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiol, Boston, MA 02215 USA. [Ebel, Andreas; Mueller, Susanne; Schuff, Norbert; Weiner, Michael W.] Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, VA Med Ctr, San Francisco, CA 94143 USA. [Bremner, J. Douglas] Emory Univ, Sch Med, Emory Clin Neurosci Res Unit, Atlanta VA Med Ctr, Atlanta, GA USA. [D'Esposito, Mark] Univ Calif Berkeley, Helen Wills Neurosci Inst, Henry H Wheeler Jr Brain Imaging Ctr, Berkeley, CA 94720 USA. [Detre, John A.] Univ Penn, Dept Neurol & Radiol, Ctr Funct Neuroimaging, Philadelphia, PA 19104 USA. [Haacke, E. Mark] Wayne State Univ, Magnet Resonance Imaging Inst Biomed Res, Detroit, MI USA. [Jack, Clifford R., Jr.] Mayo Clin, Rochester, MN USA. [Le Bihan, Denis] CEA Saclay, F-91191 Gif Sur Yvette, France. [Mathis, Chester A.] Univ Pittsburgh, PET Facil, Pittsburgh, PA USA. [Chen, Anthony] San Francisco VA Med Ctr, Program Rehabil Neurosci, San Francisco, CA USA. RP Van Boven, RW (reprint author), Irwin Army Community Hosp, Mild Traumat Brain Injury Clin, 600 Caisson Hill Rd, Ft Riley, KS 66442 USA. EM Robert.vanboven@us.army.mil RI Jack, Clifford/F-2508-2010; Mukherjee, Pratik/A-5446-2008; Bremner, James/B-1632-2013; Hackney, David/A-5337-2010; OI Jack, Clifford/0000-0001-7916-622X; Mukherjee, Pratik/0000-0001-7473-7409 FU NCATS NIH HHS [UL1 TR000454]; NCRR NIH HHS [P41 RR023953, P41 RR023953-05, S10 RR017238, S10 RR017238-01]; NHLBI NIH HHS [R01 HL088726, R01 HL088726-04]; NIA NIH HHS [R01 AG010897, R01 AG010897-26, RC2 AG036535, RC2 AG036535-02, U01 AG024904, U01 AG024904-08]; NIAAA NIH HHS [P01 AA011493, P01 AA011493-05]; NIMH NIH HHS [K24 MH076955, K24 MH076955-05, R01 MH056120, R01 MH056120-12, R21 MH080208, R21 MH080208-02, T32 MH067547, T32 MH067547-05] NR 344 TC 51 Z9 52 U1 8 U2 36 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 6 BP 717 EP 755 DI 10.1682/JRRD.2008.12.0161 PG 39 WC Rehabilitation SC Rehabilitation GA 531BQ UT WOS:000272638100009 PM 20104401 ER PT J AU Halbauer, JD Ashford, JW Zeitzer, JM Adamson, MM Lew, HL Yesavage, JA AF Halbauer, Joshua D. Ashford, J. Wesson Zeitzer, Jamie M. Adamson, Maheen M. Lew, Henry L. Yesavage, Jerome A. TI Neuropsychiatric diagnosis and management of chronic sequelae of war-related mild to moderate traumatic brain injury SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE affective; aggression; agitation; attention; communication; executive function; language; memory; pain; PTSD; rehabilitation ID POSTTRAUMATIC-STRESS-DISORDER; CLOSED-HEAD-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEPRESSION FOLLOWING MILD; QUALITY-OF-LIFE; MEDICATION ALGORITHM PROJECT; RANDOMIZED CONTROLLED-TRIAL; AUTISTIC SPECTRUM DISORDER; CONSENSUS CONFERENCE PANEL; DIFFUSE AXONAL INJURY AB Soldiers with a traumatic brain injury (TBI) present with an array of neuropsychiatric symptoms that can be grouped into nosological clusters: (1) cognitive dysfunctions: difficulties in memory, attention, language, visuospatial cognition, sensory-motor integration, affect recognition, and/or executive function typically associated with neocortical damage; (2) neurobehavioral disorders: mood, affect, anxiety, posttraumatic stress, and psychosis, as well as agitation, sleep problems, and libido loss, that may have been caused by damage to the cortex, limbic system, and/or brain stem monoaminergic projection systems; (3) somatosensory disruptions: impaired smell, vision, hearing, equilibrium, taste, and somatosensory perception frequently caused by trauma to the sensory organs or their projections through the brain stem to central processing systems; (4) somatic symptoms: headache and chronic pain; and (5) substance dependence. TBI-related cognitive impairment is common in veterans who have served in recent conflicts in the Middle East and is often related to blasts from improvised explosive devices. Although neurobehavioral disorders such as depression and posttraumatic stress disorder commonly occur after combat, the presentation of such disorders in those with head injury may pass undetected with use of current diagnostic criteria and neuropsychological instruments. With a multidimensional approach (such as the biopsychosocial model) applied to each symptom cluster, psychological, occupational, and social dysfunction can be delineated and managed. C1 [Ashford, J. Wesson] VA Palo Alto Hlth Care Syst, War Related Illness & Injury Study Ctr, Dept Vet Affairs, Palo Alto, CA 94304 USA. [Halbauer, Joshua D.; Ashford, J. Wesson; Zeitzer, Jamie M.; Adamson, Maheen M.; Yesavage, Jerome A.] Sierra Pacific Mental Illness Res Educ & Clin Ctr, VA, Palo Alto, CA USA. [Halbauer, Joshua D.; Ashford, J. Wesson; Zeitzer, Jamie M.; Adamson, Maheen M.; Yesavage, Jerome A.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Lew, Henry L.] VA Boston Healthcare Syst, Boston, MA USA. RP Ashford, JW (reprint author), VA Palo Alto Hlth Care Syst, War Related Illness & Injury Study Ctr, Dept Vet Affairs, 151-W,3801 Miranda Ave, Palo Alto, CA 94304 USA. EM wes.ashford@va.gov OI Zeitzer, Jamie/0000-0001-6174-5282 FU Medical Research Service of the Department of Veterans Affairs (VA) Palo Alto Health Care System; VA Sierra-Pacific Mental Illness Research, Education and Clinical Center; War-Related Illness and Injury Study Center FX This material is the result of work supported with resources and the use of facilities at the Medical Research Service of the Department of Veterans Affairs (VA) Palo Alto Health Care System and the VA Sierra-Pacific Mental Illness Research, Education and Clinical Center and War-Related Illness and Injury Study Center. The content is solely the responsibility of the authors and does not necessarily represent the official view of the VA. NR 286 TC 54 Z9 58 U1 9 U2 35 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 6 BP 757 EP 795 DI 10.1682/JRRD.2008.08.0119 PG 39 WC Rehabilitation SC Rehabilitation GA 531BQ UT WOS:000272638100010 PM 20104402 ER PT J AU Fausti, SA Wilmington, DJ Gallun, FJ Myers, PJ Henry, JA AF Fausti, Stephen A. Wilmington, Debra J. Gallun, Frederick J. Myers, Paula J. Henry, James A. TI Auditory and vestibular dysfunction associated with blast-related traumatic brain injury SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE auditory dysfunction; blast; central auditory processing; hearing loss; polytrauma; prevention; rehabilitation; tinnitus; traumatic brain injury; vestibular ID INDUCED HEARING-LOSS; HEAD-INJURY; CLINICAL MANAGEMENT; OTOLITH DISORDERS; BOMB EXPLOSION; GUINEA-PIG; FOLLOW-UP; OTOTOXICITY; NOISE; DIZZINESS AB The dramatic escalation of blast exposure in military deployments has created an unprecedented amount of traumatic brain injury (TBI) and associated auditory impairment. Auditory dysfunction has become the most prevalent individual service-connected disability, with compensation totaling more than 1 billion dollars annually. Impairment due to blast can include peripheral hearing loss, central auditory processing deficits, vestibular impairment, and tinnitus. These deficits are particularly challenging in the TBI population, as symptoms can be mistaken for posttraumatic stress disorder, mental-health issues, and cognitive deficits. In addition, comorbid factors such as attention, cognition, neuronal loss, noise toxicity, etc., can confound assessment, causing misdiagnosis. Furthermore, some auditory impairments, such as sensorineural hearing loss, will continue to progress with age, unlike many other injuries. In the TBI population, significant clinical challenges are the accurate differentiation of auditory and vestibular impairments from multiple, many times overlapping, symptoms and the development of multidisciplinary rehabilitation strategies to improve treatment outcomes and quality of life for these patients. C1 [Fausti, Stephen A.; Wilmington, Debra J.; Gallun, Frederick J.; Henry, James A.] Natl Ctr Rehabil Auditory Res, VA Rehabil Res & Dev Serv, Portland VA Med Ctr, Dept Vet Affairs, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. [Myers, Paula J.] James A Haley Vet Hosp, Polytrauma Rehabil Ctr, Tampa, FL 33612 USA. RP Wilmington, DJ (reprint author), Natl Ctr Rehabil Auditory Res, VA Rehabil Res & Dev Serv, Portland VA Med Ctr, Dept Vet Affairs, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM debra.wilmington@med.va.gov RI Gallun, Frederick/G-3792-2012 OI Gallun, Frederick/0000-0002-4145-2199 FU VA Rehabilitation Research and Development Service [C4844C, B5067R, C4488R, C6770R, CDA2 C4963W]; National Center for Rehabilitative Auditory Research FX This material was based on work supported by the VA Rehabilitation Research and Development Service (grants C4844C, B5067R, C4488R, C6770R, C4488R, CDA2 C4963W) and the National Center for Rehabilitative Auditory Research. NR 75 TC 56 Z9 58 U1 1 U2 16 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 6 BP 797 EP 809 DI 10.1682/JRRD.2008.09.0118 PG 13 WC Rehabilitation SC Rehabilitation GA 531BQ UT WOS:000272638100011 PM 20104403 ER PT J AU Cockerham, GC Goodrich, GL Weichel, LTCED Orcutt, JC Rizzo, JF Bower, COLKS Schuchard, RA AF Cockerham, Glenn C. Goodrich, Gregory L. Weichel, L. T. C. Eric D. Orcutt, James C. Rizzo, Joseph F. Bower, C. O. L. Kraig S. Schuchard, Ronald A. TI Eye and visual function in traumatic brain injury SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE blast injury; blindness; eye trauma; oculomotor; quality of life; rehabilitation; traumatic brain injury; vision; visual disturbance; visual field ID COMBAT OCULAR TRAUMA; OPTIC NEUROPATHY; BLAST INJURY; IRAQ; WAR; REHABILITATION; DYSFUNCTION; MILITARY; PROGRAM; NEGLECT AB Combat blast is an important cause of traumatic brain injury (TBI) in the Department of Veterans Affairs polytrauma population, whereas common causes of TBI in the civilian sector include motor vehicle accidents and falls. Known visual consequences of civilian TBI include compromised visual acuity, visual fields, and oculomotor function. The visual consequences of TBI related to blast remain largely unknown. Blast injury may include open globe (eye) injury, which is usually detected and managed early in the rehabilitation journey. The incidence, locations, and types of ocular damage in eyes without open globe injury after exposure to powerful blast have not been systematically studied. Initial reports and preliminary data suggest that binocular function, visual fields, and other aspects of visual function may be impaired after blast-related TBI, despite relatively normal visual acuity. Damage to the ocular tissues may occur from blunt trauma without rupture or penetration (closed globe injury). Possible areas for research are development of common taxonomy and assessment tools across services, surgical management, and outcomes for blast-related eye injury; the incidence, locations, and natural history of closed globe injury; binocular and visual function impairment; quality of life in affected service-members; pharmacological and visual therapies; and practice patterns for screening, management, and rehabilitation. C1 [Cockerham, Glenn C.] Dept Vet Affairs VA Palo Alto Hlth Care Syst, Ophthalmol Sect, Palo Alto, CA 94304 USA. [Cockerham, Glenn C.] Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA. [Goodrich, Gregory L.] VA Palo Alto Hlth Care Syst, Psychol Serv, Palo Alto, CA USA. [Weichel, L. T. C. Eric D.; Bower, C. O. L. Kraig S.] Walter Reed Army Med Ctr, Ophthalmol Serv, Washington, DC 20307 USA. [Orcutt, James C.] VA Puget Sound Hlth Care Syst, Ophthalmol Sect, Seattle, WA USA. [Orcutt, James C.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA. [Rizzo, Joseph F.] VA Jama Plain, Ctr Innovat Visual Restorat, Boston, MA USA. [Rizzo, Joseph F.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. [Bower, C. O. L. Kraig S.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Schuchard, Ronald A.] Atlanta VA Med Ctr, Res & Dev Ctr Excellence, Atlanta, GA USA. [Schuchard, Ronald A.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. RP Cockerham, GC (reprint author), Dept Vet Affairs Palo Alto Hlth Care Syst, Ophthalmol Sect 112 B1, 3801 Miranda Ave, Palo Alto, CA 94304 USA. EM glenn.cockerham@va.gov FU VA [C5018R]; Quality Enhancement Research Initiative [RRP 07-339] FX This material was based in part on work supported by the VA through Merit Review Award C5018R and Quality Enhancement Research Initiative grant RRP 07-339. NR 44 TC 44 Z9 44 U1 7 U2 30 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 6 BP 811 EP 818 DI 10.1682/JRRD.2008.08.0109 PG 8 WC Rehabilitation SC Rehabilitation GA 531BQ UT WOS:000272638100012 PM 20104404 ER PT J AU Lew, HL Garvert, DW Pogoda, TK Hsu, PT Devine, JM White, DK Myers, PJ Goodrich, GL AF Lew, Henry L. Garvert, Donn W. Pogoda, Terri K. Hsu, Pei-Te Devine, Jennifer M. White, Daniel K. Myers, Paula J. Goodrich, Gregory L. TI Auditory and visual impairments in patients with blast-related traumatic brain injury: Effect of dual sensory impairment on Functional Independence Measure SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE blast-related; brain injuries; dual sensory impairment; Functional Independence Measure; hearing; outcomes assessment; polytrauma; rehabilitation; sensory disorders; vision ID HEARING; SOLDIERS; POPULATION; DEPRESSION; VISION; IRAQ AB The frequencies of hearing impairment (HI), vision impairment (VI), or dual (hearing and vision) sensory impairment (DSI) in patients with blast-related traumatic brain injury (TBI) and their effects on functional recovery are not well documented. In this preliminary study of 175 patients admitted to a Polytrauma Rehabilitation Center, we completed hearing and vision examinations and obtained Functional Independence Measure (FIM) scores at admission and discharge for 62 patients with blast-related TBI. We diagnosed HI only, VI only, and DSI in 19%, 34%, and 32% of patients, respectively. Only 15% of the patients had no sensory impairment in either auditory or visual modality. An analysis of variance showed a group difference for the total and motor FIM scores at discharge (p < 0.04). Regression model analyses demonstrated that DSI significantly contributed to reduced gain in total (t = -2.25) and motor (t = -2.50) FIM scores (p < 0.05). Understanding the long-term consequences of sensory impairments in the functional recovery of patients with blast-related TBI requires further research. C1 [Lew, Henry L.; Hsu, Pei-Te; Devine, Jennifer M.] VA Boston Healthcare Syst, Dept Vet Affairs, Phys Med & Rehabil Serv, Boston, MA USA. [Lew, Henry L.; Hsu, Pei-Te] Harvard Univ, Sch Med, Boston, MA USA. [Lew, Henry L.] VA Boston Healthcare Syst, Def & Vet Brain Injury Ctr, Boston, MA USA. [Lew, Henry L.; Pogoda, Terri K.; Hsu, Pei-Te] VA Boston Healthcare Syst, Traumat Brain Injury Ctr Excellence, Boston, MA USA. [Pogoda, Terri K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA. [White, Daniel K.] Boston Univ, Med Ctr, Boston, MA USA. [Myers, Paula J.] James A Haley Vet Hosp, Audiol Sect, Tampa, FL 33612 USA. RP Goodrich, GL (reprint author), VA Palo Alto Hlth Care Syst, Psychol Serv, 3801 Miranda Ave, Palo Alto, CA 94304 USA. EM gregory.goodrich@va.gov FU VA Merit Review [BR5008]; Quality Enhancement Research Initiative [RRP 07-339] FX This material was based on work supported in part by a VA Merit Review grant (BR5008) to Dr. Lew and a Quality Enhancement Research Initiative grant (RRP 07-339) to Dr. Goodrich. NR 22 TC 41 Z9 43 U1 1 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 6 BP 819 EP 826 DI 10.1682/JRRD.2008.09.0129 PG 8 WC Rehabilitation SC Rehabilitation GA 531BQ UT WOS:000272638100013 PM 20104405 ER PT J AU Chew, E Zafonte, RD AF Chew, Effie Zafonte, Ross. D. TI Pharmacological management of neurobehavioral disorders following traumatic brain injury-A state-of-the-art review SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE aggression; agitation; arousal; attention; depression; mania; memory; neuroprotection; pharmacology; psychosis; traumatic brain injury ID CLOSED-HEAD-INJURY; DEFICIT HYPERACTIVITY DISORDER; RANDOMIZED CONTROLLED-TRIAL; MINIMALLY CONSCIOUS STATE; ACUTE ISCHEMIC-STROKE; MOTOR CORTEX INJURY; SEMI-COMATOSE STATE; VEGETATIVE STATE; CLINICAL-TRIALS; COGNITIVE PERFORMANCE AB Pharmacological management of neurobehavioral disorders following traumatic brain injury (TBI) is common practice. However, the evidence available to guide this practice remains sparse. This review summarizes, in brief, the state of knowledge, organized via a time continuum from injury as well as by symptom complex. The areas of neuroprotection, hypoarousal, attention and memory deficits, aggression, agitation, depression, and mania are reviewed. The literature was searched with PubMed on the terms "traumatic brain injury" or "brain injury" with "pharmacology" (and the symptoms according to which this review is arranged). Additional searches were conducted with the specific symptoms as search terms, crossed with the therapeutic agents or drug classes discussed. Where a paucity of prospective data exists, case reports and retrospective studies are included. Studies to date have yielded minimal positive evidence for enhancing function, memory, and behavior after TBI. No single agent likely will become sentinel in the recovery process, and combination therapy in the acute and postacute settings are required. A need exists to further define the role of psychopharmacology in postacute TBI medicine and the specific characteristics of subpopulations who might benefit. C1 [Chew, Effie] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Med, Div Neurol, Singapore, Singapore. [Chew, Effie; Zafonte, Ross. D.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Zafonte, Ross. D.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA. [Zafonte, Ross. D.] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA. RP Zafonte, RD (reprint author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA. EM rzafonte@partners.org NR 155 TC 69 Z9 69 U1 2 U2 8 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 6 BP 851 EP 878 DI 10.1682/JRRD.2008.09.0120 PG 28 WC Rehabilitation SC Rehabilitation GA 531BQ UT WOS:000272638100016 PM 20104408 ER PT J AU Bohnen, NI Muller, MLTM Kuwabara, H Cham, R Constantine, GM Studenski, SA AF Bohnen, Nicolaas I. Muller, Martijn L. T. M. Kuwabara, Hiroto Cham, Rakie Constantine, Gregory M. Studenski, Stephanie A. TI Age-associated striatal dopaminergic denervation and falls in community-dwelling subjects SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE AASDD; age-associated striatal dopaminergic denervation; aging; basal ganglia; dopamine transporter; fall diary; falls; nigrostriatal; Parkinson; positron emission tomography; recurrent falls ID C-11 METHYL TRIFLATE; PARKINSONS-DISEASE; BRAIN DOPAMINE; PET RADIOLIGANDS; ELDERLY PERSONS; OLDER-ADULTS; DECLINE; BALANCE; IMPAIRMENT; INJURIES AB Older adults have a high prevalence of gait and balance disturbances and falls. Normal aging is associated with significant striatal dopaminergic denervation, which might be a previously unrecognized additional contributor to geriatric falls. This study investigated the relationship between the severity of age-associated striatal dopaminergic denervation (AASDD) and falls in community-dwelling subjects. Community-dwelling subjects who did not have a clinical diagnosis to explain falls (n = 77: 43 female, 34 male; mean age 61.4 +/- 16.4; range 20-85) completed clinical assessment and brain dopamine transporter (DAT) [(11)C]beta-CFT (2-beta-carbomethoxy-3-beta-(4-fluorophenyl) tropane) positron emission tomography imaging followed by 6 months of prospective fall monitoring using diaries. Results showed a significant inverse relationship between striatal DAT activity and age (r = -0.82, p < 0.001). A total of 26 subjects (33.8%) reported at least one fall, with 5 Subjects (6.5%) reporting two or more falls. While no significant difference was noted in striatal DAT activity between nonfallers (n = 51) and fallers (n = 26; f = 0.02, not significant), striatal DAT activity was modestly reduced in the small subgroup of recurrent fallers compared with the other subjects (f = 5.07, p < 0.05). Findings indicate that AASDD does not explain isolated self-reported falls in community-dwelling subjects. However, it may be a contributing factor in the small subgroup of subjects with recurrent falls. C1 [Bohnen, Nicolaas I.; Muller, Martijn L. T. M.] Univ Michigan, Funct Neuroimaging Cognit & Mobil Lab, Dept Radiol, Ann Arbor, MI 48105 USA. [Bohnen, Nicolaas I.; Muller, Martijn L. T. M.] Univ Michigan, Funct Neuroimaging Cognit & Mobil Lab, Dept Neurol, Ann Arbor, MI 48105 USA. [Bohnen, Nicolaas I.] Dept Vet Affairs Ann Arbor Healthcare Syst, GRECC, Ann Arbor, MI USA. [Kuwabara, Hiroto] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA. [Cham, Rakie] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Constantine, Gregory M.] Univ Pittsburgh, Dept Math & Stat, Pittsburgh, PA 15260 USA. [Studenski, Stephanie A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Studenski, Stephanie A.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. RP Bohnen, NI (reprint author), Univ Michigan, Funct Neuroimaging Cognit & Mobil Lab, Dept Radiol, 24 Frank Lloyd Wright Dr,Box 362, Ann Arbor, MI 48105 USA. EM nbohnen@umich.edu RI Muller, Martijn/A-7205-2010 FU VA; National Institutes of Health National Institute on Aging [AG023641, AG024827] FX This material was based oil work supported by VA and the National Institutes of Health National Institute on Aging (grants AG023641 and AG024827). NR 36 TC 7 Z9 7 U1 1 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 8 BP 1045 EP 1052 DI 10.1682/JRRD.2009.03.0030 PG 8 WC Rehabilitation SC Rehabilitation GA 550YO UT WOS:000274171000007 PM 20157861 ER PT J AU Bui, KM Raugi, GJ Nguyen, VQ Reiber, GE AF Bui, Kelly M. Raugi, Gregory J. Nguyen, Viet Q. Reiber, Gayle E. TI Skin problems in individuals with lower-limb loss: Literature review and proposed classification system SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Review DE amputation; epidemiology; lower-limb loss; prosthetic limb; rehabilitation; residual limb; review; skin diseases; skin integrity; skin problems ID AMPUTEES; AMPUTATIONS; STUMP; REHABILITATION; PROSTHESIS AB Problems with skin integrity can disrupt daily prosthesis use and lead to decreased mobility and function in individuals with lower-limb loss. This study reviewed the literature to examine how skin problems are defined and diagnosed and to identify the prevalence and types of skin problems in individuals with lower-limb loss. We searched the literature for terms related to amputation and skin problems. We identified 777 articles. Of the articles, 90 met criteria for review of research methodology. Four clinical studies met our selection criteria. The prevalence rate of skin problems was 15% to 41%. The most commonly reported skin problems were wounds, abscesses, and blisters. Given the lack of standardized definitions of skin problems on residual limbs, we conclude this article with a system for classification. C1 [Raugi, Gregory J.; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Dept Vet Affairs, Seattle, WA 98108 USA. [Bui, Kelly M.; Nguyen, Viet Q.] Univ Washington, Sch Med, Seattle, WA USA. [Raugi, Gregory J.] VA Puget Sound Hlth Care Syst, Div Dermatol, Primary & Specialty Med Serv, Seattle, WA 98108 USA. [Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. RP Reiber, GE (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Dept Vet Affairs, MS 152,1660 S Columbian Way, Seattle, WA 98108 USA. EM greiber@u.washington.edu FU Department of Veterans Affairs Health Services Research and Development Service [HR 05-244]; Career Scientist Award [RCS 98-353] FX [h is material was based on work supported by the Department of Veterans Affairs Health Services Research and Development Service (grant HR 05-244) and a Career Scientist Award (grant RCS 98-353) to Dr. Reiber. NR 23 TC 5 Z9 5 U1 2 U2 5 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 9 BP 1085 EP 1090 DI 10.1682/JRRD.2009.04.0052 PG 6 WC Rehabilitation SC Rehabilitation GA 580JJ UT WOS:000276444000003 PM 20437314 ER PT J AU Gagnon, D Koontz, AM Brindle, E Boninger, ML Cooper, RA AF Gagnon, Dany Koontz, Alicia M. Brindle, Eric Boninger, Michael L. Cooper, Rory A. TI Does upper-limb muscular demand differ between preferred and nonpreferred sitting pivot transfer directions in individuals with a spinal cord injury? SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE activities of daily living; elbow; electromyography; paraplegia; rehabilitation; shoulder; spinal cord injury; task analysis; task performance; tetraplegia; upper limb ID MANUAL WHEELCHAIR USERS; UPPER EXTREMITY; SHOULDER; FORCES; IMPINGEMENT; PARAPLEGIA; KINEMATICS; PATTERNS; MUSCLES; SURFACE AB This study's main objective was to determine if upper-limb (UL) muscular demand was reduced when individuals with a spinal cord injury (SCI) performed a sitting pivot transfer (SPT) in the preferred direction compared with that in a nonpreferred direction. Fourteen individuals (mean +/- standard deviation age 47.0 +/- 8.3 yr. height 1.80 +/- 0.08 m, and weight 75.3 +/- 11.3 kg) with SCI levels ranging from the sixth cervical to first sacral vertebra levels volunteered to participate in this study during the 2008 National Disabled Veterans Winter Sports Clinic. Surface electromyography (EMG) was used to record activity of the biceps, triceps, deltoid, pectorahs major, trapezius, and latissimus dorsi bilaterally during SPTs. These transfers were performed in each of the preferred and nonpreferred directions from the individuals' wheelchairs to a padded tub bench of even height. To quantify electromyographic muscular utilization ratio (MUR(EMG)), we normalized EMG data recorded during the transfer tasks to values obtained during static maximum voluntary contraction and then multiplied this ratio by 100 to obtain a percentage MUR(EMG) (%MUR(EMG)). The overall peak %MUR(EMG) and the area under the %MUR(EMG) curve were selected as primary outcome measures. Similar peak %MUR(EMGs) were found between the preferred and nonpreferred transfer directions for all muscles from which data were recorded (p = 0.053 to 0.961). The peak %MUR(EMGs) were also found to be similar between the leading and trailing ULs during the transfers in all muscles from which data were recorded (p = 0.125 to 0.838), except for the anterior deltoid, which was found to be solicited the most in the trailing UL (p = 0.008). Comparable areas under the %MUR(EMG) curves were calculated between the preferred and nonpreferred transfer directions for all muscles (p = 0.289 to 0.678) and between the leading and trailing ULs (p = 0.104 to 0.946). These results indicate that direction preference expressed by individuals with SCI when transferring between seats of even height is not explained by relative muscular demand differences. C1 [Gagnon, Dany; Koontz, Alicia M.; Brindle, Eric; Boninger, Michael L.; Cooper, Rory A.] Dept Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Gagnon, Dany; Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Gagnon, Dany; Koontz, Alicia M.; Brindle, Eric; Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol & Bioengn, Pittsburgh, PA USA. [Gagnon, Dany] Univ Montreal, Sch Rehabil, Montreal, PQ, Canada. RP Koontz, AM (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr,151R1-H, Pittsburgh, PA 15206 USA. EM akoontz@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU Office or Research and Development, Rehabilitation Research and Development Service [A4489R, B3142C]; National Science Foundation [EEC 0552351]; Paralyzed Veterans of America; Fond de la recherche en sante du Quebec FX This material was based on work supported in pan by the VA. Office or Research and Development, Rehabilitation Research and Development Service, grants A4489R and B3142C; the National Science Foundation, grant EEC 0552351 and a donation from the Paralyzed Veterans of America. This material is the result of work supported with resources and the use of facilities at HERL, VA Pittsburgh Healthcare System. Dr. Gagnon held a postdoctoral research scholarship from the Fond de la recherche en sante du Quebec at the time of the study. NR 26 TC 7 Z9 7 U1 2 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2009 VL 46 IS 9 BP 1099 EP 1108 PG 10 WC Rehabilitation SC Rehabilitation GA 580JJ UT WOS:000276444000005 PM 20437316 ER PT J AU Andreas, JB O'Farrell, TJ AF Andreas, Jasmina Burdzovic O'Farrell, Timothy J. TI Alcoholics Anonymous attendance following 12-step treatment participation as a link between alcohol-dependent fathers' treatment involvement and their children's externalizing problems SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Children of alcoholics; COA; Alcoholism treatment; Alcoholics Anonymous; AA; Structural Equation Modeling; SEM ID PEDIATRIC SYMPTOM CHECKLIST; SUBSTANCE-ABUSING FATHERS; PARENTAL ALCOHOLISM; USE DISORDERS; TIMELINE FOLLOWBACK; FAMILY CONFLICT; HIGH-RISK; PSYCHOPATHOLOGY; VALIDATION; MODERATORS AB We investigated longitudinal associations between alcohol-dependent fathers' 12-step treatment involvement and their children's internalizing and externalizing problems (N = 125, M(age) = 9.8 +/- 3.1), testing the hypotheses that fathers' greater treatment involvement would benefit later child behavior and that this effect would be mediated by fathers' posttreatment behaviors. The initial association was established between fathers' treatment involvement and children's externalizing problems only, whereas Structural Equation Modeling (SEM) results supported mediating hypotheses. Fathers' greater treatment involvement predicted children's lower externalizing problems 12 months later, and fathers' posttreatment behaviors mediated this association: Greater treatment involvement predicted greater posttreatment Alcoholics Anonymous attendance, which in turn predicted greater abstinence. Finally, fathers' abstinence was associated with lower externalizing problems in children. Theoretical and practical implications of these findings are discussed. (C) 2009 Elsevier Inc. All rights reserved. C1 [Andreas, Jasmina Burdzovic] Brown Univ, Dept Community Hlth, Ctr Hlth & Clin Epidemiol, Providence, RI 02912 USA. [O'Farrell, Timothy J.] Harvard Univ, Sch Med, Dept Psychiat, Families & Addict Program, Boston, MA 02115 USA. [O'Farrell, Timothy J.] VA Boston Healthcare Syst, Boston, MA 02115 USA. RP Andreas, JB (reprint author), Brown Univ, Dept Community Hlth, Ctr Hlth & Clin Epidemiol, 121 S Main St, Providence, RI 02912 USA. EM jba@brown.edu FU NIAAA NIH HHS [R01 AA010796, K02 AA000234, K02AA00234, R01 AA010796-05, K02 AA000234-10]; NIDA NIH HHS [R01DA12189, R01 DA012189-05, R01 DA012189]; NIMH NIH HHS [T32 MH016259-22, T32MH16259]; PHS HHS [R0JAA10796] NR 55 TC 9 Z9 9 U1 3 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JAN PY 2009 VL 36 IS 1 BP 87 EP 100 DI 10.1016/j.jsat.2008.05.006 PG 14 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 383XZ UT WOS:000261709000011 PM 18715745 ER PT J AU Eisenberg, BL Harris, J Blanke, CD Demetri, GD Heinrich, MC Watson, JC Hoffman, JP Okuno, S Kane, JM von Mehren, M AF Eisenberg, Burton L. Harris, Jonathan Blanke, Charles D. Demetri, George D. Heinrich, Michael C. Watson, James C. Hoffman, John P. Okuno, Scott Kane, John M. von Mehren, Margaret TI Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST): Early Results of RTOG 0132/ACRIN 6665 SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Article DE GIST; neoadjuvant imatinib; locally advanced GIST; metastatic GIST ID SURGICAL-MANAGEMENT; PROGNOSTIC-FACTORS; RESIDUAL DISEASE; DOSE IMATINIB; THERAPY; RESECTION; SURVIVAL; LEIOMYOSARCOMAS; PATTERNS; SURGERY AB Background: Therapy for gastrointestinal stromal tumors (GIST) has changed significantly with the use of imatinib mesylate (IM). Despite the success of this drug in metastatic GIST, disease progression remains a perplexing clinical issue suggesting the need for multimodality management. There have been no prospective studies either evaluating the neoadjuvant use of IM in primary GIST or as a preoperative cytoreduction agent for metastatic GIST. Methods: RTOG 0132/ACRIN 6665 was a prospective phase II study evaluating safety and efficacy of neoadjuvant IM (600 mg/day) for patients with primary GIST or the preop use of IM in patients with operable metastatic GIST. The trial continued postop IM for 2 years. Results: Sixty-three patients were entered (52 analyzable), 30 patients with primary GIST (Group A) and 22 with recurrent metastatic GIST (Group B). Response (RECIST) in Group A was (7% partial, 83% stable. 10% unknown), in Group B (4.5% partial, 91% stable, 4.5% progression). Two-year progression free survival (Group A 83%, Group B 77%). Estimated overall survival (Group A 93%, Group B 91%). Complications of surgery and IM toxicity were minimal. Conclusion: This trial represents the first prospective report of preop IM in GIST. This approach is feasible, requires multidisciplinary consultations, and is not associated with notable postop complications. C1 [Eisenberg, Burton L.] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Sect Surg Oncol, Lebanon, NH 03756 USA. [Harris, Jonathan] Amer Coll Radiol, Dept Stat, Philadelphia, PA USA. [Blanke, Charles D.] Univ British Columbia, Head Div Med Oncol, Vancouver, BC V5Z 1M9, Canada. [Demetri, George D.] Dana Farber Canc Inst, Sarcoma Ctr, Boston, MA 02115 USA. [Heinrich, Michael C.] Portland VA Med Ctr, Div Hematol Med Oncol, Portland, OR USA. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Watson, James C.; Hoffman, John P.; von Mehren, Margaret] Fox Chase Canc Ctr, Dept Surg & Med Oncol, Philadelphia, PA 19111 USA. [Okuno, Scott] Mayo Clin, Dept Med Oncol, Rochester, MN USA. Roswell Pk Canc Inst, Dept Surg Oncol, Buffalo, NY 14263 USA. RP Eisenberg, BL (reprint author), Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Sect Surg Oncol, 1 Med Ctr Dr, Lebanon, NH 03756 USA. EM burton.l.eisenber@dartmouth.edu FU NCI [RTOG U10CA21661, CCOP U10CA37422, Stat U10 CA32115]; VA Merit Review Grant (MCH) FX Supported by RTOG U10CA21661, CCOP U10CA37422, and Stat U10 CA32115 grants from the NCI and a VA Merit Review Grant (MCH). This manuscript's contents are the sole responsibility of the authors and do not necessarily represent the official view of the NCI or the Veterans Administration. NR 28 TC 142 Z9 159 U1 1 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0022-4790 J9 J SURG ONCOL JI J. Surg. Oncol. PD JAN 1 PY 2009 VL 99 IS 1 BP 42 EP 47 DI 10.1002/jso.21160 PG 6 WC Oncology; Surgery SC Oncology; Surgery GA 391KN UT WOS:000262232300011 PM 18942073 ER PT J AU O'Neill, AC Randolph, MA Bujold, KE Kochevar, IE Redmond, RW Winograd, JM AF O'Neill, Anne C. Randolph, Mark A. Bujold, Kenneth E. Kochevar, Irene E. Redmond, Robert W. Winograd, Jonathan M. TI Photochemical Sealing Improves Outcome Following Peripheral Neurorrhaphy SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE peripheral nerve; neurorrhaphy; photochemical tissue bonding; nerve wrapping; human amniotic membrane ID HUMAN AMNIOTIC MEMBRANE; BLOOD NERVE BARRIER; CORNEAL INCISIONS; PENETRATING KERATOPLASTY; WALLERIAN DEGENERATION; COMPRESSIVE NEUROPATHY; HUMAN FOREARM; ULNAR NERVES; RAT MODEL; LONG-TERM AB Introduction. Peripheral nerve transection initiates a complex molecular response in the severed nerve endings, resulting in the release of neurotrophic and neurotropic factors that are central to axonal survival and regeneration. In this study we tested the hypothesis that sealing the neurorrhaphy site from the surrounding environment using a photochemically bonded nerve wrap would optimize the endoneural environment and enhance regeneration and nerve function recovery. Materials and methods. Adult rats underwent unilateral sciatic nerve transection and standard epineural nerve repair. The repair site was wrapped with amniotic membrane or autologous vein and then was either sealed using photochemical tissue bonding (PTB) or secured with sutures. Photochemical sealing without a wrap was also carried out. Functional recovery was assessed at 2-wk intervals using walking track analysis and nerve histomorphometry was assessed at 12 wk. Results. Treating nerves with PTB-sealed amnion significantly improved functional recovery and increased distal axon and fiber diameters and myelin thickness compared to nerves treated with standard neurorrhaphy alone. Direct PTB sealing of the repair site also improved function. Neither amnion secured with sutures nor vein wraps exhibited improved functional or histological recovery compared to standard neurorrhaphy. Conclusions. These results suggest that sealing the peripheral nerve repair site with amnion using a photochemical technique may lead to earlier restoration of neural homeostasis and consequent enhanced repair of nerve injury. (C) 2009 Elsevier Inc. All rights reserved. C1 [Randolph, Mark A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Plast Surg,Plast Surg Res Lab, Boston, MA 02114 USA. [Bujold, Kenneth E.; Kochevar, Irene E.; Redmond, Robert W.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Randolph, MA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Plast Surg,Plast Surg Res Lab, WAC 435,15 Parkman St, Boston, MA 02114 USA. EM marandolph@partners.org FU DOD Medical Free Electron Laser Program [F4 9620-01-1-0014]; CIMIT (Center for Integration of Medicine and Innovative Technology) FX The authors gratefully acknowledge support from the DOD Medical Free Electron Laser Program F4 9620-01-1-0014 and from CIMIT (Center for Integration of Medicine and Innovative Technology). NR 44 TC 28 Z9 30 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD JAN PY 2009 VL 151 IS 1 BP 33 EP 39 DI 10.1016/j.jss.2008.01.025 PG 7 WC Surgery SC Surgery GA 388FG UT WOS:000262005100007 PM 18599081 ER PT J AU Dausch, BM Miklowitz, DJ Nagamoto, HT Adler, LE Shore, JH AF Dausch, Barbara M. Miklowitz, David J. Nagamoto, Herbert T. Adler, Lawrence E. Shore, Jay H. TI Family-focused therapy via videoconferencing SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID RANDOMIZED-TRIAL; BIPOLAR DISORDER; TELEPSYCHIATRY; DEPRESSION AB A 30-year-old veteran with a diagnosis of schizoaffective disorder and his mother were referred for family-focused therapy (FFT), an empirically-supported, manual-based treatment. The veteran had had multiple hospitalizations and experienced chronic auditory hallucinations for self-harm. Minor modifications to FFT were made for implementation via videoconferencing (at a bandwidth of 384 kbit/s). This may have enhanced the treatment by making the process of communication and problem-solving more explicit. The course of FFT was successfully completed, and the veteran and family showed a high level of satisfaction with care as well as improved medication adherence, good quality of life, high levels of hope, good interpersonal functioning, and very mild negative and positive psychiatric symptoms. This veteran had previous exposure to telemental health, which may have influenced his willingness to receive tele-FFT and perhaps affected the outcome of the case. The ability to provide this type of service to people in rural areas is important. C1 [Dausch, Barbara M.; Nagamoto, Herbert T.; Shore, Jay H.] Eastern Colorado Hlth Care Syst, Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. [Adler, Lawrence E.] Mental Illness Res Educ & Clin Ctr VISN 19, Denver, CO USA. [Miklowitz, David J.] Univ Colorado, Dept Psychol, Boulder, CO 80309 USA. [Dausch, Barbara M.; Miklowitz, David J.; Nagamoto, Herbert T.; Shore, Jay H.] Univ Colorado, Dept Psychiat, Denver, CO 80202 USA. [Dausch, Barbara M.; Miklowitz, David J.; Nagamoto, Herbert T.; Shore, Jay H.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Dausch, BM (reprint author), Eastern Colorado Hlth Care Syst, Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM Barbara.Dausch@va.gov FU Office of Mental Health Services, Department of Veterans Affairs Central Office FX The project was funded by Mental Health Enhancement Initiative Funding from the Office of Mental Health Services, Department of Veterans Affairs Central Office. NR 17 TC 6 Z9 6 U1 2 U2 5 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2009 VL 15 IS 4 BP 211 EP 214 DI 10.1258/jtt.2009.081216 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 467DX UT WOS:000267718600011 PM 19471035 ER PT J AU Wozniak, J AF Wozniak, Janet TI Clinical Manual of Child and Adolescent Psychopharmacology SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Book Review C1 [Wozniak, Janet] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. RP Wozniak, J (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. EM jwozniak@partners.org NR 1 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD JAN PY 2009 VL 48 IS 1 BP 89 EP 90 DI 10.1097/01.CHI.0000314045.38727.58 PG 2 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 386PF UT WOS:000261894400014 ER PT J AU Ponte, M Klemperer, E Sahay, A Chen, MM AF Ponte, Maya Klemperer, Erika Sahay, Anju Chen, Mary Margaret TI Effects of vulvodynia on quality of life SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-DermatoEpidemiology-Network CY MAY 12, 2007 CL Los Angeles, CA SP Amer DermatoEpidemiol Network ID INTERSTITIAL CYSTITIS; VULVAR VESTIBULITIS; PAIN AB Background: The experiences of women with vulvodynia are poorly understood. Objective. We Sought to determine the effects Of vulvodynia on quality of life. Methods: We conducted a Survey of 280 patients in a university-based vulvar disorders clinic. Skin-related quality of life was measured with a vulvar-specific version of Skindex-29. Results: The response rate was 95%; 101 patients (36%) had vulvodynia, and 179 patients (64%) had other vulvar conditions. Women with vulvodynia had significantly worse quality of life than patients with many other dermatologic conditions, and worse functioning than women with other vulvar conditions (mean functioning scores [+/- SD] of patients with psoriasis, other vulvar conditions, and vulvodynia were 23 27, 34 24, and 44 22, respectively, P = .05). A diagnosis Of vulvodynia was the strongest independent correlate of poor quality of life (eg, for poor functioning, odds ratio = 1.8, 95% confidence interval 1.0-3-1). Limitations: Limitations are single academic medical center and comorbid illnesses determined by self-report. Conclusion: Vulvodynia has broad and Substantial effects on quality of life. (J Am Acad Dermatol 2009;60:70-6) C1 [Ponte, Maya] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Klemperer, Erika; Chen, Mary Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Sahay, Anju] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Chen, MM (reprint author), San Francisco VA Med Ctr, 4150 Clement St,151R, San Francisco, CA 94121 USA. EM chrenm@derm.ucsf.edu FU NIAMS NIH HHS [K24 AR052667-01, K02 AR 02203, K02 AR002203, K24 AR052667, K24-AR052667] NR 14 TC 31 Z9 32 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD JAN PY 2009 VL 60 IS 1 BP 70 EP 76 DI 10.1016/j.jaad.2008.06.032 PG 7 WC Dermatology SC Dermatology GA 391VG UT WOS:000262261700007 PM 19022532 ER PT J AU Price, M Norris, DM AF Price, Marilyn Norris, Donna M. TI Health Care Fraud: Physicians as White Collar Criminals? SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Editorial Material C1 [Price, Marilyn; Norris, Donna M.] Harvard Univ, Sch Med, Boston, MA USA. RP Price, M (reprint author), Massachusetts Gen Hosp, Law & Psychiat Serv, 15 Parkman St,WAC812, Boston, MA 02114 USA. EM marilynpricemd@comcast.net NR 11 TC 1 Z9 1 U1 0 U2 7 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2009 VL 37 IS 3 BP 286 EP 289 PG 4 WC Law; Psychiatry SC Government & Law; Psychiatry GA 504ET UT WOS:000270599100001 PM 19767491 ER PT J AU Price, M Norris, DM AF Price, Marilyn Norris, Donna M. TI White-Collar Crime: Corporate and Securities and Commodities Fraud SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID PERCEPTIONS; OFFENDERS; PERSONALITY; PUNISHMENT AB In this era of increased interest in white-collar crime, forensic psychiatrists are in a key position to study the individual characteristics of offenders. While a comprehensive theory of high-level white-collar crime should consider societal and organizational contributions, there is value in understanding the personal traits that place an individual at high risk for offending. As the impact of the criminal acts of this group has been increasingly felt by larger groups from all socioeconomic strata, there is less willingness by the public to view these crimes as victimless and harmless. C1 [Price, Marilyn; Norris, Donna M.] Harvard Univ, Sch Med, Boston, MA USA. RP Price, M (reprint author), Massachusetts Gen Hosp, Law & Psychiat Serv, 15 Parkman St,WAC 812, Boston, MA 02114 USA. EM marilynpricemd@comcast.net NR 35 TC 5 Z9 5 U1 5 U2 10 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2009 VL 37 IS 4 BP 538 EP 544 PG 7 WC Law; Psychiatry SC Government & Law; Psychiatry GA 541RA UT WOS:000273435400011 PM 20019002 ER PT J AU Duran-Struuck, R Dyskoz, RC AF Duran-Struuck, Raimon Dyskoz, Robert C. TI Principles of Bone Marrow Transplantation (BMT): Providing Optimal Veterinary and Husbandry Care to Irradiated Mice in BMT Studies SO JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE LA English DT Review ID VERSUS-HOST-DISEASE; HEMATOPOIETIC STEM-CELLS; TOTAL-BODY IRRADIATION; PARVOVIRUS MINUTE VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; RADIATION DOSE-FRACTIONATION; ANTIGEN-PRESENTING CELLS; ACUTE GRAFT; PSEUDOMONAS-AERUGINOSA; T-CELLS AB Bone marrow transplantation (BMT) is the treatment of choice for many leukemias, solid tumors, and metabolic diseases. The field of bone marrow research is highly dependent on in vivo experimentation, because in vitro techniques do not mimic these complicated in vivo systems. Therefore, understanding the medical and husbandry care needs of these transiently immunodeficient bone marrow recipient animals is crucial for researchers, veterinary and animal care personnel. Here we discuss the principles of bone marrow transplantation, mouse pathogens that can interfere with transplantation research, and important husbandry and veterinary practices for mice that may help to minimize unnecessary infections during the transplantation process. Whole-body irradiation is one of the most common tools for myeloablation of the recipient's bone marrow. We discuss the crucial role of the irradiator for BMT research and the importance of aseptic husbandry practices to lessen the possibility of the irradiator for being a source for disease transmission. Finally, we discuss some important guidelines for Institutional Animal Use and Care Committees reviewing irradiation and BMT protocols. C1 [Duran-Struuck, Raimon] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02115 USA. [Dyskoz, Robert C.] Univ Michigan, Sch Med, Unit Lab Anim Med, Ann Arbor, MI USA. RP Duran-Struuck, R (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02115 USA. EM raimon.duran-struuck@tbrc.mgh.harvard.edu FU National Center for Research Resources (RDS) [T32-RR07008, K01RR024466] FX This study was supported by grant T32-RR07008 and K01RR024466 from the National Center for Research Resources (RDS) and internal funds for the Unit for Laboratory Animal Medicine. We would like to thank James L.M. Ferrara MD from the University of Michigan Cancer Center for sharing the mouse bone marrow transplantation protocols. NR 111 TC 47 Z9 47 U1 0 U2 8 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1559-6109 J9 J AM ASSOC LAB ANIM JI J. Amer. Assoc. Lab. Anim. Sci. PD JAN PY 2009 VL 48 IS 1 BP 11 EP 22 PG 12 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 404FZ UT WOS:000263137800003 PM 19245745 ER PT J AU Morrison, RS Flanagan, S Fischberg, D Cintron, A Siu, AL AF Morrison, R. Sean Flanagan, Steven Fischberg, Daniel Cintron, Alexie Siu, Albert L. TI A Novel Interdisciplinary Analgesic Program Reduces Pain and Improves Function in Older Adults After Orthopedic Surgery SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pain; function; orthopedic surgery ID TOTAL KNEE ARTHROPLASTY; HIP-FRACTURE PATIENTS; LOWER-EXTREMITY FUNCTION; POSTOPERATIVE PAIN; PROPENSITY SCORES; DELIRIUM; MORTALITY; OUTCOMES; REHABILITATION; INTERVENTION AB To examine the effect of a multicomponent intervention on pain and function after orthopedic surgery. Controlled prospective propensity score-matched clinical trial. New York City acute rehabilitation hospital. Two hundred forty-nine patients admitted to rehabilitation after hip fracture repair (n=51) or hip (n=64) or knee (n=134) arthroplasty. Pain assessment at rest and with physical therapy (PT) by staff using numeric rating scales (1 to 5). Physician protocols for standing analgesia and preemptive analgesia before PT were implemented on the intervention unit. Control unit patients received usual care. Pain, analgesic prescribing, gait speed, transfer time, and percentage of PT sessions completed during admission. Pain and difficulty walking at 6, 12, 18, and 24 weeks after discharge. In multivariable analyses intervention patients were significantly more likely than controls to report no or mild pain at rest (66% vs 49%, P=.004) and with PT (52% vs 38%, P=.02) on average for the first 7 days of rehabilitation, had faster 8-foot-walk times on Days 4 (9.3 seconds vs 13.2 seconds, P=.02) and 7 (6.9 vs 9.2 seconds, P=.02), received more analgesia (23.6 vs 15.6 mg of morphine sulfate equivalents per day, P <.001), were more likely to receive standing orders for analgesia (98% vs 48%, P <.001), and had significantly shorter lengths of stay (10.1 vs 11.3 days, P=.005). At 6 months, intervention patients were less likely than controls to report moderate to severe pain with walking (4% vs 15%, P=.02) and that pain did not interfere with walking (7% vs 18%, P=.004) and were less likely to be taking analgesics (35% vs 51%, P=.03). The intervention improved postoperative pain, reduced chronic pain, and improved function. C1 [Morrison, R. Sean; Fischberg, Daniel; Cintron, Alexie; Siu, Albert L.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. [Morrison, R. Sean; Siu, Albert L.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. [Flanagan, Steven] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Morrison, RS (reprint author), Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. EM sean.morrison@mssm.edu FU National Institute on Aging (NIA) [R01AG022108]; NIA [K24 AG022345, K24 AG000918, R01AG022108-S1] FX The authors would like to acknowledge the invaluable assistance of Susan Calise and Saima Siddiqui.; Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this manuscript. This study was supported by Grant R01AG022108 from the National Institute on Aging (NIA). Drs. Morrison and Siu are recipients of mid-career investigator awards in patient-oriented research from the NIA (K24 AG022345 and K24 AG000918, respectively). Dr. Cintron was supported by a Diversity Supplement from the NIA (R01AG022108-S1).; Author Contributions: R. Sean Morrison and Steven Flanagan: study concept and design, acquisition of subjects and data, analysis and interpretation of data, and preparation of manuscript. Daniel Fischberg and Albert Siu: study concept and design, analysis and interpretation of data, and preparation of manuscript. Alexie Cintron: acquisition of subjects and data, analysis and interpretation of data, and preparation of manuscript.; Sponsors' Role: The funding agencies had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. NR 46 TC 37 Z9 38 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2009 VL 57 IS 1 BP 1 EP 10 DI 10.1111/j.1532-5415.2008.02063.x PG 10 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 389YD UT WOS:000262130600001 PM 19054187 ER PT J AU Goroll, AH Simon, SR Tripathi, M Ascenzo, C Bates, DW AF Goroll, Allan H. Simon, Steven R. Tripathi, Micky Ascenzo, Carl Bates, David W. TI Community-wide Implementation of Health Information Technology: The Massachusetts eHealth Collaborative Experience SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID ELECTRONIC MEDICAL-RECORDS; PRIMARY-CARE AB The Massachusetts eHealth Collaborative (MAeHC) was formed to improve patient safety and quality of care by promoting the use of health information technology through community-based implementation of electronic health records (EHRs) and health information exchange. The Collaborative has recently implemented EHRs in a diverse set of competitively selected communities, encompassing nearly 500 physicians serving over 500,000 patients. Targeting both EHR implementation and health information exchange at the community level has identified numerous challenges and strategies for overcoming them. This article describes the formation and implementation phases of the Collaborative, focusing on barriers identified, lessons learned, and policy issues. C1 [Goroll, Allan H.] Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA. [Goroll, Allan H.] Harvard Univ, Sch Med, Boston, MA USA. [Simon, Steven R.] Harvard Univ, Sch Med, Boston, MA USA. [Simon, Steven R.] Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA. [Tripathi, Micky] Massachusetts eHlth Collaborat, Waltham, MA USA. [Ascenzo, Carl] Blue Cross & Blue Shield Massachusetts, Boston, MA USA. [Bates, David W.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Bates, David W.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RP Goroll, AH (reprint author), Massachusetts Gen Hosp, Med Serv, 15 Parkman St,Suite 645, Boston, MA 02114 USA. EM ahgoroll@partners.org NR 21 TC 39 Z9 39 U1 6 U2 17 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD JAN-FEB PY 2009 VL 16 IS 1 BP 132 EP 139 DI 10.1197/jamia.M2899 PG 8 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 396UB UT WOS:000262615600018 PM 18952937 ER PT J AU Baumgartner, H Hung, J Bermejo, J Chambers, JB Evangelista, A Griffin, BP Iung, B Otto, CM Pellikka, PA Quinones, M AF Baumgartner, Helmut Hung, Judy Bermejo, Javier Chambers, John B. Evangelista, Arturo Griffin, Brian P. Iung, Bernard Otto, Catherine M. Pellikka, Patricia A. Quinones, Miguel TI Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY LA English DT Review ID VALVULAR AORTIC-STENOSIS; PRESSURE HALF-TIME; PERCUTANEOUS MITRAL COMMISSUROTOMY; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; PULMONARY-ARTERY PRESSURE; RHEUMATIC HEART-DISEASE; DOPPLER-ECHOCARDIOGRAPHY; TRICUSPID STENOSIS; RISK STRATIFICATION; NONINVASIVE ASSESSMENT C1 [Baumgartner, Helmut] Univ Munster, Munster, Germany. [Hung, Judy] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bermejo, Javier] Hosp Gen Univ Gregorio Maranon, Barcelona, Spain. [Chambers, John B.] Huys & St Thomas Hosp, London, England. [Evangelista, Arturo] Hosp Valle De Hebron, Barcelona, Spain. [Griffin, Brian P.] Cleveland Clin, Cleveland, OH 44106 USA. [Iung, Bernard] Univ Paris 07, Paris, France. [Otto, Catherine M.] Univ Washington, Seattle, WA 98195 USA. [Pellikka, Patricia A.] Mayo Clin, Rochester, MN USA. [Quinones, Miguel] Methodist Hosp, Houston, TX 77030 USA. RP Hung, J (reprint author), Amer Soc Echocardiog, 2100 Gateway Ctr Blvd,Suite 310, Morrisville, NC 27560 USA. EM ase@asecho.org OI Otto, Catherine/0000-0002-0527-9392 NR 109 TC 772 Z9 786 U1 3 U2 30 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0894-7317 J9 J AM SOC ECHOCARDIOG JI J. Am. Soc. Echocardiogr. PD JAN PY 2009 VL 22 IS 1 BP 1 EP 23 DI 10.1016/j.echo.2008.11.029 PG 23 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 391PL UT WOS:000262245100003 PM 19130998 ER PT J AU Martin, NM Picard, MH AF Martin, Nicole M. Picard, Michael H. TI Use and Appropriateness of Transthoracic Echocardiography in an Academic Medical Center: A Pilot Observational Study SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY LA English DT Article DE Appropriateness; Echocardiography; Utilization ID CRITERIA WORKING GROUP; COMPUTED-TOMOGRAPHY; NUCLEAR-CARDIOLOGY; AMERICAN-SOCIETY AB Background: Few studies have examined the use of echocardiography in relation to recently released appropriateness criteria for echocardiography. Methods: By using the American College of Cardiology Foundation/American Society of Echocardiography appropriateness criteria, we examined transthoracic echocardiogram (TTE) ordering on the general medicine service at a tertiary referral center. Results: During the 35-day study period, 351 TTE orders in the queue were placed by residents. Of the 274 eligible TTEs, a large majority (86%) were appropriate. The 4 most common indications were heart failure (23%), known or suspected endocarditis (16%), syncope (14%), and arrhythmia (10%). Suspicion of endocarditis was the most common misuse, with 22% of this indication and 13% of the total studied either inappropriate or unclear. Conclusion: Medical house officers at Massachusetts General Hospital are typically using TTE appropriately. Future studies are needed to characterize ordering behavior in various settings and to refine the appropriateness criteria for specific, common indications. (J Am Soc Echocardiogr 2009; 22: 48-52.) C1 [Martin, Nicole M.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Martin, NM (reprint author), Massachusetts Gen Hosp, Div Cardiol, 15 Parkman St,WACC 535, Boston, MA 02114 USA. EM nmartin2@partners.org OI Picard, Michael/0000-0002-9264-3243 NR 10 TC 42 Z9 42 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0894-7317 J9 J AM SOC ECHOCARDIOG JI J. Am. Soc. Echocardiogr. PD JAN PY 2009 VL 22 IS 1 BP 48 EP 52 DI 10.1016/j.echo.2008.10.003 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 391PL UT WOS:000262245100007 PM 19022620 ER PT J AU Maynard, SE Thadhani, R AF Maynard, Sharon E. Thadhani, Ravi TI Pregnancy and the Kidney SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID PLACENTAL GROWTH-FACTOR; CIRCULATING ANGIOGENIC FACTORS; GLOMERULAR-FILTRATION-RATE; LOW-DOSE ASPIRIN; SUBSEQUENTLY DEVELOP PREECLAMPSIA; TYROSINE KINASE-1; SOLUBLE ENDOGLIN; MATERNAL PLASMA; CHRONIC GLOMERULONEPHRITIS; PATHOLOGICAL PREGNANCIES AB Nephrologists are frequently called on to diagnose and treat renal disorders in pregnant women. In this review, we update recent literature pertinent to pregnancy and renal disease. We initially begin by describing the application of common clinical estimators of GFR and proteinuria in pregnancy and then summarize recent studies regarding pregnancy in women with chronic kidney disease and the latest information on the use of common renal medications in pregnancy. In the final section, we describe advances in our understanding of the pathophysiology of preeclampsia and the potential clinical implications of these discoveries for screening, prevention, and treatment of preeclampsia. C1 [Maynard, Sharon E.] George Washington Univ, Sch Med & Hlth Sci, Dept Med, Div Renal Dis & Hypertens,Med Fac Associates, Washington, DC 20037 USA. [Thadhani, Ravi] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Renal Unit, Boston, MA USA. RP Maynard, SE (reprint author), George Washington Univ, Sch Med & Hlth Sci, Dept Med, Div Renal Dis & Hypertens,Med Fac Associates, 2150 Penn Ave NW, Washington, DC 20037 USA. EM sharonmaynard@gmail.com; thadhani.r@mgh.harvard.edu FU Charles E. Culpeper Scholarship in Medical Sciences; National Institutes of Health [DK67397] FX S.E.M. is supported by the Charles E. Culpeper Scholarship in Medical Sciences. R.T. is supported by grant DK67397 from the National Institutes of Health. NR 107 TC 52 Z9 60 U1 0 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2009 VL 20 IS 1 BP 14 EP 22 DI 10.1681/ASN.2008050493 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 397QM UT WOS:000262677200007 PM 19118150 ER PT J AU Huckans, M Seelye, A Parcel, T Mull, L Woodhouse, J Bjornson, D Fuller, BE Lofris, JM Morasco, BJ Sasaki, AW Storzbach, D Hauser, P AF Huckans, Marilyn Seelye, Adriana Parcel, Tiffany Mull, Lisa Woodhouse, Jonathan Bjornson, Danell Fuller, Bret E. Lofris, Jennifer M. Morasco, Benjamin J. Sasaki, Anna W. Storzbach, Daniel Hauser, Peter TI The cognitive effects of hepatitis C in the presence and absence of a history of substance use disorder SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Neuropsychology; Delirium; Dementia; Amnestic; Cognitive disorders; Infectious hepatitis virus; Substance-related disorders; Depression; Pain ID CENTRAL-NERVOUS-SYSTEM; HIV-INFECTION; NEUROPSYCHOLOGICAL IMPAIRMENT; CEREBROSPINAL-FLUID; VIRUS-INFECTION; LIVER-DISEASE; INTERFERON-ALPHA; RESERVE; PERFORMANCE; PAIN AB The aim of the study was to determine whether infection with the hepatitis C virus (HCV) is associated with cognitive impairment beyond the effects of prevalent comorbidities and a history of substance use disorder (SUD). Adult veterans were recruited from the Portland Veterans Affairs Medical Center into three groups: (1) HCV+/SUD+ (n = 39), (2) HCV+/SUD- (n = 24), and (3) HCV-/SUD- (n = 56). SUD+ participants were in remission for >= 90 days, while SUD- participants had no history of SUD. Groups did not significantly differ in terms of rates of psychiatric or medical comorbidities. Procedures included clinical interviews, medical record reviews, and neuropsychological testing. Significant group differences were found in the domains of Verbal Memory, Auditory Attention, Speeded Visual Information Processing, and Reasoning/Mental Flexibility (p <= .05). Post hoc comparisons indicated that HCV+/SUD- patients performed significantly worse than HCV-/SUD- controls on tests measuring verbal learning, auditory attention, and reasoning/mental flexibility, but only HCV+/SUD+ patients did worse than HCV-/SUD- controls on tests of speeded visual information processing, Results indicate that chronic HCV is associated with cognitive impairment in the absence of a history of SUD. The most robust deficits appear to be in verbal learning and reasoning/mental flexibility. (JINS, 2009,15, 69-82.) C1 [Huckans, Marilyn; Seelye, Adriana; Parcel, Tiffany; Mull, Lisa; Woodhouse, Jonathan; Bjornson, Danell; Fuller, Bret E.; Lofris, Jennifer M.; Sasaki, Anna W.; Hauser, Peter] Portland VA Med Ctr, NW Hepatitis Resource Ctr C, Portland, OR USA. [Huckans, Marilyn; Lofris, Jennifer M.; Morasco, Benjamin J.; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Seelye, Adriana; Parcel, Tiffany; Mull, Lisa] Pacific Univ, Dept Psychol, Portland, OR USA. [Woodhouse, Jonathan] George Fox Univ, Dept Psychol, Portland, OR USA. [Bjornson, Danell] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Lofris, Jennifer M.; Hauser, Peter] Portland VA Med Ctr, JENS Lab, Portland, OR USA. [Sasaki, Anna W.; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Huckans, Marilyn; Fuller, Bret E.; Lofris, Jennifer M.; Morasco, Benjamin J.; Storzbach, Daniel; Hauser, Peter] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. RP Huckans, M (reprint author), Portland VA Med Ctr P3MHDC, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM marilyn.huckans@va.gov FU Northwest Health Foundation; VA Career Development Award FX We Would like to thank William Hoffman for his editorial comments and for invaluable professional guidance and scientific mentorship over the years; Diane Howieson, Alexander Stevens, and Arthur Vandenbark for their continued mentorship and consultation; Rdie Nelligan and Ashlee Whitehead for their initial input in terais of study design and planning; Betsy Zucker, Glen Kenoski, and the other providers within the PVAMC Liver Clinic for their continued collaboration with the Northwest Hepatitis C Resource Center; and Alex Mitchell, Daniel Schwartz, Emily Kizer, Laura Parisi, and Samantha Ruimy for administrative support. This study was Supported in part by a Northwest Health Foundation grant and a VA Career Development Award to Dr. Huckans. NR 72 TC 20 Z9 20 U1 2 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD JAN PY 2009 VL 15 IS 1 BP 69 EP 82 DI 10.1017/S1355617708090085 PG 14 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 398NR UT WOS:000262739300008 PM 19128530 ER PT J AU Burstein, HJ AF Burstein, Harold J. TI On Sequencing the Full Genome of a Cancerous Cell SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Editorial Material C1 [Burstein, Harold J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Burstein, Harold J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Burstein, Harold J.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Burstein, HJ (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JONES AND BARTLETT PUBLISHERS PI SUDBURY PA 40 TALL PINE DR, SUDBURY, MA 01776 USA SN 1540-1405 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JAN PY 2009 VL 7 IS 1 BP 1 EP 1 PG 1 WC Oncology SC Oncology GA 498UG UT WOS:000270169000001 ER PT J AU Montie, JE Clark, PE Eisenberger, MA El-Galley, R Greenberg, RE Herr, HW Hudes, GR Kuban, DA Kuzel, TM Lange, PH Lele, SM Michalski, J Patterson, A Pohar, KS Richie, JP Sexton, WJ Shipley, WU Small, EJ Trump, DL Walther, PJ Wilson, TG AF Montie, James E. Clark, Peter E. Eisenberger, Mario A. El-Galley, Rizk Greenberg, Richard E. Herr, Harry W. Hudes, Gary R. Kuban, Deborah A. Kuzel, Timothy M. Lange, Paul H. Lele, Subodh M. Michalski, Jeffrey Patterson, Anthony Pohar, Kamal S. Richie, Jerome P. Sexton, Wade J. Shipley, William U. Small, Eric J. Trump, Donald L. Walther, Phillip J. Wilson, Timothy G. TI Bladder Cancer SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Review ID TRANSITIONAL-CELL-CARCINOMA; BACILLUS-CALMETTE-GUERIN; PHASE-II TRIAL; INTERNATIONAL CONSENSUS PANEL; RANDOMIZED CLINICAL-TRIALS; GEMCITABINE PLUS CISPLATIN; NEOADJUVANT CHEMOTHERAPY; TRANSURETHRAL RESECTION; UROTHELIAL CARCINOMA; MITOMYCIN-C C1 [Montie, James E.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Clark, Peter E.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Eisenberger, Mario A.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [El-Galley, Rizk] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL USA. [Herr, Harry W.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Kuban, Deborah A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kuzel, Timothy M.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Lange, Paul H.] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA. [Lele, Subodh M.] UNMC Eppley Canc Ctr, Nebraska Med Ctr, Lincoln, NE USA. [Michalski, Jeffrey] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Patterson, Anthony] Univ Tennessee, Inst Canc, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA. [Pohar, Kamal S.] Ohio State Univ, Authur G James Canc Hosp, Columbus, OH 43210 USA. [Pohar, Kamal S.] Ohio State Univ, Richard J Solove Res Inst, Columbus, OH 43210 USA. [Richie, Jerome P.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. [Shipley, William U.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Small, Eric J.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Wilson, Timothy G.] City Hope Natl Med Ctr, Duarte, CA 91010 USA. RP Montie, JE (reprint author), Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. RI Clark, Peter/E-1423-2011 OI Clark, Peter/0000-0002-8006-7015 NR 52 TC 49 Z9 50 U1 0 U2 0 PU JONES AND BARTLETT PUBLISHERS PI SUDBURY PA 40 TALL PINE DR, SUDBURY, MA 01776 USA SN 1540-1405 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JAN PY 2009 VL 7 IS 1 BP 8 EP 39 PG 32 WC Oncology SC Oncology GA 498UG UT WOS:000270169000002 PM 19176203 ER PT J AU Crawford, J Armitage, J Balducci, L Bennett, C Blayney, DW Cataland, SR Dale, DC Demetri, GD Erba, HR Foran, J Freifeld, AG Goemann, M Heaney, ML Htoy, S Hudock, S Kloth, DD Kuter, DJ Lyman, GH Michaud, LB Miyata, SC Tallman, MS AF Crawford, Jeffrey Armitage, James Balducci, Lodovico Bennett, Charles Blayney, Douglas W. Cataland, Spero R. Dale, David C. Demetri, George D. Erba, Harry R. Foran, James Freifeld, Alison G. Goemann, Marti Heaney, Mark L. Htoy, Sally Hudock, Susan Kloth, Dwight D. Kuter, David J. Lyman, Gary H. Michaud, Laura Boehnke Miyata, Sarah C. Tallman, Martin S. TI Myeloid Growth Factors SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Review ID COLONY-STIMULATING FACTOR; NON-HODGKINS-LYMPHOMA; CHEMOTHERAPY-INDUCED NEUTROPENIA; PATIENTS RECEIVING CHEMOTHERAPY; INDUCED FEBRILE NEUTROPENIA; CONTROLLED PHASE-III; CELL LUNG-CANCER; DOSE-INTENSITY; BREAST-CANCER; CHOP CHEMOTHERAPY C1 [Armitage, James; Freifeld, Alison G.] UNMC Eppley Canc Ctr, Nebraska Med Ctr, Lincoln, NE USA. [Bennett, Charles] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Blayney, Douglas W.; Erba, Harry R.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Cataland, Spero R.] Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH 43210 USA. [Cataland, Spero R.] Ohio State Univ, Richard J Solove Res Inst, Columbus, OH 43210 USA. [Dale, David C.] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA. [Demetri, George D.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA. [Foran, James] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL USA. [Goemann, Marti] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Heaney, Mark L.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Htoy, Sally] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Hudock, Susan] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [Kuter, David J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Michaud, Laura Boehnke] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Miyata, Sarah C.; Tallman, Martin S.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. OI Kloth, Dwight/0000-0001-7220-2830 NR 55 TC 24 Z9 25 U1 0 U2 1 PU JONES AND BARTLETT PUBLISHERS PI SUDBURY PA 40 TALL PINE DR, SUDBURY, MA 01776 USA SN 1540-1405 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JAN PY 2009 VL 7 IS 1 BP 64 EP 83 PG 20 WC Oncology SC Oncology GA 498UG UT WOS:000270169000006 PM 19176207 ER PT J AU Wadleigh, M Stone, RM AF Wadleigh, Martha Stone, Richard M. TI The Role of Myeloid Growth Factors in Acute Leukemia SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article DE Myeloid growth factors; acute myeloid leukemia; acute lymphoblastic leukemia; priming ID COLONY-STIMULATING FACTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; PLACEBO-CONTROLLED TRIAL; FACTOR GM-CSF; ADVANCED MYELODYSPLASTIC SYNDROME; REMISSION INDUCTION CHEMOTHERAPY; COOPERATIVE-ONCOLOGY-GROUP; ACUTE LYMPHOCYTIC-LEUKEMIA AB Myeloid growth factors granulocyte-colony stimulating and granulocyte macrophage colony-stimulating factors have been extensively studied in acute leukemias. Whether administered before, during, or after chemotherapy for acute myeloid leukemia and acute lymphoblastic leukemia, these agents reduce the duration of neutropenia and seem to be safe and well tolerated. Despite consistently showing a shorter duration of neutropenia, multiple, prospective, randomized trials have documented only modest benefits in terms of reduction in the incidence and severity of infections, without substantial gains or impact in complete remission, overall survival, and disease-free survival rates. Growth factors have also been used to recruit quiescent leukemia cells into the S-phase of the cell cycle to increase their susceptibility to chemotherapy with the goal to reduce relapse and resistance. Randomized trials evaluating this priming strategy have consistently shown improvement in disease- or event-free survival in the intermediate-risk group of patients with acute myeloid leukemia, but no overall survival benefit. This article focuses on the clinical experience with these agents as adjuncts to the treatment of acute leukemias. (JNCCN 2009;7:84-91) C1 [Wadleigh, Martha; Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Wadleigh, M (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM Martha_wadleigh@DFCI.Harvard.edu NR 45 TC 7 Z9 7 U1 0 U2 0 PU JONES AND BARTLETT PUBLISHERS PI SUDBURY PA 40 TALL PINE DR, SUDBURY, MA 01776 USA SN 1540-1405 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD JAN PY 2009 VL 7 IS 1 BP 84 EP 91 PG 8 WC Oncology SC Oncology GA 498UG UT WOS:000270169000007 PM 19176208 ER PT J AU Lin, Y Lipsitz, S Sinha, D Gawande, AA Regenbogen, SE Greenberg, CC AF Lin, Yan Lipsitz, Stuart Sinha, Debajyoti Gawande, Atul A. Regenbogen, Scott E. Greenberg, Caprice C. TI Using Bayesian p-values in a 2 x 2 table of matched pairs with incompletely classified data SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS LA English DT Article DE Dirichlet prior; Exact McNemar test; Ignorable missing data ID MISSING DATA; CORRELATED PROPORTIONS; CONTINGENCY-TABLES AB Altham proposed Bayesian p-values for the analysis of a 2x2 contingency table that is formed from matched pairs. Using the same Bayesian perspective, we develop an extension of Altham's Bayesian p-values to a 2x2 table from matched pairs with missing data that are missing at random. The approach is applied to a rater agreement study, in which two surgeon-reviewers rated whether or not there was a communication breakdown in malpractice cases. We also use a simulation study to explore the power and type I error rate of the Bayesian p-values. C1 [Lin, Yan] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA. [Lipsitz, Stuart; Gawande, Atul A.; Greenberg, Caprice C.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Lipsitz, Stuart] Med Univ S Carolina, Charleston, SC USA. [Sinha, Debajyoti] Florida State Univ, Tallahassee, FL 32306 USA. [Regenbogen, Scott E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Lin, Y (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA. EM hyanlin@mdanderson.org FU US National Institutes of Health [AI 60373, MH 054693, CA 74015, CA 069222] FX We are grateful for the support from the US National Institutes of Health grants AI 60373, MH 054693, CA 74015 and CA 069222. We are also extremely indebted to Dr David Studdert for allowing the data to be used in this analysis. NR 20 TC 6 Z9 6 U1 1 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0035-9254 J9 J ROY STAT SOC C-APP JI J. R. Stat. Soc. Ser. C-Appl. Stat. PY 2009 VL 58 BP 237 EP 246 DI 10.1111/j.1467-9876.2008.00645.x PG 10 WC Statistics & Probability SC Mathematics GA 429AF UT WOS:000264892500006 PM 19657473 ER PT J AU Najita, JS Li, Y Catalano, PJ AF Najita, Julie S. Li, Yi Catalano, Paul J. TI A novel application of a bivariate regression model for binary and continuous outcomes to studies of fetal toxicity SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS LA English DT Article DE Clustering; Correlated probit model; Dose response modelling; Fetal toxicity; Partial likelihood ID SUBUNIT-SPECIFIC OUTCOMES; LATENT VARIABLE MODELS; DEVELOPMENTAL TOXICITY; CLUSTERED BINARY; RISK-ASSESSMENT; DOSE-RESPONSE; LITTER SIZE; TOXICOLOGY; WEIGHT; RAT AB Public health concerns over the occurrence of birth defects and developmental abnormalities that may occur as a result of prenatal exposure to drugs, chemicals and other environmental factors has led to an increasing number of developmental toxicity studies. Because fetal pups are commonly evaluated for multiple outcomes, data analysis frequently involves a joint modelling approach. We focus on modelling clustered binary and continuous outcomes in the setting where both outcomes are potentially observable in all offspring but, owing to practical limitations, the continuous outcome is only observed in a subset of offspring. The subset is not a simple random sample but is selected by the experimenter under a prespecified probability model. Although joint models for binary and continuous outcomes have been developed when both outcomes are available for every fetus, many existing approaches are not directly applicable when the continuous outcome is not observed in a simple random sample. We adapt a likelihood-based approach for jointly modelling clustered binary and continuous outcomes when the continuous response is missing by design and missingness depends on the binary trait. The approach takes into account the probability that a fetus is selected in the subset. Through the use of a partial likelihood, valid estimates can be obtained by a simple modification to the partial likelihood score. Data involving the herbicide 2,4,5-trichlorophenoxyacetic-acid are analysed. Simulation results confirm the approach. C1 [Najita, Julie S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RP Najita, JS (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, 44 Binney St, Boston, MA 02115 USA. EM jnajita@hsph.harvard.edu FU National Institute of Environmental Health Sciences of the US National Institutes of Health [ES07142] FX The authors express their appreciation to David W. Gaylor and the National Center for Toxicological Research for use of the example data. The authors also thank Louise M. Ryan for helpful comments on early drafts and two referees for comments that greatly improved the manuscript. This work was supported in part by grant ES07142 from the National Institute of Environmental Health Sciences of the US National Institutes of Health. NR 28 TC 3 Z9 3 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0035-9254 J9 J ROY STAT SOC C-APP JI J. R. Stat. Soc. Ser. C-Appl. Stat. PY 2009 VL 58 BP 555 EP 573 PG 19 WC Statistics & Probability SC Mathematics GA 480EC UT WOS:000268714000008 PM 20357904 ER PT J AU Chu, D Bakaeen, FG Wang, XL Coselli, JS LeMaire, SA Huh, J AF Chu, Danny Bakaeen, Faisal G. Wang, Xing Li Coselli, Joseph S. LeMaire, Scott A. Huh, Joseph TI The impact of placing multiple grafts to each myocardial territory on long-term survival after coronary artery bypass grafting SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID COMPLETE REVASCULARIZATION; CARDIAC-SURGERY; DISEASE; COMPLETENESS AB Objective: Incomplete myocardial revascularization decreases survival for patients undergoing coronary artery bypass grafting. The effects of constructing multiple grafts to each major diseased artery territory are unknown. We aimed to determine the impact on long-term survival after coronary artery bypass grafting of placing multiple grafts to each myocardial territory. Methods: We reviewed data from 1129 consecutive patients who underwent coronary artery bypass grafting at our institution between 1997 and 2007 and compared outcomes between patients who received multiple grafts to each major diseased artery territory (n = 549) with those of patients who received single grafts to each territory (n = 580). We assessed long-term survival with Kaplan-Meier curves generated by log-rank tests, adjusting for confounding factors with Cox proportional hazards regression analysis. Results: Patients who received multiple grafts to each major diseased artery territory had longer cardiopulmonary bypass and aortic crossclamp times than patients who received single grafts per territory. Patient groups had similar early outcomes, including 30-day mortalities (1.3% vs 1.4%, P>.999) and incidences of major adverse cardiac events (2.9% vs 2.2%, P = .57). Cox regression 10-year survival curves were also similar between groups (adjusted hazard ratio 0.94, 95% confidence interval 0.67-1.34, P = .74). Conclusion: Patients who received multiple grafts to each major diseased artery territory had early outcomes similar to those who received single grafts per territory. Constructing multiple grafts to each major diseased artery territory increases operative time and does not improve long-term survival. C1 [Chu, Danny] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, Houston, TX 77030 USA. [Wang, Xing Li; Coselli, Joseph S.; LeMaire, Scott A.] St Lukes Episcopal Hosp, Texas Heart Inst, Sect Adult Cardiac Surg, Houston, TX USA. RP Chu, D (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM dchumd@gmail.com NR 12 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JAN PY 2009 VL 137 IS 1 BP 60 EP 64 DI 10.1016/j.jtcvs.2008.09.018 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 396SJ UT WOS:000262611100011 PM 19154904 ER PT J AU Lanuti, M Sharma, A Digumarthy, SR Wright, CD Donahue, DM Wain, JC Mathisen, DJ Shepard, JAO AF Lanuti, Michael Sharma, Amita Digumarthy, Subba R. Wright, Cameron D. Donahue, Dean M. Wain, John C. Mathisen, Douglas J. Shepard, Jo-Anne O. TI Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID RADIOTHERAPY; EXPERIENCE; TUMORS; RESECTION; CT; LOBECTOMY; CARCINOMA; OUTCOMES AB Objective: This study evaluated long-term results of radiofrequency ablation for medically inoperable early-stage lung cancer. Methods: Thirty-one consecutive patients with biopsy-proven non-small cell lung cancer underwent 38 treatments of computed tomographically guided radiofrequency ablation in a 4.5-year period. All patients were carefully selected and deemed medically ineligible for resection by a multidisciplinary team. Radiofrequency ablation was performed with curative intent with a single or cluster cool-tip electrode. Patients were hospitalized for 23-hour observation. Results: Treatment was complete in all cases, with no 30-day mortality. Local recurrence was confirmed radiographically by computed tomography, positron emission tomography, or both after 31.5% of treatments (12/38). Two patients were successfully retreated for technical failures related to pneumothorax; 3 underwent radiotherapy with stable disease. Mean maximal diameter of 38 tumors treated was 2.0 +/- 1.0 cm ( range 0.8-4.4 cm). After median follow-up of 17 +/- 11 months, 74% of patients (23/31) were alive. Three patients died of metastatic disease; 5 died of pneumonia remote from treatment. The 2- and 4-year survivals were 78% and 47%, respectively. Median overall survival was 30 months. Pneumothorax (13%), pneumonia (16%), and pleural effusion (21%), were the most common complications. Conclusions: Radiofrequency ablation of medically inoperable early-stage lung cancer in carefully selected patients yields encouraging midterm results without significant loss of pulmonary function. Local tumor progression appears related to lung tumors larger than 3 cm. Computed tomography and positron emission tomography need further validation for the early identification of local tumor progression following radiofrequency ablation. C1 [Lanuti, Michael; Wright, Cameron D.; Donahue, Dean M.; Wain, John C.; Mathisen, Douglas J.] Harvard Univ, Div Thorac Surg, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sharma, Amita; Digumarthy, Subba R.; Shepard, Jo-Anne O.] Harvard Univ, Div Thorac Radiol, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Lanuti, M (reprint author), Harvard Univ, Div Thorac Surg, Sch Med, Massachusetts Gen Hosp, 55 Fruit St,Blake 1570, Boston, MA 02114 USA. EM Mlanuti@partners.org NR 23 TC 77 Z9 79 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JAN PY 2009 VL 137 IS 1 BP 160 EP 166 DI 10.1016/j.jtcvs.2008.08.034 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 396SJ UT WOS:000262611100026 PM 19154919 ER PT J AU Guy, TS Tseng, E Ratcliffe, MB Azakie, A Karl, TR AF Guy, T. Sloane Tseng, Elaine Ratcliffe, Mark B. Azakie, Anthony Karl, Tom R. TI A simple correction for anomalous coronary arteries in adults SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Editorial Material ID SINUS; ORIGIN; VALSALVA C1 [Guy, T. Sloane] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg, San Francisco, CA 94121 USA. RP Guy, TS (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg, 4150 Clement St, San Francisco, CA 94121 USA. EM sloane.guy@va.gov RI karl, tom/J-4010-2012 NR 5 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JAN PY 2009 VL 137 IS 1 BP E50 EP E51 DI 10.1016/j.jtcvs.2008.05.045 PG 2 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 396SJ UT WOS:000262611100075 PM 19154886 ER PT J AU Edell, E Lam, S Pass, H Miller, YE Sutedja, T Kennedy, T Loewen, G Keith, RL AF Edell, Eric Lam, Stephen Pass, Harvey Miller, York E. Sutedja, Thomas Kennedy, Timothy Loewen, Gregory Keith, Robet L. TI Detection and Localization of Intraepithelial Neoplasia and Invasive Carcinoma Using Fluorescence-Reflectance Bronchoscopy An International, Multicenter Clinical Trial SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Autofluorescence; Bronchoscopy; Early detection; Lung neoplasm; Screening; Intraepithelial neoplasm; Dysplasia ID EARLY LUNG-CANCER; WHITE-LIGHT BRONCHOSCOPY; AUTOFLUORESCENCE BRONCHOSCOPY; PRENEOPLASTIC LESIONS; SPUTUM CYTOLOGY; HIGH-RISK; DYSPLASIA; ENDOSCOPY; SMOKERS AB Objectives: The primary objective of this study was to evaluate the benefit of using a new fluorescence-reflectance imaging system, Onco-LIFE, for the detection and localization of intraepitheal neoplasia and early invasive squamous cell carcinoma. A secondary objective was to evaluate the potential use of quantitative image analysis with this device for objective classification of abnormal sites. Design: This study was a prospective, multicenter, comparative, single arm trial. Subjects for this study were aged 45 to 75 years and either current or past smokers of more than 20 pack-years with airflow obstruction, forced expiratory volume in 1 second/forced vital capacity less than 75%, suspected to have lung cancer based oil either sputum atypia, abnormal chest roentgenogram/chest computed tomography, or patients with previous curatively treated lung or head and neck cancer within 2 years. Materials and Methods: The primary endpoint of the study was to determine the relative sensitivity of white light bronchoscopy (WLB) plus autofluorescence-reflectance bronchoscopy compared with WLB alone. Bronchoscopy with Onco-LIFE was carried out in two stages. The first stage was performed under white light and mucosal lesions were visually classified. Mucosal lesions were classified using the same scheme in the second stage when viewed with Onco-LIFE in the fluorescence-reflectance mode. All regions classified as suspicious for moderate dysplasia or worse were biopsied, plus at least one nonsuspicious region for control. Specimens were evaluated by the site pathologist and then sent to a reference pathologist, each blinded to the endoscopic findings. Positive lesions were defined as those with moderate/severe dysplasia, carcinoma in situ (CIS), or invasive carcinoma. A positive patient was defined as having at least one lesion of moderate/severe dysplasia, CIS, or invasive carcinoma. Onco-LIFE was also used to quantify the fluorescence-reflectance response (based on the proportion of reflected red light to green fluorescence) for each suspected lesion before biopsy. Results: There were 115 men and 55 women with median age of 62 years. Seven hundred seventy-six biopsy specimens were included. Seventy-six were classified as positive (moderate dysplasia or worse) by pathology. The relative sensitivity oil a per-lesion basis of WLB + FLB versus WLB was 1.50 (95% confidence interval [CI], 1.26-1.89). The relative sensitivity oil a per-patient basis was 1.33 (95% CI, 1.13-1.70). The relative sensitivity to detect intraepithelial neoplasia (moderate/severe dysplasia or CIS) was 4.29 (95% CI, 2.00-16.00) and 3.50 (95% CI, 1.63-12.00) on a per-lesion and per-patient basis, respectively. For a quantified fluorescence reflectance response value of more than or equal to 0.40, a sensitivity and specificity of 51% and 80%, respectively, could be achieved for detection of moderate/severe dsyplasia, CIS, and microinvasive cancer. Conclusions: Using autofluorescence-reflectance bronchoscopy as an adjunct to WLB with the Onco-LIFE system improves the detection and localization or intraepitheal neoplasia and invasive carcinoma compared with WLB alone. The use of quantitative image analysis to minimize interobserver variation in grading of abnormal sites should be explored further in future prospective clinical trial. C1 [Edell, Eric] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN 55905 USA. [Lam, Stephen] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada. [Pass, Harvey] Harper Clin Ctr, Karmanos Canc Inst, Detroit, MI USA. [Miller, York E.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Sutedja, Thomas] Vrije Univ Amsterdam, Med Ctr, Dept Pulm Med, Amsterdam, Netherlands. [Kennedy, Timothy] St Lukes Hosp, HealthONE Presbyterian, Denver, CO USA. [Loewen, Gregory] Providence Canc Ctr, Spokane, WA USA. [Keith, Robet L.] Univ Colorado, Ctr Canc, Denver Vet Affairs Med Ctr, Denver, CO 80262 USA. RP Edell, E (reprint author), Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN 55905 USA. EM edell.eric@mayo.edu FU NCI NIH HHS [P50 CA070907, P50 CA070907-05S89001, U01 CA084971, U01 CA084971-08] NR 40 TC 62 Z9 64 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD JAN PY 2009 VL 4 IS 1 BP 49 EP 54 PG 6 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 390XH UT WOS:000262196500008 PM 19096306 ER PT J AU Thomas, D Giugliano, RP AF Thomas, Deepak Giugliano, Robert P. TI ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Article DE Anticoagulants; Enoxaparin; Unfractionated heparin; Myocardial infarction; ExTRACT-TIMI 25 ID ELEVATION MYOCARDIAL-INFARCTION; MOLECULAR-WEIGHT HEPARIN; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; UNFRACTIONATED HEPARIN; ANTITHROMBIN THERAPY; EXTRACT-TIMI-25 TRIAL; RANDOMIZED-TRIAL; SERUM CREATININE; RISK INDEX AB Unfractionated heparin (UFH) for 48 h has been the traditional standard anticoagulant with fibrinolytics. The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction (ExTRACT)-Thrombolysis in Myocardial Infarction (TIMI) 25 trial prospectively studied the usefulness of enoxaparin and found that in patients treated with fibrinolysis, enoxaparin administered throughout the index hospitalization was superior to the standard 48-h UFH infusion. However, enoxaparin increased major bleeding. The data from this large trial were further analyzed across various subgroups and these results support the use of enoxaparin in a broad range of patients. The ExTRACT-TIMI 25 trial employed a novel dosing regimen for enoxaparin adjusted for age and renal function, which was designed to minimize bleeding risk while maintaining the beneficial effects of enoxaparin. Based on the evidence from this trial, the 2007 ST-segment elevation myocardial infarction guidelines now preferentially recommend enoxaparin to be administered throughout the index hospitalization as per the dosing regimen used in ExTRACT-TIMI 25 in most patients treated with fibrinolytic therapy. C1 [Giugliano, Robert P.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, Boston, MA 02115 USA. [Thomas, Deepak] Brigham & Womens Hosp, Dept Nucl Cardiol, Boston, MA 02115 USA. RP Giugliano, RP (reprint author), Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. EM DTHOMAS13@PARTNERS.ORG; rgiugliano@partners.org FU Sanofi-Aventis FX However, the authors were fully responsible for contents and editorial decisions for this manuscript. Dr. Giugliano had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr Giugliano has received honoraria for CME related activity from Sanofi-Aventis and Bristol Myers Squibb and served on the ECG Core Laboratory for the ExTRACT-TIMI 25 Trial, which was supported by a research grant from ]Sanofi-Aventis. Dr Thomas has no conflicts of interest to disclose. NR 36 TC 2 Z9 2 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD JAN PY 2009 VL 27 IS 1 BP 1 EP 10 DI 10.1007/s11239-008-0284-0 PG 10 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 408EZ UT WOS:000263419600001 PM 18931978 ER PT J AU Gibson, CM Pride, YB Aylward, PE Col, JJ Goodman, SG Gulba, D Bergovec, M Kunadian, V Zorkun, C Buros, JL Murphy, SA Antman, EM AF Gibson, C. Michael Pride, Yuri B. Aylward, Philip E. Col, Jacques J. Goodman, Shaun G. Gulba, Dietrich Bergovec, Mijo Kunadian, Vijayalakshmi Zorkun, Cafer Buros, Jacqueline L. Murphy, Sabina A. Antman, Elliott M. TI Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Article DE ST-segment elevation myocardial infarction; Fibrinolytic therapy; Nonsteroidal antiinflammatory drugs ID PLATELET CYCLOOXYGENASE; UNFRACTIONATED HEPARIN; RHEUMATOID-ARTHRITIS; PRIMARY PREVENTION; RANDOMIZED-TRIALS; ASPIRIN; RISK; INHIBITION; IBUPROFEN; DISEASE AB Background Non-steroidal anti-inflammatory drugs (NSAIDs) may be prothrombotic, may worsen hypertension or congestive heart failure and obstruct access to the binding site of aspirin to cyclooxygenase-1 and thereby interfere with aspirin's mechanism of action in reducing death and recurrent myocardial infarction (MI). We hypothesized that treatment with NSAIDs prior to an index MI would be associated with an increase in the risk of death, heart failure and recurrent MI among patients with ST-segment elevation MI (STEMI) treated with fibrinolytic therapy. Methods In ExTRACT-TIMI 25, patients with STEMI were treated with aspirin and fibrinolytic therapy and randomized to either enoxaparin or unfractionated heparin. We included patients who had received NSAIDs within 7 days of enrollment and evaluated the incidence of MI, the composite of death and MI and the composite of death, MI, severe heart failure and shock through 30 days. Results Of 20,479 patients enrolled, 572 (2.8%) received an NSAID within 7 days of enrollment. NSAID treatment prior to entry was associated with a higher incidence of 30-day death or nonfatal recurrent MI (15.9% vs. 10.8%, univariate P < 0.001). In multivariable models adjusting for randomization group and differences in baseline characteristics, NSAID use was associated with higher odds of MI (adjusted odds ratio [OR(adj)] 1.44, 95% confidence interval [CI] 1.01-2.07, P = 0.047), the composite of death and MI (OR(adj) 1.29, 95% CI 1.00-1.66, P = 0.051), and the composite of death, MI, severe heart failure and shock (OR(adj) 1.29, 95% CI 1.02-1.65, P = 0.037). Conclusions Among STEMI patients treated with a fibrinolytic agent and aspirin, use of NSAIDs in the week preceding the incident event was associated with a higher incidence of MI, the composite of death and MI as well as the composite of death, MI, severe heart failure and shock at 30 days. C1 [Gibson, C. Michael; Kunadian, Vijayalakshmi; Zorkun, Cafer; Buros, Jacqueline L.; Murphy, Sabina A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med,Med Sch,TIMI Study Grp, Boston, MA 02115 USA. [Aylward, Philip E.] Flinders Med Ctr, Adelaide, SA, Australia. [Col, Jacques J.] Clin Univ St Luc, Serv Cardiol, B-1200 Brussels, Belgium. [Goodman, Shaun G.] Univ Toronto, St Michaels Hosp, Div Cardiol, Terrence Donnelly Heart Ctr, Toronto, ON M5B 1W8, Canada. [Goodman, Shaun G.] Canadian Heart Res Ctr, Toronto, ON, Canada. [Gulba, Dietrich] Klinikum Rudolph Virchow, Stockheim, Germany. [Bergovec, Mijo] Univ Zagreb, Univ Hosp Dubrava, Dept Cardiol, Zagreb, Croatia. [Antman, Elliott M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,TIMI Study Grp,Cardiovasc Div, Boston, MA 02115 USA. RP Gibson, CM (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med,Med Sch,TIMI Study Grp, 350 Longwood Ave, Boston, MA 02115 USA. EM mgibson@perfuse.org OI Buros, Jacqueline/0000-0001-9588-4889 FU Sanofi-Aventis Pharma, Antony, France FX The ExTRACT-TIMI 25 study was supported in part by a grant from Sanofi-Aventis Pharma, Antony, France. NR 35 TC 11 Z9 14 U1 4 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD JAN PY 2009 VL 27 IS 1 BP 11 EP 17 DI 10.1007/s11239-008-0264-4 PG 7 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 408EZ UT WOS:000263419600002 PM 18695943 ER PT J AU Counter, SA Buchanan, LH Ortega, F AF Counter, S. Allen Buchanan, Leo H. Ortega, Fernando TI Neurocognitive Screening of Lead-Exposed Andean Adolescents and Young Adults SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES LA English DT Article ID ZINC PROTOPORPHYRIN; DOWN-SYNDROME; BREAST-MILK; CHILDREN; BLOOD; PERFORMANCE; SYSTEM AB This study was designed to assess the utility of two psychometric tests with putative minimal cultural bias for use in field screening of lead (Pb)-exposed Ecuadorian Andean workers. Specifically, the study evaluated the effectiveness in Pb-exposed adolescents and young adults of a nonverbal reasoning test standardized for younger children, and compared the findings with performance on a test of auditory memory. The Raven Coloured Progressive Matrices (RCPM) was used as a test of nonverbal intelligence, and the Digit Span subtest of the Wechsler IV intelligence scale was used to assess auditory memory/attention. The participants were 35 chronically Pb-exposed Pb-glazing workers, aged 12-21 yr. Blood lead (PbB) levels for the study group ranged from 3 to 86 g/dl, with 65.7% of the group at and above 10 g/dl. Zinc protoporphyrin heme ratios (ZPP/heme) ranged from 38 to 380 mol/mol, with 57.1% of the participants showing abnormal ZPP/heme (69 mol/mol). ZPP/heme was significantly correlated with PbB levels, suggesting chronic Pb exposure. Performance on the RCPM was less than average on the U.S., British, and Puerto Rican norms, but average on the Peruvian norms. Significant inverse associations between PbB/ZPP concentrations and RCPM standard scores using the U.S., Puerto Rican, and Peruvian norms were observed, indicating decreasing RCPM test performance with increasing PbB and ZPP levels. RCPM scores were significantly correlated with performance on the Digit Span test for auditory memory. Mean Digit Span scale score was less than average, suggesting auditory memory/attention deficits. In conclusion, both the RCPM and Digit Span tests were found to be effective instruments for field screening of visual-spatial reasoning and auditory memory abilities, respectively, in Pb-exposed Andean adolescents and young adults. C1 [Counter, S. Allen] Harvard Univ, Sch Med, Biol Labs, Dept Neurol, Cambridge, MA 02138 USA. [Buchanan, Leo H.] Univ Massachusetts, Sch Med, Eunice Kennedy Shriver Ctr, Dept Pediat, Waltham, MA USA. [Ortega, Fernando] Univ San Francisco Quito, Integrated Commun Dev Dept, Coll Hlth Sci, Quito, Ecuador. [Buchanan, Leo H.] Harvard Univ, Dept Otolaryngol, Hlth Serv, Cambridge, MA 02138 USA. [Counter, S. Allen] Massachusetts Gen Hosp, Dept Neurophysiol, Boston, MA 02114 USA. RP Counter, SA (reprint author), Harvard Univ, Sch Med, Biol Labs, Dept Neurol, 16 Divin Ave, Cambridge, MA 02138 USA. EM allen_Counter@harvard.edu FU David Rockefeller Center for Latin American Studies at Harvard; University of Massachusetts Medical School/Shriver Center; Harvard Biological Laboratories FX This study was conducted under the auspices of Universidad San Francisco de Quito Medical School in Quito, Ecuador. The authors thank Dr. Enrique Noboa, Dean of the College of Health Sciences, Universidad San Francisco de Quito; Dr. Jose Izurieta, Director of Health, Cotopaxi Province; Dr. Galo Tapia, Director of Pujil Hospital; Dr. Cecilia Zambrano, Director of La Victoria Subcentro de Salud; Gladys Pacheco, nurse, Subcentro de Salud, La Victoria; and Universidad San Francisco de Quito Medical School for continued support of this project. The authors are also grateful to Dr. Nader Rifai, Patricia Nolan Hoover, Aruna Rabari, and Gary Bradwin of the Department of Laboratory Medicine, Children's Hospital Boston, for generous laboratory support. The authors thank Anthony B. Jacobs for his continued excellent technical support. Lauren Kessler, Gabriela Aguirre, Manuela Dousdebes, and Rosana Teran are thanked for exceptional technical assistance in the field. The authors are grateful to the David Rockefeller Center for Latin American Studies at Harvard and its director, Dr. Merilee Grindle, for support of this project. Dr. David Rosenthal and Benedict J. DiRusso, Jr., RPh, of the Harvard University Health Services are thanked for their support. The authors thank Dr. Harry Mackay of the University of Massachusetts Medical School/Shriver Center for review of the article and helpful suggestions. The authors thank the Harvard Biological Laboratories for support. NR 32 TC 20 Z9 20 U1 1 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1528-7394 J9 J TOXICOL ENV HEAL A JI J. Toxicol. Env. Health Part A PY 2009 VL 72 IS 10 BP 625 EP 632 AR PII 909798779 DI 10.1080/15287390902769410 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 435YZ UT WOS:000265380700001 PM 19308847 ER PT J AU Counter, SA Buchanan, LH Ortega, F AF Counter, S. Allen Buchanan, Leo H. Ortega, Fernando TI Neurophysiologic and Neurocognitive Case Profiles of Andean Patients with Chronic Environmental Lead Poisoning SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES LA English DT Article ID AUDITORY-EVOKED POTENTIALS; BLOOD LEAD; BRAIN-STEM; EXPOSED CHILDREN; NEUROBEHAVIORAL DEVELOPMENT; CHELATION-THERAPY; BREAST-MILK; INTOXICATION; IMPAIRMENT; WORKERS AB This report presents case profiles of three siblings in a family of lead (Pb) glazing workers living in a Pb-contaminated Andean village who presented with extreme plumbism (blood Pb levels: 47 to 128 mu g/d1) from childhood to adolescence. These cases are examples of persons who have chronic Pb poisoning as a result of prolonged occupational and environmental exposure in a Pb-glazing ceramic cottage industry in the study area. Using behavioral and physiological techniques for measuring the integrity of the peripheral and central auditory systems, including otoacoustic emissions, and replicated auditory brainstem electrophysiological potentials, the authors found normal auditory neurosensory function in each patient, thus ruling out hearing impairment as a basis for adverse neurocognitive outcomes. This finding is contrary to the prevailing view regarding the detrimental effects of Pb poisoning on the cochlear and auditory brainstem of children. Performance on tests of visual spatial intelligence and auditory memory/attention was below average in these patients, which may underlie their reported learning disabilities. In two of the cases, there was an improvement in cognitive performance following a lowering of PbB levels from chelation therapy and Pb prevention education, suggesting some level of reversibility of their neurocognitive deficits. Nevertheless, these case profiles suggest that if the patients persist in Pb-glazing activities, in spite of repeated chelation therapy and family counseling, they may continue to be re-intoxicated and remain at risk for learning disabilities and other neurological impairments. C1 [Counter, S. Allen] Harvard Univ, Sch Med, Biol Labs, Dept Neurol, Cambridge, MA 02138 USA. [Counter, S. Allen] Massachusetts Gen Hosp, Dept Neurophysiol, Boston, MA 02114 USA. [Buchanan, Leo H.] Univ Massachusetts, Sch Med, Shriver Ctr, Dept Pediat, Waltham, MA USA. [Buchanan, Leo H.] Harvard Univ, Hlth Serv, Dept Otolaryngol, Cambridge, MA 02138 USA. [Ortega, Fernando] Univ San Francisco Quito, Coll Hlth Sci, Integrated Community Dev Dept, Quito, Ecuador. RP Counter, SA (reprint author), Harvard Univ, Sch Med, Biol Labs, Dept Neurol, 16 Divin Ave, Cambridge, MA 02138 USA. EM allen_Counter@harvard.edu NR 53 TC 23 Z9 24 U1 1 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1528-7394 J9 J TOXICOL ENV HEAL A JI J. Toxicol. Env. Health Part A PY 2009 VL 72 IS 19 BP 1150 EP 1159 DI 10.1080/15287390903091772 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 514ZD UT WOS:000271434600005 PM 20077183 ER PT J AU Greenwell, AN Cosden, M AF Greenwell, Ashley N. Cosden, Merith TI The Relationship Between Fatalism, Dissociation, and Trauma Symptoms in Latinos SO JOURNAL OF TRAUMA & DISSOCIATION LA English DT Article DE Latino; PTSD; trauma; dissociation; fatalism ID POSTTRAUMATIC-STRESS-DISORDER; ATAQUES-DE-NERVIOS; PTSD; PREVALENCE; EXPERIENCES; ETHNICITY; VETERANS; DISASTER; EXPOSURE; CULTURE AB Numerous studies have documented an overrepresentation of post-traumatic stress disorder in the Latino population. However, the contributing factors to trauma symptomatology among Latinos are not fully understood. The present study examined 112 low-income, Latino outpatients in a mental health clinic to identify culturally relevant variables that predict trauma symptomatology. Fatalism, peritraumatic dissociation, acculturation, and demographic variables were analyzed. Peritraumatic dissociation was found to account for a significant percentage of the variance in trauma symptoms (21%) as measured by the Peritraumatic Dissociative Experiences Questionnaire-Modified and the Trauma Symptom Inventory. Fatalism measured by the Multiphasic Assessment of Cultural Constructs was not found to be significantly associated with symptom severity. Also, acculturation variables did not predict peritraumatic dissociation. Implications of the findings for trauma research and practice are discussed. C1 [Greenwell, Ashley N.; Cosden, Merith] Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA. RP Greenwell, AN (reprint author), VA Boston Healthcare Syst, Psychol Serv 116B, Jamaica Plain, MA 02130 USA. EM Ashley.greenwell@va.gov NR 32 TC 5 Z9 5 U1 0 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1529-9732 J9 J TRAUMA DISSOCIATIO JI J. Trauma Dissociation PY 2009 VL 10 IS 3 BP 334 EP 345 DI 10.1080/15299730902956820 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 542MO UT WOS:000273497900009 PM 19585340 ER PT J AU Mimiaga, MJ Reisner, SL Tinsley, JP Mayer, KH Safren, SA AF Mimiaga, Matthew J. Reisner, Sari L. Tinsley, Jake P. Mayer, Kenneth H. Safren, Steven A. TI Street Workers and Internet Escorts: Contextual and Psychosocial Factors Surrounding HIV Risk Behavior among Men Who Engage in Sex Work with Other Men SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE MSM; Sex work; HIV; STI; Intervention development ID BASE-LINE DATA; COMMERCIAL SEX; CAGE QUESTIONNAIRE; SAN-FRANCISCO; BISEXUAL MEN; DRUG-USE; PREVENTION; CHILDHOOD; ABUSE; GAY AB Sex work has been associated with elevated risk for HIV infection among men who have sex with men (MSM) in many settings. This mixed methods study examined sexual risk among MSM sex workers in Massachusetts, collecting formative data on HIV risk behavior by sex worker type in order to gain a better understanding of how to tailor prevention interventions to this unique and high-risk subgroup of MSM. Two groups of MSM sex workers were recruited between January and March 2008: street workers (n = 19) and internet escorts (n = 13). Participants completed a semistructured qualitative interview and quantitative psychosocial assessment battery; interviews were conducted until redundancy in responses was achieved. Almost one third (31%) were HIV-infected. The majority of participants (69%) reported at least one episode of unprotected serodiscordant anal sex (either insertive or receptive) with a mean of 10.7 (SD = 42.2) male sex partners of an unknown or different HIV serostatus in the past 12 months. Salient findings included: (a) internet sex workers reported being paid substantially more for sex than street sex workers; (b) inconsistent condom use, high rates of unprotected sex, and low rates of HIV status disclosure with sex work partners for both internet and street workers; general perceptions of a lack of trust on the part of sex work partners (i.e., telling them what they want to hear), offers of more money for unprotected sex; (c) contextual differences in risk taking: internet sex workers reported that they are more likely to engage in sexual risk-taking with noncommercial sex partners than sex partners who pay; (d) HIV status and STI history: two street workers became infected in the context of sex work, and 25% of the entire sample had never been tested for sexually transmitted infections (STI); and (e) motivations and reasons for doing sex work, such as the "lucrativeness" of sex work, as a means to obtain drugs, excitement, power, "why not?" attitude, and because social norms modeled this behavior. Study findings can be used to generate hypotheses for designing and providing tailored primary and secondary prevention interventions for this at-risk subgroup of MSM. C1 [Mimiaga, Matthew J.; Reisner, Sari L.; Tinsley, Jake P.; Mayer, Kenneth H.; Safren, Steven A.] Fenway Community Hlth, Fenway Inst, Boston, MA 02119 USA. [Mimiaga, Matthew J.; Safren, Steven A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Mayer, Kenneth H.] Miriam Hosp, Brown Med Sch, Providence, RI 02906 USA. RP Mimiaga, MJ (reprint author), Fenway Community Hlth, Fenway Inst, Prudential Tower,4th Floor,800 Boylston St, Boston, MA 02119 USA. EM mmimiaga@fenwayhealth.org NR 39 TC 33 Z9 33 U1 3 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD JAN PY 2009 VL 86 IS 1 BP 54 EP 66 DI 10.1007/s11524-008-9316-5 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 397PK UT WOS:000262674400007 PM 18780186 ER PT J AU Chen, AB D'Amico, AV Neville, BA Steyerberg, EW Earle, CC AF Chen, Aileen B. D'Amico, Anthony V. Neville, Bridget A. Steyerberg, Ewout W. Earle, Craig C. TI Provider Case Volume and Outcomes Following Prostate Brachytherapy SO JOURNAL OF UROLOGY LA English DT Article DE prostate; prostatic neoplasms; brachytherapy; SEER program; mortality ID RADICAL PROSTATECTOMY; HOSPITAL VOLUME; COMORBIDITY INDEX; CANCER-TREATMENT; POPULATION; MORBIDITY; PATIENT; TRENDS; CARE AB Purpose: We assessed the relationship between provider volume and outcomes following brachytherapy in a population based cohort of men. Materials and Methods: We analyzed the claims of Medicare enrolled men older than 65 years living in Surveillance, Epidemiology and End Results surveillance areas who were diagnosed with prostate cancer from 1991 to 1999 and underwent brachytherapy as initial treatment. Case volume was calculated for each physician and hospital from 1991 to 2001 from Medicare claims. Outcomes of interest were recurrence, prostate cancer death, all deaths and 2-year complications. Analyses were adjusted by patient and treatment characteristics. Results: We identified 5,595 men for whom a radiation oncologist and a hospital provider could be identified. Men who were older, nonwhite, lower income, unmarried, living in nonurban areas or had more comorbidities were more likely to see lower volume physicians. Physician volume was not associated with the complication rate after brachytherapy. However, men treated at higher volume hospitals had a slightly lower rate of combined complication diagnoses and procedures (OR 0.94/100 cases, p < 10.01). Patients treated by higher volume physicians had a lower recurrence rate (HR 0.89/100 cases, p = 0.01) and rate of prostate cancer death (HR 0.80/100 cases, p = 0.03) with a borderline significant decrease in all deaths (HR 0.95/100 cases, p = 0.05). There was no significant association between hospital volume and recurrence, prostate cancer death or all deaths. Conclusions: Men treated with brachytherapy by higher volume physicians were at lower risk for recurrence and prostate cancer death, and showed a borderline decrease in total deaths. We did not observe a clear relationship between provider volume and complications following treatment. C1 [Chen, Aileen B.; D'Amico, Anthony V.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Chen, Aileen B.; D'Amico, Anthony V.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Neville, Bridget A.; Earle, Craig C.] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA. [Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands. RP Chen, AB (reprint author), Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. OI Chen, Aileen/0000-0002-5385-3360; Steyerberg, Ewout/0000-0002-7787-0122 NR 18 TC 27 Z9 27 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2009 VL 181 IS 1 BP 113 EP 118 DI 10.1016/j.juro.2008.09.034 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 383WU UT WOS:000261705900049 PM 19012905 ER PT J AU Gervais, DA Goldberg, SN Brown, DB Soulen, MC Millward, SF Rajan, DK AF Gervais, Debra A. Goldberg, S. Nahum Brown, Daniel B. Soulen, Michael C. Millward, Steven F. Rajan, Dheeraj K. TI Society of Interventional Radiology Position Statement on Percutaneous Radiofrequency Ablation for the Treatment of Liver Tumors SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID SMALL HEPATOCELLULAR-CARCINOMA; ETHANOL INJECTION; RISK-FACTORS; HEPATIC METASTASES; BREAST-CANCER; INITIAL-EXPERIENCE; SURGICAL RESECTION; THERMAL ABLATION; SINGLE-CENTER; TRANSPLANTATION AB Focal tumor ablation-whether applied percutanously, laparoscopically, or by means of open surgery-is an effective therapy for selected liver tumors. The choice of liver ablation as well as the choice between percutaneous and surgical approaches is dependent on tumor factors, patient factors, and other viable treatment options. Currently, the largest cumulative reported experience is with radiofrequency (RF) ablation of hepatocellular carcinoma and colorectal metastases. This document is a position statement of the Interventional Oncology Task Force and the Standards Division of the Society of Interventional Radiology regarding the use of percutaneous RF ablation for the treatment of liver tumors. C1 [Gervais, Debra A.] Massachusetts Gen Hosp, Dept Radiol, Div Abdonimal Imaging & Intervent, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA. [Brown, Daniel B.] Thomas Jefferson Univ Hosp, Dept Radiol, Philadelphia, PA 19107 USA. [Soulen, Michael C.] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Millward, Steven F.] Univ Western Ontario, Dept Radiol, London, ON, Canada. [Millward, Steven F.] Peterborough Reg Hlth Ctr, Peterborough, ON, Canada. [Rajan, Dheeraj K.] Univ Toronto, Dept Med Imaging, Div Vasc & Intervent Radiol, Univ Hlth Network, Toronto, ON, Canada. RP Gervais, DA (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Abdonimal Imaging & Intervent, White 270,55 Fruit St, Boston, MA 02114 USA. EM dgervais@partners.org NR 60 TC 15 Z9 16 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD JAN PY 2009 VL 20 IS 1 BP 3 EP 8 DI 10.1016/j.jvir.2008.09.007 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 394DS UT WOS:000262426400002 PM 18948025 ER PT J AU Jones, JA Spinale, FG Ikonomidis, JS AF Jones, Jeffrey A. Spinale, Francis G. Ikonomidis, John S. TI Transforming Growth Factor-beta Signaling in Thoracic Aortic Aneurysm Development: A Paradox in Pathogenesis SO JOURNAL OF VASCULAR RESEARCH LA English DT Review DE TGF-beta; Aneurysm; Signal transduction; Extracellular matrix; Remodeling ID PRIMARY PULMONARY-HYPERTENSION; SMOOTH-MUSCLE-CELLS; BONE MORPHOGENETIC PROTEIN; CONNECTIVE-TISSUE DISORDER; COLLAGEN GENE-EXPRESSION; TUMOR-SUPPRESSOR SMAD4; HUMAN-SKIN FIBROBLASTS; EHLERS-DANLOS-SYNDROME; TGF-BETA; MARFAN-SYNDROME AB Thoracic aortic aneurysms (TAAs) are potentially devastating, and due to their asymptomatic behavior, pose a serious health risk characterized by the lack of medical treatment options and high rates of surgical morbidity and mortality. Independent of the inciting stimuli (biochemical/mechanical), TAA development proceeds by a multifactorial process influenced by both cellular and extracellular mechanisms, resulting in alterations of the structure and composition of the vascular extracellular matrix (ECM). While the role of enhanced ECM proteolysis in TAA formation remains undisputed, little attention has been focused on the upstream signaling events that drive the remodeling process. Recent evidence highlighting the dysregulation of transforming growth factor-beta (TGF-beta) signaling in ascending TAAs from Marfan syndrome patients has stimulated an interest in this intracellular signaling pathway. However, paradoxical discoveries have implicated both enhanced TGF-beta signaling and loss of function TGF-beta receptor mutations, in aneurysm formation; obfuscating a clear functional role for TGF-beta in aneurysm development. In an effort to elucidate this subject, TGF-beta signaling and its role in vascular remodeling and pathology will be reviewed, with the aim of identifying potential mechanisms of how TGF-beta signaling may contribute to the formation and progression of TAA. Copyright (C) 2008 S. Karger AG, Basel C1 [Jones, Jeffrey A.; Spinale, Francis G.; Ikonomidis, John S.] Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg Res, Charleston, SC 29425 USA. [Jones, Jeffrey A.; Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Jones, JA (reprint author), Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg Res, Strom Thurmond Res Bldg,114 Doughty St,Suite 625, Charleston, SC 29425 USA. EM jonesja@musc.edu FU NHLBI NIH HHS [R01 HL075488, R01 HL075488-04, R01 HL075488-05, R01 HL102121]; NIA NIH HHS [R01 AG036954] NR 185 TC 78 Z9 84 U1 3 U2 11 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2009 VL 46 IS 2 BP 119 EP 137 DI 10.1159/000151766 PG 19 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 412AZ UT WOS:000263696900005 PM 18765947 ER PT J AU Mimura, T Han, KY Onguchi, T Chang, JH Kim, TI Kojima, T Zhou, ZJ Azar, DT AF Mimura, Tatsuya Han, Kyu Yeon Onguchi, Tatsuya Chang, Jin-Hong Kim, Tae-im Kojima, Takashi Zhou, Zhongjun Azar, Dimitri T. TI MT1-MMP-Mediated Cleavage of Decorin in Corneal Angiogenesis SO JOURNAL OF VASCULAR RESEARCH LA English DT Article DE Corneal neovascularization; Angiogenesis; Metalloproteinase; MMP-14; Membrane type 1-matrix metalloproteinase; Decorin; Extracellular matrix ID I-MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; MOUSE CORNEA; MEMBRANE; GROWTH; ACTIVATION; INVASION; MT1-MMP; CELLS; SUPPRESSION AB Background/Aims: Decorin has been shown to have antiangiogenic properties. In this study, we evaluate the involvement of membrane type 1-matrix metalloproteinase (MT1-MMP), a proangiogenic enzyme, in decorin cleavage in the cornea. Methods: MT1-MMP expression was confirmed immunohistochemically in keratocytes and immortalized corneal fibroblast cell lines. Corneal micropockets of bFGF were used to assess the expression of decorin and MT1-MMP. Western blotting was used to evaluate decorin degradation by MT1-MMP. Aortic ring tube formation assays were used to assay the inhibitory effect of decorin and stimulatory effect of MT1-MMP on vascular endothelial cells in vitro. Results: We show that MT1-MMP expression is upregulated following bFGF pellet implantation in the cornea in vivo, and that MT1-MMP cleaves decorin in a time-and concentration-dependent manner in vitro. Furthermore, the addition of MT1-MMP reduces the inhibitory effects of decorin on aortic ring tube formation in vitro. Cleavage of decorin by MT1-MMP-deficient corneal cell lysates is diminished relative to that by wild-type corneal cell lysates, and an MT1-MMP knockin restores decorin processing in vitro. Conclusion: The proangiogenic role of MT1-MMP in the cornea may be mediated, in part, by facilitated cleavage of corneal decorin. Copyright (C) 2009 S. Karger AG, Basel C1 [Mimura, Tatsuya; Han, Kyu Yeon; Onguchi, Tatsuya; Chang, Jin-Hong; Kojima, Takashi; Azar, Dimitri T.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA. [Chang, Jin-Hong; Kim, Tae-im; Kojima, Takashi; Azar, Dimitri T.] Harvard Univ, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Sch Med,Dept Ophthalmol, Boston, MA USA. [Zhou, Zhongjun] Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China. RP Azar, DT (reprint author), Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 W Taylor St, Chicago, IL 60612 USA. EM dazar@uic.edu FU National Institutes of Health [EY10101, P30EY001792, EY14048] FX This study was funded by grants from the National Institutes of Health EY10101 (D. T. A.), P30EY001792 (D. T. A.), and EY14048 (J.- H. C.). NR 41 TC 27 Z9 27 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 J9 J VASC RES JI J. Vasc. Res. PY 2009 VL 46 IS 6 BP 541 EP 550 DI 10.1159/000226222 PG 10 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA 506MW UT WOS:000270780200003 PM 19571574 ER PT J AU Hein, J Boichuk, S Wu, JP Cheng, Y Freire, R Jat, PS Roberts, TM Gjoerup, OV AF Hein, Jennifer Boichuk, Sergei Wu, Jiaping Cheng, Yuan Freire, Raimundo Jat, Parmjit S. Roberts, Thomas M. Gjoerup, Ole V. TI Simian Virus 40 Large T Antigen Disrupts Genome Integrity and Activates a DNA Damage Response via Bub1 Binding SO JOURNAL OF VIROLOGY LA English DT Article ID SPINDLE-ASSEMBLY CHECKPOINT; ONCOGENE-INDUCED SENESCENCE; TELANGIECTASIA-MUTATED ATM; LARGE TUMOR-ANTIGEN; ATAXIA-TELANGIECTASIA; SIMIAN VIRUS-40; HUMAN-CELLS; CELLULAR-TRANSFORMATION; RADIOSENSITIZING AGENT; INDEPENDENT EXPRESSION AB Simian virus 40 (SV40) large T antigen (LT) is a multifunctional protein that is important for viral replication and oncogenic transformation. Previously, infection of monkey or human cells with SV40 was shown to lead to the induction of DNA damage response signaling, which is required for efficient viral replication. However, it was not clear if LT is sufficient to induce the damage response and, if so, what the genetic requirements and functional consequences might be. Here, we show that the expression of LT alone, without a replication origin, can induce key DNA damage response markers including the accumulation of gamma-H2AX and 53BP1 in nuclear foci. Other DNA damage-signaling components downstream of ATM/ATR kinases were induced, including chk1 and chk2. LT also bound the Claspin mediator protein, which normally facilitates the ATR activation of chk1 and monitors cellular replication origins. Stimulation of the damage response by LT depends mainly on binding to Bub1 rather than to the retinoblastoma protein. LT has long been known to stabilize p53 despite functionally inactivating it. We show that the activation of a DNA damage response by LT via Bub1 appears to play a major role in p53 stabilization by promoting the phosphorylation of p53 at Ser15. Accompanying the DNA damage response, LT induces tetraploidy, which is also dependent on Bub1 binding. Taken together, our data suggest that LT, via Bub1 binding, breaches genome integrity mechanisms, leading to DNA damage responses, p53 stabilization, and tetraploidy. C1 [Hein, Jennifer; Boichuk, Sergei; Gjoerup, Ole V.] Univ Pittsburgh, Hillman Canc Ctr, Mol Virol Program, Inst Canc, Pittsburgh, PA 15213 USA. [Freire, Raimundo] Hosp Univ Canarias, Unidad Invest, Tenerife 38320, Spain. [Jat, Parmjit S.] UCL, Dept Neurodegenerat Dis, Inst Neurol, London WC1N 3BG, England. [Wu, Jiaping; Cheng, Yuan; Roberts, Thomas M.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Wu, Jiaping; Cheng, Yuan; Roberts, Thomas M.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Gjoerup, OV (reprint author), Univ Pittsburgh, Hillman Canc Ctr, Mol Virol Program, Inst Canc, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA. EM ovg27@pitt.edu FU NIH [P01-CA50661, CA30002]; Wellcome Trust [072672, 078305] FX We gratefully acknowledge financial support from the NIH (P01-CA50661 and CA30002 to T. M. R.) and the Wellcome Trust (072672 and 078305 to P. S. J.). In compliance with Harvard Medical School guidelines on possible conflict of interest, we disclose that T. M. R. has consulting relationships with Novartis Pharmaceuticals. NR 71 TC 66 Z9 69 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN 1 PY 2009 VL 83 IS 1 BP 117 EP 127 DI 10.1128/JVI.01515-08 PG 11 WC Virology SC Virology GA 381TP UT WOS:000261559100012 PM 18922873 ER PT J AU Miura, T Brockman, MA Brumme, ZL Brumme, CJ Pereyra, F Trocha, A Block, BL Schneidewind, A Allen, TM Heckerman, D Walker, BD AF Miura, Toshiyuki Brockman, Mark A. Brumme, Zabrina L. Brumme, Chanson J. Pereyra, Florencia Trocha, Alicja Block, Brian L. Schneidewind, Arne Allen, Todd M. Heckerman, David Walker, Bruce D. TI HLA-Associated Alterations in Replication Capacity of Chimeric NL4-3 Viruses Carrying gag-protease from Elite Controllers of Human Immunodeficiency Virus Type 1 SO JOURNAL OF VIROLOGY LA English DT Article ID T-LYMPHOCYTE RESPONSES; CTL ESCAPE MUTATIONS; DISEASE PROGRESSION; ANTIRETROVIRAL THERAPY; HIV-1 INFECTION; VIRAL FITNESS; IN-VITRO; TRANSMISSION; EPITOPE; SUPPRESSORS AB Human immunodeficiency virus type 1 (HIV-1)-infected persons who maintain plasma viral loads of <50 copies RNA/ml without treatment have been termed elite controllers (EC). Factors contributing to durable control of HIV in EC are unknown, but an HLA-dependent mechanism is suggested by overrepresentation of "protective" class I alleles, such as B*27, B*51, and B*57. Here we investigated the relative replication capacity of viruses (VRC) obtained from EC (n = 54) compared to those from chronic progressors (CP; n = 41) by constructing chimeric viruses using patient-derived gag-protease sequences amplified from plasma HIV RNA and inserted into an NL4-3 backbone. The chimeric viruses generated from EC displayed lower VRC than did viruses from CP (P < 0.0001). HLA-B*57 was associated with lower VRC (P = 0.0002) than were other alleles in both EC and CP groups. Chimeric viruses from B*57(+) EC (n = 18) demonstrated lower VRC than did viruses from B*57(+) CP (n = 8, P = 0.0245). Differences in VRC between EC and CP were also observed for viruses obtained from individuals expressing no described "protective" alleles (P = 0.0065). Intriguingly, two common HLA alleles, A*02 and B*07, were associated with higher VRC (P = 0.0140 and 0.0097, respectively), and there was no difference in VRC between EC and CP sharing these common HLA alleles. These findings indicate that cytotoxic T-lymphocyte (CTL) selection pressure on gag-protease alters VRC, and HIV-specific CTLs inducing escape mutations with fitness costs in this region may be important for strict viremia control in EC of HIV. C1 [Miura, Toshiyuki; Brockman, Mark A.; Brumme, Zabrina L.; Brumme, Chanson J.; Pereyra, Florencia; Trocha, Alicja; Block, Brian L.; Schneidewind, Arne; Allen, Todd M.; Walker, Bruce D.] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA. [Miura, Toshiyuki; Brockman, Mark A.; Brumme, Zabrina L.; Pereyra, Florencia; Schneidewind, Arne; Allen, Todd M.; Walker, Bruce D.] Harvard Univ, Ctr AIDS Res, Boston, MA 02115 USA. [Miura, Toshiyuki; Trocha, Alicja; Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. [Heckerman, David] Microsoft Res, Redmond, WA 98052 USA. RP Walker, BD (reprint author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, 149 13th St,Room 5212, Charlestown, MA 02129 USA. EM bwalker@partners.org RI Allen, Todd/F-5473-2011; OI Brumme, Chanson/0000-0003-2722-5288; Brockman, Mark/0000-0001-6432-1426 FU NIAID/NIH [AI028568, AI030914]; Howard Hughes Medical Institute; Harvard University Center for AIDS Research (CFAR) FX This work was supported by grants AI028568 and AI030914 from the NIAID/NIH, the Howard Hughes Medical Institute, the Harvard University Center for AIDS Research (CFAR), and a gift from the Mark and Lisa Schwartz Foundation. NR 45 TC 84 Z9 85 U1 1 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN 1 PY 2009 VL 83 IS 1 BP 140 EP 149 DI 10.1128/JVI.01471-08 PG 10 WC Virology SC Virology GA 381TP UT WOS:000261559100014 PM 18971283 ER PT J AU Borrero, S Schwarz, EB Creinin, M Ibrahim, S AF Borrero, Sonya Schwarz, Eleanor B. Creinin, Mitchell Ibrahim, Said TI The Impact of Race and Ethnicity on Receipt of Family Planning Services in the United States SO JOURNAL OF WOMENS HEALTH LA English DT Article ID QUALITY-OF-CARE; RACIAL-DIFFERENCES; MEDICARE BENEFICIARIES; DISPARITIES; ACCESS; HEALTH; STERILIZATION; APPROPRIATE; POPULATION; MORTALITY AB Objective: This study sought to examine the independent effect of patient race or ethnicity on the use of family planning services and on the likelihood of receiving counseling for sterilization and other birth control methods. Methods: This study used national, cross-sectional data collected by the 2002 National Survey of Family Growth (NSFG). Our analysis included women aged 18-44 years who had heterosexual intercourse within the past 12 months, who were not actively seeking to get pregnant, and who had not undergone surgical sterilization. The primary outcome was receipt of family planning services within the past 12 months. Specific services we examined were (1) provision of or prescription for a method of birth control, (2) checkup related to using birth control, (3) counseling about sterilization, and (4) counseling about birth control. Results: Although we found no racial/ethnic differences in the overall use of family planning services, there were racial/ethnic differences in the specific type of service received. Hispanic and black women were more likely than white women to receive counseling for birth control (adjusted OR 1.5, 95% confidence interval [ CI] 1.2, 1.8, and adjusted OR 1.3, 95% CI 1.1, 1.7, respectively). Hispanic women were more likely than white women to report having been counseled about sterilization (adjusted OR 1.5, 95% CI 1.0, 2.3). Conclusions: Minority women were more likely to receive counseling about sterilization and other birth control methods. However, there were no differences in access to family planning services by race or ethnicity. Future studies are needed to examine the quality and content of contraceptive counseling received by minority compared with nonminority women. C1 [Borrero, Sonya; Schwarz, Eleanor B.; Ibrahim, Said] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Borrero, Sonya; Ibrahim, Said] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Schwarz, Eleanor B.; Creinin, Mitchell] Univ Pittsburgh, Sch Med, Dept Obstet Gynaecol & Reprod Sci, Pittsburgh, PA USA. [Schwarz, Eleanor B.; Creinin, Mitchell] Magee Womens Res Inst, Pittsburgh, PA USA. [Creinin, Mitchell] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. RP Borrero, S (reprint author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu RI Potter, Joseph/A-3122-2008; OI Schwarz, Eleanor Bimla/0000-0002-9912-8236 FU National Center for Research Resources (NCRR) [1 KL2 RR02415402]; National Institutes of Health (NIH) FX This publication was made possible by a grant to S. B. (1 KL2 RR02415402) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The sponsors had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official view of NCRR or NIH. NR 31 TC 25 Z9 25 U1 2 U2 14 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD JAN PY 2009 VL 18 IS 1 BP 91 EP 96 DI 10.1089/jwh.2008.0976 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 395AX UT WOS:000262495500013 PM 19072728 ER PT J AU Lohr, PA Schwarz, EB Gladstein, JE Nelson, AL AF Lohr, Patricia A. Schwarz, Eleanor Bimla Gladstein, Jay E. Nelson, Anita L. TI Provision of Contraceptive Counseling by Internal Medicine Residents SO JOURNAL OF WOMENS HEALTH LA English DT Article ID EMERGENCY CONTRACEPTION; AMBULATORY GYNECOLOGY; WOMENS HEALTH; CARE; ATTITUDES; PROVIDERS AB Background: Internists care for women of reproductive age, but little is known about internists' training in contraceptive counseling or provision of contraceptive methods. Methods: We surveyed 152 residents in nine internal medicine programs in Los Angeles County during the 2004-2005 academic year. The self-administered, 29-item survey included demographic, contraceptive practice pattern, and training variables. Descriptive statistics and multivariable logistic regression were used to illustrate counseling and prescribing practices and to identify predictors of counseling and provision of contraceptives. Results: Most (95%) future internists surveyed reported clinical responsibility for women of reproductive age. However, few (17%) routinely provided contraceptive counseling, and 39% rarely or never provided contraceptive counseling. Residents had prescribed contraception on a median of 2 (range 0-30) occasions in the past year. Some formal education in contraceptive methods was reported by 51% of respondents; however, 75% of residents reported a desire for more training about contraception. Conclusions: Internal medicine residents commonly care for women of reproductive age but infrequently assess or address contraceptive needs. Further training on how to provide contraception is desired by many internal medicine residents. C1 [Lohr, Patricia A.] bpas, Stratford Upon Avon CV37 9BF, Warwick, England. [Schwarz, Eleanor Bimla] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. [Gladstein, Jay E.] VA Greater Angeles Healthcare Syst, Div Gen Med, Los Angeles, CA USA. [Nelson, Anita L.] Harbor UCLA Med Ctr, Dept Obstet & Gynecol, Los Angeles, CA USA. RP Lohr, PA (reprint author), bpas, 20 Timothys Bridge Rd,Stratford Enterprise Pk, Stratford Upon Avon CV37 9BF, Warwick, England. EM patricia.lohr@bpas.org OI Schwarz, Eleanor Bimla/0000-0002-9912-8236 NR 19 TC 12 Z9 12 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD JAN PY 2009 VL 18 IS 1 BP 127 EP 131 DI 10.1089/jwh.2008.0809 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 395AX UT WOS:000262495500018 PM 19072725 ER PT J AU Thameem, F He, X Voruganti, VS Nath, SD Fanti, P Blangero, J MacCluer, JW Comuzzie, AG Arar, NH Abboud, HE AF Thameem, Farook He, Xin Voruganti, V. Saroja Nath, Subrata D. Fanti, Paolo Blangero, John MacCluer, Jean W. Comuzzie, Anthony G. Arar, Nedal H. Abboud, Hanna E. TI Evaluation of Polymorphisms in Paraoxonase 2 (PON2) Gene and Their Association with Cardiovascular-Renal Disease Risk in Mexican Americans SO KIDNEY & BLOOD PRESSURE RESEARCH LA English DT Article DE PON2; Genetic polymorphisms; Association analyses; Systolic blood pressure; Mexican Americans ID LOW-DENSITY-LIPOPROTEIN; GLOMERULAR-FILTRATION-RATE; TRANSMISSION DISEQUILIBRIUM; OXIDATIVE MODIFICATION; DIABETIC NEPHROPATHY; RUIZ,J 2001; LINKAGE; SUSCEPTIBILITY; PINIZZOTTO,M; GAILLARD,RC AB Background/Aims: Genetic polymorphisms in the paraoxonase 2 (PON2) gene are thought to alter its activity and contribute to the development of cardiovascular and renal disease risk. The purpose of this study is to determine whether the Arg148Gly, Cys311Ser and rs12794795 polymorphisms of PON2 examined previously by others, are associated with type 2 diabetes (T2DM), and subclinical measures of cardiovascular and renal disease risk in Mexican Americans. Methods: Study participants (n = 848; 21 families) were genotyped for the three polymorphisms by TaqMan assay. Association between the genotypic and phenotypic data was performed by measured genotype approach as implemented in the variance component analytical tools. Results: The Arg148Gly variant was found to be monomorphic in our dataset. Of the phenotypes examined for association, the A/C variant located in intron-1 (rs12794795) exhibited statistically significant association only with diastolic blood pressure p = 0.018) after accounting for the trait-specific covariate effects. The Cys311Ser variant failed to show statistically significant association with any of the phenotypes examined. Conclusion: In conclusion, the variants examined at the PON2 locus in Mexican Americans do not appear to be a major contributor to T2DM, cardiovascular or renal disease risk, although they exhibited a small effect on the blood pressure values. Copyright (C) 2009 S. Karger AG, Basel C1 [Thameem, Farook; He, Xin; Nath, Subrata D.; Fanti, Paolo; Arar, Nedal H.; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Fanti, Paolo; Arar, Nedal H.; Abboud, Hanna E.] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Voruganti, V. Saroja; Blangero, John; MacCluer, Jean W.; Comuzzie, Anthony G.] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA. RP Thameem, F (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM thameem@uthscsa.edu FU American Heart Association; Satellite Healthcare; American Society of Nephrology; San Antonio Area Foundation; NIH [P01 HL45522]; National Center for Research Resources [UL1 RR025767, KL2 RR025766]; [R01 MH59490]; [M01RR01346] FX This study was supported by Grant-in-Aid from the American Heart Association, Norman S. Coplan Extramural Grant from the Satellite Healthcare, Carl W. Gottschalk Research Scholar Grant from the American Society of Nephrology, Semp Russ Foundation from the San Antonio Area Foundation (F.T.), and VA MERIT Review (H.E.A., N.H.A.). We thank the members of SAFHS for their participation and cooperation. SAFHS is supported by NIH grant P01 HL45522. The development of SOLAR was supported by R01 MH59490. We are also indebted to Frederic C. Bartter General Clinical Research Center grant M01RR01346 for clinical support. This work was also supported by the National Center for Research Resources contracts UL1 RR025767 and KL2 RR025766 for the Institute for Integration of Medicine and Science. NR 28 TC 6 Z9 8 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-4096 J9 KIDNEY BLOOD PRESS R JI Kidney Blood Pressure Res. PY 2009 VL 32 IS 3 BP 200 EP 204 DI 10.1159/000225943 PG 5 WC Physiology; Urology & Nephrology; Peripheral Vascular Disease SC Physiology; Urology & Nephrology; Cardiovascular System & Cardiology GA 475PR UT WOS:000268372600007 PM 19546579 ER PT J AU Anderson, S Komers, R AF Anderson, Sharon Komers, Radko TI Inhibition of the renin-angiotensin system: is more better ? SO KIDNEY INTERNATIONAL LA English DT Editorial Material ID CONVERTING-ENZYME-INHIBITION; TYPE-2 DIABETIC-PATIENTS; PANCREAS TRANSPLANTATION; NEPHROPATHY; MICROALBUMINURIA; ALBUMINURIA; LOSARTAN; TRIAL; RISK AB Inhibitors of the renin-angiotensin-aldosterone system (RAS) exert beneficial effects in diabetic nephropathy, but the possibility of regression of existing renal lesions remains to be investigated. Teles et al. tested the effects of the RAS inhibitor losartan in rats starting 10 months after induction of diabetes, when glomerular lesions were already present. They linked the reductions of proteinuria with regression of mesangial expansion. More advanced lesions were not affected. There were no dose-response renal effects of losartan. C1 [Anderson, Sharon; Komers, Radko] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. [Anderson, Sharon] Portland VA Med Ctr, Med Serv, Portland, OR USA. RP Anderson, S (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM anderssh@ohsu.edu FU NIDDK NIH HHS [DK63231] NR 14 TC 8 Z9 11 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2009 VL 75 IS 1 BP 12 EP 14 DI 10.1038/ki.2008.556 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 384YW UT WOS:000261781100004 PM 19092813 ER PT J AU Sugimoto, M Sakai, K Kita, M Imanishi, J Yamaoka, Y AF Sugimoto, Mitsushige Sakai, Kyoko Kita, Masakazu Imanishi, Jiro Yamaoka, Yoshio TI Prevalence of Helicobacter pylori infection in long-term hemodialysis patients SO KIDNEY INTERNATIONAL LA English DT Article DE Helicobacter pylori; hemodialysis; chronic renal failure; peptic ulcer ID CHRONIC-RENAL-FAILURE; AMBULATORY PERITONEAL-DIALYSIS; UPPER GASTROINTESTINAL-TRACT; UREMIC PATIENTS; GASTRODUODENAL LESIONS; TRANSPLANT RECIPIENTS; DIABETES-MELLITUS; DISEASE PATIENTS; ANTIBODIES; GASTRITIS AB Patients on hemodialysis often have gastrointestinal complications; however, it is unclear if Helicobacter pylori infection is present in these patients. Here we determined the prevalence of H. pylori infection in 539 Japanese hemodialysis patients by measuring serum anti-H. pylori IgG antibodies. Endoscopy was performed on 299 of these patients and the results were compared to 400 patients with normal renal function who had also undergone endoscopy and sero-testing. A second cohort of 478 dialysis patients, within the original group, was checked serologically for H. pylori infection three times over a four-year observation period. The prevalence of infection in these patients was significantly lower than in those patients with normal renal function, irrespective of the clinical outcomes. The prevalence of H. pylori infection significantly decreased as the duration of dialysis increased, particularly within the first four years following initiation of dialysis. About one-third of patients on dialysis for less than four years became serologically negative for H. pylori infection within this observation period. Our study suggests that although long-term dialysis patients have low prevalence of H. pylori, they still have significant gastroduodenal diseases, such as peptic ulcers, that require endoscopic follow-up. C1 [Sakai, Kyoko] Nara City Hosp, Dept Gastroenterol & Hepatol, Nara, Japan. [Kita, Masakazu; Imanishi, Jiro] Kyoto Prefectural Univ Med, Dept Microbiol, Kyoto 602, Japan. [Sugimoto, Mitsushige; Yamaoka, Yoshio] Baylor Coll Med, Gastroenterol Sect, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Baylor Coll Med, Gastroenterol Sect, Dept Med, Michael E DeBakey Vet Affairs Med Ctr 111D, Rm 3A-320,2002 Holcombe Blvd, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU National Institutes of Health (NIH) [R01 DK62813] FX The project described was supported by grant number R01 DK62813 from National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. We thank Dr Yoshiko Masugi, Dr Koji Okino, and all staffs in Tojinkai hospital, Kyoto, Japan for obtaining informed consent and for providing samples. We also thank Dr Takeshi Okanoue and Dr Shoji Mitsufuji (Kyoto Prefectural University of Medicine, Kyoto, Japan) for providing samples. We especially thank Dr Tadashi Kodama (Second Okamoto Hospital, Kyoto, Japan) for providing prudent NR 67 TC 36 Z9 40 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2009 VL 75 IS 1 BP 96 EP 103 DI 10.1038/ki.2008.508 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 384YW UT WOS:000261781100014 PM 18843261 ER PT J AU Liu, F Wei, CC Wu, SJ Chenier, I Zhang, SL Filep, JG Ingelfinger, JR Chan, JSD AF Liu, Fang Wei, Chih-Chang Wu, Shyh-Jong Chenier, Isabelle Zhang, Shao-Ling Filep, Janos G. Ingelfinger, Julie R. Chan, John S. D. TI Apocynin attenuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension SO KIDNEY INTERNATIONAL LA English DT Article DE angiotensinogen; reactive oxygen species; apoptosis and kidney ID GLOMERULOTUBULAR JUNCTION ABNORMALITIES; ANGIOTENSIN-II; ATUBULAR GLOMERULI; NAD(P)H OXIDASE; CELL APOPTOSIS; BLOOD-PRESSURE; DIABETIC-NEPHROPATHY; GENE-EXPRESSION; NADPH OXIDASE; RAT-KIDNEY AB Angiotensin II stimulates the formation of reactive oxygen species by increased NADPH oxidase activity, which contributes to proapoptotic and profibrotic mechanisms critical in renal injury. Here we determine if apocynin, an inhibitor of NADPH oxidase, interferes with the action of the intrarenal renin-angiotensin system to minimize the progression of renal disease. Transgenic mice that overexpress rat angiotensinogen in their proximal tubule cells were given either apocynin, perindopril, or hydralazine while untreated or apocynin-treated non-transgenic littermates served as controls. Untreated transgenic mice had significant elevations of their systolic blood pressure, albuminuria, reactive oxygen species production, NADPH oxidase activity, tubular apoptosis, active caspase-3, Bax, transforming growth factor-beta 1, plasminogen activator inhibitor-1, extracellular matrix proteins, collagen type IV, and phosphorylated p47phox expression compared to untreated non-transgenic mice. Apocynin and perindopril blunted these changes; however, apocynin had no effect on the systolic blood pressure whereas hydralazine prevented hypertension and tubulointerstitial fibrosis but not proximal tubule cell apoptosis. Our study shows that the intrarenal renin-angiotensin system stimulates proximal tubule cell apoptosis and tubulointerstitial fibrosis, in part, by enhanced NADPH oxidase activity and reactive oxygen species generation independent of systemic hypertension. C1 [Liu, Fang; Wei, Chih-Chang; Wu, Shyh-Jong; Chenier, Isabelle; Zhang, Shao-Ling; Chan, John S. D.] Univ Montreal, CHUM, Hotel Dieu, Dept Med,Res Ctr, Montreal, PQ H2W 1T8, Canada. [Filep, Janos G.] Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ H1T 2M4, Canada. [Ingelfinger, Julie R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Nephrol Unit, Boston, MA USA. RP Chan, JSD (reprint author), Univ Montreal, CHUM, Hotel Dieu, Dept Med,Res Ctr, Pavillon Masson,3850 St Urbain St, Montreal, PQ H2W 1T8, Canada. EM john.chan@umontreal.ca FU Kidney Foundation of Canada; Canadian Institutes of Health Research [MOP-84363, MT-12573]; National Institutes of Health of the USA [HL-48455]; Research Centre, CHUM FX This work was supported by grants from the Kidney Foundation of Canada, the Canadian Institutes of Health Research (CIHR, MOP-84363 to J. S. D. C. and MT-12573 to J. G. F.) and the National Institutes of Health of the USA (HL-48455 to J. R. I.). We thank Mr. Ovid M. Da Silva, Research Support Office, Research Centre, CHUM, for editing this article. NR 57 TC 44 Z9 44 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD JAN PY 2009 VL 75 IS 2 BP 156 EP 166 DI 10.1038/ki.2008.509 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 392HT UT WOS:000262294500007 PM 18923387 ER PT J AU Mckenna, BK Selim, AA Bringhurst, FR Ehrlich, DJ AF Mckenna, Brian K. Selim, A. A. Bringhurst, F. Richard Ehrlich, Daniel J. TI 384-Channel parallel microfluidic cytometer for rare-cell screening SO LAB ON A CHIP LA English DT Article ID CARBOXYL-TERMINAL REGION; HIGH-THROUGHPUT; FLOW-CYTOMETRY; SYSTEM; RECEPTORS; SORTER AB We have constructed a 384-channel parallel microfluidic cytometer (PMC). The multichannel architecture allows 384 unique samples for a cell-based screen to be read out in approximately 6-10 min, about 30-times the speed of a conventional fluorescence-activated cytometer system (FACS). This architecture also allows the signal integration time to be varied over a larger range than is practical in single-channel FACS and is suitable for detection of rare-cells in a high background of negatives. The signal-to-noise advantages have been confirmed by using the system to count rare clonal osteocytes in the most difficult early stages of an expression-cloning screen for the carboxy- terminal parathyroid hormone receptor (CPTHR). This problem requires finding several dozen positive cells in a background of one million negatives. The system is automated around a scanning laser confocal detector and a 96-tip robotic pipettor and can maintain in vitro cultures on-system in 384-well plates. It is therefore directly practical for biology applications using existing high-throughput culture facilities. The PMC system lends itself to high-sample-number cytometry with an unusual capability for time synchronization and rare-cell sensitivity. A limited ability to handle large sample numbers has restricted applications of single-channel FACS in combinatorial cell assays; therefore the PMC could have a significant application in high-throughput screening. C1 [Mckenna, Brian K.; Ehrlich, Daniel J.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Selim, A. A.; Bringhurst, F. Richard] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Selim, A. A.; Bringhurst, F. Richard] Harvard Univ, Sch Med, Boston, MA USA. [Ehrlich, Daniel J.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. [Ehrlich, Daniel J.] Boston Univ, Dept Elect & Comp Engn, Boston, MA 02215 USA. RP Ehrlich, DJ (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA. EM danehr@bu.edu FU National Institutes of Health [HG-01389, AR-47062, DK-02889, DK-65032] FX We thank James Evans and Paul Matsudaira for helpful discussions. This work was supported by National Institutes of Health grants, HG-01389 ( to DJE, AR-47062 ( to FRB) and DK-02889 and DK-65032. NR 14 TC 23 Z9 24 U1 1 U2 10 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2009 VL 9 IS 2 BP 305 EP 310 DI 10.1039/b811889b PG 6 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 397FY UT WOS:000262649500018 PM 19107289 ER PT J AU Edd, JF Humphry, KJ Irimia, D Weitz, DA Toner, M AF Edd, Jon F. Humphry, Katherine J. Irimia, Daniel Weitz, David A. Toner, Mehmet TI Nucleation and solidification in static arrays of monodisperse drops SO LAB ON A CHIP LA English DT Article ID INTRACELLULAR ICE FORMATION; HOMOGENEOUS NUCLEATION; MICROFLUIDIC DEVICE; SUPERCOOLED WATER; AQUEOUS-SOLUTIONS; PROTEIN CRYSTALS; CRYSTALLIZATION; RATES; VITRIFICATION; EMULSIONS AB The precise measurement of nucleation and non-equilibrium solidification are vital to fields as diverse as atmospheric science, food processing, cryopreservation and metallurgy. The emulsion technique, where the phase under study is partitioned into many droplets suspended within an immiscible continuous phase, is a powerful method for uncovering rates of nucleation and dynamics of phase changes as it isolates nucleation events to single droplets. However, averaging the behavior of many drops in a bulk emulsion leads to the loss of any drop-specific information, and drop polydispersity clouds the analysis. Here we adapt a microfluidic technique for trapping monodisperse drops in planar arrays to characterize solidification of highly supercooled aqueous solutions of glycerol. This system measured rates of nucleation between 10(-5) and 10(-2) pL(-1) s(-1), yielded an ice-water interfacial energy of 33.4 mJ m(-2) between -38 and -35 degrees C, and enabled the specific dynamics of solidification to be observed for over a hundred drops in parallel without any loss of specificity. In addition to the physical insights gained, the ability to observe the time and temperature of nucleation and subsequent growth of the solid phase in static arrays of uniform drops provides a powerful tool to discover thermodynamic protocols that generate desirable crystal structures. C1 [Edd, Jon F.; Irimia, Daniel; Toner, Mehmet] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Shriners Hosp Children, Ctr Engn Med,BioMEMS Resource Ctr, Boston, MA 02115 USA. [Humphry, Katherine J.; Weitz, David A.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA. [Weitz, David A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. RP Toner, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Shriners Hosp Children, Ctr Engn Med,BioMEMS Resource Ctr, Boston, MA 02115 USA. EM mehmet_toner@hms.harvard.edu OI Humphry, Katherine/0000-0002-9098-6402; Irimia, Daniel/0000-0001-7347-2082 FU NIBIB [P41 EB002503]; HFSP [RGP0004/2005-C102]; NSF [DMR-0602684, DBI-0649865]; Harvard MRSEC [DMR-0820484]; NIH [F32 EB007901] FX This work was supported by the NIBIB (P41 EB002503), the HFSP (RGP0004/2005-C102), the NSF (DMR-0602684 and DBI-0649865) and the Harvard MRSEC (DMR-0820484). JFE was supported by an NIH Postdoctoral Fellowship through the NIBIB (F32 EB007901). NR 41 TC 25 Z9 25 U1 3 U2 26 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2009 VL 9 IS 13 BP 1859 EP 1865 DI 10.1039/b821785h PG 7 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 459RP UT WOS:000267124400006 PM 19532960 ER PT J AU Irimia, D AF Irimia, Daniel TI Cutting edge: Electronic counting of white blood cells SO LAB ON A CHIP LA English DT Editorial Material C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. RP Irimia, D (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. OI Irimia, Daniel/0000-0001-7347-2082 FU NIAID NIH HHS [R21 AI076760]; NIBIB NIH HHS [P41 EB002503] NR 1 TC 0 Z9 0 U1 0 U2 2 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2009 VL 9 IS 20 BP 2875 EP 2876 DI 10.1039/b917138j PG 2 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 500GB UT WOS:000270285600001 PM 19789737 ER PT J AU Watkins, N Venkatesan, BM Toner, M Rodriguez, W Bashir, R AF Watkins, Nicholas Venkatesan, Bala Murali Toner, Mehmet Rodriguez, William Bashir, Rashid TI A robust electrical microcytometer with 3-dimensional hydrofocusing SO LAB ON A CHIP LA English DT Article ID HIV-INFECTED SUBJECTS; IMPEDANCE SPECTROSCOPY; DIELECTRIC-SPECTROSCOPY; FLOW CYTOMETER; CELL; CHIP; PARTICLES; MICROCHIP; COUNTER AB In this paper, we present a device to electrically count blood cell populations using an AC impedance interrogation technique in a microfabricated cytometer (microcytometer). Specifically, we direct our attention to obtaining the concentration of human CD4+ T lymphocytes (helper T cells), which is a necessary method to diagnose patients for HIV/AIDS and to give an accurate prognosis on the effectiveness of ARV (anti-retroviral) drug treatments. We study the effectiveness of a simple-to-fabricate 3-dimensional (3D) hydrodynamic focusing mechanism through fluidic simulations and corresponding experiments to increase the signal-to-noise ratio of impedance pulses caused by particle translocation and ensure lower variance in particle translocation height through the electrical sensing region. We found that the optimal 3D sheath flow settings result in a 44.4% increase in impedance pulse signal-to-noise ratio in addition to giving a more accurate representation of particle size distribution. Our microcytometer T cell counts closely with those found using an industry-standard flow cytometer for the concentration range of over three orders of magnitude and using a sample volume approximately the size of a drop of blood (similar to 20 mu L). In addition, our device displayed the capability to differentiate between live and dead/dying lymphocyte populations. This microcytometer can be the basis of a portable, rapid, inexpensive solution to obtaining live/dead blood cell counts even in the most resource-poor regions of the world. C1 [Watkins, Nicholas; Venkatesan, Bala Murali; Bashir, Rashid] Univ Illinois, Micro & Nanotechnol Lab, Dept Elect & Comp Engn, Urbana, IL 61801 USA. [Bashir, Rashid] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA. [Toner, Mehmet] Harvard Univ, Sch Med, Shiners Hosp Children, Surg Serv, Boston, MA 02114 USA. [Toner, Mehmet] Harvard Univ, Sch Med, Shiners Hosp Children, Bio MEMS Resource Ctr,Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rodriguez, William] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Partners AIDS Res Ctr,Brigham & Womens Hosp, Boston, MA 02115 USA. [Rodriguez, William] Harvard Univ, Sch Med, Div Aids, Brigham & Womens Hosp, Boston, MA 02115 USA. RP Bashir, R (reprint author), Univ Illinois, Micro & Nanotechnol Lab, Dept Elect & Comp Engn, Urbana, IL 61801 USA. EM rbashir@illinois.edu FU United States Department of Homeland Security; National Institute of Biomedical Imaging and Bioengineering (BioMEMS Resource Center) [P41 EB002503] FX The authors would like to thank Dr. Yi-Shao Liu and Bobby Reddy, Jr., for their helpful comments during device fabrication. Partial support was provided by the United States Department of Homeland Security graduate student fellowship and from the National Institute of Biomedical Imaging and Bioengineering (BioMEMS Resource Center, P41 EB002503). NR 34 TC 57 Z9 58 U1 3 U2 21 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 J9 LAB CHIP JI Lab Chip PY 2009 VL 9 IS 22 BP 3177 EP 3184 DI 10.1039/b912214a PG 8 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA 512JH UT WOS:000271243600001 PM 19865723 ER PT J AU Koplin, SA Nielsen, GP Rosenberg, AE AF Koplin, S. A. Nielsen, G. P. Rosenberg, A. E. TI Heterotopic Bone in Epithelioid Sarcomas: A Histopathological Review of 4 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Koplin, S. A.; Nielsen, G. P.; Rosenberg, A. E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 59 BP 16A EP 16A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300060 ER PT J AU Morgan, EA Kozono, DE Butrynski, JE Baldini, EH Raut, CP Nascimento, AF AF Morgan, E. A. Kozono, D. E. Butrynski, J. E. Baldini, E. H. Raut, C. P. Nascimento, A. F. TI Radiation-Associated Sarcoma of Soft Tissue and Bone: A Clinicopathologic Study of 70 Cases in a Single Institution SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 76 BP 19A EP 20A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300077 ER PT J AU Nielsen, GP Deshpande, V Rosenberg, AE Batten, JM Hornicek, F Iafrate, J AF Nielsen, G. P. Deshpande, V. Rosenberg, A. E. Batten, J. M. Hornicek, F. Iafrate, J. TI Recurrent Chromosomal Copy Number Alterations in Chordoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Nielsen, G. P.; Deshpande, V.; Rosenberg, A. E.; Batten, J. M.; Hornicek, F.; Iafrate, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 78 BP 20A EP 20A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300079 ER PT J AU Romeo, S Duim, RAJ Mertens, F De Jong, D Dal Cin, P Debiec-Rychter, M Sciot, R Rosenberg, A Szuhai, K Hogendoorn, PCW AF Romeo, S. Duim, R. A. J. Mertens, F. De Jong, D. Dal Cin, P. Debiec-Rychter, M. Sciot, R. Rosenberg, A. Szuhai, K. Hogendoorn, P. C. W. TI Balanced and Unbalanced Rearrangement of Chromosome Arm 6q in Chondromyxoid Fibroma (CMF): Delineation of Breakpoints and Analysis of Candidate Target Genes SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Leiden Univ, Med Ctr, Leiden, Netherlands. Univ Lund Hosp, S-22185 Lund, Sweden. Brigham & Womens Hosp, Boston, MA 02115 USA. Catholic Univ, Louvain, Belgium. Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Szuhai, Karoly/A-1100-2008 OI Szuhai, Karoly/0000-0002-1228-4245 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 84 BP 21A EP 21A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300085 ER PT J AU Belsley, NA Collins, LC Rice, MS Walker, S Tworoger, S Frank, DA AF Belsley, N. A. Collins, L. C. Rice, M. S. Walker, S. Tworoger, S. Frank, D. A. TI Expression of Phospho(p)STAT3 and Phospho(p)STAT5 in Breast Cancer and Correlation with Plasma Prolactin Levels SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 121 BP 30A EP 30A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300122 ER PT J AU Corben, AD Abi-Raad, R Boutrus, R Sgroi, DC Taghian, A Brachtel, EF AF Corben, A. D. Abi-Raad, R. Boutrus, R. Sgroi, D. C. Taghian, A. Brachtel, E. F. TI Pathologic Response and Microvascular Surface Area in Breast Cancer Treated with Neoadjuvant Chemotherapy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Corben, A. D.; Abi-Raad, R.; Boutrus, R.; Sgroi, D. C.; Taghian, A.; Brachtel, E. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 148 BP 35A EP 36A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300149 ER PT J AU Culhane, AC Nasir, A Chen, DT Venkataramu, C White, J Andersson, T Gruidl, M Bloom, G Rubio, R Centeno, BA Quackenbush, J Yeatman, TJ AF Culhane, A. C. Nasir, A. Chen, D. T. Venkataramu, C. White, J. Andersson, T. Gruidl, M. Bloom, G. Rubio, R. Centeno, B. A. Quackenbush, J. Yeatman, T. J. TI A 19-Gene Classifier Distinguishes Invasive Ductal and Classic Lobular Breast Carcinomas: Amplification of Chromosome 8q Characterizes Ductal While Estrogen-Related EGR-1 Characterizes Lobular Cancers SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 149 BP 36A EP 36A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300150 ER PT J AU Gill, RM Brachtel, EF Horvai, AE Chen, YY Rabban, JT AF Gill, R. M. Brachtel, E. F. Horvai, A. E. Chen, Y. Y. Rabban, J. T. TI Immunoexpression of Fli-1 by Metaplastic Breast Cancer: A Potential Pitfall in Cases Morphologically Resembling Epithelioid Angiosarcoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 UCSF, San Francisco, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 177 BP 42A EP 42A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300178 ER PT J AU Herberger, SD Kaul, D Adkins, CB Smith, BL Cheng, LL Lentz, MR Brachtel, EF AF Herberger, S. D. Kaul, D. Adkins, C. B. Smith, B. L. Cheng, L. L. Lentz, M. R. Brachtel, E. F. TI A Glimpse into Tumor Metabolism by Magnetic Resonance Spectroscopy: Choline Compounds and Choline Kinase Gene Expression in Human Breast Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Herberger, S. D.; Kaul, D.; Adkins, C. B.; Smith, B. L.; Cheng, L. L.; Lentz, M. R.; Brachtel, E. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 196 BP 46A EP 46A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300197 ER PT J AU Nasir, A Chen, DT Culhane, AC Gruidl, M McCarthy, SM Venkataramu, C Quackenbush, J Yeatman, TJ AF Nasir, A. Chen, D. T. Culhane, A. C. Gruidl, M. McCarthy, S. M. Venkataramu, C. Quackenbush, J. Yeatman, T. J. TI Immunohistochemical Validation of Topoisomerase 2 alpha and BubR1 as Novel Breast Cancer Risk Genes in Benign Breast Tissue SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 250 BP 58A EP 58A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300251 ER PT J AU Ryan, JL Morgan, DR Dominguez, RL Thorne, LB Elmore, SH Mino-Kenudson, M Lauwers, GY Booker, JK Gulley, ML AF Ryan, Julie L. Morgan, Douglas R. Dominguez, Ricardo L. Thorne, Leigh B. Elmore, Sandra H. Mino-Kenudson, Mari Lauwers, Gregory Y. Booker, Jessica K. Gulley, Margaret L. TI High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Article DE Epstein-Barr virus; gastric adenocarcinoma; latency; replication; viral load ID IN-SITU HYBRIDIZATION; NF-KAPPA-B; HELICOBACTER-PYLORI; MOLECULAR DIAGNOSIS; HODGKINS-DISEASE; LYTIC INFECTION; CARCINOMA; EBV; CANCER; TUMORS AB Gastric adenocarcinoma is the second leading cause of cancer death worldwide. Epstein-Barr virus (EBV) is present in the malignant cells of approximately 10% of cases. It is unclear whether EBV is being missed in some gastric adenocarcinomas due to insensitive test methods or partial EBV genome loss. In this study, we screened 113 gastric adenocarcinomas from low-and high-incidence regions ( United States and Central America) for the presence of EBV using a battery quantitative real-time PCR (Q-PCR) assays targeting disparate segments of the EBV genome (BamH1W, EBNA1, LMP1, LMP2, BZLF1, EBER1) and histochemical stains targeting EBV-encoded RNA ( EBER), the latent proteins LMP1 and LMP2, and the lytic proteins BMRF1 and BZLF1. EBV DNA was detected by Q-PCR in 48/75 United States cancers (64%) and in 38/38 Central American cancers (100%), which was a significant differrence. EBER was localized to malignant epithelial cells in 8/48 (17%) United States and 3/38 (8%) Central American cancers. Viral loads were considerably higher for EBER-positive vs EBER-negative cancers ( mean 162 986 vs 62 EBV DNA copies per 100 000 cells). A viral load of 2000 copies per 100 000 cells is recommended as the threshold distinguishing EBER-positive from EBER-negative tumors. One infected cancer selectively failed to amplify the LMP2 gene because of a point mutation, whereas another cancer had an atypical pattern of Q-PCR positivity suggesting deletion of large segments of the EBV genome. Three different viral latency profiles were observed in the cancers based on constant expression of EBER and focal or variable expression of LMP1 or LMP2, without lytic protein expression. We conclude that EBV DNA levels generally reflect EBER status, and a panel of at least two Q-PCR assays is recommended for sensitive identification of infected cancers. C1 [Thorne, Leigh B.; Elmore, Sandra H.; Booker, Jessica K.; Gulley, Margaret L.] Univ N Carolina, Dept Pathol, Chapel Hill, NC 27599 USA. [Thorne, Leigh B.; Elmore, Sandra H.; Booker, Jessica K.; Gulley, Margaret L.] Univ N Carolina, Lab Med, Chapel Hill, NC 27599 USA. [Ryan, Julie L.] Univ Rochester, Med Ctr, Dept Dermatol, Rochester, NY 14642 USA. [Ryan, Julie L.] Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA. [Morgan, Douglas R.] Univ N Carolina, Dept Gastroenterol, Chapel Hill, NC 27599 USA. [Morgan, Douglas R.; Thorne, Leigh B.; Gulley, Margaret L.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Dominguez, Ricardo L.] Western Reg Hosp, Dept Med, Santa Rosa De Copan, Honduras. [Mino-Kenudson, Mari; Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Mino-Kenudson, Mari; Lauwers, Gregory Y.] Harvard Univ, Sch Med, Boston, MA USA. RP Gulley, ML (reprint author), Univ N Carolina, Dept Pathol, 913 Brinkhous Bullitt Bldg, Chapel Hill, NC 27599 USA. EM margaret_gulley@med.unc.edu FU NIH [K12 RR1667]; UNC Center for Gastrointestinal Biology and Disease [P30 DK 034987] FX The study was also sponsored in part by the NIH Mentored Scholars Research Award (K12 RR1667) and the UNC Center for Gastrointestinal Biology and Disease (P30 DK 034987) supporting Douglas Morgan, MD MPH. NR 68 TC 28 Z9 32 U1 1 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 IS 1 BP 80 EP 90 DI 10.1038/labinvest.2008.103 PG 11 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 388UX UT WOS:000262046000009 PM 19002111 ER PT J AU Faquin, WC Baloch, ZW AF Faquin, W. C. Baloch, Z. W. TI Fine-Needle Aspiration of Follicular Patterned Lesions of the Thyroid: Diagnosis, Management and Follow-Up According to National Cancer Institute Recommendations SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Upenn Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 367 BP 84A EP 84A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300368 ER PT J AU Pitman, MB Desphpande, V AF Pitman, M. B. Desphpande, V. TI Tissue Microarray Immunohistochemical Analysis To Distinguish Contaminating Gastrointestinal Epithelium from Non-Malignant Branch Duct IPMN SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Pitman, M. B.; Desphpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 408 BP 93A EP 93A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300409 ER PT J AU Shen, J Pinkus, GS Deshpande, V Cibas, ES AF Shen, J. Pinkus, G. S. Deshpande, V. Cibas, E. S. TI Utility of EMA, XIAP, and GLUT-1 for the Diagnosis of Malignant Mesothelioma in Body Cavity Fluids SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 419 BP 95A EP 96A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300420 ER PT J AU Wilbur, DC Black-Schaffer, WS Luff, RD Molina, TM Abraham, KP Kemper, C Tench, WD AF Wilbur, D. C. Black-Schaffer, W. S. Luff, R. D. Molina, T. M. Abraham, K. P. Kemper, C. Tench, W. D. TI Clinical Trials of the FocalPoint GS System Show Significant Improvements in Sensitivity for the Detection of Squamous Intraepithelial Lesions When Compared to Manual Screening SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Quest Diagnost, Teterboro, NJ USA. Cyto Labs, San Antonio, TX USA. Quest Diagnost, Schaumburg, IL USA. Boyce & Bynum Pathol, Columbia, MO USA. Palomar Med Ctr, Escondido, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 426 BP 97A EP 97A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300427 ER PT J AU Mandal, RV Murali, R Lundquist, KF Ragsdale, BD Heenan, PJ McCarthy, SW Mihm, MJ Scolyer, RA Zembowicz, A AF Mandal, R. V. Murali, R. Lundquist, K. F. Ragsdale, B. D. Heenan, P. J. McCarthy, S. W. Mihm, M. J. Scolyer, R. A. Zembowicz, A. TI Long Term Follow-Up in Patients with Pigmented Epithelioid Melanocytoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia. Cent Coast Pathol, San Luis Obispo, CA USA. Cutaneous Pathol, Nedlands, WA, Australia. Lahey Clin Fdn, Burlington, MA USA. Dermatopathol Consultat Com, Belmont, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 470 BP 106A EP 107A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300471 ER PT J AU Nazarian, RM Kapur, P Piris, A Mihm, MC Hoang, MP AF Nazarian, R. M. Kapur, P. Piris, A. Mihm, M. C. Hoang, M. P. TI Expression of Ki-67 in Benign, Atypical, and Malignant Hidradenomas SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. UT SW Med Ctr, Dallas, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 476 BP 108A EP 108A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300477 ER PT J AU Valentino, CM Krouse, R Bradely-Dunlop, D Nagle, R Akporiaye, E Prasad, A AF Valentino, C. M. Krouse, R. Bradely-Dunlop, D. Nagle, R. Akporiaye, E. Prasad, A. TI Immunopathological Features of Cutaneous Squamous Cell Carcinomas in Immunocompromised Patients SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Arizona, Tucson, AZ USA. US Dept Vet Affairs, Tucson, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 495 BP 111A EP 112A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300496 ER PT J AU Sohani, AR Chande, H Vyas, V AF Sohani, A. R. Chande, H. Vyas, V. TI Diagnostic and Educational Support to Pathologists in the Developing World through Telepathology SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Aga Khan Hosp, Dar Es Salaam, Tanzania. Muhimbili Hosp, Dar Es Salaam, Tanzania. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 510 BP 115A EP 115A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300511 ER PT J AU Lovitch, SB Faquin, W Nose, V AF Lovitch, S. B. Faquin, W. Nose, V. TI Cribriform-Morular Variant of Thyroid Carcinoma: Distinct Immunohistochemical Profile from Other Papillary Thyroid Carcinoma Variants SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 523 BP 117A EP 118A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300524 ER PT J AU Nucera, C Porrello, A Antonello, Z Finn, S Priolo, C Giordano, T Jarzab, B Trimarchi, F Pontecorvi, A Nose, V Lawler, J Parangi, S AF Nucera, C. Porrello, A. Antonello, Z. Finn, S. Priolo, C. Giordano, T. Jarzab, B. Trimarchi, F. Pontecorvi, A. Nose, V. Lawler, J. Parangi, S. TI Thrombospondin-1 Is Modulated by the B-Raf(V600E) Pathway in Papillary Thyroid Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Harvard Univ, Sch Med, MGH, Boston, MA USA. Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. Duke Univ, Durham, NC 27706 USA. Harvard Univ, Sch Med, DFCI, Boston, MA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Gliwice Univ, Gliwice, Poland. Univ Messina, Messina, Italy. Catholic Univ, Rome, Italy. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 528 BP 118A EP 119A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300529 ER PT J AU Brown, IS Whiteman, DC Lauwers, GY AF Brown, I. S. Whiteman, D. C. Lauwers, G. Y. TI Gastric Foveolar Type Dysplasia Is Common Adjacent to Esophageal Invasive Adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Sullivan Nicolaides Pathol, Brisbane, Qld, Australia. Queensland Inst Med Res, Brisbane, Qld 4006, Australia. Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Brown, Ian/R-7763-2016 OI Brown, Ian/0000-0001-6329-2547 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 555 BP 124A EP 125A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300556 ER PT J AU Brown, IS Carr, NJ Srivastava, A Lauwers, GY AF Brown, I. S. Carr, N. J. Srivastava, A. Lauwers, G. Y. TI Collagenous Gastritis - A Clinicopathological Study of Nineteen (19) Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Sullivan Nicolaides Pathol, Brisbane, Qld, Australia. So IML Pathol, Wollongong, NSW, Australia. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Brown, Ian/R-7763-2016 OI Brown, Ian/0000-0001-6329-2547 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 556 BP 125A EP 125A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300557 ER PT J AU Firestein, R Shima, K Nosho, K Kure, S Irahara, N Bojarski, E Kirkner, GJ Hahn, WC Giovannucci, EL Fuchs, CS Ogino, S AF Firestein, R. Shima, K. Nosho, K. Kure, S. Irahara, N. Bojarski, E. Kirkner, G. J. Hahn, W. C. Giovannucci, E. L. Fuchs, C. S. Ogino, S. TI CDK8 Expression Is Associated with beta-Catenin Activation and Poor Outcome in Colon Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 578 BP 129A EP 129A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300579 ER PT J AU Huang, Q Fan, XS Agoston, AT Feng, AN Lauwers, G Odze, RD Zhang, LH AF Huang, Q. Fan, X. S. Agoston, A. T. Feng, A. N. Lauwers, G. Odze, R. D. Zhang, L. H. TI Gastroesophageal Junctional Carcinomas in Chinese Patients Show Distinct Clinicopathologic Features SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Boston VA Healthcare Syst, Boston, MA USA. Nanjing Drum Tower Hosp, Nanjing, Peoples R China. Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 598 BP 133A EP 134A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300599 ER PT J AU Kang, HJ Lee, JH Kim, GH Lauwers, GY Shin, DH Choi, KU Lee, CH Huh, GY Sol, MY Park, DY AF Kang, H. J. Lee, J. H. Kim, G. H. Lauwers, G. Y. Shin, D. H. Choi, K. U. Lee, C. H. Huh, G. Y. Sol, M. Y. Park, D. Y. TI The Variants of Gastric Epithelial Dysplasia Display Different Biologic Characteristics: An Immunohistochemical Study of p53, Ki-67, beta Catenin and Smad4 Expression SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Pusan Natl Univ Hosp, Pusan, South Korea. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 603 BP 135A EP 135A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300604 ER PT J AU Kang, HJ Kim, HY Kim, GH Shin, DH Song, GA Kim, DH Jeon, TY Kim, DH Cho, BM Lauwers, GY Park, DY AF Kang, H. J. Kim, H. Y. Kim, G. H. Shin, D. H. Song, G. A. Kim, D. H. Jeon, T. Y. Kim, D. H. Cho, B. M. Lauwers, G. Y. Park, D. Y. TI Mucin Phenotype and beta-Catenin Are Useful Markers To Predict Submucosal Invasion and Lymph Node Metastasis in Intestinal Type Early Gastric Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Pusan Natl Univ Hosp, Pusan, South Korea. Pusan Natl Univ, Sch Med, Pusan, South Korea. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 604 BP 135A EP 135A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300605 ER PT J AU Nosho, K Shima, K Kure, S Irahara, N Baba, Y Chen, L Kirkner, GJ Fuchs, CS Ogino, S AF Nosho, K. Shima, K. Kure, S. Irahara, N. Baba, Y. Chen, L. Kirkner, G. J. Fuchs, C. S. Ogino, S. TI JC Virus T-Antigen Is Associated with p53 Expression, Chromosomal Instability and LINE-1 Hypomethylation in Colorectal Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 638 BP 142A EP 142A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300639 ER PT J AU Ogawa, F Srivastava, A Lauwers, GY Mino-Kenudson, M AF Ogawa, F. Srivastava, A. Lauwers, G. Y. Mino-Kenudson, M. TI Development of Multilayerd Epithelium (ME) after Photodynamic Therapy (PDT): Does MLE Represent an Inevitable Progression to Barrett's Esophagus (BE)? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 639 BP 142A EP 142A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300640 ER PT J AU Ogawa, F Genevay, M Lisovsky, M Mino-Kenudson, M Deshpande, V Odze, RD Lauwers, GY AF Ogawa, F. Genevay, M. Lisovsky, M. Mino-Kenudson, M. Deshpande, V. Odze, R. D. Lauwers, G. Y. TI Natural History of Sporadic Gastric Dysplasia in the USA: Follow up Study of 54 Patients SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 640 BP 142A EP 142A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300641 ER PT J AU Ogino, S Nosho, K Kirkner, GJ Kawasaki, T Chan, AT Schernhammer, ES Giovannucci, EL Fuchs, CS AF Ogino, S. Nosho, K. Kirkner, G. J. Kawasaki, T. Chan, A. T. Schernhammer, E. S. Giovannucci, E. L. Fuchs, C. S. TI LINE-1 Hypomethylation Is an Independent Predictor of Poor Prognosis in Colon Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 641 BP 142A EP 143A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300642 ER PT J AU Ogino, S Nosho, K Kure, S Irahara, N Shima, K Baba, Y Giovannucci, EL Fuchs, CS AF Ogino, S. Nosho, K. Kure, S. Irahara, N. Shima, K. Baba, Y. Giovannucci, E. L. Fuchs, C. S. TI Cyclin D1 Expression Marks a Subset of Colon Cancer with Good Prognosis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 643 BP 143A EP 143A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300644 ER PT J AU Ogino, S Nosho, K Kirkner, GJ Shima, K Irahara, N Kure, S Chan, AT Engelman, JA Kraft, P Cantley, LC AF Ogino, S. Nosho, K. Kirkner, G. J. Shima, K. Irahara, N. Kure, S. Chan, A. T. Engelman, J. A. Kraft, P. Cantley, L. C. TI PIK3CA Mutation Predicts Poor Prognosis in Stage I-III Colorectal Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RI Cantley, Lewis/D-1800-2014 OI Cantley, Lewis/0000-0002-1298-7653 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 642 BP 143A EP 143A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300643 ER PT J AU Pettus, JR Butterly, L Lauwers, GY Srivastava, A AF Pettus, J. R. Butterly, L. Lauwers, G. Y. Srivastava, A. TI Sessile Serrated Adenoma: Do Clinicians Understand the Concept and Manage Patients Appropriately? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 653 BP 145A EP 145A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300654 ER PT J AU Soucy, G Schmidt, JF Greenberg, JA Cerda, S Dendrinos, K Farraye, F Farris, AB Lauwers, GY Wang, HH Odze, RD AF Soucy, G. Schmidt, J. F. Greenberg, J. A. Cerda, S. Dendrinos, K. Farraye, F. Farris, A. B. Lauwers, G. Y. Wang, H. H. Odze, R. D. TI Colonic Crohn's Disease: A Clinical/Pathologic and Outcome Study of 120 Patients SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Boston Univ, Med Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 669 BP 149A EP 149A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300670 ER PT J AU Fiorentino, M Mucci, L Fall, K Bailey, D Fiore, C Judson, G Andren, O Andersson, SO Loda, M AF Fiorentino, M. Mucci, L. Fall, K. Bailey, D. Fiore, C. Judson, G. Andren, O. Andersson, S. O. Loda, M. TI Immunohistochemical Expression of BRCA1 in Prostate Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Univ Orebro, Orebro, Sweden. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 760 BP 169A EP 169A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300761 ER PT J AU Genega, EM Ghebremichael, M Najarian, R Fu, Y Wang, Y Grisanzio, C Signoretti, S AF Genega, E. M. Ghebremichael, M. Najarian, R. Fu, Y. Wang, Y. Grisanzio, C. Signoretti, S. TI CAIX Expression in Renal Neoplasms: Correlation with Tumor Type and Grade SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Harvard Univ, Boston, MA 02115 USA. Dana Farber Canc Ctr, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 768 BP 170A EP 170A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300769 ER PT J AU Svensson, MA Perner, S Demichelis, F Helenius, G Kantoff, PW Andersson, SO Andren, O Rubin, MA AF Svensson, M. A. Perner, S. Demichelis, F. Helenius, G. Kantoff, P. W. Andersson, S. O. Andren, O. Rubin, M. A. TI Frequency of ERG Rearrangement in a Swedish Hospital Based Biopsy Cohort SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Weill Cornell Med Coll, New York, NY USA. Orebro Univ Hosp, Orebro, Sweden. Harvard Univ, Sch Med, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 885 BP 195A EP 195A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300886 ER PT J AU Umar, SA Fiorentino, M Magi-Galluzzi, C Bailey, D Fiore, C Montironi, R Loda, M AF Umar, S. A. Fiorentino, M. Magi-Galluzzi, C. Bailey, D. Fiore, C. Montironi, R. Loda, M. TI Different Immunohistochemical Expression of CD44v6 and ALDH1 in Prostate Cancer before and after Androgen Deprivation Therapy SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Univ Ancona, Ancona, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 902 BP 199A EP 199A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300903 ER PT J AU DeLair, D Soslow, R Gilks, B Macias, A Oliva, E AF DeLair, D. Soslow, R. Gilks, B. Macias, A. Oliva, E. TI The Morphologic Spectrum of Immunohistochemically Characterized Clear Cell Carcinoma of the Ovary: A Study of 83 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Vancouver Gen Hosp, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 961 BP 211A EP 211A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300962 ER PT J AU Gupta, M Gonzalez, JL Lefferts, JA Quer, A Tsongalis, GJ Oliva, E AF Gupta, M. Gonzalez, J. L. Lefferts, J. A. Quer, A. Tsongalis, G. J. Oliva, E. TI Primary Ovarian Mucinous Tumors (OMT) Lack Loss of MLH-1 and MGMT and Are Characterized by KRAS Mutations and Aberrant p53 Expression When They Progress to Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 984 BP 216A EP 216A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486300985 ER PT J AU Kojiro, S Growdon, WB Orezzoli, JP Borger, DR Rueda, BR Boisvert, SL Iafrate, AJ Oliva, E AF Kojiro, S. Growdon, W. B. Orezzoli, J. P. Borger, D. R. Rueda, B. R. Boisvert, S. L. Iafrate, A. J. Oliva, E. TI Expression of p16, p53 and EGFR in Squamous Cell Carcinoma (SCC) of the Vulva: A Study of 96 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Kojiro, S.; Growdon, W. B.; Orezzoli, J. P.; Borger, D. R.; Rueda, B. R.; Boisvert, S. L.; Iafrate, A. J.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1009 BP 221A EP 221A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301010 ER PT J AU Kojiro, S Quer, A Snuderl, M Daya, D Hayashi, T Bosincu, L Ogawa, F Vu, Q Rosenberg, AE Iafrate, AJ Oliva, E AF Kojiro, S. Quer, A. Snuderl, M. Daya, D. Hayashi, T. Bosincu, L. Ogawa, F. Vu, Q. Rosenberg, A. E. Iafrate, A. J. Oliva, E. TI Primitive Neuroectodermal Tumors (PNETs) of the Female Genital Tract (FGT): A Morphologic, Immunohistochemical, and Molecular Study of 18 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. McMaster Hosp, Hamilton, ON, Canada. Saitama Int Med Ctr, Saitama, Japan. Univ Sassari, I-07100 Sassari, Italy. Prefectural Miyazaki Hosp, Miyazaki, Japan. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1010 BP 222A EP 222A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301011 ER PT J AU Lamb, CA Young, RH AF Lamb, C. A. Young, R. H. TI Myxoid Leiomyomas of the Uterus: A Report of 14 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Lamb, C. A.; Young, R. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1017 BP 223A EP 223A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301018 ER PT J AU Lamb, CA Young, RH AF Lamb, C. A. Young, R. H. TI Apoplectic Change in Uterine Leiomyomas: An Analysis of 70 Cases Highlighting Previously Underemphasized Aspects SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Lamb, C. A.; Young, R. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1018 BP 223A EP 223A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301019 ER PT J AU Levanon, K Ng, V Chang, MC Vermeer, PD Zabner, JL Crum, CP Drapkin, RI AF Levanon, K. Ng, V. Chang, M. C. Vermeer, P. D. Zabner, J. L. Crum, C. P. Drapkin, R. I. TI The DNA Damage Response of Fallopian Tube Secretory Epithelial Cells Renders Them Susceptible to Carcinogenesis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Iowa, Iowa City, IA USA. RI Drapkin, Ronny/E-9944-2016 OI Drapkin, Ronny/0000-0002-6912-6977 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1021 BP 224A EP 224A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301022 ER PT J AU Levanon, K Folkins, AK Drapkin, RI AF Levanon, K. Folkins, A. K. Drapkin, R. I. TI Novel Model Systems To Study the Fallopian Tube Secretory Epithelium - The Cell-of-Origin of Serous Pelvic Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. RI Drapkin, Ronny/E-9944-2016 OI Drapkin, Ronny/0000-0002-6912-6977 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1022 BP 224A EP 224A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301023 ER PT J AU Lin, MC Burkholder, KA Viswanathan, AN Neuberg, D Mutter, GL AF Lin, M. C. Burkholder, K. A. Viswanathan, A. N. Neuberg, D. Mutter, G. L. TI Involution of Latent Endometrial Precancers by Hormonal and Non Hormonal Mechanisms SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1023 BP 224A EP 224A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301024 ER PT J AU McDonald, AG Cin, PD Ganguly, A Campbell, S Imai, Y Rosenberg, AE Oliva, E AF McDonald, A. G. Cin, P. D. Ganguly, A. Campbell, S. Imai, Y. Rosenberg, A. E. Oliva, E. TI Liposarcoma Arising in Uterine Lipoleiomyoma: A Report of Three Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Kobe City Gen Hosp, Kobe, Hyogo, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1039 BP 228A EP 228A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301040 ER PT J AU McDonald, AG Della Pelle, P De Nictolis, M Garcia-Fernandez, E Hardisson, D Prat, J Oliva, E AF McDonald, A. G. Della Pelle, P. De Nictolis, M. Garcia-Fernandez, E. Hardisson, D. Prat, J. Oliva, E. TI Expression of Platelet-Derived Growth Factor Receptor alpha (PDGFR alpha) and Vascular Endothelial Growth Factor (VEGF) in Intravenous Leiomyomatosis (IVL): An Immunohistochemical Study of 29 Cases SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Ist Anat & Istol Pathol, Ancona, Italy. Hosp Univ La Paz, Madrid, Spain. Hosp Santa Creu & Sant Pau, Barcelona, Spain. RI Hardisson, David/E-2832-2010 OI Hardisson, David/0000-0002-2183-3699 NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1038 BP 228A EP 228A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301039 ER PT J AU Pinto, AP Miron, A Yassin, Y Monte, N Woo, TYC Medeiros, F Crum, CP AF Pinto, A. P. Miron, A. Yassin, Y. Monte, N. Woo, T. Y. C. Medeiros, F. Crum, C. P. TI Differentiated Vulvar Intraepithelial Neoplasia Contains p53 Mutations and Is Genetically Linked to Vulvar Squamous Cell Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Mayo Clin Fdn, Rochester, NM USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1056 BP 232A EP 232A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301057 ER PT J AU Roh, MH Yassin, Y Miron, A Crum, CP Hirsch, MS AF Roh, M. H. Yassin, Y. Miron, A. Crum, C. P. Hirsch, M. S. TI High Grade Serous and Endometrioid Carcinomas: A Convergence of Two Pathways in Pelvic Cancer Differentiation? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1067 BP 234A EP 234A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301068 ER PT J AU Santacana, M Pallares, J Lopez, S Yeramian, A Dolcet, X Oliva, E Matias-Guiu, X AF Santacana, M. Pallares, J. Lopez, S. Yeramian, A. Dolcet, X. Oliva, E. Matias-Guiu, X. TI Immunohistochemical Features of Post-Radiation Recurrences of Endometrioid Carcinomas of the Endometrium SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Hosp U Arnau de Vilanova, Lleida, Spain. Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Pallares, Judit/A-6635-2010 NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1075 BP 236A EP 236A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301076 ER PT J AU Sioletic, S Orezzoli, JP Olawaiye, A Russell, AH Del Carmen, M Oliva, E AF Sioletic, S. Orezzoli, J. P. Olawaiye, A. Russell, A. H. Del Carmen, M. Oliva, E. TI Cervical Stromal Invasion in Endometrioid Endometrial Carcinoma (EEC) Does Not Correlate with Overall Survival SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Sioletic, S.; Orezzoli, J. P.; Olawaiye, A.; Russell, A. H.; Del Carmen, M.; Oliva, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1084 BP 237A EP 238A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301085 ER PT J AU Turbiner, J Ferry, JA Harris, NL Young, RH Zukerberg, LR AF Turbiner, J. Ferry, J. A. Harris, N. L. Young, R. H. Zukerberg, L. R. TI Lymphoma-Like Lesions of the Lower Female Genital Tract: Morphology, Immunophenotype and Molecular Features SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Turbiner, J.; Ferry, J. A.; Harris, N. L.; Young, R. H.; Zukerberg, L. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1090 BP 239A EP 239A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301091 ER PT J AU Turbiner, J Pilch, BZ Harris, NL Stone, JH Ganguly, A Ferry, JA Deshpande, V AF Turbiner, J. Pilch, B. Z. Harris, N. L. Stone, J. H. Ganguly, A. Ferry, J. A. Deshpande, V. TI Kuttner's Tumor Is a IgG4 Associated Disease SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Turbiner, J.; Pilch, B. Z.; Harris, N. L.; Stone, J. H.; Ganguly, A.; Ferry, J. A.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1148 BP 252A EP 252A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301149 ER PT J AU Kluk, M Toomey, C Hochberg, E Hasserjian, R AF Kluk, M. Toomey, C. Hochberg, E. Hasserjian, R. TI Myelodysplastic Syndromes Following Therapy with Purine Analogues - Therapy Related Myeloid Neoplasms? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Kluk, M.; Toomey, C.; Hochberg, E.; Hasserjian, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1234 BP 272A EP 272A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301234 ER PT J AU Kluk, MJ Hoyt, KM Bifulco, C AF Kluk, M. J. Hoyt, K. M. Bifulco, C. TI Role of Macrophage Migration Inhibitory Factor (MIF) in Hodgkin Lymphoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Yale New Haven Med Ctr, New Haven, CT 06504 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1235 BP 272A EP 272A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301235 ER PT J AU Rodig, SJ Juszczynski, P Takeyama, K Ouyang, J Faber, J Armstrong, S Shipp, MA Kutok, JL AF Rodig, S. J. Juszczynski, P. Takeyama, K. Ouyang, J. Faber, J. Armstrong, S. Shipp, M. A. Kutok, J. L. TI Selective Expression of the Immunoregulatory Lectin, Galectin-1, Identifies Precursor B Cell Acute Lymphoblastic Leukemias (ALL) with MLL Rearrangements SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1280 BP 282A EP 282A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301280 ER PT J AU Sohani, AR Brodsky, V Ackerman, AM Hochberg, EP Gilbertson, JR Yagi, Y AF Sohani, A. R. Brodsky, V. Ackerman, A. M. Hochberg, E. P. Gilbertson, J. R. Yagi, Y. TI Three-Dimensional (3D) Image Analysis of Benign vs Malignant Follicular Lymphoid Proliferations (FLPs) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1299 BP 287A EP 287A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301299 ER PT J AU Brodsky, V Louissaint, A Gilbertson, J Yagi, Y AF Brodsky, V. Louissaint, A. Gilbertson, J. Yagi, Y. TI Case of the Month and the Virtual Slidebox Implementation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Brodsky, V.; Louissaint, A.; Gilbertson, J.; Yagi, Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1351 BP 298A EP 299A PG 3 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301351 ER PT J AU Collins, AB Farris, AB Smith, RN Adams, CD Della Pelle, PA Saidman, S Wong, W Colvin, RB AF Collins, A. B. Farris, A. B. Smith, R. N. Adams, C. D. Della Pelle, P. A. Saidman, S. Wong, W. Colvin, R. B. TI Challenges in the Diagnosis of Chronic Antibody Mediated Rejection Due to Loss of Peritubular Capillaries and Low Extent and Transient Nature of C4d Deposition SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Collins, A. B.; Farris, A. B.; Smith, R. N.; Adams, C. D.; Della Pelle, P. A.; Saidman, S.; Wong, W.; Colvin, R. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1364 BP 301A EP 302A PG 3 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301364 ER PT J AU Collins, AB Farris, AB Wong, W Saidman, S Tolkoff-Rubin, N Goes, NB Ko, DS Cosimi, AB Colvin, RB AF Collins, A. B. Farris, A. B. Wong, W. Saidman, S. Tolkoff-Rubin, N. Goes, N. B. Ko, D. S. Cosimi, A. B. Colvin, R. B. TI De Novo Membranous Glomerulonephritis Is Associated with C4d Depostion in Peritubular Capillaries and Basement Membrane Multilamination: Putative Variant of Chronic Humoral Rejection SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Collins, A. B.; Farris, A. B.; Wong, W.; Saidman, S.; Tolkoff-Rubin, N.; Goes, N. B.; Ko, D. S.; Cosimi, A. B.; Colvin, R. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1363 BP 301A EP 301A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301363 ER PT J AU Farris, AB Adams, CD Brousaides, N Della Pelle, PA Collins, AB Colvin, RB AF Farris, A. B. Adams, C. D. Brousaides, N. Della Pelle, P. A. Collins, A. B. Colvin, R. B. TI Novel Subtraction Morphometry Technique for Assessing Fibrosis in Renal Biopsies SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1368 BP 302A EP 302A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301368 ER PT J AU Farris, AB Gaut, J Wong, W Della Pelle, P Brousaides, N Collins, AB Saidman, S Schneeberger, EE Smith, RN Colvin, RB AF Farris, A. B. Gaut, J. Wong, W. Della Pelle, P. Brousaides, N. Collins, A. B. Saidman, S. Schneeberger, E. E. Smith, R. N. Colvin, R. B. TI Pathology, Serology and Clinical Characteristics of 68 Patients with Chronic Humoral Renal Allograft Rejection (CHR) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Farris, A. B.; Gaut, J.; Wong, W.; Della Pelle, P.; Brousaides, N.; Collins, A. B.; Saidman, S.; Schneeberger, E. E.; Smith, R. N.; Colvin, R. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1369 BP 302A EP 303A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301369 ER PT J AU Konstantinidis, I Ferrone, CR Genevay, M Lauwers, GY Deshpande, V AF Konstantinidis, I. Ferrone, C. R. Genevay, M. Lauwers, G. Y. Deshpande, V. TI Intrapancreatic Cholangiocarcinomas. A Clinicopathological Study SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 [Konstantinidis, I.; Ferrone, C. R.; Genevay, M.; Lauwers, G. Y.; Deshpande, V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1416 BP 313A EP 313A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301416 ER PT J AU Mandal, RV Notohara, K Deshpande, V Farris, AB Lisovsky, M Smyrk, TC Lauwers, GY Mino-Kenudson, M AF Mandal, R. V. Notohara, K. Deshpande, V. Farris, A. B. Lisovsky, M. Smyrk, T. C. Lauwers, G. Y. Mino-Kenudson, M. TI Foxp3 and IgG4 Expression in Subtypes of Autoimmune Pancreatitis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Kurashiki Cent Hosp, Kurashiki, Okayama, Japan. Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1429 BP 315A EP 316A PG 2 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301429 ER PT J AU Mino-Kenudson, M Smyrk, TC Notohara, K AF Mino-Kenudson, M. Smyrk, T. C. Notohara, K. TI Pathology of Pancreas in Inflammatory Bowel Disease: An Etiology of Idiopathic Ductocentric Chronic Pancreatitis? SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Mayo Clin, Rochester, MN USA. Kurashiki Cent Hosp, Kurashiki, Okayama, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1435 BP 317A EP 317A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301435 ER PT J AU Notohara, K Smyrk, TC Mizuno, N Mino-Kenudson, M AF Notohara, K. Smyrk, T. C. Mizuno, N. Mino-Kenudson, M. TI The Role of Biopsies in the Diagnosis of Autoimmune Pancreatitis (Lymphoplasmacytic Sclerosing Pancreatitis) SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Kurashiki Cent Hosp, Kurashiki, Okayama, Japan. Mayo Clin, Rochester, MN USA. Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1441 BP 318A EP 318A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301441 ER PT J AU Rubbia-Brandt, L Lauwers, GY Wang, H Majno, PE Tanabe, K Zhu, A Brezault, C Soubrane, O Abdalla, EK Vauthey, JN Mentha, G Terris, B AF Rubbia-Brandt, L. Lauwers, G. Y. Wang, H. Majno, P. E. Tanabe, K. Zhu, A. Brezault, C. Soubrane, O. Abdalla, E. K. Vauthey, J-N Mentha, G. Terris, B. TI Sinusoidal Obstruction Syndrome and Nodular Regenerative Hyperplasia Are Major Hepatic Lesions Associated with Oxaliplatin Based Chemotherapy for Colorectal Liver Metastases and Partially Prevented by Bevacizumab SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Hosp Geneva, Geneva, Switzerland. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Hosp Geneva, Geneva, Switzerland. Hop Cochin, F-75674 Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 SU 1 MA 1452 BP 320A EP 320A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301452 ER PT J AU Snyder, EL Sandstrom, DJ Law, K Sicinska, E Loda, M Rodig, SJ Dal Cin, P Fletcher, CDM AF Snyder, E. L. Sandstrom, D. J. Law, K. Sicinska, E. Loda, M. Rodig, S. J. Dal Cin, P. Fletcher, C. D. M. TI c-Jun Amplification and Overexpression Are Oncogenic in Liposarcoma but Not Sufficient To Inhibit Adipocytic Differentiation SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1553 BP 343A EP 343A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301553 ER PT J AU Zhang, X Parangi, S Lawler, J AF Zhang, X. Parangi, S. Lawler, J. TI Regulation of VEGF-Induced Vascular Permeability and VEGFR2 Signaling by Thrombospondin-1 SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Chicago, Med Ctr, Chicago, IL 60637 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1559 BP 344A EP 344A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301559 ER PT J AU Beheshti, J Xiao, Y Yonesaka, K Jackman, D Joshi, V Lee, C Janne, P Lindeman, N AF Beheshti, J. Xiao, Y. Yonesaka, K. Jackman, D. Joshi, V. Lee, C. Janne, P. Lindeman, N. TI Amphiregulin-2 Immunoreactivity Is Superior to EGFR FISH for Predicting Favorable Response to Tyrosine Kinase Inhibitors in EGFR-Wild Type Lung Adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Partners Ctr Genet & Genom, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1585 BP 350A EP 350A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301585 ER PT J AU Matsubara, O Ohba, T Ninomiya, H Ishikawa, Y Mark, EJ AF Matsubara, O. Ohba, T. Ninomiya, H. Ishikawa, Y. Mark, E. J. TI Histological Characteristics in the Prediction of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (IPF) Following Surgery for Primary Lung Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Natl Defense Med Coll, Tokorozawa, Saitama, Japan. Japanese Fdn Canc Res, Inst Canc, Tokyo 170, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1623 BP 358A EP 358A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301622 ER PT J AU Rodig, SJ Dacic, S Yeap, BY Barletta, JA Law, K Lindeman, N Iafrate, AJ Chirieac, LR AF Rodig, S. J. Dacic, S. Yeap, B. Y. Barletta, J. A. Law, K. Lindeman, N. Iafrate, A. J. Chirieac, L. R. TI Phenotype of Lung Adenocarcinoma with EML-ALK Fusion in the Western Population SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1635 BP 360A EP 360A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301634 ER PT J AU Ruzinova, MB Joshi, V Jackman, D Janne, P Lindeman, NI AF Ruzinova, M. B. Joshi, V. Jackman, D. Janne, P. Lindeman, N. I. TI ERK Immunostaining Predicts EGFR and/or KRAS Mutation in Lung Adenocarcinomas, and Can Be Used To Prescreen Tumors for Subsequent Molecular Testing SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Beigham & Womens Hosp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1637 BP 361A EP 361A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301636 ER PT J AU Sholl, LM Joshi, V Jackman, D Xiao, Y Lee, C Janne, P Lindeman, N AF Sholl, L. M. Joshi, V. Jackman, D. Xiao, Y. Lee, C. Janne, P. Lindeman, N. TI EGFR Mutation Is a Better Predictor of Response to TKIs in NSCLC Than FISH, CISH, or IHC SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1639 BP 361A EP 361A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301638 ER PT J AU Wagner, PL Perner, S Soltermann, A LaFargue, CL Tischler, V Weir, BA Weder, W Meyerson, M Giordano, TJ Moch, H Rubin, MA AF Wagner, P. L. Perner, S. Soltermann, A. LaFargue, C. L. Tischler, V. Weir, B. A. Weder, W. Meyerson, M. Giordano, T. J. Moch, H. Rubin, M. A. TI TTF1 Expression in Non-Small Cell Lung Carcinoma: Association with TTF1 Gene Amplification and Improved Survival SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Cornell Univ, Weill Med Coll, New York, NY 10021 USA. Univ Zurich Hosp, CH-8091 Zurich, Switzerland. Univ Zurich, Zurich, Switzerland. Univ Michigan, Ann Arbor, MI 48109 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1648 BP 363A EP 363A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301647 ER PT J AU Yu, J Benedettini, E Li, DQ Gu, T Herebert, H Smith, B Polakiewicz, R Zhou, XM Loda, M Comb, M AF Yu, J. Benedettini, E. Li, D. Q. Gu, T. Herebert, H. Smith, B. Polakiewicz, R. Zhou, X. M. Loda, M. Comb, M. TI Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Cell Signaling Technol Inc, Danvers, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Second Xiangya Hosp, Changsha, Hunan, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1651 BP 364A EP 364A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301650 ER PT J AU Benedettini, E Saad, AG Loda, M Chirieac, LR AF Benedettini, E. Saad, A. G. Loda, M. Chirieac, L. R. TI Molecular Characteristics of Matched Primary Non-Small-Cell Lung Carcinomas (NSCLC) and Metastases to the Brain SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1670 BP 368A EP 368A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301669 ER PT J AU Demichelis, F Setlur, SR Beroukhim, R Perner, S Korbel, JO Lafargue, C Pflueger, D Pina, C Hofer, MD Sboner, A Svensson, MA Rickman, DS Meyerson, M Lee, C Gerstein, MB Kuefer, R Rubin, MA AF Demichelis, F. Setlur, S. R. Beroukhim, R. Perner, S. Korbel, J. O. Lafargue, C. Pflueger, D. Pina, C. Hofer, M. D. Sboner, A. Svensson, M. A. Rickman, D. S. Meyerson, M. Lee, C. Gerstein, M. B. Kuefer, R. Rubin, M. A. TI Distinct Genomic Aberrations Associated with TMPRSS2-ERG Fusion Prostate Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Weill Cornell Med Coll, New York, NY USA. Brigham & Womens Hosp, Boston, MA 02115 USA. MIT & Harvard, Broad Inst, Cambridge, MA USA. Dana Farber Canc Inst, Cambridge, MA USA. Yale Univ, New Haven, CT USA. Univ Hosp Ulm, Ulm, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1677 BP 370A EP 370A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301676 ER PT J AU Firestein, R Barletta, JA Ligon, A Loda, M Hahn, WC Chirieac, LR AF Firestein, R. Barletta, J. A. Ligon, A. Loda, M. Hahn, W. C. Chirieac, L. R. TI IKBKe Copy Number Gain in Lung Adenocarcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Harvard Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1683 BP 371A EP 371A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301682 ER PT J AU Priolo, C Lamb, J Zadra, G Oldridge, D Palescandolo, E Sicinska, E Loda, M AF Priolo, C. Lamb, J. Zadra, G. Oldridge, D. Palescandolo, E. Sicinska, E. Loda, M. TI A Bioinformatic Approach to Identify New Metabolic Targets in Prostate Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Harvard & MIT, Broad Inst, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1699 BP 375A EP 375A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301698 ER PT J AU Roehrl, MH Rho, JH Wang, JY AF Roehrl, M. H. Rho, J. H. Wang, J. Y. TI Lung Adenocarcinoma and Its Stroma: Tissue Proteomics Reveals Differential and Compartment-Specific Roles for the Homologs Transgelin and Transgelin-2 SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1700 BP 375A EP 375A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301699 ER PT J AU Kindelberger, DW Flores, LM Cibas, ES Ligon, AH Loda, MF Krop, IE Janne, PA AF Kindelberger, D. W. Flores, L. M. Cibas, E. S. Ligon, A. H. Loda, M. F. Krop, I. E. Janne, P. A. TI Determining the Recovery Efficiency and Relative Enrichment of Circulating Tumor Cells Using the CellSearch System in Patients with Metastatic Lung Cancer SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 07-13, 2009 CL Boston, MA SP US & Canadian Acad Pathol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RI Robertson, Simon/D-1549-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD JAN PY 2009 VL 89 MA 1738 BP 384A EP 384A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 394XK UT WOS:000262486301737 ER PT J AU Tyler, KL AF Tyler, Kenneth L. TI Neurological infections: advances in therapy, outcome, and prediction SO LANCET NEUROLOGY LA English DT Editorial Material ID NILE-VIRUS-INFECTION; BACTERIAL-MENINGITIS; ADULTS C1 [Tyler, Kenneth L.] Univ Colorado, Denver Hlth Sci Ctr, Denver, CO 80220 USA. [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Tyler, KL (reprint author), Univ Colorado, Denver Hlth Sci Ctr, Denver, CO 80220 USA. EM ken.tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 NR 7 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 J9 LANCET NEUROL JI Lancet Neurol. PD JAN PY 2009 VL 8 IS 1 BP 19 EP 21 DI 10.1016/S1474-4422(08)70279-5 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 386CU UT WOS:000261860700011 PM 19081508 ER PT J AU Hermsen, JL Sano, Y Kudsk, KA AF Hermsen, Joshua L. Sano, Yoshifumi Kudsk, Kenneth A. TI Food fight! Parenteral nutrition, enteral stimulation and gut-derived mucosal immunity SO LANGENBECKS ARCHIVES OF SURGERY LA English DT Review DE Parenteral nutrition; Mucosal immunity; Immunoglobulin A; Polymeric immunoglobulin receptor; Pneumonia ID POLYMERIC IMMUNOGLOBULIN RECEPTOR; UPPER RESPIRATORY-TRACT; INDUCED BACTERIAL TRANSLOCATION; ADHESION MOLECULE-1 EXPRESSION; LYMPHOID-TISSUE; PEYERS-PATCHES; J-CHAIN; SECRETORY COMPONENT; IG RECEPTOR; EXTERNAL SECRETIONS AB Nutrition support is an integral component of modern patient care. Type and route of nutritional support impacts clinical infectious outcomes in critically injured patients. This article reviews the relationships between type and route of nutrition and gut-derived mucosal immunity in both the clinical and laboratory settings. C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI 53792 USA. [Hermsen, Joshua L.; Sano, Yoshifumi; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. RP Kudsk, KA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, 600 Highland Ave,H4-736 CSC, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU NIH [R01 GM53439] FX This study was supported by NIH grant R01 GM53439. This material is based upon work supported in part by the Office of Research and Development, Biomedical Laboratory R&D Service, Department of Veterans Affairs. NR 114 TC 12 Z9 17 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1435-2443 J9 LANGENBECK ARCH SURG JI Langenbecks Arch. Surg. PD JAN PY 2009 VL 394 IS 1 BP 17 EP 30 DI 10.1007/s00423-008-0339-x PG 14 WC Surgery SC Surgery GA 370NE UT WOS:000260768100002 PM 18521625 ER PT J AU Aw, S Levin, M AF Aw, Sherry Levin, Michael BE Sommer, IEC Kahn, RS TI Molecular mechanisms establishing consistent left-right asymmetry during vertebrate embryogenesis SO LANGUAGE LATERALIZATION AND PSYCHOSIS LA English DT Article; Book Chapter ID LEFT-RIGHT AXIS; HOLT-ORAM-SYNDROME; RIGHT CEREBRAL-CORTEX; SITUS-INVERSUS; RETINOIC ACID; NODAL FLOW; CONJOINED TWINS; GAP-JUNCTIONS; WILMS-TUMOR; EARLY STEP AB The physiology and behavior of all animals are strongly dependent on the large-scale structure of the body plan. While many animals are fundamentally bilaterally symmetric, vertebrates and many invertebrates exhibit a consistently oriented left-right (LR) asymmetry of the heart, viscera, and brain. The biased asymmetry of LR patterning is distinct from environmentally determined asymmetry or the random developmental noise that gives rise to fluctuating asymmetries. How the LR axis is oriented in a world in which no macroscopic force distinguishes left from right is a profound puzzle linking evolutionary, developmental, and cell biology to cognitive science and perhaps even to quantum parity violations. Embryonic LR patterning includes a sequential process of symmetry breaking ( likely on the intracellular level), consistent axis orientation, amplification to diverse multicellular targets, and restriction via the midline. Key questions include the timing of the first LR-asymmetric computation during embryonic development, the molecular nature of mechanisms underlying each of the necessary steps, and the degree of conservation of these mechanisms among taxa. The field of LR asymmetry has made striking progress over the last two decades, uncovering a plethora of molecular details in a wide range of model organisms. Here, we present an overview of what is known about the phases of asymmetry initiation, physiological/biophysical signaling upstream of asymmetric gene expression cascades, and ultimate morphogenesis of the asymmetric organs. While the transcriptional programs specific to the left and right sides universally feed into the signaling protein Nodal, the degree of evolutionary conservation of various upstream mechanisms is more controversial. The two major directions in the field are defined by models focusing on ciliary motion vs. physiological signaling. The former hold that asymmetry is bootstrapped from the B biochemical structure of cilia via rotary motion that redistributes an extracellular morphogen or activates asymmetric Ca++ signaling in sensory cilia. In this scheme, most thoroughly explored in mouse and zebrafish embryos, asymmetry is generated fairly late - during gastrulation. In contrast, work in the frog and chick embryo identified modules based on ion transport, serotonin gradients, and gap junctional communication. The earliest steps (asymmetric localization of maternal ion transporter proteins) occur in the cleavage stage embryo (shortly after fertilization) and rely on cytoskeletal (intracellular) asymmetries that appear to be an evolutionarily ancient mechanism for generating chirality, although they have not been explored in mammals. Future experiments must address whether cilia are primary to asymmetry or a mid-pathway step, and whether physiological mechanisms are relevant in mammals. The early steps of asymmetry in human development are still poorly understood. It is clear that clinical data must be integrated in this field, because of key phenomena that are not predicted by any of the current theoretical constructs derived from model species. These include unilateral presentation of genetic syndromes, cryptic functional asymmetries in anatomically symmetrical structures, conservation of hair whorl direction and other characteristics in monozygotic twins, and normal handedness (brain asymmetry) in patients of fully inverted body laterality. Future work in this fascinating field will have wide-ranging implications for basic biology, psychology, and clinical medicine. C1 [Aw, Sherry] Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA 02114 USA. [Aw, Sherry; Levin, Michael] Forsyth Inst, Forsyth Ctr Regenerat & Dev Biol, Boston, MA USA. [Levin, Michael] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. RP Aw, S (reprint author), Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA 02114 USA. NR 134 TC 0 Z9 0 U1 1 U2 4 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-0-521-88284-2 PY 2009 BP 3 EP 18 DI 10.1017/CBO9780511576744.002 D2 10.1017/CBO9780511576744 PG 16 WC Psychology, Clinical; Neurosciences; Psychiatry SC Psychology; Neurosciences & Neurology; Psychiatry GA BFE94 UT WOS:000319561400002 ER PT J AU Long, JL Strocker, AM Wang, MB Blackwell, KE AF Long, Jennifer L. Strocker, Ali M. Wang, Marilene B. Blackwell, Keith E. TI EGFR Expression in Primary Squamous Cell Carcinoma of the Thyroid SO LARYNGOSCOPE LA English DT Article; Proceedings Paper CT Annual Meeting of the Western Section of the Triological-Society CY JAN 31-FEB 02, 2008 CL Rancho Mirage, CA SP Triol Soc, Western Sect DE Thyroid; EGFR; squamous cell carcinoma ID EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR AB We present the case of a 57-year-old male with primary squamous cell carcinoma of the thyroid (PSCCT). Epidermal growth factor receptor (EGFR) staining was strongly positive. Pharmaceuticals targeting EGFR may provide an additional therapeutic option for this rare disease with extremely poor prognosis. C1 [Long, Jennifer L.; Wang, Marilene B.; Blackwell, Keith E.] Univ Calif Los Angeles, Div Head & Neck Surg, Los Angeles, CA 90024 USA. [Wang, Marilene B.; Blackwell, Keith E.] Childrens Hosp Los Angeles, W Los Angeles Vet Affairs Med Ctr, Dept Otolaryngol, Los Angeles, CA 90027 USA. [Strocker, Ali M.] Childrens Hosp Los Angeles, Dept Pediat Otolaryngol, Los Angeles, CA 90027 USA. RP Long, JL (reprint author), Univ Calif Los Angeles, Div Head & Neck Surg, 10833 LeConte Ave,Room CHS 62-150, Los Angeles, CA 90024 USA. EM jlong@mednet.ucla.edu OI Long, Jennifer/0000-0002-4185-2328 NR 8 TC 5 Z9 6 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2009 VL 119 IS 1 BP 89 EP 90 DI 10.1002/lary.20062 PG 2 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 396EO UT WOS:000262575200016 PM 19117291 ER PT J AU Brigger, MT Hartnick, CJ AF Brigger, Matthew T. Hartnick, Christopher J. TI Drilling Speaking Valves: A Modification to Improve Vocalization in Tracheostomy Dependent Children SO LARYNGOSCOPE LA English DT Article DE Pediatric; tracheostomy; speaking valve; voice ID POSITIVE AIRWAY PRESSURE; PASSY-MUIR VALVE; YOUNG-CHILDREN; TRACHEOBRONCHOMALACIA; INFANTS; CPAP; BRONCHOMALACIA; SPEECH AB Pediatric tracheostomy dependence is associated with a variety of sequelae. Vocalization delay is commonplace and may result in long-term communication disability. Passy-Muir speaking valves are routinely used to allow such children to vocalize. Unfortunately, not all tracheostomy dependent children can tolerate the placement of a speaking valve. Elevated transtracheal pressures are often associated with failure. We describe a method of modifying a standard Passy-Muir valve to decrease transtracheal pressures and thus improve tolerance of the valve. In our practice, the modification allows a broader range of children experience the benefit of speaking valve placement. C1 [Brigger, Matthew T.; Hartnick, Christopher J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. RP Brigger, MT (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. EM matt.brigger@alumni.vanderbilt.edu NR 13 TC 2 Z9 4 U1 1 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2009 VL 119 IS 1 BP 176 EP 179 DI 10.1002/lary.20077 PG 4 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 396EO UT WOS:000262575200031 PM 19117281 ER PT J AU Jung, D Hasserjian, RP Faquin, WC Deschler, DG AF Jung, David Hasserjian, Robert P. Faquin, William C. Deschler, Daniel G. TI Granulocytic Sarcoma of the Submandibular Gland SO LARYNGOSCOPE LA English DT Article AB Objectives: 1) To describe the diagnosis and treatment of granulocytic sarcoma presenting in a submandibular gland; and 2) to identify granulocytic sarcoma as a rare but important diagnosis to be considered in patients presenting with a submandibular gland mass. Study Design: The study is a case report and review of the literature. Methods: The patient data relevant to the case were reviewed. An extensive literature search was carried out using the PubMed NIH database. Results: A young woman, with medical history significant for radiation exposure at a young age, presented with a submandibular gland mass. Excision of the mass and subsequent analysis revealed the presence of a GS subtype within the mass. The rapid diagnosis of GS allowed for timely treatment of this patient, and the patient remains disease free more than one year later. Conclusions: Early diagnosis of GS is important for both staging and treatment. It may therefore be important to entertain the relatively rare diagnosis of GS within the broader differential diagnosis of salivary gland tumors, especially in patients with previous radiation exposure. Understanding the mechanisms by which GS can present as a salivary gland mass may eventually shed light on general principles determining tumorigenesis within salivary glands. C1 [Jung, David] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Jung, D (reprint author), Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S11 EP S11 DI 10.1002/lary.20303 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500011 ER PT J AU Kakarala, K Richmon, JD Deschler, DG AF Kakarala, Kiran Richmon, Jeremy D. Deschler, Daniel G. TI Radial Forearm Free Flap Reconstruction of a Nasopharyngeal Defect Secondary to Cervical Osteoradionecrosis SO LARYNGOSCOPE LA English DT Article AB Objectives: 1) Present a case of cervical spine osteoradionecrosis and nasopharyngeal defect which was reconstructed with a radial forearm free flap; and 2) review the literature on the management and reconstruction of cervical spine osteoradionecrosis. Study Design: Case report. Methods: Retrospective case review including a review of the relevant literature. Results: The case of a 57 year old man with osteoradionecrosis of the cervical spine is presented. He had previously undergone surgery and proton beam radiation for hepatocellular carcinoma metastatic to the C2 body, and subsequently developed osteoradionecrosis and osteomyelitis of the cervical spine. Biopsy of the area was negative for tumor recurrence. Treatment with hyperbaric oxygen and intravenous antibiotics was unsuccessful. Operative debridement of the necrotic bone was therefore performed, and the nasopharyngeal soft tissue defect was reconstructed with a radial forearm free flap. At 3 months follow-up he was doing well with normal swallow function. Conclusions: Osteoradionecrosis of the cervical spine is an uncommon complication of radiation treatment of head and neck tumors. Management with hyperbaric oxygen therapy and intravenous antibiotics for associated osteomyelitis has been described, however, operative management may be required. The use of the fibula osteocutaneous free flap has been described for reconstruction of both bony and composite defects related to cervical spine osteoradionecrosis. For patients where bone is not required, the radial forearm free flap provides thin, pliable soft tissue which is advantageous in pharyngeal reconstruction. C1 [Kakarala, Kiran; Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. [Richmon, Jeremy D.] Dept Otolaryngol Head & Neck Surg, Div Head & Neck Surg, Baltimore, MD USA. RP Kakarala, K (reprint author), Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. OI Kakarala, Kiran/0000-0002-1003-8024 NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S12 EP S12 DI 10.1002/lary.20304 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500012 ER PT J AU Kakarala, K Brigger, MT Faquin, WC Hartnick, CJ Cunningham, MJ AF Kakarala, Kiran Brigger, Matthew T. Faquin, William C. Hartnick, Christopher J. Cunningham, Michael J. TI Cystic Pilomatrixoma: A Diagnostic Challenge SO LARYNGOSCOPE LA English DT Article AB Objectives: 1) Present two childhood cases of preauricular cystic pilomatrixoma; and 2) review the literature on the diagnosis and management of pilomatrixoma. Study Design: Case report series. Methods: Retrospective review of two childhood cases of cystic pilomatrixoma including a comprehensive review of the relevant literature. Results: Two children, ages 11 and 7, with cystic preauricular masses are presented. FNA of cyst contents was nondiagnostic and cyst cultures were negative. Computed tomography scans revealed cystic masses superficial to the parotid gland but no distinctive radiologic features characteristic of pilomatrixoma. Complete lesion excision via a preauricular facelift approach was performed in both cases. The histopathologic features included basaloid cells surrounding a cystic space containing keratin debris and characteristic ghost cells consistent with the diagnosis of pilomatrixoma. There has been no evidence of recurrence at 1 and 6 years follow-up, respectively. Conclusions: Pilomatrixoma is a benign neoplasm which manifests frequently in the head and neck in children, typically with quite classic physical examination and radiologic features. However, clinical misdiagnosis may occur in the setting of a preauricular cystic mass presentation. Such cases may be challenging to diagnose even with preoperative imaging and cytology. The treatment of pilomatrixoma is surgical with complete excision yielding a low recurrence rate. C1 [Kakarala, Kiran; Brigger, Matthew T.; Hartnick, Christopher J.; Cunningham, Michael J.] Massachusetts Eye & Ear Infirm, Div Pediat Otolaryngol, Dept Otol & Laryngol, Boston, MA 02114 USA. [Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Kakarala, K (reprint author), Massachusetts Eye & Ear Infirm, Div Pediat Otolaryngol, Dept Otol & Laryngol, Boston, MA 02114 USA. OI Kakarala, Kiran/0000-0002-1003-8024 NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S53 EP S53 DI 10.1002/lary.20324 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500053 ER PT J AU Kieff, DA Busaba, NY AF Kieff, David A. Busaba, Nicolas Y. TI Reformation of Conchae Bullosae Following Treatment with Crushing Technique: Implications for Balloon Sinuplasty SO LARYNGOSCOPE LA English DT Article DE concha bullosa; sinuplasty; balloon; rhinosinusitis AB Introduction/Background: There are various surgical techniques designed to treat conchae bullosae (CB). These include partial or total resection, as well as crushing. Frontal sinus balloon sinuplasty is thought to work by the crushing/remodeling of the agger nasi and frontal recess air cells. The long term of sinuplasty in the frontal/ethmoid air cell region is unknown. To date, no study has been done on the reformation of CB after crushing. We report on the long-term outcome of a series of patients who underwent crushing of their CB and suggest implications for frontal sinus balloon sinuplasty. Methods: retrospective case series of 10 patients who represented with CB as a component of their nasal obstructive symptoms despite previously undergoing crushing of their CB. Data analyzed included paranasal sinus CTs and operative reports. Results: These 10 patients represented with recurrent rhinosinutis and nasal obstructive symptoms. The patients had previously undergone septoplasty surgery with crushing of the CB and were noted to have reformed the CB on their most recent sinus CT. The previous surgeries were preformed from 2-15 years prior to their representation. Conclusion: CB can reform following crushing technique. One may extrapolate that agger nasi and frontal recess air cells may reform following balloon sinuplasty leading to recurrent obstruction of the frontal sinus outflow tract. C1 [Kieff, David A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Kieff, DA (reprint author), Harvard Vanguard Med Associates, 230 Worcester St, Wellesley, MA 02481 USA. EM david_kieff@vmed.org NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S54 EP S54 DI 10.1002/lary.20325 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500054 ER PT J AU Leuin, SC Deschler, DG AF Leuin, Shelby C. Deschler, Daniel G. TI The Missing Tracheo-Esophageal Puncture Prosthesis: Evaluation and Management SO LARYNGOSCOPE LA English DT Article C1 [Leuin, Shelby C.; Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. RP Leuin, SC (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. NR 9 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S15 EP S15 DI 10.1002/lary.20308 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500015 ER PT J AU Lin, HW Richmon, JD Emerick, KS de Venecia, RK Zeitels, SM Faquin, WC Lin, DT AF Lin, Harrison W. Richmon, Jeremy D. Emerick, Kevin S. de Venecia, Ronald K. Zeitels, Steven M. Faquin, William C. Lin, Derrick T. TI Malignant transformation of HPV-11-associated recurrent respiratory papillomatosis SO LARYNGOSCOPE LA English DT Article AB Objective: To present an uncommon case of squamous cell carcinoma (SCC) arising from severe recurrent respiratory papillomatosis (RRP) involving the upper and lower airway and temporal bone. Study Design: Case report and a review of the literature. Methods: We describe a case of a 24 year old woman with a history of human papilloma virus (HPV) type-11 since childhood originating in the larynx and trachea, then progressing to involve the distal pulmonary alveoli and right middle ear through the Eustachian tube. Papillomatous growth was treated with multiple surgeries including laser cytoreduction of laryngotracheal papillomatosis and radical mastoidectomy, followed by a trial of chemotherapy. Despite this aggressive treatment regimen, papillomatous growth progressed with recurrence in the right Eustachian tube, middle ear and mastoid extending to involve the calvarium and scalp. Results: The patient underwent a composite resection of involved tissues, including the scalp, auricle and lateral temporal bone, with reconstruction using a latissimus dorsi free flap. Final pathologic analysis revealed an extensive infiltrative well-differentiated squamous cell carcinoma arising from the papilloma. A review of the literature on aggressive respiratory papillomatosis suggests that malignant transformation of juvenile-onset RRP occurs exclusively in cases positive for HPV-11. Conclusions: We report an unusual case of SCC originating from extensive RRP involving the airway, temporal bone and scalp and describe the medical and surgical management. Although the incidence of juvenile-onset RRP transformation to SCC is very low, the presence of HPV-11 as a risk factor for malignant transformation of RRP is becoming evident. C1 [Lin, Harrison W.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Surg, Ctr Laryngeal Surg, Div Thorac Surg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Lin, HW (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S70 EP S70 DI 10.1002/lary.20345 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500070 ER PT J AU Lin, HW Bhattacharyya, N AF Lin, Harrison W. Bhattacharyya, Neil TI Incidence Of Perioperative Airway Complications In Patients With Previous Medialization Thyroplasty SO LARYNGOSCOPE LA English DT Article ID INTUBATION AB Objectives: Determine the incidence and characterize perioperative airway complications in patients who have undergone medialization thyroplasty (MT) and subsequently undergo procedures requiring anesthesia. Study Design: Retrospective review of post-MT anesthesia encounters in a large academic hospital. Methods: A series of post-MT patients was reviewed, identifying anesthesia encounters undergoing endotracheal intubation (ETI) or laryngeal mask airway (LMA) placement. Details on the perioperative course of each encounter were extracted and examined for evidence of airway complications. The incidence of airway obstruction and need for airway intervention were determined and compared to those of control patients matched for type of procedure. Relationships between complications and perioperative management were analyzed. Results: A total of 74 anesthesia encounters were identified among 219 post-MT patients. Perioperative airway complications among post-MT patients arose in 5 procedures (6.8%; 95% CI: 1.0-12.4%). Stridor in the operating or recovery room was exhibited three times, with all episodes requiring nebulized racemic epinephrine and intravenous steroids for resolution of symptoms. One patient underwent an urgent tracheotomy for severe stridor leading to airway compromise in the recovery room. Immediately after induction with an LMA, one patient failed to maintain oxygen saturations above 90% and consequently required conversion to ETI. Among 79 matched controls without prior MT, no perioperative complications (0%) occurred (p=0.027). Conclusion: The incidence of perioperative airway complications in post-MT patients is non-neglible and may be serious. Surgical, anesthesia and recovery room staff should be made aware of the significantly increased risk of airway complications in post-MT patients. C1 [Lin, Harrison W.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. Brigham & Womens Hosp, Div Otolaryngol Head & Neck Surg, Boston, MA 02115 USA. RP Lin, HW (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S32 EP S32 DI 10.1002/lary.20346 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500032 ER PT J AU Lutch, MJ Burns, JA Friedman, AD Zeitels, SM AF Lutch, Matthew J. Burns, James A. Friedman, Aaron D. Zeitels, Steven M. TI Submucosal Neoplasms of the Laryngeal Introitus SO LARYNGOSCOPE LA English DT Article C1 [Lutch, Matthew J.] Harvard Univ, Sch Med, Dept Surg, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Lutch, MJ (reprint author), Harvard Univ, Sch Med, Dept Surg, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02115 USA. FU Eugene B. Casey Foundation; Institute of Laryngology and Voice Restoration FX The authors would like to gratefully acknowledge James Heaton, PhD for assistance in the preparation of this poster. This work was supported in part by the Eugene B. Casey Foundation and the Institute of Laryngology and Voice Restoration. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S33 EP S33 DI 10.1002/lary.20347 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500033 ER PT J AU Mehta, DD Deliyski, DD Zeitels, SM Zanartu, M Hillman, RE AF Mehta, Daryush D. Deliyski, Dimitar D. Zeitels, Steven M. Zanartu, Matas Hillman, Robert E. TI Integration of Ultra High-Speed Color Videoendoscopy with Time-Synchronized Measures of Vocal Function SO LARYNGOSCOPE LA English DT Article C1 [Mehta, Daryush D.; Zeitels, Steven M.; Hillman, Robert E.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA. [Mehta, Daryush D.; Hillman, Robert E.] Harvard Mit Div Hlth Sci & Technol, Speech & Hearing Biosci & Technol Program, Cambridge, MA USA. [Deliyski, Dimitar D.] Univ S Carolina, Dept Commun Sci & Disorders, Columbia, SC 29208 USA. [Zeitels, Steven M.; Hillman, Robert E.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Zanartu, Matas] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA. RP Mehta, DD (reprint author), Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA. RI Zanartu, Matias/I-3133-2012; researchers, ac3e/N-2008-2016 OI Zanartu, Matias/0000-0001-5581-4392; FU NIH National Institute on Deafness and Other Communication Disorders [T32 DC00038, R01 DC007640]; Institute for Laryngology and Voice Restoration FX This project is supported by grants from the NIH National Institute on Deafness and Other Communication Disorders (T32 DC00038 and R01 DC007640) and by the Institute for Laryngology and Voice Restoration. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. We would like to thank Thomas F. Quatieri for valuable discussions regarding signal and image processing algorithms. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S34 EP S34 DI 10.1002/lary.20351 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500034 ER PT J AU Mong, S Nichols, AC Deschler, DG AF Mong, Sandy Nichols, Anthony C. Deschler, Daniel G. TI Work Type II First Branchial Cleft Cyst with External Auditory Canal Duplication SO LARYNGOSCOPE LA English DT Article AB A 25 year-old male presented with a tender, fixed 3-cm right parotid mass persisting over 2 years with recent interval enlargement. CT scan demonstrated a cystic mass that did not invade adjacent soft tissue or bone. Fine needle aspiration (FNA) yielded cyst fluid. Total parotidectomy with facial nerve dissection for a presumed parotid tumor demonstrated a mass tracking deep to the facial nerve, coursing medially and superiorly to terminate adjacent to the cartilaginous external auditory canal (EAC). Pathology revealed an epithelial-lined cyst with hair matrix surrounded by elastic cartilage in focal areas consistent with a Work type II first branchial cleft cyst with EAC duplication. This case supports the literature in demonstrating that 1. misdiagnosis occurs commonly and frequently necessitates revision; 2. full facial nerve dissection reduces incidence of its injury; and 3. increased familiarity with its clinical symptoms, inclusion on the differential for parotid masses, preoperative imaging, and identification of a tract in the specimen can reduce recurrence rates. Work type II first branchial cleft anomalies must be included in the differential diagnosis for head and neck masses above the level of the hyoid bone. Preoperative imaging, more so than FNA, can confirm the diagnosis. Improved diagnosis can ensure the appropriate surgical approach, and decrease the risk of post-operative complications. C1 [Mong, Sandy] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Nichols, Anthony C.; Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Mong, S (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S17 EP S17 DI 10.1002/lary.20310 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500017 ER PT J AU Quesnel, AM Geyer, JT Deschler, DG AF Quesnel, Alicia M. Geyer, Julia T. Deschler, Daniel G. TI Disseminated Fusariosis Presenting with Mucosal Ulcers SO LARYNGOSCOPE LA English DT Article AB Objectives: 1) Describe an unusual presentation of a rare, but highly lethal fungal infection relevant to the otolaryngologist 2) Raise awareness of Fusarium, an emerging pathogenic mold, with potential for serious infection in the immunocompromised patient 3) Emphasize the need for prompt diagnosis and treatment in invasive fusarial infection Disseminated fusarial infection is a rare, highly lethal fungal infection that may present with invasive rhinosinusitis in the immunocompromised patient. We present a case of disseminated fusarial infection in a neutropenic patient presenting with odynophagia as the only localizing symptom. Biopsies of nasal and laryngeal ulcers diagnosed an invasive fungal infection, and subsequent cultures identified fusarium as the causative organism. The patient was treated with emergent surgical debridement and amphotericin, but passed away five days later due to multi-organ failure. Like other invasive fungal infections in the immunocompromised host, fusarial infection is life-threatening and necessitates aggressive surgical and medical management. C1 [Quesnel, Alicia M.; Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. [Quesnel, Alicia M.; Deschler, Daniel G.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Geyer, Julia T.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Quesnel, AM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S56 EP S56 DI 10.1002/lary.20327 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500056 ER PT J AU Richmon, JD Samji, HA Deschler, DG AF Richmon, Jeremy D. Samji, Hussein A. Deschler, Daniel G. TI National Laryngopharyngectomy and Reconstructive Surgery Survey SO LARYNGOSCOPE LA English DT Article AB The surgical treatment of advanced carcinomas of the hypopharynx and larynx present many therapeutic challenges. Numerous reconstructive options have emerged but there has been little study why particular reconstructive options are selected. A nationwide survey was performed of otolaryngologists and plastic surgeons who perform head and neck reconstruction for laryngopharyngectomy defects. 200 surveys were mailed with a 36% response rate. Otolaryngologists were more likely to consider voice (p = 0.003) and swallowing (p = 0.02) outcomes compared to plastic surgeons. In contrast, plastic surgeons more often included cosmesis (p = 0.05) among those factors influencing their reconstructive choice. However, rank order analysis demonstrated no statistical difference between plastic surgeons and otolaryngologists with respect to each factor. Our study sought to: 1) understand which, and to what degree, various factors influence the surgeon in choosing a particular reconstructive method and, 2) study the various methods available to reconstruct total laryngopharyngectomy defects. Further research is necessary to provide an evidence base for which reconstructive method offers the optimal functional restoration. C1 [Richmon, Jeremy D.; Samji, Hussein A.; Deschler, Daniel G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. RP Deschler, DG (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA. EM Daniel_deschler@meei.harvard.edu NR 10 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S76 EP S76 DI 10.1002/lary.20354 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500076 ER PT J AU Scott, AR Lin, DT AF Scott, Andrew R. Lin, Derrick T. TI A combined transoral and transnasal endoscopic approach to resection of maxillary ameloblastoma with extension to the anterior skull base SO LARYNGOSCOPE LA English DT Article C1 [Scott, Andrew R.; Lin, Derrick T.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. RP Scott, AR (reprint author), Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. NR 3 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S78 EP S78 DI 10.1002/lary.20357 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500078 ER PT J AU Silver, AL Masia, R Hasserjian, RP Deschler, DG AF Silver, Amanda L. Masia, Ricard Hasserjian, Robert P. Deschler, Daniel G. TI High-grade lymphoma mimicking advanced nasopharyngeal carcinoma SO LARYNGOSCOPE LA English DT Article C1 [Silver, Amanda L.; Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. [Masia, Ricard; Hasserjian, Robert P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Silver, AL (reprint author), Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. NR 11 TC 0 Z9 0 U1 2 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S27 EP S27 DI 10.1002/lary.20323 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500027 ER PT J AU Silverman, JB Faquin, WC Richmon, JD Lin, DT AF Silverman, Joshua B. Faquin, William C. Richmon, Jeremy D. Lin, Derrick T. TI Cervical Thymic Cyst in Adults: Consideration in a Neck Mass Algorithm SO LARYNGOSCOPE LA English DT Article AB Objectives: 1) Review the epidemiology, clinical features, and histopathology of cervical thymic cysts; 2) Compare differences in presentation of cystic neck masses among disparate age populations; 3) Discuss proposed pathogenetic mechanisms for development of thymic cysts as well as the proper management; and 4) Understand a comprehensive algorithm for the workup of cystic neck masses. Methods: Retrospective case series and literature review. Results: Cervical thymic cysts are rare lesions that most often occur in the pediatric age group; there are few published reports of thymic cysts in the adult population. In reviewing our records over a ten year period, we have found 5 incidences of thymic cysts. We present one example in detail, and a comparison of the 5 cases. In addition to a discussion of proposed pathogenetic mechanisms and characteristic pathologic features of thymic cysts, we propose an algorithm for workup of cystic lateral neck masses. Conclusions: Despite its rare occurrence, thymic cyst can present in adult patients as a unilateral cystic cervical neck mass. Surgical management is an essential component for both diagnosis and treatment of cystic neck masses. C1 [Silverman, Joshua B.; Faquin, William C.; Richmon, Jeremy D.; Lin, Derrick T.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. RP Silverman, JB (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. NR 10 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S85 EP S85 DI 10.1002/lary.20370 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500085 ER PT J AU Tierney, HT Lin, HW Holbrook, EH Franco, RA Pilch, BZ Lin, DT AF Tierney, Hien T. Lin, Harrison W. Holbrook, Eric H. Franco, Ramon A. Pilch, Ben Z. Lin, Derrick T. TI Regional spread of recurrent respiratory papillomatosis to bilateral cervical lymph nodes SO LARYNGOSCOPE LA English DT Article C1 [Tierney, Hien T.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Tierney, HT (reprint author), Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Head & Neck Surg, Boston, MA 02114 USA. NR 6 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S90 EP S90 DI 10.1002/lary.20378 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500090 ER PT J AU Wieland, AM Richmon, JD Gray, ST Lin, DT AF Wieland, Aaron M. Richmon, Jeremy D. Gray, Stacey T. Lin, Derrick T. TI An Unusual Case of Trismus and Epistaxis SO LARYNGOSCOPE LA English DT Article AB Educational Objectives: At the conclusion of this presentation, the participants should be able to explain the clinical presentation of an infratemporal fossa (ITF) foreign body and discuss the various surgical approaches for removal. Objective: Head and neck foreign bodies have a variety of distinct clinical presentations. We present an unusual case of an ITF foreign body requiring operative removal and discuss surgical approaches to this space. Study design: A case report and review of the literature. Methods: Case report and Medline search of the terms "infratemporal fossa" and "foreign body." Results: A 64 year old male sustained a laceration to his right cheek after a window pane shattered over his head. Plain film x-rays were unremarkable and the laceration was closed primarily. He developed mid-right face weakness, progressive trismus to 1.5 cm and salivary-like drainage from his cheek wound. He also developed intermittent right-sided epistaxis that was exacerbated with chewing. After referral to several dentists and an oral surgeon a CT scan revealed a 5 cm foreign body extending through the superior parotid gland into the ITF terminating in the middle turbinate. Through a modified Blair approach to the parotid gland two glass fragments were removed. Nasal endoscopy was used to visualize the glass imbedded in the middle turbinate. At three months follow up he had no trismus and facial nerve function was normal. A review of the literature identified several reports of displaced maxillary molars and traumatic foreign bodies of the ITF. This case is unique in its surgical approach and the concomitant presentation of trismus and epistaxis. Conclusions: ITF foreign bodies may present a diagnostic and therapeutic challenge. The surgical approach to removal is dictated by the nature of the injury. C1 [Wieland, Aaron M.; Gray, Stacey T.; Lin, Derrick T.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol Head & Neck Surg,Dept Otol & Lar, Boston, MA 02115 USA. [Richmon, Jeremy D.] Johns Hopkins, Dept Otolaryngol, Baltimore, MA USA. RP Wieland, AM (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol Head & Neck Surg,Dept Otol & Lar, Boston, MA 02115 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PY 2009 VL 119 SU 1 BP S94 EP S94 DI 10.1002/lary.20386 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA V16IE UT WOS:000207862500094 ER PT J AU Tannous, Z Al-Arashi, M Shah, S Yaroslavsky, AN AF Tannous, Zeina Al-Arashi, Munir Shah, Sonali Yaroslavsky, Anna N. TI Delineating Melanoma Using Multimodal Polarized Light Imaging SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE melanoma; polarization imaging; tetracycline; methylene blue; reflectance; fluorescence ID METHYLENE-BLUE; LOCALIZATION; CANCER; TUMORS; TETRACYCLINE; RADIOTHERAPY; METAPLASIA AB Background and Significance: Melanoma accounts for 3% of all skin cancers but causes 83% of skin cancer deaths. The first step in treatment of melanoma is the removal of the lesions, usually by surgical excision. Currently most lesions are removed without intraoperative margin control. Post-operative methods inspect 1-2% of the surgical margin and are prone to sampling errors. In this study we evaluate the use of reflectance and fluorescence polarization imaging for the demarcation of melanoma in thick fresh skin excisions. Materials and Methods: Pigmented lesions clinically suspicious for melanoma were elliptically excised with proper margins. Elliptical surgical excisions were vertically bisected along the short axis of the specimen into two halves in the middle of the pigmented lesions. The vertically bisected tumor face was imaged. After that, one half of the sample was briefly stained in aqueous 2 mg/ml solution of tetracycline, whereas another half was stained in 0.2 mg/ml aqueous solution of methylene blue. Then both specimens were reimaged. Reflectance images were acquired in the spectral range between 390 and 750 nm. Fluorescence images of the tetracycline-stained tissue were excited at 390 nm and registered between 450 and 700 nm. Fluorescence of the methylene blue-stained samples was excited at 630 nm and registered between 650 and 750 nm. After imaging, the tissue was processed for standard H&E histopathology. The resulting histological and optical images were compared to each other. Results and Conclusions: Our findings demonstrate that both tetracycline and methylene blue are suitable for imaging dysplastic and benign nevi. Melanoma is better delineated in the samples stained in methylene blue. Accurate and rapid delineation of melanoma in standard fresh surgical excisions appears feasible. Lasers Surg. Med. 41:10-16,2009. (C) 2008 Wiley-Liss, Inc. C1 [Tannous, Zeina; Shah, Sonali] Boston Vet Affairs Med Ctr, Boston, MA USA. [Tannous, Zeina; Al-Arashi, Munir; Yaroslavsky, Anna N.] Harvard Univ, Sch Med, Boston, MA USA. [Tannous, Zeina; Al-Arashi, Munir; Yaroslavsky, Anna N.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Al-Arashi, Munir; Yaroslavsky, Anna N.] Harvard Univ, Sch Med, Wellman Ctr Photomed, Boston, MA USA. [Shah, Sonali] Harvard Univ, Sch Med, Div Hlth Sci & Technol, Boston, MA USA. RP Yaroslavsky, AN (reprint author), MGH BAR314B,55 Fruit St, Boston, MA 02114 USA. EM yaroslav@helix.mgh.harvard.edu NR 19 TC 12 Z9 12 U1 1 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD JAN PY 2009 VL 41 IS 1 BP 10 EP 16 DI 10.1002/lsm.20736 PG 7 WC Dermatology; Surgery SC Dermatology; Surgery GA 400DI UT WOS:000262847800002 PM 19143015 ER PT J AU Dai, TH Tegos, G Lu, ZS Huang, LY Hamblin, M AF Dai, Tianghong Tegos, George Lu, Zongshun Huang, Liyi Hamblin, Michael TI PHOTODYNAMIC THERAPY FOR MULTI-DRUG RESISTANT ACINETOBACTER BAUMMNII BURN-WOUND INFECTIONS: AN IN VIVO STUDY SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 01-05, 2009 CL National Harbor, MD SP Amer Soc Laser Med & Surg C1 [Dai, Tianghong; Tegos, George; Lu, Zongshun; Huang, Liyi; Hamblin, Michael] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Tegos, George/C-8830-2011 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2009 BP 3 EP 4 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 464RV UT WOS:000267524700009 ER PT J AU Yao, M Redmond, RW Kochevar, IE Wang, Y AF Yao, Min Redmond, Redmond W. Kochevar, Irene E. Wang, Ying TI A LIGHT-ACTIVATED TECHNOLOGY FOR AMNIOTIC MEMBRANE TRANSLATION TO THE CORNEA SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 01-05, 2009 CL National Harbor, MD SP Amer Soc Laser Med & Surg C1 [Yao, Min; Redmond, Redmond W.; Kochevar, Irene E.; Wang, Ying] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2009 BP 3 EP 3 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 464RV UT WOS:000267524700007 ER PT J AU Purschke, M Laubach, HJ Anderson, RR Manstein, D AF Purschke, Martin Laubach, Hans J. Anderson, R. Rox Manstein, Dieter TI THERMAL INJURY CAUSES LETHALITY AND DNA DAMAGE IN UNHEATED SURROUNDING CELLS: ACTIVE THERMAL BYSTANDER EFFECT SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 01-05, 2009 CL National Harbor, MD SP Amer Soc Laser Med & Surg C1 [Purschke, Martin; Laubach, Hans J.; Anderson, R. Rox; Manstein, Dieter] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2009 BP 6 EP 6 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 464RV UT WOS:000267524700017 ER PT J AU Salomatina, E Cordero, M Yaroslavsky, A AF Salomatina, Elena Cordero, Mauricio Yaroslavsky, Anna TI TEMPERATURE INDUCED CHANGES IN THE OPTICAL PROPERTIES OF SKIN IN VIVO SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 01-05, 2009 CL National Harbor, MD SP Amer Soc Laser Med & Surg C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. Univ Tokyo, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2009 BP 7 EP 7 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 464RV UT WOS:000267524700020 ER PT J AU Park, J Mroz, P Hamblin, M Salomatina, E Yaroslavsky, A AF Park, Jesung Mroz, Pawel Hamblin, Michael Salomatina, Elena Yaroslavsky, Anna TI OPTICAL MAPPING OF NONMELANOMA SKIN CANCERS USING WIDE-FIELD HIGH-RESOLUTION1 OPTICAL IMAGER SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 01-05, 2009 CL National Harbor, MD SP Amer Soc Laser Med & Surg C1 [Park, Jesung; Mroz, Pawel; Hamblin, Michael; Salomatina, Elena; Yaroslavsky, Anna] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2009 BP 13 EP 13 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 464RV UT WOS:000267524700037 ER PT J AU Yaroslavsky, AN Salomatina, E Li, CQ Lin, C Al-Arashi, M Neel, V AF Yaroslavsky, Anna N. Salomatina, Elena Li, Chunqiang Lin, Charles Al-Arashi, Munir Neel, Victor TI HIGH CONTRAST MAPPING OF NONMELANOMA SKIN CANCERS SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 01-05, 2009 CL National Harbor, MD SP Amer Soc Laser Med & Surg C1 [Yaroslavsky, Anna N.; Salomatina, Elena; Li, Chunqiang; Lin, Charles; Al-Arashi, Munir; Neel, Victor] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2009 BP 13 EP 13 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 464RV UT WOS:000267524700036 ER PT J AU Avram, MM Tope, WD Szachowiez, E Nelson, JS AF Avram, Mathew M. Tope, Whitney D. Szachowiez, Edward Nelson, J. Stuart TI HYPERTROPHIC SCARRING OF THE NECK FOLLOWING FRACTIONATED CO2 RESURFACING SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 01-05, 2009 CL National Harbor, MD SP Amer Soc Laser Med & Surg C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Advancements Dermatol, Edina, MN USA. Facial Plast Surg, Edina, MN USA. Univ Calif Irvine, Beckman Laser Inst & Med Clin, Irvine, CA 92715 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2009 SU 21 BP 25 EP 25 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 464RV UT WOS:000267524700071 ER PT J AU Sakamoto, FH Wanner, M Farinelli, WA Doukas, AG Anderson, RR AF Sakamoto, Fernanda H. Wanner, Molly Farinelli, William A. Doukas, Apostolos G. Anderson, R. Rox TI AMINOLEVULINIC ACID PHOTODYNAMIC THERAPY DELIVERED AFTER ABLATIVE FRACTIONAL RESURFACING IN AN ANIMAL MODEL SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 01-05, 2009 CL National Harbor, MD SP Amer Soc Laser Med & Surg C1 [Sakamoto, Fernanda H.; Wanner, Molly; Farinelli, William A.; Doukas, Apostolos G.; Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2009 BP 28 EP 28 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 464RV UT WOS:000267524700079 ER PT J AU Tannous, Z Lin, J Izikson, L AF Tannous, Zeina Lin, Jennifer Izikson, Leonid TI PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY ON THE TREATMENT OF HYPERTROPHIC SCAR WITH NON-ABLATIVE FRACTIONAL PHOTOTHERMOLYSIS SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 01-05, 2009 CL National Harbor, MD SP Amer Soc Laser Med & Surg C1 [Tannous, Zeina; Lin, Jennifer; Izikson, Leonid] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2009 BP 35 EP 35 PG 1 WC Dermatology; Surgery SC Dermatology; Surgery GA 464RV UT WOS:000267524700099 ER PT J AU Waibel, J Lupo, M Beer, K Anderson, RR AF Waibel, Jill Lupo, Mary Beer, Kenneth Anderson, R. Rox TI TREATMENT OF BURN SCARS WITH 1550 nm NONABLATIVE FRACTIONAL ERBIUM LASER SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 01-05, 2009 CL National Harbor, MD SP Amer Soc Laser Med & Surg C1 Palm Beach Esthet Dermatol & Laser Ctr, W Palm Beach, FL USA. Lupo Ctr Aesthet & Gen Dermatol, New Orleans, LA USA. Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2009 BP 35 EP 36 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 464RV UT WOS:000267524700101 ER PT J AU Yu, CS Negishi, K Shek, S Chan, N Chan, HHL AF Yu, Carol S. Negishi, Kei Shek, Samantha Chan, Nicola Chan, Henry H. L. TI PERCUTANEOUS LASER BLEPHAROPLASTY SO LASERS IN SURGERY AND MEDICINE LA English DT Meeting Abstract CT 29th Annual Conference of the American-Society-for-Laser-Medicine and Surgery CY APR 01-05, 2009 CL National Harbor, MD SP Amer Soc Laser Med & Surg C1 Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. Tokyo Womens Med Univ, Tokyo, Japan. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PY 2009 SU 21 BP 42 EP 43 PG 2 WC Dermatology; Surgery SC Dermatology; Surgery GA 464RV UT WOS:000267524700122 ER EF